<SEC-DOCUMENT>0000721371-22-000013.txt : 20220203
<SEC-HEADER>0000721371-22-000013.hdr.sgml : 20220203
<ACCEPTANCE-DATETIME>20220203162435
ACCESSION NUMBER:		0000721371-22-000013
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220203
DATE AS OF CHANGE:		20220203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		22588641

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20211231.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d933fb5b-1648-4e2f-85b6-17909e6e7a92,g:b7c819a0-6ebd-409c-a3ca-466b0ca5332e,d:6bdf7a21332a418cb7d5503f4cc4365e--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cah="http://www.cardinal.com/20211231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY18yLTEtMS0xLTQ3MjI2_6e2686d5-0025-4999-9c92-86b73d7ce41a">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY18zLTEtMS0xLTQ3MjI2_9f5465a6-42eb-46f5-9693-db055a03af22">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY180LTEtMS0xLTQ3MjI2_763f4353-4a13-48a3-9a29-9d936240d5d0">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY181LTEtMS0xLTQ3MjI2_a6b5db89-d2a1-4696-946c-1354df4176d2">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY182LTEtMS0xLTQ3MjI2_2fa900ee-e13f-4955-b9c7-4e919478cd73">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a27e14071854942b0925c5b161e2e00_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idf89a8993ffb426a9d8312715526954c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica8231a36d054c5eace0ac4a74d6041c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7986a43d300d47c7b6781e8e97cd047e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4dc68631d57443d8738c75aa59831eb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7dbe5b201c74f1b89a35df6592c99e4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iada0f823a0f947a3a53d2ee1b5d23237_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db9ab51c3284580bbffafef36fcd2aa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ee4fa253c140b78f57a286ba3fd59b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4a82ec00b448529c5c4233322d86fa_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icead1849b2874394884eddb24215c104_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i126ccb95fe4446f895412bf247fc34d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1422fa549c8c4fd78d87a5e7bddef0cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e9b369a2e249aa9c82e841d358043c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b36454ae8f34474b633982b25f47ddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76f5c033b2b34568b248de95ea9ae8d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0f360bdd494ffaacb98ba69e7d9980_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c7f983dad174a65a853a11d93cbf864_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21dcf5c494534e31b313419407cf51a9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia792665ddedb4fd1be35d86aaee95caa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5840b125eaa8414f900e6f2f22ba8df4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d4a4c75a9a47f69d54b19dbcb1e52b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3118c657b147452e88b2cb76079e167a_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib353deb7360145ecb2e83ab126e17961_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00621486915144c58fbb572a1f95a310_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b596c976f3b4341a633bdc33702ce6d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669eb53209e44369b85bd08b8337e1a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4abc0866cbe848d3893f1f444f75cfc0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28be4398d9154a6ca1b5b457f10d7867_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ee22a4b8ab44809caa91d6c1c1eeaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e7de7ce1574c48a5037263df2cd692_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15c5d3332d947399180c64379abbaad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb92e4042fd492b81f82838ab7dfa53_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4ca91c9613414a94f9900f8909af66_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed791e44eac4a27bd9c7d44a85d03fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeeec8b34c774e7b9466d999568a65a0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2689810533ba4608b106bf844d197fb4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i247ac8c144e2402e9b7a5cdf73e42b35_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72771dd6f35d4ef389cc86b92183c631_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if521936d67844e53ad65faa8fee63ccc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81fff506366476385ee6cedef0c063c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09481b076c1d445abdc3ed3a80f5911a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20d6610e65a457a868d48435b845bbf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43dfa1a7cdf74ea793edc03f0339f726_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1620d434ff84017a4abba4b2b674fee_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i056f47607d66400ab28d51e4b4199aaf_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i006f51b5845242aab04f6d1e5bd5574d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f992d37c9445a39ce463c943d8a4b4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6898a41bdf2840358d646c0919f44974_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f438da6cbd845748e199c85aa4cdde7_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689ae4253cf44b73ac84db72214af2a4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6d5f06ee3664cac9f54724c815b9d73_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4761d672de014c8e9dad6c7102688227_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b760199824642c0a8d322009fa28dcc_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485b4945d9224029a35f582637d5d038_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54300086ab194a77aea92977e16df53b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db397a74a1042b9aafec1289ddba925_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i066955108bab4e7e95ad3b02cf4ef347_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa7745fb78df449faba2302b50698592_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6dedadffb54d5285c2b49eea80de65_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3492d85ea7b24e60910262ee6d3033ee_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39aff34d5814c78ac189de6dab4b7ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie965b585dfd74a75884609384471b2b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6990beeb1e8488aa56f362d54b5ae9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf07a0233e7740e1b2eaf72c788bc28f_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="i4e7b338780e74021a81ef74ef08b7a25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bebd2a91ae417eb4439959bf9f6d31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823151805e0f490888d034841f637bc5_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505ef6105727459882cd4fed2648f6c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a15392899d2482fbb95514624452a8d_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a85889e6ab440f18e191494e3590714_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa68d96ad1e4049873af142ed3aef39_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5005f9b9f5c748b6b3dc0a951c8577da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab78dc9db493437ebf096a1f66c9842d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a260218f5c74e0a818560db3bc26ab5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7828cce062bc44f0951fdcd8139d81b9_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e4b2aae2ad40a09418ad56348b3b01_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a126ed6a3341d7babdddc3b8c5a1af_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab62d58a2744c7d96ab48d178c5edc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11e26319ddf483d88eafb2ba45b91cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7293644d26734b97832a304248e0d4f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8531707da0e64febbba666aed40d8040_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285548e776cd4b929eae18d3e9002181_D20140731-20140731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-31</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a27d05945443ad96f59cdcb1edc420_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e6258348ea4fc89eb5ef7eb0cb10fe_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1795ede44ce94976805d345dedf32727_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29dc2aedb8bc420db59f14dd8db4e352_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6542622e5ef24933a209e2a96b41e83a_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a5d7197ac224ce9bf2facd8d7e90d5f_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i36ac058f78664b5dbeba5619bf856f61_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stateag"><xbrli:measure>cah:StateAG</xbrli:measure></xbrli:unit><xbrli:context id="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c999577462049eda357e2ab78e71683_I20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40eadd91b0ae47328a2ae28ff036f822_I20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id13e0ec03eda43788abcd88f803bccd1_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i1de5fd1605f748fdb2806fef4a6523c5_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib222890e5cd8438eae755da882ac9b57_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d18e9c334304d17b47512697546cdfe_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e01245b5cf74dc58ec5bf20e479c9f0_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2fd3c70f184444bdcf9b9585835c51_D20210731-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d6b6246aa54ad59d9d645973f16b87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i726a9874ca6a4682a0a961cf53f77d36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f5f0000b10443bb904f81c8727295ea_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib576ab5afad44195a834e1e7faeb7d53_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37746254b4ef462ab66acbee39610807_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220be912f8c445d583c34c9d7a197d21_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6fc69a919e428a9249914f94b4e705_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9770cc98f0834ead8999bddd6f93e81a_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c85c93cd4f49ccadff2110a5afb040_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838623ba3e424777903a3d4ab8c49dc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b171a8060ae4f008d8e6a25869806bf_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d6f83592a1426993ab2a13d023f8f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00fa788fc87340c384b2380104923f42_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7499fd6ae8f450daef1e62b7f4adf5b_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i25f55518522b4794b80ca287b166f5cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263e5ca49fed4bdbba6851bf32da93f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68578f163e6b4179847e8b41663e8613_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43784f138b914b8391cd15843d15c989_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488515e2c1534dd59e7585b97320412d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f1090b7d5ea42a8a285ffc9484f2981_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5176a75ae1064d6387d055928f4a88c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec263fc27faf41e9a416ab2454257578_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife056180602548b8811ec73a324b2646_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490f28555d6e44018c5fb0a7112b17fa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2308b88f9c42b991c03554e3e0145e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97efabb7eafb457086138a0357aee526_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib440b67408ee4c8fb412aeaaf58be6c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f6c7a9a75f64986aefb952c73f437f8_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2aace5f028f4f5594de1fcc97eebe25_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2850c2b1a44cd8880a41a004525e24_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb4d97276663428da969d731f48e6813_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357254d5ee414518a4eac711d1ad0070_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531458b265ea402180368f22e3a18010_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3347233009744e6cb9cc4557b43f558b_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67592a92eea436081db481ac7010f0d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72d4b7997b54c948eff89cce7d0a30e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8c386ef058467d89edcdc41c5d7497_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1ca71b66fd44c99dc3a2f276433c1d_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48423edd0fde4582afae650327df3fb4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if691da9b0c7f435b9a6464ebf9174366_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734031661a944622a2d44f3f789e8f7c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87549c698d84454483818bad997efd4b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b64ec0efad4987b3cd7ad0a3914253_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23cd0947b184af3834849f94339a4a7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f3694f60c043b6910488f3f4214356_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9442aa8d69b64b3bbce3a40e922f013a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5e2906bad1404691be6f731cf43612_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02be3554e0b34c02ba6b5f8f3ae72ad0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="i20447894cbce4626a6e15d3def1fdb5f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib05957b8776e49b29c6ad2637c8b07dd_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8dc329406284cab850531d536265617_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf577b417acb4a57824e42c61874c5f4_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a28033a8f04045b695c45def69a4ab_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2139bac4734db0b0818999413985f5_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7d6f1a08182423896d73aea639446c1_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a826fe2301345b7bcd24179b92b1b2a_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a0384798971475ca8af194b0bac9c64_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6de15b3c68241ae9c0af7734cf7ea0b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1ac584a6af4ec58101540fb78560fa_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67c60168405428b9e40371da416b3fc_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947e256fc55c4846ac6b1768ff3934ad_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3e1e7ccb99f4738bdd4ea38594a9397_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717134e53834433e8d6ee1a235075718_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7b6c1cd2234d3a84ff74926dba30cd_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4501b440f44a0d8c0bc1a50fdbff39_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee36791593e44892a333aec11370f06c_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c216eac9e0457da077b8544a667522_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b04e2a62607413897d3432b37ed8267_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec0426076dc43be9eb018d81b355af4_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e5a616b51d46cd9609f9b8cb936e1b_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad497ebaf0d74ac488be3fdfe5b45c13_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f557d65bffa4e22abc5d6a0ee5bf2c4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7026229bffa24d75a300958db5493173_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0ef5db6f8c49e99cf83c70272570db_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabe27c3053040afbee1de4f02ae3a1d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2324d519bd54f24aca9e312c213d51f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcd214eafc844838d0428eba45ceb81_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b9c7da4d6b4d138668a8f96ece269b_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8afe0411ae4297994e96fc737d451b_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105c393d6342437baf627222f66216c9_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c720c252b6845929ee256ffd982829d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib075c6eb340b4000b99c1e4260fff944_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d97aa974df4ac6bbf2e22959990798_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41706ccf867d4e078fa68264b8ecf4b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id27ed30ba0c447d8a9e0d8a5e753260e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644ca4beadff4da38d7416eb70d4e113_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3617e648d299450da968eaf742edafd8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a5635665184a6cb80b94e96e68ca69_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ae447d46854b319eaccc5ea8e28c28_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia478e26ea8e448b39f3752efae199cfa_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b6e1f67cfe47c5a29aaad5984e138e_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic237dc8d2be649c6873fe2eb206f1e73_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7abdec1bde440c4b7d2d3fbdb599cd2_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398269cbf0e54afe862fe609d2944418_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa1d951b73947c3936f78f13c7eaa01_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66dbff1954b94c7c9982013468c26bfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if137af18fd604b45a04f086112f3f149_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898c45d5227a4196aece99539dfb04a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10f071711d1b4e4ca40dd648ab7f15a4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f70075253b4b6f834c3408cbaaac75_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i548763c20950426faab587ffdc5af9cc_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be505b893554e2596656d949aede2e1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c55723711e41b596452e6d75618784_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37383edad9446b08331ba5cadd97680_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716d6753e4e540af82ae6e591c9bdeb0_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea669b2da0d447318754dc385014d7b6_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0018e1126c834a38ae1193472508f95b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.461%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M184NA_8a6e11b6-f2a0-4001-bb78-f8d26c4215f7">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MWM1ZTE4NTA2MDJkNDgyMjhlNjc0YzBhMTkwNjViZTAvdGFibGVyYW5nZToxYzVlMTg1MDYwMmQ0ODIyOGU2NzRjMGExOTA2NWJlMF8wLTAtMS0xLTQ3MjI2_cb7c8025-7411-481b-bd7e-34f925e53d73">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xMjE_16cf2228-4572-4852-9555-ab7e61073c8f">December 31, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6YTMwMTk0MTcxZDgxNGNjYWE4NTBlOThlZTZhNzhjOGYvdGFibGVyYW5nZTphMzAxOTQxNzFkODE0Y2NhYTg1MGU5OGVlNmE3OGM4Zl8wLTAtMS0xLTQ3MjI2_5b57d9af-e332-431d-ab82-447caafae442">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTgy_975dc3fc-ca0e-4157-9efe-c109a5b29f52">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTc4_29d21ea7-18b3-46f6-aa3e-aeb2d9fde424">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.282%"><tr><td style="width:1.0%"></td><td style="width:24.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8wLTAtMS0xLTQ3MjI2_abb5cdd8-4b31-4768-8c1a-b9dd98d58e5c">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8wLTYtMS0xLTQ3MjI2_b97ec9cb-3fa7-4507-959f-ac98c5dff662">31-0958666</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTAtMS0xLTQ3MjI2_bdabed56-31f9-4010-93d0-1bf3dc8bfe11">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTItMS0xLTQ3MjI2_dac0d492-f191-4400-bd1c-7a88dea023c8">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTQtMS0xLTQ3MjI2_c621c84f-ae56-46c9-99ab-eb79af38e920">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTYtMS0xLTQ3MjI2_4b4b8abc-233f-459c-b3bd-d5ff5e1b332b">43017</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV82LTQtMS0xLTQ3MjI2_bb59ade0-24a7-44e5-8d75-72d502e21464">(614)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV82LTYtMS0xLTQ3MjI2_cd6ab6a4-a58f-4a03-855d-267ab7b96567">757-5000</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.435%"><tr><td style="width:1.0%"></td><td style="width:35.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MjliZjZiZjEzNjM1NGM1YmJjZDk0MjVmMTVhYTFjNzgvdGFibGVyYW5nZToyOWJmNmJmMTM2MzU0YzViYmNkOTQyNWYxNWFhMWM3OF8yLTAtMS0xLTQ3MjI2_e46d7109-0bf4-4a58-8548-f5c334881a23">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MjliZjZiZjEzNjM1NGM1YmJjZDk0MjVmMTVhYTFjNzgvdGFibGVyYW5nZToyOWJmNmJmMTM2MzU0YzViYmNkOTQyNWYxNWFhMWM3OF8yLTEtMS0xLTQ3MjI2_b022d027-1567-41c3-ab8b-c7d5c0da325b">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MjliZjZiZjEzNjM1NGM1YmJjZDk0MjVmMTVhYTFjNzgvdGFibGVyYW5nZToyOWJmNmJmMTM2MzU0YzViYmNkOTQyNWYxNWFhMWM3OF8yLTItMS0xLTQ3MjI2_3bb125a7-499b-4f05-943d-c77d59fb2291">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTc5_843bc66f-ba48-4220-9edf-1ddcc4155f34">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTgw_dbe7aa36-478b-4ab0-8785-60cd90dc2fd7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZDFhZmMyM2VkMWZhNDZkZWJiZjUzYTI5YTg3ODY5YzIvdGFibGVyYW5nZTpkMWFmYzIzZWQxZmE0NmRlYmJmNTNhMjlhODc4NjljMl8wLTAtMS0xLTQ3MjI2_6c8718aa-9daa-4351-a48d-1e82a2fdae67">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZDFhZmMyM2VkMWZhNDZkZWJiZjUzYTI5YTg3ODY5YzIvdGFibGVyYW5nZTpkMWFmYzIzZWQxZmE0NmRlYmJmNTNhMjlhODc4NjljMl8xLTQtMS0xLTQ3MjI2_3584c629-b2a4-428e-ba74-65a009f3f10c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZDFhZmMyM2VkMWZhNDZkZWJiZjUzYTI5YTg3ODY5YzIvdGFibGVyYW5nZTpkMWFmYzIzZWQxZmE0NmRlYmJmNTNhMjlhODc4NjljMl8yLTQtMS0xLTQ3MjI2_3024d2ec-27a2-4889-ae50-62b0a15a121a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTgx_6723a33b-1e10-43d5-988c-63ec2b731840">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of January&#160;31, 2022, was the following: <ix:nonFraction unitRef="shares" contextRef="i5a27e14071854942b0925c5b161e2e00_I20220131" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTc2_1196a648-a52f-45e1-94d9-1073119521bb">277,061,392</ix:nonFraction>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q2 Fiscal 2022 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_34">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_34">17</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_43">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_43">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_46">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_49">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_52">23</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_58">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_58">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_64">Financial Statemen</a>ts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_64">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_127">45</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_130">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_130">46</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_133">47</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to fiscal 2022 and fiscal 2021 and to FY22 and FY21 are to the fiscal years ending or ended June&#160;30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2021 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (our &#8220;2021 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at December&#160;31, 2021 and June&#160;30, 2021, and in our condensed consolidated statements of earnings for the three and six months ended December&#160;31, 2021 and 2020. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2021 Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20211231_g1.jpg" alt="cah-20211231_g1.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, revenue increased 9 percent and 11 percent to $45.5 billion and $89.4 billion, respectively, primarily due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which largely consisted of branded pharmaceutical sales to large customers.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,295</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating losses of $950 million and $535 million during the three and six months ended December&#160;31, 2021, respectively, due to a $1.3 billion pre-tax non-cash goodwill impairment charge related to the Medical segment. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a GAAP operating loss of $163 million during the six months ended December 31, 2020 due to the $1.02&#160;billion pre-tax charge recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits and claims in the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP operating earnings during the three and six months ended December&#160;31, 2021 decreased 26 percent and 20 percent, respectively, due to the decrease in Medical segment profit resulting from increased inflationary impacts, primarily related to commodities and transportation, global supply chain constraints, the adverse impact of the net positive impact of PPE in the prior year and the impact of the divestiture of the Cordis business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.77</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.78</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Diluted earnings per share attributable to Cardinal Health, Inc. ("diluted EPS").</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Impairments and (gain)/loss on disposals of assets, net includes a pre-tax impairment charge of $1.3 billion related to our Medical segment recorded in the second quarter of fiscal 2022. For fiscal 2022, the estimated net tax benefit related to the impairment is $92 million and is included in the annual effective tax rate. As a result, the amount of tax benefit in the current quarter increased by approximately $1.0 billion and is expected to significantly increase the provision for income taxes during the remainder of the fiscal year.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Litigation (recoveries)/charges, net, includes a tax benefit recorded during the three months ended December&#160;31, 2020 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. During the three months ended December&#160;31, 2020, the total benefit from the net operating loss carryback was $420 million; however, for purposes of Non-GAAP financial measures, we allocated $394 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $26 million is included in non-GAAP measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, GAAP diluted EPS was adversely impacted by the goodwill impairment charge related to the Medical segment, which had a $(0.77) and $(0.76) per share after-tax impact, respectively. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. During the six months ended December&#160;31, 2021, GAAP diluted EPS was also adversely impacted by the factors impacting non-GAAP operating earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2020, GAAP diluted EPS included a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss. Refer to </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail. During the six months ended December&#160;31, 2020, GAAP diluted EPS was adversely impacted by the opioid litigation charge recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications, which had a $(2.38) per share after-tax impact on GAAP diluted EPS. See the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, non-GAAP diluted EPS decreased 27 percent and 21 percent to $1.27 and $2.56 per share, respectively. This decrease was primarily due to the factors impacting non-GAAP operating earnings and the prior-year tax benefit from the net operating loss carryback, partially offset by lower share count as a result of share repurchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.2 billion at December&#160;31, 2021 compared to $3.4 billion at June&#160;30, 2021. During the six months ended December&#160;31, 2021, net cash provided by operating activities was $549 million, which includes the payment into escrow of the majority of our first annual settlement payment under the Proposed Settlement Agreement related to state and local governmental opioid claims, and we deployed $800 million for share repurchases, $592&#160;million for debt repayment, and $289 million for cash dividends. We also received proceeds of $927 million, net of cash transferred, from the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2022 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Opioid Lawsuits Development</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#8220;Proposed Settlement Agreement&#8221;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement includes a cash component, pursuant to which we would pay up to approximately $6.37&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against us after the Proposed Settlement Agreement becomes effective.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the three distributors determined that a sufficient number of states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which was the subdivision sign-on period. The subdivision sign-on period ended January 26, 2022. Each participating state will now make a determination as to whether a sufficient number of its political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. Following that determination by participating states, each of the three distributors will independently determine whether a sufficient number of subdivisions, including both those litigating and those that have not sued, have agreed to participate in the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed to execution. This process is currently contemplated to end in February 2022. The Proposed Settlement Agreement remains subject to contingencies. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the required contingencies are satisfied, the Proposed Settlement Agreement is expected to become effective in April 2022. During the period between the satisfaction of contingencies and the effective date, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Proposed Settlement Agreement in each participating state and dismissing lawsuits of participating states and subdivisions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors have entered into a settlement with each of the States of Florida, New York, Ohio and Rhode Island and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, these states and their participating subdivisions will become a part of it.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other national distributors, executed a term sheet with the Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a bench trial in the case brought by the Washington Attorney General against us and the same two other national distributors began in November 2021 in Washington state court. A trial in a case brought by private plaintiffs is scheduled to begin in state court in Georgia in March 2022. Trials are inherently unpredictable and it is possible that the outcome of these trials, either individually or in the aggregate, could materially negatively impact our financial results, cash flows or results of operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68&#160;billion accrued at December&#160;31, 2021, of which $480&#160;million is included in other accrued liabilities, and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inflationary Impacts and Global Supply Chain Constraints, and Medical Goodwill</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively impacted by increased inflationary impacts, primarily related to commodities and transportation (including ocean and domestic freight), and global supply constraints during the three and six months ended December&#160;31, 2021. Due to the risks and uncertainties related to these impacts, we performed interim goodwill impairment testing, which resulted in a pre-tax non-cash goodwill impairment charge of $1.3 billion, included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal 2022, the estimated net tax benefit related to the impairment is $92 million and is included in the annual effective tax rate. As a result, the amount of tax benefit in the current quarter increased by approximately $1.0 billion and is expected to significantly increase the provision for income taxes during the remainder of the fiscal year. Refer to </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_106">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these inflationary impacts and global supply chain constraints to continue to adversely impact Medical segment profit. In order to partially mitigate the impact, we are taking cost-savings measures and intend to implement price increases. If these increased costs and the adverse impact of supply chain disruptions are greater than we expect, continue beyond our expectations, or we are unable to increase prices or achieve the cost-savings measures that we expect, our results of operations will be adversely impacted to a greater extent than we currently anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also experienced increased costs in the Pharmaceutical segment, primarily related to transportation and labor, during the three and six months ended December&#160;31, 2021. However, we do not expect the impact to be meaningful to Pharmaceutical segment profit for fiscal 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") had a net negative impact on our consolidated operating earnings during the three and six months ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Pharmaceutical segment, volumes within our generics program were lower compared to levels prior to COVID-19, which negatively impacted Pharmaceutical segment profit during the six months ended December&#160;31, 2021. However, volumes within our generics program continued to improve and approximated levels prior to COVID-19 during the three months ended December&#160;31, 2021. On a year-over-year basis, the impact to segment profit was favorable due to improvement in volume during the three and six months ended December&#160;31, 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively impacted by COVID-19 during the three and six months ended December&#160;31, 2021 and on a year-over-year basis primarily due to the net impact of personal protective equipment ("PPE"), which we expect to improve during the remainder of fiscal 2022. During the three months and six ended December&#160;31, 2021, demand for surgical products related to elective procedures was comparable to levels in the prior year. Higher volumes in our laboratory business continued to positively impact Medical segment profit, but did not have a meaningful impact on a year-over-year basis due to relatively higher volumes in the prior periods.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that the negative impact of the COVID-19 pandemic on consolidated operating earnings will be less in fiscal 2022 than in the prior year, which included an inventory reserve of $197&#160;million for certain Medical segment PPE during the fourth quarter of fiscal 2021. As a result, we expect the COVID-19 impact for fiscal 2022 will be positive in comparison to prior year. However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow. Its impact may be greater or less than we anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cordis Divestiture</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold our Cordis business to Hellman &amp; Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." In connection with the closing, we entered into a Transition Services Agreement ("TSA") with the buyer to provide support functions for a period of up to twenty-four months following the sale. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_85">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As anticipated, Medical segment revenue and Medical segment profit were adversely impacted during the three and six months ended December&#160;31, 2021 due to the divestiture of the Cordis business. We expect the divestiture will decrease Medical segment revenue by approximately $700 million and adversely impact Medical segment profit by approximately $70 million in fiscal 2022. The divestiture of the Cordis business resulted in a decrease in amortization of acquisition-related intangible assets during the three and six months ended December&#160;31, 2021, which we expect to continue for the remainder of fiscal 2022. The divestiture of the Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit. For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20211231_g2.jpg" alt="cah-20211231_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20211231_g3.jpg" alt="cah-20211231_g3.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,236&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,197</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,348&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,615&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,457</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,541&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,606&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, revenue increased primarily due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $4.1&#160;billion and $8.8&#160;billion, respectively, and largely consisted of branded pharmaceutical sales to large customers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue decreased during the three months ended December&#160;31, 2021 primarily due to the impact of the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue was flat during the six months ended December&#160;31, 2021. The adverse impact of the divestiture of the Cordis business was offset primarily due to the positive impact of PPE within products and distribution and sales growth in at-Home solutions.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold for the three and six months ended December&#160;31, 2021 increased 10 percent to $43.8 billion and 12 percent to $86.2 billion, respectively, compared to the respective prior-year periods as a result of the factors affecting the changes in revenue and gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20211231_g4.jpg" alt="cah-20211231_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20211231_g5.jpg" alt="cah-20211231_g5.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,616</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,258</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,491&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the three and six months ended December&#160;31, 2021 was adversely impacted due to the divestiture of the Cordis business and increased costs in the Medical segment due to inflationary impacts and global supply chain constraints.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 72 basis points and 69 basis points during the three and six months ended&#160;December&#160;31, 2021, respectively, mainly due to changes in product mix resulting from pharmaceutical distribution branded sales, which have a dilutive impact on our overall gross margin rate. The performance of Medical segment products and distribution, which reflects the divestiture of the Cordis business and increased costs due to inflationary impacts and global supply chain constraints, also had an adverse impact on gross margin rate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,151</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,265</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, SG&amp;A expenses were flat primarily due to increased expenses related to investments in information technology infrastructure and higher operations expenses, mostly offset by the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, the year-over-year comparison was also favorably impacted by the prior-year $41 million accrual for our estimated portion of the assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018, which was recognized during the three months ended September 30, 2020. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_121">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20211231_g6.jpg" alt="cah-20211231_g6.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20211231_g7.jpg" alt="cah-20211231_g7.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">426</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">832</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, Pharmaceutical segment profit increased primarily due to the performance of our generics program, including an improvement in volumes compared to the prior year, which were adversely impacted by COVID-19. This was partially offset by increased expenses related to investments in information technology infrastructure. During the three months ended December&#160;31, 2021, Pharmaceutical segment profit was also adversely impacted by higher operations expenses.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit during the three and six months ended December&#160;31, 2021 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit decreased during the three and six months ended December&#160;31, 2021 largely due to increased inflationary costs, primarily related to commodities and transportation, and the adverse impact of global supply chain constraints. Medical segment profit also reflects an adverse impact related to the prior-year net positive impact of PPE and the impact of the divestiture of the Cordis business. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three and six months ended&#160;December&#160;31, 2021&#160;were due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,295</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance during the three and six months ended December&#160;31, 2021 and 2020 was primarily related to the implementation of certain enterprise-wide cost-saving measures. Restructuring costs during the three and six months ended December&#160;31, 2021 also included costs related to the divestiture of the Cordis business.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $79 million and $113 million for the three months ended December 31, 2021 and 2020, respectively, and $157 million and $228 million for the six months ended December&#160;31, 2021 and 2020, respectively. The decrease in amortization of acquisition-related intangible assets was primarily due to the divestiture of the Cordis business.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2021, we recognized a $1.3 billion pre-tax non-cash goodwill impairment charge related to our Medical segment, as discussed further in the "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020, we recognized a pre-tax charge of $1.02&#160;billion associated with certain opioid matters. See the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized estimated losses and legal defense costs associated with the IVC filter product liability claims of $13 million and $18 million during the three months ended December&#160;31, 2021 and 2020, respectively, and $39 million and $28 million during the six months ended December&#160;31, 2021 and 2020, respectively. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we recognized income of $17 million for recoveries in class action antitrust lawsuits in which we were a class member.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended December&#160;31, 2020, we recognized a $13 million charge in connection with a civil investigation by the United States Attorney&#8217;s Office for the District of Massachusetts related to discounts and rebates offered or provided to certain Specialty Solutions customers, as described further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense during the three and six months ended&#160;December&#160;31, 2021 was primarily due to less debt outstanding.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Early Extinguishment of Debt</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During six months ended&#160;December&#160;31, 2021, we recognized a $10 million loss in connection with the debt redemption as described further in</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_100">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;105.0 percent and&#160;(47.6)&#160;percent, respectively. The effective tax rate for the three months ended December&#160;31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual effective tax rate. The estimated annual effective tax rate for the three months ended December 31, 2020 included a benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the treatment of the tax impacts of the opioid litigation accrual.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was 153.1 percent and 259.7 percent. The effective tax rate for the six months ended December&#160;31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual effective tax rate. The effective tax rate for the six months ended December&#160;31, 2020 included a benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss and the net tax benefit related to the treatment of the tax impacts of opioid litigation charges.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we recognized a $1.3 billion pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $92 million for fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended December 31, 2021 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2022. Applying the higher tax rate to the current quarter loss resulted in recognizing an interim tax benefit of approximately $1.0 billion, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months and six months ended December 31, 2021 and prepaid expenses and other assets in the condensed consolidated balance sheets at December 31, 2021. This interim tax benefit will reverse in future quarters of fiscal 2022.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; current and projected debt service requirements, dividends and share repurchases; and opioid litigation settlement payments associated with the Proposed Settlement Agreement, the state agreements and Cherokee Nation and Native American tribes agreements. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.2 billion at December&#160;31, 2021 compared to $3.4 billion at June&#160;30, 2021. At December&#160;31, 2021, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, net cash provided by operating activities was $549 million, which includes the payment into escrow of the majority of our first annual settlement payment under the Proposed Settlement Agreement related to state and local governmental opioid claims, and we deployed $800 million for share repurchases, $592&#160;million for debt repayment, and $289 million for cash dividends. We also received proceeds of $927 million, net of cash transferred, from the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases, and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at December&#160;31, 2021 includes $722 million of cash held by subsidiaries outside of the United States. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at December&#160;31, 2021 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2021, we were in compliance with this financial covenant. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2021 and June&#160;30, 2021, we had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$5.6 billion and $6.2 billion, respectively. During the six months ended December&#160;31, 2021, we redeemed $572 million of the 2.616% Notes due 2022 with available cash. In connection with this redemption, we recorded a $10 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt. The early redemption was funded with available cash.  </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Anticipated Capital Resources</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss as described further in our 2021 Form 10-K, we have filed for a refund of $974&#160;million, which we expect to receive within 12 months. Accordingly, we have a current asset for this amount on our condensed consolidated balance sheets at both December&#160;31, 2021 and June&#160;30, 2021. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Opioid Litigation Settlement Agreement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $6.68&#160;billion accrued at December&#160;31, 2021 related to certain opioid litigation, as further described within the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the payment amounts to be spread over 18 years. During the six months ended December&#160;31, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. If the Proposed Settlement Agreement does not become effective, this payment will be returned to us. We also made certain payments under the separate New York and Ohio settlements. We expect to pay the remainder of our first annual payment into escrow in February 2022 and, if the Proposed Settlement Agreement becomes effective, to make subsequent annual payments under the Proposed Settlement Agreement every July for the term of our agreement beginning in July 2022. The amounts of these future payments may differ from the payment made during the six months ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the six months ended December&#160;31, 2021 and 2020 were $141 million and $174 million, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 5, 2021, August 4, 2021, and November 4, 2021 our Board of Directors approved a quarterly dividend of $0.4908 per share, or $1.96 per share on an annualized basis, which were paid on July 15, 2021, October 15, 2021 and January 15, 2022 to shareholders of record on July 1, 2021, October 1, 2021 and January 3, 2022 respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we repurchased $800&#160;million of our common shares, in the aggregate, under accelerated share repurchase ("ASR") programs. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2021, our Board of Directors approved a $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. As of January&#160;31, 2022, we had $2.9&#160;billion remaining authorized for share repurchases under this program.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2021 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2021. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_31"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June&#160;30, 2021. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2021 Form 10-K and our Form 10-Q for the quarter ended September 30, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risks discussed in "Risk Factors" and other risks discussed in our 2021 Form 10-K and our other filings with the SEC since June 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our inventories are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These are primarily merchandise inventories at the core pharmaceutical distribution facilities within our Pharmaceutical segment (&#8220;distribution facilities&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method ("FIFO"), or net realizable value. We reserve for the lower of cost or net realizable value using the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for certain PPE as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in periods prior to COVID-19. As selling prices and customer demand decreased compared to the peak of COVID-19, we recorded a reserve of $197&#160;million in fiscal 2021, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to monitor and assess changes in selling prices and customer demand related to PPE during the six months ended December&#160;31, 2021. While we consider that our assumptions continue to be reasonable and appropriate, our estimates for selling prices and demand are inherently uncertain and if our assumptions decline in the future, additional inventory reserves may be required. </span></div></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Unit Goodwill </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;December&#160;31, 2021, the Medical Unit continued to experience adverse financial results related to inflationary impacts and global supply chain constraints.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment and perform interim goodwill impairment testing for the Medical Unit. We updated our assumptions from prior periods to include the increased magnitude and breadth of the inflationary impacts to supply chain and commodities costs as well as adverse impacts due to supply chain disruptions.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our planned price increases did not impact the second quarter of fiscal 2022 and therefore, we updated our assumptions to reflect a longer duration to implement such actions. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 9 percent and a terminal growth rate of 2 percent), and the market-based approach. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $1.3 billion for the Medical Unit, which was recognized during the three months ended&#160;December&#160;31, 2021 and is included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings. The carrying value of the Medical Unit at December&#160;31, 2021 after recognizing the impairment charge was $8.1 billion, of which $2.8&#160;billion was goodwill. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">Note 4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for further discussion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider these assumptions to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impact, including price increases or surcharges; further disruptions in the supply chain; the impact of the Cordis divestiture; the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates (including potential tax reform); or a significant change in industry or economic trends. Adverse changes in key assumptions may result in further decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations. For example, if we were to increase the discount rate by a hypothetical 0.25 percent or decrease the terminal growth rate by a hypothetical 0.70 percent, the fair value for the Medical Unit would have further decreased by approximately $225 million.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs or income</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges. Additionally, during fiscal 2022 our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits. This judgment was the result of an ordinary course intellectual property rights claim and, therefore, is not adjusted in calculating the litigation recoveries or charges, net adjustment. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">(Gain)/Loss on sale of equity interest in naviHealth</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Transitional tax benefit, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net divided by (earnings/(loss) before income taxes adjusted for the first nine items).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliation</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/<br/>(Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(950)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(973)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,022)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">443</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.27</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.73)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(604)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(925)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">320</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">934</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">728</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21)</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.26&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairments and (gain)/loss on disposals of assets, net includes a pre-tax impairment charge of $1.3 billion related to our Medical segment recorded in the second quarter of fiscal 2022. For fiscal 2022, the estimated net tax benefit related to the impairment is $92 million and is included in the annual effective tax rate. As a result, the amount of tax benefit in the current quarter increased by approximately $1.0 billion and is expected to significantly increase the provision for income taxes during the remainder of the fiscal year. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net for the second quarter of fiscal 2022 does not include a $16 million judgement for lost profits related to an ordinary course intellectual property claim, which positively impacted Pharmaceutical segment profit in the quarter. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes a pre-tax charge of $1.02 billion recorded in the first quarter of fiscal 2021 related to the opioid litigation. For fiscal 2021, the amount of tax expense increased by approximately $150&#160;million during the three months ended December 31, 2020 while the amount of tax benefit increased by approximately $300 million during the six months ended December 31, 2020 compared to the tax impacts that would have been recognized without the opioid litigation charge. The net tax benefit associated with the opioid litigation charges was $228 million for fiscal 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Litigation(recoveries)/charges, net also includes a tax benefit recorded during the three months ended December&#160;31, 2020 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. During the six months ended</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">December&#160;31, 2020,</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> t</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">he total net benefit was $420 million; however, for purposes of reconciling Non-GAAP financial measures, we allocated $394 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $26 million is included in non-GAAP measures. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_43"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2021&#160;Form 10-K since the end of fiscal&#160;2021&#160;through&#160;December&#160;31, 2021.</span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of December&#160;31, 2021. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As explained below, there were changes in our internal control over financial reporting during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Pharmaceutical Segment Information Technology Initiative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. During the three and six months ended December 31, 2021, we transitioned selected processes to the new systems which affected our internal control over financial reporting. It is possible that ongoing transitions to new systems may adversely impact internal control over financial reporting. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to definitive documentation and court approval and notice process, the parties have reached an agreement in principle to resolve these lawsuits. Under this agreement, our director and officer's liability insurance carriers, on behalf of the defendants, would pay Cardinal Health $124 million, less any attorneys' fees and expenses awarded by the court to plaintiffs' counsel. This settlement does not include any admission of liability. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the risk factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2021 Form 10-K and our filings with the SEC since June&#160;30, 2021. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant number of states, counties, municipalities and other governmental entities have filed lawsuits against pharmaceutical manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others relating to the manufacturing, marketing or distribution of prescription opioid pain medications. In July 2021, we announced that, as a result of the previously disclosed settlement framework, we and two other national distributors have negotiated a Proposed Settlement Agreement and settlement process that, if all conditions are satisfied (including the approval of the Board of Directors), would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. This Proposed Settlement Agreement is subject to contingencies and there is no assurance that a sufficient number of states and subdivisions will agree to the proposed settlement agreement or that the required contingencies will be satisfied. It is possible that the settlement will not become effective. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American Tribes are not a part of this settlement process. In September 2021, we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other national distributors, agreed to a term sheet with the Native American tribes. We have had negotiations with the West Virginia subdivisions from time to time. For more information on the proposed settlement and other opioid-related litigation matters, see Note 6 to the Consolidated Financial Statements.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a bench trial in the case brought by the Washington Attorney General against us and the same two other national distributors began in November 2021 in Washington state court. It is also possible that, even if the Proposed Settlement </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement becomes effective, we could have trials for lawsuits brought by other states or subdivisions as well. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to claims brought by governmental entities, we are also being sued by private plaintiffs, such as unions, other health and welfare funds, hospital systems, other healthcare providers and individuals alleging personal injury for the same activities and we could be named as a defendant in additional lawsuits. A trial in Georgia in a lawsuit brought by private plaintiffs against us and two other distributors is scheduled to begin in March 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that the outcome of these trials or any future opioid-related trials, either individually or in the aggregate, could materially negatively impact our financial results, cash flows or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defense and resolution of current and future lawsuits and investigations are subject to uncertainty and could have a material adverse effect on our results of operations, financial condition, cash flows, liquidity, or our ability to pay dividends or repurchase our shares, beyond the amounts accrued. In addition, they could have adverse reputational or operational effects on our business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict. For example, several states have now adopted or proposed taxes or other fees on the sale of opioids. These laws and proposals vary in the tax amounts imposed and the means of calculation. Liabilities for taxes or assessments under any such laws could have an adverse impact on our results of operations unless we are able to mitigate them through operational changes or commercial arrangements where permitted.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing unfavorable publicity regarding the abuse or misuse of prescription opioid pain medications and the role of wholesale distributors in the supply chain of such prescription medications, as well as the continued proliferation of the opioid lawsuits, investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs, availability and regulatory risk associated with these products and raw materials. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products. Prices of oil and gas also affect our distribution and transportation costs. Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate. Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply chain costs, primarily related to international freight and commodities, which had a negative impact on Medical segment profit in fiscal 2021 and the first two quarters of fiscal 2022. Supply chain constraints have also had a negative impact on sales within our Medical segment. We expect these cost increases and supply chain constraints to continue to have a negative impact on segment profit, primarily in the Medical segment, in fiscal 2022. Due to competitive dynamics and contractual limitations, we may be unable to pass along cost increases through higher prices. If we continue to have challenges sufficiently offsetting these cost increases through other cost reductions, or recovering these costs through price increases or surcharges, Medical segment profit could be negatively impacted to a greater extent than we currently anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on others to manufacture some products that we market and distribute. Our operations are also dependent on various components, compounds, raw materials and energy supplied by others. We purchase many of these components, raw materials and energy, and source certain products from numerous suppliers in various countries. In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier. Our supplier relationships could be interrupted, become less favorable to us or be terminated and the supply of these components, compounds, raw materials or products could be interrupted or become insufficient. These supply interruptions or other disruptions in manufacturing processes could be caused by events beyond our control, including natural disasters, supplier facility shut-downs, defective raw materials, the impact of epidemics or pandemics, such as COVID-19, and actions by U.S. or international governments, including export restrictions or tariffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, due to the stringent regulatory requirements regarding the manufacture and sourcing of our products, we may not be able to quickly establish additional or replacement sources for certain components, materials or products. A sustained supply reduction or interruption, and an inability to develop alternative and additional sources for such supply, could result in lost sales, increased cost, damage to our reputation, and may have an adverse effect on our business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential employee attrition due to COVID-19 vaccine mandates or otherwise may have an adverse impact on our business and results of operations. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we announced that we would be requiring certain groups of U.S. and Canadian employees, including salaried and office-based employees and sales teams, to be fully vaccinated against COVID-19 by December 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, an executive order was issued requiring all employers with U.S. Government contracts to ensure that their U.S. based employees, contractors and subcontractors that work on or in support of U.S. Government contracts are fully vaccinated against COVID-19. While effectiveness of this executive order has been stayed, if it goes into effect, it would increase the number of our employees who will be required to be vaccinated against COVID-19 and is applicable to certain employees working in distribution centers and manufacturing facilities who would not have otherwise been covered by our company's vaccination requirement. Implementation of these mandates may result in attrition, including attrition of key or critical employees, and difficulty in attracting or securing new employees, which could have an adverse impact on our business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the global labor market is competitive and it is possible that our ability to attract and retain employees in key functions, including in our distribution centers and manufacturing facilities, could be negatively impacted.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our goodwill may become further impaired, which could require us to record additional significant charges to earnings in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP requires us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist. As a result of adverse financial results in our Medical Unit resulting from inflationary impacts and global supply chain constraints, we performed interim goodwill impairment testing for the Medical Unit for the period ended December 31, 2021. As a result of this interim test, we recorded a $1.3 billion impairment to goodwill related to our Medical Unit. This testing involves estimates and significant judgments by management. We believe our assumptions and estimates are reasonable and appropriate; however additional adverse changes in key assumptions,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> including a failure to meet expected earnings or other financial plans, unanticipated events and circumstances such as changes in assumptions about the duration and magnitude of increased supply chain and commodities costs and our planned efforts to mitigate such impacts, further disruptions in the supply chain, the impact of the Cordis divestiture, estimated demand and selling prices for PPE, an increase in the discount rate, a decrease in the terminal growth rate, increases in tax rates (including potential tax reform) or a significant change in industry or economic trends </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could affect the accuracy or validity of such estimates and may result in an additional goodwill impairment in our Medical Unit. It is also possible that we may record significant charges related to other reporting units. Any charge or charges could adversely affect our results of operations. See "Critical Accounting Policies and Sensitive Accounting Estimates" in MD&amp;A above for more information regarding goodwill impairment testing.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_58"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share (2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3,4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(4)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,023,918&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.45&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022,057&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,771,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,771,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.88&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,003&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,796,063</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50.05</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,793,429</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,003</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 1,861, 517, and 256 common shares purchased in October, November, and December 2021, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On August 19, 2021, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="idf89a8993ffb426a9d8312715526954c_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ5Nw_d611f62f-7999-4a12-9f47-3151a00cd3ab">500</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQyOQ_040f0199-7eb1-499a-bbd0-bcd5d23b9ac9">7.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ0NQ_cc6f49b0-14ee-4fcc-a6f4-3c2e1cccf644">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ2MA_5c155015-2d9d-4e22-8002-ad1ee8a4d6f9">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ3OA_1b9c0c80-6f76-426f-bf93-4713cdcf934b">2.0</ix:nonFraction> million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 10, 2021, we entered into an ASR program to purchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODUyNw_7c05aa20-5dad-46dc-a70d-6cfea97d68b4">300</ix:nonFraction> million and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ica8231a36d054c5eace0ac4a74d6041c_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODU0NQ_67f9c0ce-e63e-4559-b6fd-33f5e371e187">4.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODU1OA_36135926-ccdc-4fde-9dd5-04af2fea3efd">50.30</ix:nonFraction>. The program concluded on January&#160;31, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODY5Ng_978afb2b-7197-4f61-817d-ad5292e2a005">49.39</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODcwMw_cafdcd34-8bea-4d35-9067-b525acdf31af">1.3</ix:nonFraction> million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_115">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expired on December 31, 2021. On November 4, 2021, our Board of Directors approved a new $3.0&#160;billion share repurchase program, which will expire on December 31, 2024. The ASR program with an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQwNw_7c05aa20-5dad-46dc-a70d-6cfea97d68b4">300</ix:nonFraction> million concluded on January&#160;31, 2022, which reduced the amount remaining under our existing share repurchase authorization to $2.9&#160;billion.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_64"></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi0xLTEtMS00NzIyNg_0e0ae643-a02f-4865-a238-f27ae35300e0">45,457</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi0zLTEtMS00NzIyNg_94cc4876-9965-4162-bf9c-01436770cd1d">41,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi01LTEtMS00NzIyNg_f09d20ba-cc5f-4211-b54c-6240846c4312">89,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi03LTEtMS00NzIyNg_9697ca9e-7f78-4415-baa0-79d714dd448e">80,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy0xLTEtMS00NzIyNg_8bed938a-12e6-430f-b711-52c91d22452a">43,841</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy0zLTEtMS00NzIyNg_845f7bfb-a570-4f2a-84f8-9545f8a5bef9">39,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy01LTEtMS00NzIyNg_737d99c4-9caf-4701-bcc7-bc5e53c94976">86,167</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy03LTEtMS00NzIyNg_e9e3ca14-8c8a-4463-82a5-667a6ebcd2ad">77,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC0xLTEtMS00NzIyNg_7dbcb773-4a10-445f-9c77-998b87c7e4e2">1,616</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC0zLTEtMS00NzIyNg_76beb785-3021-4957-8389-ebf19cc54bec">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC01LTEtMS00NzIyNg_6ca27d13-2b1b-4848-8049-f7aef7cc61f9">3,258</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC03LTEtMS00NzIyNg_5a8122e1-7618-48ed-8b8b-8f2ef5c45fbe">3,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy0xLTEtMS00NzIyNg_949574db-3fa3-4de5-b65e-d929cf635953">1,151</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy0zLTEtMS00NzIyNg_a5e4662c-d8ac-4078-a908-ea1377f95270">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy01LTEtMS00NzIyNg_c0385ba1-e2bc-462d-bc18-918cbe512bc6">2,265</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy03LTEtMS00NzIyNg_d2c5e4e3-d843-493f-84a2-f641eef3c28b">2,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC0xLTEtMS00NzIyNg_c8b69298-7d46-4f7a-ad0c-f97d04b2beba">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC0zLTEtMS00NzIyNg_f109ea05-94e4-437e-818d-c150b9e79d86">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC01LTEtMS00NzIyNg_9bb0214a-b7cc-4c62-a606-dddf8be8403b">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC03LTEtMS00NzIyNg_9126ad52-7e5e-4c84-876d-ccb152275427">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS0xLTEtMS00NzIyNg_72df85c2-491b-4f52-b3e1-d690e2c5a18a">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS0zLTEtMS00NzIyNg_800a6e18-07b3-4ed5-9a5a-93dc586b8878">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS01LTEtMS00NzIyNg_03ab190d-742a-4c16-8296-c770e688ade0">158</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS03LTEtMS00NzIyNg_604d8a28-cf20-4882-b52e-372a8fbc6fa4">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtMS0xLTEtNDcyMjY_7c6abda5-55a3-40c6-96e9-55da0197498b">1,295</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtMy0xLTEtNDcyMjY_63cca583-80f6-4916-a91c-9aa2a72273cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtNS0xLTEtNDcyMjY_00885525-3792-4c8c-bf61-eadc1ca03b25">1,293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtNy0xLTEtNDcyMjY_3bc507da-d736-47aa-bc72-8c1272a068c5">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtMS0xLTEtNDcyMjY_9b31f3e3-5d3e-4cb7-a65c-0074bd45bf9b">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtMy0xLTEtNDcyMjY_6f37f935-48e0-43fe-87c8-b3d44b74f282">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtNS0xLTEtNDcyMjY_17f31f04-d776-43ff-bc73-b23b6fe7d31b">52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtNy0xLTEtNDcyMjY_6f7fe958-6460-4852-a814-976c23e07a71">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItMS0xLTEtNDcyMjY_0b4cabe8-14c8-439a-80ac-45e14fa93157">950</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItMy0xLTEtNDcyMjY_7fc1cfa6-c4cf-4b28-a143-b827bed4bdbe">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItNS0xLTEtNDcyMjY_13c61c1f-5fc1-44af-8386-768eeb7386c1">535</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItNy0xLTEtNDcyMjY_ea9cc0c8-773b-495a-b3ca-daef8aaeb904">163</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtMS0xLTEtNDcyMjY_15f00e32-6569-4dbc-9912-c4bd90510186">13</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtMy0xLTEtNDcyMjY_6c4ca3f9-9395-4688-a949-eaf0c3908376">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtNS0xLTEtNDcyMjY_5af8f889-f7f5-4ade-9f27-a87f3fa76b8f">17</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtNy0xLTEtNDcyMjY_37853e7c-6b0b-4088-bc7a-5b469bb7f096">19</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtMS0xLTEtNDcyMjY_f5879ddf-66ff-4607-8c53-ddc96856b96a">37</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtMy0xLTEtNDcyMjY_93e27324-1a7f-495e-8a9a-5d906c42381c">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtNS0xLTEtNDcyMjY_d45f0275-4d72-44ba-bdd3-2db4369dbe8a">77</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtNy0xLTEtNDcyMjY_3891a1dc-8f78-416e-9ad7-e4f2900cf47c">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtMS0xLTEtNDcyMjY_aa096397-51f9-43b0-a1e8-ff0d93a08fe2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtMy0xLTEtNDcyMjY_2eb1e529-97ab-4ad9-ad25-36c32aca6464"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtMy0xLTEtNDcyMjY_6096310b-eb3a-4239-9d07-2de4dee901a1">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtNS0xLTEtNDcyMjY_dba5ee7e-1bca-4c3d-a3ea-210af48101f6">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtNy0xLTEtNDcyMjY_3b88c3e7-e86a-43ca-80f6-9d0457f0a9cf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMS0xLTEtNzQ2NTQ_e1edd092-ff46-439c-b966-09db976b97dc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMy0xLTEtODY4OTk_f2f77317-2168-4667-9cf9-7c690ce8a0ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNS0xLTEtNzQ2NTE_9b313438-eb71-47ee-91e6-0bd048b58d6e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNy0xLTEtODY5MDI_3a689123-38cb-48b9-9a82-4828732d31df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMS0xLTEtNDcyMjY_cecd9aab-43f7-44ed-8818-0f511a47a753">973</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMy0xLTEtNDcyMjY_af9669ce-0e5f-453d-ad7c-674291eae60f">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNS0xLTEtNDcyMjY_4e5149d5-ba71-470c-905e-385f49a5d754">604</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNy0xLTEtNDcyMjY_e65181ac-974c-4fbc-9b5a-8af1ca312dbb">236</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktMS0xLTEtNDcyMjY_6018ce24-2f79-485e-95f8-4a1f50b764f5">1,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktMy0xLTEtNDcyMjY_79f0803a-c422-4f0e-a0b9-685af78e4e60">203</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktNS0xLTEtNDcyMjY_37a32831-dbea-45f7-ad57-8ff42d3b94a5">925</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktNy0xLTEtNDcyMjY_6876234a-675c-4fee-9e28-af9c61250fcd">613</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtMS0xLTEtNDcyMjY_10d55440-4d7d-4987-a1cf-bd97074c2308">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtMy0xLTEtNDcyMjY_1819bdf9-619b-4456-9bb2-2060e97e2b20">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtNS0xLTEtNDcyMjY_c698196e-d36f-4095-a09e-9b69a84eb582">321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtNy0xLTEtNDcyMjY_df13af41-6ddf-48cf-8a99-f4b2a2b970e3">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtMS0xLTEtNDcyMjY_db6b24a9-6324-4078-9845-e3b6cd1d1ff7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtMy0xLTEtNDcyMjY_88ed0536-ff65-4792-a447-1882eba681ae">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtNS0xLTEtNDcyMjY_10780e4d-14f3-4b0f-8aa3-fc54cd7a690e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtNy0xLTEtNDcyMjY_21a02de6-bf83-4500-a624-0e6950295b62">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtMS0xLTEtNDcyMjY_f4d0f4d1-b1be-402e-881b-0ed0ffc7b290">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtMy0xLTEtNDcyMjY_96e1c5f2-6cd4-4c58-985c-5994da8675e2">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtNS0xLTEtNDcyMjY_9d58d5c1-bde8-435a-ba87-05af261304cc">320</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtNy0xLTEtNDcyMjY_a0db859c-6d17-4adf-b050-22b7e06642ca">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktMS0xLTEtNDcyMjY_3428c6d5-a67a-4573-af03-a0b3aa4f5501">0.17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktMy0xLTEtNDcyMjY_cdffa050-ea62-4795-becf-74c2e83a29df">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktNS0xLTEtNDcyMjY_bf8b3c2f-9af2-44e1-b006-71d6252d0b1b">1.13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktNy0xLTEtNDcyMjY_3b254c30-e985-46a5-b706-5006811c5211">1.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtMS0xLTEtNDcyMjY_740d9408-6d27-475a-bb79-8721f273004f">0.17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtMy0xLTEtNDcyMjY_7fd52753-4086-4a83-931d-e2c6844e84dc">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtNS0xLTEtNDcyMjY_afe2d31c-5c9c-4ea3-99a9-c7731f46fcbe">1.12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtNy0xLTEtNDcyMjY_375c6bcb-d805-4573-bb7e-292372e23892">1.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtMS0xLTEtNDcyMjY_a10979f4-6999-433c-8cff-383059b72483">279</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtMy0xLTEtNDcyMjY_181361bd-e496-46a4-b6e3-a068966ce137">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtNS0xLTEtNDcyMjY_381e56df-d239-4bd0-8ff0-7596e1263aaf">283</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtNy0xLTEtNDcyMjY_bec77474-58c0-4c13-905a-ebbf3628f0e3">293</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtMS0xLTEtNDcyMjY_48eb6580-864f-4e28-acd4-958d55b497eb">281</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtMy0xLTEtNDcyMjY_3049e1a9-4128-4c2f-ba1a-aceb40071729">295</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtNS0xLTEtNDcyMjY_1a2e212d-a9ff-40c5-87d9-8d3e3633461d">285</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtNy0xLTEtNDcyMjY_f75a943f-4a13-4d23-aaf4-51df022392b9">295</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtMS0xLTEtNDcyMjY_3aa6314a-a114-42c7-b5a9-c06e5cdac8cb">0.4908</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtMy0xLTEtNDcyMjY_dbae9395-8c14-4b84-9c59-c99d0f4dac5f">0.4859</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtNS0xLTEtNDcyMjY_35b6345e-7c75-4a77-9354-e67c912abfc4">0.9816</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtNy0xLTEtNDcyMjY_d23eaf03-af4b-4f0a-89c2-4b3703ef0aca">0.9718</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi0xLTEtMS00NzIyNg_1e9917e2-0176-44b0-9fe3-ac8aabfd0cb3">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi0zLTEtMS00NzIyNg_9e52f929-00da-4afa-a6bc-ea979a816b69">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi01LTEtMS00NzIyNg_26299ebb-9a05-4cbe-b77e-92b79b5b19e0">321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi03LTEtMS00NzIyNg_6fe7e1ed-42c8-4675-a052-091d7b6e09da">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS0xLTEtMS00NzIyNg_bab49f3d-03b7-4fb8-8e0b-7cb09dcf390c">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS0zLTEtMS00NzIyNg_4a72128d-075d-4cb3-ad84-0f0c7feeca0b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS01LTEtMS00NzIyNg_48b4c2f9-3f7d-4abd-9b08-8c2649e80355">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS03LTEtMS00NzIyNg_389e90a4-c7b1-46dd-98c1-b1bbb2901d2b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy0xLTEtMS00NzIyNg_d46a1ebd-0191-40f0-82ae-5a6e5cd2a8f3">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy0zLTEtMS00NzIyNg_23891904-68cc-4fe9-baf9-06ecc6541a62">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy01LTEtMS00NzIyNg_be7c0b56-a981-4b3a-8c42-c67276931440">8</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy03LTEtMS00NzIyNg_f0eb2b1e-145c-4a7e-b27c-1b1ad3a77ba2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC0xLTEtMS00NzIyNg_3a5cb8d0-558e-42f5-adaf-18716b4e47a1">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC0zLTEtMS00NzIyNg_6b5ae12a-eedb-4b2f-8627-eda370014dc5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC01LTEtMS00NzIyNg_b57a1e2a-2b1e-484e-9581-064d9a0ed16a">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC03LTEtMS00NzIyNg_2e97a0f1-e027-4b47-8b23-2b82e9962abb">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtMS0xLTEtNDcyMjY_c4b6db70-c94e-48c2-bd38-a4eb6f692538">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtMy0xLTEtNDcyMjY_7c64c126-73d0-4ec5-b7c7-8360656c9f09">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtNS0xLTEtNDcyMjY_a0fd569d-1167-42f0-9c94-e4358c427e56">270</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtNy0xLTEtNDcyMjY_bd382f1f-e2b5-49bf-8e77-97a99147d341">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItMS0xLTEtNDcyMjY_a8df9a13-a742-4cdf-aea2-e82e34151d39">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItMy0xLTEtNDcyMjY_493f0541-7e15-4d49-a7a8-45b0f9d4949a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItNS0xLTEtNDcyMjY_df29547e-85c6-42ba-8def-8f37d757630d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItNy0xLTEtNDcyMjY_7b9f004b-3583-4ca2-aeae-48afd1b13164">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtMS0xLTEtNDcyMjY_d3eac66f-101d-4a06-a33c-1b2001d7a9a1">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtMy0xLTEtNDcyMjY_cba3a038-fa88-4717-9cee-2c8176505660">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtNS0xLTEtNDcyMjY_87692fe4-e3a7-4d4b-a3bf-955b4ae15616">269</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtNy0xLTEtNDcyMjY_71094e1c-b697-48be-b01a-772afc4d82b3">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNC0xLTEtMS00NzIyNg_c7509dbc-8808-4f41-9116-f102a3872631">3,161</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNC0zLTEtMS00NzIyNg_01dadc52-80cf-4aa9-a458-dd6619935b9e">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNS0xLTEtMS00NzIyNg_c4f045e6-f739-48f9-bdd4-038a3d6d314c">9,406</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNS0zLTEtMS00NzIyNg_7e795dd4-1f2c-4d65-b0fd-ba5eac7c64f9">9,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNi0xLTEtMS00NzIyNg_31f91099-9f30-409e-a94c-1c50d1bc4ac0">14,941</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNi0zLTEtMS00NzIyNg_23e4374f-3e22-403f-b7b6-1d0aca577154">14,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNy0xLTEtMS00NzIyNg_cb7d4764-9f5b-4406-881c-64bd2bf4233f">4,339</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNy0zLTEtMS00NzIyNg_294119bb-9c93-4de5-836c-90f2f151c501">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOC0xLTEtMS00NzIyNg_af609370-c169-4bcb-bff7-281629f5fd76">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOC0zLTEtMS00NzIyNg_84d6c9bb-0e51-4181-ae20-3e1cca4c5ddb">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOS0xLTEtMS00NzIyNg_6826a023-debd-4e28-82d3-79694031d570">31,847</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOS0zLTEtMS00NzIyNg_2a581f4f-7aad-4908-862e-9fe30c877ce9">31,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTEtMS0xLTEtNDcyMjY_1e066842-d855-4dca-81ed-daebd144d070">2,321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTEtMy0xLTEtNDcyMjY_24a24057-ef17-4ec7-9791-dd0bbb93c730">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTItMS0xLTEtNDcyMjY_58be6934-8de4-4d63-8013-fc76d523f8fa">8,599</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTItMy0xLTEtNDcyMjY_f193a5de-c9da-4518-9c02-4594f33f1b0b">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTQtMS0xLTEtNDcyMjY_4468b775-fb91-4d9f-8637-0c274c96c08b">913</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTQtMy0xLTEtNDcyMjY_1c3ad139-321c-4296-b49a-31d6ac20c786">951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTUtMS0xLTEtNDcyMjY_896b69d6-32ba-44f6-b4c1-f264135f306f">43,680</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTUtMy0xLTEtNDcyMjY_05e3cdc6-a000-44be-a46e-b2137ba26401">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTktMS0xLTEtNDcyMjY_0d0e6225-ad41-4363-bd06-b2c4cf943aa5">24,759</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTktMy0xLTEtNDcyMjY_d5b4ac86-9b04-459c-99b8-24f7f3d82e38">23,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjAtMS0xLTEtNDcyMjY_238188f8-5866-4c52-9f7b-7ed76bead861">301</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjAtMy0xLTEtNDcyMjY_346acd72-183f-4a42-92ce-62fb715e3ec8">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjEtMS0xLTEtNDcyMjY_8ac285c6-7a68-4d03-a31d-c1cf153d4c3f">2,669</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjEtMy0xLTEtNDcyMjY_f25a49a6-09d0-4999-a764-920e26274820">2,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjItMS0xLTEtNDcyMjY_9cfd6462-2db1-431d-86b2-e32d1943b404">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjItMy0xLTEtNDcyMjY_33409db7-329f-465a-b9ed-302b510542c3">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjMtMS0xLTEtNDcyMjY_e683e3d2-4652-4ad0-a620-63cdf26a3794">27,729</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjMtMy0xLTEtNDcyMjY_d90941d0-e263-4f04-ba18-88216ff31d7c">27,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjUtMS0xLTEtNDcyMjY_7fe6c725-00fa-4877-806a-24ea602604d2">5,342</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjUtMy0xLTEtNDcyMjY_729c1501-7d4a-4f0f-b89a-a607ca742e3f">5,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjYtMS0xLTEtNDcyMjY_d9543620-8c38-44e8-8558-3f8b67f68c48">9,607</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjYtMy0xLTEtNDcyMjY_6a3328b9-6bd5-407f-9bcd-0494a34e8b22">9,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8xNQ_11b4cc79-b576-4e1a-9044-81120b4bdfc3"><ix:nonFraction unitRef="shares" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8xNQ_2a8e9401-7492-4edf-aa88-62e078bcaeb4">500</ix:nonFraction></ix:nonFraction> thousand shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8zMw_2ba74721-572e-4711-b573-8d255ef5edf5"><ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8zMw_709cea3a-2643-4331-94bc-5506aa868197">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMS0xLTEtNDcyMjY_ff7d329e-0698-4a29-b5ee-d5e4e9765286">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMy0xLTEtNDcyMjY_c04a8417-f473-4c9e-add2-99dabbce4fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18xNg_b1dba955-1fe0-4655-bf91-9aebfc9fe241"><ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18xNg_ff8a2387-a65d-4d40-80a2-b0fbb32cdfb2">755</ix:nonFraction></ix:nonFraction> million shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18zNA_5224094e-e339-477b-b9ed-4d8f0b8c5538"><ix:nonFraction unitRef="shares" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18zNA_703cd52e-7634-42e0-b77f-0d81253bd9ae">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMS0xLTEtNDcyMjY_abfe37cc-3894-4d17-920b-1bba5f63e604">2,721</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMy0xLTEtNDcyMjY_de6a1dcb-2212-47c3-8bad-85961971d6b2">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzMtMS0xLTEtNDcyMjY_ad3b3241-4383-4c90-b521-4fad951559ca">1,245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzMtMy0xLTEtNDcyMjY_f1ab5242-700b-4165-9b19-f30ed3adeeb6">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common shares in treasury, at cost: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0NTU2YzFhNDZkZTA0ODAzODczMGUwMjQ2MTYzYmRlOV80MQ_b9364d76-541a-4f33-aa56-cc9d331b7dd4">50</ix:nonFraction> million </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shares and <ix:nonFraction unitRef="shares" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0NTU2YzFhNDZkZTA0ODAzODczMGUwMjQ2MTYzYmRlOV81Ng_1a940049-352a-461c-b92b-758d43fec979">36</ix:nonFraction> million shares at</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> December&#160;31, 2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMS0xLTEtNDcyMjY_024ebd54-8c48-4916-a75b-f16521d260ee">2,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMy0xLTEtNDcyMjY_e6023588-e95c-4950-90f4-8ba13b975c75">2,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzUtMS0xLTEtNDcyMjY_0da633f4-3feb-4b54-9663-ca181050d839">85</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzUtMy0xLTEtNDcyMjY_8b458751-2ecb-4622-bd3e-90f10d2b0e43">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzYtMS0xLTEtNDcyMjY_65fa8986-9a94-42aa-9932-c3ce9c88d207">998</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzYtMy0xLTEtNDcyMjY_869a9c4f-b94e-4631-8877-773f9a5e273a">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzctMS0xLTEtNDcyMjY_afe6f533-271a-4a00-a5e8-71a6b57c4e76">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzctMy0xLTEtNDcyMjY_33b6ea6e-01ae-48e7-9d50-0ac9ba98fc05">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzgtMS0xLTEtNDcyMjY_a78422ab-e979-4802-aff6-d28ee6017152">1,002</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzgtMy0xLTEtNDcyMjY_3cc29855-f3e7-4b49-ab5c-64565f400e4f">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzktMS0xLTEtNDcyMjY_d6e91355-02d5-4909-85b9-a0c951abd643">43,680</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzktMy0xLTEtNDcyMjY_2cd8fcdb-31ee-46d6-b91e-011d7bfb52bd">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Equity</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7986a43d300d47c7b6781e8e97cd047e_I20210930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xLTEtMS00NzIyNg_b5462808-bb11-4c75-af56-a96d8bf2e213">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7986a43d300d47c7b6781e8e97cd047e_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0zLTEtMS00NzIyNg_8ea26423-ec54-4a90-9337-d0e10788bb52">2,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4dc68631d57443d8738c75aa59831eb_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy01LTEtMS00NzIyNg_be3c188d-a747-4ffb-a056-0685b962506a">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7dbe5b201c74f1b89a35df6592c99e4_I20210930" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy03LTEtMS00NzIyNg_e8d03adf-dbaa-400d-80c7-75b9f81ec604">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7dbe5b201c74f1b89a35df6592c99e4_I20210930" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy05LTEtMS00NzIyNg_6444be0b-f0f7-43ca-8a5a-145381a87a7c">2,547</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iada0f823a0f947a3a53d2ee1b5d23237_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xMS0xLTEtNDcyMjY_45b6f0e0-e30d-4d43-9b4b-ee1d0b332304">61</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db9ab51c3284580bbffafef36fcd2aa_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xMy0xLTEtNDcyMjY_86edecae-8bb5-4972-bff8-40187496f5a9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ee4fa253c140b78f57a286ba3fd59b_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xNS0xLTEtNDcyMjY_f558c8d7-996e-48f2-9e64-da29dc8fc87e">1,396</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNC01LTEtMS00NzIyNg_f4d0f4d1-b1be-402e-881b-0ed0ffc7b290">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a82ec00b448529c5c4233322d86fa_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNC0xMy0xLTEtNDcyMjY_2c5192ea-4bde-45e0-98b1-9efa1528ca31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNC0xNS0xLTEtNDcyMjY_4c440ecb-1937-4cda-8194-f6847551910d">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNS0xMS0xLTEtNDcyMjY_3a5cb8d0-558e-42f5-adaf-18716b4e47a1">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNS0xNS0xLTEtNDcyMjY_43df1be7-888d-4928-82f2-8c4ea935cd58">24</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy0xLTEtMS00NzIyNg_88fbec25-2ce0-413d-89fd-a36a168eaf30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy0zLTEtMS00NzIyNg_f72d9406-ee4a-423c-b176-d0da360a8324">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231" xsi:nil="true" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy03LTEtMS00NzIyNg_15a444bf-9e42-4655-9274-8b68b78cb830"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy05LTEtMS00NzIyNg_da1d505e-3ffb-4ac2-8133-8f4bdbdca246">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy0xNS0xLTEtNDcyMjY_7e4be696-88f4-4fab-b6f9-8cf6e09587eb">19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC0zLTEtMS00NzIyNg_8f30dbc4-3aef-4de1-9439-c88a6bcb7dec">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC03LTEtMS00NzIyNg_6b5d61bf-8436-46c9-98f1-aaf279ca8bdc">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC05LTEtMS00NzIyNg_b4e98091-7ef0-4f32-8f85-d231ab2e9fe6">340</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC0xNS0xLTEtNDcyMjY_e1ab3b5f-1929-4b53-8603-a528a3f3dbd8">300</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icead1849b2874394884eddb24215c104_D20211001-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOS01LTEtMS00NzIyNg_fd6d1de3-1bfb-4421-a226-c37c75c1311d">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOS0xNS0xLTEtNDcyMjY_81318d36-7ab6-45f6-8a1c-727ab839539e">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtMy0xLTEtNDcyMjY_44329c5d-283a-4de0-bb90-1177fa7b0337"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icead1849b2874394884eddb24215c104_D20211001-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtNS0xLTEtNDcyMjY_f0c25d36-60ae-4dca-9997-4fd5a2d7b2b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtNy0xLTEtNDcyMjY_6bdcb543-72b1-4f4d-9cba-d81e3922935d"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a82ec00b448529c5c4233322d86fa_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtMTMtMS0xLTQ3MjI2_bb653d6b-e929-4697-ae32-fe4d8639a20c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtMTUtMS0xLTQ3MjI2_3c885858-e6a2-4e88-b825-822fbda8b331">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMS0xLTEtNDcyMjY_79d5a720-7642-4798-8954-8fdd2785f429">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMy0xLTEtNDcyMjY_b72aeee3-b366-4704-87f1-b5e9e1eaafdc">2,721</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1422fa549c8c4fd78d87a5e7bddef0cb_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItNS0xLTEtNDcyMjY_cce56877-c054-449b-aa01-903bb646e214">1,245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItNy0xLTEtNDcyMjY_771aaaa1-1747-4852-a5b5-46f08665da77">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItOS0xLTEtNDcyMjY_bb0ad5b3-6254-416d-bdee-a4058cc7c679">2,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b36454ae8f34474b633982b25f47ddf_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMTEtMS0xLTQ3MjI2_9265a0fe-ac6b-41d8-b1f4-a6dabf63b3b4">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f5c033b2b34568b248de95ea9ae8d7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMTMtMS0xLTQ3MjI2_6647d893-435c-4ec8-99f1-98656dcc377d">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMTUtMS0xLTQ3MjI2_f9f3dd51-cf5b-414c-ac76-ae7ee0b94d11">1,002</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc0f360bdd494ffaacb98ba69e7d9980_I20200930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xLTEtMS00NzIyNg_44dfd6af-6e34-4697-81a1-ad821322cfcb">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0f360bdd494ffaacb98ba69e7d9980_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0zLTEtMS00NzIyNg_8c83b7fb-86a9-4525-a173-0427fee1659b">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7f983dad174a65a853a11d93cbf864_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS01LTEtMS00NzIyNg_828b3aed-e6b7-46dc-a4bd-69b0d0404c99">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i21dcf5c494534e31b313419407cf51a9_I20200930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS03LTEtMS00NzIyNg_4b411a53-65c6-42c1-937d-48def336b0a5">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21dcf5c494534e31b313419407cf51a9_I20200930" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS05LTEtMS00NzIyNg_237d0a39-3e6f-464f-b885-72c12eefdee2">2,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia792665ddedb4fd1be35d86aaee95caa_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xMS0xLTEtNDcyMjY_493026df-8829-4de5-b48b-54fb99867825">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5840b125eaa8414f900e6f2f22ba8df4_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xMy0xLTEtNDcyMjY_a60af51d-9d72-4d1d-8fa9-f00010393545">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d4a4c75a9a47f69d54b19dbcb1e52b_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xNS0xLTEtNDcyMjY_9d1a636d-d5b6-4c7e-bce2-002bac6f9bfd">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMi01LTEtMS00NzIyNg_4d1a5326-ddae-4485-8783-fbc193eb5c3a">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3118c657b147452e88b2cb76079e167a_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMi0xMy0xLTEtNDcyMjY_678141ae-a0a1-4076-b6dc-b009d92be3e4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMi0xNS0xLTEtNDcyMjY_410f8591-f2bb-45fd-943c-b7bf4917ee9f">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib353deb7360145ecb2e83ab126e17961_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMy0xMS0xLTEtNDcyMjY_0f306fc3-1a88-48db-83d2-d19137a57c7d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMy0xNS0xLTEtNDcyMjY_13c33558-ffce-435a-aaca-2d9b160b7e55">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS0xLTEtMS00NzIyNg_4cd97e58-8047-41bf-bef1-3a81d9a1500a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS0zLTEtMS00NzIyNg_995ff222-4e20-4d94-aa5c-3135865fd01c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00621486915144c58fbb572a1f95a310_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS03LTEtMS00NzIyNg_efefa1d4-f61e-47b2-b9c8-f3e0fe1a2bb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00621486915144c58fbb572a1f95a310_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS05LTEtMS00NzIyNg_86ce7e8c-f736-43be-8887-6c51cea6a6ad">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS0xNS0xLTEtNDcyMjY_73086a45-b5a2-4910-912c-0d5f6e43d9b7">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b596c976f3b4341a633bdc33702ce6d_D20201001-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNy01LTEtMS00NzIyNg_c73d0ee6-d399-4f53-96b1-7de00f8e28bf">144</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNy0xNS0xLTEtNDcyMjY_2f594da4-b97f-41df-9766-1d156df950ac">144</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC0zLTEtMS01OTIzOA_448c3e49-41b7-4c11-a6db-3ba3618cbfb4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b596c976f3b4341a633bdc33702ce6d_D20201001-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC01LTEtMS00NzIyNg_e6b71460-affd-4bd4-a5b4-bbb3f43c7975">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3118c657b147452e88b2cb76079e167a_D20201001-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC0xMy0xLTEtNDcyMjY_8ca13d44-3932-4897-8d56-e580e927a82d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC0xNS0xLTEtNDcyMjY_2fb07d14-cacf-4a87-a28f-ee8b48e6fefa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMS0xLTEtNDcyMjY_f1c8699b-84f7-4825-b67e-f516cd9657be">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMy0xLTEtNDcyMjY_3c493cbd-c2ca-4a0a-9cb5-f62591f8ec4e">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abc0866cbe848d3893f1f444f75cfc0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtNS0xLTEtNDcyMjY_cc12274a-2079-4c48-9ea7-edf11570ae96">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtNy0xLTEtNDcyMjY_22c0d499-c2c4-4a19-b762-755c56288820">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtOS0xLTEtNDcyMjY_221caf7d-3350-4d9a-87f6-2296a793dd81">2,009</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30ee22a4b8ab44809caa91d6c1c1eeaf_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMTEtMS0xLTQ3MjI2_091401b0-25c8-4073-9a13-dfcf1eb9a723">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12e7de7ce1574c48a5037263df2cd692_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMTMtMS0xLTQ3MjI2_3be0f9d2-c2ec-433d-a67f-ebe2534a355d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15c5d3332d947399180c64379abbaad_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMTUtMS0xLTQ3MjI2_4b746441-d771-4263-8591-cf7e934f192c">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7eb92e4042fd492b81f82838ab7dfa53_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xLTEtMS00NzIyNg_b2361bc1-0e7c-49f7-b8d3-fb7dabd8db8d">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb92e4042fd492b81f82838ab7dfa53_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0zLTEtMS00NzIyNg_8e354a2a-b0ea-461b-83f5-c937f2d5b0ce">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4ca91c9613414a94f9900f8909af66_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy01LTEtMS00NzIyNg_5e677403-2700-48b6-bf8d-c6d336090a85">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8ed791e44eac4a27bd9c7d44a85d03fb_I20210630" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy03LTEtMS00NzIyNg_c581fcfc-84ba-4e2d-973d-d3021eff7291">36</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ed791e44eac4a27bd9c7d44a85d03fb_I20210630" decimals="-6" sign="-" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy05LTEtMS00NzIyNg_0e03c227-75d6-4dfa-b67e-aebd50361566">2,186</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeeec8b34c774e7b9466d999568a65a0_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xMS0xLTEtNDcyMjY_1d2ee540-8f98-4043-a77f-bc229c8b2e06">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2689810533ba4608b106bf844d197fb4_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xMy0xLTEtNDcyMjY_9ceba5ea-6127-42b9-9a6d-39fc108ad5ec">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xNS0xLTEtNDcyMjY_16e0542e-353a-4dc9-add8-6d48a35f9157">1,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNC01LTEtMS00NzIyNg_96f44a9b-1e7d-4481-a3ab-61d1eda25139">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247ac8c144e2402e9b7a5cdf73e42b35_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNC0xMy0xLTEtNDcyMjY_e5aabae2-816f-48cc-9ed7-080dd0b8d2f2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNC0xNS0xLTEtNDcyMjY_96a93bdc-a3d0-40ad-b648-7c956214d33a">321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNS0xMS0xLTEtNDcyMjY_861559ca-e990-4476-8d47-1bcbf840494a">51</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNS0xNS0xLTEtNDcyMjY_9629d886-2239-44cc-8a64-f4000a8f45fb">51</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy0xLTEtMS00NzIyNg_bb7eb49d-7374-4ef7-8991-73b9e30e62ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy0zLTEtMS00NzIyNg_077785a8-284b-4230-a250-de3b4bdf704b">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy03LTEtMS00NzIyNg_4775b011-8b56-414e-954b-f6ac9515c59d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy05LTEtMS00NzIyNg_daba13f8-0d0f-473e-9cb6-64404aabba12">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy0xNS0xLTEtNDcyMjY_794d5ea2-79a6-4265-8fbb-1b4d72f11dce">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC0zLTEtMS00NzIyNg_7e664dcf-6345-4ef6-97d4-3b6903342926">60</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC03LTEtMS00NzIyNg_332f5f78-5b10-4385-8d3f-72a3c48ae212">15</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC05LTEtMS00NzIyNg_a3574cb4-20a7-4dd4-adac-ebf2d192dfc7">740</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC0xNS0xLTEtNDcyMjY_324d05da-c7a2-4a94-8f9e-5d83b50eb36b">800</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72771dd6f35d4ef389cc86b92183c631_D20210701-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOS01LTEtMS00NzIyNg_a45db2ea-f640-4c1a-81af-77f452bba7b5">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOS0xNS0xLTEtNDcyMjY_e93f11af-24b2-46a1-a313-827f7af5fbcc">280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72771dd6f35d4ef389cc86b92183c631_D20210701-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtNS0xLTEtNDcyMjY_71f74dd9-e1c4-41f9-855b-69f67fa219ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtNy0xLTEtNDcyMjY_53fc3d29-7683-4816-b56b-5ebc6e5afc6c"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247ac8c144e2402e9b7a5cdf73e42b35_D20210701-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtMTMtMS0xLTQ3MjI2_7a6e2b87-1400-415e-b2ad-af7578307572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtMTUtMS0xLTQ3MjI2_e4bb478f-7485-4a07-9d86-8c43c94dc3b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMS0xLTEtNDcyMjY_8f975390-b47c-4b17-9450-fefea6f035ab">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMy0xLTEtNDcyMjY_8e71ac3a-a313-4b2f-aecf-8161f5fae651">2,721</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1422fa549c8c4fd78d87a5e7bddef0cb_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItNS0xLTEtNDcyMjY_e46015cb-c15d-4815-8396-a2af952a9bd7">1,245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItNy0xLTEtNDcyMjY_15553481-09a8-4b55-8b62-42a3798531c1">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItOS0xLTEtNDcyMjY_ffc4570b-61c9-4574-bfbf-e13645b38f04">2,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b36454ae8f34474b633982b25f47ddf_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMTEtMS0xLTQ3MjI2_422ee3fb-da72-4cb0-bc54-30138ac97125">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f5c033b2b34568b248de95ea9ae8d7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMTMtMS0xLTQ3MjI2_353821fb-8d72-462e-96cf-043f12b71319">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMTUtMS0xLTQ3MjI2_3d53c03d-b01a-4f9e-9211-5f426f7df3a5">1,002</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if521936d67844e53ad65faa8fee63ccc_I20200630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xLTEtMS00NzIyNg_0484d611-1720-4988-bc20-c75c077a623c">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if521936d67844e53ad65faa8fee63ccc_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0zLTEtMS00NzIyNg_6e3e6e50-ceca-4020-993c-889a0ecd7e8e">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81fff506366476385ee6cedef0c063c_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS01LTEtMS00NzIyNg_1c8c5a89-71e1-410b-b1de-792d1beaea71">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i09481b076c1d445abdc3ed3a80f5911a_I20200630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS03LTEtMS00NzIyNg_35357e72-2506-4ed9-b2f7-d621d746005b">35</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09481b076c1d445abdc3ed3a80f5911a_I20200630" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS05LTEtMS00NzIyNg_44ab30ae-95c1-4bd5-90aa-b58e7c353b9e">2,066</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia20d6610e65a457a868d48435b845bbf_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xMS0xLTEtNDcyMjY_aecf53e1-6c71-4d7b-a4c5-bff99093e7d5">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43dfa1a7cdf74ea793edc03f0339f726_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xMy0xLTEtNDcyMjY_e151c20d-5dfa-48fe-8e37-f61c04ffdfae">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1620d434ff84017a4abba4b2b674fee_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xNS0xLTEtNDcyMjY_571f86c4-da32-4826-900e-b367f4647837">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMi01LTEtMS00NzIyNg_f0d0c6b4-2b0e-44db-8ec3-f8a0258fcb88">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056f47607d66400ab28d51e4b4199aaf_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMi0xMy0xLTEtNDcyMjY_ceb51bcf-4937-4b3c-b7f8-65c2e39f8d37">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMi0xNS0xLTEtNDcyMjY_1edda86e-ff06-455a-82d0-d65ef0da1f84">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i006f51b5845242aab04f6d1e5bd5574d_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMy0xMS0xLTEtNDcyMjY_8939aded-0ef1-4ebe-8ffa-5d74b245ef64">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMy0xNS0xLTEtNDcyMjY_0ec63712-300b-481b-b27f-20cfd7dd8ec2">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25f992d37c9445a39ce463c943d8a4b4_D20200701-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS0xLTEtMS00NzIyNg_b9cd2bf8-7b07-43b6-ab26-421a51b96cb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25f992d37c9445a39ce463c943d8a4b4_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS0zLTEtMS00NzIyNg_0f94909f-058b-40d6-8faf-3630fb88b91c">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6898a41bdf2840358d646c0919f44974_D20200701-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS03LTEtMS00NzIyNg_fa82e931-5701-4abb-bcf9-76504f108f29">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6898a41bdf2840358d646c0919f44974_D20200701-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS05LTEtMS00NzIyNg_6fbfab2a-9ae6-492f-8bd4-34a757b79254">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS0xNS0xLTEtNDcyMjY_ce47f134-61a8-4abf-a959-7cc38b912892">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f438da6cbd845748e199c85aa4cdde7_D20200701-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNy01LTEtMS00NzIyNg_2740e362-a444-4b40-9a23-ac6c8654a4ae">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNy0xNS0xLTEtNDcyMjY_31af18af-601c-4739-948a-14fb9f9033f4">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f438da6cbd845748e199c85aa4cdde7_D20200701-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOC01LTEtMS00NzIyNg_d0499e08-fb1f-4ae2-97cf-4b91cf62c2a0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056f47607d66400ab28d51e4b4199aaf_D20200701-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOC0xMy0xLTEtNDcyMjY_b2787bae-9314-4901-8c2d-f9d344b4696b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOC0xNS0xLTEtNDcyMjY_4cf46bd4-f460-45a2-8cdf-00f5f67769dd">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xLTEtMS00NzIyNg_a0833886-c9a2-4456-a6aa-0510c60fcb19">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0zLTEtMS00NzIyNg_68eaceaf-6abb-4307-b473-1166c043cc93">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abc0866cbe848d3893f1f444f75cfc0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS01LTEtMS00NzIyNg_085639f2-3e3e-48aa-b634-d5c12e4c16be">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS03LTEtMS00NzIyNg_d6b964e9-56d8-4df8-813d-7308a611b20e">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS05LTEtMS00NzIyNg_d0bc5e9e-d977-49ec-9b37-5a3ab0a048b4">2,009</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30ee22a4b8ab44809caa91d6c1c1eeaf_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xMS0xLTEtNDcyMjY_e8c106ba-9297-4348-8f39-0b0c639b1fbd">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12e7de7ce1574c48a5037263df2cd692_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xMy0xLTEtNDcyMjY_45257e8f-7d66-40dc-b947-e878858afe61">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15c5d3332d947399180c64379abbaad_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xNS0xLTEtNDcyMjY_c4ca6bf3-b104-402d-be77-7dbeb29f12fc">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMy0xLTEtMS00NzIyNg_32c3064d-4743-4b0f-bef6-7da34646b842">321</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMy0zLTEtMS00NzIyNg_c1b39db7-ac68-4ba7-86e0-83c5d61dba4b">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNi0xLTEtMS00NzIyNg_1d32073b-8069-4adb-8c0a-6af22d986417">332</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNi0zLTEtMS00NzIyNg_5b66933d-6143-406b-987f-86b190e6ccb1">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/Loss on sale of equity interest in naviHealth</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0xLTEtMS03NTc5NA_f26f159e-b9f4-4355-8c53-8eb4a94ffe07">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0zLTEtMS03NTc5Nw_45013e52-29f1-4039-9bc9-e2d2a552711d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0xLTEtMS00NzIyNg_b94145e3-193a-493a-965c-b01910af1de4">1,293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0zLTEtMS00NzIyNg_c33f3f5b-d36f-49e8-ad21-7bd3ac383b11">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOS0xLTEtMS00NzIyNg_2c0ed403-230d-4907-8147-f624df06d76f">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOS0zLTEtMS00NzIyNg_a1281eca-c8ba-4326-aae9-1b9cc8c01903">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTAtMS0xLTEtNDcyMjY_646b36ec-38f9-4f4d-bb70-859e99f82b46">42</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTAtMy0xLTEtNDcyMjY_ec124612-38f0-463b-a51f-3c87f3f70358">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTItMS0xLTEtNDcyMjY_129814f2-137a-40d1-b90e-76b97e307c00">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTItMy0xLTEtNDcyMjY_8785974a-642a-4336-a0d0-1e5bc784b226">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTQtMS0xLTEtNDcyMjY_cc143305-e61d-42c7-8059-de4add81815e">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTQtMy0xLTEtNDcyMjY_e5a03a82-6749-4550-a5dc-33c91c87fd9a">499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTUtMS0xLTEtNDcyMjY_03df3f82-ae57-4b8d-bf00-d9f4a467f8e7">361</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTUtMy0xLTEtNDcyMjY_0c5a4525-a64e-4e45-8476-08fee58ef50f">1,256</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTYtMS0xLTEtNDcyMjY_c1ee48db-0a44-4750-95ff-814a7eeb903d">1,059</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTYtMy0xLTEtNDcyMjY_90b20e78-a637-447b-baa4-e6864a54156c">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTctMS0xLTEtNDcyMjY_bd45483a-1f7d-4e51-b5a6-1c71c1de9fa4">1,842</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTctMy0xLTEtNDcyMjY_4c7eceee-1be1-4fbd-afc7-e0121f5312bf">504</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTgtMS0xLTEtNDcyMjY_7e3b1844-bd43-4260-b692-2009b30919d4">549</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTgtMy0xLTEtNDcyMjY_4a9d6d0f-7146-442e-95da-ac163249b024">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash transferred, and disposal of property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMS0xLTEtNjA3MzE_c3188336-9894-48ee-bf39-89e26776dd66">938</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMy0xLTEtNjA3MzE_eac1ab0b-0e84-4b12-9557-92b741eb7686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMS0xLTEtNDcyMjY_3d7318a8-387a-4d5b-9a05-8b67167dba01">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMy0xLTEtNDcyMjY_357f9d84-4289-4dac-a715-34f78a7ab096">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjItMS0xLTEtNDcyMjY_598d9d8a-9f08-4fcd-ac09-b8fb21ec7872">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjItMy0xLTEtNDcyMjY_5e6d496a-e08c-4330-a61a-880722dca560">174</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjMtMS0xLTEtNDcyMjY_9cb0ecf4-92f9-4438-9f78-ce01e3cbd84d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjMtMy0xLTEtNDcyMjY_60c4b002-4861-43a4-b7dc-e5e8f8620ecb">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjQtMS0xLTEtNDcyMjY_4847b580-99fc-495b-bf2e-e33041804c7d">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjQtMy0xLTEtNDcyMjY_d5ba404c-668e-4369-b6f2-33b73a7c6710">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjctMS0xLTEtNDcyMjY_6bacd0c6-f5b1-4f1e-9401-55ae669c6088">815</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjctMy0xLTEtNDcyMjY_27bf3044-e131-4c26-9074-72afca4a135d">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzItMS0xLTEtNDcyMjY_4074b3a8-5ebc-41cf-b47a-dbe528f0614d">592</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzItMy0xLTEtNDcyMjY_4c37f356-f937-4eba-ba4c-4c61f2610d81">49</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzMtMS0xLTEtNDcyMjY_f0d1cd6f-ade2-4ad6-8538-e88c497ad30e">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzMtMy0xLTEtNDcyMjY_7111e920-3d0b-4e3a-b700-b60cdcb6af73">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzUtMS0xLTEtNDcyMjY_b758e889-9530-43ba-8c3d-34bb127f5b4c">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzUtMy0xLTEtNDcyMjY_140aad58-1312-4785-9e03-18ed77cad8b7">289</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzYtMS0xLTEtNDcyMjY_64856848-6e87-45e6-a0c7-779dbd2a2d02">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzYtMy0xLTEtNDcyMjY_a92145ed-45c2-4606-a1e4-d597e5790d46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzctMS0xLTEtNDcyMjY_7072fd6c-4e43-404b-b2fe-fc921b100072">1,708</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzctMy0xLTEtNDcyMjY_21866da3-1daa-41e5-88c2-5356e87f7c11">344</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzktMS0xLTEtNDcyMjY_6a24d0d6-cb4e-4bc2-a41d-8d6ff989e471">11</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzktMy0xLTEtNDcyMjY_11c3a831-df3e-4471-9774-f3354cf28edb">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash reclassified from assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDAtMS0xLTEtNDcyMjY_fb74adea-a58d-411b-b1bf-ffbd90aa7047">109</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:CashReclassifiedToAssetHeldForSale" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDAtMy0xLTEtNDcyMjY_d595a1b0-11e1-43a7-8ac8-bce13c6a5bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDItMS0xLTEtNDcyMjY_2f8d4677-4917-4ece-923e-05189e4d0447">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDItMy0xLTEtNDcyMjY_a4d71062-70f6-45ec-a2df-9623e0c008c3">966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDMtMS0xLTEtNDcyMjY_01dadc52-80cf-4aa9-a458-dd6619935b9e">3,407</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1620d434ff84017a4abba4b2b674fee_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDMtMy0xLTEtNDcyMjY_1ca467fc-1f1d-4a40-8e47-693b7ac44240">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDQtMS0xLTEtNDcyMjY_11985bf1-dd4b-4626-9efc-7ddc73fc8478">3,161</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15c5d3332d947399180c64379abbaad_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDQtMy0xLTEtNDcyMjY_7752529a-2d2b-4c16-8743-d7fef0c0bbc0">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_82"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84Mi9mcmFnOjg3NjNmMzhjNjBjMTQxMDhiOGFmODEwODFhOTg3MGQzL3RleHRyZWdpb246ODc2M2YzOGM2MGMxNDEwOGI4YWY4MTA4MWE5ODcwZDNfMzY4Mg_f1fc814d-5077-423f-bbd5-e323658889c0" continuedAt="i27ed503c331847cca20ab35928e21b08" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84Mi9mcmFnOjg3NjNmMzhjNjBjMTQxMDhiOGFmODEwODFhOTg3MGQzL3RleHRyZWdpb246ODc2M2YzOGM2MGMxNDEwOGI4YWY4MTA4MWE5ODcwZDNfMzY4MA_5e538940-9c98-4bd0-a790-ea004ec438a2" continuedAt="i7090e4b559e745428aa92206407fd0f4" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i27ed503c331847cca20ab35928e21b08"><ix:continuation id="i7090e4b559e745428aa92206407fd0f4"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84Mi9mcmFnOjg3NjNmMzhjNjBjMTQxMDhiOGFmODEwODFhOTg3MGQzL3RleHRyZWdpb246ODc2M2YzOGM2MGMxNDEwOGI4YWY4MTA4MWE5ODcwZDNfMzY4Ng_1eaf0828-5ef7-4b5f-be59-35652a26b26c" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the six months ended December 31, 2021.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_85"></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84NS9mcmFnOmY3OThiOWQ0NjBmYjQwNjk5MTA5YTU1ZjUxNzIxYjA3L3RleHRyZWdpb246Zjc5OGI5ZDQ2MGZiNDA2OTkxMDlhNTVmNTE3MjFiMDdfMjUwNQ_66f3189c-24df-47c8-a749-b8bc16a7eeb6" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84NS9mcmFnOmY3OThiOWQ0NjBmYjQwNjk5MTA5YTU1ZjUxNzIxYjA3L3RleHRyZWdpb246Zjc5OGI5ZDQ2MGZiNDA2OTkxMDlhNTVmNTE3MjFiMDdfMjE5OTAyMzI1ODE0Mw_1624bf29-0c84-4c51-a82b-88be72345f3b">927</ix:nonFraction> million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">No</a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">te</a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103"> </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RleHRyZWdpb246OGFkMTRiYzlmNTBlNGI2NmI5MmU1ZWRkYTEzN2JkY2RfMTExNQ_a2e8268c-3789-429a-9428-b016b29f641e" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RleHRyZWdpb246OGFkMTRiYzlmNTBlNGI2NmI5MmU1ZWRkYTEzN2JkY2RfMTEyMg_6379577c-5ef2-4041-842c-9ccb2b8c198e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMi0xLTEtMS00NzIyNg_32cc95ce-1b9a-4dba-8f5d-1121b29e8a93">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMi0zLTEtMS00NzIyNg_deb46a8c-3db1-4e6e-9e04-b32c100e41b5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMy0xLTEtMS00NzIyNg_0e1e4fa9-9311-4cd5-bf57-d394b3e9a5cf">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMy0zLTEtMS00NzIyNg_f752ecde-51c2-4faf-a03e-62bb947fa065">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfNC0xLTEtMS00NzIyNg_0d33bb3e-3f56-4003-bdd6-fd3c62213b94">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfNC0zLTEtMS00NzIyNg_c1fbe86c-6c39-45d9-8d80-1bde2605b146">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMi0xLTEtMS00NzIyNg_8b364fa2-9170-4d8f-b52d-ca5d82c0289f">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMi0zLTEtMS00NzIyNg_c6ee7f6c-0897-484b-935e-cd162d094d5e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMy0xLTEtMS00NzIyNg_612ef0f3-d23e-4bcf-8ead-f3db230ef9ed">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMy0zLTEtMS00NzIyNg_342d1e0d-46a6-45d5-8d5e-f60301035e33">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfNC0xLTEtMS00NzIyNg_f02371ea-66aa-4f4d-9d34-c77e442f4d10">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfNC0zLTEtMS00NzIyNg_f59ad1b9-909f-4e30-94b2-b7b7f9aa16cb">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and six months ended December&#160;31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three and six months ended December&#160;31, 2021 also included costs related to the divestiture of the Cordis business. </span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RleHRyZWdpb246OGFkMTRiYzlmNTBlNGI2NmI5MmU1ZWRkYTEzN2JkY2RfMTExMg_2ee5176b-e56d-40b0-ba1a-e7d3710a408f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689ae4253cf44b73ac84db72214af2a4_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMS0xLTEtMS00NzIyNg_446ee48e-240c-4171-be93-9ff7f561f263">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6d5f06ee3664cac9f54724c815b9d73_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMS0zLTEtMS00NzIyNg_42b4be39-7ef0-4d48-b17c-f6cf4b88582d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMS01LTEtMS00NzIyNg_3968e6e1-2216-469f-a656-31919a9c0ca4">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4761d672de014c8e9dad6c7102688227_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMi0xLTEtMS00NzIyNg_731f4a2a-e315-4a69-aeba-bfaa76b65420">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b760199824642c0a8d322009fa28dcc_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMi0zLTEtMS00NzIyNg_9460a4c7-2e83-4da7-b046-2b92e42b277a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMi01LTEtMS00NzIyNg_1e78fb94-8f1b-455b-a5d3-133f8370b333">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4761d672de014c8e9dad6c7102688227_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMy0xLTEtMS00NzIyNg_597df185-75f0-4033-91f3-e7078134eeea">25</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b760199824642c0a8d322009fa28dcc_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMy0zLTEtMS00NzIyNg_1ca3030c-e06e-4b0a-bbbe-4aad749d88e9">9</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMy01LTEtMS00NzIyNg_3c3651ab-a785-4d6d-b3ce-c6ecc8d3538e">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485b4945d9224029a35f582637d5d038_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfNC0xLTEtMS00NzIyNg_8ceeb66a-4064-484a-92fc-e8532a70c3b0">44</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54300086ab194a77aea92977e16df53b_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfNC0zLTEtMS00NzIyNg_985429a6-883c-4d20-9a31-6e8c3a5ebb6a">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfNC01LTEtMS00NzIyNg_c6d9bea7-066a-40d7-8e17-e27f5e5a64d3">62</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="i6bdf7a21332a418cb7d5503f4cc4365e_91"></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTExNA_539c1932-52a8-4778-9f29-750856a01ccb" continuedAt="i511e1dd6059a46519171e95fe59f9f64" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTEzMw_d785ab1d-50fb-4004-a3f1-f0c27a5c6bfb" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db397a74a1042b9aafec1289ddba925_I20210630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMS0xLTEtMS00NzIyNg_7234de77-d0e6-44ca-9fd0-6d46cbfb4cb8">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066955108bab4e7e95ad3b02cf4ef347_I20210630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMS0zLTEtMS00NzIyNg_f7e1802d-8fca-4951-b74c-b38691fe6748">5,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMS01LTEtMS00NzIyNg_ea9eba39-e667-4939-8338-e943f00e2756">7,989</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7745fb78df449faba2302b50698592_D20210701-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMi0xLTEtMS00NzIyNg_2ac0b219-09ae-40bd-a003-b521b4f2be73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6dedadffb54d5285c2b49eea80de65_D20210701-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMi0zLTEtMS00NzIyNg_598b5e3c-d468-4ea5-8c56-796ddcd0917b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMi01LTEtMS00NzIyNg_36268ce2-9de9-43f3-97c3-31f9d1f67567">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7745fb78df449faba2302b50698592_D20210701-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMy0xLTEtMS00NzIyNg_c95e8192-2b2f-407a-aea7-d91cdd0bb291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief6dedadffb54d5285c2b49eea80de65_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMy0zLTEtMS00NzIyNg_63a25188-3add-4766-b571-2270e9ea49b6">26</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMy01LTEtMS00NzIyNg_83d989ee-b0b5-489b-8641-f0405d5bfa19">26</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa7745fb78df449faba2302b50698592_D20210701-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNC0xLTEtMS00NzIyNg_717dc63b-9e39-4cf2-9a7b-67ee767c95f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3492d85ea7b24e60910262ee6d3033ee_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNC0zLTEtMS00NzIyNg_70c63a57-a9a5-4c97-a398-54dc8d68b2bf">1,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNC01LTEtMS00NzIyNg_31aaa87c-2eb0-40e0-984f-a9e0e431f07f">1,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39aff34d5814c78ac189de6dab4b7ce_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNS0xLTEtMS00NzIyNg_1604f72a-97f0-4ccb-b445-5dbe8da08a6b">2,659</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie965b585dfd74a75884609384471b2b7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNS0zLTEtMS00NzIyNg_8a0a803f-d01a-4344-895b-3283b84b7a2b">3,997</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNS01LTEtMS00NzIyNg_b387ccc2-4123-4ffa-a6e4-2a0820a24a5b">6,656</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2021 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="i1db397a74a1042b9aafec1289ddba925_I20210630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUzNQ_348f92ed-3a66-401c-9584-33e23d50c1ce"><ix:nonFraction unitRef="usd" contextRef="ie39aff34d5814c78ac189de6dab4b7ce_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUzNQ_4dc902c6-1583-4b2d-b1be-9465605f1475">829</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2021 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $<ix:nonFraction unitRef="usd" contextRef="ie965b585dfd74a75884609384471b2b7_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUyMQ_b7286b45-772d-43e5-b0c8-4f4c43948fed">2.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i066955108bab4e7e95ad3b02cf4ef347_I20210630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUwNw_62a53e65-3774-4a7b-819e-5efaf6cc1a16">1.4</ix:nonFraction>&#160;billion, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2021, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment and perform interim goodwill impairment testing for the Medical Unit. This quantitative test resulted in a pre-tax $<ix:nonFraction unitRef="usd" contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNDM5ODA0NjUyMzQ5Ng_6332aef6-cd71-4abc-8723-b09b71db798c">1.3</ix:nonFraction>&#160;billion goodwill impairment charge related to the Medical Unit, which is included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings. The goodwill balance of the Medical Unit, after recognizing the impairment, was $<ix:nonFraction unitRef="usd" contextRef="ic6990beeb1e8488aa56f362d54b5ae9d_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDQ5Mw_1447ebce-081f-4ac9-84bc-29f51966dd05">2.8</ix:nonFraction>&#160;billion at December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of estimated fair value of our reporting units is based on a combination of the income-based approach (using a discount rate of <ix:nonFraction unitRef="rate" contextRef="iaf07a0233e7740e1b2eaf72c788bc28f_D20210701-20211231" decimals="2" name="cah:DiscountRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDU0OQ_9428df11-b575-4022-adae-c116c3f22456">9</ix:nonFraction> percent and a terminal growth rate of <ix:nonFraction unitRef="rate" contextRef="iaf07a0233e7740e1b2eaf72c788bc28f_D20210701-20211231" decimals="2" name="cah:TerminalGrowthRateFairValueInput" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDU1NQ_fa4be533-c20d-4bab-bbea-f0ec971befba">2</ix:nonFraction> percent percent), and the market-based approach. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i511e1dd6059a46519171e95fe59f9f64"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTEzNQ_931dcb75-b262-4602-a08b-4746ab16a649" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7b338780e74021a81ef74ef08b7a25_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMy0xLTEtMS00NzIyNg_8468ae88-5390-4fcf-8c68-e8ea7a117b81">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7b338780e74021a81ef74ef08b7a25_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMy01LTEtMS00NzIyNg_cfb9eb11-4ffb-45cd-b3ab-d9dd7b8f0863">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNC0xLTEtMS00NzIyNg_1593cd82-ad8a-4094-8152-573fac7ac53f">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNC01LTEtMS00NzIyNg_5e291c48-5f30-4aa0-b7bd-45cb59343a1e">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bebd2a91ae417eb4439959bf9f6d31_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy0xLTEtMS00NzIyNg_fbab86e7-d962-4eae-b276-da1948c36fe7">3,317</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bebd2a91ae417eb4439959bf9f6d31_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy0zLTEtMS00NzIyNg_e4d7e821-5cef-4c98-9323-b0f60d29c73f">2,089</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77bebd2a91ae417eb4439959bf9f6d31_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy01LTEtMS00NzIyNg_e70cf81c-02f5-451e-a234-80dc84176aad">1,228</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i823151805e0f490888d034841f637bc5_D20210701-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy03LTEtMS00NzIyNg_0c2030d2-6aba-4980-aa9e-6d4830dd7001">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505ef6105727459882cd4fed2648f6c1_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC0xLTEtMS00NzIyNg_4e6ddca0-98bf-4362-b591-8c5ab916e9d2">552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505ef6105727459882cd4fed2648f6c1_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC0zLTEtMS00NzIyNg_4e46f15a-eab0-4f14-acd1-33a6cd702916">344</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505ef6105727459882cd4fed2648f6c1_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC01LTEtMS00NzIyNg_4077281b-01b3-4c6a-9e64-13964cb90d7c">208</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7a15392899d2482fbb95514624452a8d_D20210701-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC03LTEtMS00NzIyNg_bd8c10d8-c824-4aef-87d1-41374e571d9f">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a85889e6ab440f18e191494e3590714_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS0xLTEtMS00NzIyNg_df88c0ad-92d4-4b7e-a930-3c066dd423ac">1,036</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a85889e6ab440f18e191494e3590714_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS0zLTEtMS00NzIyNg_c97062b6-b787-4a11-80df-e487cf86d936">541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a85889e6ab440f18e191494e3590714_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS01LTEtMS00NzIyNg_a9263eca-922d-4fc0-8c34-860bd8e43fd6">495</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3aa68d96ad1e4049873af142ed3aef39_D20210701-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS03LTEtMS00NzIyNg_1101eede-266e-49ec-a2cf-2945966dab23">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtMS0xLTEtNDcyMjY_5e6645a6-e5fd-4738-9681-3616f02c3a39">4,905</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtMy0xLTEtNDcyMjY_537ec560-f840-4206-a0dc-d999164de512">2,974</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtNS0xLTEtNDcyMjY_cb4574cb-7391-49b9-b8c8-7472f41bcd36">1,931</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtNy0xLTEtNDcyMjY_2983b0c2-4ca2-4fa5-aec7-efb2f77b7e4c">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTEtMS0xLTEtNDcyMjY_744765a1-0bed-4814-84f5-ae1561923147">4,917</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTEtMy0xLTEtNDcyMjY_6f638467-9521-4b81-9eb3-4e3c1f8f462c">2,974</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTEtNS0xLTEtNDcyMjY_2ccf4666-2d64-4fd1-838e-37852badf3da">1,943</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5005f9b9f5c748b6b3dc0a951c8577da_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMy0xLTEtMS00NzIyNg_abd57583-a5ff-4c59-9b14-e35984a219e6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5005f9b9f5c748b6b3dc0a951c8577da_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMy01LTEtMS00NzIyNg_58ba23e0-e209-47f9-9826-3fcef55ddaf7">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNC0xLTEtMS00NzIyNg_ee05be38-db98-46cd-a492-2f55463823d9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNC01LTEtMS00NzIyNg_19ac08d0-8bee-4768-a472-4117a32cd404">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab78dc9db493437ebf096a1f66c9842d_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNy0xLTEtMS00NzIyNg_e90ea0d2-0b05-4f15-beec-1ebf11d7b0f4">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab78dc9db493437ebf096a1f66c9842d_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNy0zLTEtMS00NzIyNg_9ada11b5-5c1c-4bbb-825a-278ee66917f9">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab78dc9db493437ebf096a1f66c9842d_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNy01LTEtMS00NzIyNg_32c26ba8-a5f4-4328-afaa-5f8206b61990">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOC0xLTEtMS00NzIyNg_1520e6ff-9743-4f14-a324-b4b1f6ec577c">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOC0zLTEtMS00NzIyNg_88676d5c-0d1a-482e-bdbf-1367fbff2858">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOC01LTEtMS00NzIyNg_13ae84d2-c547-4c04-b773-3bdc9e23c358">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a260218f5c74e0a818560db3bc26ab5_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOS0xLTEtMS00NzIyNg_6136b76d-c391-4750-a6a0-83e22ece55b1">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a260218f5c74e0a818560db3bc26ab5_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOS0zLTEtMS00NzIyNg_fe4fe31a-bfd5-4b1e-83fa-a81cdf98abfb">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a260218f5c74e0a818560db3bc26ab5_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOS01LTEtMS00NzIyNg_5ddc31db-073e-47db-bea3-b5209a70888c">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTAtMS0xLTEtNDcyMjY_46996364-704f-4fc0-baf9-206213237004">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTAtMy0xLTEtNDcyMjY_d30cae1b-0e6c-4d55-8464-e362ba49c770">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTAtNS0xLTEtNDcyMjY_e7f9bb83-7e28-4d4b-aeef-e9c8b7e98bff">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTEtMS0xLTEtNDcyMjY_b516d8c5-3769-47cd-bfeb-c693aa32a5b6">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTEtMy0xLTEtNDcyMjY_92ff6174-8c6f-4cea-b78a-edfd4a23886a">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTEtNS0xLTEtNDcyMjY_c51096ab-843a-4f80-8dc8-93d3ca3f42f5">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNjU5_ab106d74-7450-489f-bf24-4cc7741a57e7">79</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNjY2_4d3af82d-9b2c-43a0-839b-ba2b42dfad4a">113</ix:nonFraction> million for the three months ended December 31, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNzI1_a00bd5f6-c368-4371-be48-25d82a69d506">157</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNzMy_69f39c53-37e0-40fb-830b-8b76375274e2">228</ix:nonFraction> million for the six months ended December&#160;31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODc5_b405f7d1-2b7a-4c30-87cf-5690df68adc5">157</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODgz_c83a583e-f945-4872-9b97-26a710862f9f">286</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODg3_8acd32b8-4209-4671-8438-9780c4ab655a">262</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODkx_3043f048-c80b-4572-8662-735ac8c6244b">237</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODk4_420fd482-ba25-4be2-962c-17ea04f302a9">210</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="i6bdf7a21332a418cb7d5503f4cc4365e_100"></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIzNDg_7ac5fc54-6d80-4b3b-bc69-dcbedc66cf21" continuedAt="i0dec945dab7c4762bc9591ce03471350" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-8" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTgwMTI_89df79b8-a148-4d9f-aebd-3ca2dda6dae6">5.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-8" name="cah:TotalLongTermandShortTermObligations" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTgwMjA_30198895-1a96-45f6-b642-f3b80535172a">6.2</ix:nonFraction> billion at December&#160;31, 2021 and June&#160;30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzU1Nw_c60717bf-39ee-4f21-ac3d-f69be7cc4dd3">24.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-8" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzU2NA_bdcda125-44e2-429a-ab60-c2686a314b84">23.7</ix:nonFraction> billion at December&#160;31, 2021 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we redeemed all outstanding $<ix:nonFraction unitRef="usd" contextRef="i7828cce062bc44f0951fdcd8139d81b9_D20210701-20211231" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTgyMDk_30073f49-2161-4ac1-84ad-61762c988c02">572</ix:nonFraction> million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i7828cce062bc44f0951fdcd8139d81b9_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTg0NTY_2e7a4d5d-9542-45bd-ac26-8ac132e370ed">10</ix:nonFraction>&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020, we early repurchased a total of $<ix:nonFraction unitRef="usd" contextRef="i88e4b2aae2ad40a09418ad56348b3b01_D20200701-20201231" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzcxNDY4MjU1ODUzMDI_0f566414-52f5-416c-97a5-673c7a89e650">40</ix:nonFraction> million of the Floating Rate Notes due 2022 and $<ix:nonFraction unitRef="usd" contextRef="i01a126ed6a3341d7babdddc3b8c5a1af_D20200701-20201231" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzcxNDY4MjU1ODU2MjQ_329da6ce-89ba-4e06-af22-af9f8f4333a5">2</ix:nonFraction> million of the 2.616% Notes due 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzcxNDY4MjU1ODU2NTk_3b88c3e7-e86a-43ca-80f6-9d0457f0a9cf">1</ix:nonFraction> million loss on early extinguishment of debt during the six months ended December&#160;31, 2020.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="i7ab62d58a2744c7d96ab48d178c5edc9_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzE0NDA_f0f1e29a-689e-4622-bca2-ebe7ba8d8c9f">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="id11e26319ddf483d88eafb2ba45b91cc_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzE0ODA_2181d63d-aae7-449e-afe6-5dac86d16d87">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="i7293644d26734b97832a304248e0d4f2_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzE1MjU_79efa988-b6c3-4bad-81e3-fd8e8c710228">1.0</ix:nonFraction> billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2021, we had <ix:nonFraction unitRef="usd" contextRef="i8531707da0e64febbba666aed40d8040_I20211231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzQzOTgwNDY1MTYyNzA_d45b5f2f-6a66-4bd7-aab0-ff301cfd9ed0">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0dec945dab7c4762bc9591ce03471350">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2021, we were in compliance with this financial covenant.</ix:continuation> </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzE3MDU4_fe641388-d2db-4a57-9e1f-61fc2eef79e5" continuedAt="ib0186095f189411698c9e00d5e86bb42" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i285548e776cd4b929eae18d3e9002181_D20140731-20140731" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMyNzMyMDA_c0798c92-c7f3-4dc5-9e53-e840ce224e79">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i62a27d05945443ad96f59cdcb1edc420_I20180430" decimals="-6" name="cah:AggregateAnnualAssessment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzY5NA_cd93fa11-30c0-4d7a-8fb5-3c55578f6e58">100</ix:nonFraction>&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i66e6258348ea4fc89eb5ef7eb0cb10fe_D20200701-20201231" decimals="-6" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIwNDA_6611db5f-c447-4ef9-8a97-400947903dfb">41</ix:nonFraction>&#160;million for calendar year 2017 and 2018 during the six months ended December 31, 2020 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $<ix:nonFraction unitRef="usd" contextRef="i1795ede44ce94976805d345dedf32727_D20211001-20211231" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA4MzU_62a10cf3-1046-486b-a209-d3264dea15ae">20</ix:nonFraction>&#160;million, our portion of the assessment for calendar year 2017. As a result, as of December 31, 2021, we had an accrual of $<ix:nonFraction unitRef="usd" contextRef="i29dc2aedb8bc420db59f14dd8db4e352_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA4MjI_91406b64-1ff7-43f1-b649-53f4fcc0b5f1">20</ix:nonFraction>&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ib0186095f189411698c9e00d5e86bb42" continuedAt="i472c88c5d24445ad8dff899feab95843"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i6542622e5ef24933a209e2a96b41e83a_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTEyNDY_27f44988-c8e4-46fc-80a8-507342d539ad">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i1a5d7197ac224ce9bf2facd8d7e90d5f_I20220131" decimals="-2" name="cah:LossContingencyLawsuitsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzU2Nzc_4877fc0a-09a0-48c1-a595-9809ea1c2039">3,400</ix:nonFraction> lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i36ac058f78664b5dbeba5619bf856f61_I20220131" decimals="-2" name="cah:LossContingencyLawsuitsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzYyNDA_9b19d1ce-d07d-4d3e-9dbc-57f7c4a47fb4">2,900</ix:nonFraction> of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, <ix:nonFraction unitRef="stateag" contextRef="i1a5d7197ac224ce9bf2facd8d7e90d5f_I20220131" decimals="0" name="cah:NumberofStateAttorneysGeneralfilinglawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzY2NDg_90d3a02e-56ed-4508-9c9d-4bd0ebed9224">25</ix:nonFraction> state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#8220;Proposed Settlement Agreement&#8221;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement includes a cash component, pursuant to which we would pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231" decimals="-7" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxNDQwNDc2ODEwNDIx_e2626fe7-c130-46aa-b963-d5f57e76b906">6.37</ix:nonFraction>&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against us after the Proposed Settlement Agreement becomes effective.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As contemplated under the Proposed Settlement Agreement, in September 2021, the three distributors determined that a sufficient number of states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which was the subdivision sign-on period. The subdivision sign-on period ended January 26, 2022. Each participating state will now make a determination as to whether a sufficient number of its political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. Following that determination by participating states, each of the three distributors will independently determine whether a sufficient number of subdivisions, including both those litigating and those that have not sued, have agreed to participate in the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed to execution. This process is currently contemplated to end in February 2022. The Proposed Settlement Agreement remains subject to contingencies. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the required contingencies are satisfied, the Proposed Settlement Agreement is expected to become effective in April 2022. During the period between the satisfaction of contingencies and the effective date, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Proposed Settlement Agreement in each participating state and dismissing lawsuits of participating states and subdivisions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors have entered into a settlement with each of the states of Florida, New York, Ohio and Rhode Island and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, these states and their participating subdivisions will become a part of it. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i472c88c5d24445ad8dff899feab95843" continuedAt="i53848a473c2b488bb2be21e3cde6fe30"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national distributors, entered into a term sheet with the Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a bench trial in the case brought by the Washington Attorney General against us and the same two other national distributors began in November 2021 in Washington state court. Trials are inherently unpredictable and it is possible that the outcome of these trials, either individually or in the aggregate, could materially negatively impact our financial results, cash flows or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $<ix:nonFraction unitRef="usd" contextRef="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMDQ3MzY_61ece980-2df9-48e2-9242-8726475bdea6">6.68</ix:nonFraction>&#160;billion accrued at December&#160;31, 2021, of which $<ix:nonFraction unitRef="usd" contextRef="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzEzNzQzODk1NDE1NTk0_20e67206-cc01-4761-8d97-755827cec904">480</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the six months ended December 31, 2020, we recorded total pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231" decimals="-7" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA4OTI_35152ff2-5ba4-498b-8656-e80e9db2b6e0">1.02</ix:nonFraction>&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">businesses and individuals alleging personal injury. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="i9c999577462049eda357e2ab78e71683_I20220125" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMDk4NTA_36ce283b-c704-433e-b7d0-2604931d4269">464</ix:nonFraction> lawsuits as of January 25, 2022. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="i40eadd91b0ae47328a2ae28ff036f822_I20220125" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMDk4OTc_bfb9294e-e40f-4686-952a-30735093e04e">147</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving <ix:nonFraction unitRef="plaintiff" contextRef="id13e0ec03eda43788abcd88f803bccd1_D20220131-20220131" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA5MDA_97588f81-5d8d-47b3-b9f3-e067fd4a53e8">21</ix:nonFraction> plaintiffs is scheduled to begin in state court in Georgia in March 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 25, 2022, we are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i1de5fd1605f748fdb2806fef4a6523c5_D20220125-20220125" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTEyODI_220d5d41-2d26-4311-9fb6-1658d2e2a01a">443</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="ib222890e5cd8438eae755da882ac9b57_D20220125-20220125" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE0MDY_f8f3cf92-0aef-4efb-a754-e11d9b737017">5,750</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="i8d18e9c334304d17b47512697546cdfe_D20220125-20220125" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE1NTg_b194af45-d9a1-4e80-8ba4-2c546b82da45">32</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i5e01245b5cf74dc58ec5bf20e479c9f0_D20220125-20220125" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE2MTM_42b6bd3f-c197-41e8-b811-440df12fb4da">36</ix:nonFraction> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately <ix:nonFraction unitRef="lawsuit" contextRef="ifb2fd3c70f184444bdcf9b9585835c51_D20210731-20210731" decimals="-2" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE4MTQ_69c6949a-f2c3-4886-8de5-affbee63f8a9">1,300</ix:nonFraction> claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i68d6b6246aa54ad59d9d645973f16b87_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTM1OTM_ac77fbfd-bcff-48f8-9782-f7cb60bef68e">554</ix:nonFraction>&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="i726a9874ca6a4682a0a961cf53f77d36_I20211231" decimals="-7" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTQwNTA_192156c0-1d26-4159-822d-684a2ae33c90">1.09</ix:nonFraction>&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i53848a473c2b488bb2be21e3cde6fe30" continuedAt="if5047faf58e54da7a95cdccc6bd11750"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Action </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related requests and cannot predict the outcome or duration of the investigation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="if5047faf58e54da7a95cdccc6bd11750" continuedAt="ifaadb11053374404b75c1bf799aac62d"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $<ix:nonFraction unitRef="usd" contextRef="i6f5f0000b10443bb904f81c8727295ea_D20200701-20210630" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzE1MDA2_955d1cb5-5f71-4d41-807c-15021dfb05cf">13</ix:nonFraction> million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings during the fiscal year ended June&#160;30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifaadb11053374404b75c1bf799aac62d">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</ix:continuation> </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzg4NDk_82784c4f-a439-443e-9f24-545d19549cdb" continuedAt="i9873196d55254fb9b1efe140978f5b93" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we recognized a $<ix:nonFraction unitRef="usd" contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEyODY_6332aef6-cd71-4abc-8723-b09b71db798c">1.3</ix:nonFraction>&#160;billion pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $<ix:nonFraction unitRef="usd" contextRef="ib576ab5afad44195a834e1e7faeb7d53_D20210701-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjExODQ_ed4078e0-b277-42d7-9769-59827c7b72b1">92</ix:nonFraction>&#160;million for fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended December&#160;31, 2021 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2022. Applying the higher tax rate to the current quarter loss resulted in recognizing an interim tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i37746254b4ef462ab66acbee39610807_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEzMTU_0f407073-5dea-4c8e-a2d2-d06a95679b2b">1.0</ix:nonFraction>&#160;billion, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months and six months ended December 31, 2021 and prepaid expenses and other assets in the condensed consolidated balance sheets at December 31, 2021. This interim tax benefit will reverse in future quarters of fiscal 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $<ix:nonFraction unitRef="usd" contextRef="i220be912f8c445d583c34c9d7a197d21_D20211001-20211231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjExOTc_a6235101-b6d5-42e8-aac1-5e12e2780335">10</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjM1MTU_e4a0c750-ee5e-4c10-8e29-43f429c7ac2d">19</ix:nonFraction>&#160;million during the three and six months ended December&#160;31, 2021, respectively. The tax effects of these matters during the six months ended December 31, 2021 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $<ix:nonFraction unitRef="usd" contextRef="i0c6fc69a919e428a9249914f94b4e705_D20210701-20220630" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIxOTkwMjMyNjQ4NzI_a34fe44c-3a41-43b4-8b8e-561fd9c327cd">38</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $<ix:nonFraction unitRef="usd" contextRef="i9770cc98f0834ead8999bddd6f93e81a_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjM0OTg_10716a38-799f-4c56-b448-fcf7bac29639">420</ix:nonFraction>&#160;million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a U.S. federal income tax refund of $<ix:nonFraction unitRef="usd" contextRef="i71c85c93cd4f49ccadff2110a5afb040_I20211231" decimals="-6" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjM5OTc_f6c657c3-83e3-4223-8f18-c531bf4dac3b">974</ix:nonFraction>&#160;million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have a current asset on our condensed consolidated balance sheets at December&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $<ix:nonFraction unitRef="usd" contextRef="i838623ba3e424777903a3d4ab8c49dc4_I20201231" decimals="-6" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjQwMTg_e7188dd7-de5e-4606-b26d-edebe2ea4e6e">700</ix:nonFraction>&#160;million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $<ix:nonFraction unitRef="usd" contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1Mjc1MDM_56ce0272-e8d0-47b9-adbd-de25ed64c097">1.02</ix:nonFraction>&#160;billion pre-tax charges for the opioid litigation recorded during the six months ended December&#160;31, 2020, the net tax benefits were approximately $<ix:nonFraction unitRef="usd" contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIyNzI_bfdf9f5f-4399-43ff-8b06-206a1fd4c9e0">300</ix:nonFraction> million for the six months ended December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2b171a8060ae4f008d8e6a25869806bf_D20200701-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIyNzk_086583d7-3b8a-492d-8468-04c0d3f70e39">228</ix:nonFraction> million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i07d6f83592a1426993ab2a13d023f8f3_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzI1Njk_91e3f7a3-035e-4a32-bf4a-8679b1603d76">34</ix:nonFraction> million during the six months ended December&#160;31, 2020, and $<ix:nonFraction unitRef="usd" contextRef="i00fa788fc87340c384b2380104923f42_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzI1NzY_b5f7b474-3d16-4b24-98b4-dda3dad264d9">219</ix:nonFraction> million for fiscal 2021. We have recognized <ix:nonFraction unitRef="usd" contextRef="ia7499fd6ae8f450daef1e62b7f4adf5b_D20210701-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEzMzM_56e60415-3f70-4419-ae47-79730d147eb7">no</ix:nonFraction> tax benefit associated with Opioid accruals made in fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;<ix:nonFraction unitRef="number" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzU0MzA_bb49119c-7f58-4b60-a5a9-5942c8ba0c00">105.0</ix:nonFraction> percent and&#160;(<ix:nonFraction unitRef="number" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzU0NDU_3259b70d-d91f-45e3-b0eb-32c687b31ff3">47.6</ix:nonFraction>) percent, respectively. The effective tax rate for the three months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i9873196d55254fb9b1efe140978f5b93" continuedAt="i116971b760ac4f18bd9ca30be404d093"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective tax rate. The estimated annual effective tax rate for the three months ended December 31, 2020 included the benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the treatment of the tax impacts of the opioid litigation accrual recorded in the prior year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIxOTkwMjMyNzE1Mzc_93643e5e-7e54-4440-9dc3-b225e308bb36">153.1</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1MzI5MDI_9d8792ec-c826-4ef5-920b-b12561339404">259.7</ix:nonFraction> percent. The effective tax rate for the six months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual effective tax rate. The effective tax rate for the six months ended December&#160;31, 2020 included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss and net tax benefit related to the treatment of the tax impacts of opioid litigation charges.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYxODI_d5f6a079-723d-4be1-8650-cbc5eb50e308">937</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYxODk_b1b99f7d-b302-4f4a-8c0d-575040ae3aa6">932</ix:nonFraction> million of unrecognized tax benefits, at December&#160;31, 2021 and June&#160;30, 2021 respectively. The December&#160;31, 2021 and June&#160;30, 2021 balances include $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYyNjc_6829d7d3-ba37-4830-93fb-8b994f210f28">854</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYyNzQ_cce58d64-3f74-4513-8e6a-600114cfa380">849</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and June&#160;30, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzY0MTE_1852f43c-1a62-4133-a9c5-77f6b58750d7">45</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzY0MTg_6e30a823-2433-4cc5-a682-ce5bcd16d859">49</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="i25f55518522b4794b80ca287b166f5cc_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzczMDE_f29cc5fa-4699-4130-a63b-e2cb8cfe234e">zero</ix:nonFraction> and a net decrease of up to $<ix:nonFraction unitRef="usd" contextRef="i263e5ca49fed4bdbba6851bf32da93f2_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzczMzI_9968eb75-1d1b-4b4c-99da-47138687f6e0">20</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i68578f163e6b4179847e8b41663e8613_I20211231" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzgwMzk_12af4753-5db8-442d-a00d-470ab752e79a"><ix:nonFraction unitRef="usd" contextRef="i43784f138b914b8391cd15843d15c989_I20210630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzgwMzk_5c2e14df-66ee-4c22-a5be-27030b45a6e3">72</ix:nonFraction></ix:nonFraction> million at both December&#160;31, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures </span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i116971b760ac4f18bd9ca30be404d093">and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i488515e2c1534dd59e7585b97320412d_I20211231" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzg1NDk_ca151fc2-820a-45bd-8e34-35229b8c24f2">3</ix:nonFraction> million at December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i0f1090b7d5ea42a8a285ffc9484f2981_I20210630" decimals="-6" name="cah:IndemnificationReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEyMzk_eb3f4e0e-7e47-4cd5-a23c-9fc77774355c">12</ix:nonFraction>&#160;million at June&#160;30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.</ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_109"></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90ZXh0cmVnaW9uOjdmYzJjMzhlMmYzYzQ1NWRhYWZlMWJlOGI1NGZlZmMxXzE3MTk_b55938ff-c69e-4d7e-aebc-86d9685db75f" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90ZXh0cmVnaW9uOjdmYzJjMzhlMmYzYzQ1NWRhYWZlMWJlOGI1NGZlZmMxXzE3MTY_18fc9bad-bc7a-4c0e-a610-6c5d1609cc00" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5176a75ae1064d6387d055928f4a88c6_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtMS0xLTEtNDcyMjY_3a96eb36-6b56-43f6-a85f-0c6cc8205aa1">1,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtMy0xLTEtNDcyMjY_7f963bc9-38b7-4926-a6f2-ed32acaee7b7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec263fc27faf41e9a416ab2454257578_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtNS0xLTEtNDcyMjY_8974b65f-924e-4e9d-8267-90ac88d29001">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife056180602548b8811ec73a324b2646_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtNy0xLTEtNDcyMjY_08396da6-3f3c-462b-9ce6-4b5475698f3e">1,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5176a75ae1064d6387d055928f4a88c6_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtMS0xLTEtNDcyMjY_3ccb7533-7690-4979-ba0e-b54a48b79517">125</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtMy0xLTEtNDcyMjY_d7afbc57-9895-4812-aa25-8f6dfab699b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec263fc27faf41e9a416ab2454257578_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtNS0xLTEtNDcyMjY_ad7ede8a-f629-4dc0-96ed-21900abb9450">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife056180602548b8811ec73a324b2646_I20211231" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtNy0xLTEtNDcyMjY_623f1979-62b5-41ca-a13b-71941434e13c">125</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5176a75ae1064d6387d055928f4a88c6_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtMS0xLTEtNDcyMjY_f41cdd2b-1df4-4b0f-a80b-ffbb67b71ec1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtMy0xLTEtNDcyMjY_590fd848-7a56-4d02-858e-b789000ece1f">62</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec263fc27faf41e9a416ab2454257578_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtNS0xLTEtNDcyMjY_49cc1d4b-b3b1-40c5-9e7c-e04622a67894">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife056180602548b8811ec73a324b2646_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtNy0xLTEtNDcyMjY_7a04f7ee-a602-47b0-922b-6f3d0c2181b2">62</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490f28555d6e44018c5fb0a7112b17fa_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtMS0xLTEtNDcyMjY_57234b8b-4bbc-4e34-837f-b7ae772d6573">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtMy0xLTEtNDcyMjY_678bc735-6f63-4097-ac2f-35738cd3b7c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtNS0xLTEtNDcyMjY_809405fa-5e60-4184-a848-a3bbff931433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2308b88f9c42b991c03554e3e0145e_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtNy0xLTEtNDcyMjY_35cb04af-1dc2-4b6c-bf39-ba1f5a0987bb">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490f28555d6e44018c5fb0a7112b17fa_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtMS0xLTEtNDcyMjY_96dd243f-f32d-4569-8516-7633fcd663fc">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtMy0xLTEtNDcyMjY_40e0ab3d-bc6c-496b-85f1-5ea459b9f3b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtNS0xLTEtNDcyMjY_6d10b030-3fe2-475c-9c2f-46f1f54bd426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2308b88f9c42b991c03554e3e0145e_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtNy0xLTEtNDcyMjY_4fb6d2bf-a8ea-4994-97ea-7ad12363f2bb">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490f28555d6e44018c5fb0a7112b17fa_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtMS0xLTEtNDcyMjY_63474099-0c31-429e-9eb7-5d38ace896f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtMy0xLTEtNDcyMjY_4ee763a8-3c5a-4b55-b8a1-bce95a17209c">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtNS0xLTEtNDcyMjY_c552fa68-7cd2-4b95-9cca-ca0bd3d9bc4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2308b88f9c42b991c03554e3e0145e_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtNy0xLTEtNDcyMjY_ef365bd1-a754-4f28-b985-623ca1d4d082">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_112"></div><ix:nonNumeric contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzkwODg_e7e4507c-840c-4c67-b627-37d2cc0b03d6" continuedAt="i4ceb27039a534e38b1e54b395804760d" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i4ceb27039a534e38b1e54b395804760d" continuedAt="ie2fef086776449129ce951d959235978"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and six months ended December&#160;31, 2021 and 2020, there was <ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_19c87aee-222b-4cec-afd2-d8b9d1237225"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_4b30138e-39cb-4c58-95a2-27efd500b454"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_7e7bdfba-a878-48db-a003-4da50f949f99"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_9f12a482-9ca1-4441-a5bf-991af521927c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended December&#160;31, 2021, we entered into pay-floating interest rate swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i97efabb7eafb457086138a0357aee526_I20210930" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU0OTc1NTgxNTIyNjE_a549df71-daf0-4d7b-9163-27fb1f9d3ccd">100</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib440b67408ee4c8fb412aeaaf58be6c6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU0OTc1NTgxNTIyNjU_a9efafc3-b451-4351-be3e-7fb992592a28">200</ix:nonFraction> million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $<ix:nonFraction unitRef="usd" contextRef="i7f6c7a9a75f64986aefb952c73f437f8_D20211001-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU1Mjc_017dfefe-57fd-4f87-a570-b763fa75f9af">1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2aace5f028f4f5594de1fcc97eebe25_D20201001-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzIxOTkwMjMyNjc1NDk_c48374d5-dd22-4c23-b926-92e186ee3053">8</ix:nonFraction>&#160;million for the three months ended December&#160;31, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ice2850c2b1a44cd8880a41a004525e24_D20210701-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU2MTI_5fbebb2e-de51-4be5-861f-1a9453a1e73a">3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idb4d97276663428da969d731f48e6813_D20200701-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU2MjY_e5967267-6589-485b-a402-cb90bb5c926c">7</ix:nonFraction>&#160;million for the six months ended December&#160;31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="i357254d5ee414518a4eac711d1ad0070_D20211001-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcwMTY_43de0d3c-3cf3-4b15-b203-0b1ff082d0c2">17</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="i531458b265ea402180368f22e3a18010_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcwMzA_cd84c687-59df-472a-99fa-4cbc9e37d3b2">27</ix:nonFraction>&#160;million loss during the three months ended December&#160;31, 2021 and 2020, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i3347233009744e6cb9cc4557b43f558b_D20210701-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcwOTk_eedbd01b-846b-4e4f-be79-79e332ab7a70">22</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="id67592a92eea436081db481ac7010f0d_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcxMTM_74c606e4-41e4-48c4-99f5-ece188c8faed">52</ix:nonFraction>&#160;million loss during the six months ended December&#160;31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="i357254d5ee414518a4eac711d1ad0070_D20211001-20211231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzczNjQ_7cbbb518-e3b5-47c4-b5a4-ab06cc7b24bc"><ix:nonFraction unitRef="usd" contextRef="i531458b265ea402180368f22e3a18010_D20201001-20201231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzczNjQ_d3db5e29-0c4e-45b3-8e3d-63cc7b6598d4">5</ix:nonFraction></ix:nonFraction>&#160;million during both the three months ended December&#160;31, 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="i3347233009744e6cb9cc4557b43f558b_D20210701-20211231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzc0MTI_38e54d8f-003c-49a4-83d5-ba294f7fc0d0">11</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id67592a92eea436081db481ac7010f0d_D20200701-20201231" decimals="-6" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzc0MTk_584521b1-174f-44e1-96ba-7c404460486d">10</ix:nonFraction>&#160;million during the six months ended December&#160;31, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ie2fef086776449129ce951d959235978"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="ic72d4b7997b54c948eff89cce7d0a30e_D20211001-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzIxOTkwMjMyNjc1NjM_e4481161-d1eb-4885-8406-532f0cebf6dd">2</ix:nonFraction> million gain and a $<ix:nonFraction unitRef="usd" contextRef="i9a8c386ef058467d89edcdc41c5d7497_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzIxOTkwMjMyNjY5MDQ_b3a0b888-33b7-4453-8a79-560437e7ba59">4</ix:nonFraction> million loss during the three months ended December 31, 2021 and 2020, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="ibc1ca71b66fd44c99dc3a2f276433c1d_D20210701-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzgyNDA_a0fa1a18-7b01-463f-bab2-1ffd6569dd85">4</ix:nonFraction> million gain and $<ix:nonFraction unitRef="usd" contextRef="i48423edd0fde4582afae650327df3fb4_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzgyNTI_c60c6cff-d4aa-40fe-a8cc-b85e48232b10">5</ix:nonFraction> million loss during the six months ended December&#160;31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December&#160;31, 2021 and June&#160;30, 2021 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzkwOTI_5453b4e7-cc11-4cea-89c2-333cbc567433" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if691da9b0c7f435b9a6464ebf9174366_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzEtMS0xLTEtNDcyMjY_661df82b-206a-4259-af64-3ffc1f783f67">6,074</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734031661a944622a2d44f3f789e8f7c_I20210630" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzEtMy0xLTEtNDcyMjY_27f0b6fd-b414-453e-8580-2a2f568df4a7">6,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzItMS0xLTEtNDcyMjY_48ec2530-03b2-43ce-b646-c13cd5ac5613">5,643</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzItMy0xLTEtNDcyMjY_b6a79267-81db-4dc8-af9e-a16edfb50ae8">6,236</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="i6bdf7a21332a418cb7d5503f4cc4365e_115"></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzkyNA_5174001f-cd38-4b34-8273-83d18d17c84b" continuedAt="ib61b58d4457e429794eda79d8d996bb5" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc4MTI_81f8a17f-03b9-4b25-a08d-b53eaa637e43">800</ix:nonFraction>&#160;million of our common shares, in the aggregate, through share repurchase programs during the six months ended December&#160;31, 2021. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1OTk_7c05aa20-5dad-46dc-a70d-6cfea97d68b4">300</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ica8231a36d054c5eace0ac4a74d6041c_D20211001-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM2MDc_67f9c0ce-e63e-4559-b6fd-33f5e371e187">4.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc1MDM_36135926-ccdc-4fde-9dd5-04af2fea3efd">50.30</ix:nonFraction>. The program concluded on January 31, 2022 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc1MDc_978afb2b-7197-4f61-817d-ad5292e2a005">49.39</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc1MTI_cafdcd34-8bea-4d35-9067-b525acdf31af">1.3</ix:nonFraction> million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="idf89a8993ffb426a9d8312715526954c_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzQzOTgwNDY1MTQ3MDE_d611f62f-7999-4a12-9f47-3151a00cd3ab">500</ix:nonFraction>&#160;million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1NTU_040f0199-7eb1-499a-bbd0-bcd5d23b9ac9">7.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1Njg_cc6f49b0-14ee-4fcc-a6f4-3c2e1cccf644">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ib61b58d4457e429794eda79d8d996bb5"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1Nzc_5c155015-2d9d-4e22-8002-ad1ee8a4d6f9">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1OTE_1b9c0c80-6f76-426f-bf93-4713cdcf934b">2.0</ix:nonFraction> million common shares. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzkzOA_451a5534-f79d-45d3-836b-ad02c12a74d4" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87549c698d84454483818bad997efd4b_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzEtMS0xLTEtNDcyMjY_335bb8a2-fedf-4e64-9830-1f69c7396f37">46</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b64ec0efad4987b3cd7ad0a3914253_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzEtMy0xLTEtNDcyMjY_b49a05a8-4d5f-4d5c-aecc-80019b5f161c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie23cd0947b184af3834849f94339a4a7_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzEtNS0xLTEtNDcyMjY_78df97fb-79fa-4d9b-9daa-127002377ffc">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzItMS0xLTEtNDcyMjY_92d99113-f047-4bd7-b18f-c193b1630237">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzItMy0xLTEtNDcyMjY_a663d1fe-1da8-4d11-b043-1419be14da12">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzItNS0xLTEtNDcyMjY_46c76763-296f-47f7-939f-c0f7c8d50a92">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzMtMS0xLTEtNDcyMjY_35b4b9ed-50df-42a9-8254-7388052d4025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzMtMy0xLTEtNDcyMjY_dfbd0bbb-8325-4da0-bfc7-ff9df0153f0f">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzMtNS0xLTEtNDcyMjY_50a1b8fe-b4c5-474b-8533-96c2f6369bcc">3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzQtMS0xLTEtNDcyMjY_3fee1bcd-4f1a-447f-9f8b-3f7de38eaef2">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzQtMy0xLTEtNDcyMjY_94af688e-c3d2-40ae-a74c-572d2f0ed5b8">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0f3694f60c043b6910488f3f4214356_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzQtNS0xLTEtNDcyMjY_b46fab36-09d2-4fb1-9895-b93f7ccfc0c0">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9442aa8d69b64b3bbce3a40e922f013a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzUtMS0xLTEtNDcyMjY_867617e4-9074-4bff-920f-02f4cf9b626f">89</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc5e2906bad1404691be6f731cf43612_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzUtMy0xLTEtNDcyMjY_cbe54bd1-5e8b-4a43-8802-5dab2f3b87a4">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02be3554e0b34c02ba6b5f8f3ae72ad0_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzUtNS0xLTEtNDcyMjY_765d7efc-2cfa-49b9-abe3-4e4f835f58d0">85</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_118"></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzYxMg_f8645ffc-894c-46fc-94ba-579aa34f8636" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings Per Share Attributable to Cardinal Health, Inc.</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzYxMA_2a949af8-a045-405a-a1df-b51abb18d7b8" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzItMS0xLTEtNDcyMjY_2eef7b7b-2c1e-4ab2-8dc0-779d0004ffea">279</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzItMy0xLTEtNDcyMjY_8108b7bc-669c-4548-bb95-4d40624cd787">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzQtMS0xLTEtNDcyMjY_2f919906-1acd-4c6e-8741-b32deb7ca3db">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzQtMy0xLTEtNDcyMjY_10420bb8-a4e2-4f09-b9d4-d4f13e2a1a29">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzUtMS0xLTEtNDcyMjY_1d3fc3de-c594-424e-a33c-ffff659378d3">281</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzUtMy0xLTEtNDcyMjY_2a29d4c9-1dee-4342-8896-b18f6ac7a0c0">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzItMS0xLTEtNDcyMjY_cf632032-7a7a-4eea-a9f5-3d03a137c12c">283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzItMy0xLTEtNDcyMjY_c99420d8-4df5-428b-bbb3-7524ba5743d7">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzQtMS0xLTEtNDcyMjY_9f8c4c31-6e0e-4939-8089-14ac2e9004c2">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzQtMy0xLTEtNDcyMjY_02947e26-df0d-4d4b-8a03-6b5bda3bf53c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzUtMS0xLTEtNDcyMjY_d9a9fdb1-acaa-4e15-b710-af36c8db1197">285</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzUtMy0xLTEtNDcyMjY_2e4f4336-29c2-4ab6-a512-8ef675f5207f">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive were <ix:nonFraction unitRef="shares" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzEwOTk1MTE2MjkzNTE_c6bd8671-d561-425e-a9fa-24ee9afa361b">5</ix:nonFraction> million during both the three and six months ended December&#160;31, 2021 and <ix:nonFraction unitRef="shares" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzEwOTk1MTE2MjkyNzU_7aae5cfe-0876-423f-afb4-3485a725357b">4</ix:nonFraction> million during both the three months and the six months ended December 31, 2020.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1OTI_aebad472-c194-4565-bc2c-855fc216c042" continuedAt="i5ffc939b04cc45929ab43d6527fb0949" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzEwMQ_def2e543-4b34-47a3-9c89-ffe88e24998f"><ix:nonFraction unitRef="segment" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzEwMQ_e2aa9cfa-b9f2-4c6e-821f-383b0cce4e41">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our <ix:nonFraction unitRef="segment" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzE4NDc_def2e543-4b34-47a3-9c89-ffe88e24998f"><ix:nonFraction unitRef="segment" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzE4NDc_e2aa9cfa-b9f2-4c6e-821f-383b0cce4e41">two</ix:nonFraction></ix:nonFraction> reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1NzQ_5778630e-270b-46ac-b959-a6236ab77e66" continuedAt="i3f5585e1205b4ca289e0d1976afdb6fa" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20447894cbce4626a6e15d3def1fdb5f_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzItMS0xLTEtNDcyMjY_873842dd-5310-4ca6-991a-a35ce17bdc5c">41,164</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib05957b8776e49b29c6ad2637c8b07dd_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzItMy0xLTEtNDcyMjY_bca1ff3c-8014-4670-b7e2-c113994b4fcd">37,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8dc329406284cab850531d536265617_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzMtMS0xLTEtNDcyMjY_a6165a60-9e13-47ac-a529-259324631006">211</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf577b417acb4a57824e42c61874c5f4_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzMtMy0xLTEtNDcyMjY_1dc7d72e-f1b1-43fd-8ace-f23ea8fccde0">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzQtMS0xLTEtNDcyMjY_d6d3e1de-b089-46e9-93c5-7bececbf2af3">41,375</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a28033a8f04045b695c45def69a4ab_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzQtMy0xLTEtNDcyMjY_2cd527de-94c3-43f1-b82d-2175fc0663f1">37,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2139bac4734db0b0818999413985f5_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzUtMS0xLTEtNDcyMjY_847f7e99-c681-46e7-9894-387a5a15fd0f">3,446</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7d6f1a08182423896d73aea639446c1_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzUtMy0xLTEtNDcyMjY_e18eb451-1d67-4263-9304-105f3e28d80d">3,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a826fe2301345b7bcd24179b92b1b2a_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzYtMS0xLTEtNDcyMjY_6b37b6be-e6d7-4234-8c7a-0f4c8d4da105">639</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a0384798971475ca8af194b0bac9c64_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzYtMy0xLTEtNDcyMjY_91f3b39f-598f-434c-ae08-e7404adade62">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6de15b3c68241ae9c0af7734cf7ea0b_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzctMS0xLTEtNDcyMjY_24f6e199-5d2e-44b6-a468-e72f0dd02853">4,085</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1ac584a6af4ec58101540fb78560fa_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzctMy0xLTEtNDcyMjY_0563317f-9350-46fe-b764-8c75d382083d">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67c60168405428b9e40371da416b3fc_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzgtMS0xLTEtNDcyMjY_7a768936-25c7-466b-ba79-c2185426c316">45,460</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzgtMy0xLTEtNDcyMjY_09fe1a4f-ad98-4aac-bfef-297d1d9eed0a">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzktMS0xLTEtNDcyMjY_c3ff7ee5-4cb9-4d21-92e0-aadb148546c6">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzktMy0xLTEtNDcyMjY_8471bb0c-286e-4692-b294-b2e4c1861e09">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzEwLTEtMS0xLTQ3MjI2_710de791-cf53-44f8-8a6f-3a8d67247cd7">45,457</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzEwLTMtMS0xLTQ3MjI2_c68b3a5f-f0bd-49d9-822a-94ff60411ce4">41,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i3f5585e1205b4ca289e0d1976afdb6fa"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947e256fc55c4846ac6b1768ff3934ad_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzItMS0xLTEtNDcyMjY_27738125-73fe-428e-8fbf-c02be4c75f44">80,778</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3e1e7ccb99f4738bdd4ea38594a9397_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzItMy0xLTEtNDcyMjY_4e388b3c-3624-4f99-ba59-4929e3a3b609">71,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717134e53834433e8d6ee1a235075718_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzMtMS0xLTEtNDcyMjY_9273a13e-4b0c-4172-b475-3cd89b20271b">419</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7b6c1cd2234d3a84ff74926dba30cd_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzMtMy0xLTEtNDcyMjY_96e456a4-8cd0-402c-9b18-667ef6ca8366">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4501b440f44a0d8c0bc1a50fdbff39_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzQtMS0xLTEtNDcyMjY_62f33b68-7af3-4e13-b481-f6516e6f02d3">81,197</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee36791593e44892a333aec11370f06c_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzQtMy0xLTEtNDcyMjY_f87b4408-bc17-45ff-ac25-b1b7faed3567">72,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c216eac9e0457da077b8544a667522_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzUtMS0xLTEtNDcyMjY_8f46c77f-0a14-4577-b7c4-f399d05e247e">7,013</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b04e2a62607413897d3432b37ed8267_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzUtMy0xLTEtNDcyMjY_e7bb5788-3434-4dd8-b1d0-fe6e07b812de">7,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec0426076dc43be9eb018d81b355af4_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzYtMS0xLTEtNDcyMjY_84ef9821-e53c-4f5d-a6ed-2fc0cc9fbca1">1,221</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e5a616b51d46cd9609f9b8cb936e1b_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzYtMy0xLTEtNDcyMjY_33b8b9e1-3495-4e06-81d7-0e681669c9d6">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad497ebaf0d74ac488be3fdfe5b45c13_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzctMS0xLTEtNDcyMjY_b1f0a309-3e0c-4156-b0ca-5a4184621559">8,234</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f557d65bffa4e22abc5d6a0ee5bf2c4_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzctMy0xLTEtNDcyMjY_fbf7f13f-115e-4731-9e31-4cad41abbaeb">8,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzgtMS0xLTEtNDcyMjY_2e425339-a2f6-48c5-8d70-5b3857604ec6">89,431</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzgtMy0xLTEtNDcyMjY_7bca5db9-8a96-4e29-a3da-f058d9fac01e">80,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7026229bffa24d75a300958db5493173_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzktMS0xLTEtNDcyMjY_7ad95923-ba21-45de-a2bd-0d14ef263f11">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzktMy0xLTEtNDcyMjY_09330410-6b7b-41dc-9401-44d656a0bee4">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzEwLTEtMS0xLTQ3MjI2_54c70f86-ac0e-4c10-98d5-a4a2ca5aa75d">89,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzEwLTMtMS0xLTQ3MjI2_9697ca9e-7f78-4415-baa0-79d714dd448e">80,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:continuation><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1NzU_9604a418-7504-42cb-b211-0a1225cdb251" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0ef5db6f8c49e99cf83c70272570db_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzItMS0xLTEtNDcyMjY_f0040995-6d25-4bc9-84e2-8112fa53abc0">44,382</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabe27c3053040afbee1de4f02ae3a1d_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzItMy0xLTEtNDcyMjY_342ca1a8-a958-4107-916d-e4b9ca24677b">40,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2324d519bd54f24aca9e312c213d51f_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzMtMS0xLTEtNDcyMjY_859b7a56-b696-4723-a5a3-81f6d83b1c9a">1,078</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcd214eafc844838d0428eba45ceb81_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzMtMy0xLTEtNDcyMjY_492658e1-0ae2-4583-a630-4e8796adb20b">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67c60168405428b9e40371da416b3fc_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzQtMS0xLTEtNDcyMjY_b376c7f9-fe4c-48de-98c1-1e9ab2ac283a">45,460</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzQtMy0xLTEtNDcyMjY_0f112500-4d86-413a-91cd-7d6ae4191e83">41,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzUtMS0xLTEtNDcyMjY_dfcfb0e1-dec7-4b89-a760-8fd288a1005b">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzUtMy0xLTEtNDcyMjY_5b39f1e8-488f-4451-a030-081cd2004831">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzYtMS0xLTEtNDcyMjY_01bb18d1-1c04-4e77-8756-4889b764d681">45,457</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzYtMy0xLTEtNDcyMjY_8714ba0e-0e20-45c5-8500-8018daddcda8">41,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b9c7da4d6b4d138668a8f96ece269b_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzItMS0xLTEtNDcyMjY_c4e1cbd9-2112-45c1-be9c-2c7a4b007ed3">87,223</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8afe0411ae4297994e96fc737d451b_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzItMy0xLTEtNDcyMjY_d98f2c35-ccfd-43f7-b6fd-10236ed8d569">78,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105c393d6342437baf627222f66216c9_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzMtMS0xLTEtNDcyMjY_f6670c56-76ed-4ba6-b102-6677a8d15e3d">2,208</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c720c252b6845929ee256ffd982829d_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzMtMy0xLTEtNDcyMjY_3f6d1a81-5fbe-4966-a3da-66b1c7646b53">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzQtMS0xLTEtNDcyMjY_c18e4d42-b685-416c-9c3e-d7874f5f7eb9">89,431</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzQtMy0xLTEtNDcyMjY_d964c64d-f7d4-4bca-9234-ce955d10e21b">80,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7026229bffa24d75a300958db5493173_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzUtMS0xLTEtNDcyMjY_390dcb88-ab37-4ca7-9da9-6e2d1e060e18">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzUtMy0xLTEtNDcyMjY_73407b48-622a-4e44-8ebf-8cf877c4c9d5">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzYtMS0xLTEtNDcyMjY_8f1cea6a-4db0-43a9-a5c4-0d46595c7097">89,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzYtMy0xLTEtNDcyMjY_58ca3bd6-c4b6-4455-8b67-ca85d291a6f3">80,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation </span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i5ffc939b04cc45929ab43d6527fb0949" continuedAt="i97e4b6cfcf14425ab0f7781bfbfe77d9"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzMTg_86d61049-bbc1-4ded-bb8c-3e5ee06c9267">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzMjU_e072bd4d-ab5f-46d4-a400-7b39dd640e9b">6</ix:nonFraction> million for the three months ended December&#160;31, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzNzA_d33a06e9-5dda-4586-b0fd-b2d1a1f63c79">18</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="cah:ProjectCostsOnInvestmentAndOtherSpending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzNzc_7440661e-973e-4552-8da9-9e3769a8f126">11</ix:nonFraction> million for the six months ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_91">4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a $<ix:nonFraction unitRef="usd" contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwNTk_6332aef6-cd71-4abc-8723-b09b71db798c">1.3</ix:nonFraction>&#160;billion goodwill impairment charge during the three and six months ended December&#160;31, 2021 which was retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_103">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231" decimals="-7" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQ3Mjc_35152ff2-5ba4-498b-8656-e80e9db2b6e0">1.02</ix:nonFraction>&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended December&#160;31, 2020 which was retained at Corporate.</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1ODk_b7944e2c-cff8-438e-85a3-ef4af822eb70" continuedAt="i4167b5339f3f4c1a84894d0d607c8e5d" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:50.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzItMS0xLTEtNDcyMjY_636da8a6-e47f-49bc-b062-88d880cdb21c">426</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a28033a8f04045b695c45def69a4ab_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzItMy0xLTEtNDcyMjY_5f7c9229-815d-4d93-b7bd-741985bc56de">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6de15b3c68241ae9c0af7734cf7ea0b_D20211001-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzMtMS0xLTEtNDcyMjY_296027d9-5a23-44db-9f76-d861437d707c">50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1ac584a6af4ec58101540fb78560fa_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzMtMy0xLTEtNDcyMjY_a25389b7-b2ca-47ac-861a-774b8129bd2c">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67c60168405428b9e40371da416b3fc_D20211001-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzQtMS0xLTEtNDcyMjY_b5baa21e-beda-4fe0-9b94-51d306d40516">476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzQtMy0xLTEtNDcyMjY_9b503814-bc89-4cbe-b810-5230414dad41">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzUtMS0xLTEtNDcyMjY_f8a771dc-6f7a-4196-9b13-55fc82f49e17">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzUtMy0xLTEtNDcyMjY_16a739e3-251b-4932-a993-281f0f14b0b5">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzYtMS0xLTEtNDcyMjY_0e6df7f8-c4f0-4c08-9f92-7a280dab1e4d">950</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzYtMy0xLTEtNDcyMjY_c936338f-8653-4c26-8350-ea079817941c">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i97e4b6cfcf14425ab0f7781bfbfe77d9" continuedAt="i04ded5f8b5b54d9585b91504416d0132"><ix:continuation id="i4167b5339f3f4c1a84894d0d607c8e5d"><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4501b440f44a0d8c0bc1a50fdbff39_D20210701-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzItMS0xLTEtNDcyMjY_d1920df8-4d57-4243-876a-11b152a0abe7">832</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee36791593e44892a333aec11370f06c_D20200701-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzItMy0xLTEtNDcyMjY_fefc919b-ec39-4d28-b564-61845b5f86f6">815</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad497ebaf0d74ac488be3fdfe5b45c13_D20210701-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzMtMS0xLTEtNDcyMjY_801e4f86-3ec1-4d79-825d-5ae3179d88f7">173</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f557d65bffa4e22abc5d6a0ee5bf2c4_D20200701-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzMtMy0xLTEtNDcyMjY_90117858-8346-4d22-8b82-b7ea5e9aafa5">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzQtMS0xLTEtNDcyMjY_d0a38457-86bb-41de-bd86-03df51ec5a6b">1,005</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzQtMy0xLTEtNDcyMjY_fab43758-4b8d-4518-8900-a779061b96c5">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7026229bffa24d75a300958db5493173_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzUtMS0xLTEtNDcyMjY_d3a913c6-aa25-4894-aad4-601cecb6a0f0">1,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzUtMy0xLTEtNDcyMjY_3e9f8fd4-116b-4b6e-81bf-3f889c952ec5">1,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzYtMS0xLTEtNDcyMjY_c2c12d63-2989-4208-bce1-69eb42f8ed7d">535</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzYtMy0xLTEtNDcyMjY_7297dcbe-0e7d-4bc8-b516-40653a40422c">163</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $<ix:nonFraction unitRef="usd" contextRef="i6542622e5ef24933a209e2a96b41e83a_D20211001-20211231" decimals="-6" name="cah:JudgmentForLostProfits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwMzc_27f44988-c8e4-46fc-80a8-507342d539ad">16</ix:nonFraction>&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div></ix:continuation><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwNDk_5915b352-5f08-4eab-b702-fce8588c148d" continuedAt="i57893e90007143a1941f3abd2e116aa9" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib075c6eb340b4000b99c1e4260fff944_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzEtMS0xLTEtODYxMDg_7fe5da15-8f8d-41f7-814c-9f67f0fb54ed">24,427</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d97aa974df4ac6bbf2e22959990798_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzEtMy0xLTEtODYxMDg_104659fa-c901-4ada-9925-48ab2d5ef2e5">23,624</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1) (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41706ccf867d4e078fa68264b8ecf4b3_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzItMS0xLTEtODYxMDg_8189d257-10fd-4cd5-9035-0d790ee79acd">12,737</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id27ed30ba0c447d8a9e0d8a5e753260e_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzItMy0xLTEtODYxMDg_6090a712-de3f-4cf3-b7f0-831765e7f139">15,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644ca4beadff4da38d7416eb70d4e113_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzMtMS0xLTEtODYxMDg_3195dfb4-ff61-411f-b80b-6da15d5c2991">6,516</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617e648d299450da968eaf742edafd8_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzMtMy0xLTEtODYxMDg_f006e525-7a5e-4209-b238-47d989b6d182">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzQtMS0xLTEtODYxMDg_5bd4d6c1-0deb-4bab-95f2-d1f5feddf859">43,680</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzQtMy0xLTEtODYxMDg_75d61afd-c5bf-4b44-a343-5a06a8e98d36">44,453</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $<ix:nonFraction unitRef="usd" contextRef="id6a5635665184a6cb80b94e96e68ca69_I20210630" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzEwOTk1MTE2NDUwNDI_86af476a-2658-4b99-b045-48139175fd1a">1.1</ix:nonFraction> billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i04ded5f8b5b54d9585b91504416d0132" continuedAt="i1f306b80e42743e8b25cdb3675b87da7"><ix:continuation id="i57893e90007143a1941f3abd2e116aa9" continuedAt="if489e6cc8a6945db87c39b80a5f0fafa">(2)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"><ix:continuation id="i1f306b80e42743e8b25cdb3675b87da7"><ix:continuation id="if489e6cc8a6945db87c39b80a5f0fafa">Medical reflects a $<ix:nonFraction unitRef="usd" contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwNTQ_6332aef6-cd71-4abc-8723-b09b71db798c">1.3</ix:nonFraction>&#160;billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.</ix:continuation></ix:continuation> </span></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_124"></div><ix:nonNumeric contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzOTc_3847e718-68e9-494e-b9e5-ccea92b2ab30" continuedAt="if27228d9adba4b10b40d611989d268da" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzNzU_2803eebe-e4c9-4176-a561-7af1dffc1c36" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ae447d46854b319eaccc5ea8e28c28_D20211001-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzItMS0xLTEtNDcyMjY_40464854-70ca-457a-bc0a-f99ee6a12734">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia478e26ea8e448b39f3752efae199cfa_D20201001-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzItMy0xLTEtNDcyMjY_f7e3489f-3b87-45e2-ad59-e867f838c0e8">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b6e1f67cfe47c5a29aaad5984e138e_D20211001-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzQtMS0xLTEtNDcyMjY_8473e398-67d8-417f-81b0-126f6dabc1a0">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic237dc8d2be649c6873fe2eb206f1e73_D20201001-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzQtMy0xLTEtNDcyMjY_f29e5104-c136-4d80-9c4d-914b3dd05208">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzUtMS0xLTEtNDcyMjY_182fb7b6-e1ae-44db-80a8-c450ae914353">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzUtMy0xLTEtNDcyMjY_da435184-6c22-4501-b5c3-43ce5c510ddb">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzItMS0xLTEtNDcyMjY_4810924c-015e-4c72-a838-6f20849a2b59">35</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7abdec1bde440c4b7d2d3fbdb599cd2_D20200701-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzItMy0xLTEtNDcyMjY_1e617bc6-34b7-4ead-81f8-2cc56c9695a0">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzQtMS0xLTEtNDcyMjY_55d5153a-ed45-478b-9baa-4710da61199a">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398269cbf0e54afe862fe609d2944418_D20200701-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzQtMy0xLTEtNDcyMjY_58eeaa41-ff1e-484f-acd3-f269d5e97a2b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzUtMS0xLTEtNDcyMjY_d4a48946-b3a7-4ab0-877b-aeed78259199">42</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzUtMy0xLTEtNDcyMjY_bd8ae8c3-cb5b-4328-a127-534c8158ac24">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzI5Mw_7f17194c-2f6d-4b50-a128-08d8a4c97ea0">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzYwNDczMTM5NTY3Njg_c77c0c30-a13f-414e-b909-76d37125bc44">3</ix:nonFraction> million for the three months ended December&#160;31, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzM1Nw_0bcf7086-5979-4f60-a6ca-aa89e2f0e62c">6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIxOTkwMjMyNTgwNTM_dd430fbe-2c88-475c-a67b-94a4d5d418ad">7</ix:nonFraction> million for the six months ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzUyMA_d5f24758-9c27-4bb2-8fcb-85a0e57161ce">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="if27228d9adba4b10b40d611989d268da"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzOTI_293cbd54-cfd8-467d-ad5d-fc29b124c567" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8aa1d951b73947c3936f78f13c7eaa01_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzEtMS0xLTEtNDcyMjY_2875fd5c-c8d6-4626-987b-5d31de36940d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8aa1d951b73947c3936f78f13c7eaa01_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzEtMy0xLTEtNDcyMjY_066e4df6-199c-4db4-b25d-5c8309b1dce9">49.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzItMS0xLTEtNDcyMjY_fa6fb9fb-7279-49ae-9861-02f6bbd7a8b7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzItMy0xLTEtNDcyMjY_4621c237-d97e-4222-8843-651b5903efda">51.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzMtMS0xLTEtNDcyMjY_5e95fc7b-af12-44ca-8b23-a415b74462b1">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzMtMy0xLTEtNDcyMjY_8fd55a17-1c3d-4f17-b690-a2bfde12d345">49.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzQtMS0xLTEtNDcyMjY_2e13e8da-c390-46e7-9c3d-d51e1353c457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzQtMy0xLTEtNDcyMjY_bf554a3f-b349-445b-85bf-b99324363342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66dbff1954b94c7c9982013468c26bfd_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzUtMS0xLTEtNDcyMjY_fbb7b26d-345c-4ad2-a867-3f8c5faa76bd">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i66dbff1954b94c7c9982013468c26bfd_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzUtMy0xLTEtNDcyMjY_c7d8868b-804d-4e5c-8328-ac1e2cffacfe">45.66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i66dbff1954b94c7c9982013468c26bfd_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzg2Nw_56df157d-ad08-4770-b896-7066a27597af">103</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzk0MA_c3cf5e7a-4643-4fda-a922-1acbc50403e1">two years</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzEwNTQ_c69d967a-29d5-45a6-8aa5-8391b91e1439">three years</ix:nonNumeric> and are exercisable for <ix:nonNumeric contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231" name="cah:ExercisablePeriodOfPlansInYears" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzEwODE_0c6fcaad-c823-404d-8a4f-4274ad72ca12">ten years</ix:nonNumeric> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzOTM_1c931525-42f3-4461-9098-ddc3724bfbc2" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzEtMS0xLTEtNDcyMjY_ae8587f0-e065-4d1e-9c36-fc235fed08cd">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzEtMy0xLTEtNDcyMjY_888fda4e-128f-449b-ba07-3dfc9318116c">68.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzItMS0xLTEtNDcyMjY_621e38a9-45fa-4cfd-8e3c-231065c2c8f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzItMy0xLTEtNDcyMjY_0988a683-1def-4e5d-a088-17f161cda28b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzMtMS0xLTEtNDcyMjY_83077b57-622d-4251-aea3-047b816a0a57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzMtMy0xLTEtNDcyMjY_5f16eeb0-338e-4fcb-8c8d-d464b565d08f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzQtMS0xLTEtNDcyMjY_8280368b-1d61-4482-89ea-968708aae4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzQtMy0xLTEtNDcyMjY_962e568a-0e4c-46e5-854a-b0bbf4ac2735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzUtMS0xLTEtNDcyMjY_b1f68564-102c-4ab9-9075-b8147607ebcf">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzUtMy0xLTEtNDcyMjY_fd91c779-87e9-407d-8313-99d023758508">69.24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzYtMS0xLTEtNDcyMjY_779b977c-4f95-4dbd-ab16-702d335c071c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzYtMy0xLTEtNDcyMjY_dcbc35f5-b066-4500-93e1-7479bb67f434">69.41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i898c45d5227a4196aece99539dfb04a9_I20211231" decimals="5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE0NTA_a8e90967-c94b-4c6b-aaa1-805f8a94a342">0.2</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzU0OTc1NTgxNDI4Mzc_579bdd7e-ae69-4c4a-97e8-21f6a555417c">two years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="cah:AdditionalStockOptionPlanDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzI0MDk_ad612053-b025-4a7e-9c4b-3cf8585ffc3b" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898c45d5227a4196aece99539dfb04a9_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzEtMS0xLTEtNDcyMjY_3ea7bcb9-40d8-4dbf-8c38-c8999a5ded17">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10f071711d1b4e4ca40dd648ab7f15a4_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzEtMy0xLTEtNDcyMjY_35f1bc0a-9bde-4a47-b042-6bed43ee36f3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898c45d5227a4196aece99539dfb04a9_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzItMS0xLTEtNDcyMjY_36bdab3b-ffd6-4a60-a2a0-a3644cce663d">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10f071711d1b4e4ca40dd648ab7f15a4_I20210630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzItMy0xLTEtNDcyMjY_52476cd1-bfb2-4d00-be6e-f6d6297bdeb3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzEtMS0xLTEtNDcyMjY_9dee9a87-c70f-4602-9917-b320c1a46083">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91f70075253b4b6f834c3408cbaaac75_D20200701-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzEtMy0xLTEtNDcyMjY_2493d6d1-d140-439b-a340-2493eb89f989">4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzItMS0xLTEtNDcyMjY_1ce8a4a4-5ffc-48d5-b14f-ca43b370042d">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91f70075253b4b6f834c3408cbaaac75_D20200701-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzItMy0xLTEtNDcyMjY_03720720-7a80-431a-9d97-baf4ab8d12fc">4</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NjU_920681ee-4f41-4c66-91f1-ffe8d558145e">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="i548763c20950426faab587ffdc5af9cc_D20200701-20210630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MTE_04a5a128-6eb5-4ad0-8f41-d64ca9aadfc3"><ix:nonFraction unitRef="number" contextRef="i2be505b893554e2596656d949aede2e1_D20190701-20200630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MTE_d1ddeb9d-0a87-4981-ad0b-1daeeb835b04">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="ib4c55723711e41b596452e6d75618784_D20190701-20200630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MDE_4617cfbc-5a81-460a-a685-c41d95373e43"><ix:nonFraction unitRef="number" contextRef="ie37383edad9446b08331ba5cadd97680_D20200701-20210630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MDE_a15bb4ba-e7e3-49bf-9f8f-ec2a24d40542">240</ix:nonFraction></ix:nonFraction> percent of the target award amount for the fiscal 2020 and 2021 grants and <ix:nonFraction unitRef="number" contextRef="i716d6753e4e540af82ae6e591c9bdeb0_D20210701-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE4Mjg_b411cef9-17ed-4e55-a453-d899004864aa">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="iea669b2da0d447318754dc385014d7b6_D20210701-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE4MzQ_c8463a0b-682a-4bbb-a4f3-854311629823">234</ix:nonFraction> percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzNjA_c2e528d6-cb88-489e-b816-0d3648f90266" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzEtMS0xLTEtNDcyMjY_482198d7-1b97-4605-9966-9a30d6085eaf">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzEtMy0xLTEtNDcyMjY_a0c708b4-4920-47ba-83ad-7732a3f901a0">54.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzItMS0xLTEtNDcyMjY_aa8808cf-07e4-467b-9671-da7da4df5f10">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzItMy0xLTEtNDcyMjY_e3b1a47d-4c6c-4763-8665-786307b1288e">51.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzMtMS0xLTEtNDcyMjY_09f6e05e-d588-4c9a-9ebd-fe7f355e7aa5">0.3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzMtMy0xLTEtNDcyMjY_a4ade0cb-5359-43bd-bed1-bea49783856a">52.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzQtMS0xLTEtNDcyMjY_a1b0f8fe-0240-4cd0-84e0-3d0d62e62918">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzQtMy0xLTEtNDcyMjY_30fa2774-89ce-4453-b636-63bbd14bdbc3">52.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0018e1126c834a38ae1193472508f95b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzUtMS0xLTEtNDcyMjY_adc8ee87-348b-4c4f-b2d8-f143b33ec27b">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0018e1126c834a38ae1193472508f95b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzUtMy0xLTEtNDcyMjY_aa673b8f-7e10-4ba7-91d4-f7c7690a9ed6">52.99</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i0018e1126c834a38ae1193472508f95b_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIyNDM_1ebf0415-5a21-406b-a076-4426aee58a36">28</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzMTY_ea25ae38-93a3-44b4-a98c-7142131a2617">two years</ix:nonNumeric> if performance goals are achieved.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000116/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations, as amended  (incorporated by reference to Exhibit 3.2 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000120/exhibit101-2021ltip.htm">Cardinal Health, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to Cardinal Health's Current Report on Form 8-K filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000120/exhibit102-formof2021ltipr.htm">Form of Restricted Share Units Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2 to Cardinal Health's Current Report on Form 8-K filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xex1022.htm">Form of Restricted Share Units Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000120/exhibit103-formof2021ltipp.htm">Form of Performance Share Units Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to Cardinal Health's Current Report on Form 8-K filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xex1032.htm">Form of Performance Share Units Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000120/exhibit104-formof2021ltipn.htm">Form of Nonqualified Stock Option Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Cardinal Health's Current Report on Form 8-K filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xex1042.htm">Form of Nonqualified Stock Option Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000120/exhibit105-formof2021ltipd.htm">Form of Directors' Restricted Share Units Agreement under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan ( incorporated by reference to Exhibit 10.5 to Cardinal Health's Current Report on Form 8-K filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137121000120/exhibit106-mip.htm">Cardinal Health, Inc. Management Incentive Plan (incorporated by reference to Exhibit 10.6 to Cardinal Health's Current Report on Form 8-K filed on November 9, 2021, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xexhibit107.htm">Aircraft Time Sharing Agreement, effective as of January 1, 2022, by and between Cardinal Health, Inc. and Michael C. Kaufmann</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q2_10qx123121xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_64">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_64">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_43">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_43">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_46">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_46">21</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_49">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_52">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_58">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_58">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_127">45</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6bdf7a21332a418cb7d5503f4cc4365e_133">47</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i6bdf7a21332a418cb7d5503f4cc4365e_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.182%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MICHAEL C. KAUFMANN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael C. Kaufmann</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>a22q2_10qx123121xexhibit107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia50fb09473e94bdc94aa846ee6e57db5_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AIRCRAFT TIME SHARING AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Aircraft Time Sharing Agreement (&#8220;Agreement&#8221;) by and between Cardinal Health, Inc. (&#8220;Operator&#8221;), an Ohio corporation whose address is 7000 Cardinal Place, Dublin, Ohio 43017 and Michael C. Kaufmann (&#8220;User&#8221;), whose address is 7000 Cardinal Place, Dublin, Ohio 43017 (collectively the &#34;Parties&#34;), is effective January 1, 2022, and shall terminate on December 31, 2024, unless terminated sooner by either party pursuant to Article I below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, Operator has the right of possession of the aircraft (&#8220;Aircraft&#8221;) described in the Leased Aircraft Subject to the Aircraft Time Sharing Agreement attached hereto and made a part hereof, as Exhibit A&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, Operator employs a fully qualified flight crew to operate the Aircraft&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, Operator desires to provide to User, and User desires to have the use of said Aircraft with flight crew on a non-exclusive time sharing basis as defined in Section 91.501(c)(1) of the Federal Aviation Regulations (&#34;FAR&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, this Agreement sets forth the understanding of the Parties as to the terms under which Operator will provide User with the use, on a periodic basis, of the Aircraft as described in Exhibit A hereto, currently operated by Operator&#59; and </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, the use of the Aircraft will at all times be pursuant to and in full compliance with the requirements of Part 91 (General Operating and Flight Rules) of FAR&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the Parties agree as follows&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1. Termination. </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Either party may terminate this Agreement for any reason upon written notice to the other, such termination to become effective thirty (30) days from the date of the notice&#59; provided that this Agreement may be terminated on such shorter notice as may be required to comply with applicable laws, regulations, insurance requirements or in the event the insurance required hereunder is not in full force and effect.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2. Use of Aircraft. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) User may use the Aircraft from time to time, with the permission and approval of Operator's Flight Operations Department, for any and all lawful purposes allowed by FAR Part 91 (General Operating and Flight Rules) at such times as the Operator does not require the use of the Aircraft for the business purposes of Operator or an affiliate.  User&#8217;s use may include the use of the Aircraft by his family members (including children or grandchildren) and guests if they accompany him on the flight. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) User represents, warrants and covenants to Operator that&#58;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt">User shall use each Aircraft for and on his own account only and shall not use any Aircraft for the purposes of providing </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">transportation of passengers or cargo in air commerce for compensation or hire and shall not accept any </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reimbursement from a passenger or otherwise for charges under this Agreement&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt">User shall refrain from incurring any mechanics lien or other lien in connection with inspection, preventative maintenance, maintenance or storage of the Aircraft, whether permissible or impermissible under this Agreement, and User shall not attempt to convey, mortgage, assign, lease or any way alienate the Aircraft or create any kind of lien or security interest involving the Aircraft or do anything or take any action that might mature into such a lien&#59; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt">During the term of this Agreement, User will abide by and conform to all such laws, governmental and airport orders, rules and regulations as shall from time to time be in effect relating in any way to the operation and use of the Aircraft by a time-sharing User. </font></div><div style="text-indent:31.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) User shall provide Operator's Flight Operations Department with notice of his desire to use the Aircraft and proposed flight schedules pursuant to and in accordance with Operator&#8217;s Corporate Aircraft Utilization Policy, as amended from time to time.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Operator shall have sole and exclusive authority over the scheduling of the Aircraft, including which Aircraft is used for any particular flight. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e) Operator shall not be liable to User or any other person for loss, injury or damage occasioned by the delay or failure to furnish the Aircraft and crew pursuant to this Agreement for any reason.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3. Time-Sharing Arrangement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is intended that this Agreement is and will meet the requirements of a &#34;Time Sharing Agreement&#34; as that term is defined in FAR Section 91.501(c)(1). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4. Cost of Use of Aircraft. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) In exchange for use of the Aircraft, User shall pay the following amounts for each flight, pursuant to FAR Section 91.501(d)&#58; </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)        The cost of fuel, oil, lubricants and other additives. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)       Travel expenses of the crew, including food, lodging and ground transportation.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)       Hangar and tie-down costs when the Aircraft is required by the User to be away from the Aircraft's base of </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">           operation. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)        Insurance obtained for the specific flight.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)        Landing fees, airport taxes and similar assessments. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)        Customs, foreign permit and similar fees directly related to the flight.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(7)        In flight food and beverages. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(8)        Passenger ground transportation. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9)        Flight planning and weather contract services. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)      An additional charge comprised of the allocable share attributable to such flight of the average quarterly cost of &#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">             trip-related repairs and maintenance and other similar incremental costs, which shall not exceed 100% of the  </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">             expenses listed in Paragraph 4(a)(1).</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Operator will invoice, and User will pay, for all appropriate charges. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) In addition to the rental rate referenced in Paragraph 4(a) above, User shall also be assessed the Federal Excise Taxes as imposed under Section 4261 of the Internal Revenue Code and any applicable state and local taxes associated with such flight(s) required by law to be collected and remitted by Operator (&#34;Transportation Taxes&#34;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5. Invoicing and Payment.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font></div><div style="text-indent:0.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All payments to be made to Operator by User hereunder shall be paid in the manner set forth in this Paragraph 5.  Operator will pay to suppliers, employees, contractors, and government entities all expenses related to the operation and maintenance of the Aircraft hereunder in the ordinary course.  For all flights operated hereunder in each calendar month, Operator shall provide to User an initial invoice for the charges specified in Paragraph 4 of this Agreement (including Transportation Taxes), such invoice to be issued within thirty (30) days after the end of the calendar month in which such flights were completed.  The initial invoice for the costs specified in Paragraph 4(a) above may be based, in whole or in part, on average or estimated costs subject to reconciliation as provided in this Paragraph 5.  User shall pay Operator the full amount of such monthly invoice within thirty (30) days after receipt of the invoice.  After the completion of each calendar quarter, Operator shall also provide to User final invoices for all flights operated hereunder in each calendar month of such calendar quarter.  Such final invoices will be based on the actual costs for such flights, based on the billings received by Operator from third party vendors.  To the extent that User is required to pay Operator any additional amounts under the final invoices, it will do so within thirty (30) days after receipt of the final invoice.  In the event that the final invoice reduces the amounts paid as reimbursement under the initial invoices for such flights, the Operator shall return any overage or provide a credit to the User.  All invoices shall separately itemize the expenses in items (1) through (10) of Paragraph 4(a) for the collective flights included in that invoice.  User shall further pay all costs incurred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">by Operator in collecting any amounts due from User pursuant to the provisions of this Paragraph 5 after delinquency, including court costs and reasonable attorneys' fees.</font></div><div style="text-indent:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6. Insurance and Limitation of Liability. </font></div><div><font><br></font></div><div style="text-indent:0.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator represents that the flight operations for the Aircraft as contemplated in this Agreement will be covered by the Operator's aircraft all-risk physical damage insurance (hull coverage), aircraft bodily injury and property damage liability insurance, passenger, pilot and crew voluntary settlement insurance and statutory workers compensation and employer's liability insurance. </font></div><div style="text-indent:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) Insurance. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.         Operator will maintain or cause to be maintained in full force and effect throughout the term of this Agreement aircraft liability insurance in respect of the Aircraft in an amount at least equal to $100 million combined single limit for bodily injury to or death of persons (including passengers) and property damage liability.  Operator will retain all rights and benefits with respect to the proceeds payable under policies of hull insurance that may be payable as a result of any incident or occurrence while an Aircraft is being operated on behalf of User under this Agreement. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.             Operator shall use best efforts to procure such additional insurance coverage as User may request naming User as an additional insured&#59; provided, that the cost of such additional insurance shall be borne by User pursuant to Paragraph 4(a)(4) hereof. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Limitation of Liability.  User agrees that the insurance specified in paragraph 6(a) shall provide its sole recourse for all claims, losses, liabilities, obligations, demands, suits, judgments or causes of action, penalties, fines, costs and expenses of any nature whatsoever, including attorneys' fees and expenses for or on account of or arising out of, or in any way connected with, the use of the Aircraft by User, family members or guests, including injury to or death of any persons, including User, family members and guests which may result from or arise out of the use or operation of the Aircraft during the term of this Agreement (&#34;Claims&#34;).  This Paragraph 6 shall survive termination of this Agreement. </font></div><div><font><br></font></div><div style="text-indent:0.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) User agrees that when, in the reasonable view of Operator's Flight Operations Department or the pilots of the Aircraft, safety may be compromised, Operator or the pilots may terminate a flight, refuse to commence a flight or take other action necessitated by such safety considerations without liability for loss, injury, damage or delay. </font></div><div style="text-indent:0.2pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) In no event shall Operator be liable to User or his family members, employees, agents, representatives, guests or invitees for any claims or liabilities, including property damage or injury and death, and expenses, including attorney's fees, in excess of the amount paid by Operator's insurance carrier in the event of such loss. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e) OPERATOR SHALL IN NO EVENT BE LIABLE TO USER OR HIS FAMILY MEMBERS, EMPLOYEES, AGENTS, REPRESENTATIVES, GUESTS OR INVITEES FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES AND&#47;OR PUNITIVE DAMAGES OF ANY KIND OR NATURE UNDER ANY CIRCUMSTANCES OR FOR ANY REASON INCLUDING ANY DELAY OR FAILURE TO FURNISH THE AIRCRAFT OR CAUSED OR OCCASIONED BY THE PERFORMANCE OR NON-PERFORMANCE OF ANY SERVICES COVERED BY THIS AGREEMENT. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7. Covenants Regarding Aircraft Maintenance. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator shall, at its own expense, inspect, maintain, service, repair, overhaul and test the Aircraft in accordance with FAR Part 91.  Each Aircraft will remain in good operating condition and in a condition consistent with its airworthiness certification, including all FAA-issued airworthiness directives and mandatory service bulletins.  In the event that any non-standard maintenance is required at a time when a flight has been scheduled for User, Operator or Operator's Pilot-In-Command shall immediately notify User of the maintenance required, the effect on the ability to comply with User's dispatch requirements and the manner in which the Parties will proceed with the performance of such maintenance and conduct of the balance of the planned flight(s). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8. No Warranty. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NEITHER OPERATOR (NOR ITS AFFILIATES) MAKES, HAS MADE OR SHALL BE DEEMED TO MAKE OR HAVE MADE ANY WARRANTY OR REPRESENTATION, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, WITH RESPECT TO ANY AIRCRAFT TO BE USED HEREUNDER OR ANY ENGINE OR COMPONENT THEREOF, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS TO DESIGN, COMPLIANCE WITH SPECIFICATIONS, QUALITY OF MATERIALS OR </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANY PURPOSE, USE OR OPERATION, AIRWORTHINESS, SAFETY, PATENT, TRADEMARK OR COPYRIGHT INFRINGEMENT OR TITLE. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9. Operational Control. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator shall be responsible for the physical and technical operation of the Aircraft and the safe performance of all flights and shall retain full authority and control, including exclusive operational control, and possession of the Aircraft at all times during the term of this Agreement.  In accordance with applicable FARs, the qualified flight crew provided by Operator will exercise all required and&#47;or appropriate duties and responsibilities in regard to the safety of each flight conducted hereunder.  The Pilot-In-Command shall have absolute discretion in all matters concerning the preparation of the Aircraft for flight and the flight itself, the load carried and its distribution, the decision whether or not a flight shall be undertaken, the route to be flown, the place where landings shall be made and all other matters relating to operation of the Aircraft.  User specifically agrees that the flight crew shall have final and complete authority to delay or cancel any flight for any reason or condition which, in sole judgment of the Pilot-In-Command, could compromise the safety of the flight and to take any other action which, in the sole judgment of the Pilot-In-Command, is necessitated by considerations of safety.  No such action of the Pilot-In-Command shall create or support any liability to User or any other person for loss, injury, damages or delay.  The Parties further agree that Operator shall not be liable for delay or failure to furnish the Aircraft and crew pursuant to this Agreement which is caused by government regulation or authority, mechanical difficulty or breakdown, war, civil commotion, strikes or labor disputes, weather conditions, acts of God or other circumstances beyond Operator's reasonable control.  User agrees that Operator's operation of aircraft is within the operation guidelines of the Operator's Flight Operations Department manual and the crews are responsible to operate within the guidelines of FAR 91 and the Operator's Flight Operations Department manual. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">10. Governing Law. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Parties hereto acknowledge that this Agreement shall be governed by and construed in all respects in accordance with the laws of the State of Ohio. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11. Counterparts. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Agreement may be executed in one or more counterparts each of which will be deemed an original, all of which together shall constitute one and the same agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12. Notices and Communications.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All notices, requests, demands and other communications required or desired to be given hereunder shall be in writing (except as permitted pursuant to Paragraph 2(c)) and shall be deemed to be given&#58; (i) if personally delivered, upon such delivery&#59; (ii) if mailed by certified mail, return receipt requested, postage pre-paid, addressed as (to the extent applicable for mailing) listed in the preamble hereto, upon the earlier to occur of actual receipt, refusal to accept receipt or three (3) days after such mailing&#59; (iii) if sent by regularly scheduled overnight delivery carrier with delivery fees either prepaid or an arrangement, satisfactory with such carrier, made for the payment of such fees, addressed (to the extent applicable for overnight delivery) as listed in the preamble hereto, upon the earlier to occur of actual receipt or the next &#8220;Business Day&#8221; (as hereafter defined) after being sent by such delivery&#59; or (iv) upon actual receipt when sent by fax.  Notice given by other means shall be deemed to be given only upon actual receipt.  Addresses may be changed by written notice given as provided herein and signed by the party giving the notice. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">13. Further Acts. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator and User shall from time to time perform such other and further acts and execute such other and further instruments as may be required by law or may be reasonably necessary to&#58; (i) carry out the intent and purpose of this Agreement&#59; and (ii) establish, maintain and protect the respective rights and remedies of the other party. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">14. Successors and Assigns. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Neither this Agreement nor any party&#8217;s interest herein shall be assignable to any other party whatsoever, except that Operator may assign its interest to an affiliate without the consent of the User.  This Agreement shall inure to the benefit of and be binding upon the Parties hereto, their heirs, representatives and successors. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">15. Severability. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable, those provisions shall be replaced by provisions acceptable to both Parties to this Agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">16. Flight Crew. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator is responsible for providing a qualified flight crew for all flight operations under this Agreement.  The Operator will furnish two experienced and competent pilots who shall be under the direction and control of the Operator at all times. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">17. Taxes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Parties acknowledge that reimbursement of all items specified in Paragraph 4, except for subsections (a)(7) and (a)(8) thereof, are subject to the Transportation Taxes.  User shall pay to Operator (for payment to the appropriate governmental agency) any Transportation Taxes applicable to flights of the Aircraft conducted hereunder.  Operator shall indemnify User for any claims related to the Transportation Taxes to the extent that User has paid Operator the amounts necessary to pay such taxes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">18. Right of Possession. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operator has the right of possession to each Aircraft in Exhibit A pursuant to an Aircraft Lease Agreement.  Nothing herein shall constitute a transfer of Operator's possessory rights to the Aircraft. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">19. Truth-in-Leasing. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Operator shall mail a copy of this Agreement for and on behalf of both Parties to&#58; Federal Aviation Administration, Aircraft Registration Branch (AFS-750), Attention&#58; Technical Section, P.O. Box 25724, Oklahoma City, Oklahoma 73125, within twenty-four (24) hours of its execution, as provided by FAR 91.23 (c)(1).  Additionally, Operator agrees to comply with the notification requirements of FAR Section 91.23 by notifying by telephone or in person the FAA Flight Standards Office nearest to the originating point of the first flight under this Agreement at least forty-eight (48) hours prior to such flight. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) OPERATOR CERTIFIES THAT EACH AIRCRAFT HAS BEEN INSPECTED AND MAINTAINED WITHIN THE 12-MONTH PERIOD PRECEDING THE DATE OF THIS AGREEMENT IN ACCORDANCE WITH THE PROVISIONS OF PART 91 OF THE FEDERAL AVIATION REGULATIONS AND THAT ALL APPLICABLE REQUIREMENTS FOR EACH AIRCRAFT'S MAINTENANCE AND INSPECTION HEREUNDER WILL BE MET AND ARE VALID FOR THE OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT DURING THE DURATION OF THIS AGREEMENT. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) OPERATOR, WHOSE ADDRESS APPEARS AND AUTHORIZED SIGNATURE APPEARS BELOW, AGREES, CERTIFIES AND ACKNOWLEDGES THAT WHENEVER EACH AIRCRAFT IS OPERATED UNDER THIS AGREEMENT, OPERATOR SHALL BE KNOWN AS, CONSIDERED AND SHALL IN FACT BE THE OPERATOR OF THE AIRCRAFT AND THAT OPERATOR UNDERSTANDS ITS RESPONSIBILITIES FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) THE PARTIES UNDERSTAND THAT AN EXPLANATION OF FACTORS AND PERTINENT FEDERAL AVIATION REGULATIONS BEARING ON OPERATIONAL CONTROL CAN BE OBTAINED FROM THE RESPONSIBLE FAA FLIGHT STANDARDS OFFICE. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) OPERATOR AGREES TO KEEP A COPY OF THIS AGREEMENT IN THE AIRCRAFT AT ALL TIMES DURING THE TERM OF THIS AGREEMENT.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to be duly executed on November __, 2021. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OPERATOR&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">____________________________________</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;   Carrie S. Cox</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;    Chairman of the Human Resources and Compensation Committee of the Board of Directors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">USER&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michael C. Kaufmann </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">____________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Leased Aircraft Subject to Aircraft Time Sharing Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of the undersigned is a party to the Aircraft Time Sharing Agreement dated November __, 2021, by and between Cardinal Health, Inc. (&#8220;Operator&#8221;) and Michael C. Kaufmann (&#8220;User&#8221;) (together the &#8220;Parties&#8221;), and agrees that from and after January 1, 2022, until this Exhibit A shall be superseded and replaced through agreement of the Parties or the Aircraft Time Sharing Agreement shall be terminated pursuant to its terms, the Aircraft described below shall constitute the &#8220;Aircraft&#8221; described in and subject to the terms of the Aircraft Time Sharing Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N600CH 2019 EMB-550 Serial#054</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N200CH 2016 Falcon 2000LXS Serial#319</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OPERATOR&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">____________________________________</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;   Carrie S. Cox</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;    Chairman of the Human Resources and Compensation Committee of the Board of Directors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">USER&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michael C. Kaufmann</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">____________________________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2.2
<SEQUENCE>3
<FILENAME>a22q2_10qx123121xex1022.htm
<DESCRIPTION>EX-10.2.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id9402d3d8fdc4c1a98e587bcbd529581_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.2.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESTRICTED SHARE UNITS AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Restricted Share Units Agreement (this &#8220;Agreement&#8221;) is entered into in Franklin County, Ohio.  On &#91;grant date&#93; (the &#8220;Grant Date&#8221;), Cardinal Health, Inc., an Ohio corporation (the &#8220;Company&#8221;), has awarded to &#91;employee name&#93; (&#8220;Awardee&#8221;) &#91;# of shares&#93; Stock Units (the &#8220;Restricted Share Units&#8221; or &#8220;Award&#8221;), representing an unfunded unsecured promise of the Company to deliver common shares, without par value, of the Company (the &#8220;Shares&#8221;) to Awardee as set forth in this Agreement.  The Restricted Share Units have been granted pursuant to the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (the &#8220;Plan&#8221;), and are subject to all provisions of the Plan, all of which are incorporated in this Agreement by reference and are subject to the provisions of this Agreement.  Capitalized terms used in this Agreement which are not specifically defined have the meanings ascribed to such terms in the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Vesting of Restricted Share Units</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  &#91;CLIFF ALTERNATIVE&#58;  The Restricted Share Units vest on the &#91;          &#93; anniversary of the Grant Date (the &#8220;Vesting Date&#8221;), subject to the provisions of this Agreement, including those relating to Awardee&#8217;s continued employment with the Company and its Affiliates (collectively, the &#8220;Cardinal Group&#8221;).&#93;  &#91;INSTALLMENT ALTERNATIVE&#58;  The Restricted Share Units vest in &#91;         &#93; installments, which will be as nearly equal as possible, on the &#91;          &#93; anniversaries of the Grant Date (each a &#8220;Vesting Date&#8221; with respect to the portion of the Restricted Share Units scheduled to vest on such date), subject in each case to the provisions of this Agreement, including those relating to Awardee&#8217;s continued employment with the Company and its Affiliates (collectively, the &#8220;Cardinal Group&#8221;).&#93; </font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  In the event of a Change of Control prior to a Termination of Employment, the Restricted Share Units (to the extent not previously vested or forfeited) vest in full, except to the extent that a Replacement Award is provided to Awardee in accordance with Section 16(b) of the Plan.  Any Replacement Award must vest in full upon (i) a Termination for Good Reason by Awardee, (ii) a Termination of Employment by the Company or its successor in the Change of Control other than a Termination for Cause, or (iii) Awardee&#8217;s death or Disability, in each case, occurring at or during the period of two years after the Change of Control.  In addition, if a Replacement Award is provided, any Restricted Share Units that would vest in accordance with Paragraphs 3(b) or (c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in connection with Awardee&#8217;s Retirement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or Disability if Awardee&#8217;s Termination of Employment occurred on the date of the Change of Control will for purposes of this Agreement vest at the time of the Change of Control.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Restricted Share Units are not transferable other than by beneficiary designation, will, or by the laws of descent or distribution.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Except as set forth in Paragraphs 1(b) and 3(b), (c) and (d), if a Termination of Employment occurs, then any unvested Restricted Share Units are forfeited by Awardee immediately upon such Termination of Employment.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Awardee&#8217;s death occurs after the Grant Date or a Termination of Employment by reason of Awardee&#8217;s Disability occurs at least 6 months after the Grant Date, then any outstanding unvested Restricted Share Units immediately vest in full and are not forfeited.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.62pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Awardee&#8217;s Retirement occurs at least 6 months after the Grant Date, then a Ratable Portion of each unvested installment of the outstanding Restricted Share Units immediately vests and is not forfeited.  Such &#8220;Ratable Portion,&#8221; with respect to the applicable installment, is an amount (rounded down to the nearest whole Share) equal to such installment of the Restricted Share Units scheduled to vest on a future Vesting Date multiplied by a fraction, the numerator of which is the number of days from the Grant Date through the date of the Termination of Employment, and the denominator of which is the number of days from the Grant Date through such Vesting Date.</font><font style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This provision is an alternative that may not be included in every award agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Involuntary Termination with Separation Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If (i) Paragraph 3(c) is not applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Cardinal Group or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least 6 months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release of claims with the Cardinal Group (in such form as may reasonably be presented by the Company) (a &#8220;Separation Agreement&#8221;), and Awardee does not timely revoke such Separation Agreement, then a Ratable Portion of each unvested installment of the outstanding Restricted Share Units immediately vests and is not forfeited.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Special Forfeiture and Repayment Rules</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group&#8217;s legitimate business assets and discourage conduct that threatens or harms those assets.  The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below.  Activities that trigger the forfeiture and repayment rules are divided into two categories&#58; Misconduct and Competitor Conduct.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  During employment with the Cardinal Group and with respect to clauses (A), (D), (E), (F) and (G), for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct.  If Awardee engages in Misconduct during employment or within three years after the Termination of Employment for any reason, then </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Restricted Share Units that have not yet vested or that vested at any time within three years prior to the date the Misconduct first occurred and have not yet been paid pursuant to Paragraph 5, and those forfeited Restricted Share Units automatically terminate, and </font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee resulting from the payment of Restricted Share Units pursuant to Paragraph 5 that had vested at any time within three years prior to the date the Misconduct first occurred less (B) $1.00.  The gross gain is the Fair Market Value of the Shares represented by the Restricted Share Units on the date of receipt.</font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means </font></div><div><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">disclosing or using any of the Cardinal Group&#8217;s confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee&#8217;s assigned duties for the Cardinal Group&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.81pt">fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.81pt">directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee&#8217;s Termination of Employment&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his&#47;her employment or a contract worker to terminate his&#47;her contract with a member of the Cardinal Group&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.72pt">any action by Awardee and&#47;or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee&#59; or </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.34pt">breaching any provision of any employment or severance agreement with a member of the Cardinal Group.  </font></div><div style="padding-left:108pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group&#8217;s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.  </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If Awardee engages in Competitor Conduct during employment or  &#160;&#160;&#160;&#160;                                                           within one year after the Termination of Employment for any reason, then </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Restricted Share Units that have not yet vested or that vested at any time within one year prior to the date the Competitor Conduct first occurred and have not yet been paid pursuant to Paragraph 5, and those forfeited Restricted Share Units automatically terminate, and </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee resulting from the payment of Restricted Share Units pursuant to Paragraph 5 that had vested at any time since the earlier of one year prior to the date the Competitor Conduct first occurred or one year prior to the Termination of Employment, if applicable, less (B) $1.00.  The gross gain is the Fair Market Value of the Shares represented by the Restricted Share Units on the date of receipt.</font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States.  If Awardee has a Termination of Employment and Awardee&#8217;s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct will be limited to that specific territory or territories.  A &#8220;Competitor&#8221; means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;c. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Nothing in this Paragraph 4 constitutes or is to be construed as a &#8220;noncompete&#8221; covenant or other restraint on employment or trade.  The provisions of this Paragraph 4 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group.  The execution of this Agreement is voluntary.  Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee&#8217;s employment with the Cardinal Group.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee agrees to provide the Company with at least 10 days&#8217; written notice prior to accepting employment with or providing services to a Competitor within one year after Termination of Employment.  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-25.74pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 4, including Awardee&#8217;s receipt of the Restricted Share Units.  Awardee further acknowledges that the Company would not provide the Restricted Share Units to Awardee without Awardee&#8217;s promise to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">abide by the terms of this Paragraph 4.  The parties also acknowledge that the provisions contained in this Paragraph 4 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-26.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee may be released from the obligations of this Paragraph 4 if and only if the Administrator determines, in writing and in the Administrator&#8217;s sole discretion, that a release is in the best interests of the Company.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Subject to the provisions of Paragraph 4 and Paragraphs 5(b), (c), (d) and &#160;&#160;&#160;&#160; (e), Awardee is entitled to receive from the Company (without any payment by or on behalf of Awardee other than as described in Paragraph 9) the Shares represented by the vested Restricted Share Units on the Vesting Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent that Restricted Share Units are vested on the date of Awardee&#8217;s Termination of Employment due to death, Awardee&#8217;s estate or designated beneficiary is entitled to receive the corresponding Shares from the Company on the date of death.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.62pt;text-decoration:underline">Disability, Retirement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">and Other Separations from Service</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent that Restricted Share Units are vested as the result of Disability, Retirement or otherwise on the date of Awardee&#8217;s &#8220;separation from service&#8221; (determined in accordance with Section 409A of the Code), Awardee is entitled to receive the corresponding Shares from the Company on the date that is not later than 60 days after Awardee&#8217;s &#8220;separation from service&#8221;&#59; provided, however, that if Awardee on the date of separation from service is a &#8220;specified employee&#8221; (certain employees of the Cardinal Group within the meaning of Section 409A of the Code determined using the identification methodology selected by the Company from time to time), to the extent necessary to avoid the imposition of tax under Section 409A of the Code, Awardee is entitled to receive the corresponding Shares from the Company six months after the date of Awardee&#8217;s separation from service or, if earlier, the date of Awardee&#8217;s death.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent that Restricted Share Units are vested on the date of a Change of Control, Awardee is entitled to receive the corresponding Shares from the Company on the date of the Change of Control&#59; provided, however, that if such Change of Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, and where Section 409A of the Code applies to such distribution as a deferral of compensation, Awardee is entitled to receive the corresponding Shares from the Company on the date that would have otherwise applied pursuant to Paragraphs 5(a), (b) or (c).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Elections to Defer Receipt</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Elections to defer receipt of the Shares beyond the date of payment provided in this Agreement may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee is not entitled to receive cash dividends on the Restricted  Share Units but will receive a dividend equivalent payment from the Company in an amount equal to the dividends that would have been paid on each Share underlying the Restricted Share Units if it had been outstanding between the Grant Date and the payment date of any such Share (i.e., based on the record date for cash dividends).  Subject to an election to defer receipt if permitted under Paragraph 5(e), the Company shall pay dividend equivalent payments in cash as soon as reasonably practicable after the payment date of the Restricted Share Units to which such dividend equivalents relate.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Right of Set-Off</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  By accepting the Restricted Share Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee has no rights of a shareholder with respect to the Restricted Share Units, including no right to vote the Shares represented by the Restricted Share Units, until such Shares vest and are paid to Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding Tax</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee is liable and responsible for all taxes owed in connection with the Restricted Share Units (including taxes owed with respect to the cash payments described in Paragraph 6), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Restricted Share Units.  The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant, vesting or payment of the Restricted Share Units or the subsequent sale of Shares issuable pursuant to the Restricted Share Units.  The Company does not commit and is under no obligation to structure the Restricted Share Units to reduce or eliminate Awardee&#8217;s tax liability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Prior to any event in connection with the Restricted Share Units (e.g., vesting or payment) that the Company determines may result in any domestic or foreign tax withholding amounts being paid by the Company, whether national, federal, state or local, including any employment tax obligation (the &#8220;Tax Withholding Obligation&#8221;), Awardee is required to arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.  Awardee&#8217;s acceptance of this Agreement constitutes Awardee&#8217;s instruction and authorization to the Company to withhold on Awardee&#8217;s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company determines to be sufficient to satisfy the Tax Withholding Obligation.  In the case of any amounts withheld for taxes pursuant to this provision in the form of Shares, the amount withheld may not exceed the amount legally required and withholding above the minimum withholding requirements shall be available only if and to the extent that the Administrator has authorized such.  The Company has the right to deduct from all cash payments paid pursuant to Paragraph 6 the amount of any taxes which the Company is required to withhold with respect to such payments.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law&#47;Venue for Dispute Resolution&#47;Costs and Legal Fees</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and&#47;or this Agreement and that the Restricted Share Units and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio.  In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awardee acknowledges that the covenants contained in Paragraph 4 are reasonable in nature, are fundamental for the protection of the Company&#8217;s legitimate business and proprietary interests, and do not adversely affect Awardee&#8217;s ability to earn a living.  If it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings.  Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Defend Trade Secrets Act Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; (b) is made to Awardee&#8217;s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law&#59; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Action by the Administrator</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator.  The parties agree to be bound by the decisions of the Administrator regarding the interpretation of this Agreement and regarding any and all matters set forth in this Agreement.  In fulfilling its responsibilities under this Agreement, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate.  The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including whether conduct constitutes Misconduct or Competitor Conduct, is final and binding.  The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Prompt Acceptance of Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Restricted Share Unit grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee&#8217;s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company&#8217;s third-party equity plan administrator&#8217;s web site, within 90 days of the Grant Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Electronic Delivery and Consent to Electronic Participation</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Share Unit grant under and participation in the Plan or future Restricted Share Units that may be granted under the Plan by electronic means or to request Awardee&#8217;s consent to participate in the Plan by electronic means.  Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of restricted share unit grants and the execution of restricted share unit agreements through electronic signature.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        Cardinal Health, Inc.</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        7000 Cardinal Place</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        Dublin, Ohio 43017</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        Attention&#58;  Corporate Secretary</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Employment Agreement, Offer Letter or Other Arrangement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent a written employment agreement, offer letter or other arrangement (&#8220;Employment Arrangement&#8221;) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to vesting of the Award on Termination of Employment by reason of specified events than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Award on Termination of Employment by reason of such specified events supersede the terms of this Agreement to the extent permitted by the terms of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Recoupment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement will be administered in compliance with Section 10D of the Exchange Act and any applicable rules or regulations promulgated by the Securities and Exchange Commission or any national securities exchange or national securities association on which the Shares may be traded.   In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company&#8217;s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to Awardee had the financial results been properly reported.  This Paragraph 17 is not the Company&#8217;s exclusive remedy with respect to such matters.  Except as otherwise required by Applicable Law, this Paragraph 17 will not apply after a Change of Control.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Any amendment to the Plan is deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto&#59; provided, however, that no amendment may impair the rights of Awardee with respect to an outstanding Restricted Share Unit unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company.  Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Restricted Share Units to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">under the Restricted Share Units, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The number of Shares issuable for each Restricted Share Unit and the other terms and conditions of the Award evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Compliance with Section 409A of the Code</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Code.  This Agreement shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of Awardee).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">No Right to Future Awards or Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The grant of the Restricted Share Units under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards.  The grant of the Restricted Share Units and any payments made under this Agreement will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law.  Nothing contained in this Agreement confers upon Awardee any right to be employed or remain employed by the Company or any of its Affiliates, nor limits or affects in any manner the right of the Company or any of its Affiliates to terminate the employment or adjust the compensation of Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Review</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Awardee agrees and represent that the Awardee has been advised to consult with an attorney prior to executing this Agreement and fully understands the Awardee&#8217;s right to discuss all aspects of this Agreement with an attorney of the Awardee&#8217;s choice.  The Awardee&#8217;s execution of this Agreement establishes that, if the Awardee wishes the advice of an attorney, the Awardee has done so by the date the Awardee signed the Agreement, and that the Awardee was given at least 14 days to consider whether to sign.  The Awardee may sign this Agreement before the end of the 14-day period and the Awardee agrees that if the Awardee decides to shorten this time period for signing, the Awardee&#8217;s decision was knowing and voluntary.  The parties agree that a change, whether material or immaterial, does not restart the running of said period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                            CARDINAL HEALTH, INC.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                            By&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                  </font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                            Its&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                  </font></div><div style="padding-left:72pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ACCEPTANCE OF AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awardee hereby&#58; (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company&#8217;s most recent annual report to shareholders and other communications routinely distributed to the Company&#8217;s shareholders, and a copy of the Plan Description pertaining to the Plan&#59; (b) accepts this Agreement and the Restricted Share Units granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the Agreement regarding &#8220;Special Forfeiture and Repayment Rules&#8221; set forth in Paragraph 4 and &#8220;Recoupment&#8221; set forth in Paragraph 17&#59; (c) represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement&#59; (d) agrees that no transfer of the Shares delivered in respect of the Restricted Share Units may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration&#59; and (e) acknowledges that any Awards granted to Awardee under the Cardinal Health, Inc. Management Incentive Plan (&#8220;MIP&#8221;) are subject to the recoupment and special forfeiture and repayment rules set forth in Section 7 of the MIP and agrees to be bound by these provisions with respect to such Awards.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                       &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    Awardee&#8217;s Signature</font></div><div><font><br></font></div><div style="padding-left:288pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                     &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    Date&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3.2
<SEQUENCE>4
<FILENAME>a22q2_10qx123121xex1032.htm
<DESCRIPTION>EX-10.3.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7721aa0b636c430786e7476cef2dbaa4_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.3.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PERFORMANCE SHARE UNITS AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Performance Share Units Agreement (this &#8220;Agreement&#8221;) is entered into in Franklin County, Ohio.  On &#91;grant date&#93; (the &#8220;Grant Date&#8221;), Cardinal Health, Inc., an Ohio corporation (the &#8220;Company&#8221;), has awarded to &#91;employee name&#93; (&#8220;Awardee&#8221;) &#91;target # of units&#93; performance-based Stock Units (the &#8220;Performance Share Units&#8221; or &#8220;Award&#8221;).  The Performance Share Units have been granted pursuant to the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (the &#8220;Plan&#8221;), and are subject to all provisions of the Plan, all of which are incorporated in this Agreement by reference and are subject to the provisions of this Agreement.  Capitalized terms used in this Agreement which are not specifically defined have the meanings ascribed to them in the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Vesting of Performance Share Units</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Subject to the provisions of this Agreement, zero to &#91;maximum percentage&#93; of the Performance Share Units vest when the Administrator certifies the payout level (&#8220;Payout Level&#8221;) as a result of achievement of specific performance criteria (the &#8220;Performance Goals&#8221;) for a performance period (&#8220;Performance Period&#8221;) set forth in the Statement of Performance Goals provided to the Awardee with respect to the Award and approved by the Committee (the &#8220;Statement of Performance Goals&#8221;).</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Performance Share Units are not transferable other than by beneficiary designation, will, or by the laws of descent or distribution.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Except to the extent that vesting occurs pursuant to Paragraphs 3(b), (c), (d) or (e) or Paragraph 5, if a Termination of Employment occurs prior to the &#91;applicable payment date in Paragraph 6(a) (the &#8220;Payment Date&#8221;)&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;First Payment Date (as defined in Paragraph 6(a))&#93;</font><font style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;2&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> associated with a Performance Period, any Performance Share Units allocated to that Performance Period, whether vested or unvested, are forfeited by Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Awardee&#8217;s death occurs after the Grant Date or a Termination of Employment by reason of Awardee&#8217;s Disability occurs at least 6 months after the Grant Date, then the outstanding unvested Performance Share Units for a Performance Period will vest (or in the case of an ongoing Performance Period, be eligible to vest) as if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Payment Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.62pt">&#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Awardee&#8217;s Retirement occurs at least 6 months after the Grant Date, then the outstanding unvested Performance Share Units for a Performance Period will be eligible to vest in an amount equal to the number of Performance Share Units that would have vested if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Payment Date multiplied by a fraction, the numerator of which is the number of days in the Performance Period up to the date of such Termination of Employment, and the denominator of which is the total number of days in such Performance Period.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Involuntary Termination with Separation Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If (i) neither Paragraph 3(c) nor Paragraph 3(e) is applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Company and its Affiliates (collectively, the &#8220;Cardinal Group&#8221;), or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least 6 months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release with the Cardinal Group (in such form as may reasonably be presented by the Company) (a &#8220;Separation Agreement&#8221;), and Awardee does not timely revoke such Separation Agreement, then the outstanding unvested Performance Share Units for a Performance Period will be eligible to vest in an amount equal to the number of Performance Share Units that would have vested if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Payment Date multiplied by a fraction, the numerator of which is the </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For awards without deferred settlement.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards with deferred settlement.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This provision is an alternative that may not be included in every award agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">number of days in the Performance Period up to the date of such Termination of Employment, and the denominator of which is the total number of days in such Performance Period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Involuntary Termination After Completion of a Performance Period</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs after the completion of a Performance Period but prior to the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Payment Date, then the Performance Share Units for the applicable Performance Period will vest as if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Payment Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Special Forfeiture and Repayment Rules</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group&#8217;s legitimate business assets and discourage conduct that threatens or harms those assets.  The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below.  Activities that trigger the forfeiture and repayment rules are divided into two categories&#58; Misconduct and Competitor Conduct.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  During employment with the Cardinal Group and with respect to clauses (A), (D), (E), (F) and (G), for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct.  If Awardee engages in Misconduct during employment or within three years after the Termination of Employment for any reason, then</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Performance Share Units that have not yet vested or that vested at any time within three years prior to the date the Misconduct first occurred and have not yet been paid pursuant to Paragraph 6, and those forfeited Performance Share Units automatically terminate, and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to&#58; (A) the gross gain to Awardee resulting from the payment of the Performance Share Units pursuant to Paragraph 6 that had vested at any time within three years prior to the date the Misconduct first occurred less (B) $1.00.  The gross gain is the Fair Market Value of the Shares represented by the Performance Share Units on the &#91;Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;applicable payment date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">disclosing or using any of the Cardinal Group&#8217;s confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee&#8217;s assigned duties for the Cardinal Group&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.81pt">fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.81pt">directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee&#8217;s Termination of Employment&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his&#47;her employment or a contract worker to terminate his&#47;her contract with a member of the Cardinal Group&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.72pt">any action by Awardee and&#47;or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee&#59; or</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.34pt">breaching any provision of any employment or severance agreement with a member of the Cardinal Group.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group&#8217;s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Performance Share Units that have not yet vested or that vested at any time within one year prior to the date the Competitor Conduct first occurred and have not yet been paid pursuant to Paragraph 6, and those forfeited Performance Share Units automatically terminate, and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay the Company an amount equal to&#58; (A) the gross gain to Awardee resulting from the payment of Performance Share Units pursuant to Paragraph 6 that had vested at any time since the earlier of one year prior to the date the Competitor Conduct first occurred or one year prior to the Termination of Employment, if applicable, less (B) $1.00.  The gross gain is the Fair Market Value of the Shares represented by the Performance Share Units on the </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;applicable payment date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States.  If Awardee has a Termination of Employment and Awardee&#8217;s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct is limited to that specific territory or territories.  A &#8220;Competitor&#8221; means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.62pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Nothing in this Paragraph 4 constitutes or is to be construed as a &#8220;noncompete&#8221; covenant or other restraint on employment or trade.  The provisions of this Paragraph 4 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group.  The execution of this Agreement is voluntary.  Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee&#8217;s employment with the Cardinal Group.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee agrees to provide the Company with at least 10 days written notice prior to accepting employment with or providing services to a Competitor within one year after Termination of Employment.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-25.74pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 4, including Awardee&#8217;s receipt of the Performance Share Units.  Awardee further acknowledges that the Company would not provide the Performance Share Units to Awardee without Awardee&#8217;s promise to abide by the terms of this Paragraph 4.  The parties also acknowledge that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provisions contained in this Paragraph 4 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-26.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee may be released from the obligations of this Paragraph 4 if and only if the Administrator determines, in writing and in the Administrator&#8217;s sole discretion, that a release is in the best interests of the Company.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Valuation</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  In the event of a Change of Control prior to &#91;a Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;the First Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the Administrator, as constituted immediately before such Change of Control, shall determine and certify the Payout Level (the &#8220;Change of Control Payout Level&#8221;) based on (i) actual performance through the most recent date prior to the Change of Control for which achievement of the Performance Goals can reasonably be determined&#59; and (ii) the expected performance for the remainder of the Performance Period based on information reasonably available.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Vesting and Substitute Awards</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.9pt">In the event of a Change of Control prior to &#91;a Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;the First Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the percentage of the Performance Share Units determined in accordance with the Statement of Performance Goals at the Change of Control Payout Level vests unless an award meeting the requirements of Paragraph 5(b)(ii) (a &#8220;Substitute Award&#8221;) is provided to Awardee to replace or adjust the Award.  If a Substitute Award is provided, any Performance Share Units that (A) except to the extent that clause (B) applies, would vest in accordance with Paragraphs 3(b) or (c) in connection with Awardee&#8217;s Retirement or Disability if Awardee&#8217;s Termination of Employment occurred on the date of the Change of Control or (B) are eligible to vest in accordance with Paragraph 3(d) as a result of Awardee&#8217;s Termination of Employment that actually occurs prior to the Change of Control, vest at the time of the Change of Control.  No Substitute Award will be provided in the event of Awardee&#8217;s Termination of Employment by reason of death, Disability, Retirement, or the circumstances described in Paragraph 3(d) prior to a Change of Control.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.08pt">An award meets the conditions of this Paragraph 5(b)(ii) (and hence qualifies as a Substitute Award) if, as determined by the Administrator as constituted immediately before the Change of Control, (A) it has a value at the time of grant or adjustment at least equal to the value of the Performance Share Units that would vest under Paragraph 5(b)(i) if there were no Substitute Award&#59; (B) it is paid in publicly traded equity securities of the Company or its successor in the Change of Control or another entity that is affiliated with the Company or its successor following the Change of Control&#59; (C) it is a restricted stock unit award with vesting and payment not conditioned on the achievement of any performance criteria or conditions&#59; (D) it vests in full upon (1) a Termination for Good Reason by Awardee, (2) a Termination of Employment by the Company or its successor in the Change of Control other than a Termination for Cause, or (3) Awardee&#8217;s death or Disability, in each case, occurring at or during the period of two years after the Change of Control&#59; (E) if Awardee is subject to U.S. federal income tax under the Code, the tax consequences to Awardee under the Code of the Substitute Award are not less favorable to Awardee than the tax consequences of the Award&#59; and (F) its other terms and conditions are not less favorable to Awardee than the terms and conditions of the Award (including the provisions that would apply in the event of a subsequent Change of Control).  Without limiting the generality of the foregoing, the Substitute Award may take the form of a continuation of the Award if the requirements of the preceding sentence are satisfied.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  &#91;The Company shall pay Performance Share Units in Shares.  Subject to the provisions of Paragraph 4 and Paragraphs 6(b) and (c), Awardee is entitled to receive from the Company (without any payment on behalf of Awardee other than as described in Paragraph 10) one Share for each vested Performance Share Unit not later than the 60</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> day after the end of a Performance Period, except that if Awardee&#8217;s Termination of Employment occurs due to death after the end of the Performance Period, Awardee is entitled to receive, with respect to any Performance Shares Units which are not subject to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;substantial risk of forfeiture&#8221; as determined for purposes of Section 409A of the Code on the date of Awardee&#8217;s death, the corresponding Shares from the Company on the date of death.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;The Company shall pay Performance Share Units in Shares.  Subject to the provisions of Paragraph 4, Awardee is entitled to receive from the Company (without any payment on behalf of Awardee other than as described in Paragraph 10) one Share for each vested Performance Share Unit. Subject to the provisions of Paragraph 6(b) and (c), payment with respect to any vested Performance Share Units shall be made in three installments.  The first installment, which shall be with respect to &#91;percentage&#93; of the total number of vested Performance Share Units, shall be paid no later than the 60</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> day after the end of the Performance Period (the &#8220;First Payment Date&#8221;).  The second installment, which shall be with respect to &#91;percentage&#93; of the total number of vested Performance Share Units, shall be paid on the first anniversary of the last day of the Performance Period.  &#91;The third installment, which shall be with respect to &#91;percentage&#93; of the total number of vested Performance Share Units, shall be paid on the second anniversary of the last day of the Performance Period.&#93;  Notwithstanding the above, in the event of an Awardee's death after the end of the Performance Period, Awardee is entitled to receive, with respect to any Performance Shares Units which are not subject to a &#8220;substantial risk of forfeiture&#8221; as determined for purposes of Section 409A of the Code on the date of Awardee&#8217;s death, corresponding Shares from the Company on account of any vested Performance Share Units which have not yet been paid as soon as practical following the date of death.  Payment shall be made at each of the times specified above unless the Administrator makes a finding that the number of vested Performance Share Units shall be reduced pursuant to Paragraph 4 due to Misconduct or Competitor Conduct.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Notwithstanding Paragraph 6(a) but subject to the provisions of Paragraph 4, to the extent that the Performance Share Units are not subject to a &#8220;substantial risk of forfeiture&#8221; as determined for purposes of Section 409A of the Code on the dates set forth below, payment with respect to such Performance Share Units will be made as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.9pt">On the date of a Change of Control, Awardee is entitled to receive one Share for each such Performance Share Unit, subject to any adjustments made pursuant to Section 16(a) of the Plan, from the Company&#59; provided, however, that if such Change of Control would not qualify as a permissible date of distribution under Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, and where Section 409A of the Code applies to such distribution as a deferral of compensation, Awardee is entitled to receive the corresponding Shares from the Company on the date that would have otherwise applied pursuant to Paragraphs 6(a), 6(b)(i), 6(b)(ii), or 6(b)(iii).  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.08pt">If Awardee&#8217;s separation from service occurs during the period of two years following a Change of Control (and such Change of Control constitutes a change of control event as defined in accordance with Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder), Awardee is entitled to receive one Share for each such Performance Share Unit from the Company on the date of Awardee&#8217;s separation from service&#59; provided, in such event that if Awardee on the date of separation from service is a &#8220;specified employee&#8221; (certain employees of the Cardinal Group within the meaning of Section 409A of the Code determined using the identification methodology selected by the Company from time to time), Awardee is entitled to receive the corresponding Shares from the Company on the first day of the seventh month after the date of Awardee&#8217;s separation from service or, if earlier, the date of Awardee&#8217;s death.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">On the date of Awardee's Termination of Employment due to death following a Change of Control, Awardee is entitled to receive one Share for each such Performance Share Unit from the Company on the date of death.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.62pt;text-decoration:underline">Elections to Defer Receipt</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Elections to defer receipt of the Shares beyond the &#91;Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#47; &#91;applicable payment date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> applicable payment date may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code.  &#91;Any election to defer will be valid only if the elected payment date is a date that is later than the date payment would have otherwise occurred.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee is not entitled to receive cash dividends on the Performance Share Units but will receive a dividend equivalent payment from the Company in an amount equal to the dividends that would have been paid on each Share underlying the Performance Share Units if it had been outstanding between the Grant Date and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the &#91;applicable&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> payment date of any such Share (i.e., based on the record date for cash dividends).  Subject to an election to defer receipt as permitted under Paragraph 6(c), the Company shall pay dividend equivalent payments in cash (without interest) as soon as reasonably practicable after the &#91;applicable&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> payment date of (and to the same extent as) the Performance Share Units to which such dividend equivalents relate.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Right of Set-Off</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  By accepting the Performance Share Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee has no rights of a shareholder with respect to the Performance Share Units, including no right to vote any Shares represented by the Performance Share Units, until such Shares are paid to Awardee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Withholding Tax</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee is liable and responsible for all taxes owed in connection with the Performance Share Units (including taxes owed with respect to the cash payments described in Paragraph 7), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Performance Share Units.  The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant, vesting or payment of the Performance Share Units or the subsequent sale of Shares issuable pursuant to vested Performance Share Units.  The Company does not commit and is under no obligation to structure the Performance Share Units to reduce or eliminate Awardee&#8217;s tax liability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Prior to any event in connection with the Performance Share Units (e.g., vesting or payment) that the Company determines may result in any domestic or foreign tax withholding amounts being paid by the Company, whether national, federal, state or local, including any employment tax obligation (the &#8220;Tax Withholding Obligation&#8221;), Awardee is required to arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.  Awardee&#8217;s acceptance of this Agreement constitutes Awardee&#8217;s instruction and authorization to the Company to withhold on Awardee&#8217;s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company determines to be sufficient to satisfy the Tax Withholding Obligation.  In the case of any amounts withheld for taxes pursuant to this provision in the form of Shares, the amount withheld may not exceed the amount legally required and withholding above the minimum withholding requirements shall be available only if and to the extent that the Administrator has authorized such.  The Company has the right to deduct from all cash payments paid pursuant to Paragraph 7 the amount of any taxes which the Company is required to withhold with respect to such payments.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Governing Law&#47;Venue for Dispute Resolution&#47;Costs and Legal Fees</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and&#47;or this Agreement and that the Performance Share Units and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio.  In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awardee acknowledges that the covenants contained in Paragraph 4 are reasonable in nature, are fundamental for the protection of the Company&#8217;s legitimate business and proprietary interests, and do not adversely affect Awardee&#8217;s ability to earn a living.  If it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings.  Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Defend Trade Secrets Act Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; (b) is made to Awardee&#8217;s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law&#59; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Action by the Administrator</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator.  The parties agree to be bound by the decisions of the Administrator regarding the interpretation of this Agreement and regarding all matters set forth in this Agreement.  In fulfilling its responsibilities under this Agreement, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate.  The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including whether conduct constitutes Misconduct or Competitor Conduct, is final and binding.  The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Prompt Acceptance of Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Performance Share Units grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee&#8217;s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company&#8217;s third-party equity plan administrator&#8217;s web site, within 90 days of the Grant Date.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Electronic Delivery and Consent to Electronic Participation</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Company may, in its sole discretion, decide to deliver any documents related to the Performance Share Unit grant under and participation in the Plan or future Performance Share Units that may be granted under the Plan by electronic means or to request Awardee&#8217;s consent to participate in the Plan by electronic means.  Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of performance share unit grants and the execution of performance share unit agreements through electronic signature.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below&#58;</font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardinal Health, Inc.</font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7000 Cardinal Place</font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dublin, Ohio 43017</font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attention&#58;  Corporate Secretary</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Employment Agreement, Offer Letter or Other Arrangement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent a written employment agreement, offer letter or other arrangement (&#8220;Employment Arrangement&#8221;) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to vesting of the Award on Termination of Employment by reason of specified events than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Award on Termination of Employment by reason of such specified events supersede the terms of this Agreement to the extent permitted by the terms of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Recoupment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement will be administered in compliance with Section 10D of the Exchange Act and any applicable rules or regulations promulgated by the Securities and Exchange Commission or any national securities exchange or national securities association on which the Shares may be traded.  In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company&#8217;s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to Awardee had the financial results been properly reported.  This Paragraph 18 is not the Company&#8217;s exclusive remedy with respect to such matters.  Except as otherwise required by Applicable Law, this Paragraph 18 will not apply after a Change of Control.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Any amendment to the Plan is deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto&#59; provided, however, that no amendment may impair the rights of Awardee with respect to an outstanding Performance Share Unit unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company.  Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Performance Share Units to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Performance Share Units, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The number of Shares issuable for each Performance Share Unit and the other terms and conditions of the Award evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Compliance with Section 409A of the Code</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Code.  This Agreement shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of Awardee).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Review</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Awardee agrees and represent that the Awardee has been advised to consult with an attorney prior to executing this Agreement and fully understands the Awardee&#8217;s right to discuss all aspects of this Agreement with an attorney of the Awardee&#8217;s choice.  The Awardee&#8217;s execution of this Agreement establishes that, if the Awardee wishes the advice of an attorney, the Awardee has done so by the date the Awardee signed the Agreement, and that the Awardee was given at least 14 days to consider whether to sign.  The Awardee may sign this Agreement before the end of the 14-day period and the Awardee agrees that if the Awardee decides to shorten this time period for signing, the Awardee&#8217;s decision was knowing and voluntary.  The parties agree that a change, whether material or immaterial, does not restart the running of said period.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">No Right to Future Awards or Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The grant of the Performance Share Units under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards.  The grant of the Performance Share Units and any payments made under this Agreement will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law.  Nothing contained in this Agreement confers upon Awardee any right to be employed or remain employed by the Company or any of its Affiliates, nor limits or affects in any manner the right of the Company or any of its Affiliates to terminate the employment or adjust the compensation of Awardee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.</font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CARDINAL HEALTH, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ACCEPTANCE OF AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awardee hereby&#58; (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company&#8217;s most recent annual report to shareholders and other communications routinely distributed to the Company&#8217;s shareholders, and a copy of the Plan Description pertaining to the Plan&#59; (b) accepts this Agreement and the Performance Share Units granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in this Agreement regarding &#8220;Special Forfeiture and Repayment Rules&#8221; set forth in Paragraph 4 and &#8220;Recoupment&#8221; set forth in Paragraph 18&#59; (c)  represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement&#59; and (d) agrees that no transfer of the Shares delivered in respect of the Performance Share Units may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration.</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                               &#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                Awardee&#8217;s Signature</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                               Date&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4.2
<SEQUENCE>5
<FILENAME>a22q2_10qx123121xex1042.htm
<DESCRIPTION>EX-10.4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0c2b6a2feb8f492a91759f2747e87db1_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.4.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CARDINAL HEALTH, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NONQUALIFIED STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Nonqualified Stock Option Agreement (this &#8220;Agreement&#8221;) is entered into in Franklin County, Ohio.  On &#91;date of grant&#93; (the &#8220;Grant Date&#8221;), Cardinal Health, Inc., an Ohio corporation (the &#8220;Company&#8221;), has awarded to &#91;employee name&#93; (&#8220;Awardee&#8221;), a Nonqualified Stock Option (the &#8220;Option&#8221;) to purchase &#91;# of shares&#93; common shares, without par value, of the Company (the &#8220;Shares&#8221;) for an exercise price of &#91;$X.XX&#93; per share.  The Option has been granted under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan (the &#8220;Plan&#8221;) and will include and be subject to all provisions of the Plan, all of which are incorporated in this Agreement by reference, and will be subject to the provisions of this Agreement.  Capitalized terms used in this Agreement which are not specifically defined will have the meanings ascribed to such terms in the Plan.  &#91;CLIFF ALTERNATIVE&#58; This Option vests and becomes exercisable on the &#91;           &#93; anniversary of the Grant Date (the &#8220;Vesting Date&#8221;), subject to the provisions of this Agreement, including those relating to Awardee&#8217;s continued employment with the Company and its Affiliates (collectively, the &#8220;Cardinal Group&#8221;).&#93;  &#91;INSTALLMENT ALTERNATIVE&#58; This Option vests and becomes exercisable in &#91;           &#93; installments, which will be as nearly equal as possible, on the &#91;           &#93; anniversaries of the Grant Date (each a &#8220;Vesting Date&#8221; with respect to the portion of the Option scheduled to vest on such date), subject in each case to the provisions of this Agreement, including those relating to Awardee&#8217;s continued employment with the Company and its Affiliates (collectively, the &#8220;Cardinal Group&#8221;).&#93;  This Option will expire on &#91;date of expiration&#93; (the &#8220;Grant Expiration Date&#8221;), subject to Section 3 hereof.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Method of Exercise and Payment of Price</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  At any time when all or a portion of the Option is exercisable under the Plan and this Agreement, some or all of the exercisable portion of the Option may be exercised from time to time by written notice to the Company, or such other method of exercise as may be specified by the Company, including without limitation, exercise by electronic means on the web site of the Company&#8217;s third-party equity plan administrator, which will&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">state the number of whole Shares with respect to which the Option is being exercised&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">if the Option is being exercised by anyone other than Awardee, if not already provided, be accompanied by proof satisfactory to counsel for the Company of the right of such person or persons to exercise the Option under the Plan and all applicable laws and regulations.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Payment of Price</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The full exercise price for the portion of the Option being exercised shall be paid to the Company as provided below&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">in cash&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">by check acceptable to the Company or wire transfer (denominated in U.S. Dollars)&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-25.74pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">subject to any conditions or limitations established by the Administrator, other Shares owned by Awardee that have a Fair Market Value on the date of surrender equal to or greater than the aggregate exercise price of the Shares as to which said Option is exercised (it being agreed that the excess of the Fair Market Value over the aggregate exercise price will be refunded to Awardee)&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-26.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">if permitted by the Administrator, consideration received by the Company under a broker-assisted sale and remittance program acceptable to the Administrator&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-24.38pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">v.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">if permitted by the Administrator, and subject to any conditions or limitations established by the Administrator, the Company&#8217;s withholding Shares otherwise issuable upon exercise of the Option pursuant to a &#8220;net exercise&#8221; arrangement&#59; or</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-26.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">vi.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">any combination of the foregoing methods of payment.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Option is transferable (a) at Awardee&#8217;s death, by Awardee by will or pursuant to the laws of descent and distribution, and (b) by Awardee during Awardee&#8217;s lifetime, without payment of consideration, to (i) the spouse, former spouse, parents, stepparents, grandparents, parents-in-law, siblings, siblings-in-law, children, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">stepchildren, children-in-law, grandchildren, nieces or nephews of Awardee, or any other persons sharing Awardee&#8217;s household (other than tenants or employees) (collectively, &#8220;Family Members&#8221;) or (ii) a trust, partnership or other entity controlled by Awardee or Awardee&#8217;s Family Members and in which Awardee or Awardee&#8217;s Family Members have 100% of the pecuniary interest&#59; provided, however, that subsequent transfers of the transferred Option are prohibited, except (X) if the transferee is an individual, at the transferee&#8217;s death by the transferee by will or pursuant to the laws of descent and distribution, and (Y) without payment of consideration to the individuals or entities listed in Paragraphs (b)(i) or (ii) above, with respect to the original Awardee.  The Administrator may, in its discretion, permit transfers to other persons and entities as permitted by the Plan.  Neither a transfer under a domestic relations order in settlement of marital property rights nor a transfer to an entity in which more than 50% of the voting interests are owned by Awardee or Family Members in exchange for an interest in that entity will be a transfer for consideration.  Within 10 days of any transfer, Awardee shall notify the Company in writing of the transfer. Following transfer, the Option continues to be subject to the same terms and conditions as were applicable immediately prior to transfer and, except as otherwise provided in the Plan or this Agreement, references to the original Awardee are deemed to refer to the transferee.  The events of a Termination of Employment of Awardee provided in Paragraph 3 continue to be applied with respect to the original Awardee, following which the Option is exercisable by the transferee only to the extent, and for the periods, specified in Paragraph 3.  The Company has no obligation to notify any transferee of Awardee&#8217;s Termination of Employment with the Cardinal Group for any reason.  The conduct prohibited of Awardee in Paragraph 5 continues to be prohibited of Awardee following transfer to the same extent as immediately prior to transfer and the Option (or its economic value, as applicable) is subject to forfeiture by the transferee and recoupment from Awardee to the same extent as would have been the case of Awardee had the Option not been transferred.  Awardee remains subject to the recoupment provisions of Paragraphs 5 and 15 of this Agreement and tax withholding provisions of Section 31 of the Plan following transfer of the Option.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Termination of Employment by Reason of Death or Disability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of death occurs after the Grant Date or a Termination of Employment by reason of Disability occurs at least six months after the Grant Date, then any outstanding unvested portion of the Option vests upon and becomes exercisable in full from and after such Termination of Employment.  The entire Option (including previously vested but unexercised portions) may thereafter be exercised by Awardee, any transferee of Awardee, if applicable, or by the legal representative of the estate or by the legatee of Awardee under the will of Awardee from the date of such Termination of Employment until the Grant Expiration Date.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Termination of Employment by Reason of Retirement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Retirement occurs at least six months after the Grant Date, then a Ratable Portion of each unvested installment of the outstanding Option immediately vests and becomes exercisable.  Such &#8220;Ratable Portion,&#8221; with respect to the applicable installment, is an amount (rounded down to the nearest whole Share) equal to such installment of the Option scheduled to vest on a future Vesting Date multiplied by a fraction, the numerator of which is the number of days from the Grant Date through the date of the Termination of Employment, and the denominator of which is the number of days from the Grant Date through such Vesting Date.  The Option, to the extent vested, may be exercised by Awardee (or any transferee, if applicable) until the Grant Expiration Date.  If Awardee dies after Retirement, but before the Grant Expiration Date, the Option, to the extent vested, may be exercised by any transferee of the Option, if applicable, or by the legal representative of the estate or by the legatee of Awardee under the will of Awardee from and after such death until the Grant Expiration Date.&#91;1&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.62pt;text-decoration:underline">Involuntary Termination of Employment with Separation Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If (i) Paragraph 3(b) is not applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Cardinal Group, or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs at least six months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release of claims with the Cardinal Group (in such form as may reasonably be presented by the Cardinal Group) (a &#8220;Separation Agreement&#8221;), and Awardee does not timely revoke such Separation Agreement, then a Ratable Portion of each unvested installment of the outstanding Option immediately vests and becomes exercisable.  The Option, to the extent vested, may be exercised by Awardee (or any transferee, if applicable) until the Grant Expiration Date.  If Awardee dies after such Termination of Employment, but before the Grant Expiration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date, the Option, to the extent vested, may be exercised by any transferee of the Option, if applicable, or by the legal representative of the estate or by the legatee of Awardee under the will of Awardee from and after such death until the Grant Expiration Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  In the event of a Change of Control prior to the Participant&#8217;s Termination of Employment, any outstanding unvested portion of the Option vests in full, except to the extent a Replacement Award is provided to the Participant in accordance with Section 16(b) of the Plan.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Other Termination of Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Except as set forth in Paragraphs 3(a), (b) and (c) , if a Termination of Employment occurs, any unexercised portion of the Option that has not vested on such date of Termination of Employment is automatically immediately forfeited.  Unless a longer period is applicable as specified in Section 16(b)(iv) of the Plan or Paragraphs 3(a) through (c), Awardee (or any transferee, if applicable) has 90 days from the date of Termination of Employment or until the Grant Expiration Date, whichever period is shorter, to exercise any portion of the Option that is vested and</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">exercisable on the date of Termination of Employment&#59; provided, however, that if the Termination of Employment was a Termination for Cause, as determined by the Administrator, the Option may be immediately canceled by the Administrator (whether then held by Awardee or any transferee).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Restrictions on Exercise</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Option is subject to all restrictions in this Agreement and in the Plan.  As a condition of any exercise of the Option, the Company may require Awardee or his or her transferee or successor to make any representation and warranty to comply with any applicable law or regulation or to confirm any factual matters (including Awardee&#8217;s compliance with the terms of Paragraph 5 or any employment or severance agreement between the Cardinal Group and Awardee) reasonably requested by the Company.  The Option is not exercisable if such exercise would involve a violation of any Applicable Law.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Special Forfeiture and Repayment Rules</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group&#8217;s legitimate business assets and discourage conduct that threatens or harms those assets.  The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below.  Activities that trigger the forfeiture and repayment rules are divided into two categories&#58; Misconduct and Competitor Conduct.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  During employment with the Cardinal Group and for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct.  If Awardee engages in Misconduct during employment or with respect to clauses (A), (D), (E), (F) and (G), within three years after the Termination of Employment for any reason, then </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Option (or any part of the Option that has not been exercised) which automatically terminates, and </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee or any transferee from each and every exercise of the Option at any time within three years prior to the date the Misconduct first occurred less (B) $1.00.  The gross gain is calculated by subtracting the exercise price paid for the Shares from the Fair Market Value of the Shares on the exercise date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means </font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">disclosing or using any of the Cardinal Group's confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee's assigned duties for the Cardinal Group&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.81pt">fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.81pt">directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee&#8217;s Termination of Employment&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.26pt">directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his&#47;her employment or a contract worker to terminate his&#47;her contract with a member of the Cardinal Group&#59; </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.72pt">any action by Awardee and&#47;or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee&#59; or </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.34pt">breaching any provision of any employment or severance agreement with a member of the Cardinal Group.  </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group&#8217;s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Option (or any part of the Option that has not been exercised) which automatically terminates, and </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to (A) the gross gain to Awardee or any transferee from each and every exercise of the Option at any time since the earlier of one year prior to the date the Competitor Conduct first occurred and one year prior to the Termination of Employment, if applicable, less (B) $1.00.  The gross gain is calculated by subtracting the exercise price paid for the Shares from the Fair Market Value of the Shares on the exercise date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States.  If Awardee has a Termination of Employment and Awardee&#8217;s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct will be limited to that specific territory or territories.  A &#8220;Competitor&#8221; means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c. </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.1pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Nothing in this Paragraph 5 constitutes or is to be construed as a &#8220;noncompete&#8221; covenant or other restraint on employment or trade.  The provisions of this Paragraph 5 do not prevent, nor are they </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group.  The execution of this Agreement is voluntary.  Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee&#8217;s employment with the Cardinal Group.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-23.92pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee agrees to provide the Company with at least 10 days&#8217; written notice prior to accepting employment with or providing services to a Competitor prior to one year after Termination of Employment.  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-25.74pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 5, including Awardee&#8217;s receipt of the Option.  Awardee further acknowledges that the Company would not provide the Option to Awardee without Awardee's promise to abide by the terms of this Paragraph 5.  The parties also acknowledge that the provisions contained in this Paragraph 5 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-26.2pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee may be released from the obligations of this Paragraph 5 if and only if the Administrator determines, in writing and in the Administrator's sole discretion, that a release is in the best interests of the Company.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Right of Set-Off</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  By accepting the Option, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Withholding Tax</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Awardee is liable and responsible for all taxes owed in connection with the exercise of the Option, regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Option.  The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the exercise of the Option.  The Company does not commit and is under no obligation to structure the Option or the exercise of the Option to reduce or eliminate Awardee's tax liability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Concurrently with the payment of the exercise price pursuant to Paragraph 1, Awardee is required to arrange for the satisfaction of the minimum amount of any domestic or foreign tax withholding obligation, whether national, federal, state, or local, including any employment tax obligation (the &#8220;Tax Withholding Obligation&#8221;) in a manner acceptable to the Company.  Any manner provided for in Paragraph 1(b) is an acceptable manner to satisfy the Tax Withholding Obligation unless otherwise determined by the Administrator.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Governing Law&#47;Venue for Dispute Resolution&#47;Costs and Legal Fees</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and&#47;or this Agreement and that the Option and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio.  In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Awardee acknowledges that the covenants contained in Paragraph 5 are reasonable in nature, are fundamental for the protection of the Company&#8217;s legitimate business and proprietary interests, and do not adversely affect Awardee&#8217;s ability to earn a living.  If it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings.  Any provision of this Agreement which is determined by a court of competent jurisdiction to be invalid or unenforceable or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.16pt;text-decoration:underline">Defend Trade Secrets Act Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; (b) is made to Awardee&#8217;s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law&#59; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Action by the Administrator</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator.  The parties agree to be bound by the decisions of the Administrator regarding the interpretation of this Agreement and regarding all matters set forth in this Agreement.  In fulfilling its responsibilities, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate.  The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including without limitation whether conduct constitutes Misconduct or Competitor Conduct, is final and binding.  The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Prompt Acceptance of Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Option grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee&#8217;s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company&#8217;s third-party equity plan administrator&#8217;s web site, within 90 days of the Grant Date.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Electronic Delivery and Consent to Electronic Participation</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Company may, in its sole discretion, decide to deliver any documents related to the Option grant under and participation in the Plan or future options that may be granted under the Plan by electronic means or to request Awardee&#8217;s consent to participate in the Plan by electronic means.  Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of option grants and the execution of option agreements through electronic signature.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        Cardinal Health, Inc.</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        7000 Cardinal Place</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        Dublin, Ohio 43017</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                        Attention&#58;  Corporate Secretary</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All notices, requests, consents, and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Employment Agreement, Offer Letter or Other Arrangement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  To the extent a written employment agreement, offer letter or other arrangement (&#8220;Employment Arrangement&#8221;) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to (a) vesting of the Option on Termination of Employment by reason of specified events or (b) exercisability of the Option following Termination of Employment, than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Option on Termination of Employment by reason of such specified events or exercisability of the Option following Termination of Employment supersede the terms of this Agreement to the extent permitted by the terms of the Plan.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Recoupment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement will be administered in compliance with Section 10D of the Exchange Act and any applicable rules or regulations promulgated by the Securities and Exchange Commission or any national securities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">exchange or national securities association on which the Shares may be traded.  In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company&#8217;s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to Awardee had the financial results been properly reported.  This Paragraph 15 is not the Company&#8217;s exclusive remedy with respect to such matters.  Except as otherwise required by Applicable Law, this Paragraph 15 will not apply after a Change of Control.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Amendments.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Any amendment to the Plan will be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto&#59; provided, however, that no amendment will impair the rights of Awardee with respect to an outstanding Award unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company.  Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Option to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Option, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The number of Shares issuable subject to the Option and the other terms and conditions of the grant evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Review</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Awardee agrees and represent that the Awardee has been advised to consult with an attorney prior to executing this Agreement and fully understands the Awardee&#8217;s right to discuss all aspects of this Agreement with an attorney of the Awardee&#8217;s choice.  The Awardee&#8217;s execution of this Agreement establishes that, if the Awardee wishes the advice of an attorney, the Awardee has done so by the date the Awardee signed the Agreement, and that the Awardee was given at least 14 days to consider whether to sign.  The Awardee may sign this Agreement before the end of the 14-day period and the Awardee agrees that if the Awardee decides to shorten this time period for signing, the Awardee&#8217;s decision was knowing and voluntary.  The parties agree that a change, whether material or immaterial, does not restart the running of said period.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">No Right to Future Awards or Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The grant of the Option under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards.  The grant of the Option and any related payments made to Awardee will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by Applicable Law.  Nothing contained in this Agreement confers upon Awardee any right with respect to continuance of employment or other service with the Company or any Affiliate, nor interferes in any way with any right the Company or any Affiliate would otherwise have to terminate Awardee&#8217;s employment or other service at any time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.6pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.</font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CARDINAL HEALTH, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                  </font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Its&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                   </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ACCEPTANCE OF AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Awardee hereby&#58; (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company&#8217;s most recent annual report to shareholders and other communications routinely distributed to the Company&#8217;s shareholders, and a copy of the Plan Description pertaining to the Plan&#59; (b) accepts this Agreement and the Option granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in the Agreement regarding &#8220;Special Forfeiture and Repayment Rules&#8221; set forth in Paragraph 5 and &#8220;Recoupment&#8221; set forth in Paragraph 15&#59; (c) represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement&#59; and (d) agrees that no transfer of the Shares delivered in respect of the Option may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                               &#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                Awardee&#8217;s Signature</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                               Date&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a22q2_10qx123121xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib519d57f3e49419a8e4fee0d6294028e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael C. Kaufmann, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;3, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a22q2_10qx123121xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icc3a7c8ef85a41289ad950fa041433be_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;3, 2022 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> JASON M. HOLLAR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a22q2_10qx123121xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9f22dac5327b4509b39e94c58d836af1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended December&#160;31, 2021 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February&#160;3, 2022 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>9
<FILENAME>a22q2_10qx123121xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7adc164ebd6f468b9589f18a135c7ac9_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2021 (the &#8220;2021 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases in demand or selling price&#59; the risk that we may not be able to offset significant cost increases for certain personal protective equipment (PPE) products or inflationary pressures impacting our Medical segment&#59; the possibility that sustained reduced demand for generic pharmaceutical product may continue to adversely impact our pharmaceutical generics program&#59; and the possibility that we could experience employee attrition as a result of our COVID-19 vaccine mandate or the expected governmental mandates&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including risks associated with the proposed settlement agreement and process designed to resolve lawsuits and claims brought by states and local governmental entities, including the risk that we could fail to reach a final resolution and that any injunctive or non-monetary relief that we may agree to could have unintended consequences&#59; and the risk that the outcome of other opioid-related lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity or the operations of our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59; the possibility that we may receive additional negative or unfavorable publicity or that the IRS may not agree with our underlying assumptions and judgments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on ethylene oxide (&#34;EtO&#34;) to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2021 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cah-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d933fb5b-1648-4e2f-85b6-17909e6e7a92,g:b7c819a0-6ebd-409c-a3ca-466b0ca5332e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>2104102 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsTables" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables">
        <link:definition>2305301 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsDetails" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails">
        <link:definition>2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>2107103 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails">
        <link:definition>2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>2112104 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsTables" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables">
        <link:definition>2318304 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails">
        <link:definition>2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
        <link:definition>2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails">
        <link:definition>2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>2123107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2424412 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>2125108 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>2326305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>2128109 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>2329306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2430414 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>2132110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>2333307 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>2140112 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>2341309 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2442420 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
        <link:definition>2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>2147113 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>2348310 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsStateMember" abstract="true" name="OpioidLawsuitsStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicalUnitGoodwillImpairmentMember" abstract="true" name="MedicalUnitGoodwillImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePrinceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicalUnitMember" abstract="true" name="MedicalUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackAxis" abstract="true" name="NetOperatingLossCarrybackAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackMember" abstract="true" name="NetOperatingLossCarrybackMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NumberofStateAttorneysGeneralfilinglawsuits" abstract="false" name="NumberofStateAttorneysGeneralfilinglawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_GoodwillImpairmentAxis" abstract="true" name="GoodwillImpairmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_AdditionalStockOptionPlanDataTableTextBlock" abstract="false" name="AdditionalStockOptionPlanDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A300MillionShareRepurchaseProgramMember" abstract="true" name="A300MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DiscountRateFairValueInput" abstract="false" name="DiscountRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LawsuitTypeDomain" abstract="true" name="LawsuitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" abstract="true" name="LongTermObligationsandOtherShortTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PatientRecoveryBusinessMember" abstract="true" name="PatientRecoveryBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TerminalGrowthRateFairValueInput" abstract="false" name="TerminalGrowthRateFairValueInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TotalLongTermandShortTermObligations" abstract="false" name="TotalLongTermandShortTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_DOJInvestigationMember" abstract="true" name="DOJInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" abstract="true" name="ShareRepurchaseProgramAggregatePurchasePrinceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" abstract="false" name="Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CARESActDomain" abstract="true" name="CARESActDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_FloatingRateNotesdue2022Member" abstract="true" name="FloatingRateNotesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A500MillionShareRepurchaseProgramMember" abstract="true" name="A500MillionShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ExercisablePeriodOfPlansInYears" abstract="false" name="ExercisablePeriodOfPlansInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cah_JudgmentForLostProfits" abstract="false" name="JudgmentForLostProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_TaxMattersAgreementAxis" abstract="true" name="TaxMattersAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NarativeAbstract" abstract="true" name="NarativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeMember" abstract="true" name="CardinalHealthAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CashReclassifiedToAssetHeldForSale" abstract="false" name="CashReclassifiedToAssetHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_GoodwillImpairmentDomain" abstract="true" name="GoodwillImpairmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthServicesMember" abstract="true" name="NuclearPrecisionHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cah-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d933fb5b-1648-4e2f-85b6-17909e6e7a92,g:b7c819a0-6ebd-409c-a3ca-466b0ca5332e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8c93fe6-8e17-4d26-a435-d6e0ae7b36f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_66c6a680-7bc5-4ad1-88c1-3fe813a2035c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8c93fe6-8e17-4d26-a435-d6e0ae7b36f7" xlink:to="loc_us-gaap_OperatingIncomeLoss_66c6a680-7bc5-4ad1-88c1-3fe813a2035c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_02674769-db0c-48ce-a940-ccdb0445930f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8c93fe6-8e17-4d26-a435-d6e0ae7b36f7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_02674769-db0c-48ce-a940-ccdb0445930f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_592058b7-ab4a-4d9b-be05-1cc682374066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8c93fe6-8e17-4d26-a435-d6e0ae7b36f7" xlink:to="loc_us-gaap_InterestExpense_592058b7-ab4a-4d9b-be05-1cc682374066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_adcb3381-cc44-4366-b08c-3e56a5d7cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8c93fe6-8e17-4d26-a435-d6e0ae7b36f7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_adcb3381-cc44-4366-b08c-3e56a5d7cfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a1ee9897-0c7a-4e01-8766-585bb169fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e8c93fe6-8e17-4d26-a435-d6e0ae7b36f7" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a1ee9897-0c7a-4e01-8766-585bb169fc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4df1fc78-4aab-4562-ba52-365d5a14bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7524cdca-eeb3-4094-b8dd-096a86e6aa75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_4df1fc78-4aab-4562-ba52-365d5a14bb68" xlink:to="loc_us-gaap_Revenues_7524cdca-eeb3-4094-b8dd-096a86e6aa75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_45f7e7c3-ddbb-4b42-b109-2bbe2d6739e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_4df1fc78-4aab-4562-ba52-365d5a14bb68" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_45f7e7c3-ddbb-4b42-b109-2bbe2d6739e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c55ed893-3f4e-4143-b4f4-5e70b24b8699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4de622e8-f877-4727-8826-385f72482d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c55ed893-3f4e-4143-b4f4-5e70b24b8699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4de622e8-f877-4727-8826-385f72482d4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15999592-e6d7-47dd-9d8f-7aa1c9db01bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c55ed893-3f4e-4143-b4f4-5e70b24b8699" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15999592-e6d7-47dd-9d8f-7aa1c9db01bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_00c097a3-6087-47e5-a2f8-89168304c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:to="loc_us-gaap_GrossProfit_00c097a3-6087-47e5-a2f8-89168304c742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d4e35b3e-3217-4a9e-879e-13a4a6e1f776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d4e35b3e-3217-4a9e-879e-13a4a6e1f776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d833ad34-0e4c-4436-b0d1-f64dfeec7944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:to="loc_us-gaap_RestructuringCharges_d833ad34-0e4c-4436-b0d1-f64dfeec7944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_8cdcc179-7d8d-4428-abab-b987fa52c66b" xlink:href="cah-20211231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_8cdcc179-7d8d-4428-abab-b987fa52c66b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_bb5c2fe6-0743-45c0-a497-0d6bf44496bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_bb5c2fe6-0743-45c0-a497-0d6bf44496bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_78612144-41e7-42aa-82df-5bfb11c381b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c33c10a0-6d1e-433d-8e64-f0bb6aaddfce" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_78612144-41e7-42aa-82df-5bfb11c381b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aed3d563-34ae-4de7-a1c8-26b6b9221c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1566239d-ba85-4a2b-888c-3c2d4ec8802d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aed3d563-34ae-4de7-a1c8-26b6b9221c7c" xlink:to="loc_us-gaap_ProfitLoss_1566239d-ba85-4a2b-888c-3c2d4ec8802d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3cc384f4-4598-4522-8397-733530df9dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aed3d563-34ae-4de7-a1c8-26b6b9221c7c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3cc384f4-4598-4522-8397-733530df9dbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0529c21a-04fb-47e3-86bc-b61245648088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_289470dd-a167-4bb1-b933-ff078ef2fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0529c21a-04fb-47e3-86bc-b61245648088" xlink:to="loc_us-gaap_ProfitLoss_289470dd-a167-4bb1-b933-ff078ef2fcd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3786430d-a989-4c40-871a-b8f65b14b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0529c21a-04fb-47e3-86bc-b61245648088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3786430d-a989-4c40-871a-b8f65b14b53c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a4138048-748a-4b33-8318-201f6cb96e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f80a8f82-00da-4199-b245-901d0a9cb114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a4138048-748a-4b33-8318-201f6cb96e94" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f80a8f82-00da-4199-b245-901d0a9cb114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_307febe2-82e8-4492-b2bb-1e9fabd50255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a4138048-748a-4b33-8318-201f6cb96e94" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_307febe2-82e8-4492-b2bb-1e9fabd50255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_eaa275f1-39ee-49ae-9c3c-902c9c7c5b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ffbd1d43-e5f0-4027-ab6a-c71fae25c5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_eaa275f1-39ee-49ae-9c3c-902c9c7c5b7c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ffbd1d43-e5f0-4027-ab6a-c71fae25c5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_db5d01f5-2879-400c-a3c7-615ee2982e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_eaa275f1-39ee-49ae-9c3c-902c9c7c5b7c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_db5d01f5-2879-400c-a3c7-615ee2982e14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8f056042-4f6e-4c3b-9ac7-ac9a70cd18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8671912d-137d-4470-92e3-d217556135b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8f056042-4f6e-4c3b-9ac7-ac9a70cd18e8" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8671912d-137d-4470-92e3-d217556135b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7fa1ba3a-d067-4447-a5c4-ba7de52f37fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8f056042-4f6e-4c3b-9ac7-ac9a70cd18e8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7fa1ba3a-d067-4447-a5c4-ba7de52f37fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7852b762-2d94-4a23-a905-2ecab4146ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8f056042-4f6e-4c3b-9ac7-ac9a70cd18e8" xlink:to="loc_us-gaap_AccountsPayableCurrent_7852b762-2d94-4a23-a905-2ecab4146ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f43866e2-c020-4f5b-b24c-037c66ffbd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8f056042-4f6e-4c3b-9ac7-ac9a70cd18e8" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f43866e2-c020-4f5b-b24c-037c66ffbd41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_098dc72d-10e0-44e6-9df2-a0ab77d317ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9acba3e6-5756-4ee4-b4a0-da6ba7a53a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_098dc72d-10e0-44e6-9df2-a0ab77d317ee" xlink:to="loc_us-gaap_LiabilitiesCurrent_9acba3e6-5756-4ee4-b4a0-da6ba7a53a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5ead5be7-601c-4180-a6e3-8a5a2dab4b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_098dc72d-10e0-44e6-9df2-a0ab77d317ee" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5ead5be7-601c-4180-a6e3-8a5a2dab4b48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_2c62742e-0924-4717-95e7-93b5fa822ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_098dc72d-10e0-44e6-9df2-a0ab77d317ee" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_2c62742e-0924-4717-95e7-93b5fa822ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aff89c4b-35d1-4266-b4af-684b5679417b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_098dc72d-10e0-44e6-9df2-a0ab77d317ee" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aff89c4b-35d1-4266-b4af-684b5679417b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76406074-1d51-47e5-9d19-b2b6cec70de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75c72253-6d4c-45e0-8670-ab16887aa182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_76406074-1d51-47e5-9d19-b2b6cec70de6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75c72253-6d4c-45e0-8670-ab16887aa182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1624c424-47f1-4959-ac39-212cb93d1a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_76406074-1d51-47e5-9d19-b2b6cec70de6" xlink:to="loc_us-gaap_PreferredStockValue_1624c424-47f1-4959-ac39-212cb93d1a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2541ed6-9f83-41a5-a050-bb7a92eaaf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_76406074-1d51-47e5-9d19-b2b6cec70de6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2541ed6-9f83-41a5-a050-bb7a92eaaf5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7238c2be-5513-462e-a6f0-0c2f54fd41a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_76406074-1d51-47e5-9d19-b2b6cec70de6" xlink:to="loc_us-gaap_CommonStockValue_7238c2be-5513-462e-a6f0-0c2f54fd41a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_22eae984-6117-41ab-b586-b8d8075c3e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_76406074-1d51-47e5-9d19-b2b6cec70de6" xlink:to="loc_us-gaap_TreasuryStockValue_22eae984-6117-41ab-b586-b8d8075c3e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fc4138ec-cbdd-4ddf-92c2-17a0b16a5509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a8fec277-0a31-4c8d-a670-54f856989489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fc4138ec-cbdd-4ddf-92c2-17a0b16a5509" xlink:to="loc_us-gaap_AssetsCurrent_a8fec277-0a31-4c8d-a670-54f856989489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_489afff4-ffc7-4ddb-8eb9-a89e774a3f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fc4138ec-cbdd-4ddf-92c2-17a0b16a5509" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_489afff4-ffc7-4ddb-8eb9-a89e774a3f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_bcc2c948-2c2a-4a0a-9c1e-cf1f084596c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fc4138ec-cbdd-4ddf-92c2-17a0b16a5509" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_bcc2c948-2c2a-4a0a-9c1e-cf1f084596c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_94237181-a721-4d99-887b-603ea909df7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fc4138ec-cbdd-4ddf-92c2-17a0b16a5509" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_94237181-a721-4d99-887b-603ea909df7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b306cce-5c7e-4e59-9804-7dbeedcdc675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5144f227-e300-4278-9616-b849d82e9bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b306cce-5c7e-4e59-9804-7dbeedcdc675" xlink:to="loc_us-gaap_CommonStockValue_5144f227-e300-4278-9616-b849d82e9bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19771606-d6e7-47db-b7f1-d454b48ca749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b306cce-5c7e-4e59-9804-7dbeedcdc675" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19771606-d6e7-47db-b7f1-d454b48ca749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7ab2a0f7-3259-4c94-b819-ff072ed2615f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b306cce-5c7e-4e59-9804-7dbeedcdc675" xlink:to="loc_us-gaap_TreasuryStockValue_7ab2a0f7-3259-4c94-b819-ff072ed2615f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1db512e2-b6b4-4db7-bdd1-20f7b4018022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b306cce-5c7e-4e59-9804-7dbeedcdc675" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1db512e2-b6b4-4db7-bdd1-20f7b4018022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_215d2b89-d85d-4b22-bb36-e74f1438e8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b306cce-5c7e-4e59-9804-7dbeedcdc675" xlink:to="loc_us-gaap_MinorityInterest_215d2b89-d85d-4b22-bb36-e74f1438e8d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ebbb0d4-2503-48d1-a557-59a4846f316a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd3d7930-d60b-4c8e-94ee-f3af6242e521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ebbb0d4-2503-48d1-a557-59a4846f316a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd3d7930-d60b-4c8e-94ee-f3af6242e521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_29775551-f258-439d-b1c7-f9d2d5a4fb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ebbb0d4-2503-48d1-a557-59a4846f316a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_29775551-f258-439d-b1c7-f9d2d5a4fb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1d864113-a4dc-4334-8d49-8c41f447b346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ebbb0d4-2503-48d1-a557-59a4846f316a" xlink:to="loc_us-gaap_InventoryNet_1d864113-a4dc-4334-8d49-8c41f447b346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1fa9c8eb-d56b-4e01-9398-77271297f688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ebbb0d4-2503-48d1-a557-59a4846f316a" xlink:to="loc_us-gaap_OtherAssetsCurrent_1fa9c8eb-d56b-4e01-9398-77271297f688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5d308eb6-ef3d-4413-95a7-006e7a247ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6ebbb0d4-2503-48d1-a557-59a4846f316a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_5d308eb6-ef3d-4413-95a7-006e7a247ef2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766532e4-560f-43f1-ab00-c1ad3645dee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_42d30864-31ca-48b0-a19c-8ce9a5773d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766532e4-560f-43f1-ab00-c1ad3645dee8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_42d30864-31ca-48b0-a19c-8ce9a5773d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_531fd94f-837d-4ad9-8285-04b63784cc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766532e4-560f-43f1-ab00-c1ad3645dee8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_531fd94f-837d-4ad9-8285-04b63784cc90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_095e878f-5ef5-4b17-9e1b-bc8e62dd972c" xlink:href="cah-20211231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766532e4-560f-43f1-ab00-c1ad3645dee8" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_095e878f-5ef5-4b17-9e1b-bc8e62dd972c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_d3386deb-a7be-4882-8422-bf56fb59cd8f" xlink:href="cah-20211231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766532e4-560f-43f1-ab00-c1ad3645dee8" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_d3386deb-a7be-4882-8422-bf56fb59cd8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_67e3617e-a55d-4d85-b819-833a03935602" xlink:href="cah-20211231.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766532e4-560f-43f1-ab00-c1ad3645dee8" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_67e3617e-a55d-4d85-b819-833a03935602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd8817a3-8113-44d3-85ad-7a71fdb064a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf78498e-c0a0-4c17-8324-5011f80e2754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd8817a3-8113-44d3-85ad-7a71fdb064a5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf78498e-c0a0-4c17-8324-5011f80e2754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4ad7cf4-6793-4042-874b-f95dfcf08055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd8817a3-8113-44d3-85ad-7a71fdb064a5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4ad7cf4-6793-4042-874b-f95dfcf08055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_667b65e5-6f41-430e-a8df-9ca71ac9f7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd8817a3-8113-44d3-85ad-7a71fdb064a5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_667b65e5-6f41-430e-a8df-9ca71ac9f7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8fe0b79a-4442-41c9-8fd3-26550ce645be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd8817a3-8113-44d3-85ad-7a71fdb064a5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8fe0b79a-4442-41c9-8fd3-26550ce645be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_9023b57b-8655-43d0-9619-07a4e6c7fecf" xlink:href="cah-20211231.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd8817a3-8113-44d3-85ad-7a71fdb064a5" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_9023b57b-8655-43d0-9619-07a4e6c7fecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b2b92a6-0cbe-4c9d-be48-4312ed837760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cf73e583-7795-43af-81b6-911c87078072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b2b92a6-0cbe-4c9d-be48-4312ed837760" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cf73e583-7795-43af-81b6-911c87078072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_16f463f9-eb14-4039-b664-c7803cf2fdf1" xlink:href="cah-20211231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b2b92a6-0cbe-4c9d-be48-4312ed837760" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_16f463f9-eb14-4039-b664-c7803cf2fdf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_59cd053d-02ab-49a2-b6b3-70415b9a9822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b2b92a6-0cbe-4c9d-be48-4312ed837760" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_59cd053d-02ab-49a2-b6b3-70415b9a9822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2a57aaf5-f6d0-45c0-aab3-7a553809ec0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b2b92a6-0cbe-4c9d-be48-4312ed837760" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2a57aaf5-f6d0-45c0-aab3-7a553809ec0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_24bd6344-0da8-49f1-a352-6be62a2bee96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_ProfitLoss_24bd6344-0da8-49f1-a352-6be62a2bee96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_191f3c50-9958-4791-b98d-3d28568875f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_191f3c50-9958-4791-b98d-3d28568875f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_fa341320-99dc-4642-a2d9-f05b6709763e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_fa341320-99dc-4642-a2d9-f05b6709763e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_830e7f55-138a-46d8-b786-f31b6a132933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_830e7f55-138a-46d8-b786-f31b6a132933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7127bc27-68d5-4ae6-a1db-ea5c7fe91199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_ShareBasedCompensation_7127bc27-68d5-4ae6-a1db-ea5c7fe91199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1f08674f-8d0f-4b86-9594-544ef8add340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1f08674f-8d0f-4b86-9594-544ef8add340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_b2c5970e-03bb-41c8-b989-c01dcfc7ee9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_b2c5970e-03bb-41c8-b989-c01dcfc7ee9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a1c64347-5cb7-4b4b-8b45-518e4ab3044e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a1c64347-5cb7-4b4b-8b45-518e4ab3044e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4845ce50-8e7e-4203-816d-54bdf91bb219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4845ce50-8e7e-4203-816d-54bdf91bb219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_eb2a8c72-f7bb-4d3a-a0c4-3df312df247c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_eb2a8c72-f7bb-4d3a-a0c4-3df312df247c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_c52c0239-32a3-4df6-be1a-9ad62e14c073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c025ed25-d414-4bd5-9ef8-e335b6496697" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_c52c0239-32a3-4df6-be1a-9ad62e14c073" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_19dbf5af-c3d0-4d06-9289-af59b44ddd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_fb578d34-cc5b-4426-8ce8-8eb4ab3697df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_19dbf5af-c3d0-4d06-9289-af59b44ddd63" xlink:to="loc_us-gaap_SeveranceCosts1_fb578d34-cc5b-4426-8ce8-8eb4ab3697df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_51e5f248-ad17-4dd9-b971-5606901c4f5a" xlink:href="cah-20211231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_19dbf5af-c3d0-4d06-9289-af59b44ddd63" xlink:to="loc_cah_FacilityExitAndOtherCosts_51e5f248-ad17-4dd9-b971-5606901c4f5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6b8281e1-8e98-46b7-abb9-2b723687383b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_0497f6ab-48fa-4241-acd2-032dbe36a0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6b8281e1-8e98-46b7-abb9-2b723687383b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_0497f6ab-48fa-4241-acd2-032dbe36a0f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_601112af-eb23-4cfc-8dfd-46e5acf555b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6b8281e1-8e98-46b7-abb9-2b723687383b" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_601112af-eb23-4cfc-8dfd-46e5acf555b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a0ff5d0-9569-4dcc-98f9-567c4a20464a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63024278-084b-48db-8355-60ebcadcdba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a0ff5d0-9569-4dcc-98f9-567c4a20464a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63024278-084b-48db-8355-60ebcadcdba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d0034da1-a496-45db-a922-3de4796142b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a0ff5d0-9569-4dcc-98f9-567c4a20464a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d0034da1-a496-45db-a922-3de4796142b8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cah-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d933fb5b-1648-4e2f-85b6-17909e6e7a92,g:b7c819a0-6ebd-409c-a3ca-466b0ca5332e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="icd6e55514ddd45a589bf742e6f6e0298_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f9e25a5e-8e97-42ff-a102-8e5dea31946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_f9e25a5e-8e97-42ff-a102-8e5dea31946b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0499d553-5546-4bc5-9bbe-637d4a356757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0499d553-5546-4bc5-9bbe-637d4a356757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_fd1663a0-68f0-4f2d-8e63-c6dc30c124fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockShares_fd1663a0-68f0-4f2d-8e63-c6dc30c124fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_605a0aa6-aaa8-4cd4-bce3-974e95327411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockValue_605a0aa6-aaa8-4cd4-bce3-974e95327411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_242956b4-712a-4b63-b364-d947412c1db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_ProfitLoss_242956b4-712a-4b63-b364-d947412c1db1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d56c987-3032-49d0-84ab-32a4db740651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_NetIncomeLoss_9d56c987-3032-49d0-84ab-32a4db740651" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ed56843-2a49-4709-b4ca-fd9eb0f35779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ed56843-2a49-4709-b4ca-fd9eb0f35779" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92c889a8-ba75-45fb-90cb-204f36bbb53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92c889a8-ba75-45fb-90cb-204f36bbb53b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f627c97e-b170-4e26-bd76-cdf952c94ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f627c97e-b170-4e26-bd76-cdf952c94ffe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_55384b8a-0ec4-4aaf-8895-53a9217ca4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_55384b8a-0ec4-4aaf-8895-53a9217ca4dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36ebef86-e970-4623-adef-3e6dac6cc2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36ebef86-e970-4623-adef-3e6dac6cc2cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e4729a31-9626-4928-bb7b-fe9cdf5b1370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e4729a31-9626-4928-bb7b-fe9cdf5b1370" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8a7f49b7-b3cd-42f2-8f6a-a89555afad77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_Dividends_8a7f49b7-b3cd-42f2-8f6a-a89555afad77" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_0cb63a2e-36b2-456b-90b5-374ce0473953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_0cb63a2e-36b2-456b-90b5-374ce0473953" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_f35ae08c-967b-41ee-ae80-7f5c6a52c280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityOther_f35ae08c-967b-41ee-ae80-7f5c6a52c280" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_43f69208-cd5b-48e2-8190-e68f849d683d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06f0b4f1-b6f3-4afc-bdc5-910af38ef93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_1375e81f-cdf6-4465-931f-ed544db0059e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_fc3dc838-84ec-4ebc-9e97-dbcd06998a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a79c6195-5e7e-4aee-80e1-bf87cd089ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a79c6195-5e7e-4aee-80e1-bf87cd089ee2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5f54719c-c629-45f9-885e-c98395de4a0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:to="loc_us-gaap_EquityComponentDomain_5f54719c-c629-45f9-885e-c98395de4a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:to="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb676ad6-4bb8-4910-93fe-ddea1d029bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_CommonStockMember_eb676ad6-4bb8-4910-93fe-ddea1d029bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_058dcc32-2c3e-4425-ab27-7467eee06fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_RetainedEarningsMember_058dcc32-2c3e-4425-ab27-7467eee06fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_00224101-58cc-4112-bede-7cfb1340c148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_TreasuryStockMember_00224101-58cc-4112-bede-7cfb1340c148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b92676c8-1c43-431d-afd7-c3fe2f3ca62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b92676c8-1c43-431d-afd7-c3fe2f3ca62c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2ad252eb-6e23-4495-b06b-71dcf162e2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2ad252eb-6e23-4495-b06b-71dcf162e2a5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended" id="ib03f1e399682449f8dc5fc0a94aa62ae_DiscontinuedOperationsandDisposalGroupsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_376af766-3c7f-468b-b500-36d131ae8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ab8f0654-29ba-4274-ac1a-12747326aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_376af766-3c7f-468b-b500-36d131ae8e7d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ab8f0654-29ba-4274-ac1a-12747326aaf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_376af766-3c7f-468b-b500-36d131ae8e7d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7e613a42-e96d-4c64-bc75-da6bba784348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7e613a42-e96d-4c64-bc75-da6bba784348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c6363c4f-a5ad-4e86-9a1e-f6a045f7065b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c6363c4f-a5ad-4e86-9a1e-f6a045f7065b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:to="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_ca8ec254-abb2-4571-8a4b-6498fa52323b_default" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:to="loc_cah_CordisDivestitureDomain_ca8ec254-abb2-4571-8a4b-6498fa52323b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_e4058ce0-a099-4064-82a7-46b019f6b7a1" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:to="loc_cah_CordisDivestitureDomain_e4058ce0-a099-4064-82a7-46b019f6b7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_07331462-1017-4ca1-893e-27fb0cf25ab2" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_e4058ce0-a099-4064-82a7-46b019f6b7a1" xlink:to="loc_cah_CordisDivestitureMember_07331462-1017-4ca1-893e-27fb0cf25ab2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="iee07863f23af4670a37b64dcd482eb15_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4e55748a-16d4-4f69-8530-0b79e7551d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4e55748a-16d4-4f69-8530-0b79e7551d2a" xlink:to="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_848410f0-ca61-4048-9ad9-a7f45df9cbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_RestructuringReserve_848410f0-ca61-4048-9ad9-a7f45df9cbfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_f6f7b87f-5005-4313-b737-5b49258a322a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_RestructuringCosts_f6f7b87f-5005-4313-b737-5b49258a322a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_9def9cb5-9801-430b-8646-da30aa9b479b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_PaymentsForRestructuring_9def9cb5-9801-430b-8646-da30aa9b479b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_210b7b25-9966-45c8-981a-ca114e87a484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4e55748a-16d4-4f69-8530-0b79e7551d2a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1710f18d-8de4-4636-90ca-d69ef73a7016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1710f18d-8de4-4636-90ca-d69ef73a7016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_8a96745e-2297-4bf1-844e-b4754d0a6064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:to="loc_us-gaap_EmployeeSeveranceMember_8a96745e-2297-4bf1-844e-b4754d0a6064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_d404f6c5-2fe6-40e3-84a9-080f1e4b2cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:to="loc_us-gaap_FacilityClosingMember_d404f6c5-2fe6-40e3-84a9-080f1e4b2cd3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended" id="i05ac3b16bb284a03a4170d409dd3f46c_RestructuringandEmployeeSeveranceNarativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ad2a387d-ee0a-4724-bd29-d5c5ed5c8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:to="loc_us-gaap_SeveranceCosts1_ad2a387d-ee0a-4724-bd29-d5c5ed5c8aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_26c5af8e-cf2b-4e73-a682-53d563e8f7dd" xlink:href="cah-20211231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:to="loc_cah_FacilityExitAndOtherCosts_26c5af8e-cf2b-4e73-a682-53d563e8f7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:to="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_90ad1eff-1cb3-4226-8845-10a657292085_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:to="loc_us-gaap_RestructuringPlanDomain_90ad1eff-1cb3-4226-8845-10a657292085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_dc743802-7baf-4cc4-be56-88842ffdb248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:to="loc_us-gaap_RestructuringPlanDomain_dc743802-7baf-4cc4-be56-88842ffdb248" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="ibdfba967cbd749baa08f239e6d47215c_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:to="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95740580-1f19-4108-b3c9-972ae6d405d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_Goodwill_95740580-1f19-4108-b3c9-972ae6d405d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe9fd3b4-7290-47b7-b285-4afc8beca0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe9fd3b4-7290-47b7-b285-4afc8beca0f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fbd8630d-1c21-457c-b091-9e89f65326bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fbd8630d-1c21-457c-b091-9e89f65326bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ed124624-16ca-470f-be4e-610265a0eda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ed124624-16ca-470f-be4e-610265a0eda8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_36e32856-2649-4a6d-904d-336d880ffcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_be0be3b8-ca0c-475a-a777-6d2b064b2bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_be0be3b8-ca0c-475a-a777-6d2b064b2bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b39b100-994b-4edc-a3df-f23aa4b160e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:to="loc_us-gaap_SegmentDomain_8b39b100-994b-4edc-a3df-f23aa4b160e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:to="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_ad8119e0-9375-4b08-9baa-623daa01a3a5" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:to="loc_cah_PharmaceuticalMember_ad8119e0-9375-4b08-9baa-623daa01a3a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_b96f3bf7-6de4-4263-ba4b-708ed9c0ce45" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:to="loc_cah_MedicalMember_b96f3bf7-6de4-4263-ba4b-708ed9c0ce45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:to="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_21297c7c-13f8-4393-b8c7-c6179b96f8f0_default" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:to="loc_cah_CordisDivestitureDomain_21297c7c-13f8-4393-b8c7-c6179b96f8f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_9cac14af-df99-45cc-9590-4bd58569f642" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:to="loc_cah_CordisDivestitureDomain_9cac14af-df99-45cc-9590-4bd58569f642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_aea6e994-3f40-4772-a4a5-5551e3c3e611" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_9cac14af-df99-45cc-9590-4bd58569f642" xlink:to="loc_cah_CordisDivestitureMember_aea6e994-3f40-4772-a4a5-5551e3c3e611" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i839c17e984db41ea9a691ac719ba2841_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c086aa80-965a-4822-a2b2-81c69a1ace04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4145fa9c-4452-44f0-842e-3a2407de8077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c086aa80-965a-4822-a2b2-81c69a1ace04" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4145fa9c-4452-44f0-842e-3a2407de8077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c086aa80-965a-4822-a2b2-81c69a1ace04" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_10b23a67-9464-4a12-b76c-c7d333559fd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_10b23a67-9464-4a12-b76c-c7d333559fd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ae35827-9b32-480a-ab20-eaf9461c04d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ae35827-9b32-480a-ab20-eaf9461c04d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_f6d4e031-f1dd-4cb0-911a-602b857cd961" xlink:href="cah-20211231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ae35827-9b32-480a-ab20-eaf9461c04d0" xlink:to="loc_cah_IPRDTrademarksandOtherMember_f6d4e031-f1dd-4cb0-911a-602b857cd961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8cf820e3-0bfd-4fc0-a22f-3d2688b01e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8cf820e3-0bfd-4fc0-a22f-3d2688b01e5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54c894f3-74ae-4c55-a088-e13b6c777ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54c894f3-74ae-4c55-a088-e13b6c777ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cc501e39-589d-4565-9114-5bad68df4204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cc501e39-589d-4565-9114-5bad68df4204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_ba00cca1-47f5-4a8e-8422-ffd4578c4227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_ba00cca1-47f5-4a8e-8422-ffd4578c4227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6645baef-87f2-4290-a459-326e70b7e123_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6645baef-87f2-4290-a459-326e70b7e123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_d90d7e3a-8324-495d-bb7a-e145e50cda81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:to="loc_us-gaap_CustomerRelationshipsMember_d90d7e3a-8324-495d-bb7a-e145e50cda81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_4b6574bf-58dd-4c44-82f1-dd198c954216" xlink:href="cah-20211231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:to="loc_cah_TrademarksAndPatentsMember_4b6574bf-58dd-4c44-82f1-dd198c954216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f28690a3-2e12-475a-a3af-1bdbac4578ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f28690a3-2e12-475a-a3af-1bdbac4578ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i1ec71bb360bc46b4bdf6dc10ec2e8374_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aa5bedb7-042b-4da3-9bf8-4325ca4d6b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_us-gaap_Goodwill_aa5bedb7-042b-4da3-9bf8-4325ca4d6b86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8eab452a-eb67-41ed-b19c-bf36a4b40605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8eab452a-eb67-41ed-b19c-bf36a4b40605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_fc2630bd-f887-4d04-9cac-d42219ce9dea" xlink:href="cah-20211231.xsd#cah_DiscountRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_cah_DiscountRateFairValueInput_fc2630bd-f887-4d04-9cac-d42219ce9dea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_b4f37265-4f4a-486a-8185-4e277e0059ef" xlink:href="cah-20211231.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_b4f37265-4f4a-486a-8185-4e277e0059ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_2d3efd54-7107-4be0-82d3-8a31d919b61b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:to="loc_us-gaap_ReportingUnitDomain_2d3efd54-7107-4be0-82d3-8a31d919b61b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_89a2dd72-dfdc-418c-83c5-f4b3dda5bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:to="loc_us-gaap_ReportingUnitDomain_89a2dd72-dfdc-418c-83c5-f4b3dda5bb28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_e9c55ca4-df64-48ae-b77f-e496f09f2dc7" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_89a2dd72-dfdc-418c-83c5-f4b3dda5bb28" xlink:to="loc_cah_MedicalUnitMember_e9c55ca4-df64-48ae-b77f-e496f09f2dc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:to="loc_us-gaap_SegmentDomain_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a3e39475-ce00-48a4-a43c-4fa4a63da872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:to="loc_us-gaap_SegmentDomain_a3e39475-ce00-48a4-a43c-4fa4a63da872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_7d04f29f-f196-4bd5-932d-8e0cc2b31288" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a3e39475-ce00-48a4-a43c-4fa4a63da872" xlink:to="loc_cah_MedicalMember_7d04f29f-f196-4bd5-932d-8e0cc2b31288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_ed0dcab6-e7f8-483e-a724-d2096cf21515_default" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:to="loc_cah_GoodwillImpairmentDomain_ed0dcab6-e7f8-483e-a724-d2096cf21515_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_11396f54-e9b0-47df-8807-334c3c0330bf" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:to="loc_cah_GoodwillImpairmentDomain_11396f54-e9b0-47df-8807-334c3c0330bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_bdf3a556-bc68-4c2a-9a91-b6dc108fdc96" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_11396f54-e9b0-47df-8807-334c3c0330bf" xlink:to="loc_cah_MedicalUnitMember_bdf3a556-bc68-4c2a-9a91-b6dc108fdc96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended" id="i6610c0481a894abe8073526f36675569_LongTermObligationsandOtherShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_fa1abfed-f102-40bf-bc59-3d54828786e0" xlink:href="cah-20211231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_cah_TotalLongTermandShortTermObligations_fa1abfed-f102-40bf-bc59-3d54828786e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af8f2e82-f247-4f88-86f8-a64e3a080407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af8f2e82-f247-4f88-86f8-a64e3a080407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce960055-b317-4b06-8c8e-418e85cd250a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce960055-b317-4b06-8c8e-418e85cd250a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_951af543-c5c8-409f-a916-fdfdf65d9162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_951af543-c5c8-409f-a916-fdfdf65d9162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9a7299eb-ca0f-4f3c-8b19-27a6b118558d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9a7299eb-ca0f-4f3c-8b19-27a6b118558d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_5e39d6aa-2061-447c-85a5-7960bea8eb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_OtherShortTermBorrowings_5e39d6aa-2061-447c-85a5-7960bea8eb27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1a64f31-a0b9-435f-bcf3-75078797651d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1a64f31-a0b9-435f-bcf3-75078797651d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_726fdd00-6a41-4c8e-afca-281f67c3cadb" xlink:href="cah-20211231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:to="loc_cah_A2.616Notesdue2022Member_726fdd00-6a41-4c8e-afca-281f67c3cadb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3252a28f-82dc-455e-8a30-62fcf67a71cf" xlink:href="cah-20211231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3252a28f-82dc-455e-8a30-62fcf67a71cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_aa1abbc0-641e-4afa-8f2c-1e415cdebb17" xlink:href="cah-20211231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:to="loc_cah_FloatingRateNotesdue2022Member_aa1abbc0-641e-4afa-8f2c-1e415cdebb17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:to="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d87d3733-424a-4df8-b681-4273287ec926_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:to="loc_us-gaap_CreditFacilityDomain_d87d3733-424a-4df8-b681-4273287ec926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:to="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_475e21dd-7f95-4413-a5ea-631d0222b54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_us-gaap_CommercialPaperMember_475e21dd-7f95-4413-a5ea-631d0222b54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c686b8b0-0d99-461a-adae-244a4864f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c686b8b0-0d99-461a-adae-244a4864f47b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_b24a3f93-14c2-4375-ae94-03622bc21e22" xlink:href="cah-20211231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_b24a3f93-14c2-4375-ae94-03622bc21e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_87c9a20e-3e75-4fb7-a510-22064443d206" xlink:href="cah-20211231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_87c9a20e-3e75-4fb7-a510-22064443d206" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended" id="ie1a6540d88de49e29177ece3a2dce828_LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_52d5dc33-5843-4e32-89ac-6c9fd62d24bd" xlink:href="cah-20211231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_cah_TotalLongTermandShortTermObligations_52d5dc33-5843-4e32-89ac-6c9fd62d24bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b7947b11-1aa5-439b-8b54-8bec685b76cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b7947b11-1aa5-439b-8b54-8bec685b76cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_62f7a90d-1335-4323-bf7b-4a50b19c7d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_62f7a90d-1335-4323-bf7b-4a50b19c7d8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77711ac4-06d8-4bc0-8341-5881aa38e2eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77711ac4-06d8-4bc0-8341-5881aa38e2eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1fbfc7cc-79e1-4ffd-bebe-c9afddd62cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1fbfc7cc-79e1-4ffd-bebe-c9afddd62cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_035b11df-da1c-4740-87e6-f54f0014f3ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_035b11df-da1c-4740-87e6-f54f0014f3ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_2246fd91-2fd2-4b2a-a028-af5bf61ebec5" xlink:href="cah-20211231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:to="loc_cah_A2.616Notesdue2022Member_2246fd91-2fd2-4b2a-a028-af5bf61ebec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_31c42f8d-a15b-4c2a-80cd-d2c5f923ceea" xlink:href="cah-20211231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:to="loc_cah_FloatingRateNotesdue2022Member_31c42f8d-a15b-4c2a-80cd-d2c5f923ceea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended" id="if4c7c0e9763b461981d69254b976fcfb_CommitmentsContingentLiabilitiesandLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f8a4d174-8dc4-4a2d-b606-93ee073e8194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f8a4d174-8dc4-4a2d-b606-93ee073e8194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_eb070f65-1902-463a-872e-bee8d070812f" xlink:href="cah-20211231.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_AggregateAnnualAssessment_eb070f65-1902-463a-872e-bee8d070812f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_95ee20a5-64e9-49b1-8a3e-8f9dbbae7b7a" xlink:href="cah-20211231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_95ee20a5-64e9-49b1-8a3e-8f9dbbae7b7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1c40964c-0508-4343-b01d-62567477f816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_1c40964c-0508-4343-b01d-62567477f816" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b2ada195-5a34-484d-a3f8-e369668617e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b2ada195-5a34-484d-a3f8-e369668617e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_1ba47399-8fc0-4402-b799-69778359f6c3" xlink:href="cah-20211231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_LossContingencyLawsuitsNumber_1ba47399-8fc0-4402-b799-69778359f6c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_268aa20e-3906-43cb-8890-79caf420c724" xlink:href="cah-20211231.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_268aa20e-3906-43cb-8890-79caf420c724" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_39a4a62b-6b64-42a8-b697-5fffde81da50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_39a4a62b-6b64-42a8-b697-5fffde81da50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_67183fc7-93f9-4114-bf8e-75be3c722e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LitigationReserve_67183fc7-93f9-4114-bf8e-75be3c722e74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_6ba0b7fe-b172-4520-bc68-05480bf67947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LitigationReserveCurrent_6ba0b7fe-b172-4520-bc68-05480bf67947" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_39793162-c0fc-4853-9c23-8e15a411696c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LitigationSettlementExpense_39793162-c0fc-4853-9c23-8e15a411696c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ed235705-d0f8-42f6-bc2f-d5ee7cd86183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ed235705-d0f8-42f6-bc2f-d5ee7cd86183" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_9a3d9129-b710-498d-ae33-000e408ceced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_9a3d9129-b710-498d-ae33-000e408ceced" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_adefb944-4790-4de7-9a7f-b9146a5e8d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_adefb944-4790-4de7-9a7f-b9146a5e8d10" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_48641c5a-8162-4cc9-bd15-24c40a791201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_48641c5a-8162-4cc9-bd15-24c40a791201" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_2d24852e-9cdd-457d-ad0c-fff3b351936d" xlink:href="cah-20211231.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_JudgmentForLostProfits_2d24852e-9cdd-457d-ad0c-fff3b351936d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5ffe355c-72e3-498a-84c8-afad1c8658af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:to="loc_srt_NameOfMajorCustomerDomain_5ffe355c-72e3-498a-84c8-afad1c8658af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5e3dc50b-3040-4805-83d7-87d36de3cc9a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:to="loc_srt_NameOfMajorCustomerDomain_5e3dc50b-3040-4805-83d7-87d36de3cc9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_b00f52aa-458a-4e31-8bd7-0b996d5c1936" xlink:href="cah-20211231.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e3dc50b-3040-4805-83d7-87d36de3cc9a" xlink:to="loc_cah_CVSHealthMember_b00f52aa-458a-4e31-8bd7-0b996d5c1936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_09b7ea60-4946-4cd0-b69e-b5c79a510190_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:to="loc_srt_LitigationCaseTypeDomain_09b7ea60-4946-4cd0-b69e-b5c79a510190_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:to="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_eec1ac04-7c79-41f4-b52f-947671c4553f" xlink:href="cah-20211231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_eec1ac04-7c79-41f4-b52f-947671c4553f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_f2046718-4630-4f8a-a997-a5a20b48b8a0" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_OpioidLawsuitsMember_f2046718-4630-4f8a-a997-a5a20b48b8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateMember_69d4fd19-8ddf-4f92-bb8d-4edb12dc4ec7" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_OpioidLawsuitsStateMember_69d4fd19-8ddf-4f92-bb8d-4edb12dc4ec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_ac9c8ef4-11d6-4e6d-8c23-5615038867c6" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_ac9c8ef4-11d6-4e6d-8c23-5615038867c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_40aa2c09-ba2c-4e76-b4e9-1538708e2d33" xlink:href="cah-20211231.xsd#cah_DOJInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_DOJInvestigationMember_40aa2c09-ba2c-4e76-b4e9-1538708e2d33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_1ba9e694-66b7-48fd-8110-16af014fc368_default" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:to="loc_cah_OpioidLitigationDomain_1ba9e694-66b7-48fd-8110-16af014fc368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_19112d6e-093b-45fd-9163-edb2d960587f" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:to="loc_cah_OpioidLitigationDomain_19112d6e-093b-45fd-9163-edb2d960587f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_bdb74d52-e57d-4489-aeef-4a668b05a79a" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_19112d6e-093b-45fd-9163-edb2d960587f" xlink:to="loc_cah_TotalOpioidLitigationMember_bdb74d52-e57d-4489-aeef-4a668b05a79a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:href="cah-20211231.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_8be1c437-a892-457b-9b3c-07d3fb31b1b5_default" xlink:href="cah-20211231.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:to="loc_cah_LawsuitTypeDomain_8be1c437-a892-457b-9b3c-07d3fb31b1b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:href="cah-20211231.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:to="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_ba9d429c-c587-4f73-a046-28249d15857e" xlink:href="cah-20211231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:to="loc_cah_ClassActionLawsuitsMember_ba9d429c-c587-4f73-a046-28249d15857e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_36affbfc-30f8-4310-aa8e-b5a8be21b3e5" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_36affbfc-30f8-4310-aa8e-b5a8be21b3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_2f9f1728-aa9c-459d-bef6-3cd316c561ff_default" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:to="loc_cah_PlaintiffTypeDomain_2f9f1728-aa9c-459d-bef6-3cd316c561ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_aaa82f2b-f6a3-47cf-87b7-cd72dd2482ed" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:to="loc_cah_PlaintiffTypeDomain_aaa82f2b-f6a3-47cf-87b7-cd72dd2482ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_89e09cf7-2f6d-421b-b17f-5fb0f115b627" xlink:href="cah-20211231.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_aaa82f2b-f6a3-47cf-87b7-cd72dd2482ed" xlink:to="loc_cah_PrivatePartiesMember_89e09cf7-2f6d-421b-b17f-5fb0f115b627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c2797989-e697-45da-bdf2-c94f988c175e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:to="loc_srt_SegmentGeographicalDomain_c2797989-e697-45da-bdf2-c94f988c175e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:to="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_0e59023b-dc3d-4915-8f13-fddf4e56fd2a" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:to="loc_stpr_GA_0e59023b-dc3d-4915-8f13-fddf4e56fd2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_2bcfd074-dd71-455e-a206-3ca7d5379878" xlink:href="cah-20211231.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:to="loc_cah_AlamedaCountyMember_2bcfd074-dd71-455e-a206-3ca7d5379878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_84330dfd-f109-432c-8a3d-f13e15db0d87" xlink:href="cah-20211231.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:to="loc_cah_OtherJurisdictionsMember_84330dfd-f109-432c-8a3d-f13e15db0d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:to="loc_srt_RangeMember_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:to="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ae8f024-7301-4d1e-99f2-464a2cf46748" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:to="loc_srt_MinimumMember_3ae8f024-7301-4d1e-99f2-464a2cf46748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c47b627-7957-45c8-8a49-162baed9f250" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:to="loc_srt_MaximumMember_0c47b627-7957-45c8-8a49-162baed9f250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_29e2b3c1-988d-4558-a9cc-8054eae03c47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:to="loc_us-gaap_LossContingencyNatureDomain_29e2b3c1-988d-4558-a9cc-8054eae03c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_0421c9c0-26bc-4965-9166-d0836f6f40da" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:to="loc_cah_OpioidLawsuitsMember_0421c9c0-26bc-4965-9166-d0836f6f40da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_4464f385-f6c5-4ce9-a7c5-c49408ffb644" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_4464f385-f6c5-4ce9-a7c5-c49408ffb644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_40f39fa2-2bab-4fb9-8537-0eee2e650e3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_40f39fa2-2bab-4fb9-8537-0eee2e650e3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b827305-1cb2-41bb-98d0-eca6f0db0660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b827305-1cb2-41bb-98d0-eca6f0db0660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5ba7502c-c89e-4d9d-98c8-68526f8397ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2b827305-1cb2-41bb-98d0-eca6f0db0660" xlink:to="loc_us-gaap_SubsequentEventMember_5ba7502c-c89e-4d9d-98c8-68526f8397ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5fdaf1e2-68e3-4900-9c3d-e6402631b09b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:to="loc_us-gaap_SegmentDomain_5fdaf1e2-68e3-4900-9c3d-e6402631b09b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e0dce768-2240-42f2-b84b-d188f5a533a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:to="loc_us-gaap_SegmentDomain_e0dce768-2240-42f2-b84b-d188f5a533a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_cb3a8756-cfd2-4785-9801-52734ba05577" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e0dce768-2240-42f2-b84b-d188f5a533a5" xlink:to="loc_cah_PharmaceuticalMember_cb3a8756-cfd2-4785-9801-52734ba05577" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ia571fcbc8a6241568c9e4454a8fa0b3b_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_6de0649a-5990-4362-b98b-a5f78077e662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_LitigationReserve_6de0649a-5990-4362-b98b-a5f78077e662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53ea631c-e63a-445f-884d-f04efa812219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_53ea631c-e63a-445f-884d-f04efa812219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d5412518-b2c6-4e48-8764-066cebbeee10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d5412518-b2c6-4e48-8764-066cebbeee10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6242efa9-f679-4d35-939b-8dcbea996423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6242efa9-f679-4d35-939b-8dcbea996423" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b822401e-d900-406e-a6e7-619506729aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b822401e-d900-406e-a6e7-619506729aa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_10c49f7b-04ec-4bcc-953d-31fe18ad1299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_10c49f7b-04ec-4bcc-953d-31fe18ad1299" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1c8b5b75-13f2-4f37-b8a6-4074e1294c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1c8b5b75-13f2-4f37-b8a6-4074e1294c76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_2c2ce109-f4d8-4397-a603-7b90ea78d8f0" xlink:href="cah-20211231.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_cah_IndemnificationReceivable_2c2ce109-f4d8-4397-a603-7b90ea78d8f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc2f3469-5452-455d-8c2c-d893b650db5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc2f3469-5452-455d-8c2c-d893b650db5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_585e06f4-e869-46ff-a856-72186c7c1f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_LitigationSettlementExpense_585e06f4-e869-46ff-a856-72186c7c1f50" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_a2eaf8f9-ca8a-469f-aaef-f54a100fa11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_a2eaf8f9-ca8a-469f-aaef-f54a100fa11b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fb29d85a-91ee-4994-b054-db0212258cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_IncomeTaxReceivable_fb29d85a-91ee-4994-b054-db0212258cc0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_d09a6edb-01bb-4b71-8114-680079676fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_d09a6edb-01bb-4b71-8114-680079676fea" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_20c3867f-1ef4-4537-8855-650f4cd51792_default" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:to="loc_cah_OpioidLitigationDomain_20c3867f-1ef4-4537-8855-650f4cd51792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_25f01a05-903f-4c13-9994-035bf2c26969" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:to="loc_cah_OpioidLitigationDomain_25f01a05-903f-4c13-9994-035bf2c26969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_e9ac3419-39fb-4ca9-a80c-46a8280065ad" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_25f01a05-903f-4c13-9994-035bf2c26969" xlink:to="loc_cah_TotalOpioidLitigationMember_e9ac3419-39fb-4ca9-a80c-46a8280065ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:href="cah-20211231.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_273bf6cb-9c3c-48de-b561-14ea2761abaf_default" xlink:href="cah-20211231.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:to="loc_cah_TaxMatterDomain_273bf6cb-9c3c-48de-b561-14ea2761abaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:href="cah-20211231.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:to="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_1b8e15d2-76ff-45b1-bb33-293fc18515a3" xlink:href="cah-20211231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:to="loc_cah_PatientRecoveryBusinessMember_1b8e15d2-76ff-45b1-bb33-293fc18515a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_3d81cc93-9087-4440-947f-53c13464c6d4" xlink:href="cah-20211231.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:to="loc_cah_CareFusionMember_3d81cc93-9087-4440-947f-53c13464c6d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68fafbb7-8ab6-485a-8d43-9883604223f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68fafbb7-8ab6-485a-8d43-9883604223f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5d95a76-ec6d-41d2-91f1-15444365c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5d95a76-ec6d-41d2-91f1-15444365c94d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_e8036761-bd05-4211-8457-5158fcaf1bdf" xlink:href="cah-20211231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5d95a76-ec6d-41d2-91f1-15444365c94d" xlink:to="loc_cah_PatientRecoveryBusinessMember_e8036761-bd05-4211-8457-5158fcaf1bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_6d25c207-7864-4966-911f-0cfb641a00d0_default" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:to="loc_cah_TaxMattersAgreementDomain_6d25c207-7864-4966-911f-0cfb641a00d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_d1e70087-c136-4976-b087-fdd930e0bcd2" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:to="loc_cah_TaxMattersAgreementDomain_d1e70087-c136-4976-b087-fdd930e0bcd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_432a254b-e6da-4efb-adf1-afec9086ddf7" xlink:href="cah-20211231.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_d1e70087-c136-4976-b087-fdd930e0bcd2" xlink:to="loc_cah_CareFusionMember_432a254b-e6da-4efb-adf1-afec9086ddf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2692021-18d7-474e-9168-1ab44e39ba04_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:to="loc_srt_RangeMember_d2692021-18d7-474e-9168-1ab44e39ba04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:to="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9be75e99-88ed-4238-975d-841d078f21fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:to="loc_srt_MinimumMember_9be75e99-88ed-4238-975d-841d078f21fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4cfd192f-abc7-4a7f-b192-c92d6f56cc6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:to="loc_srt_MaximumMember_4cfd192f-abc7-4a7f-b192-c92d6f56cc6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:href="cah-20211231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_e6cf3e0b-7343-4e70-a55d-21dc2431a727_default" xlink:href="cah-20211231.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:to="loc_cah_CARESActDomain_e6cf3e0b-7343-4e70-a55d-21dc2431a727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_bacf43fd-63d8-453f-bb69-6dabfda45459" xlink:href="cah-20211231.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:to="loc_cah_CARESActDomain_bacf43fd-63d8-453f-bb69-6dabfda45459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_420898fa-9493-4a03-9578-3db336ae493b" xlink:href="cah-20211231.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CARESActDomain_bacf43fd-63d8-453f-bb69-6dabfda45459" xlink:to="loc_cah_NetOperatingLossCarrybackMember_420898fa-9493-4a03-9578-3db336ae493b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_970ab3d6-3d0d-48d1-a121-04175f88df4b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_970ab3d6-3d0d-48d1-a121-04175f88df4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_327756b3-7026-48a9-bf2e-bcede16592e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_327756b3-7026-48a9-bf2e-bcede16592e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2244fd87-c39a-4db3-9775-c28a272cfe47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_327756b3-7026-48a9-bf2e-bcede16592e7" xlink:to="loc_srt_ScenarioForecastMember_2244fd87-c39a-4db3-9775-c28a272cfe47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68_default" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:to="loc_cah_GoodwillImpairmentDomain_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:to="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_adae2c4f-cb80-4b45-bef0-406aafe6dd13" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:to="loc_cah_MedicalUnitMember_adae2c4f-cb80-4b45-bef0-406aafe6dd13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_9b119bed-2455-449d-8f00-6b24cb3a8947" xlink:href="cah-20211231.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_9b119bed-2455-449d-8f00-6b24cb3a8947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044_default" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:to="loc_cah_CordisDivestitureDomain_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_24cbb9da-b077-4d40-bec1-e678cc2c2522" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:to="loc_cah_CordisDivestitureDomain_24cbb9da-b077-4d40-bec1-e678cc2c2522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_0f0a8263-d61f-4e4e-87e7-ac1cca23fc33" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_24cbb9da-b077-4d40-bec1-e678cc2c2522" xlink:to="loc_cah_CordisDivestitureMember_0f0a8263-d61f-4e4e-87e7-ac1cca23fc33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="ia6c8bc014f28453790971514b220d8ae_FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4f74318-1e82-4cd3-a078-54baa6433994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4f74318-1e82-4cd3-a078-54baa6433994" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5f729e3-b036-42f4-b4cc-ee1facfe1a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5f729e3-b036-42f4-b4cc-ee1facfe1a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e4a31089-68d5-4f56-bc7e-e30c4633b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e4a31089-68d5-4f56-bc7e-e30c4633b416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_3e94ac82-1a8c-46c1-a053-f66fcf1c9306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_3e94ac82-1a8c-46c1-a053-f66fcf1c9306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4f74318-1e82-4cd3-a078-54baa6433994" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29832c61-bbc9-4f17-a754-eba4442a8e6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29832c61-bbc9-4f17-a754-eba4442a8e6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8ae13a2-073b-4ff7-af74-623e90f0513e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8ae13a2-073b-4ff7-af74-623e90f0513e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7d591fd3-b651-4b93-8e17-d9bf16c64b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7d591fd3-b651-4b93-8e17-d9bf16c64b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f765bda0-201f-4651-8be4-6e8e467785f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f765bda0-201f-4651-8be4-6e8e467785f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_29c4b874-a1f4-4f21-9df5-76c9886f60da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_29c4b874-a1f4-4f21-9df5-76c9886f60da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8cd961ba-a1d0-4b36-ab17-064518684410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8cd961ba-a1d0-4b36-ab17-064518684410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_981c1b11-a45e-49b1-81ec-d3cc1fba26f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8cd961ba-a1d0-4b36-ab17-064518684410" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_981c1b11-a45e-49b1-81ec-d3cc1fba26f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i7b30f6646e154eb0b9c44ab6e6d5b56c_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_19837f0c-8ce7-43db-9525-5f83883caa05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_19837f0c-8ce7-43db-9525-5f83883caa05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cc4028d3-01ae-4a74-b3a3-49240b3d2e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cc4028d3-01ae-4a74-b3a3-49240b3d2e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_f8fce85f-726d-4853-9e80-518e92117b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_f8fce85f-726d-4853-9e80-518e92117b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b41f1416-aea4-4839-bc52-2b31f84974d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b41f1416-aea4-4839-bc52-2b31f84974d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd519620-5027-499b-a81e-f41620b97f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd519620-5027-499b-a81e-f41620b97f43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_df5811ce-e2b4-4cec-9b4e-cee015d7cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_df5811ce-e2b4-4cec-9b4e-cee015d7cdc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d0033f73-e643-464e-925e-e46f335b491b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d0033f73-e643-464e-925e-e46f335b491b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0739b1ba-b89a-4e5c-ac37-ec63eca3812b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0739b1ba-b89a-4e5c-ac37-ec63eca3812b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7094d3f7-e3cf-4e4f-a88a-cd47c447de82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0739b1ba-b89a-4e5c-ac37-ec63eca3812b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7094d3f7-e3cf-4e4f-a88a-cd47c447de82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57bab21b-bc48-49bd-bf11-c3ea793c9dca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57bab21b-bc48-49bd-bf11-c3ea793c9dca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c02ad18-2ad7-42c1-ae90-8d19eaa89fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c02ad18-2ad7-42c1-ae90-8d19eaa89fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ad4cf8d8-9c2f-4dff-9044-02cb0fed0528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c02ad18-2ad7-42c1-ae90-8d19eaa89fec" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ad4cf8d8-9c2f-4dff-9044-02cb0fed0528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7dd286b2-1a13-4099-93db-f9d9eaf4033e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:to="loc_us-gaap_HedgingDesignationDomain_7dd286b2-1a13-4099-93db-f9d9eaf4033e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:to="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_95c6734a-6d23-49ad-870b-3f13f2895a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_95c6734a-6d23-49ad-870b-3f13f2895a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5ed2e5bb-2056-42b9-a79c-fff54432f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:to="loc_us-gaap_NondesignatedMember_5ed2e5bb-2056-42b9-a79c-fff54432f7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_003d4988-ea7c-427a-a7e9-13722275777a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_003d4988-ea7c-427a-a7e9-13722275777a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e6582903-0932-4b2c-8367-e9bcdf25d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e6582903-0932-4b2c-8367-e9bcdf25d9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e7a41c43-03eb-4fae-94c1-f376cdc2fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e6582903-0932-4b2c-8367-e9bcdf25d9ca" xlink:to="loc_us-gaap_FairValueHedgingMember_e7a41c43-03eb-4fae-94c1-f376cdc2fc01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0e1966f4-0368-471c-b282-366b586ed1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:to="loc_us-gaap_CashFlowHedgingMember_0e1966f4-0368-471c-b282-366b586ed1d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_44b982cb-5ffb-4c7c-9eb0-cea39bcb805a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:to="loc_us-gaap_InterestRateSwapMember_44b982cb-5ffb-4c7c-9eb0-cea39bcb805a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9bd1463d-f2f5-452c-a4ee-1f19514d89f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9bd1463d-f2f5-452c-a4ee-1f19514d89f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i3b07b79e017a41b98ec3bd8932441b64_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_394c4569-d696-467f-b7f6-549fc55c955d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:to="loc_us-gaap_DebtInstrumentFairValue_394c4569-d696-467f-b7f6-549fc55c955d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_b62c5cc6-9576-46ac-b6c6-de149a5a2392" xlink:href="cah-20211231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_b62c5cc6-9576-46ac-b6c6-de149a5a2392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7d9615f-72de-4590-82ab-96c13472bb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7d9615f-72de-4590-82ab-96c13472bb17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94ce7ab0-ae84-4928-9213-5cfc9c041c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7d9615f-72de-4590-82ab-96c13472bb17" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94ce7ab0-ae84-4928-9213-5cfc9c041c79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="i1e321a5f5a334803a16ddd34395c8b2f_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e86ff39b-1311-4348-8b2f-abb3e9fa412c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e86ff39b-1311-4348-8b2f-abb3e9fa412c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4d4330c9-604d-4c3e-93cc-c13fa52956b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4d4330c9-604d-4c3e-93cc-c13fa52956b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_34d95709-80ce-4284-9498-5a9d9b97a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_34d95709-80ce-4284-9498-5a9d9b97a8a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a180f999-5d86-4475-b83c-f3b2fcea4afb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:to="loc_us-gaap_EquityComponentDomain_a180f999-5d86-4475-b83c-f3b2fcea4afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_823585bd-bb4f-4a35-bef4-4ad7535ced35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:to="loc_us-gaap_EquityComponentDomain_823585bd-bb4f-4a35-bef4-4ad7535ced35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_91f7922a-7770-415f-b474-6488c3def09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_823585bd-bb4f-4a35-bef4-4ad7535ced35" xlink:to="loc_us-gaap_TreasuryStockMember_91f7922a-7770-415f-b474-6488c3def09b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_f829f667-4f79-4f78-971f-f68362159c59_default" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_f829f667-4f79-4f78-971f-f68362159c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_e3cb5378-e9a7-4ca0-812d-7fc1a2bf6dff" xlink:href="cah-20211231.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_e3cb5378-e9a7-4ca0-812d-7fc1a2bf6dff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_b55077ec-b00f-409a-8b5e-4b6c7fbe933d" xlink:href="cah-20211231.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_b55077ec-b00f-409a-8b5e-4b6c7fbe933d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ca51a1af-2d1e-46a8-a404-ec762140ca02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ca51a1af-2d1e-46a8-a404-ec762140ca02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fda0a9cd-3da4-490d-95fd-a629252ef3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fda0a9cd-3da4-490d-95fd-a629252ef3e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6d43c8c3-c118-4689-b210-06b3ea67c857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fda0a9cd-3da4-490d-95fd-a629252ef3e8" xlink:to="loc_us-gaap_SubsequentEventMember_6d43c8c3-c118-4689-b210-06b3ea67c857" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ice47f9f5a44e48c1a8ec3581fd31de02_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f35176f9-96e8-4edb-9c7a-553bb4ef155e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f35176f9-96e8-4edb-9c7a-553bb4ef155e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e491a442-cd48-4579-95c0-30620c8640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e491a442-cd48-4579-95c0-30620c8640e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7d7604c1-1740-4dc6-8f9e-f7eaf3b50a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7d7604c1-1740-4dc6-8f9e-f7eaf3b50a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d63d0187-08c4-4f7e-9593-35b70a386c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d63d0187-08c4-4f7e-9593-35b70a386c88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f07b6d14-ad69-4127-a36e-d6c470423927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f07b6d14-ad69-4127-a36e-d6c470423927" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb4f3aba-91f7-4f8f-8f86-b3799fc09669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f35176f9-96e8-4edb-9c7a-553bb4ef155e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a557dc6-be9b-4c22-be08-61f5d4941e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:to="loc_us-gaap_EquityComponentDomain_2a557dc6-be9b-4c22-be08-61f5d4941e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:to="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4b44a3d7-72c3-4d87-98f6-119af6c86abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4b44a3d7-72c3-4d87-98f6-119af6c86abc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c115ff69-d133-4510-bb7f-2ec9de694b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c115ff69-d133-4510-bb7f-2ec9de694b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a5c7d0d1-1dc7-42f6-bf11-bafb95f1b466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a5c7d0d1-1dc7-42f6-bf11-bafb95f1b466" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f82df23f-acee-49d0-81b6-4768734b69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f82df23f-acee-49d0-81b6-4768734b69d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i79c31eea20164840add7ad36e554acdd_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9165df76-254c-4bb6-9160-2ebdd07ea054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9165df76-254c-4bb6-9160-2ebdd07ea054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_664bb8b2-96c0-48e8-9d5b-76fb49d5b9ee" xlink:href="cah-20211231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_664bb8b2-96c0-48e8-9d5b-76fb49d5b9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cbebcc00-6bcd-41d2-8742-27b2a9765767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_NumberOfReportableSegments_cbebcc00-6bcd-41d2-8742-27b2a9765767" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0571ca7d-3672-4efa-8048-771f428a79dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0571ca7d-3672-4efa-8048-771f428a79dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f261ff09-0b48-452c-9318-027f2ff8b34e" xlink:href="cah-20211231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f261ff09-0b48-452c-9318-027f2ff8b34e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_aae11544-cf54-4b17-98fb-7807b2664c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_aae11544-cf54-4b17-98fb-7807b2664c73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_774ada83-2d33-4fc0-9140-3fe0d16f90d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_LitigationSettlementExpense_774ada83-2d33-4fc0-9140-3fe0d16f90d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_ff4065a4-ab28-4538-b36a-69dc77886801_default" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:to="loc_cah_OpioidLitigationDomain_ff4065a4-ab28-4538-b36a-69dc77886801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_1be9e1a1-3d17-4ea3-9550-02fe65facba4" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:to="loc_cah_OpioidLitigationDomain_1be9e1a1-3d17-4ea3-9550-02fe65facba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_108a8409-01d0-421b-9108-59bb445849dd" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_1be9e1a1-3d17-4ea3-9550-02fe65facba4" xlink:to="loc_cah_TotalOpioidLitigationMember_108a8409-01d0-421b-9108-59bb445849dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f216acc3-8695-4ac4-b5f6-c5514b8accde_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:to="loc_srt_LitigationCaseTypeDomain_f216acc3-8695-4ac4-b5f6-c5514b8accde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b82981e-593f-4a1e-9cf5-1b3bfdaec898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:to="loc_srt_LitigationCaseTypeDomain_9b82981e-593f-4a1e-9cf5-1b3bfdaec898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_0b4eca63-2958-4d9c-b687-96ea9ea4fd44" xlink:href="cah-20211231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b82981e-593f-4a1e-9cf5-1b3bfdaec898" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_0b4eca63-2958-4d9c-b687-96ea9ea4fd44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_a3d580f5-700c-46c0-b698-811f18990529_default" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:to="loc_cah_CordisDivestitureDomain_a3d580f5-700c-46c0-b698-811f18990529_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_d6547a7c-a0c0-490e-9fda-a8cd050bc29e" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:to="loc_cah_CordisDivestitureDomain_d6547a7c-a0c0-490e-9fda-a8cd050bc29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_fbf9d608-808d-447c-bf88-54cef16d6005" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_d6547a7c-a0c0-490e-9fda-a8cd050bc29e" xlink:to="loc_cah_CordisDivestitureMember_fbf9d608-808d-447c-bf88-54cef16d6005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_acebe3a9-5052-440f-98a7-3d3502048cf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:to="loc_us-gaap_SegmentDomain_acebe3a9-5052-440f-98a7-3d3502048cf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45efa746-5d24-4fe0-9f64-84e573eafa85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:to="loc_us-gaap_SegmentDomain_45efa746-5d24-4fe0-9f64-84e573eafa85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a785b831-757f-492f-b81e-6c14992f3c3d" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_45efa746-5d24-4fe0-9f64-84e573eafa85" xlink:to="loc_cah_MedicalMember_a785b831-757f-492f-b81e-6c14992f3c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_c6d99c3d-1f13-4211-b33d-cea1c912e379_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:to="loc_us-gaap_ReportingUnitDomain_c6d99c3d-1f13-4211-b33d-cea1c912e379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_034cd126-42f1-43da-a898-c627998ad2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:to="loc_us-gaap_ReportingUnitDomain_034cd126-42f1-43da-a898-c627998ad2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_8b2f9c71-2688-464b-a808-42c8f75045b4" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_034cd126-42f1-43da-a898-c627998ad2cc" xlink:to="loc_cah_MedicalUnitMember_8b2f9c71-2688-464b-a808-42c8f75045b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="i4aa2859f176844df990bb0f99ec99391_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_45769ea2-bdb2-4bd1-b6e6-edca55b31005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_939a3495-0669-4937-a8b1-062bf9888074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45769ea2-bdb2-4bd1-b6e6-edca55b31005" xlink:to="loc_us-gaap_Revenues_939a3495-0669-4937-a8b1-062bf9888074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45769ea2-bdb2-4bd1-b6e6-edca55b31005" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f9f77dbb-394e-43bb-851a-09e393de8ea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:to="loc_us-gaap_SubsegmentsDomain_f9f77dbb-394e-43bb-851a-09e393de8ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:to="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_8d6f3f9c-877c-4892-92a7-8eb4a02a90d2" xlink:href="cah-20211231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_8d6f3f9c-877c-4892-92a7-8eb4a02a90d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_8fa64933-54ec-4633-a90c-94a98d2bfa9d" xlink:href="cah-20211231.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_8fa64933-54ec-4633-a90c-94a98d2bfa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_06b77d08-52a2-4549-9075-bf4b8d469a04" xlink:href="cah-20211231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_MedicaldistributionandproductsMember_06b77d08-52a2-4549-9075-bf4b8d469a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_96ba0285-7457-44be-aa5f-dad9702b41ee" xlink:href="cah-20211231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_CardinalHealthAtHomeMember_96ba0285-7457-44be-aa5f-dad9702b41ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_de993d21-dba8-42e0-a365-9a78179620a7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:to="loc_srt_ConsolidationItemsDomain_de993d21-dba8-42e0-a365-9a78179620a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:to="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ad991aa5-0725-4a69-971f-d67d7415030f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:to="loc_us-gaap_OperatingSegmentsMember_ad991aa5-0725-4a69-971f-d67d7415030f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ffb72a78-d2ee-404c-8e1a-41a5b2ee0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ffb72a78-d2ee-404c-8e1a-41a5b2ee0d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_37bdeef2-baec-4ea0-a3e6-513da009ac55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:to="loc_us-gaap_SegmentDomain_37bdeef2-baec-4ea0-a3e6-513da009ac55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:to="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_a5d3cbdf-8126-4ecb-89a7-93ae4afc8a76" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:to="loc_cah_PharmaceuticalMember_a5d3cbdf-8126-4ecb-89a7-93ae4afc8a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_db0ca563-65ac-4efe-9301-1474dac2b014" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:to="loc_cah_MedicalMember_db0ca563-65ac-4efe-9301-1474dac2b014" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="i50cdb74605024d7aa183aec44148d266_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0094f247-9d0b-46ca-aef3-11b22989e9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:to="loc_us-gaap_OperatingIncomeLoss_0094f247-9d0b-46ca-aef3-11b22989e9f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_96bea670-41fd-4fde-a03f-0122e447d32a" xlink:href="cah-20211231.xsd#cah_JudgmentForLostProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:to="loc_cah_JudgmentForLostProfits_96bea670-41fd-4fde-a03f-0122e447d32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_acfd576d-8a1c-4b46-9190-1c7ca417c750_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_acfd576d-8a1c-4b46-9190-1c7ca417c750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_38697922-e1d4-4080-ab4d-5e7d1e397ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_38697922-e1d4-4080-ab4d-5e7d1e397ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1985817a-d1d1-4839-aae4-0b04b49fa913_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:to="loc_srt_ConsolidationItemsDomain_1985817a-d1d1-4839-aae4-0b04b49fa913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:to="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ef459767-7af8-42fc-87e7-e5bde8c53132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:to="loc_us-gaap_OperatingSegmentsMember_ef459767-7af8-42fc-87e7-e5bde8c53132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_85a881e9-75d1-4e43-b855-3a582525d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:to="loc_us-gaap_CorporateNonSegmentMember_85a881e9-75d1-4e43-b855-3a582525d5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6250c388-d212-408c-98cd-a6280fb53a0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:to="loc_us-gaap_SegmentDomain_6250c388-d212-408c-98cd-a6280fb53a0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:to="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_d87b9e28-842b-4534-9b0d-9244451ce5a3" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:to="loc_cah_PharmaceuticalMember_d87b9e28-842b-4534-9b0d-9244451ce5a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_1417a483-7adb-4789-99d0-a15cdcc641f0" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:to="loc_cah_MedicalMember_1417a483-7adb-4789-99d0-a15cdcc641f0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended" id="ic2f2d8020bf3443a9a46dd3b8fe6fa19_SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_07261702-1aa4-4ef4-8a6e-94b5cbde550d" xlink:href="cah-20211231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a352af03-599a-40f5-bee1-79253057b119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_07261702-1aa4-4ef4-8a6e-94b5cbde550d" xlink:to="loc_us-gaap_Revenues_a352af03-599a-40f5-bee1-79253057b119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:href="cah-20211231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_07261702-1aa4-4ef4-8a6e-94b5cbde550d" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:to="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e614c703-7560-4a6b-9868-20c39ba115d4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:to="loc_srt_ConsolidationItemsDomain_e614c703-7560-4a6b-9868-20c39ba115d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:to="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_18695abd-70b6-454a-886d-3f8149f68ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:to="loc_us-gaap_OperatingSegmentsMember_18695abd-70b6-454a-886d-3f8149f68ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_40157db0-3ff9-497a-aca6-2c887b153eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:to="loc_us-gaap_CorporateNonSegmentMember_40157db0-3ff9-497a-aca6-2c887b153eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:to="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7a58fdf0-ecf1-44a7-9f54-2250e766646a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:to="loc_srt_SegmentGeographicalDomain_7a58fdf0-ecf1-44a7-9f54-2250e766646a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:to="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f406fc5e-fe4c-480c-a26a-54a3b16b46ee" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:to="loc_country_US_f406fc5e-fe4c-480c-a26a-54a3b16b46ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_001a1c5d-76c5-4ead-a830-f909d6bf2c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:to="loc_us-gaap_NonUsMember_001a1c5d-76c5-4ead-a830-f909d6bf2c36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i1ffba2fe4a65484cbaf80a1c57df3fe5_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_55258d88-eff5-49d3-9777-71c281dca073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_Assets_55258d88-eff5-49d3-9777-71c281dca073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e72843a0-d24d-4800-9caa-a5bf3fee104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e72843a0-d24d-4800-9caa-a5bf3fee104c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6361ceaa-f889-4a55-a594-9bb3ec3d59bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6361ceaa-f889-4a55-a594-9bb3ec3d59bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2178b4f2-2686-4d11-b026-8ccd6176a535_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:to="loc_srt_ConsolidationItemsDomain_2178b4f2-2686-4d11-b026-8ccd6176a535_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:to="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e9f560d8-7ae4-41d5-bccb-f921e1ef11de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:to="loc_us-gaap_OperatingSegmentsMember_e9f560d8-7ae4-41d5-bccb-f921e1ef11de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e49e6053-634c-4325-a053-e4860bbe206a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e49e6053-634c-4325-a053-e4860bbe206a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_20df6816-4136-4f35-8fbc-4d7f230f29e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:to="loc_us-gaap_SegmentDomain_20df6816-4136-4f35-8fbc-4d7f230f29e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:to="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_ded68bec-deeb-4cdb-ba6d-818c1c8cf347" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:to="loc_cah_PharmaceuticalMember_ded68bec-deeb-4cdb-ba6d-818c1c8cf347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_d88575ef-65cf-4490-ac88-56c201beb817" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:to="loc_cah_MedicalMember_d88575ef-65cf-4490-ac88-56c201beb817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_4deae3b4-080c-42a4-95ea-7cda0aad0698_default" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:to="loc_cah_CordisDivestitureDomain_4deae3b4-080c-42a4-95ea-7cda0aad0698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_8e8e7294-8b40-4ee1-bbd6-7c27906f53f1" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:to="loc_cah_CordisDivestitureDomain_8e8e7294-8b40-4ee1-bbd6-7c27906f53f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_4017c3ed-c6c8-4e8f-b69b-d7d5ee45ab18" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_8e8e7294-8b40-4ee1-bbd6-7c27906f53f1" xlink:to="loc_cah_CordisDivestitureMember_4017c3ed-c6c8-4e8f-b69b-d7d5ee45ab18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0f5be3ee-2af9-4c9a-b094-c615390d26df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:to="loc_us-gaap_ReportingUnitDomain_0f5be3ee-2af9-4c9a-b094-c615390d26df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_08fe3ca7-378c-4aa2-be2e-8a4955018189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:to="loc_us-gaap_ReportingUnitDomain_08fe3ca7-378c-4aa2-be2e-8a4955018189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_265ddf12-cde8-4b12-b845-291d0dd5fe9a" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_08fe3ca7-378c-4aa2-be2e-8a4955018189" xlink:to="loc_cah_MedicalUnitMember_265ddf12-cde8-4b12-b845-291d0dd5fe9a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i7c61d757b2814c50b86f66361e4c170c_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_2daf8424-5636-4702-ac35-d4bbace133d4" xlink:href="cah-20211231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_cah_VestingPeriodinyearsforShares_2daf8424-5636-4702-ac35-d4bbace133d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c4ea58b7-51a4-470c-93d2-ea442c6b4c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c4ea58b7-51a4-470c-93d2-ea442c6b4c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_143202e0-3b7e-40ac-a742-c5b881dcbeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_143202e0-3b7e-40ac-a742-c5b881dcbeef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66ef3b52-b20c-49f8-95a5-205626c612f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66ef3b52-b20c-49f8-95a5-205626c612f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bfd191bf-913f-4fbe-9f35-bb8d44448a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bfd191bf-913f-4fbe-9f35-bb8d44448a0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_f0877076-12a9-4ef5-8e3a-9c476081460f" xlink:href="cah-20211231.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_f0877076-12a9-4ef5-8e3a-9c476081460f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_73bdd033-8c33-4a03-9fa5-cbc1fa8a033e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_73bdd033-8c33-4a03-9fa5-cbc1fa8a033e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:to="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d4a6349-d67e-434e-9548-337502341c85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d4a6349-d67e-434e-9548-337502341c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8fd3761-0d33-4948-a042-b661e362c493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8fd3761-0d33-4948-a042-b661e362c493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc562ee-31f8-4114-9090-e8121e30bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc562ee-31f8-4114-9090-e8121e30bb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f892a6ea-740a-4b7c-8444-cbd4e4c59ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:to="loc_us-gaap_PerformanceSharesMember_f892a6ea-740a-4b7c-8444-cbd4e4c59ac0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:to="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_902cac97-753d-41a7-a904-ad723a820fed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:to="loc_srt_RangeMember_902cac97-753d-41a7-a904-ad723a820fed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:to="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7df86428-9a1b-477f-879e-2aa53188b64a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:to="loc_srt_MinimumMember_7df86428-9a1b-477f-879e-2aa53188b64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5356d330-e1ea-4560-b0b0-bd84e0738ae6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:to="loc_srt_MaximumMember_5356d330-e1ea-4560-b0b0-bd84e0738ae6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="ib172505a12eb4858bbbc5a685c5426a5_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1b0ab9d-b234-40af-ab2c-ab08f7cdfbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f546452-a907-4963-9e40-6deded8b1965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1b0ab9d-b234-40af-ab2c-ab08f7cdfbf2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f546452-a907-4963-9e40-6deded8b1965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1b0ab9d-b234-40af-ab2c-ab08f7cdfbf2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:to="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_da94565a-0be1-4e59-96db-4f5cd5cf39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_da94565a-0be1-4e59-96db-4f5cd5cf39cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_732a9318-c0b8-4ffe-82f7-bc95d07a3201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_732a9318-c0b8-4ffe-82f7-bc95d07a3201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8ce59a8d-61e5-4120-8373-34f4c15e8b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:to="loc_us-gaap_PerformanceSharesMember_8ce59a8d-61e5-4120-8373-34f4c15e8b5c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="i61978406e3864496b2d6b3fd8a816280_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a646acc1-1bb7-44e8-943e-ff07fc9225e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a646acc1-1bb7-44e8-943e-ff07fc9225e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_440a7d88-5a7f-44dc-b909-672e3849048f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_440a7d88-5a7f-44dc-b909-672e3849048f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab936b94-c65a-42e3-adf5-ff29100ccc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab936b94-c65a-42e3-adf5-ff29100ccc50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_69baefd9-b3fc-4468-bd20-8307ebe607d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_69baefd9-b3fc-4468-bd20-8307ebe607d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77746f20-4555-4504-8050-dd1bfa63d6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77746f20-4555-4504-8050-dd1bfa63d6aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:to="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1040603e-2d18-4729-bcb8-869190ec3d8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1040603e-2d18-4729-bcb8-869190ec3d8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95cc50eb-3a4c-4cd9-b8e5-0a1f816bef7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95cc50eb-3a4c-4cd9-b8e5-0a1f816bef7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2f17f311-94b9-46cb-be37-a4784117e6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95cc50eb-3a4c-4cd9-b8e5-0a1f816bef7a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2f17f311-94b9-46cb-be37-a4784117e6c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i063e8162e039411e91d4b401fbeccc20_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_992e5d5d-af77-499d-b5e3-281f015c4c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_992e5d5d-af77-499d-b5e3-281f015c4c5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1c144baa-fad8-4353-9a59-9c64323acf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1c144baa-fad8-4353-9a59-9c64323acf73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ddd7e6c-c17f-402e-b574-728f3bacd947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ddd7e6c-c17f-402e-b574-728f3bacd947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed3d922d-0f8a-4e59-8c93-36680ad050fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed3d922d-0f8a-4e59-8c93-36680ad050fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af3ff126-fba3-4ba4-8695-2049a05ae87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af3ff126-fba3-4ba4-8695-2049a05ae87e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_720ca6df-d22c-4d2a-9463-e914ab7142c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_720ca6df-d22c-4d2a-9463-e914ab7142c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5b8684e-712c-4e61-ad5a-8d77cc269877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca1385a1-ab26-46fa-8753-3235af0368c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca1385a1-ab26-46fa-8753-3235af0368c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5720183-40d1-4c15-9a31-b9acca91f20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5720183-40d1-4c15-9a31-b9acca91f20c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6b564b81-10ef-4a0a-9ec1-58f773ed02ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6b564b81-10ef-4a0a-9ec1-58f773ed02ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_74df89ec-f543-42c7-8882-f0eae80c7625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_74df89ec-f543-42c7-8882-f0eae80c7625" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6919cd39-e173-41bb-a890-2e8cc3125634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:to="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b858dae-7187-49fc-b824-7f7be2d8ecf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b858dae-7187-49fc-b824-7f7be2d8ecf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_191c8457-9990-4503-b71f-9200f3f8e5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_191c8457-9990-4503-b71f-9200f3f8e5a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8734d220-639d-4ffe-b95e-167ba61acc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8734d220-639d-4ffe-b95e-167ba61acc00" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="i5e475ce39f5c4651b311de62c56d72ce_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97ca06f8-1c5e-49c6-aa8c-e83f955f6bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97ca06f8-1c5e-49c6-aa8c-e83f955f6bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6660f508-3e89-4fef-aa6b-ad3e52dc9073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6660f508-3e89-4fef-aa6b-ad3e52dc9073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27a1050b-a1f5-4878-a919-49792564a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27a1050b-a1f5-4878-a919-49792564a71f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38852659-d57e-42b2-84ab-c794ba0c42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38852659-d57e-42b2-84ab-c794ba0c42e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4e98c816-267d-4eb8-9af0-d785bf614259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4e98c816-267d-4eb8-9af0-d785bf614259" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2677047d-c622-47c9-9210-e099b0926679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c66a3696-c199-4015-9ce7-74a1012a21d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c66a3696-c199-4015-9ce7-74a1012a21d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be7d185e-c832-4d49-b537-54d01bb961fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be7d185e-c832-4d49-b537-54d01bb961fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe991b3f-f423-4fdc-99bb-0e3d5146d7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe991b3f-f423-4fdc-99bb-0e3d5146d7f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ad30b08-1f3d-4819-a9d7-0a93b2f0fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ad30b08-1f3d-4819-a9d7-0a93b2f0fbe0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f35c2f0d-559f-4df5-81a3-03a6d2984760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_07729959-9c76-450d-973f-1d25f3c62dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_07729959-9c76-450d-973f-1d25f3c62dbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ebad70e8-4097-4545-8cb4-ab333492bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ebad70e8-4097-4545-8cb4-ab333492bcb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_16afd12f-3bb7-4690-ab57-9fef347f31e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_16afd12f-3bb7-4690-ab57-9fef347f31e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:to="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14ab9a8f-8498-4f01-a41e-a75e302b05ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_14ab9a8f-8498-4f01-a41e-a75e302b05ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2e2a387-b3cf-4672-af95-48a4feb4356c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2e2a387-b3cf-4672-af95-48a4feb4356c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e7d9aafc-a08a-466c-b00a-acb6e9bb2480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2e2a387-b3cf-4672-af95-48a4feb4356c" xlink:to="loc_us-gaap_PerformanceSharesMember_e7d9aafc-a08a-466c-b00a-acb6e9bb2480" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cah-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d933fb5b-1648-4e2f-85b6-17909e6e7a92,g:b7c819a0-6ebd-409c-a3ca-466b0ca5332e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_HedgingDesignationDomain_3efec55d-7306-4338-ad77-1fc7590db0ed_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_339aaab4-8e1c-48df-98b2-1ad8c908604d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_37479617-d0ad-4ef9-8e0a-680b63b6de82_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e0a1fbb7-ddc3-456c-b5da-ea92ac45f2c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_741391a6-cead-40b5-a69e-2b78c86b0b95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_647388d2-4f6a-42c4-afb4-eafcdc0bc66c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_66c80dff-4118-40be-9746-ac7214cdc036_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9a36a4d9-6840-44ca-8814-22268f08a886_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_10b3cd04-84cd-4963-a346-801bcada8544_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cd4ce33d-cf03-4e90-a565-f10a008fb39d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cdc922ae-cc6e-460d-8aa6-37d32b1627b3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9d904e41-8775-40b0-a6bd-e9d40d254c22_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_adbc0fb6-7c80-4157-a0b7-358081507958_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_6e9cf578-0d5b-4a46-ad17-cea522ece0ae_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase price [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase prince [Axis]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase prince</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cc84a706-b86b-4347-bde4-be93deeccf3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_206ba14f-dce2-488d-993f-723123125800_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:href="cah-20211231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d930085c-e9fe-4d8a-960f-cffb237ba0ea_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_915e448b-9d80-4a5f-abe8-68883692daaf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7929a3cb-881d-4c4e-8346-7e52c68c201e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c58c175-4378-4cb5-a764-0e452ae7aa0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d3f1c5e1-6142-4365-9efb-188b6367ca78_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_43a5eb3f-deb5-489a-bffb-ffe8b1afd3fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_df4a7d97-560b-4fcc-a60d-b87572021603_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20211231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2ce128b0-6a56-4b81-ae71-5247cc54d563_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_a81b627b-f7d1-4eec-9912-6a1f8d384435_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_57100fd2-f115-404f-b633-5c034dfbfc61_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_03c33b55-0834-4d30-84c0-20e012c3d894_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_1e5ff234-4657-4aa2-b971-1915773c3658_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20211231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f2fb1e8c-e8d9-42ae-8f9e-4a94059acd8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_14d813dd-cf2d-4f0b-8182-739c43e7157b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4c5c4b89-6230-47fa-b909-e5b9f40f26d2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_b6d93653-2f65-4a5f-b3be-1f16282e38b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_89588f66-5151-4714-b4a5-4668af2b7867_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_8a0c9cd8-1e2c-4c95-bf60-23d9de9e5944_terseLabel_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_label_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_documentation_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:href="cah-20211231.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:to="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_3a5770e0-54c1-4771-9e42-b7f99255d18f_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_903cd9c2-836c-4c83-9745-3521c9c35d69_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1b7140e8-c0c9-473b-a6fb-83d58a55ed37_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_492fdcbd-7085-4874-a878-0c5664437c11_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5e59c4f6-68ad-4972-91a7-1033d11957fd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e7822fc6-6e6c-4c3c-a6f6-4ae276ce0e7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_8b27937d-96ff-4336-a702-d6b39cef475f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_faaa5921-4053-44af-8222-8331ba1a1d43_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_69856070-8d7f-4051-a572-13ba35d7e65a_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember" xlink:href="cah-20211231.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthServicesMember" xlink:to="lab_cah_NuclearPrecisionHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e1d0d28c-5863-4b41-98d8-6a1f94261c02_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9ed1b727-c126-4c75-960e-e0b582e28e76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_ba080cea-113a-4a8e-a2d9-b7591adbed0a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_0018d1b1-bddf-41d2-bc99-26e18ddb6b8e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7c338ce8-f403-402d-a71a-55039efb1119_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_6181e706-3c03-4797-9647-69bce5abe06f_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified from assets held for sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_label_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:href="cah-20211231.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:to="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_5aa8c647-8552-42d7-a881-d50c2c1242dd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b378c64-1995-4be9-b0ed-17c579fb2a62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_671f0e4a-e3f3-4904-90d1-020e8d8ea207_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6a74fe2f-688a-4d6d-8357-4ccba19f6029_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d738d71d-6ef5-4309-b0f2-e2588b639a42_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_4830a7c6-b9b0-4269-8da3-fb8e92831ac0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) on sale of equity interest in naviHealth</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_d1bf23f3-62cb-43bd-b193-3e7b67297f94_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) on sale of equity interest in naviHealth</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_eeb27df9-d76a-4922-83c9-aad6b5cef70d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6e73e8a1-40ee-43d9-9194-2efc1657c93a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_af1d1694-94a8-45f9-bf00-c8175ec8b861_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_67719a34-2b74-4131-8ac1-573063f94c0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b8a36cf7-4c0c-4e17-86a6-a1274d1c5800_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_c26f31b6-5169-4ee0-85ab-7ed1ee9545aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_81ab0fb5-f467-4489-97fc-4b7135ba2942_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_630188c5-978a-41a7-9c22-00d1faa2483e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;500 thousand shares, Issued&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_e5ecea18-cdf3-4eb7-91a0-3eed14d4ea9c_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20211231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc6519cb-7c1d-4bf9-90f9-cf5662aa59b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12386181-d1c7-41df-bd8a-30f3859d7a2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fceb5320-1472-45c5-a2fa-dd076c978f71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_320d62eb-cb6a-45cb-a061-24146c1d886d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6083115f-3cf1-42b1-91c4-4602987988af_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2b2c9f6d-e94a-4e10-b20c-4391fe619a39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_b0e80833-ad02-4d86-978b-5adb44371445_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project costs on investment and other spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20211231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_35af9ea3-2fe8-4aef-8af5-5647024e3f54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_88110bd6-b0d6-4f26-a116-b64c2fa5409c_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65e84dc3-cb50-4bc8-9e32-bf89893d2add_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DOJInvestigationMember_d3a67716-5964-4756-912a-4dc022ffe7b1_terseLabel_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_label_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_documentation_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember" xlink:href="cah-20211231.xsd#cah_DOJInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DOJInvestigationMember" xlink:to="lab_cah_DOJInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_0693a6ec-c718-443f-bdc2-0efaec9b1ff5_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20211231.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_9bc12121-5156-42f7-93f1-26970bdb77f8_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20211231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_02dc5239-4e34-43d9-a3bf-ac2947b08d76_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_603113a6-e96e-4e67-90cc-a34b85690266_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_193ff686-e36c-489a-8efa-1acbb9e9f808_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d8f9fdee-5f2a-4c54-ad45-46880536f337_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8cd46c76-5ba0-4878-99b5-ba5e4ae9e6c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_527b23f4-c6f4-45e9-ab25-2d3555324838_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fd5b8295-3a40-4d3a-9e2a-7294e9756d2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_b388046c-8275-47bc-b4f8-97d5ca25fc6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dfc1d765-f6b3-4808-829d-aab1d3c05d43_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_2eebf1f7-2fda-40ea-ba90-f39b93e234b7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_29600054-f10b-4471-bade-755886ed71ba_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_c870eace-a84e-45f6-8d7e-8106e4bbd45c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_30e6e252-7622-45f5-a426-422696081c54_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60ef7932-46ab-4758-88ba-3f70499f231f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9db2dcea-6505-4002-965e-30ebce80777e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_556ec0bb-45ba-499b-b595-44d55d00a3b1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_98bc1f60-81da-4647-951c-ce3fcac400ca_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_3450834d-a5ec-4098-8ce0-aee6ab3aeb92_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_258cdacd-f0f4-482c-b533-303acb6bcce9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6bbcd20-8951-4601-ba10-737287c6d9da_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_22369f94-52a4-40e0-ab72-5212ab937255_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_c6d297fd-ee65-4d15-bfb3-8275880839af_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_e53e10bc-d20f-4629-81fe-9b068f983482_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_5d4b33ea-ede0-4e0a-8a60-e953c2f5a48a_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_4bbdc7bd-fc8a-424e-85bb-a595cb7c061f_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20211231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_7dd0cd96-0df0-4e69-ad08-d28d22c891ea_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20211231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6605aa1c-3c7a-4b48-b887-ff30c60b85d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_3e979d28-314f-4107-bea0-665678ebe8c4_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c570ad6c-ed93-446d-a317-84468ec77440_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b9f95503-8d2f-4627-bff8-fef5bcdb07a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Held for Sale [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_90303452-0ff3-4e8f-8dbd-0b20ae3b4cf6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_d539e515-1cbd-48a0-9c30-d171be4e223b_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ad3d5f71-67cf-4284-8db0-f9863b2c3392_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_c0374840-d9a9-4849-bea6-1b2d50f69ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_880b433c-ef10-440b-8a1d-ca046701dd94_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c0286533-8563-4f7c-9729-747d964f604e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_e1577d07-18c1-4b5c-92da-50d18a9fc45f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d4091491-07a1-48dd-bbcd-aabf274979c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7279ecf2-cfed-426f-b289-1cff1531488f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_c4849b68-effe-4a5b-ac3c-2949a0d9888d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_37373a0f-af48-4cc9-86c9-b1999682059e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3d9a8933-390d-4eb9-921b-737990015381_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_957d7aea-b3b2-4454-8d47-0f0d531c5580_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20211231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d3c46cda-1637-481a-8cd5-ae86a78bf432_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_627b9fb1-cc20-4a10-9525-c5497c4db186_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a2549fc6-bdb9-4cf3-800b-85640cb2b9e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_761d3de8-4a7c-417d-924f-33d909efb834_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_0355d85d-19a8-4adf-bf14-074cf1a1c6eb_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be039399-5d41-45db-bfdf-a61bf5f99c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a28f86e6-1e08-4f3c-8905-e7c2c4b5bbf0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f98018e7-b8ae-4823-a62c-f9e5273ee35f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_a45dedcf-3cc1-4334-ac1e-b4160eca4a0f_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember" xlink:href="cah-20211231.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackMember" xlink:to="lab_cah_NetOperatingLossCarrybackMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1f44bee3-3340-4178-8781-f0c50d85aabd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_9c0deb51-3977-423f-9143-2e156c51dd4a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_7b990ddf-82dc-416a-8e66-0d09a8784ef9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_769ab09e-568f-4680-973f-0ab81bda4e5f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_81c2d0f6-3696-425d-8c49-83fe9ebf4776_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7e6ff6e1-4b26-438b-bfbb-eb8ceec698e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_16e2e36b-d1b7-41ee-bc32-2755c2e8ef0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_3807328b-3d33-48a8-bcab-6fbdcb220c28_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8110c6ab-7ad7-4a50-ac92-fbb00dcc4fb8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_669b7074-24dd-4edb-865f-e5527dd15b3a_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20211231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1663822b-6a13-4195-8e73-ca69561b680b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_ed335e47-2ddd-4efa-9d97-fa5f6f1ee7bc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fca81b35-85df-4a32-b7fc-db36120ff81f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentAxis_7aaae5bc-9699-4cec-916c-bbf133b0c882_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_label_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Axis]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentAxis_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentAxis" xlink:to="lab_cah_GoodwillImpairmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_151cf987-8df3-43cc-a990-f20d6baa76e4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_0bd30e2f-99ae-401c-b323-c0a4a2afe6b7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2a7e0b58-28ac-4f0a-9938-3e13ef532c8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_06417eba-6b76-4e2d-ae69-03b9c1625f6c_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2297c934-cdb7-4425-9326-7a11f1b06118_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c2ab44f9-d1d7-432d-a41b-3d671e4e72ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_974fa356-6cbc-4c55-b187-755c8013d580_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_98655056-1ab9-49f6-9456-9626a6b06bb4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_eeadf8ab-0e9b-47e8-a45d-471ebe4a69ad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_fe42b2d2-3d9d-4448-bed0-d8523248387e_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_45e411cf-4e9a-4737-a4e0-900cdcfa3301_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1981eb51-556a-4afb-87e9-31da350aff45_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_33435baf-5296-424f-ae79-f1b6c3ffc3c8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_e404dac4-61fa-4989-93fe-dd01265e1214_terseLabel_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_label_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_TerminalGrowthRateFairValueInput_documentation_en-US" xlink:label="lab_cah_TerminalGrowthRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminal Growth Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput" xlink:href="cah-20211231.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TerminalGrowthRateFairValueInput" xlink:to="lab_cah_TerminalGrowthRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_17cd2d77-9b19-4931-a04a-c698105bebcd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of subsidiaries, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_722967cc-7bea-4619-a356-5fc8d9b8ca15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_dde38356-5e51-40d2-a2ac-ec993d7c66ee_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3da371c8-e2e1-4b06-9dfa-5175fc5fcf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_444e13d0-ebc8-480a-af0a-b483df4af274_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_184242b3-bef7-4e02-a73d-3d7442c867ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_c514e883-9e24-49cf-bf18-12b56fd184ef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_643ea21a-fd36-4f98-9c27-77a0ff6385a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4d8c6e35-76e7-4a0d-be34-570b999db538_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17403605-5f6a-47e3-8628-a8faa513aabe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2491c2ae-08eb-444c-a2c1-c1867fa7eac1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_1250c97f-8be0-45e2-b317-85981c549067_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_a4df80cf-a8d6-4963-b5f5-ce7754857a3a_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20211231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0d04ea27-f545-4cdf-9dbf-7c4b2c9bfd06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at December&#160;31, 2021 and June 30, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_a89fbcbe-5484-4dd0-8648-3806690b2c3d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f827387c-d9d0-47c4-981b-213a562e1193_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c9ff3377-a2ec-4cc3-a3e6-b13588779b62_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_422d1194-164b-44ab-b7f1-f98a72b61f58_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4dd57afe-6056-42de-887b-1cd51b35d7e7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_034c8adb-8f0b-400e-ae01-1dac5ffad0b6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3c26bf81-33e2-4cd3-86d6-eff1a8f2d009_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f7b108a7-e3db-4b75-a235-ae1d25e30ab4_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8cf7140e-6ae8-4425-b6d7-61d9d3f24296_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e62197e8-2075-4ffe-8eea-25209a7275b5_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20211231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_JudgmentForLostProfits_ca4eab7f-47d9-4f44-b4a4-19a35922422b_terseLabel_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_label_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:label id="lab_cah_JudgmentForLostProfits_documentation_en-US" xlink:label="lab_cah_JudgmentForLostProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment for lost profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits" xlink:href="cah-20211231.xsd#cah_JudgmentForLostProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_JudgmentForLostProfits" xlink:to="lab_cah_JudgmentForLostProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_480b3176-8f34-4e3f-8f07-e6ccc5a2aa3d_terseLabel_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_label_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:href="cah-20211231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:to="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1698b108-ce9e-4c4e-97ec-0b2d88cfdc6f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_ad8be828-b5ae-420c-9ecd-f1e5ddbda851_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_683f0594-afab-400a-b412-164c72332aaa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_311728a6-46a0-4200-90cb-c86b1548ea71_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_809f88af-8477-4851-bb86-3358649699bb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a6d0f90e-8106-4d7f-abd5-124e4bbdf7b0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_6a9be55f-7c10-4830-b763-2b6e5784ff02_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20211231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_921c6f3b-cdea-425a-822a-77c8c89a9475_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_a1a82691-5416-4721-9b3e-7b08f662eddd_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_34c5e99b-65f3-4daa-b9a1-cf32e32b91ff_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_ec6a6ec9-9a0f-4d75-aadd-9cac915d8bfa_terseLabel_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_label_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_documentation_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations" xlink:href="cah-20211231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalLongTermandShortTermObligations" xlink:to="lab_cah_TotalLongTermandShortTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CARESActDomain_761e6b6f-0237-4d32-be36-cde04c9f2f1c_terseLabel_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_label_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_documentation_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain" xlink:href="cah-20211231.xsd#cah_CARESActDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CARESActDomain" xlink:to="lab_cah_CARESActDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_d83759d7-c1ba-42fb-9cdf-64e962d28f09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_6b10bcf3-4f97-46c0-83be-aefac616d74e_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20211231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_13db2c2b-b5c3-4826-90be-06fb7713eec1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7dabc253-bc48-4a73-b953-b6a6e0f7d600_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_48fee358-b426-4aa8-a76e-a5cec48c122f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e8692cb7-f165-4158-8ba9-efaa58655b8b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_03bdfa8d-bb5f-4178-8d49-4bb29b87b457_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_a343b1db-e8a9-4920-9a04-dcefe1eee400_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_6059e289-3543-4260-97f5-7b5ef4db8091_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_a540e542-9034-4ee9-a1be-45b6ba3cccac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8eae83e9-c383-410b-bfad-9f5d7dd0f64f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_d1c6c5a0-ec71-458b-b192-0d13d0e9e8fd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_93d068ee-ec4e-47dd-8ef2-1d7dfd2da92e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9779132c-9de6-4f6b-8f19-2472bfa7ec53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad74aabd-5752-4573-8869-b3df71f9d68e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_a7c02344-c7f4-4c0c-91cf-31657c8b8301_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_81f25535-5049-4d41-9dc8-3a848b21f28b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0aea86e2-eee1-46de-8207-b9e3684ef17e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc9808a1-851e-419f-aa76-85a2d22329d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7c0d864-bb8c-41f5-b8ea-5f2731c8936f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0bf58ec-fe25-4732-963d-13ad557311ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_9125bb96-84d5-4b50-a782-fc00c9e9876f_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20211231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_4cfd5f5b-d5c2-44cf-8679-298daabd74d3_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20211231.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_703753e0-5b4f-470b-a340-baf43eba801d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_b4e3af56-77a5-47fb-b4d3-4eb9d5dddede_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_047e2bcd-b390-48cb-8826-c88fa633ddc3_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_fb832d28-542a-402b-bf7d-50a8ad54d2d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_f6cbd854-07ff-4690-b0ff-611ca0ddb0a0_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_label_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitGoodwillImpairmentMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit Goodwill Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:href="cah-20211231.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitGoodwillImpairmentMember" xlink:to="lab_cah_MedicalUnitGoodwillImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_df9e6e16-8511-4b09-aac5-7dab4f899ca5_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_85b7aba5-d633-4165-ae63-540ccdb99da5_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe7ef48f-3769-407b-811d-3cab29f33513_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_89b4784d-a166-4591-b3d7-aa9acb9bfc32_terseLabel_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_label_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_documentation_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member" xlink:href="cah-20211231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FloatingRateNotesdue2022Member" xlink:to="lab_cah_FloatingRateNotesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_c1bfa132-7880-45f5-a0a9-45dc96be3203_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0dd4e7b3-6db4-4772-8947-2b49e1a2007c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2388c1b2-2158-4f39-bc50-32a1e26b41d0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_b7cb62db-b4e0-425f-bf18-b2dd38b45745_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_b01df981-588e-48aa-ae57-ec2bb23d1502_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_28747503-a302-4e9f-b1b0-15ee823fdaab_terseLabel_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A300MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$300 million share repurchase program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:href="cah-20211231.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A300MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A300MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_59ada6e0-5a47-4d84-bbd7-6eaf51ede2e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_13db2a7a-9c93-4fc5-ac78-c76d77363eaa_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_560f5b82-324a-4e90-a94f-a46944b0a2a3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7d58064b-b08f-489e-96f7-2135c3b6c182_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_de7c48f6-a45d-4a49-bbd6-b0bfa79d0e09_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c21b087f-f453-457c-9634-c7fc36da9aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of outstanding options at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_4eeb74bb-d54e-45a3-8852-f9573de2353f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ab34a673-a367-41a2-af79-8f9f60b6feef_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_ac2ee3f0-62d4-458e-b8a9-006f2e94e212_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20211231.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a0fd8803-c8f4-45f5-88e3-c99594972e67_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ab1e5e21-fe81-4187-995c-47295fc0704e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bb41e7a3-1d36-4317-89a0-33cabe7399b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_48617ef2-4f43-44ef-b529-612b39b2248a_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20211231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_53264738-3ee7-4dbe-adfd-609ec48985a9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9c9bd08b-7cb7-4da8-a5ea-e047d1479a97_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d8a042de-14bb-48ed-96b9-437a8182eddf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of exercisable options at period end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeDomain_c2892565-117e-422d-b4a0-8fa6616cb6f2_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_label_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_documentation_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain" xlink:href="cah-20211231.xsd#cah_LawsuitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeDomain" xlink:to="lab_cah_LawsuitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_7274e84a-8c42-42a1-8e21-3b09367a1a66_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4213bf57-03c9-43df-8600-93023f64f66a_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_4b7075c8-21cb-48a0-9c56-0aa9f7e76979_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3f5a5d67-72c8-4f68-9109-fc62926c3879_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_b662156f-e4a6-48ae-b893-8a85bea769f2_terseLabel_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_label_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Member]</link:label>
    <link:label id="lab_cah_A500MillionShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million share repurchase program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:href="cah-20211231.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A500MillionShareRepurchaseProgramMember" xlink:to="lab_cah_A500MillionShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_29517c2e-7043-4a88-a069-dbc4b8b0e491_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2651900a-39de-4a84-99a2-b814aefc8202_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_8db23c6c-1105-4971-a4fd-b3af70b589d5_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20211231.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GoodwillImpairmentDomain_7c3c0d45-4a86-498e-857c-2d528b4ec82c_terseLabel_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_label_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:label id="lab_cah_GoodwillImpairmentDomain_documentation_en-US" xlink:label="lab_cah_GoodwillImpairmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Impairment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GoodwillImpairmentDomain" xlink:to="lab_cah_GoodwillImpairmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6427088c-dd4b-4ee0-b716-79097f2c2831_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6b3ed6ea-b0a6-4db0-b9cc-53a2d88b040c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ed6d8472-1c7d-4156-9b75-5c8f34befa3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4dda39d1-6515-4bb0-a88a-290e1dd18e12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_b445fd58-82c9-4d5c-8cd2-e9b498bfd930_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1f4b0d31-f0ce-4856-81ac-410a60c4ffdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_fdc455e6-9ba0-4537-b23c-6e14fbbd102f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7bfb1a70-7f92-451f-8166-3a4c9c4879fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_1899fde3-a374-4070-857d-30d8a1c6fdb8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb14e61e-08b1-4bb9-9195-960f9a676ed9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d292bd60-9f54-479c-bdf7-63e5a11f23c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_42824611-c3eb-4e44-b08f-ce2d13a8656c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4351842d-fc11-460a-bd4c-7cf92738d806_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_fa07e098-49a3-428b-b4bb-705fc4eb8dff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e7d7498d-9f2b-482e-82ee-0fc1ff2c8ed5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_64b42a2f-cfc3-40a4-8509-6455c1423037_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_faf4a52d-b96e-4069-95db-3a7b59069001_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ad0bdd54-dbed-4082-bb26-4bc5eb04074d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_b0f6678b-27e4-49fc-8cd7-474a27f77cc7_terseLabel_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_label_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_documentation_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember" xlink:href="cah-20211231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PatientRecoveryBusinessMember" xlink:to="lab_cah_PatientRecoveryBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalUnitMember_e187c7f7-171c-4e36-8fe2-7337c5b55cf5_terseLabel_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:label id="lab_cah_MedicalUnitMember_label_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit [Member]</link:label>
    <link:label id="lab_cah_MedicalUnitMember_documentation_en-US" xlink:label="lab_cah_MedicalUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalUnitMember" xlink:to="lab_cah_MedicalUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_4b4188ab-7adb-45a8-b716-4a44a435db66_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_db973c77-cbef-4d94-8d73-0d5c5a549c8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0de0a583-925c-46ce-87ea-70b34b17bef6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_fba6d7a0-feb9-40d8-ac45-bcd22645b7fb_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20211231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ef82e03c-abf5-4966-872d-12266dba47fd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_9da62f44-47e6-4d9a-b99c-8dc42c8fe9a2_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1bd3a81c-28b8-47a3-8f07-f17a2c67633c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5c0c8e38-008c-456e-85ef-7feaac00c04d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c39b363-2184-4dd3-b4c4-ea88180bf3f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c9baf01e-c6c5-45e0-9e9c-deaca43bc1ea_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_47f4a062-b232-4438-a191-0c74c4317eec_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_841f949f-64b6-40f8-8dbc-6b5de0ef935b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d6b0bc8e-b2e3-4004-b574-b5f82b1b0da9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2b0fa3bc-74cb-4779-bef4-d471a4144f78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_58c9e4b1-af60-45a0-b65a-257f9861380e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5d4df054-3b2e-43b2-ab7b-1a8a0840b018_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_707e5109-05c7-4e12-aa66-e428f2c01d6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_26159dfb-f0f9-407c-82f6-37020e6abc73_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c06396fb-0219-438e-90c1-5432f1a93c67_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_bb296cdf-684b-4820-80a0-aeb665eff8d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fe3045d8-464f-448c-b9aa-5e6966ee2e89_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2788e35b-db8b-4e93-82fd-d58464ecc41c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c266bfa1-8979-46f6-bf70-9414c6ea6031_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_c63ebd23-59fb-4548-bbb4-1f646922773d_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember" xlink:href="cah-20211231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeMember" xlink:to="lab_cah_CardinalHealthAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_953db32e-1c3b-4b73-963a-4b3cecfcc869_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e87bccf5-53f5-4967-b22d-8bc9b4d3f5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_538ff607-6622-414d-bec8-dbfe04b78e7e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_c3e4139d-5307-4511-9b62-0532afe0aad6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4824f1bb-40cc-483c-920e-aec2f7d0c2ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_931518b6-82ad-4985-b6a6-051d3993a95c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_60aaee0d-f8a9-4f40-8cbf-a9be6d505e91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_25d62337-12d6-414b-a939-04b3f317dc0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_07be2383-b14d-4c3f-bdb4-5876954ea65b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_16786dba-f0df-4573-8004-5aa98859fa51_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6c9d21ad-8d4e-404f-b4ec-bb53cb6e0292_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ea18a0d3-9b41-4db9-9580-a8ae81381061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Common Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b7eaefb8-72b0-4db4-ab31-7e6f59c294d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_d11aee3f-c413-4ee4-86b7-be159b723774_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_297c482b-ab29-4bbb-badb-5b92e15cb945_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_d5916403-f4b4-4b02-adaf-31993eff3b65_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsStateMember_539189ae-9cae-4a42-ba14-6688e43d35b6_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State and Political Subdivisions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateMember" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsStateMember" xlink:to="lab_cah_OpioidLawsuitsStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9e49a3cb-c2cb-425e-b4ab-d5ea3341feb0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9d82eb01-15cd-4807-8f64-18d74d1439dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_188b217f-79d8-4620-9554-1d959268d12e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2a8203b-e6ff-4626-8cb9-c17c66eaf599_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_aec5cd6a-02e0-451d-bee0-98994b049626_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_85208c1e-03ec-4ab9-abe9-9db479de371f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_ce3b7ef5-0e4f-4300-ae44-7d157bdb3ffd_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_00d225ee-d682-4fed-a174-77f0a6ff67e2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f65f1d8e-611a-42c9-8c03-22b608bce0a7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_46d9032c-1cdf-4871-a15b-def156b1b12c_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20211231.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_40d14331-98aa-42db-b1f1-15c3a575fbca_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_09b80dc7-0b6c-409a-8588-2d7b77a05f6d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0b1636e3-6dbb-4863-bc8a-56955524a834_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_535d3976-9044-4460-99d2-302ffc8ec931_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7ccaa880-f885-412f-8683-e495525ba5cc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_625e288f-4b38-41cd-87c9-41b8b6eedce0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_fcef1fd1-25d1-4b32-8ef8-27792ecea1c1_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3428448c-1d71-4084-94d4-1e6fa1ac9177_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_4e07ee4d-236d-4e49-b659-32afa8a9336a_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_cf7c259d-1708-4030-baf4-e44686611b7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_c2eb211e-401c-4607-9a37-133b6e0181c9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3cf6cbc0-7414-4ce6-8257-079be815628c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ec7a7a63-9126-4dee-87f0-d96e5e1d6999_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_b475ca26-f2c0-492a-b6e0-e8aa24ea6fe8_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9f177ba8-4962-44bb-950e-92eb39113059_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_5331b0a4-c563-41c3-9d9f-77aa3804d3c9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8d209b1c-4352-4a0e-bfdd-a1201cda69c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddbb6d4a-b7e3-4739-9138-71f62d2eb139_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_6d541509-7cf2-4374-bfad-c021edb3bc30_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8c3effbf-f9e6-41e4-ba86-2ab518e342bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bb35164-9982-4b55-8922-1c66fd71b8e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_275addbc-80a6-4697-b5c9-55903f6ece9d_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_label_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_documentation_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:href="cah-20211231.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:to="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_b8727b0b-ed38-472e-8cbc-03882ccb24a4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58251cbc-bd01-4160-b4bf-fefe5df9fb0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cba9bda1-6546-49ef-a46e-2204ed95e44a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a8cb6c3a-6451-4af9-8693-f28a77723207_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_f79c22d8-212a-4a01-acdb-18e433b46214_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9a8cfe48-ba8c-45e1-8dea-8e554e166834_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_c7e36778-67a3-4cfc-a8e6-80064542ed8a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_927f4b9f-c034-4e4d-bb8f-5a55f79e0c62_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0bfe237b-c566-4243-b597-41222f76e030_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a970ba7-0a4e-41b4-92e9-86c5ef00233f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_8541926b-7abd-4822-b434-87dfd91196ca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_079b63fb-75e6-4bee-b4b3-588329d5a210_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_591dc150-9acf-4124-9015-9bf439e295d9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options, restricted share units, and performance share units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_252079be-37f5-42b5-a517-241806989167_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_c593fdad-2cb4-4fbe-8e04-832c1d4e69e7_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis" xlink:href="cah-20211231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackAxis" xlink:to="lab_cah_NetOperatingLossCarrybackAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ab65374e-f483-44a1-910c-8c8ffa0e22e5_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_13d2da98-563e-4824-9de4-a8b5dba630cb_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c141e766-d9a6-4b97-92b7-cc835cb5e0a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3ca062a3-43a9-485f-8487-b7e0cfb175d6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_faebb45d-df99-499b-b1e0-215ec85c67d9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_308e89ae-7216-475c-9e5c-511179167f01_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_6bbf684c-97bc-4e32-8aac-298c4d6f7099_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost: 50 million shares and 36 million shares at December&#160;31, 2021 and June 30, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_7123a6c3-03f7-45ab-a730-a511a0844aa0_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_cd6fa0de-8ff5-4d8a-8f5c-66a338dcd729_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_47a5b08b-7ccb-4a9c-8cce-4f7734e85b48_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d86cff79-1388-46d1-afa1-945686fe3fe5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_f70c7b50-3fea-40ab-ab26-2c1adee8d3e7_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20211231.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe43d78f-1a8c-4876-addc-e4175600495c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_cdc89c7c-75a3-41ae-8d46-a8f0d90f935f_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20211231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d9968d51-51bb-4620-be20-234561aa5a19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_cf6ea311-f6b5-4110-9491-f5fed32ca75b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_e882e317-4224-423e-85cf-1abd72aa88a2_terseLabel_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans (in years)</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_label_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans, in years</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_documentation_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The instrument's contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears" xlink:href="cah-20211231.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ExercisablePeriodOfPlansInYears" xlink:to="lab_cah_ExercisablePeriodOfPlansInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_00aa9a9e-5e50-4adb-8d3a-d2d7701adc5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_dd4b88dd-30f4-4be8-93d9-536f3d708ecb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fec908c8-43e0-4ede-99aa-7d1443be5bae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d1692fd1-ccb8-4a11-bd8d-4b5cb0515cd5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_60fc5a2e-c84d-4eed-9fb5-0e4966d5cb25_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6ea4a4a4-8947-4d25-86fb-8ca55d208d4e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_53e375d2-2f86-446a-9cbc-6c87aeed5b3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c2880083-0943-49ee-8f86-9dd4ae477355_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_3101eb75-4813-4da0-8747-22171bcccfc4_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c139cc5e-ef6e-4052-82a6-8b3e57bc0afa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_10031065-f935-4fae-bd28-d0d4cbcaf173_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f15ab99f-1e69-47ae-b19d-96c3315dad6b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_03e44ee4-d563-4db3-948d-2d47408346be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f9b0c7d2-2e6c-49e1-9a6e-40520cd76a55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_3fbcc734-0d41-42f3-afc9-70a497c4d1bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_be431042-5350-4055-9ebe-e15d947ed62c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_1c335cdf-0375-492f-960a-9bf8fe0c1752_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a3d55d54-04df-4be7-a3e8-8e325bd11a97_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_877cbf42-2137-430a-b5ad-59b3840ff035_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_cc5a7705-5abc-4be6-ad92-33441668d643_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d6e1d30a-ae0c-462b-9ac8-5b0bc5eed157_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ad936f76-6f79-45ea-9c2e-10aa8b13af16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_183c71c3-2b43-4b4d-ac83-d34fa35407c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_6e10ac7d-8df5-4f09-96f9-73b78cb221c5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_99af0821-637d-4053-a944-88c617317b34_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_8f6a7e23-13c8-4357-9349-d94868b639de_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2b4b4df5-e539-4f8e-b3ae-7d0cba6a1a4a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_fd20c663-f79f-4387-a280-0143535cc050_terseLabel_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase prince [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_label_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase prince [Domain]</link:label>
    <link:label id="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_documentation_en-US" xlink:label="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program aggregate purchase prince [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" xlink:to="lab_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_5178e28e-9de6-4cfd-9f36-295bc395144e_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_d35878cd-5a51-4e4e-8f2f-a4db8d8a3894_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_5789e009-f824-464f-a374-f8d2f15e531e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_af98e6ef-cc71-4549-9854-ea4bfbc672a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a7d1b700-8830-480a-b42d-dd65f6f573a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_935edae6-d8c1-46cc-9e14-79e36f38cd5d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_a49df817-3068-49d2-9c6c-41d75ac2edba_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_953dd474-a4a7-4db7-a8a4-374b8d7586d3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_6b257416-48e0-443b-8288-c23a44e7478c_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_6f349b20-d34e-49d1-8935-ed9aea7ab58a_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NarativeAbstract_64479394-a6a9-4d49-94ca-30b6d8761ff0_terseLabel_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_label_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_documentation_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract" xlink:href="cah-20211231.xsd#cah_NarativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NarativeAbstract" xlink:to="lab_cah_NarativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_5b1b1002-6078-4395-9fde-b9be0a87216b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_941a6d18-a39c-4a1f-85d1-fd9cd2952168_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_2fc4d02a-4b91-48e9-8ad3-8e7026259e46_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_d6b1dc10-c93a-405c-9e6d-034fccd044b9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82e861db-91c5-4e12-97b4-543fec66b38e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ab1540a7-8188-481a-bad3-e5c290177aec_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dd537dbd-e904-438d-8cbc-ac9163b78357_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_47494ad7-316f-4415-8432-7fad066fb113_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_49ae202a-3ff3-4624-a9ca-475b61c7edbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_205df7a1-5425-49a5-a15b-d9727e19199e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0da6ea0e-393a-438f-afab-049d982b198a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_d40c3dc4-9718-41ab-8245-67604deb1871_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20211231.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_166ddec7-aed6-43f3-81f6-d50a54a4855f_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_2d01c192-a104-4e9f-8a1f-efd8b53e3742_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_2cfef314-46a9-4fee-8e34-bca6aeb3b28d_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20211231.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba7e9a39-1d6c-4139-81c6-edf6d4ba7513_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7056c88-01e8-4e57-a68e-e732c44bf045_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a45210c5-1ba8-426c-959c-57c0c15159a7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_67eaf67a-9f97-47bb-9432-4717d75ed8fd_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20211231.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1e38b1bc-b220-4d65-8218-581b82ca5288_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_e79f6b8f-dcf8-41f0-8d9e-6f7ef36cb4ae_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_159a0062-6e82-4775-bbf0-65222317cad9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d2cc2501-3431-44d1-965b-8fefb5262d6b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_73b052e6-6273-4c03-84f0-f3a040a2bd46_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DiscountRateFairValueInput_1170efaf-42f5-4fbc-bfb9-9fc6fb9a41a6_terseLabel_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_label_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:label id="lab_cah_DiscountRateFairValueInput_documentation_en-US" xlink:label="lab_cah_DiscountRateFairValueInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate, Fair Value Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput" xlink:href="cah-20211231.xsd#cah_DiscountRateFairValueInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DiscountRateFairValueInput" xlink:to="lab_cah_DiscountRateFairValueInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_c2d64b8e-8228-4b6d-b850-80902f8f74f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f86ab477-6dcb-4763-b58e-984a730dca3f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_eefbb78a-c0f8-495b-b571-08c9d7560014_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_73701eeb-3ad1-412b-a190-f0c3d717d51e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3d954ee8-8552-4a92-9ffc-8d4bdee16e73_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_e25ed52f-6f4f-4491-9897-f92b0fcc83e4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b556d63e-4ee2-401c-a0ff-949b0881b834_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_13c0edac-7cc5-4c50-832a-bd242d5a0b6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_a86dad04-5aba-446b-958e-279395751d09_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_bd70fb57-985f-4a99-be0b-d019e6a2a341_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_eb385611-7f76-443e-9f1a-a3064a8b0c57_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_7ce257fb-9a78-4486-979e-7a31130892b5_terseLabel_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Data Related to Stock Option Activity</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_label_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock Option Plan Data [Table Text Block]</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_documentation_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A disclosure of additional data related to all stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:href="cah-20211231.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:to="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_031fae86-88b5-4bcb-a25e-a9d742e0a33e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9383abed-8d04-46c6-a349-36cb4692799b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_64939bce-c148-4124-b050-f4e0bb44801d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_e9cab572-2573-4a67-a432-3f58ee9e5e74_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20211231.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e86305e-f94f-4c0b-84b2-fb02b5366bde_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60dfe12d-cbe3-4a1d-92a1-80323ae28e10_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4fb732f6-2ea7-4961-9ad6-c7e938d1d75f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_645eb296-4f99-41e5-907e-c89f49ff29d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9dc81124-8825-468b-a076-f32518208969_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_6a375c96-75d5-4f11-a65e-e99d4b3f260f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_87ad970f-bd49-478c-befc-6455835e470d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0f2117f5-c3a4-4f49-982a-ebf41adb4d7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3300f318-e113-4afa-a164-024e7bffbd08_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dd691339-43c0-4685-8c16-75099eb23b79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_c0d686d9-3d24-4010-9a00-1114d5f23937_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20211231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7b1a05c2-27f7-468c-b85a-3f24ce9b8b37_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a0933fdf-fe16-4a43-9c0b-0f538a4a7c99_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5513cd29-8f32-4537-ba57-5a09aaa42806_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_bc6a8b59-9921-4eff-9ed9-9f2b50c0bb09_verboseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20211231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2ef54054-8203-4840-865a-3a83cbbb80d2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_a275e1c7-1e18-4288-b48d-ad475fdece58_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_0480b201-20a5-47a2-8330-b6ff7f42ac53_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_210bb3db-5345-435f-ac29-53fc7a2a73c9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53c57b96-9359-45c3-a144-dd9548621ff4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_58ecbd63-7e80-4a59-96f1-3fde76c2da13_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_e3be4191-55e7-45c8-bbe2-eb640f117440_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d8c886-c7cd-4459-b77d-a368090845b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1e54403-3770-4278-aa7c-f19a3b14ef20_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d3edb1e6-fbef-49bf-a4bf-659148a93320_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d6385542-278b-466c-98c3-f4be65da7ffe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_94e7ec30-e144-4cf0-8fe6-841ab7ee013b_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:href="cah-20211231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_a90ba54f-30aa-42b3-8600-ff12ea8c6b49_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_16efddef-9a3c-42f2-96ea-53a352e0ae99_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_74882826-63c8-4adc-942b-beab4fdc3f00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_a3f87537-c5c4-4f51-8dce-12d7670f51d7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_853d47d6-d4d2-4510-add3-6d8e7b679438_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_145d6e9a-06c0-42d8-b174-a9c8689afa29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_c6c41d88-ec48-4d0f-ac9c-e958f3374da0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_334d4804-2395-473a-8fdf-fb3fd5751fae_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_451a9393-85fb-4588-b81d-a9aa35b4713b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fc88756d-091d-4229-94a8-11f29557483a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ac489658-e0a8-4bac-aec0-078f53bcc024_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_fb5532da-b005-47c4-8c84-5f08a5176152_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_164565ec-e434-4adf-937d-aeab0b3e993e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4446db2e-faa6-4201-b448-f90c6b3453d5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_2de38897-36c5-4f19-b2e0-937846122652_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_723dfb0d-7279-4788-ae63-1c527d0a0d1b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c31bc932-c419-4407-88f9-c8a0369de35e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ec626863-a7b5-4e68-ab37-0fa00f656ee4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_585b661d-a6ea-46c1-bc2b-1759cfac09a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b3cfa908-0c31-4880-bf75-77fe328a51d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_3bbe6bac-cfe9-4c29-943b-424d20c77529_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_81da325a-c51e-47e6-a297-ee0c746880f8_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ebf79daf-38fc-4edd-b044-65e18da811cb_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_a9e93c12-f281-4614-aa12-b8b56eec5061_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ecc01720-eb7b-43c6-9738-aee0efdfe816_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f4ef687d-626c-4204-8405-f02d077fc155_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2baed5ad-a030-462d-8bcb-fc5f523abb24_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementAxis_80ae9d60-33cb-4378-bbb0-e314425343bc_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_label_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementAxis" xlink:to="lab_cah_TaxMattersAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e84764f0-7cb4-475d-8156-f80989f1b97a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_29de7364-4872-413f-9b3d-fc74fe6b6eeb_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bf7ee3ab-a635-4b88-94a1-66a395d2e5e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cah-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d933fb5b-1648-4e2f-85b6-17909e6e7a92,g:b7c819a0-6ebd-409c-a3ca-466b0ca5332e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0bb098d6-019a-40c7-8f77-5404d4f7de4d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_DocumentType_0bb098d6-019a-40c7-8f77-5404d4f7de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4f196ac5-6194-4f20-9281-bdee009d73dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_DocumentQuarterlyReport_4f196ac5-6194-4f20-9281-bdee009d73dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_149f0b06-de32-4729-8530-c939882aaa54" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_DocumentPeriodEndDate_149f0b06-de32-4729-8530-c939882aaa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8cdd3bbb-e837-438c-95a7-123f3a87be44" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_DocumentTransitionReport_8cdd3bbb-e837-438c-95a7-123f3a87be44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3e6997cc-fe02-4210-a3a0-7cb488ddf634" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityFileNumber_3e6997cc-fe02-4210-a3a0-7cb488ddf634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5ff33520-e27b-4a31-bd5e-901bcdc70305" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityRegistrantName_5ff33520-e27b-4a31-bd5e-901bcdc70305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e0fed3f9-8ab1-43fa-888d-e652b3c1983b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityCentralIndexKey_e0fed3f9-8ab1-43fa-888d-e652b3c1983b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_36ebbd97-74c5-4338-96c9-db608c48ef3a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_CurrentFiscalYearEndDate_36ebbd97-74c5-4338-96c9-db608c48ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_58b6865d-a7fb-4220-8526-21c975c28500" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_DocumentFiscalYearFocus_58b6865d-a7fb-4220-8526-21c975c28500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_09381928-fa5d-4958-878c-9fed9b17187d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_DocumentFiscalPeriodFocus_09381928-fa5d-4958-878c-9fed9b17187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_503b4cd8-90e4-4ac9-a71a-1bb3f14aeb26" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_AmendmentFlag_503b4cd8-90e4-4ac9-a71a-1bb3f14aeb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e78f3956-79f3-44ed-84f7-1315fbe85e84" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e78f3956-79f3-44ed-84f7-1315fbe85e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_775d4fd8-95a2-4190-9828-877849c3f624" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityTaxIdentificationNumber_775d4fd8-95a2-4190-9828-877849c3f624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0ab784fb-c884-4053-89f7-4432f2fe6eb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityAddressAddressLine1_0ab784fb-c884-4053-89f7-4432f2fe6eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_df7fc742-85cd-4c62-b105-6930eddc6d82" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityAddressCityOrTown_df7fc742-85cd-4c62-b105-6930eddc6d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_66942350-c8aa-4155-91ad-60efa25549fc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityAddressStateOrProvince_66942350-c8aa-4155-91ad-60efa25549fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4a45beff-82bb-4fef-81ca-b46586fc5db0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityAddressPostalZipCode_4a45beff-82bb-4fef-81ca-b46586fc5db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_74189f37-9b8f-4b12-ae40-85098cbc9f0b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_CityAreaCode_74189f37-9b8f-4b12-ae40-85098cbc9f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0a2778ff-e2cf-4a71-afd1-609a136f0685" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_LocalPhoneNumber_0a2778ff-e2cf-4a71-afd1-609a136f0685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c9f69e1b-0100-4ff4-9454-817b870216f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_Security12bTitle_c9f69e1b-0100-4ff4-9454-817b870216f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ecaa33d6-3702-4df6-9b5f-ab58d4701849" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_TradingSymbol_ecaa33d6-3702-4df6-9b5f-ab58d4701849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e2508fa-d38a-4cb4-b801-2212753ee74e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_SecurityExchangeName_8e2508fa-d38a-4cb4-b801-2212753ee74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c175a41f-7935-4de2-82c1-bc5ef8ccbf55" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityCurrentReportingStatus_c175a41f-7935-4de2-82c1-bc5ef8ccbf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7d2fac18-ebf6-45f7-a4d0-00e1c40e7acc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityInteractiveDataCurrent_7d2fac18-ebf6-45f7-a4d0-00e1c40e7acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c0a91a4d-2ae1-4433-bb5d-b3f6ace7e0ef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityFilerCategory_c0a91a4d-2ae1-4433-bb5d-b3f6ace7e0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_89a10749-6668-4ede-b764-2c4a04309cfc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntitySmallBusiness_89a10749-6668-4ede-b764-2c4a04309cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_368085dd-2923-41bf-9ccf-4b82b3c87d0f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityEmergingGrowthCompany_368085dd-2923-41bf-9ccf-4b82b3c87d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e6bc95e8-73e1-4d53-b4ae-7e2499ac0729" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityShellCompany_e6bc95e8-73e1-4d53-b4ae-7e2499ac0729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7af94f17-11b7-4c22-a64a-abfa3f6b5ca8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b2bb4413-79a9-4823-ad1d-cc1761759682" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7af94f17-11b7-4c22-a64a-abfa3f6b5ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_337ee795-4200-4ffa-9238-90997e90465d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_Revenues_337ee795-4200-4ffa-9238-90997e90465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9272db18-258e-4547-8eb7-c278596b924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9272db18-258e-4547-8eb7-c278596b924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5f9b6fc8-6fed-4da3-be70-b7a9c44c2a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_GrossProfit_5f9b6fc8-6fed-4da3-be70-b7a9c44c2a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c36e3212-224c-4461-b770-02962465da00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c36e3212-224c-4461-b770-02962465da00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_84737aa7-52f5-46d8-a5d0-0e290e204406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:to="loc_us-gaap_RestructuringCharges_84737aa7-52f5-46d8-a5d0-0e290e204406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_9e503447-ec73-462c-a6d0-0236877d4e07" xlink:href="cah-20211231.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_9e503447-ec73-462c-a6d0-0236877d4e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_94989d54-c13e-4b2b-a4bd-db75fd005372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_94989d54-c13e-4b2b-a4bd-db75fd005372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_2baddc01-392f-49eb-9cc1-3099772e8075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f3d932c3-d920-4302-a57c-2be74d22a653" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_2baddc01-392f-49eb-9cc1-3099772e8075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_83b8def4-3cf6-4275-9970-21dfbd16f907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_OperatingIncomeLoss_83b8def4-3cf6-4275-9970-21dfbd16f907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d04872db-082e-46a5-9f70-c7b7ce84306b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d04872db-082e-46a5-9f70-c7b7ce84306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c4a43bd6-c48a-4c72-aa9c-c3d755fcc50e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_InterestExpense_c4a43bd6-c48a-4c72-aa9c-c3d755fcc50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_91119cb0-0e48-4651-85dd-e8c132a135f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_91119cb0-0e48-4651-85dd-e8c132a135f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_0eeb5e1b-0083-4b1f-ba4e-91bd53fb7955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_0eeb5e1b-0083-4b1f-ba4e-91bd53fb7955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6f64e-ec9a-4a2e-9c0c-be33d9896b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dbd6f64e-ec9a-4a2e-9c0c-be33d9896b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_37f8f4c3-19fb-46e2-9466-797b4bc299c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_37f8f4c3-19fb-46e2-9466-797b4bc299c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_614da17e-86ba-4b1a-a81d-6ab20f9bb0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_ProfitLoss_614da17e-86ba-4b1a-a81d-6ab20f9bb0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d0e0018-c889-472d-9a30-8e5ee0f579ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d0e0018-c889-472d-9a30-8e5ee0f579ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_10473158-43bf-4a20-bec1-124b1ad42b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_NetIncomeLoss_10473158-43bf-4a20-bec1-124b1ad42b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_9f10cbf6-4cda-4b91-a7c3-c0e104e78d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_9f10cbf6-4cda-4b91-a7c3-c0e104e78d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3d3a265c-775e-4b0d-b1c1-6d3ff88e7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9f10cbf6-4cda-4b91-a7c3-c0e104e78d09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3d3a265c-775e-4b0d-b1c1-6d3ff88e7fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ad011410-4517-43dd-9187-c90dd424b236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9f10cbf6-4cda-4b91-a7c3-c0e104e78d09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_ad011410-4517-43dd-9187-c90dd424b236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b7c274a3-9fa0-4600-afd3-c3cb6779aa39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b7c274a3-9fa0-4600-afd3-c3cb6779aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_858b6a72-98d2-45e5-b152-9b06e45d89cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_858b6a72-98d2-45e5-b152-9b06e45d89cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_345ccb17-b6a2-478b-b929-65b9a43ee244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_858b6a72-98d2-45e5-b152-9b06e45d89cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_345ccb17-b6a2-478b-b929-65b9a43ee244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5cac48f1-6943-42c8-a2b2-941b682c9128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_858b6a72-98d2-45e5-b152-9b06e45d89cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5cac48f1-6943-42c8-a2b2-941b682c9128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d2eba277-0d1a-4cc2-9792-8b5f284cc0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_147891d7-a17d-4610-bbc3-5d903ebe11f1" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d2eba277-0d1a-4cc2-9792-8b5f284cc0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27a23535-2dd5-4618-abb0-258c91e7dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_da63cc32-8703-46eb-a6d5-0b941a5d356c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27a23535-2dd5-4618-abb0-258c91e7dda5" xlink:to="loc_us-gaap_ProfitLoss_da63cc32-8703-46eb-a6d5-0b941a5d356c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5c7d8490-7fe3-42ee-8285-384536dd7645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27a23535-2dd5-4618-abb0-258c91e7dda5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5c7d8490-7fe3-42ee-8285-384536dd7645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_89b11721-5fda-432f-bd65-6ae1724940be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5c7d8490-7fe3-42ee-8285-384536dd7645" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_89b11721-5fda-432f-bd65-6ae1724940be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0f34a40c-5577-4661-915c-a745a3c4ca86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5c7d8490-7fe3-42ee-8285-384536dd7645" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0f34a40c-5577-4661-915c-a745a3c4ca86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6212232-2986-42a6-8e83-7f25030f7be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5c7d8490-7fe3-42ee-8285-384536dd7645" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6212232-2986-42a6-8e83-7f25030f7be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ea74be9f-eef2-4b31-ab63-6fd5f41700ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27a23535-2dd5-4618-abb0-258c91e7dda5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ea74be9f-eef2-4b31-ab63-6fd5f41700ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c7201ed3-40f4-4256-b272-a9d34e6de4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27a23535-2dd5-4618-abb0-258c91e7dda5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c7201ed3-40f4-4256-b272-a9d34e6de4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f797582-f573-4f74-9876-06da3723529e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_27a23535-2dd5-4618-abb0-258c91e7dda5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2f797582-f573-4f74-9876-06da3723529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:to="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_354f7fdb-c225-45b9-8890-fc4b6efd914a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_354f7fdb-c225-45b9-8890-fc4b6efd914a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e86d6488-0137-40e6-813f-16937c211275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e86d6488-0137-40e6-813f-16937c211275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5152f8b8-fac4-45e9-bcde-6dd59ef31451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:to="loc_us-gaap_InventoryNet_5152f8b8-fac4-45e9-bcde-6dd59ef31451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f39e880f-28fb-42a9-859e-b6087e6bd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:to="loc_us-gaap_OtherAssetsCurrent_f39e880f-28fb-42a9-859e-b6087e6bd7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_23305a02-6a1d-4602-9c4d-76827c71839a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_23305a02-6a1d-4602-9c4d-76827c71839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6a6c33ca-41e6-4c95-b45e-ba4527d4f062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_196031ca-f8c4-4db9-953b-b44cf9f2c2e4" xlink:to="loc_us-gaap_AssetsCurrent_6a6c33ca-41e6-4c95-b45e-ba4527d4f062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6aade0bf-3e9b-4ebc-821c-5a45148e7d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6aade0bf-3e9b-4ebc-821c-5a45148e7d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ab63ac3c-0687-4f3d-8473-00ea40636f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ab63ac3c-0687-4f3d-8473-00ea40636f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd05e4b6-d415-4227-81b0-13a0d7a8a909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd05e4b6-d415-4227-81b0-13a0d7a8a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bbe7f8e5-32bd-4027-a6dc-67fdfaaa0245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9ca73dc3-a513-442a-bc38-0889815ec565" xlink:to="loc_us-gaap_Assets_bbe7f8e5-32bd-4027-a6dc-67fdfaaa0245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0722acf0-e9fb-4bf3-af31-361ed2d69e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:to="loc_us-gaap_AccountsPayableCurrent_0722acf0-e9fb-4bf3-af31-361ed2d69e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_0fa68d2f-41be-437c-87d6-b56cc23dad2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_0fa68d2f-41be-437c-87d6-b56cc23dad2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8bde2075-6c67-49f8-98d3-c60f5558377b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8bde2075-6c67-49f8-98d3-c60f5558377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4addd1ff-38cf-4ae1-99df-c5971395d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4addd1ff-38cf-4ae1-99df-c5971395d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8d5fe0c3-ee33-4a01-9c71-734ad725bf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2d58ba9f-9e72-4ab3-94da-3ba95a0e187d" xlink:to="loc_us-gaap_LiabilitiesCurrent_8d5fe0c3-ee33-4a01-9c71-734ad725bf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5d8c50b7-29d2-4d56-8395-1c51d1c6a8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5d8c50b7-29d2-4d56-8395-1c51d1c6a8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_291b94c3-8329-4dac-95f5-f831dec7e0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_291b94c3-8329-4dac-95f5-f831dec7e0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_11b0f1c2-8f8a-4b3b-8c37-676a298b8ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_11b0f1c2-8f8a-4b3b-8c37-676a298b8ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a74275a2-201a-41f0-914a-6734530d1420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_11b0f1c2-8f8a-4b3b-8c37-676a298b8ca0" xlink:to="loc_us-gaap_PreferredStockValue_a74275a2-201a-41f0-914a-6734530d1420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7f0d3df3-d1aa-4a99-98d6-99d8624c2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7f0d3df3-d1aa-4a99-98d6-99d8624c2cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4d03a8bb-12f1-436d-8350-db3edcca05bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7f0d3df3-d1aa-4a99-98d6-99d8624c2cf4" xlink:to="loc_us-gaap_CommonStockValue_4d03a8bb-12f1-436d-8350-db3edcca05bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4c84ea95-e1dd-4923-aef5-dfb379ef0857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4c84ea95-e1dd-4923-aef5-dfb379ef0857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_11931129-079d-4c26-82f8-1639790a1704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_TreasuryStockValue_11931129-079d-4c26-82f8-1639790a1704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_894a3c93-ea07-4bce-9ad8-f467e6081585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_894a3c93-ea07-4bce-9ad8-f467e6081585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_81747fc2-a444-4808-acc5-dce5ec67be97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_StockholdersEquity_81747fc2-a444-4808-acc5-dce5ec67be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1372a709-5c2d-483b-bd34-3d2439a7aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_MinorityInterest_1372a709-5c2d-483b-bd34-3d2439a7aae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ddda0c05-1fbe-4b9f-b8d4-600e014db814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f92d5e66-da88-44f3-94e6-891d35547baf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ddda0c05-1fbe-4b9f-b8d4-600e014db814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d566acc-2663-4bec-a10b-17de949a6482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_89d388df-d98d-416d-b0b5-d730a5efdcfb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d566acc-2663-4bec-a10b-17de949a6482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_534c69e0-66df-47a5-85e4-ce1cad366bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_534c69e0-66df-47a5-85e4-ce1cad366bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0b31f0d1-e1c9-44ae-bf6a-df8329814333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0b31f0d1-e1c9-44ae-bf6a-df8329814333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d76a34e0-84ee-4369-a246-699ceda51197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d76a34e0-84ee-4369-a246-699ceda51197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_31a6389d-5818-48fa-8b79-8b6e065e44d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_CommonStockSharesIssued_31a6389d-5818-48fa-8b79-8b6e065e44d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_d7cbf499-8d7c-4846-b590-d0c07ea7c652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97525239-bcd2-4670-8f21-3206d7468a1e" xlink:to="loc_us-gaap_TreasuryStockShares_d7cbf499-8d7c-4846-b590-d0c07ea7c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_79f3e34c-f22c-46e7-9772-45722bab707f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b616d186-1d41-45a7-ae7e-8012f4cadd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79f3e34c-f22c-46e7-9772-45722bab707f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b616d186-1d41-45a7-ae7e-8012f4cadd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b33c3cdd-339d-4cbf-8f18-47d653f19550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79f3e34c-f22c-46e7-9772-45722bab707f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b33c3cdd-339d-4cbf-8f18-47d653f19550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1552356d-2757-45d6-ab49-eb8045ad889b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79f3e34c-f22c-46e7-9772-45722bab707f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1552356d-2757-45d6-ab49-eb8045ad889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_78fb6a32-c704-4f42-91de-ec3b96d59a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79f3e34c-f22c-46e7-9772-45722bab707f" xlink:to="loc_us-gaap_CommonStockSharesIssued_78fb6a32-c704-4f42-91de-ec3b96d59a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_05b462d4-beb2-4f3b-8f03-9e5b1bfc69cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79f3e34c-f22c-46e7-9772-45722bab707f" xlink:to="loc_us-gaap_TreasuryStockShares_05b462d4-beb2-4f3b-8f03-9e5b1bfc69cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8a2e94c0-03b2-455e-a076-b764c2652184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8a2e94c0-03b2-455e-a076-b764c2652184" xlink:to="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5f54719c-c629-45f9-885e-c98395de4a0a" xlink:to="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb676ad6-4bb8-4910-93fe-ddea1d029bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_CommonStockMember_eb676ad6-4bb8-4910-93fe-ddea1d029bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_058dcc32-2c3e-4425-ab27-7467eee06fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_RetainedEarningsMember_058dcc32-2c3e-4425-ab27-7467eee06fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_00224101-58cc-4112-bede-7cfb1340c148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_TreasuryStockMember_00224101-58cc-4112-bede-7cfb1340c148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b92676c8-1c43-431d-afd7-c3fe2f3ca62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b92676c8-1c43-431d-afd7-c3fe2f3ca62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2ad252eb-6e23-4495-b06b-71dcf162e2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92cf2dba-2423-4195-bf2f-8a25cc3b6139" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2ad252eb-6e23-4495-b06b-71dcf162e2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ab52f97-ea37-4861-abf6-2e50ba8ff029" xlink:to="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f9e25a5e-8e97-42ff-a102-8e5dea31946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_f9e25a5e-8e97-42ff-a102-8e5dea31946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0499d553-5546-4bc5-9bbe-637d4a356757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0499d553-5546-4bc5-9bbe-637d4a356757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_fd1663a0-68f0-4f2d-8e63-c6dc30c124fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockShares_fd1663a0-68f0-4f2d-8e63-c6dc30c124fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_605a0aa6-aaa8-4cd4-bce3-974e95327411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockValue_605a0aa6-aaa8-4cd4-bce3-974e95327411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_242956b4-712a-4b63-b364-d947412c1db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_ProfitLoss_242956b4-712a-4b63-b364-d947412c1db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d56c987-3032-49d0-84ab-32a4db740651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_NetIncomeLoss_9d56c987-3032-49d0-84ab-32a4db740651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ed56843-2a49-4709-b4ca-fd9eb0f35779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ed56843-2a49-4709-b4ca-fd9eb0f35779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92c889a8-ba75-45fb-90cb-204f36bbb53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92c889a8-ba75-45fb-90cb-204f36bbb53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f627c97e-b170-4e26-bd76-cdf952c94ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f627c97e-b170-4e26-bd76-cdf952c94ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_55384b8a-0ec4-4aaf-8895-53a9217ca4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_55384b8a-0ec4-4aaf-8895-53a9217ca4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36ebef86-e970-4623-adef-3e6dac6cc2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36ebef86-e970-4623-adef-3e6dac6cc2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e4729a31-9626-4928-bb7b-fe9cdf5b1370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e4729a31-9626-4928-bb7b-fe9cdf5b1370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8a7f49b7-b3cd-42f2-8f6a-a89555afad77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_Dividends_8a7f49b7-b3cd-42f2-8f6a-a89555afad77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_0cb63a2e-36b2-456b-90b5-374ce0473953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_0cb63a2e-36b2-456b-90b5-374ce0473953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_f35ae08c-967b-41ee-ae80-7f5c6a52c280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityOther_f35ae08c-967b-41ee-ae80-7f5c6a52c280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_43f69208-cd5b-48e2-8190-e68f849d683d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_43f69208-cd5b-48e2-8190-e68f849d683d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06f0b4f1-b6f3-4afc-bdc5-910af38ef93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06f0b4f1-b6f3-4afc-bdc5-910af38ef93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_1375e81f-cdf6-4465-931f-ed544db0059e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockShares_1375e81f-cdf6-4465-931f-ed544db0059e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_fc3dc838-84ec-4ebc-9e97-dbcd06998a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockValue_fc3dc838-84ec-4ebc-9e97-dbcd06998a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a79c6195-5e7e-4aee-80e1-bf87cd089ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56ddeecc-c6ec-4d37-9550-1900f12489e2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_a79c6195-5e7e-4aee-80e1-bf87cd089ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20211231.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78c45611-a999-4276-815d-32c20646b764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78c45611-a999-4276-815d-32c20646b764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fe5a65f8-dd23-45b1-884f-0d3592b3ba51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78c45611-a999-4276-815d-32c20646b764" xlink:to="loc_us-gaap_ProfitLoss_fe5a65f8-dd23-45b1-884f-0d3592b3ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78c45611-a999-4276-815d-32c20646b764" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_db403227-137d-4f3b-bdc2-ede79b05e267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_db403227-137d-4f3b-bdc2-ede79b05e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_f0f629ec-03aa-4ba1-8d58-dbe27b2afba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_f0f629ec-03aa-4ba1-8d58-dbe27b2afba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5eed5cdb-14df-41a4-9d9d-a44748f460f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5eed5cdb-14df-41a4-9d9d-a44748f460f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0ac9e17d-13ca-4537-8b40-e15391bcc1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0ac9e17d-13ca-4537-8b40-e15391bcc1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6280a181-c67b-43c3-aa1f-1c3eae0756a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_ShareBasedCompensation_6280a181-c67b-43c3-aa1f-1c3eae0756a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_346f7d2b-63d4-4254-aa60-fdb9e5f77120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_346f7d2b-63d4-4254-aa60-fdb9e5f77120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e15ede9c-3642-4337-b10b-acbe47e1825f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a5dbf812-8635-4dd6-bef4-e8be2af78864" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e15ede9c-3642-4337-b10b-acbe47e1825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_3ca1a97f-985d-4c2d-b454-7cca97e871c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e15ede9c-3642-4337-b10b-acbe47e1825f" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_3ca1a97f-985d-4c2d-b454-7cca97e871c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f4a3a71c-37e0-4508-ad68-1bdec1dc5a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e15ede9c-3642-4337-b10b-acbe47e1825f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f4a3a71c-37e0-4508-ad68-1bdec1dc5a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6fe121a6-fc46-4353-915c-f6f2b51e3845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e15ede9c-3642-4337-b10b-acbe47e1825f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6fe121a6-fc46-4353-915c-f6f2b51e3845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_17643e79-96ac-4965-8cba-c44ec82235e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e15ede9c-3642-4337-b10b-acbe47e1825f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_17643e79-96ac-4965-8cba-c44ec82235e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_135beef7-0c0a-44ec-85b8-c4b8a1439b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78c45611-a999-4276-815d-32c20646b764" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_135beef7-0c0a-44ec-85b8-c4b8a1439b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d3ce4b3-cae5-47d4-b003-f81354acc5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d3ce4b3-cae5-47d4-b003-f81354acc5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f52971fd-f8e3-488f-b3fd-91658fea3ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f52971fd-f8e3-488f-b3fd-91658fea3ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_21c69ba3-3dfb-4610-a892-81dedf3df336" xlink:href="cah-20211231.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_21c69ba3-3dfb-4610-a892-81dedf3df336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_d6d04641-e0e4-464b-a618-7050615f4d11" xlink:href="cah-20211231.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_d6d04641-e0e4-464b-a618-7050615f4d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_5df09f7e-7582-431e-ba67-5ce47d067d2b" xlink:href="cah-20211231.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_5df09f7e-7582-431e-ba67-5ce47d067d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_141d2d2f-e94c-4b06-90c8-82d9880d4368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4581bf0-6668-4a4a-b68f-36a9b5a66163" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_141d2d2f-e94c-4b06-90c8-82d9880d4368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1cab27d5-d786-481a-921f-4ec01cbb5972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1cab27d5-d786-481a-921f-4ec01cbb5972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_bd3ae6f9-c19e-40cf-842f-8893624999a9" xlink:href="cah-20211231.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_bd3ae6f9-c19e-40cf-842f-8893624999a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_eb5aa23b-3068-4328-b74f-cd6f38194167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_eb5aa23b-3068-4328-b74f-cd6f38194167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c9a6b6eb-47f6-4c18-a5ad-538298877b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c9a6b6eb-47f6-4c18-a5ad-538298877b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3fe8a2ac-6024-48d4-9e30-6c23020dd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_082177f0-1253-417e-a76e-dc3794910277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3fe8a2ac-6024-48d4-9e30-6c23020dd26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1831340c-8877-48a3-a5d3-895e9d56c0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1831340c-8877-48a3-a5d3-895e9d56c0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_d30a49c9-5e58-4bb5-b263-01cea522792c" xlink:href="cah-20211231.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_d30a49c9-5e58-4bb5-b263-01cea522792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6fde6748-5c05-44b4-b782-9a98bd2e2af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6fde6748-5c05-44b4-b782-9a98bd2e2af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78e05ecf-ba20-4e22-aaf3-b52e7be8e345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_78e05ecf-ba20-4e22-aaf3-b52e7be8e345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_862eabb4-f4b9-4ca7-a64f-194ded108dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e914464e-ee56-4f68-96a6-8ea546a41a5e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_862eabb4-f4b9-4ca7-a64f-194ded108dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_50ee0933-1f9f-4ed9-ad93-df94d6ea58c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_01624305-8096-42f6-916d-9b680b907b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_50ee0933-1f9f-4ed9-ad93-df94d6ea58c3" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_01624305-8096-42f6-916d-9b680b907b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7ddc93ff-4901-42ea-86ba-7130725746ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32bad503-e150-4ef7-aca2-5c463f11c98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ddc93ff-4901-42ea-86ba-7130725746ab" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_32bad503-e150-4ef7-aca2-5c463f11c98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_643678b4-76b4-4d0c-b58e-db1cf9120fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ddc93ff-4901-42ea-86ba-7130725746ab" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_643678b4-76b4-4d0c-b58e-db1cf9120fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56b7cd5b-cfdc-4a22-8aef-19f5c7b40278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20211231.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_53eefc76-af92-4585-acbc-233136c4db57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3ad0010a-13da-4f57-b811-57900bf0f5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_53eefc76-af92-4585-acbc-233136c4db57" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3ad0010a-13da-4f57-b811-57900bf0f5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20211231.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c847a21f-bb58-4677-82b7-a59b863cb0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_df4d37ac-04a5-48f8-bb62-5280a3f477ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_df4d37ac-04a5-48f8-bb62-5280a3f477ef" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c6363c4f-a5ad-4e86-9a1e-f6a045f7065b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7e613a42-e96d-4c64-bc75-da6bba784348" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c6363c4f-a5ad-4e86-9a1e-f6a045f7065b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:to="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_e4058ce0-a099-4064-82a7-46b019f6b7a1" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_ca8ec254-abb2-4571-8a4b-6498fa52323b" xlink:to="loc_cah_CordisDivestitureDomain_e4058ce0-a099-4064-82a7-46b019f6b7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_07331462-1017-4ca1-893e-27fb0cf25ab2" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_e4058ce0-a099-4064-82a7-46b019f6b7a1" xlink:to="loc_cah_CordisDivestitureMember_07331462-1017-4ca1-893e-27fb0cf25ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_376af766-3c7f-468b-b500-36d131ae8e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4e8fe1d7-603b-4beb-a1f7-2d4250f31622" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_376af766-3c7f-468b-b500-36d131ae8e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ab8f0654-29ba-4274-ac1a-12747326aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_376af766-3c7f-468b-b500-36d131ae8e7d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ab8f0654-29ba-4274-ac1a-12747326aaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_31388705-f6b0-412a-b5b8-9ebe45e025c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0df7e204-fda1-4e84-b850-5d2ace480b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_31388705-f6b0-412a-b5b8-9ebe45e025c7" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_0df7e204-fda1-4e84-b850-5d2ace480b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_52767d48-cb5d-4b2e-942f-35b81045abae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_ed519e8a-2121-4dd9-a48b-8786be1f5c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_52767d48-cb5d-4b2e-942f-35b81045abae" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_ed519e8a-2121-4dd9-a48b-8786be1f5c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e451d100-dc80-45c7-ad3e-e01ba2506489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_52767d48-cb5d-4b2e-942f-35b81045abae" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e451d100-dc80-45c7-ad3e-e01ba2506489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_132ef766-942a-46c0-88d4-fc22a89d2474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_b1602b00-79d9-4185-a175-4aba149a24b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_132ef766-942a-46c0-88d4-fc22a89d2474" xlink:to="loc_us-gaap_SeveranceCosts1_b1602b00-79d9-4185-a175-4aba149a24b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_4788d1ef-808d-4bc0-93c6-6b8232a51d5d" xlink:href="cah-20211231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_132ef766-942a-46c0-88d4-fc22a89d2474" xlink:to="loc_cah_FacilityExitAndOtherCosts_4788d1ef-808d-4bc0-93c6-6b8232a51d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e9024621-70ef-480a-8fa2-05d969f8a535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_132ef766-942a-46c0-88d4-fc22a89d2474" xlink:to="loc_us-gaap_RestructuringCharges_e9024621-70ef-480a-8fa2-05d969f8a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_40802998-0789-4df4-b428-0f40fab3971b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_40802998-0789-4df4-b428-0f40fab3971b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1710f18d-8de4-4636-90ca-d69ef73a7016" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_8a96745e-2297-4bf1-844e-b4754d0a6064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:to="loc_us-gaap_EmployeeSeveranceMember_8a96745e-2297-4bf1-844e-b4754d0a6064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_d404f6c5-2fe6-40e3-84a9-080f1e4b2cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a6c59ef6-eec0-4b59-b6a8-0d565476a60a" xlink:to="loc_us-gaap_FacilityClosingMember_d404f6c5-2fe6-40e3-84a9-080f1e4b2cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4e55748a-16d4-4f69-8530-0b79e7551d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8550c017-dd58-4e73-bc77-e9f9afa8d8dc" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_4e55748a-16d4-4f69-8530-0b79e7551d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4e55748a-16d4-4f69-8530-0b79e7551d2a" xlink:to="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_848410f0-ca61-4048-9ad9-a7f45df9cbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_RestructuringReserve_848410f0-ca61-4048-9ad9-a7f45df9cbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_f6f7b87f-5005-4313-b737-5b49258a322a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_RestructuringCosts_f6f7b87f-5005-4313-b737-5b49258a322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_9def9cb5-9801-430b-8646-da30aa9b479b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_PaymentsForRestructuring_9def9cb5-9801-430b-8646-da30aa9b479b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_210b7b25-9966-45c8-981a-ca114e87a484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_515c86e3-0699-4015-9411-3362fb3b5fb4" xlink:to="loc_us-gaap_RestructuringReserve_210b7b25-9966-45c8-981a-ca114e87a484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract_0704f123-9412-442f-bb06-d6b81ededeed" xlink:href="cah-20211231.xsd#cah_NarativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NarativeAbstract_0704f123-9412-442f-bb06-d6b81ededeed" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:to="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_dc743802-7baf-4cc4-be56-88842ffdb248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_90ad1eff-1cb3-4226-8845-10a657292085" xlink:to="loc_us-gaap_RestructuringPlanDomain_dc743802-7baf-4cc4-be56-88842ffdb248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_ad4c083a-98ea-4bab-b735-99fb8e03be66" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ad2a387d-ee0a-4724-bd29-d5c5ed5c8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:to="loc_us-gaap_SeveranceCosts1_ad2a387d-ee0a-4724-bd29-d5c5ed5c8aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_26c5af8e-cf2b-4e73-a682-53d563e8f7dd" xlink:href="cah-20211231.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_3ce3f333-fbdd-4de8-b63b-4c1e132fdaa6" xlink:to="loc_cah_FacilityExitAndOtherCosts_26c5af8e-cf2b-4e73-a682-53d563e8f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d562d968-72ba-44e0-b016-5a875bee3864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5895ffd9-32ff-491b-9125-ca8f03755682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d562d968-72ba-44e0-b016-5a875bee3864" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5895ffd9-32ff-491b-9125-ca8f03755682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d3dfe06-8709-4c5c-b6ac-4f81de1e17e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_4b2f0317-3d0f-4f97-846f-465ea82958b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d3dfe06-8709-4c5c-b6ac-4f81de1e17e9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_4b2f0317-3d0f-4f97-846f-465ea82958b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b302c094-5a79-4352-b12d-3fd58919f85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d3dfe06-8709-4c5c-b6ac-4f81de1e17e9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b302c094-5a79-4352-b12d-3fd58919f85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_06d1cf4e-b6be-4cc6-ab82-d139c842a75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_06d1cf4e-b6be-4cc6-ab82-d139c842a75c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b39b100-994b-4edc-a3df-f23aa4b160e2" xlink:to="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_ad8119e0-9375-4b08-9baa-623daa01a3a5" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:to="loc_cah_PharmaceuticalMember_ad8119e0-9375-4b08-9baa-623daa01a3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_b96f3bf7-6de4-4263-ba4b-708ed9c0ce45" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4ca9d514-9f17-4107-a0a7-639644b00b6f" xlink:to="loc_cah_MedicalMember_b96f3bf7-6de4-4263-ba4b-708ed9c0ce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:to="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_9cac14af-df99-45cc-9590-4bd58569f642" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_21297c7c-13f8-4393-b8c7-c6179b96f8f0" xlink:to="loc_cah_CordisDivestitureDomain_9cac14af-df99-45cc-9590-4bd58569f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_aea6e994-3f40-4772-a4a5-5551e3c3e611" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_9cac14af-df99-45cc-9590-4bd58569f642" xlink:to="loc_cah_CordisDivestitureMember_aea6e994-3f40-4772-a4a5-5551e3c3e611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ceebf34f-4f78-4827-b148-a6b388a1786d" xlink:to="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:to="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95740580-1f19-4108-b3c9-972ae6d405d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_Goodwill_95740580-1f19-4108-b3c9-972ae6d405d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe9fd3b4-7290-47b7-b285-4afc8beca0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fe9fd3b4-7290-47b7-b285-4afc8beca0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fbd8630d-1c21-457c-b091-9e89f65326bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fbd8630d-1c21-457c-b091-9e89f65326bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ed124624-16ca-470f-be4e-610265a0eda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ed124624-16ca-470f-be4e-610265a0eda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_36e32856-2649-4a6d-904d-336d880ffcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_00e830e4-1b8f-4351-88c0-6da8248fbbbd" xlink:to="loc_us-gaap_Goodwill_36e32856-2649-4a6d-904d-336d880ffcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_be0be3b8-ca0c-475a-a777-6d2b064b2bde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_53dc8c62-9ac8-4691-aec8-c97fe795ae75" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_be0be3b8-ca0c-475a-a777-6d2b064b2bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09628b66-624d-4a53-a737-8a576b563afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09628b66-624d-4a53-a737-8a576b563afd" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ae35827-9b32-480a-ab20-eaf9461c04d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10b23a67-9464-4a12-b76c-c7d333559fd8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ae35827-9b32-480a-ab20-eaf9461c04d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_f6d4e031-f1dd-4cb0-911a-602b857cd961" xlink:href="cah-20211231.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4ae35827-9b32-480a-ab20-eaf9461c04d0" xlink:to="loc_cah_IPRDTrademarksandOtherMember_f6d4e031-f1dd-4cb0-911a-602b857cd961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c086aa80-965a-4822-a2b2-81c69a1ace04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_a239e7ab-23e7-49a3-aadb-93010685c808" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c086aa80-965a-4822-a2b2-81c69a1ace04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4145fa9c-4452-44f0-842e-3a2407de8077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_c086aa80-965a-4822-a2b2-81c69a1ace04" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4145fa9c-4452-44f0-842e-3a2407de8077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09628b66-624d-4a53-a737-8a576b563afd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6645baef-87f2-4290-a459-326e70b7e123" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_d90d7e3a-8324-495d-bb7a-e145e50cda81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:to="loc_us-gaap_CustomerRelationshipsMember_d90d7e3a-8324-495d-bb7a-e145e50cda81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_4b6574bf-58dd-4c44-82f1-dd198c954216" xlink:href="cah-20211231.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:to="loc_cah_TrademarksAndPatentsMember_4b6574bf-58dd-4c44-82f1-dd198c954216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f28690a3-2e12-475a-a3af-1bdbac4578ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f8d465e-297e-4e65-b578-7fdfc4db8ed9" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f28690a3-2e12-475a-a3af-1bdbac4578ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5498a133-e8a1-498e-915b-c9b77dab27b8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8cf820e3-0bfd-4fc0-a22f-3d2688b01e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8cf820e3-0bfd-4fc0-a22f-3d2688b01e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54c894f3-74ae-4c55-a088-e13b6c777ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_54c894f3-74ae-4c55-a088-e13b6c777ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cc501e39-589d-4565-9114-5bad68df4204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cc501e39-589d-4565-9114-5bad68df4204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_ba00cca1-47f5-4a8e-8422-ffd4578c4227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c56472c5-ccaf-4993-910d-3fe0a60bb46c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_ba00cca1-47f5-4a8e-8422-ffd4578c4227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dafc7aac-74df-49e6-adb0-8372faf59ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09628b66-624d-4a53-a737-8a576b563afd" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dafc7aac-74df-49e6-adb0-8372faf59ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64e673f2-df7c-421f-a144-661b0881c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09628b66-624d-4a53-a737-8a576b563afd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_64e673f2-df7c-421f-a144-661b0881c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_acaca83d-2992-481a-b017-d7352c070019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_acaca83d-2992-481a-b017-d7352c070019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bce764ef-826e-46b3-b885-663899c1a266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bce764ef-826e-46b3-b885-663899c1a266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c2bc8571-c860-47a7-b963-cc8a6161102d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c2bc8571-c860-47a7-b963-cc8a6161102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d51449b4-3503-42b3-bf0a-54425f497538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d51449b4-3503-42b3-bf0a-54425f497538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e54c08fd-7701-4976-b359-979914c5c002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e54c08fd-7701-4976-b359-979914c5c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0a0028e8-900f-441e-b3c3-adeb6ab0eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0a0028e8-900f-441e-b3c3-adeb6ab0eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_01d245b7-5bfc-435b-9acb-2eccfd9e0c18" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_89a2dd72-dfdc-418c-83c5-f4b3dda5bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2d3efd54-7107-4be0-82d3-8a31d919b61b" xlink:to="loc_us-gaap_ReportingUnitDomain_89a2dd72-dfdc-418c-83c5-f4b3dda5bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_e9c55ca4-df64-48ae-b77f-e496f09f2dc7" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_89a2dd72-dfdc-418c-83c5-f4b3dda5bb28" xlink:to="loc_cah_MedicalUnitMember_e9c55ca4-df64-48ae-b77f-e496f09f2dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a3e39475-ce00-48a4-a43c-4fa4a63da872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_568ae10f-5a86-4ce4-a126-f3c8c3b3c63b" xlink:to="loc_us-gaap_SegmentDomain_a3e39475-ce00-48a4-a43c-4fa4a63da872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_7d04f29f-f196-4bd5-932d-8e0cc2b31288" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a3e39475-ce00-48a4-a43c-4fa4a63da872" xlink:to="loc_cah_MedicalMember_7d04f29f-f196-4bd5-932d-8e0cc2b31288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_11396f54-e9b0-47df-8807-334c3c0330bf" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_ed0dcab6-e7f8-483e-a724-d2096cf21515" xlink:to="loc_cah_GoodwillImpairmentDomain_11396f54-e9b0-47df-8807-334c3c0330bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_bdf3a556-bc68-4c2a-9a91-b6dc108fdc96" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_11396f54-e9b0-47df-8807-334c3c0330bf" xlink:to="loc_cah_MedicalUnitMember_bdf3a556-bc68-4c2a-9a91-b6dc108fdc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_48daf989-bd55-424c-ac38-0f952353457a" xlink:to="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aa5bedb7-042b-4da3-9bf8-4325ca4d6b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_us-gaap_Goodwill_aa5bedb7-042b-4da3-9bf8-4325ca4d6b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8eab452a-eb67-41ed-b19c-bf36a4b40605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8eab452a-eb67-41ed-b19c-bf36a4b40605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DiscountRateFairValueInput_fc2630bd-f887-4d04-9cac-d42219ce9dea" xlink:href="cah-20211231.xsd#cah_DiscountRateFairValueInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_cah_DiscountRateFairValueInput_fc2630bd-f887-4d04-9cac-d42219ce9dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TerminalGrowthRateFairValueInput_b4f37265-4f4a-486a-8185-4e277e0059ef" xlink:href="cah-20211231.xsd#cah_TerminalGrowthRateFairValueInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b4240355-07d7-4bd0-85cc-998edafc1431" xlink:to="loc_cah_TerminalGrowthRateFairValueInput_b4f37265-4f4a-486a-8185-4e277e0059ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20211231.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_9a7b9d4d-1b35-4bc4-be48-e3e0d0a9395f" xlink:href="cah-20211231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cc044dbb-cfef-44ad-8c89-b596b70454cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_9a7b9d4d-1b35-4bc4-be48-e3e0d0a9395f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cc044dbb-cfef-44ad-8c89-b596b70454cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20211231.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_88c90a7e-203a-46ae-a019-32a458765940" xlink:href="cah-20211231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_592763cc-03b4-40e9-93bc-0e79b5bcfb32" xlink:href="cah-20211231.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_592763cc-03b4-40e9-93bc-0e79b5bcfb32" xlink:to="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1a64f31-a0b9-435f-bcf3-75078797651d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_726fdd00-6a41-4c8e-afca-281f67c3cadb" xlink:href="cah-20211231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:to="loc_cah_A2.616Notesdue2022Member_726fdd00-6a41-4c8e-afca-281f67c3cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3252a28f-82dc-455e-8a30-62fcf67a71cf" xlink:href="cah-20211231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3252a28f-82dc-455e-8a30-62fcf67a71cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_aa1abbc0-641e-4afa-8f2c-1e415cdebb17" xlink:href="cah-20211231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e3ddcd1e-26e8-4704-97ba-2234180b1217" xlink:to="loc_cah_FloatingRateNotesdue2022Member_aa1abbc0-641e-4afa-8f2c-1e415cdebb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:to="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d87d3733-424a-4df8-b681-4273287ec926" xlink:to="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_475e21dd-7f95-4413-a5ea-631d0222b54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_us-gaap_CommercialPaperMember_475e21dd-7f95-4413-a5ea-631d0222b54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c686b8b0-0d99-461a-adae-244a4864f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c686b8b0-0d99-461a-adae-244a4864f47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_b24a3f93-14c2-4375-ae94-03622bc21e22" xlink:href="cah-20211231.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_b24a3f93-14c2-4375-ae94-03622bc21e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_87c9a20e-3e75-4fb7-a510-22064443d206" xlink:href="cah-20211231.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a3f4cec-a1d8-4f7a-a6e7-267a3035658b" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_87c9a20e-3e75-4fb7-a510-22064443d206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9ad5dc94-6c54-412b-b887-c6a2c94bd091" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_fa1abfed-f102-40bf-bc59-3d54828786e0" xlink:href="cah-20211231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_cah_TotalLongTermandShortTermObligations_fa1abfed-f102-40bf-bc59-3d54828786e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af8f2e82-f247-4f88-86f8-a64e3a080407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_af8f2e82-f247-4f88-86f8-a64e3a080407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce960055-b317-4b06-8c8e-418e85cd250a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ce960055-b317-4b06-8c8e-418e85cd250a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_951af543-c5c8-409f-a916-fdfdf65d9162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_951af543-c5c8-409f-a916-fdfdf65d9162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9a7299eb-ca0f-4f3c-8b19-27a6b118558d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9a7299eb-ca0f-4f3c-8b19-27a6b118558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_5e39d6aa-2061-447c-85a5-7960bea8eb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f86be6ac-eba9-4e0d-a402-ac692d45f0a1" xlink:to="loc_us-gaap_OtherShortTermBorrowings_5e39d6aa-2061-447c-85a5-7960bea8eb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cfec94c7-e9b3-42ec-a46b-325866145cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cfec94c7-e9b3-42ec-a46b-325866145cf3" xlink:to="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1fbfc7cc-79e1-4ffd-bebe-c9afddd62cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_77711ac4-06d8-4bc0-8341-5881aa38e2eb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1fbfc7cc-79e1-4ffd-bebe-c9afddd62cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_035b11df-da1c-4740-87e6-f54f0014f3ff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_2246fd91-2fd2-4b2a-a028-af5bf61ebec5" xlink:href="cah-20211231.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:to="loc_cah_A2.616Notesdue2022Member_2246fd91-2fd2-4b2a-a028-af5bf61ebec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_31c42f8d-a15b-4c2a-80cd-d2c5f923ceea" xlink:href="cah-20211231.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_45e5cbbb-962c-4a0d-921e-978dfe983c0a" xlink:to="loc_cah_FloatingRateNotesdue2022Member_31c42f8d-a15b-4c2a-80cd-d2c5f923ceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0f2eb2d4-97ea-4456-a4a0-54f7fae395ef" xlink:to="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_52d5dc33-5843-4e32-89ac-6c9fd62d24bd" xlink:href="cah-20211231.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_cah_TotalLongTermandShortTermObligations_52d5dc33-5843-4e32-89ac-6c9fd62d24bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b7947b11-1aa5-439b-8b54-8bec685b76cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b7947b11-1aa5-439b-8b54-8bec685b76cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_62f7a90d-1335-4323-bf7b-4a50b19c7d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89d4f60e-fd2f-48c4-a762-926d8c0ce152" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_62f7a90d-1335-4323-bf7b-4a50b19c7d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20211231.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0755d387-68ec-4c7b-baec-f494e204e992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8d7920c7-5560-4969-9a98-a19ff2218270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0755d387-68ec-4c7b-baec-f494e204e992" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8d7920c7-5560-4969-9a98-a19ff2218270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf646898-fc72-4dc9-a1e6-49eb4a518753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bf646898-fc72-4dc9-a1e6-49eb4a518753" xlink:to="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5e3dc50b-3040-4805-83d7-87d36de3cc9a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5ffe355c-72e3-498a-84c8-afad1c8658af" xlink:to="loc_srt_NameOfMajorCustomerDomain_5e3dc50b-3040-4805-83d7-87d36de3cc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_b00f52aa-458a-4e31-8bd7-0b996d5c1936" xlink:href="cah-20211231.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5e3dc50b-3040-4805-83d7-87d36de3cc9a" xlink:to="loc_cah_CVSHealthMember_b00f52aa-458a-4e31-8bd7-0b996d5c1936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_09b7ea60-4946-4cd0-b69e-b5c79a510190" xlink:to="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_eec1ac04-7c79-41f4-b52f-947671c4553f" xlink:href="cah-20211231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_eec1ac04-7c79-41f4-b52f-947671c4553f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_f2046718-4630-4f8a-a997-a5a20b48b8a0" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_OpioidLawsuitsMember_f2046718-4630-4f8a-a997-a5a20b48b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateMember_69d4fd19-8ddf-4f92-bb8d-4edb12dc4ec7" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsStateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_OpioidLawsuitsStateMember_69d4fd19-8ddf-4f92-bb8d-4edb12dc4ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_ac9c8ef4-11d6-4e6d-8c23-5615038867c6" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_ac9c8ef4-11d6-4e6d-8c23-5615038867c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_40aa2c09-ba2c-4e76-b4e9-1538708e2d33" xlink:href="cah-20211231.xsd#cah_DOJInvestigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29d04f7c-f5e0-4bab-a45a-47966ef6154f" xlink:to="loc_cah_DOJInvestigationMember_40aa2c09-ba2c-4e76-b4e9-1538708e2d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_19112d6e-093b-45fd-9163-edb2d960587f" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_1ba9e694-66b7-48fd-8110-16af014fc368" xlink:to="loc_cah_OpioidLitigationDomain_19112d6e-093b-45fd-9163-edb2d960587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_bdb74d52-e57d-4489-aeef-4a668b05a79a" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_19112d6e-093b-45fd-9163-edb2d960587f" xlink:to="loc_cah_TotalOpioidLitigationMember_bdb74d52-e57d-4489-aeef-4a668b05a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:href="cah-20211231.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:href="cah-20211231.xsd#cah_LawsuitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_8be1c437-a892-457b-9b3c-07d3fb31b1b5" xlink:to="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_ba9d429c-c587-4f73-a046-28249d15857e" xlink:href="cah-20211231.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:to="loc_cah_ClassActionLawsuitsMember_ba9d429c-c587-4f73-a046-28249d15857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_36affbfc-30f8-4310-aa8e-b5a8be21b3e5" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_8519a8ac-827d-4a6c-ad08-cdc10a335c2c" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_36affbfc-30f8-4310-aa8e-b5a8be21b3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_aaa82f2b-f6a3-47cf-87b7-cd72dd2482ed" xlink:href="cah-20211231.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_2f9f1728-aa9c-459d-bef6-3cd316c561ff" xlink:to="loc_cah_PlaintiffTypeDomain_aaa82f2b-f6a3-47cf-87b7-cd72dd2482ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_89e09cf7-2f6d-421b-b17f-5fb0f115b627" xlink:href="cah-20211231.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_aaa82f2b-f6a3-47cf-87b7-cd72dd2482ed" xlink:to="loc_cah_PrivatePartiesMember_89e09cf7-2f6d-421b-b17f-5fb0f115b627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c2797989-e697-45da-bdf2-c94f988c175e" xlink:to="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_0e59023b-dc3d-4915-8f13-fddf4e56fd2a" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_GA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:to="loc_stpr_GA_0e59023b-dc3d-4915-8f13-fddf4e56fd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_2bcfd074-dd71-455e-a206-3ca7d5379878" xlink:href="cah-20211231.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:to="loc_cah_AlamedaCountyMember_2bcfd074-dd71-455e-a206-3ca7d5379878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_84330dfd-f109-432c-8a3d-f13e15db0d87" xlink:href="cah-20211231.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d1dec816-358e-404e-9b84-34bfff7c8b16" xlink:to="loc_cah_OtherJurisdictionsMember_84330dfd-f109-432c-8a3d-f13e15db0d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fe3c9597-ae3d-40c2-81c8-32a9dafb5cc9" xlink:to="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ae8f024-7301-4d1e-99f2-464a2cf46748" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:to="loc_srt_MinimumMember_3ae8f024-7301-4d1e-99f2-464a2cf46748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c47b627-7957-45c8-8a49-162baed9f250" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efad6163-5053-4d9c-b22c-034510582e92" xlink:to="loc_srt_MaximumMember_0c47b627-7957-45c8-8a49-162baed9f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_29e2b3c1-988d-4558-a9cc-8054eae03c47" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_0421c9c0-26bc-4965-9166-d0836f6f40da" xlink:href="cah-20211231.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:to="loc_cah_OpioidLawsuitsMember_0421c9c0-26bc-4965-9166-d0836f6f40da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_4464f385-f6c5-4ce9-a7c5-c49408ffb644" xlink:href="cah-20211231.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b8d44994-486c-429f-bab7-8332731bee60" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_4464f385-f6c5-4ce9-a7c5-c49408ffb644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b827305-1cb2-41bb-98d0-eca6f0db0660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_40f39fa2-2bab-4fb9-8537-0eee2e650e3f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b827305-1cb2-41bb-98d0-eca6f0db0660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5ba7502c-c89e-4d9d-98c8-68526f8397ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2b827305-1cb2-41bb-98d0-eca6f0db0660" xlink:to="loc_us-gaap_SubsequentEventMember_5ba7502c-c89e-4d9d-98c8-68526f8397ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e0dce768-2240-42f2-b84b-d188f5a533a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5fdaf1e2-68e3-4900-9c3d-e6402631b09b" xlink:to="loc_us-gaap_SegmentDomain_e0dce768-2240-42f2-b84b-d188f5a533a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_cb3a8756-cfd2-4785-9801-52734ba05577" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e0dce768-2240-42f2-b84b-d188f5a533a5" xlink:to="loc_cah_PharmaceuticalMember_cb3a8756-cfd2-4785-9801-52734ba05577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c4951dcf-babd-48b0-b74a-7ec43b6a47a2" xlink:to="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f8a4d174-8dc4-4a2d-b606-93ee073e8194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f8a4d174-8dc4-4a2d-b606-93ee073e8194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_eb070f65-1902-463a-872e-bee8d070812f" xlink:href="cah-20211231.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_AggregateAnnualAssessment_eb070f65-1902-463a-872e-bee8d070812f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_95ee20a5-64e9-49b1-8a3e-8f9dbbae7b7a" xlink:href="cah-20211231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_95ee20a5-64e9-49b1-8a3e-8f9dbbae7b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_1c40964c-0508-4343-b01d-62567477f816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_1c40964c-0508-4343-b01d-62567477f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b2ada195-5a34-484d-a3f8-e369668617e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b2ada195-5a34-484d-a3f8-e369668617e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_1ba47399-8fc0-4402-b799-69778359f6c3" xlink:href="cah-20211231.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_LossContingencyLawsuitsNumber_1ba47399-8fc0-4402-b799-69778359f6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_268aa20e-3906-43cb-8890-79caf420c724" xlink:href="cah-20211231.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_268aa20e-3906-43cb-8890-79caf420c724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_39a4a62b-6b64-42a8-b697-5fffde81da50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_39a4a62b-6b64-42a8-b697-5fffde81da50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_67183fc7-93f9-4114-bf8e-75be3c722e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LitigationReserve_67183fc7-93f9-4114-bf8e-75be3c722e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_6ba0b7fe-b172-4520-bc68-05480bf67947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LitigationReserveCurrent_6ba0b7fe-b172-4520-bc68-05480bf67947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_39793162-c0fc-4853-9c23-8e15a411696c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LitigationSettlementExpense_39793162-c0fc-4853-9c23-8e15a411696c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ed235705-d0f8-42f6-bc2f-d5ee7cd86183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_ed235705-d0f8-42f6-bc2f-d5ee7cd86183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_9a3d9129-b710-498d-ae33-000e408ceced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_9a3d9129-b710-498d-ae33-000e408ceced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_adefb944-4790-4de7-9a7f-b9146a5e8d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_adefb944-4790-4de7-9a7f-b9146a5e8d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_48641c5a-8162-4cc9-bd15-24c40a791201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_48641c5a-8162-4cc9-bd15-24c40a791201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_2d24852e-9cdd-457d-ad0c-fff3b351936d" xlink:href="cah-20211231.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ab941c0f-ec99-476a-9f89-fe8f8d95f991" xlink:to="loc_cah_JudgmentForLostProfits_2d24852e-9cdd-457d-ad0c-fff3b351936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_70d55a35-47a9-470c-8a71-2f4317ac9df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7fdb1ba2-1007-45f8-ac71-05bd47eded28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_70d55a35-47a9-470c-8a71-2f4317ac9df4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7fdb1ba2-1007-45f8-ac71-05bd47eded28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bad2915f-4b85-417d-806c-e63e7a9148e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bad2915f-4b85-417d-806c-e63e7a9148e4" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_25f01a05-903f-4c13-9994-035bf2c26969" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_20c3867f-1ef4-4537-8855-650f4cd51792" xlink:to="loc_cah_OpioidLitigationDomain_25f01a05-903f-4c13-9994-035bf2c26969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_e9ac3419-39fb-4ca9-a80c-46a8280065ad" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_25f01a05-903f-4c13-9994-035bf2c26969" xlink:to="loc_cah_TotalOpioidLitigationMember_e9ac3419-39fb-4ca9-a80c-46a8280065ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:href="cah-20211231.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:href="cah-20211231.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_273bf6cb-9c3c-48de-b561-14ea2761abaf" xlink:to="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_1b8e15d2-76ff-45b1-bb33-293fc18515a3" xlink:href="cah-20211231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:to="loc_cah_PatientRecoveryBusinessMember_1b8e15d2-76ff-45b1-bb33-293fc18515a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_3d81cc93-9087-4440-947f-53c13464c6d4" xlink:href="cah-20211231.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_d07b439d-3a5f-462c-9798-f3457c33fd6a" xlink:to="loc_cah_CareFusionMember_3d81cc93-9087-4440-947f-53c13464c6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5d95a76-ec6d-41d2-91f1-15444365c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68fafbb7-8ab6-485a-8d43-9883604223f7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5d95a76-ec6d-41d2-91f1-15444365c94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_e8036761-bd05-4211-8457-5158fcaf1bdf" xlink:href="cah-20211231.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5d95a76-ec6d-41d2-91f1-15444365c94d" xlink:to="loc_cah_PatientRecoveryBusinessMember_e8036761-bd05-4211-8457-5158fcaf1bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_d1e70087-c136-4976-b087-fdd930e0bcd2" xlink:href="cah-20211231.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_6d25c207-7864-4966-911f-0cfb641a00d0" xlink:to="loc_cah_TaxMattersAgreementDomain_d1e70087-c136-4976-b087-fdd930e0bcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_432a254b-e6da-4efb-adf1-afec9086ddf7" xlink:href="cah-20211231.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_d1e70087-c136-4976-b087-fdd930e0bcd2" xlink:to="loc_cah_CareFusionMember_432a254b-e6da-4efb-adf1-afec9086ddf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2692021-18d7-474e-9168-1ab44e39ba04" xlink:to="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9be75e99-88ed-4238-975d-841d078f21fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:to="loc_srt_MinimumMember_9be75e99-88ed-4238-975d-841d078f21fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4cfd192f-abc7-4a7f-b192-c92d6f56cc6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0179ec62-2351-4c9b-92b2-cefb523e5674" xlink:to="loc_srt_MaximumMember_4cfd192f-abc7-4a7f-b192-c92d6f56cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:href="cah-20211231.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_bacf43fd-63d8-453f-bb69-6dabfda45459" xlink:href="cah-20211231.xsd#cah_CARESActDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_e6cf3e0b-7343-4e70-a55d-21dc2431a727" xlink:to="loc_cah_CARESActDomain_bacf43fd-63d8-453f-bb69-6dabfda45459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_420898fa-9493-4a03-9578-3db336ae493b" xlink:href="cah-20211231.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CARESActDomain_bacf43fd-63d8-453f-bb69-6dabfda45459" xlink:to="loc_cah_NetOperatingLossCarrybackMember_420898fa-9493-4a03-9578-3db336ae493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_327756b3-7026-48a9-bf2e-bcede16592e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_970ab3d6-3d0d-48d1-a121-04175f88df4b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_327756b3-7026-48a9-bf2e-bcede16592e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2244fd87-c39a-4db3-9775-c28a272cfe47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_327756b3-7026-48a9-bf2e-bcede16592e7" xlink:to="loc_srt_ScenarioForecastMember_2244fd87-c39a-4db3-9775-c28a272cfe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:href="cah-20211231.xsd#cah_GoodwillImpairmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentAxis_9a5dcc11-4b33-4c24-8632-cbe6e5b95a68" xlink:to="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_adae2c4f-cb80-4b45-bef0-406aafe6dd13" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:to="loc_cah_MedicalUnitMember_adae2c4f-cb80-4b45-bef0-406aafe6dd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitGoodwillImpairmentMember_9b119bed-2455-449d-8f00-6b24cb3a8947" xlink:href="cah-20211231.xsd#cah_MedicalUnitGoodwillImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GoodwillImpairmentDomain_b249e567-6868-4ebd-b35b-b9ae3f904995" xlink:to="loc_cah_MedicalUnitGoodwillImpairmentMember_9b119bed-2455-449d-8f00-6b24cb3a8947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_24cbb9da-b077-4d40-bec1-e678cc2c2522" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_dac8b9bf-363c-4a9e-8bca-9dfc32ec9044" xlink:to="loc_cah_CordisDivestitureDomain_24cbb9da-b077-4d40-bec1-e678cc2c2522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_0f0a8263-d61f-4e4e-87e7-ac1cca23fc33" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_24cbb9da-b077-4d40-bec1-e678cc2c2522" xlink:to="loc_cah_CordisDivestitureMember_0f0a8263-d61f-4e4e-87e7-ac1cca23fc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_cd72c34f-da84-42b0-adef-85f2192bf2ee" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_6de0649a-5990-4362-b98b-a5f78077e662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_LitigationReserve_6de0649a-5990-4362-b98b-a5f78077e662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53ea631c-e63a-445f-884d-f04efa812219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_53ea631c-e63a-445f-884d-f04efa812219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d5412518-b2c6-4e48-8764-066cebbeee10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d5412518-b2c6-4e48-8764-066cebbeee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6242efa9-f679-4d35-939b-8dcbea996423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6242efa9-f679-4d35-939b-8dcbea996423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b822401e-d900-406e-a6e7-619506729aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b822401e-d900-406e-a6e7-619506729aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_10c49f7b-04ec-4bcc-953d-31fe18ad1299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_10c49f7b-04ec-4bcc-953d-31fe18ad1299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1c8b5b75-13f2-4f37-b8a6-4074e1294c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1c8b5b75-13f2-4f37-b8a6-4074e1294c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_2c2ce109-f4d8-4397-a603-7b90ea78d8f0" xlink:href="cah-20211231.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_cah_IndemnificationReceivable_2c2ce109-f4d8-4397-a603-7b90ea78d8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc2f3469-5452-455d-8c2c-d893b650db5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc2f3469-5452-455d-8c2c-d893b650db5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_585e06f4-e869-46ff-a856-72186c7c1f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_LitigationSettlementExpense_585e06f4-e869-46ff-a856-72186c7c1f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_a2eaf8f9-ca8a-469f-aaef-f54a100fa11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_a2eaf8f9-ca8a-469f-aaef-f54a100fa11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_fb29d85a-91ee-4994-b054-db0212258cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_IncomeTaxReceivable_fb29d85a-91ee-4994-b054-db0212258cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_d09a6edb-01bb-4b71-8114-680079676fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_a6a0ce81-4db4-4567-a387-efc32ddb774d" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_d09a6edb-01bb-4b71-8114-680079676fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_283ba0a0-5629-4356-adf3-04a9125bab8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c6c3455f-4747-4bb4-a843-f489bc56aace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_283ba0a0-5629-4356-adf3-04a9125bab8f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c6c3455f-4747-4bb4-a843-f489bc56aace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99216b64-7e65-450a-ad06-ffda369e10b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eadb584f-a7b6-4ce1-9d8b-f99efd6d81ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99216b64-7e65-450a-ad06-ffda369e10b8" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eadb584f-a7b6-4ce1-9d8b-f99efd6d81ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670b5f61-1d5d-449b-8eaf-69e4d14c057b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670b5f61-1d5d-449b-8eaf-69e4d14c057b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29832c61-bbc9-4f17-a754-eba4442a8e6d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8ae13a2-073b-4ff7-af74-623e90f0513e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8ae13a2-073b-4ff7-af74-623e90f0513e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7d591fd3-b651-4b93-8e17-d9bf16c64b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7d591fd3-b651-4b93-8e17-d9bf16c64b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f765bda0-201f-4651-8be4-6e8e467785f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ead89f6a-aa2b-40a5-8736-6770ef46b909" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f765bda0-201f-4651-8be4-6e8e467785f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8cd961ba-a1d0-4b36-ab17-064518684410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_29c4b874-a1f4-4f21-9df5-76c9886f60da" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8cd961ba-a1d0-4b36-ab17-064518684410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_981c1b11-a45e-49b1-81ec-d3cc1fba26f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8cd961ba-a1d0-4b36-ab17-064518684410" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_981c1b11-a45e-49b1-81ec-d3cc1fba26f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4f74318-1e82-4cd3-a078-54baa6433994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5ea1906c-c03d-4c56-8d7c-495f7e472bb3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4f74318-1e82-4cd3-a078-54baa6433994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a4f74318-1e82-4cd3-a078-54baa6433994" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5f729e3-b036-42f4-b4cc-ee1facfe1a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5f729e3-b036-42f4-b4cc-ee1facfe1a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e4a31089-68d5-4f56-bc7e-e30c4633b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e4a31089-68d5-4f56-bc7e-e30c4633b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_3e94ac82-1a8c-46c1-a053-f66fcf1c9306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_99f4f471-29b5-404d-9f98-b9586d0db3d9" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_3e94ac82-1a8c-46c1-a053-f66fcf1c9306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20211231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9cdbda64-4aaf-4cee-bb77-0eb2d21adc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_e0689c78-aeeb-45f7-9e06-ae4d32bacb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9cdbda64-4aaf-4cee-bb77-0eb2d21adc8b" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_e0689c78-aeeb-45f7-9e06-ae4d32bacb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20211231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0b802d82-6fe8-4a5b-86a7-7829b271c83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_9c6fd9b0-05ea-4e51-b161-3a5e906e7983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0b802d82-6fe8-4a5b-86a7-7829b271c83f" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_9c6fd9b0-05ea-4e51-b161-3a5e906e7983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8626df36-e30e-4fc6-bd7f-954053889d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8626df36-e30e-4fc6-bd7f-954053889d26" xlink:to="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0739b1ba-b89a-4e5c-ac37-ec63eca3812b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d0033f73-e643-464e-925e-e46f335b491b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0739b1ba-b89a-4e5c-ac37-ec63eca3812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7094d3f7-e3cf-4e4f-a88a-cd47c447de82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0739b1ba-b89a-4e5c-ac37-ec63eca3812b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_7094d3f7-e3cf-4e4f-a88a-cd47c447de82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c02ad18-2ad7-42c1-ae90-8d19eaa89fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_57bab21b-bc48-49bd-bf11-c3ea793c9dca" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c02ad18-2ad7-42c1-ae90-8d19eaa89fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ad4cf8d8-9c2f-4dff-9044-02cb0fed0528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c02ad18-2ad7-42c1-ae90-8d19eaa89fec" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ad4cf8d8-9c2f-4dff-9044-02cb0fed0528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7dd286b2-1a13-4099-93db-f9d9eaf4033e" xlink:to="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_95c6734a-6d23-49ad-870b-3f13f2895a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_95c6734a-6d23-49ad-870b-3f13f2895a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5ed2e5bb-2056-42b9-a79c-fff54432f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b00a76a6-83f2-416e-b711-1c8de797b655" xlink:to="loc_us-gaap_NondesignatedMember_5ed2e5bb-2056-42b9-a79c-fff54432f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e6582903-0932-4b2c-8367-e9bcdf25d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_003d4988-ea7c-427a-a7e9-13722275777a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e6582903-0932-4b2c-8367-e9bcdf25d9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e7a41c43-03eb-4fae-94c1-f376cdc2fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e6582903-0932-4b2c-8367-e9bcdf25d9ca" xlink:to="loc_us-gaap_FairValueHedgingMember_e7a41c43-03eb-4fae-94c1-f376cdc2fc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e9e4a2f4-0f62-4b6d-a253-837a70d7bdf1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0e1966f4-0368-471c-b282-366b586ed1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:to="loc_us-gaap_CashFlowHedgingMember_0e1966f4-0368-471c-b282-366b586ed1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_44b982cb-5ffb-4c7c-9eb0-cea39bcb805a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:to="loc_us-gaap_InterestRateSwapMember_44b982cb-5ffb-4c7c-9eb0-cea39bcb805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9bd1463d-f2f5-452c-a4ee-1f19514d89f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ab8616e0-79e1-40b6-9254-38a1c6c857ea" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9bd1463d-f2f5-452c-a4ee-1f19514d89f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5a47373a-81a1-4597-9f92-200abb2ee166" xlink:to="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_19837f0c-8ce7-43db-9525-5f83883caa05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_19837f0c-8ce7-43db-9525-5f83883caa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cc4028d3-01ae-4a74-b3a3-49240b3d2e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cc4028d3-01ae-4a74-b3a3-49240b3d2e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_f8fce85f-726d-4853-9e80-518e92117b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_f8fce85f-726d-4853-9e80-518e92117b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b41f1416-aea4-4839-bc52-2b31f84974d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_b41f1416-aea4-4839-bc52-2b31f84974d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd519620-5027-499b-a81e-f41620b97f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd519620-5027-499b-a81e-f41620b97f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_df5811ce-e2b4-4cec-9b4e-cee015d7cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_69f80ab1-bc47-4f63-8a3e-35ba99cdf9b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_df5811ce-e2b4-4cec-9b4e-cee015d7cdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46a23f38-8b39-44c8-b90f-d670b6969ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46a23f38-8b39-44c8-b90f-d670b6969ee8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7d9615f-72de-4590-82ab-96c13472bb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23d61dfb-b60d-4201-8b9a-f7e1298f2ddb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7d9615f-72de-4590-82ab-96c13472bb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94ce7ab0-ae84-4928-9213-5cfc9c041c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7d9615f-72de-4590-82ab-96c13472bb17" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94ce7ab0-ae84-4928-9213-5cfc9c041c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_81908a11-745a-4b1f-a950-a1b3b3c9658e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_394c4569-d696-467f-b7f6-549fc55c955d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:to="loc_us-gaap_DebtInstrumentFairValue_394c4569-d696-467f-b7f6-549fc55c955d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_b62c5cc6-9576-46ac-b6c6-de149a5a2392" xlink:href="cah-20211231.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_46a45311-c54f-4001-b58a-96ef2a4758c5" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_b62c5cc6-9576-46ac-b6c6-de149a5a2392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89e767b6-2a08-465c-91aa-ea27bf68c5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b9c1055c-6626-46d6-b785-05910c94a103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89e767b6-2a08-465c-91aa-ea27bf68c5fb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b9c1055c-6626-46d6-b785-05910c94a103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2c36e5e9-50c4-44cb-b2b9-49f80548415e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_76cfcce9-db54-432c-ad6e-cca1bd1249b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2c36e5e9-50c4-44cb-b2b9-49f80548415e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_76cfcce9-db54-432c-ad6e-cca1bd1249b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3577a45e-ee6e-40e4-bdd0-aab8b1e3593a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3577a45e-ee6e-40e4-bdd0-aab8b1e3593a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_823585bd-bb4f-4a35-bef4-4ad7535ced35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a180f999-5d86-4475-b83c-f3b2fcea4afb" xlink:to="loc_us-gaap_EquityComponentDomain_823585bd-bb4f-4a35-bef4-4ad7535ced35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_91f7922a-7770-415f-b474-6488c3def09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_823585bd-bb4f-4a35-bef4-4ad7535ced35" xlink:to="loc_us-gaap_TreasuryStockMember_91f7922a-7770-415f-b474-6488c3def09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:href="cah-20211231.xsd#cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis_f829f667-4f79-4f78-971f-f68362159c59" xlink:to="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A500MillionShareRepurchaseProgramMember_e3cb5378-e9a7-4ca0-812d-7fc1a2bf6dff" xlink:href="cah-20211231.xsd#cah_A500MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:to="loc_cah_A500MillionShareRepurchaseProgramMember_e3cb5378-e9a7-4ca0-812d-7fc1a2bf6dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A300MillionShareRepurchaseProgramMember_b55077ec-b00f-409a-8b5e-4b6c7fbe933d" xlink:href="cah-20211231.xsd#cah_A300MillionShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain_e1f50f75-28e9-4cf9-a940-798e2e3640de" xlink:to="loc_cah_A300MillionShareRepurchaseProgramMember_b55077ec-b00f-409a-8b5e-4b6c7fbe933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fda0a9cd-3da4-490d-95fd-a629252ef3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ca51a1af-2d1e-46a8-a404-ec762140ca02" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fda0a9cd-3da4-490d-95fd-a629252ef3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6d43c8c3-c118-4689-b210-06b3ea67c857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fda0a9cd-3da4-490d-95fd-a629252ef3e8" xlink:to="loc_us-gaap_SubsequentEventMember_6d43c8c3-c118-4689-b210-06b3ea67c857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5df7e376-0ac7-472d-8079-f26d7b737f4b" xlink:to="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e86ff39b-1311-4348-8b2f-abb3e9fa412c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e86ff39b-1311-4348-8b2f-abb3e9fa412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4d4330c9-604d-4c3e-93cc-c13fa52956b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4d4330c9-604d-4c3e-93cc-c13fa52956b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_34d95709-80ce-4284-9498-5a9d9b97a8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cfcb215-d664-4252-9389-f6a448e26291" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_34d95709-80ce-4284-9498-5a9d9b97a8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d01acb70-fbf4-4dfc-a5c4-e4a10004d845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d01acb70-fbf4-4dfc-a5c4-e4a10004d845" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2a557dc6-be9b-4c22-be08-61f5d4941e72" xlink:to="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4b44a3d7-72c3-4d87-98f6-119af6c86abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4b44a3d7-72c3-4d87-98f6-119af6c86abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c115ff69-d133-4510-bb7f-2ec9de694b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c115ff69-d133-4510-bb7f-2ec9de694b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a5c7d0d1-1dc7-42f6-bf11-bafb95f1b466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a5c7d0d1-1dc7-42f6-bf11-bafb95f1b466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f82df23f-acee-49d0-81b6-4768734b69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e12fbeb-2824-4a0a-81ae-6936368bb608" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f82df23f-acee-49d0-81b6-4768734b69d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f35176f9-96e8-4edb-9c7a-553bb4ef155e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_8ac406b4-8bdf-49e0-9c9d-c1c950591c55" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f35176f9-96e8-4edb-9c7a-553bb4ef155e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_f35176f9-96e8-4edb-9c7a-553bb4ef155e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e491a442-cd48-4579-95c0-30620c8640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e491a442-cd48-4579-95c0-30620c8640e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7d7604c1-1740-4dc6-8f9e-f7eaf3b50a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7d7604c1-1740-4dc6-8f9e-f7eaf3b50a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d63d0187-08c4-4f7e-9593-35b70a386c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d63d0187-08c4-4f7e-9593-35b70a386c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f07b6d14-ad69-4127-a36e-d6c470423927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f07b6d14-ad69-4127-a36e-d6c470423927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb4f3aba-91f7-4f8f-8f86-b3799fc09669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_ead667df-932d-4c81-942c-b2bc1fc7dd59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb4f3aba-91f7-4f8f-8f86-b3799fc09669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20211231.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_937f3c52-ca0e-4155-870a-352dcaed64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f2de7453-be1b-44b1-9f6d-e6d04fe2f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_937f3c52-ca0e-4155-870a-352dcaed64ca" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f2de7453-be1b-44b1-9f6d-e6d04fe2f58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20211231.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84495bac-768e-4378-a6d1-99057d198721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_f251407e-9761-442a-90c4-01a2d988dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84495bac-768e-4378-a6d1-99057d198721" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_f251407e-9761-442a-90c4-01a2d988dae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f992c362-6ce3-46d8-b20d-2e387ec251b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72ce4847-dc4d-4ff7-9065-e19ffa264872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f992c362-6ce3-46d8-b20d-2e387ec251b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72ce4847-dc4d-4ff7-9065-e19ffa264872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7cb22f7c-11ba-42a1-9231-01e3acd51bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cf9ee064-51d4-4086-a1e4-f494b909b2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7cb22f7c-11ba-42a1-9231-01e3acd51bb6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cf9ee064-51d4-4086-a1e4-f494b909b2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e1db3d73-1270-4d7c-b73e-e71c56918227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7cb22f7c-11ba-42a1-9231-01e3acd51bb6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e1db3d73-1270-4d7c-b73e-e71c56918227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4ad08d4e-f729-41a0-9ed5-12da8241d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e1db3d73-1270-4d7c-b73e-e71c56918227" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4ad08d4e-f729-41a0-9ed5-12da8241d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_828e86af-8498-408b-aa4c-dfbe09cd6c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7cb22f7c-11ba-42a1-9231-01e3acd51bb6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_828e86af-8498-408b-aa4c-dfbe09cd6c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7e5f195e-4ccc-4254-82ef-3d6faa75107f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_4e624308-4f25-49a7-b1e9-d61676e25b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e5f195e-4ccc-4254-82ef-3d6faa75107f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_4e624308-4f25-49a7-b1e9-d61676e25b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_02e3fc5c-2f42-406a-8696-d0b504feb004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_84daa2e1-2845-4d6f-aff9-c604005fdb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_02e3fc5c-2f42-406a-8696-d0b504feb004" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_84daa2e1-2845-4d6f-aff9-c604005fdb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24eb1e2f-8d74-4101-b8e3-8de9c4928d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_02e3fc5c-2f42-406a-8696-d0b504feb004" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_24eb1e2f-8d74-4101-b8e3-8de9c4928d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_978c42ee-7d96-4ea9-b36d-d22526de30ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_02e3fc5c-2f42-406a-8696-d0b504feb004" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_978c42ee-7d96-4ea9-b36d-d22526de30ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_20df4c5e-f8e2-42f3-9009-74cc7cd1f3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_02e3fc5c-2f42-406a-8696-d0b504feb004" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_20df4c5e-f8e2-42f3-9009-74cc7cd1f3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4d82c08e-44a9-4f7a-a005-2a1c4f024363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d82c08e-44a9-4f7a-a005-2a1c4f024363" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:href="cah-20211231.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_1be9e1a1-3d17-4ea3-9550-02fe65facba4" xlink:href="cah-20211231.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_ff4065a4-ab28-4538-b36a-69dc77886801" xlink:to="loc_cah_OpioidLitigationDomain_1be9e1a1-3d17-4ea3-9550-02fe65facba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_108a8409-01d0-421b-9108-59bb445849dd" xlink:href="cah-20211231.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_1be9e1a1-3d17-4ea3-9550-02fe65facba4" xlink:to="loc_cah_TotalOpioidLitigationMember_108a8409-01d0-421b-9108-59bb445849dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b82981e-593f-4a1e-9cf5-1b3bfdaec898" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f216acc3-8695-4ac4-b5f6-c5514b8accde" xlink:to="loc_srt_LitigationCaseTypeDomain_9b82981e-593f-4a1e-9cf5-1b3bfdaec898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_0b4eca63-2958-4d9c-b687-96ea9ea4fd44" xlink:href="cah-20211231.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b82981e-593f-4a1e-9cf5-1b3bfdaec898" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_0b4eca63-2958-4d9c-b687-96ea9ea4fd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_d6547a7c-a0c0-490e-9fda-a8cd050bc29e" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_a3d580f5-700c-46c0-b698-811f18990529" xlink:to="loc_cah_CordisDivestitureDomain_d6547a7c-a0c0-490e-9fda-a8cd050bc29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_fbf9d608-808d-447c-bf88-54cef16d6005" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_d6547a7c-a0c0-490e-9fda-a8cd050bc29e" xlink:to="loc_cah_CordisDivestitureMember_fbf9d608-808d-447c-bf88-54cef16d6005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45efa746-5d24-4fe0-9f64-84e573eafa85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_acebe3a9-5052-440f-98a7-3d3502048cf1" xlink:to="loc_us-gaap_SegmentDomain_45efa746-5d24-4fe0-9f64-84e573eafa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a785b831-757f-492f-b81e-6c14992f3c3d" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_45efa746-5d24-4fe0-9f64-84e573eafa85" xlink:to="loc_cah_MedicalMember_a785b831-757f-492f-b81e-6c14992f3c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_034cd126-42f1-43da-a898-c627998ad2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_c6d99c3d-1f13-4211-b33d-cea1c912e379" xlink:to="loc_us-gaap_ReportingUnitDomain_034cd126-42f1-43da-a898-c627998ad2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_8b2f9c71-2688-464b-a808-42c8f75045b4" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_034cd126-42f1-43da-a898-c627998ad2cc" xlink:to="loc_cah_MedicalUnitMember_8b2f9c71-2688-464b-a808-42c8f75045b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2311492c-2872-4240-a3b1-46618ce7ad1c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9165df76-254c-4bb6-9160-2ebdd07ea054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9165df76-254c-4bb6-9160-2ebdd07ea054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_664bb8b2-96c0-48e8-9d5b-76fb49d5b9ee" xlink:href="cah-20211231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_664bb8b2-96c0-48e8-9d5b-76fb49d5b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cbebcc00-6bcd-41d2-8742-27b2a9765767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_NumberOfReportableSegments_cbebcc00-6bcd-41d2-8742-27b2a9765767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0571ca7d-3672-4efa-8048-771f428a79dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0571ca7d-3672-4efa-8048-771f428a79dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f261ff09-0b48-452c-9318-027f2ff8b34e" xlink:href="cah-20211231.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_f261ff09-0b48-452c-9318-027f2ff8b34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_aae11544-cf54-4b17-98fb-7807b2664c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_aae11544-cf54-4b17-98fb-7807b2664c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_774ada83-2d33-4fc0-9140-3fe0d16f90d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1f33414b-58d8-4acb-971f-fbe14cf2fa17" xlink:to="loc_us-gaap_LitigationSettlementExpense_774ada83-2d33-4fc0-9140-3fe0d16f90d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e1568c1f-6f11-46c5-a92b-2197ca742ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d82c08e-44a9-4f7a-a005-2a1c4f024363" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e1568c1f-6f11-46c5-a92b-2197ca742ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_549626be-560a-42a8-8fb4-48a788ed48bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d82c08e-44a9-4f7a-a005-2a1c4f024363" xlink:to="loc_us-gaap_NumberOfReportableSegments_549626be-560a-42a8-8fb4-48a788ed48bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_40807844-da81-4897-9ab7-a5012254d59e" xlink:href="cah-20211231.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d82c08e-44a9-4f7a-a005-2a1c4f024363" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_40807844-da81-4897-9ab7-a5012254d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4886b797-a509-4ad0-b1ac-52bd121b84ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4886b797-a509-4ad0-b1ac-52bd121b84ab" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_f9f77dbb-394e-43bb-851a-09e393de8ea6" xlink:to="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_8d6f3f9c-877c-4892-92a7-8eb4a02a90d2" xlink:href="cah-20211231.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_8d6f3f9c-877c-4892-92a7-8eb4a02a90d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_8fa64933-54ec-4633-a90c-94a98d2bfa9d" xlink:href="cah-20211231.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_8fa64933-54ec-4633-a90c-94a98d2bfa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_06b77d08-52a2-4549-9075-bf4b8d469a04" xlink:href="cah-20211231.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_MedicaldistributionandproductsMember_06b77d08-52a2-4549-9075-bf4b8d469a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_96ba0285-7457-44be-aa5f-dad9702b41ee" xlink:href="cah-20211231.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_1dd43ef4-644e-4cad-95fe-bedce63986cb" xlink:to="loc_cah_CardinalHealthAtHomeMember_96ba0285-7457-44be-aa5f-dad9702b41ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_de993d21-dba8-42e0-a365-9a78179620a7" xlink:to="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ad991aa5-0725-4a69-971f-d67d7415030f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:to="loc_us-gaap_OperatingSegmentsMember_ad991aa5-0725-4a69-971f-d67d7415030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ffb72a78-d2ee-404c-8e1a-41a5b2ee0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b0bbae16-ffbc-4e00-8444-15e769cd240f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ffb72a78-d2ee-404c-8e1a-41a5b2ee0d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_37bdeef2-baec-4ea0-a3e6-513da009ac55" xlink:to="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_a5d3cbdf-8126-4ecb-89a7-93ae4afc8a76" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:to="loc_cah_PharmaceuticalMember_a5d3cbdf-8126-4ecb-89a7-93ae4afc8a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_db0ca563-65ac-4efe-9301-1474dac2b014" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c1c23bd0-4a7f-4a5a-bf19-0a7ea09ce147" xlink:to="loc_cah_MedicalMember_db0ca563-65ac-4efe-9301-1474dac2b014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_45769ea2-bdb2-4bd1-b6e6-edca55b31005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_b1931835-0b19-4a99-b69b-ab537f641f57" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_45769ea2-bdb2-4bd1-b6e6-edca55b31005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_939a3495-0669-4937-a8b1-062bf9888074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45769ea2-bdb2-4bd1-b6e6-edca55b31005" xlink:to="loc_us-gaap_Revenues_939a3495-0669-4937-a8b1-062bf9888074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9c9f4edb-8243-44da-b1ef-36082d3a4a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9c9f4edb-8243-44da-b1ef-36082d3a4a0d" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_38697922-e1d4-4080-ab4d-5e7d1e397ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_acfd576d-8a1c-4b46-9190-1c7ca417c750" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_38697922-e1d4-4080-ab4d-5e7d1e397ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1985817a-d1d1-4839-aae4-0b04b49fa913" xlink:to="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ef459767-7af8-42fc-87e7-e5bde8c53132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:to="loc_us-gaap_OperatingSegmentsMember_ef459767-7af8-42fc-87e7-e5bde8c53132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_85a881e9-75d1-4e43-b855-3a582525d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8b6f9b8c-c6f0-44fe-8f7a-1f2aaee7bcab" xlink:to="loc_us-gaap_CorporateNonSegmentMember_85a881e9-75d1-4e43-b855-3a582525d5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6250c388-d212-408c-98cd-a6280fb53a0f" xlink:to="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_d87b9e28-842b-4534-9b0d-9244451ce5a3" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:to="loc_cah_PharmaceuticalMember_d87b9e28-842b-4534-9b0d-9244451ce5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_1417a483-7adb-4789-99d0-a15cdcc641f0" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_97a98b87-3ae8-4ff8-b051-fd6414b42be2" xlink:to="loc_cah_MedicalMember_1417a483-7adb-4789-99d0-a15cdcc641f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_57fe53b2-6c94-4b1b-944d-77068727023f" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0094f247-9d0b-46ca-aef3-11b22989e9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:to="loc_us-gaap_OperatingIncomeLoss_0094f247-9d0b-46ca-aef3-11b22989e9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_JudgmentForLostProfits_96bea670-41fd-4fde-a03f-0122e447d32a" xlink:href="cah-20211231.xsd#cah_JudgmentForLostProfits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_dd8401ab-e5af-4d2e-afdb-42ba8376c77e" xlink:to="loc_cah_JudgmentForLostProfits_96bea670-41fd-4fde-a03f-0122e447d32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_41e9dea0-7b05-456f-9074-471984e0fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:href="cah-20211231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_41e9dea0-7b05-456f-9074-471984e0fc27" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:to="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e614c703-7560-4a6b-9868-20c39ba115d4" xlink:to="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_18695abd-70b6-454a-886d-3f8149f68ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:to="loc_us-gaap_OperatingSegmentsMember_18695abd-70b6-454a-886d-3f8149f68ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_40157db0-3ff9-497a-aca6-2c887b153eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a5e6516b-e977-43c7-af63-492049d431a9" xlink:to="loc_us-gaap_CorporateNonSegmentMember_40157db0-3ff9-497a-aca6-2c887b153eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:to="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7a58fdf0-ecf1-44a7-9f54-2250e766646a" xlink:to="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f406fc5e-fe4c-480c-a26a-54a3b16b46ee" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:to="loc_country_US_f406fc5e-fe4c-480c-a26a-54a3b16b46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_001a1c5d-76c5-4ead-a830-f909d6bf2c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_23661a59-2042-4dd4-a6fe-f9e507966f62" xlink:to="loc_us-gaap_NonUsMember_001a1c5d-76c5-4ead-a830-f909d6bf2c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_07261702-1aa4-4ef4-8a6e-94b5cbde550d" xlink:href="cah-20211231.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_69e5ee93-6d96-490f-ad3d-a47d58ad5f44" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_07261702-1aa4-4ef4-8a6e-94b5cbde550d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a352af03-599a-40f5-bee1-79253057b119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_07261702-1aa4-4ef4-8a6e-94b5cbde550d" xlink:to="loc_us-gaap_Revenues_a352af03-599a-40f5-bee1-79253057b119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dfdcda75-ba89-43e9-9a99-52ca5ce2edb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dfdcda75-ba89-43e9-9a99-52ca5ce2edb9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2178b4f2-2686-4d11-b026-8ccd6176a535" xlink:to="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e9f560d8-7ae4-41d5-bccb-f921e1ef11de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:to="loc_us-gaap_OperatingSegmentsMember_e9f560d8-7ae4-41d5-bccb-f921e1ef11de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e49e6053-634c-4325-a053-e4860bbe206a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_377f8dae-baed-4d9b-81bd-f3e288d32ec8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e49e6053-634c-4325-a053-e4860bbe206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_20df6816-4136-4f35-8fbc-4d7f230f29e5" xlink:to="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_ded68bec-deeb-4cdb-ba6d-818c1c8cf347" xlink:href="cah-20211231.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:to="loc_cah_PharmaceuticalMember_ded68bec-deeb-4cdb-ba6d-818c1c8cf347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_d88575ef-65cf-4490-ac88-56c201beb817" xlink:href="cah-20211231.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6c0493a4-d492-4ebc-a1b6-38026f054368" xlink:to="loc_cah_MedicalMember_d88575ef-65cf-4490-ac88-56c201beb817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:href="cah-20211231.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_8e8e7294-8b40-4ee1-bbd6-7c27906f53f1" xlink:href="cah-20211231.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_4deae3b4-080c-42a4-95ea-7cda0aad0698" xlink:to="loc_cah_CordisDivestitureDomain_8e8e7294-8b40-4ee1-bbd6-7c27906f53f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_4017c3ed-c6c8-4e8f-b69b-d7d5ee45ab18" xlink:href="cah-20211231.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_8e8e7294-8b40-4ee1-bbd6-7c27906f53f1" xlink:to="loc_cah_CordisDivestitureMember_4017c3ed-c6c8-4e8f-b69b-d7d5ee45ab18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_08fe3ca7-378c-4aa2-be2e-8a4955018189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_0f5be3ee-2af9-4c9a-b094-c615390d26df" xlink:to="loc_us-gaap_ReportingUnitDomain_08fe3ca7-378c-4aa2-be2e-8a4955018189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalUnitMember_265ddf12-cde8-4b12-b845-291d0dd5fe9a" xlink:href="cah-20211231.xsd#cah_MedicalUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_08fe3ca7-378c-4aa2-be2e-8a4955018189" xlink:to="loc_cah_MedicalUnitMember_265ddf12-cde8-4b12-b845-291d0dd5fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d4c3a197-a301-4d63-b07e-d25d085761fe" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_55258d88-eff5-49d3-9777-71c281dca073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_Assets_55258d88-eff5-49d3-9777-71c281dca073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e72843a0-d24d-4800-9caa-a5bf3fee104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e72843a0-d24d-4800-9caa-a5bf3fee104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6361ceaa-f889-4a55-a594-9bb3ec3d59bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8f158f86-e28a-444a-8be5-ac2d99547309" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6361ceaa-f889-4a55-a594-9bb3ec3d59bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e22640d-6d2c-4870-a10a-d973f48dc23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5627694b-dae9-4432-bc75-bfb01d05c5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e22640d-6d2c-4870-a10a-d973f48dc23f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5627694b-dae9-4432-bc75-bfb01d05c5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966eafbf-c0c7-4cd2-90b0-94f73e136f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fee3d3cf-5e85-45df-8b78-baa5f7125488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966eafbf-c0c7-4cd2-90b0-94f73e136f73" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fee3d3cf-5e85-45df-8b78-baa5f7125488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f396a812-66c7-40ed-979d-509651a1f9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966eafbf-c0c7-4cd2-90b0-94f73e136f73" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f396a812-66c7-40ed-979d-509651a1f9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_36c7d7da-c969-4072-a6ec-18ed26a9e0dd" xlink:href="cah-20211231.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966eafbf-c0c7-4cd2-90b0-94f73e136f73" xlink:to="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_36c7d7da-c969-4072-a6ec-18ed26a9e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9c64ddd5-624a-43a4-8082-1de9dd660201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966eafbf-c0c7-4cd2-90b0-94f73e136f73" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9c64ddd5-624a-43a4-8082-1de9dd660201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_d5a64ab1-7824-4fb7-ad05-9f90f004456a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966eafbf-c0c7-4cd2-90b0-94f73e136f73" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_d5a64ab1-7824-4fb7-ad05-9f90f004456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e51fbfd-ff2b-4e60-871d-29ca9e2064d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e51fbfd-ff2b-4e60-871d-29ca9e2064d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:to="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d4a6349-d67e-434e-9548-337502341c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8fd3761-0d33-4948-a042-b661e362c493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8fd3761-0d33-4948-a042-b661e362c493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc562ee-31f8-4114-9090-e8121e30bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ddc562ee-31f8-4114-9090-e8121e30bb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f892a6ea-740a-4b7c-8444-cbd4e4c59ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3b33439-5e17-4100-b53f-70026a73d380" xlink:to="loc_us-gaap_PerformanceSharesMember_f892a6ea-740a-4b7c-8444-cbd4e4c59ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:to="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_902cac97-753d-41a7-a904-ad723a820fed" xlink:to="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7df86428-9a1b-477f-879e-2aa53188b64a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:to="loc_srt_MinimumMember_7df86428-9a1b-477f-879e-2aa53188b64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5356d330-e1ea-4560-b0b0-bd84e0738ae6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_77acb398-0024-43ca-82f8-cfeffbb908c8" xlink:to="loc_srt_MaximumMember_5356d330-e1ea-4560-b0b0-bd84e0738ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_abdab13e-f61e-4bb8-ab89-6af6f5bcab05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_2daf8424-5636-4702-ac35-d4bbace133d4" xlink:href="cah-20211231.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_cah_VestingPeriodinyearsforShares_2daf8424-5636-4702-ac35-d4bbace133d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c4ea58b7-51a4-470c-93d2-ea442c6b4c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c4ea58b7-51a4-470c-93d2-ea442c6b4c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_143202e0-3b7e-40ac-a742-c5b881dcbeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_143202e0-3b7e-40ac-a742-c5b881dcbeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66ef3b52-b20c-49f8-95a5-205626c612f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_66ef3b52-b20c-49f8-95a5-205626c612f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bfd191bf-913f-4fbe-9f35-bb8d44448a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bfd191bf-913f-4fbe-9f35-bb8d44448a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_f0877076-12a9-4ef5-8e3a-9c476081460f" xlink:href="cah-20211231.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_f0877076-12a9-4ef5-8e3a-9c476081460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_73bdd033-8c33-4a03-9fa5-cbc1fa8a033e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_984e2b5a-03af-4f77-986f-c56df3fd0e87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_73bdd033-8c33-4a03-9fa5-cbc1fa8a033e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11fc9aac-b0b5-4a92-b5d6-f7c5a66b7324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11fc9aac-b0b5-4a92-b5d6-f7c5a66b7324" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:to="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6ac284e8-73e7-4f55-8f33-6ae8fd005b4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_da94565a-0be1-4e59-96db-4f5cd5cf39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_da94565a-0be1-4e59-96db-4f5cd5cf39cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_732a9318-c0b8-4ffe-82f7-bc95d07a3201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_732a9318-c0b8-4ffe-82f7-bc95d07a3201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8ce59a8d-61e5-4120-8373-34f4c15e8b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33c8c224-ae30-4f56-8963-b095ccef307a" xlink:to="loc_us-gaap_PerformanceSharesMember_8ce59a8d-61e5-4120-8373-34f4c15e8b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1b0ab9d-b234-40af-ab2c-ab08f7cdfbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0c48192-9d56-4cc1-a6ad-15e0a543a58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1b0ab9d-b234-40af-ab2c-ab08f7cdfbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f546452-a907-4963-9e40-6deded8b1965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1b0ab9d-b234-40af-ab2c-ab08f7cdfbf2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3f546452-a907-4963-9e40-6deded8b1965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5281f7d2-8315-4041-9179-746b4b91e508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5281f7d2-8315-4041-9179-746b4b91e508" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1c25c73-4548-4508-b3e0-790c6646e34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1c25c73-4548-4508-b3e0-790c6646e34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_facc827b-42ea-4601-bcd1-25cf723dbd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_facc827b-42ea-4601-bcd1-25cf723dbd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11b0ba09-6fad-41fc-8871-0d283bd2cccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11b0ba09-6fad-41fc-8871-0d283bd2cccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_22609ca9-14e9-4ab0-a116-7fd55491a5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_22609ca9-14e9-4ab0-a116-7fd55491a5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1845118e-3786-48af-a3f2-5fb261c6b334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0ee17392-834b-4982-8877-adcbe12c8292" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1845118e-3786-48af-a3f2-5fb261c6b334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_86122086-a2bb-4053-828d-c9271f268fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5281f7d2-8315-4041-9179-746b4b91e508" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_86122086-a2bb-4053-828d-c9271f268fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5281f7d2-8315-4041-9179-746b4b91e508" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ebc9b31-84b3-45e0-aa06-5712b46956fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5ebc9b31-84b3-45e0-aa06-5712b46956fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8c034a89-f6d2-4e5a-b9b5-c7ce3d3ba7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8c034a89-f6d2-4e5a-b9b5-c7ce3d3ba7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_87283b3a-c842-4e08-ae1d-a05fad063fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_87283b3a-c842-4e08-ae1d-a05fad063fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e1fe75f3-fda6-4e49-9fbf-efd285f099bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e1fe75f3-fda6-4e49-9fbf-efd285f099bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_54d6f87b-1ebd-4ea1-814b-6bd7534599e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_54d6f87b-1ebd-4ea1-814b-6bd7534599e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b09946e3-c0b2-479b-860b-257b07c1161f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c5d556c-f984-45f2-9a92-45330e205c42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b09946e3-c0b2-479b-860b-257b07c1161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb7d5ffa-488a-49ca-8a4e-719c383fe078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb7d5ffa-488a-49ca-8a4e-719c383fe078" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:to="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95cc50eb-3a4c-4cd9-b8e5-0a1f816bef7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1040603e-2d18-4729-bcb8-869190ec3d8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95cc50eb-3a4c-4cd9-b8e5-0a1f816bef7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2f17f311-94b9-46cb-be37-a4784117e6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95cc50eb-3a4c-4cd9-b8e5-0a1f816bef7a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2f17f311-94b9-46cb-be37-a4784117e6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_965597f9-c270-40ec-96f6-8191c01436bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a646acc1-1bb7-44e8-943e-ff07fc9225e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a646acc1-1bb7-44e8-943e-ff07fc9225e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_440a7d88-5a7f-44dc-b909-672e3849048f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_440a7d88-5a7f-44dc-b909-672e3849048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab936b94-c65a-42e3-adf5-ff29100ccc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab936b94-c65a-42e3-adf5-ff29100ccc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_69baefd9-b3fc-4468-bd20-8307ebe607d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_69baefd9-b3fc-4468-bd20-8307ebe607d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77746f20-4555-4504-8050-dd1bfa63d6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_963dc957-2587-4a3c-b9fd-4c8b3dcee1ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77746f20-4555-4504-8050-dd1bfa63d6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31e4b183-38af-4081-befc-fea6466c32dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31e4b183-38af-4081-befc-fea6466c32dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:to="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8b858dae-7187-49fc-b824-7f7be2d8ecf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_191c8457-9990-4503-b71f-9200f3f8e5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_191c8457-9990-4503-b71f-9200f3f8e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8734d220-639d-4ffe-b95e-167ba61acc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9452a7de-9f16-4cd0-ad8b-324950e626c3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8734d220-639d-4ffe-b95e-167ba61acc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9346dc1b-4ebd-4edb-8893-386e74252dc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_992e5d5d-af77-499d-b5e3-281f015c4c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_992e5d5d-af77-499d-b5e3-281f015c4c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1c144baa-fad8-4353-9a59-9c64323acf73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1c144baa-fad8-4353-9a59-9c64323acf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ddd7e6c-c17f-402e-b574-728f3bacd947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ddd7e6c-c17f-402e-b574-728f3bacd947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed3d922d-0f8a-4e59-8c93-36680ad050fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ed3d922d-0f8a-4e59-8c93-36680ad050fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af3ff126-fba3-4ba4-8695-2049a05ae87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_af3ff126-fba3-4ba4-8695-2049a05ae87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_720ca6df-d22c-4d2a-9463-e914ab7142c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_720ca6df-d22c-4d2a-9463-e914ab7142c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5b8684e-712c-4e61-ad5a-8d77cc269877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8045ccd3-a934-42eb-9f6e-c596a4e19a00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5b8684e-712c-4e61-ad5a-8d77cc269877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ddcee177-acf1-46b8-a9c4-a8bb25fe6401" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca1385a1-ab26-46fa-8753-3235af0368c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ca1385a1-ab26-46fa-8753-3235af0368c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5720183-40d1-4c15-9a31-b9acca91f20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e5720183-40d1-4c15-9a31-b9acca91f20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6b564b81-10ef-4a0a-9ec1-58f773ed02ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6b564b81-10ef-4a0a-9ec1-58f773ed02ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_74df89ec-f543-42c7-8882-f0eae80c7625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_74df89ec-f543-42c7-8882-f0eae80c7625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6919cd39-e173-41bb-a890-2e8cc3125634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d54bb4fb-1bdb-4f4b-8bf2-ffd8d054d053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6919cd39-e173-41bb-a890-2e8cc3125634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20211231.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5deabbb3-9ac3-4f99-892b-732df7d9866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5deabbb3-9ac3-4f99-892b-732df7d9866e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:to="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2e2a387-b3cf-4672-af95-48a4feb4356c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_14ab9a8f-8498-4f01-a41e-a75e302b05ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2e2a387-b3cf-4672-af95-48a4feb4356c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e7d9aafc-a08a-466c-b00a-acb6e9bb2480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2e2a387-b3cf-4672-af95-48a4feb4356c" xlink:to="loc_us-gaap_PerformanceSharesMember_e7d9aafc-a08a-466c-b00a-acb6e9bb2480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84edecb0-e555-41f4-be30-d5ba04a39a1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97ca06f8-1c5e-49c6-aa8c-e83f955f6bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97ca06f8-1c5e-49c6-aa8c-e83f955f6bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6660f508-3e89-4fef-aa6b-ad3e52dc9073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6660f508-3e89-4fef-aa6b-ad3e52dc9073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27a1050b-a1f5-4878-a919-49792564a71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27a1050b-a1f5-4878-a919-49792564a71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38852659-d57e-42b2-84ab-c794ba0c42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38852659-d57e-42b2-84ab-c794ba0c42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4e98c816-267d-4eb8-9af0-d785bf614259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4e98c816-267d-4eb8-9af0-d785bf614259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2677047d-c622-47c9-9210-e099b0926679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627095d0-d59c-4edd-95db-57a2f094d363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2677047d-c622-47c9-9210-e099b0926679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c66a3696-c199-4015-9ce7-74a1012a21d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c66a3696-c199-4015-9ce7-74a1012a21d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be7d185e-c832-4d49-b537-54d01bb961fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be7d185e-c832-4d49-b537-54d01bb961fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe991b3f-f423-4fdc-99bb-0e3d5146d7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fe991b3f-f423-4fdc-99bb-0e3d5146d7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ad30b08-1f3d-4819-a9d7-0a93b2f0fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ad30b08-1f3d-4819-a9d7-0a93b2f0fbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f35c2f0d-559f-4df5-81a3-03a6d2984760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_dd640957-a951-432d-9c35-27e486569d02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f35c2f0d-559f-4df5-81a3-03a6d2984760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_07729959-9c76-450d-973f-1d25f3c62dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_07729959-9c76-450d-973f-1d25f3c62dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ebad70e8-4097-4545-8cb4-ab333492bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ebad70e8-4097-4545-8cb4-ab333492bcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_16afd12f-3bb7-4690-ab57-9fef347f31e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cf036ae-6199-4ad6-bce4-f36c7665be13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_16afd12f-3bb7-4690-ab57-9fef347f31e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20211231_g1.jpg
<TEXT>
begin 644 cah-20211231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$]_CU\+M3?0-=\>Z#<Z_X=O+60AM.N[X>'KBWD1NH,;RH0>ORUYC_P '!_\
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M (5KH_A6QLY-!O,:U<FW^W/+&TJYN3(K[&7Y I&#S7UG_P %'_\ @K;^Q/\
M\$L/!^F>)/VJ_B!=0ZCKI?\ X1_PIH%C]LU74E3&]XX=RJD:Y ,DKHF3M#%N
M* /I>BOBO_@FS_P7U_X)Y?\ !4?QM<_"GX!^+-?T+QG#:/=P>#_'6E1V5[>P
M(,R26YBFFAFV#ED60N%!;;M!8;'[2?\ P7"_X)__ +(?[6E[^QS^T/X^U7PU
MXBTWPJ_B&_U>[TG.EPV:VLER!YRL7>5EC*)$D;,\C(B@EA0!]>45\#_L$_\
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M)))]S7H'_!R)^S]J?[17_!&CXS>'_#]BT^I>'-)MO%%FJ+DA--NHKJY.._\
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M;?#<:%_PFGB3_A(]-MO[.^SZW<W4W^CSW"7$VV&1'_=1OG.!D@BN7_X+1?\
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M(HKG7S&,K"WV2YN(<GH"+G7+3WX([< '[.4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-?T'1?%6A7OA
MCQ'ID-[IVI6DEK?V=R@:.>&12CQL#U5E)!'<&OD3_@C-_P $XOBS_P $M_A%
MX_\ V9O$OQ+TCQ+X#F^)%]K?PM:UDG-]IVEW(4?9+L2(J!U,:/F-F#/+*<C@
M5]C44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q=_P2[_ ."8OQ _
M9 ^/G[0'[8/[2'CC0?$OQ,^.7CR74&NO#_G-;:1HB.SVMA&TZ(Y*F0JW&"L$
M Y*YK[1HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGXR_
M$7_A4GPLUWXE_P!C_P!H?V+ISW7V+[1Y7G;?X=^UMOUP?I735YG^V5_R:SXZ
M_P"Q>G_D* /G'_A\7_U;I_Y=W_W)1_P^+_ZMT_\ +N_^Y*^):* /MK_A\7_U
M;I_Y=W_W)1_P^+_ZMT_\N[_[DKXEHH ^VO\ A\7_ -6Z?^7=_P#<E'_#XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_P!L
MK_DUGQU_V+T_\A7IE>9_ME?\FL^.O^Q>G_D* /R7HHHH **** "BBB@ K])O
M^"6G_)K*?]C#>?RCK\V:_2;_ ():?\FLI_V,-Y_*.@#Z.HHHH **** /,/C_
M /\ (2T[_KA)_P"A"O/J]!^/_P#R$M._ZX2?^A"O/J "BBB@ HHHH *GTO\
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M94A\*2Q'4=4_X1FXAGCC.8)K>U9T,:HQR5#(RLP!^E/[-/[8'[-'[8?AF_\
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M98T?='MDW%5Q]<:7_P A*W_Z[I_Z$* /HFBBB@ HHHH **** "BBB@ HHHH
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M[G\8OCA\)_V?_"L'C;XR>.+/0-+NM7M-+M;J\W'S[RZF6&"!%0%G=W8# !P
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MJ7!$UW-;LT7GSS74K^6C-Y:(BDDYKZGTO_D)6_\ UW3_ -"%05/I?_(2M_\
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M9./6M'_AL[X]_P#1B'C?_O\ -_\ &* /HFBOG;_AL[X]_P#1B'C?_O\ -_\
M&*/^&SOCW_T8AXW_ ._S?_&* /HFOES]M#P3\0/B1X%^(7@'X4>/YO"OBC6-
M"O+3PYXDMV(;3+Y[<K!<< G"2%2<#. <<UM?\-G?'O\ Z,0\;_\ ?YO_ (Q7
M"^)OC-\>_$6O7.M_\,:>-X?M$F[RO)9MO '7RQGIZ4 ?F_\ #CP1^WO^V1^T
MC:_!OXY?LQQ^#)O!OQ-\#>+/BGXUN_%5G>0>=HEBCQ1V"0L9)'OI%60.0!!&
M[*^6KLOVT?\ @@K\ ;CX$/I7[)_@7QK<>('\9Z-=?V._Q3OTM$LVUB";495B
MN;M8%98#<2#'SAQE,OMK[<C^(?QRBFDN(OV-O&:R2X\UULV!? P,GR^<"I/^
M%F?'O_HSWQO_ . S?_&Z ,#XX? *XM?V"O&O[,GP7TR\OYV^$^J>'/"UEJ&K
M&6>XE?39;>WCDN;E\LS,4!DE?J<LW4UD^%HOVDOV>OV%/AQX9^&OP*A\6^//
M#_A7PSH^J>$Y_$=M9+#LBMK>^?[2[&)C @E<!6/F>7A2=PKM?^%F?'O_ *,]
M\;_^ S?_ !NC_A9GQ[_Z,]\;_P#@,W_QN@#Q+XR_$K_@H_\ L[?M)^,M<^'?
M[.M[\<OAUXPTVPD\#Z7I/B73-)G\(:G# 8KBUN#=&,RVMPX6?SP9&B)==N-H
MKO/^"<_[-/C7]E7]E;2/AU\4M4LKSQAJ6JZGXA\8SZ83]E&J:E>S7D\4.>3'
M&TPB4_Q"/=@9Q78_\+,^/?\ T9[XW_\  9O_ (W1_P +,^/?_1GOC?\ \!F_
M^-T >V?!C_D>X/\ KA)_Z#7LM?(?@OXY_'OPAKR:W_PQAXWN-D;+Y7ELF<C'
M7RC_ "KL_P#AL[X]_P#1B'C?_O\ -_\ &* /HFBOG;_AL[X]_P#1B'C?_O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!5UO6M*\-Z+>>(M>OX[2QL+62YO;J9L)#$BEG=CV 4$GZ5^<_P.\2
M_P#!8G_@J!\/7_;7^ 7[:_AS]GKX=^(+BXF^$7P^F^$]EX@NM9TJ.5DM[[6+
MJ[</;M<["XCM@-D<B'+,/F^[?VE/A[K/Q<_9T\?_  I\.W"Q:AXG\%:KI-C*
MS[0DUS9RPHQ/;#.#FOD'_@F#^WO^S3\&O^"+OPI^)_Q@\8-X<T[X7>&=+\!_
M$:)M-N)Y_#6LV'EZ;<17T,"/);!98Q([R*%2.02,0IW4 5O O_!27]MKXO?L
M.>*].^'W[/&FR_M/^"OBQ;_"OQ=H%C:7-YH6D:O)=01MX@8)^^_LD6DXO=S'
M  *,V%+UT7P$^,'[=/[,W_!0'PI^Q)^V/^T5X=^,>D?%+X?:OX@\)^+-)\"1
M>'[_ $6_TJ6U6ZM)[>":2.2UDCNU:.4D.'0H<CFO(_V*?VR/@C\'+3]MO_@K
M)XIUN6;X4>)OC);67@F[TB+SW\4-I6FVNE*^G*IQ<F[O<PPLIVNRDDA06'NW
M_!/C]F/X_>+/C!KO_!3']N[2XM+^*WCC0$T7PC\/[:?S;;X<^%O-%Q'I8? \
MZ]FD"37<V,&15C0*J8(!]@4444 %%%% !1110 4444 %?-?_  4U_;)^)G[*
M7PP\)^#OV<O!NF>(OB]\6O&MKX.^&&D:W(ZV$5],DDLM_>>7\_V6U@BDFDV\
MG"+QNR/I2OA7_@KKK&F_!#]J;]CO]L_X@72VO@3X?_&'4='\8ZI.<6^DKKNC
MW&G6M[<.>(H$N#&K2MA4,JY(S0!P_P <?%__  5[_P""67@:W_;1_:)_;7\/
M_M#_  RT6]M3\7?!4?PGLO#U[H.ES3)%+J&D3V;E[DVYD5FBN<[XT8Y4G*>P
M_'GQ!_P4B_::_:DU#X-_L<_%G3O@U\-?"W@?3=8F^*VL?#==?/B[5+]IS%96
M"W$L=N;>WAA62>12T@>>-<*&#5P/_!=+]O;]FSP7^QS\8OV)[KQ@;GXK>/?A
MC_9O@?P7_9TXF\13:O+_ &=;"PD9/*NY$EF5WCB=GC4!F !!K5_:)^/_ .T)
M\._#7PU_X)*?L03VUU\=]5^&^GKXF\:W:>=IWPYT&&%+.;7;D?\ +:X>1'2T
MM_\ EI*-SX1<. >O_P#!+K]JSXG?M<_LN/XM^..E:1;^.?"7C77?!GC*?PZ'
M&FW^HZ3?RV<EW:;R6$,PC60 GY2S*,A0:^BZ\S_8[_94^&7[$O[-WA;]F7X2
M"[DT?PS9,AO]1F\R[U*ZED::YO;A_P".:>>265STW2$    >F4 %%%% !111
M0 4444 %?(G[97[6'QS_ &+/VYO@YXI\<^)+>Y_9X^*4S>!O$$<NFPJ_A7Q5
M,YDTR_:Y51(;:YVM:LKMY<3 .2-P%?7=>(?\%*/@?\._VC/V"/BY\)/BEH_V
MW2;_ ,!ZC/A6VR6]S;P-<VUQ&W\,L4\44J-SAHQP1Q0!Y!XS_:%_:N_:P_;X
M\<_LN?L9?%VQ\$^#/@]X N[7QYXYG\,V^JK<>-=3M2=+L(TFX=+",I>3K&ZE
MF=('*ALU\Z2:?_P75C_X**1?\$__ /A[QX2,TOP5D^(/_"5?\,ZZ7M"KJZ:;
M]B^S_:,Y)?S/-\SMMV?Q5]0_\$+?AUH/@G_@EK\)O&-I-=WNN_$;PY%XX\<:
M]J5P9KS6M=U51=WEY<2M\TCL[A 3DA(T7)VUSMQ_RL=6G_9DMQ_ZE\- 'F?Q
M'UW_ (*X_$3_ (*#6G[!7P<_X*.>'/!T_@_]G/0?%/BSQ3=?!;3]17Q#J\VI
M7ME<7"6[RJ;17\F-Q&LC*N, <DUZI^Q3^U!^V?\ #;]L[6O^";G_  40\2^%
M?%OB:7P/_P )G\,OBAX1T5M+A\2Z7'<K:WEM=69=D@O()7C;;&2K1.&ZKEJ_
M@?\ Y6(?B#_V:-X=_P#4CU*LKQIXCT3X\?\ !P;\/?#_ ,-]3@U'_A1WP'\0
MW7Q N[&421Z?=:Q>6D%GI\S+D).R6TLXB;#;!NQ@B@#[OHHHH **** "BBB@
M IES%)/;2017+PLZ%5FC"EHR1]X;@1D=>01Z@T^B@#X;_8Z_X*1>*OAE\/?C
M]\*O^"E/CBQA^(/[,M_=WWBWQ%;Z=%9Q^)/"TR/=:7K%O;QA4W2PCR#%'G$T
M:J?GD K(^$?@C_@M/^UU^R[X+^/5A^W+H7P.\1>,-0U7Q%=^#=0^#UAKG]E:
M)>O ^CZ86DDA=9K>W1WE=]SO)=E&QY(SR?\ P6"_9*^#OQF_X*6?L>ZGXOTV
M[">//%>H^%O'UG:71C@\3:+IUO\ \)!::??)C$\":A8Q2;&X(=P>H*_I/TZ4
M ?FC_P $A_%?_!7#]JSX%^!OV[?CO_P47\.ZMX+U0ZZ=7^&EM\%]/M9K@6=U
M?Z?&!J,4H9/WUO'/Q%T_=G/+'DOV'+K_ (+_ /[6_P"P]X*_;E^'W_!2KX;:
MAJ/BKP^^KZ;\-/%'P0M(+.YD261!:3:A:SI*BN8\>8D:D;NV,U[C_P $ ?\
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M **** "BBB@#\R_^"AW[2EM^RO\ \%O_ (6?$FZ_9?\ B?\ %M9_V:M?L/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20211231_g2.jpg
<TEXT>
begin 644 cah-20211231_g2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M] (4 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *_!#_@XH^-W_!176O\ @MK\(_V(/V)OVS?&7PV/Q#^'FAVM
MA9:;XXU'2M*&HW.JZI#]IN%L]Q&5CC5G6-VVQJ,' %?O?7\YG_!R_P#&WQ[^
MS;_P<-_ CX]_"WX>/XM\1^$?AQX=U/1?#,<4KMJ=Q%K6KLD 6$&0[CQA03Z4
M <O^V9H7_!S#_P $+++PK^UI\;/^"@%S\1/"TWB2'3KB*+Q]J7B'3//9'E6U
MO+74X(65)DBE7S(ER".)$<H3]&_\')O_  4R_:%?_@GA^RC^UE^R)\<?&GPR
M_P"%K6TFL:C#X1\3W-A*8Y]-M9Q:S/ R&7RGD=>>,@D=:^9OVY_VO?\ @N=_
MP<!Z#X7_ &,](_X)LZSX(\,?\)3!J-[=0^%-4MK8W*(\4<E]J-ZJPP01B61]
MH"ECC[Y55KU+_@Z\_9ZT_P#9+_X)H?L=_LQ:9JGV^/P#%/H1U#9M^UR6VEVD
M3S[?X=[JSX[;L4 ?NW>_M1?LS:;\78OV?]1_:)\"V_CR?'D>"9O%UDFKR9&X
M;;,R^<<CD83IS75^*/%7A?P/X>N_%WC7Q)8:/I.GPF:_U/5+Q+>WMHQU>220
MA44>I(%?S?\ _!?K_@AY\%?^":W["GP\_;5^'/Q0\<ZE\9)_B'I]K\0/%NM>
M(FF?5M1NK2[O)K]. T,J7=L"A5L[7.XNX#U]^_\ !7#]F[1_^"DW_!+;X ?$
MO]J#_@HGHWP,\!C1=#\2_$-M<LD\GQ-=W>GVTB1K(;B,+-&&NVBB$<V]Y0=@
M\L4 ?H9\'_VPOV2/VAM;N/#7P!_:E^'/CG4;.,O=Z?X/\;V&ISP*#@LZ6TSL
MH!X)(KH=<^,WP?\ #'C6V^&WB7XK>&M.\17EJ;FTT"^UVWAO9X ')E2!W$C(
M!'(=P&,1MS\IQ_*I\>-=_P""5'[-/_!3K]F_QC_P1)^,7C;4SHWCK3D\9:EJ
MK7:6SS"_M8T%N]S%%+()HGNHYUV^4RE0N5=A7U1_P<7_  -\3_M._P#!QS\#
MOV;O"?CB\\-S^/\ X;:%X<O=<T\_OK2PO=2UBVO649&[-K).I0D!@Q4\$T ?
MN_I'[97[(/B#P6_Q(T']JOX;7OAV/5/[-DUZT\<Z?+9+>[6?[,9UF,8FVJS>
M7G=A2<8!J]JW[4?[,N@_%'3_ ('ZY^T7X$LO&NK1QOI?@^[\764>J7BN 4:*
MT:42R!@0054Y!XK\%/\ @X&_X)/_ +/W_!(__@C'H/P9^ 'B?Q#KEGXF_:CL
M-:N]5\5R6\E]_P BYJ<"6[/;Q1(T:>4[KA%(,S=>M>5?\%BO^".GPF_8S_X)
M/?!G_@HOI7Q.\::S\;/&7B70[GQ]XFUC7FE6\N-2TRXOW:)<!HF@GAC6-PVX
MKN+$G;M /Z0O$7[3O[-?A#XJV/P)\6?M"^!M+\;ZF$.F^#=1\6V<&JW8?[GE
M6CR":3=D8VJ<]JZOQ+XF\-^#- N_%7C#Q!8Z3I=A TU_J6I7:06]M&O)>21R
M%11W)( K^9+_ (*L_P#!(CX<? G_ ((V?"G_ (*HZU\4_&GB'X\?$+6-!UWX
M@^)]=UYIUOGUBQEO&15(!1X)/)59 V3M?.<KL_1O_@I1^SNO_!2W_@B]^SC\
M0?VF_P#@HOI/P1\(3>#/#'BCXD:AXDM%>'Q/>7.E6LJQF9KB+$JL]S(D6R;S
M)'0[,Q@T ?HS\(?VQOV1/V@M?G\*? 7]JCX;^-]4M49[K3?"'CBPU*XA5>K-
M';S.R@=R1Q79>-O'7@CX:>%KSQS\1_&.E>']$TZ+S-0UC6]1BM+6V3(&Z265
ME1!D@9)'6OY._P!J?6?^"3G[,7_!07]GCQI_P1&^,_C?5;[P]XTM#XRU;5'N
MUMFF2\M%@-O)<PPR2>:C7:3J%\ED*!>&8'[V_P""ZT?C3_@J#_P7L^!__!'#
M6_B-JVA?#.TTZ#4O$-II4X5KBZ>UN[^ZN &!1I18VZ0PLZN(FDD8 AV4@'[8
M?!S]HS]GO]HG3;K6OV?OCOX,\=6=E(([V[\'>*+34XK=SG"NUM(X0G!X)'2I
M/C#^T'\ _P!GG1[;Q%\?_C?X0\#:?>3&&TOO&'B6UTR&>0 $HCW,B*S<C@'/
M-?F)^SU_P;:^-/\ @GS_ ,%2? W[7/\ P3I_:%C\,_"RQTU+;Q_X1\7:G<WE
M_JD;NZ75K'Y<*QR0O%Y4J&9\QW$8< @*%_.SXN_&C]@?_@I+_P %ROCEXM_X
M+&?M/:GX3^%7PYOM1\-?#C0+66[5;D65Z;.*)&MH96A1A'/=R8"EY9E^;:"I
M /Z:O!OC7P;\1?#%GXV^'WBW3-=T;48O-T_5]&OX[JUNH\D;XY8V9'7((R"1
MQ6=\/_C'\(?BR]\GPK^*GAOQ,VER+'J8\/ZY;WIM';=M67R7;RR=CX#8SM/H
M:_"__@V)_:(^'OP/_P""J'QS_P""<G[,GQ[OOB!\!=6TFY\2_#75;WS1MGMY
M;7E4D2,I(UO<O%,P1!(]E&VT#&.H_P"#,3_D8?VN/^QRT#_T/6: /V=M?V@O
M@)?7^OZ59?&[PA-=>%(II?%%M%XEM6DT=(6*RM=*),VX1@0QDVA2"#C%?G/_
M ,$8/^"V?CK_ (*)_MT?M%>!/C5XV\&^&O#/A;5-*T?X2>$;34H%>]'VK4XY
MYTFD(DOIY5AMV;9\BC9L1<DM\D?\$A?@5X-_:@_X+0_\%+?V</B'>:A;Z#X[
ME\;:#K,^DSI'=1VUUXDN()6B=T=5D"N=I96 .,@]*\I_X-@?^"97[/GQF_X*
M-?&+XB^*]>\517_[-?CO3Y_ "6.HP)%<L;S4X?\ 30T#&4;;2+_5F+DMZ@
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M /QZ_P"#UK_E&'\//^R\Z=_Z9=9KE?\ @YQ_Y5XO@9_V,G@S_P!1^]K]KZ*
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MR6+H2T31%2C-N5/Z8ZS?$7@WPAXO6W3Q9X5TW5!:R^;:C4;&.<0O_>3>#M/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XWXW_M$? /\ 9G\''X@_M$_&GPMX&T/S1$NK>+->M]/@>0@D
M1J\[J'<@'"C+'L*[*OYP/^"PD?P5_;(_X.9D_96_X*8_M ZE\/\ X)>%=#T^
MR\/7W]H)9VT:S:/#?8\^96AMA<7LKQR7++]V)8RR[%9 #][OV>?VWOV.OVM)
MKRU_9C_:A\!^/;C3TWW]GX5\4VM[/;)D /)%$Y=%)( 8@ GH:]1K\#OC9_P;
MF_&?]DO]L'X+_ML_\$#_ !-=>)M"L;_^T-=_M7X@V!AM1#-"-D5R6C^U6MW!
M)/&\0\S C<$D2*H_7;_@H3_P4J_9+_X)A_!V#XS?M7>.IM.M=0NS::#HNEVA
MN=1UBX"[FCMH01NVK@L[LD:94,X+*" >]T5\5_\ !-?_ (+Y_P#!/;_@J5XX
MO/A1\ ?%'B'0_&-K:/=P^$O'.E1V5Y?6Z?ZR6W,,TT,VS.619/,"Y;;M!8:_
M_!33_@M_^PA_P2BOM&\,?M*>)]<U'Q1KMK]KL/!W@W3([S419[BGVJ1998HH
M8BZLJEY%+E'V!MC;0#Z]HKX*^#__  <B_P#!,+X\_$GX4?";X5>.O$NJZY\7
MKV.QT*SB\/[3IEZT_D?9;\-(#;R!L-P'5D975F5@:Z']HG_@OW_P3A_90_:=
M^(7[)OQ]^(.M>'O$OPT\/PZMK]Q<Z(7M)TFMK.XAM[5T<O<7#K?0 1JG7>20
MJ,P /M2BOSI_9\_X.E_^"1WQ]\">-_'=W\4/$/@5? NE_P!HWNE>.M$2WO-3
MMS*L(-C';33BY<R21KY082?O Q0*&9?0/^":7_!?3]@'_@JA\2-7^#G[/>J>
M*=%\6:58O?1>'_&VCQ6<^H6B.JR3VS0SS1R!2R$H660!MVS 8@ ^UJ*^)?\
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ML]&NE.'@FFFN(0\B'AUA$I1@4;#JRCZB\+?\%"_V5?B#^Q!JO_!0WX9?$/\
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M_&&HI'+XG\-6U]:074%XMN+:6:..\*V]W;W$"KYL+'?YFY@K[QL /A7]H?\
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MDC8'S/ECDDFOHR7_ ()L_MJ-_P '347_  4<7X,?\687PS]D/C+_ (2/3?\
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M5>,-8NSKGQ=U.[MKQM(LKJ-+>[FTMXKH.YFA3*Q/;F1';.;<EG7Z(_X(C_\
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M6Q8_\(Q>:-I5M+IT/VJ]DLX_M$LERDB8DB8MMC?"X(R>*^I: "BBB@ HHHH
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MK4EM;Q6DEQ%<Q/Y-I')+$Z1L\$R%L+O9B5'V'_P6#_X*B_L_ZI_P1=\#?\%
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MG4O#E]J"2V&FW\PQ*+*-8U,$;*(UV%GPL,8!&WD ^7M/_P""!/V#_@A_??\
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MVIM7^.7Q0TW+>'+O5;65+;39O+\H74CW$\TUW.L?RQLQ18LY",RHZ>R>/_\
M@B__ ,)S_P %K_"7_!8?_AI+[+_PBVC?8/\ A77_  AV_P"U?\2N[L-_V_[8
M-G_'UYF/L[?<VY^;</N:B@#X9_;T_P""+W_#;O\ P4E^!/\ P4*_X:3_ .$8
M_P"%*7>ES_\ "(?\(=]M_MG['JC7^/M7VR+[/OW>7GRI-N-W/W:\O_X*8_\
M!NLW[5W[7 _X*!?L4?MA^(?@)\7KB%$US5=#MYFAU&1(1 )U>WG@FM96A CD
M*ETE51E Q=F_3:B@#\Y_^"4O_! .T_82_:1UK]N?]J/]J[Q#\=/C5K-A)9P^
M*M>AE1-.CD18Y'#3SSS7$QB01"5W4+$614 .:\)^#/AJ3]N+_@[A^(7QMTZ/
M[7X8_9C^'<.C)J &Z(:I-9M;?9SZ.);_ %0C/>T8]<5^QU>%_L1_\$\OV?\
M]@>/Q_=_!I]<U#5_B?XUN?%/C7Q'XGU!+J_U&_F))#2)'&!&K-(RIMX::0Y.
MXT >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>9_ME?\
MFL^.O^Q>G_D* /3**_$NB@#]M**_$NB@#]M**_$NB@#]M**_$NOTF_X):?\
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M_7"3_P!"%>?4 >V?\+<^'G_0P?\ DI-_\11_PMSX>?\ 0P?^2DW_ ,17B=%
M'MG_  MSX>?]#!_Y*3?_ !%'_"W/AY_T,'_DI-_\17B=% 'MG_"W/AY_T,'_
M )*3?_$4Z+XL> )I5ABU_+.P51]EEY)_X!7B-3Z7_P A*W_Z[I_Z$* /HFBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5EBE=_*EAN6;$HV[O,9.[ _H;I?_ "$K?_KNG_H0H ^B:*** "BBB@ HHHH
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M1W<^HSSJ%MY0Z +(L:$," %.U%XW"O&?^"0_A#QW\*[;]H/P-%<0ZOXG\/\
MB86:RRR$QWE_"EVF2S,"5>5>22.#DD=: /MR]^)?P_T[Q[9_"V_\9:;%XDU"
MR>\L=#DNU%U/;J6#2K'G<5!5N<8^4^E;E?G)\ ?AY\?? ?\ P5K\*7_[3/CF
MWUSQAXC^'UWJ^HK9#_1].5Q=11V<70;46$?= &6;[WWV_1J21(D:65PJJ"69
MC@ >IH PO&7Q1^'/P\O](TKQUXWTS2;KQ!J"V.B6]_>)$]]<L0%BB5CEV)91
M@=V'K6]7Y8_M ?%/QA^T[^VW\+/VB+.Z*_#VQ^,VF>%_ :'.+X6]Y!)=7J]M
MKR% &QRH53@QFOU.H _9/X1_\DI\,?\ 8O67_HA*Z&N>^$?_ "2GPQ_V+UE_
MZ(2NAH **** "O#/B9_R/>I?]=Q_Z"*]SKX)_P""M?[3?Q6_9N\.Z/I?P#TS
M1IO'OQ-^)^D>!O!MUXB#MI^GWM\)&-W<*A#.D<,$S!0<E@HPWW2 >S45\(?\
M$POBQ_P4;L_B._PX_:DUJ'XF^ ]=N?%S:5\2[#0FLYM%U32_$=Y8R6%V-[)Y
M$RQ&6W .8U A&53(YSQE_P %$_\ @I-X9^"NM_\ !1JZ^"G@'3?@5H6NS*_P
M[UNTU"V\97.@Q7WV-]2,KLL$%R2#*ML\>/+&,EB&(!^B5%?,/[4^O?\ !7.^
M^(-CJ7[ VF?L\W?@2ZT&WF,_Q2.MKJ37C-(7VBR=8_)\LPE<C=DOGM6#_P $
MD/VM/VUOVPO"'C_QY^U5X>^&4>AZ+XL?0O ^O?#&WU!+/7&M7FCO[E&O9I&F
MMQ*(XXI55 S1S<$!30!]>45\R?MD_M,_M1Z;^T'X+_8O_8H\+^%&\;^*?#U_
MXCUWQ7X\AN9=*\/Z-:RQ0&3R;9E>XGEFF5$7< I&6!#967]A']JKX_?$SXF_
M$_\ 91_:Z\,^&+/XE_"BZTR2]U;P29QI.N:9J,,DMI=PQW#-)"_[J1)(V8@,
M 0<'  /L'X,?\CW!_P!<)/\ T&O9:\:^#'_(]P?]<)/_ $&O9: "BBB@ KS/
M]LK_ )-9\=?]B]/_ "%>F5YG^V5_R:SXZ_[%Z?\ D* /R7HHHH **** "BBB
M@ K])O\ @EI_R:RG_8PWG\HZ_-FOTF_X):?\FLI_V,-Y_*.@#Z.HHHH ****
M /+/VB[.TU&>ST_4+6.>">TECG@F0,DB,0"K \$$$@@]:_/GX-?\$0?V(?@O
M^UG??M&>&_A1:?V990Z9=^!_"TVK7TUEH.KPS7\EQ>1VTLK0C/VF PIM*P.D
MK1A"^:_0KX__ /(2T[_KA)_Z$*\^H XWQ7\ /A'XX^,OA']H'Q3X2^U^+O E
MIJ-KX4U8W]PGV"*^2..[ B6012&18D&71BNWY2N3GE/VO?V$OV5OV\O">D^!
MOVKOA@_BK2=$U%K_ $RR&OW]@L5P8S&9";.>(N=C, &) R< 9KUVB@#Y@_9J
M_P""-'_!-K]D#XOZ=\>OV=?V</\ A'?%FDPSQ:?JO_"8:Q=^4DT30RCRKJ\D
MB;,;LO*G&<C!P:]%TG]A7]D[1O@AXL_9O@^#5C/X(\<ZQ?:KXI\/ZC>7-W%?
M7EW*)9YMT\CO&QD577RV41LJE-A ->M44 >$?LK?\$U_V//V-/%M_P#$'X'?
M#.YA\1:C8+I\OB#7O$%[JU[%9*0RVD,UY+(T,((!V)M#$+NSM&/?M+_Y"5O_
M -=T_P#0A4%3Z7_R$K?_ *[I_P"A"@#Z)HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /D;_@KS_R2GPI_P!C#)_Z(:OYROVY
MOVKY]8^-\_P'_;*^",$]KX7\4:E-X;_L;3),:QI<^EWD%HP:21B93</:OO0A
M58'@-%@_T:_\%>?^24^%/^QAD_\ 1#5^<GBWX8^$/&WBCPWXQ\06#RW_ (3U
M&6]T6592HBFDMY+=RP'WAY<K\'O@]0* /A#X>?\ !.;]K3QM\$/@AXJT3XS0
M>"O$'@;P[>M;66KV+S36,MW>3SJP0@JD@MY(4((W*8P."HQ-_P $H?AS\=](
M_:I^,=_XH^,*:A9:%XKN[#QA:BVV_P!M:F99PMX#CY0&24XX_P!9TK]":* /
MCKXA_P#*;3P)_P!D?F_]&ZC7HWQ<^,^G_'WXA?$K_@GSX*.HZ)XK7X?2W7_"
M2S!?LD<=PL$>%V/YFX"Z7/ Z-STKW^B@#\F_VC/V./VKOV=+SX(_"[6/VEK"
M_LYO'EMI_@:*QTSRH]"O7GB*W."N7P[ASG))!)SFOU/\"Z7XBT/P1HVB^+]<
M&IZM9Z5;P:IJ03:+NX2)5DFQVW.&;'O6K10!^R?PC_Y)3X8_[%ZR_P#1"5T-
M<]\(_P#DE/AC_L7K+_T0E=#0 4444 %?#O\ P5!^ G[/G[4/AX? KX[?$\^$
M+S5_%UG/\/\ 7+#78K#5+3Q!;@RVLVGM(?WER@60A%#$IOX'WA]Q5\1_\%-O
MV-]._;2T#_A#K3XBW_@SQ3X5\7V/B?P'XTTRU2>;0]8M ?)N/*<A9DVO(CQ$
M@,KGD$ @ ^&?^"9/QU_:R_9;^,W@K]DC]H?QYHOCOP!\5/$_Q(C\"^+5TX6>
MKV&KZ+K>HRZA]N"GRY([G9/<JPY5I-F=J 'T?_@L1\&OBI^T=^ROJ?[0?P<_
M:6TK6?AGX)\/?\)/KWPH:RBFT3QW#ILLEY/'/J-K*MP$:.(*(T<Q%X1N&6W*
MW_@G#_P3F^/'A#Q_I_[2_P"VW\9)/$WB'PCJGC*S\ >$[?PW'IUEH_\ :FMW
MDM]JI"R.TTM\K"1 <+%!,J88@%:MQ_P1V^/.F?#W5?V./A_^WQJ.A?LVZSJ=
MS+<?#Z#P9 ^LVFFW,[3W&C6^JM+E+5W=P&,3.$<H=P)W ':?M_\ [8>N'_@D
M_#\;/@;:RZ?XF^,WAK0M'^'EFTNV:"]\0""*$*RCB2**XDD! ^]#TKZ-_9M^
M!/@[]F+X!>#_ -GOP!;K'I'@_P /6NEVC! IF\J,*\S ?QR/ND8]V=CWK@?V
MC/V'O#GQRTSX)^$_#OBJ/PQX=^#'Q)T;Q58Z)#I1N4OH],MYH;6R#&5/)53(
MK!R),>4/E/4>D?'3P1X]^)7P>\1^ OA=\5)_ _B+5M*EMM'\7VVG+=R:3.PP
MMPL+.@E*GG:64'UH Y/]LO\ ;$^%7[$GP:F^+7Q-^UWL]Q=QZ=X7\,:1"9M1
M\1:I+D6]A:1#F261O084 L>!7G/_  3>_9H^,GP^7QY^UG^U:MM#\7/C;JMI
MJ?BC1K"7S+;PYI]K"8M.T>-_XS;PNP>0<-([?>V[VX;]K7_@E_\ M5_M#?'?
MX6?M"?#G_@HJO@K7OA9X,&E:9-??".SUT3:G*&6]U98[NZ$4,TZ>4N!&S1B+
MY7^;CV3]CSX"?MJ_!>_UZX_:T_;[_P"%U0:A#;KH=O\ \*KTWPY_9+H9#*^Z
MS=C/Y@:,8?&WR^/O&@#Z>^#'_(]P?]<)/_0:]EKQKX,?\CW!_P!<)/\ T&O9
M: "BBB@ KS/]LK_DUGQU_P!B]/\ R%>F5YG^V5_R:SXZ_P"Q>G_D* /R7HHH
MH **** "BBB@ K])O^"6G_)K*?\ 8PWG\HZ_-FOTF_X):?\ )K*?]C#>?RCH
M ^CJ*** "BBB@#S#X_\ _(2T[_KA)_Z$*\^KT'X__P#(2T[_ *X2?^A"O/J
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M[I17A?\ P@/_  4$_P"B_P#@3_PE)/\ XJC_ (0'_@H)_P!%_P# G_A*2?\
MQ5 'NE>9_ME?\FL^.O\ L7I_Y"N7_P"$!_X*"?\ 1?\ P)_X2DG_ ,569XS^
M"'[</Q!\+7_@KQ?\;O EWIFIV[07MM_PC4\?F1GJ-R.&'U!!H _-*BOM/_AU
M5X[_ .@[X$_\!=4_^2J/^'57CO\ Z#O@3_P%U3_Y*H ^+**^T_\ AU5X[_Z#
MO@3_ ,!=4_\ DJC_ (=5>._^@[X$_P# 75/_ )*H ^+**^T_^'57CO\ Z#O@
M3_P%U3_Y*H_X=5>._P#H.^!/_ 75/_DJ@#XLK])O^"6G_)K*?]C#>?RCKRS_
M (=5>._^@[X$_P# 75/_ )*KTGX6?LS?MA?!7PL/!7PR^+_@33-,%P\XMO\
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M5[P)_P"$_<__ !VEB_9I_;%AE6:+XP>! R,&4_\ "/W/!'_;2@#Z7HKPO_A
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MV@OC7\=)/^"K?_!0[1%TOXCZSHLFG?"?X6K*9+?X9>'9_F,+$@;]4N5P;F;
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M3-^I^#%TSQ!X5U&*1HY]+U*'4+>..YA=2"CB.65,C^&5AWH Y7]G+PU\1_\
M@L'\:?C=^U5J/[0WQ+\&? U[.;X;? Z'X>>,;C2GU".TN<ZGXIB*9C>66Y1[
M>WF9&*PI(, @-7@;?\$N=7'_  6.7]@+_AZ'^V+_ ,(4?V9V^()O/^%]W/\
M:/\ :@\0C3O+\WR?+\CR3G9Y>[?SOQ\M?J_^S/\ "KP#\#?V>/!'P?\ A;X<
M@TGP]X;\+6-AI&G6X^6&&.!%&3U9CU9CDLQ+$DDFODEO^5FY/^S$6_\ 4T6@
M#Q']I3]C#Q)XR_X*6? 3_@G!#^WK^TEHG@O3/V?-=U:ZU_P]\7+BUUS6+RWU
M6,1S7UR$*7+A9V7<T>[:J $ <])=_#O]H'_@BW^V5\$/[/\ VU?BQ\7?@5\=
M/'<7P\\1Z!\9_$_]MZAX=\07D4CZ7>6-V41DBDDB>.2+ 4#<3O9D,?I?Q?\
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cah-20211231_g3.jpg
<TEXT>
begin 644 cah-20211231_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M] (4 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M85"I(T29;.:^)/\ @GW^VU^U[_P;1?M$?%G_ ()[_%W]BGQ+\3(O%GB-;KP
MFB22VKZQ=(&A@N[1A!,+J"ZB\C<J O$\6TC>'0?TMV5E9Z;:1:?IUI%;P0H$
MA@AC")&H& J@< #T%?A'8_$__@Z:_P""5OQ^\;?#^T^#7B3]J;P+?W#P^"M?
MUX7&M(ENLCF"Y#VLRW,$A1@LT4_&Y?E. KL <A_P;%:K\<_$/_!>3]J/Q+^T
MQH$>D_$'4O"6MWGC/28&!2PU*;Q!82SVRX+ +&[-& "0 F,G&:]%_P"#)_\
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MV!\G&<\?LY5#1/"OA?PR]S+X;\-V&GM>S&6\:QLTB,\ASEWV@;FY/)R>:OT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRQ,FG7/ER([R3L5D5]UPC$ JAK[]_P""$/\ P2W_ ."EO_!-7]ISXR_L@_M
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M?%FQ?X%^'? &I6YU[XP^&_$\=AJ&H1PQ& 374UEJ$C7[")GQ#;I'%+(P:7&
MZ ' _P#!S#9>._CSX,_X)RZ=\?-&U72O$WC/PB\?C73]5M9+:^L[^[C\."\B
MFCD >*9)9)%9& 96!! (KOO^#Q+]D/\ 9G^ G[&WP,\0?!#X'>&/"-QHOC&;
MP_92>'M&AM&&GM8/((':-09%5X$8;R2"7.<NQ/T/_P ' 7_!+S]M7]L;XY?L
MB:Y^RM\+[WQUI'PFU>Z/C76]3\5:=;7-O";G1V2>4WEQ"]S(Z6D[L8E<DJ<@
M%E!ZO_@Z1_X)X_MA_P#!1G]E+X<_#7]C7X0?\)CK>@_$)M3U:R_X2#3]/\BU
M-C<1>9OOKB%&^=U&U26YSC )H ^3_P#@Z!U.ZU3]HO\ X)[ZSJ=PTD]QJ4LU
MQ,YR6=KOP^S,3[DDUWW_  >X31K^Q;\'("XWM\4)V5<\D#3I@3^H_.O2/^#B
MC_@DA^UQ^W/^S/\  KXD_LC:)%?_ !*^"2OYGAK^TK>WGNHKB&R,CP2RN(6F
M@FL8B$+ .KOM)(56^//^"C__  3R_P"#EW_@K_\ L^^#_B-^TW\ _"-EJG@_
M6ELO#OPJ\,ZMINFSS0S6\AN]<O'NM0:)9-\%K"L(EW?OI&6&)0Q< @_X.3?B
M=K>K?\%3?V0?@[XD^!^M?%7PKX<^&VA>((OA9HL4DL_B:>ZU2X2YLHXXXY&=
MIXM-MXB%1B5R,5S'[8GC/]K_ /:J_;]_9V_:Z_9A_P""!WQQ^!.N?#+Q59GQ
M'?V7PQU+R-7LXKRU>!91!IL"(L4:W4;,V[=%.$.%0"OT#_X+J?\ !(#]J[]J
MG3/@A^VG^P;=VMK\=_@9!9K::1<W\$#:C%!)'<PB&:8^1YUO<H[!)&6.1)Y
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M6/\ PC%YHVE6TNG0_:KV2SC^T2R7*2)B2)BVV-\+@C)XKZEH **** "BBB@
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M(*13I*ZM)MCV_-N&U_P4>_X.)_BI^P'_ ,%1C^PQ8?LLP>/-'N/"EM<Z';:
M;EM<U?6;RVD^Q6,2KN0+)=>2A81NP1F*J[ *?G;_ (.NI](\1_\ !2W]BWP7
M\(I(9/B@NO$M'9D&[6*;5]-72\[?F ^T1WI3WWX[U>_:3TG3]:_X/5/A'9ZG
M:I-&GA6&=4=<@21>'-3EC;ZAT5AZ$"@#T;]BS_@XM_;IF_X*8^'/^">W_!4/
M]AS1_A9>>/IXH/"LFEPWEO=V,EP'^QM,+B:9+N*61##YD7E[9"<@[64>@_\
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MF4@*-_A'AG7Y/V&/^#O[6? .E2FS\-_M.?#6.\N[('$(O5LY)%GQW=KK2;D
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M_P +'_X03&S&N1ZKL_L_[=S_ *OR<_:!UWXXV5[%X>_X)=_V#_P1ZD_X)/\
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M;^8DD-(D<8$:LTC*FWAII#D[C0![I1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% &7X@\9^&O"TL<.NZEY#3*6C'DNV0.OW0:S_\ A;GP\_Z&#_R4F_\
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MY<T;AT;:UT5.& .""#CD&@#Z&K])O^"6G_)K*?\ 8PWG\HZ_-FOTF_X):?\
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M@M]B_LD? *R_98_9A\ _LY6.L-J*>"O"=EI#ZBR;?M4D,*I),%YVAW#,%R<
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M3]S_ /': +%%5_\ AF7]L+_HKW@3_P )^Y_^.T?\,R_MA?\ 17O G_A/W/\
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M]9T633OA/\+5E,EO\,O#L_S&%B0-^J7*X-S-@,H/E#:N8U /M^BBB@ HHHH
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M#X?^+_&?A;P=X.URU;=;ZJ_A_2GM[VY@<<30F:X 25<JP!P3@U^@E !1110
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MQDI(C @AE)!'0UHT %%%% !1110 445YC\?_ -M7]D#]E+4=-TC]IO\ :?\
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M,^&O!%YKOASXD0R>,?V--!M[9I(YM>U*\BL[GPN@'1(;ZYAN%C!&+<R,27E
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M,^+] L];\.ZE]FE@^UV-W D]O-Y<RK)'NCD1MKJK#.& ((H WZ*** "BBB@
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M8>_X):?"O]D+]GSX=^'Y_C_=>,O"VD?!/Q7I>@PVWB#5/%D5_:2W>M&5-TR
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cah-20211231_g4.jpg
<TEXT>
begin 644 cah-20211231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7P?!?:A'=26R0)I\C7#>?9-'=++-(\4;-(LO.?+6O5?^")^IP:/_P &^_\
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MV ?^#F[]H/\ 8/BF-OX)_: TS_A.O"MCG"+J_D?;YC&O1%(;54(7J+>'LH
M/V*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _,3_ (.[/$.J:+_P1I\0:;I\C"+5_'F@VE\%/#1+<-.
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M@#[:HKXE_P"'Q?\ U;I_Y=W_ -R4?\/B_P#JW3_R[O\ [DH ^VJ*S_".O?\
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M?B)^P9\<_ $_B&X^&-_I5]XAT'6&FM(W:\LY)+6[MG@E5Y4$<DB[^ K_ .T
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M;32$U/2_$OAJTF;39%9E!MGE+R)YHWY&&!Q&X(/#'Z1KXS_9UU'XQ_LP?\%
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M?MH:]I/C'X[?#JYN-?T.U>TTWQ'H6O7FE:A':N27MFGLY8WDA)9CY;EE!9B
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M1_Z#&@_^%/8__'J_8'_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\
MB: /YDOVF_\ @D1X_P#$/[3%G\0O@1\<QX;TCQYXANI_&$%AK=C(FDRR6-T)
M;Q2+M,^=YDL.",JUVQ#%?E'V'\$_V;] ^ ?PIT/X/> M0T9-)T&Q%O:F?Q38
M-)(<EGD<B4 N[LSM@ 98X '%?M5_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1
M.]"_\%$/_P 30!^ _P"RK_P3\UW]E[]E[6OV<].^..C:C<:K+?RP>(X-0LK1
M[1[F%8U98A>N24*A@0X)/IUK&\4_\$P9?B1^QGI'[+/Q5^/UOKVM:%?2W^E^
M/YM>LQ=QW9N)Y(Y"DEY(S*L<QB*F3E5!!4A=O]"/_"KOAG_T3O0O_!1#_P#$
MT?\ "KOAG_T3O0O_  40_P#Q- '\^'[)7_!-_P 8_ WXHZI\??C=^T;9_$;Q
MO?Z4NEVFK7^O64265D"I**&NG+,VQ<MD8!88RS$_1W_"':C_ -!C0?\ PI['
M_P"/5^P/_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q- 'EGPZ_
M;1_96T+X?:%H>J_'+08KJST:U@N8OM!;9(D2JPR 0<$$9!(K9_X;G_9'_P"B
M]:#_ -_G_P#B:[K_ (5=\,_^B=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B:
M.%_X;G_9'_Z+UH/_ '^?_P")H_X;G_9'_P"B]:#_ -_G_P#B:[K_ (5=\,_^
MB=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B: .%_X;G_9'_Z+UH/_ '^?_P")
MKRCQS^T[^SYK'BR^U/3?C!H,D$TNZ-_MRC(P!T.#7TC_ ,*N^&?_ $3O0O\
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M/W_"':C_ -!C0?\ PI['_P"/4?\ "':C_P!!C0?_  I['_X]7[ _\*N^&?\
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M"_\ !1#_ /$T?\*N^&?_ $3O0O\ P40__$T <+_PW/\ LC_]%ZT'_O\ /_\
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M?^"B'_XF@#Y9_P"&BO@3_P!%9T'_ ,&*?XU+8?M'_ :&^AFE^+>@A4E5F/\
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MC$_M?>._BO<:G\0/%UUJ>G:;I>HKJTCAM3T#4+BXCAD@AL;9840,LMM-,&V
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M# , <$C/<T ?HQ17R)\*_P!N7XX>$/\ @J7XJ_X)Y?M8Z3X<M;'Q-X2A\5_
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MKO\ X*+?&I$\,/X'T.]B^*_AT*4FT77]/_=7FFK'(=PD>?8(8V.]EN(0>6H
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MX&?%;_A9?]@_\*7^)'_"6?8/[&^U?VQ_H<UM]FW^=']G_P!=N\S;)]W&WG(
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M[QEIW[*.NWWPI^ ]GJL0+:#H]W*^I3S,Q)\RY:&YMK/S1@B&W*#Y"JK]C_\
M!2#_ (*%0?L9^&="^&/PA\"R?$#XY_$NXDTWX1_#.Q;]YJ5V%^>\NB"/L]A;
M@^9-,Q4!5(W#EEZ+]D+]BC_AE3XN_'/XJ?\ "S/[>_X71\2CXM^P?V-]E_L?
M_1(;;[-O\Z3[1_J=WF;8_O8V\9/S=^T)_P $@?V[/'?_  4+\9?\%!/V:_\
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M?MO_  WU[^P?B?\ LW:S;^./AWXB2W$ACD26.*ZLI5/W[>X@8K)&?E8I'N!
M(/MO_!+K]E;PO^R#^Q)X+^&^C:M-J^KZO8CQ)XU\37@_TG7]>U$"ZOK^9CDL
MSRN0N22L:1KD[<UT7[?O[*/_  W-^QK\0OV2/^$]_P"$7_X3S0'TS_A(/[*^
MV_8=SHWF>1YL7F_=QM\Q>O6MCXD?!/QKXD_9,UC]G3X<?%R7PIKU[X!E\.Z1
MXYM]+,\FE7#69MDOT@$R;G0GS%3S!A@/FXS0!\4_M.>--2_X+7_M%O\ L!?
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MA#PGX!_X+I_LX>#? GA?3M%T?3OV?/&T.GZ5I-E';6UM&+W3,)'%& J+R>
M*^[J\1\>_L;_ /";_M]_#W]N3_A8WV7_ (0/P#KGAG_A%_[(W_;O[1FM9?M'
MVGSAY7E_9L;/*;=OSN7&#[=0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cah-20211231_g5.jpg
<TEXT>
begin 644 cah-20211231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%ZAIWA[5]<N/-NSHYTJSFT^"1@ "8K26"'@!1Y>%55 4>O?\$!_^5C;]O/\
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M7QII/B'1-1C\S3]9T/48KNUN4R1NCEB9D<9!&03TK^:?]J/XV_L._P#!1?\
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M)S_\%-_BN/@1\%-=\5>&_&L]K+<Z7X:\>:+%9SZG'$A>7[.\$\\,CH@+F/S
M^U68*51B/NB@#R_Q%^V_^Q;X/^(DGP@\6_M>_"_2_%L5]'92^%]1\?Z=!J*7
M,A4) ;9YA*)&W+A-NX[A@<BNS^)/Q/\ AI\&O!EY\1OB_P#$/0O"GA[3S&+_
M %[Q)JT-C96WF2+''YD\[*B;I'1!DC+,H') K^1+_@NEX=\97?\ P6?_ &FO
MB)X+G>";P+XBM-=N+J/[UNH?2[2.0'L1/=P?G7ZQ_P#!S_\ M?2?'C_@CQ\
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MNF7EF9(8UEMIPY\T,9XR,JO!/3&* /=?A/\ M%_L^?'JYU:R^!GQV\&^-)M
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M)?L\EO//$[HBLYC+ARJLP4A&( /NNBBB@ HHHH **** "BBB@ HHHH ****
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M":KJ&X6POHXY(FMK@H"RPS12NA902C>6^UMFT@'S=_P62_X)!_\ !/SX2?\
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M^#)SXDPW,S,EO\1H(X%)^XA\5:4V![;F8_B:^Y_^""_[#?[+7P$_X(X?#O\
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M\46GC+1=1MM#MF:0VK7<$S22+<VZR2();>.42JH8J3^[36_X-=?@WXD^!?\
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M#,8[BQEA1X)%+?,5:-D()YP>:_!#]J7]G+_@YG_X+&_#/P7^PI^U[^QK\/\
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M&0!X95#*<$8*NKJ65E8^M4 %%%% !1110 4444 %%%% !1110 45\Y?LU?\
M!2WX/?M'_MH?&/\ 8-@\(Z[X:^('P;GMY-2L->6$)K.GSA3'?V9CD8M#MDMV
M.\*P%U%P<G'T;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y#_\ !Z;_ ,HJ
M_!/_ &7K2?\ TSZU7Z\5^0__  >F_P#**OP3_P!EZTG_ -,^M4 9OC_X _\
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M^%T^GZ%X5\+0:GH_A>;5QG3M-DMWT6*$W'R,/*2*.(ME&RB/A3R*@_X*J_\
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M78NPEB1#%ECL%>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !117E/CGXE>-='\67VF:;K7EP0R[8T^S1G P#U*DT >K45XG_PMSXA
M_P#0P?\ DI#_ /$4?\+<^(?_ $,'_DI#_P#$4 >V45XG_P +<^(?_0P?^2D/
M_P 11_PMSXA_]#!_Y*0__$4 >V45XG_PMSXA_P#0P?\ DI#_ /$4?\+<^(?_
M $,'_DI#_P#$4 >V45YG\,OB#XO\0^+(M,UC5_.@:)V9/L\:Y(&1RJ@UZ90
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17F'Q_P#^0EIW_7"3
M_P!"%>?4 ?2%%?-]% 'TA17S?10!](45\WU/I?\ R$K?_KNG_H0H ^B:***
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M+I,5^9- L+66&-)'D548S7,3!_W9. I&&7GJ  ??G_#Q?]LG_HL7_EO:=_\
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M^!A_9_UOQ]<Z%H6H^(=,N_$T=K:F4ZMIUM=1W$VG,1(AC2<1A&<$X&?E89!
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M^UU^ROX@^,MQ^SMH7[1W@B\\>6C.MSX/MO%%J^I1N@)=#;A]^]0"63&Y0,D
M5W6NZ?=:MHEYI5CJTUA/<VDD4-];!3);.RD"10P(+*3D9!&1S7Y1?MO_  >_
M8J_9+^&?P?\ ^":_P/M;-?CU-\0O#>I>'/B7J^D+8W-I=G4Q<W.K7FKR*D<D
MTT<5R@MUE>5C)&JQX\L4 ?I?\;_VFOV=?V:=,L=8_:%^.?A/P3:ZG.8=.F\4
MZ_;V(NI!C<L?FNN_:""<9V@Y.!6GXC^,GPE\(?"V?XX>)OB7H5EX-MM,749O
M%,^JQ#3Q:, 5G$^[848%=K D-N&,Y%?//[6?P:_8X^!_Q:\3?\%(/VS)9/$U
MA!X/LO"^DZ'J_A,ZU;Z-$9I7D^R6L4,KF6Y>0!W*_*JD%E0MCY'^!O@G6_$'
M_!&_PM\2?"7A>;6_AS9?M)6GCVU\ Z"ZZO/I_@6+Q.MVVF&"W:02O!$&F>V&
MYEV,C ,I4 'Z;?"3X\_!?X\_#6#XQ_!OXH:)XD\+7*2-%KVDZ@DML/+)$@9P
M<(4(.Y6P5QR!6W\*/B#X,^+'AC0/B9\.]?AU70==MX+[1]3MPPCN[:3#1RIN
M )5E(8''(((X-?FQ8>)-=^*OA[XN^ _@AIVL^'M%_:\^/$6D^ 6NM(GTVY_X
M1^/1+)/$GB".VG1)(DDAM+P([JC-++"V/G!/Z3_"R/P)8Z'I/A_X:SZ<=%T<
M0Z=8P:5.DD-K' %C6!=I(&Q5"[>HQ0!]14444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'R-_P5Y_Y)3X4_P"QAD_]$-7XD?\
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MG?L4_'"V^,6NM=:IX;MOA5?_ !9MOB7K7B2YOG6]LQ;1,T]IY.W!R<D.#@*
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M .B=Z%_X*(?_ (F@#\?O^$.U'_H,:#_X4]C_ /'J/^$.U'_H,:#_ .%/8_\
MQZOV!_X5=\,_^B=Z%_X*(?\ XFC_ (5=\,_^B=Z%_P""B'_XF@#\?O\ A#M1
M_P"@QH/_ (4]C_\ 'J/^$.U'_H,:#_X4]C_\>K]@?^%7?#/_ *)WH7_@HA_^
M)H_X5=\,_P#HG>A?^"B'_P")H _'[_A#M1_Z#&@_^%/8_P#QZC_A#M1_Z#&@
M_P#A3V/_ ,>K]@?^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H
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M*?XT?\-%? G_ **SH/\ X,4_QKZF_P"%7?#/_HG>A?\ @HA_^)H_X5=\,_\
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M!C0?_"GL?_CU?L#_ ,*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
M$T ?C]_PAVH_]!C0?_"GL?\ X]1_PAVH_P#08T'_ ,*>Q_\ CU?L#_PJ[X9_
M]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \30!^/W_  AVH_\ 08T'_P *
M>Q_^/5]N?L#_ +1GP(^"OP#7P5\3?BUH.F:F-9N9S;?V@DW[M]FT[HBR\X/&
M<U]2_P#"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !- '"_\-S_L
MC_\ 1>M!_P"_S_\ Q-'_  W/^R/_ -%ZT'_O\_\ \37=?\*N^&?_ $3O0O\
MP40__$T?\*N^&?\ T3O0O_!1#_\ $T <+_PW/^R/_P!%ZT'_ +_/_P#$T?\
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MU72?!'QJ\%G1;O6K),^9/9$2R).$ )9<JV%<A65'*@'UO1110 4444 %%%%
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M?MY_&3P)=^#[W]I#XD'Q7X=\%W\>RZTG0(;2*TTTW2#A+J:"+SI%'3S$S@Y
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M_9,;P8?$?]I6W_(;/B<7WV3[/YGG_P#'L/,\SR_*_AW[OEH X3XO_P#*Q?\
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MS%Z]:V/B1\$_&OB3]DS6/V=/AQ\7)?"FO7O@&7P[I'CFWTLSR:5<-9FV2_2
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M?V7H/AIXY\;_ /"4^//$OB#4/%OQ0\5A-JZQXDU&7SKV=!@8C#;8DX!*1*2
M217T'7D'[%7P:_:P^!WPKO\ PE^V)^V=_P +S\3W&ORW=CXN_P"%=6'AC[)8
MM! B6/V6Q=XY-DD<TGG$[F\_:1A%KU^@ HHHH **** "OR^_X*L_#C]JCXJ?
M\%G_ -F[PE^QQ^TA8?"KQJ_PB\8RP>+=2\)0:U%';K-9^;#]FG^0EQ@!NJXX
MK]0:\)^)'[%/_"P?^"@OPS_;L_X67]D_X5UX(USP]_PBO]C>9_:']HM WG_:
M?.'E>7Y/W/*?=N^\N.0#*_8+^!7_  44^#%SXHD_;R_;LT;XSQ:C'9CPO'I/
MPUL_#_\ 9#(9_M!8VW^O\T/#C=]SR3C[QKX8_:1_8'T#7O\ @O%H?[--GXTF
MM?@S\;K.'XS?%#X;); VNL>(?#\CV\8/.!!<S3VMQ<1D$3/;?-_ 5_7*O"/&
MO[%'_"8?\%%/ _[?7_"S/L__  AGPUU7PE_PB?\ 8V_[9]MN89_M/VKSAY>S
MRMOE^4V[=G<N,$ [/]JW]JGX(?L5_ ;7_P!I#]H;QA'HOACP[;>9=3;=\US*
MQVQ6T$8YFGE<JB1CEF8=!DCYI_X)E_ K]H#XM_'?QI_P5F_;)\&S>$O&GQ,\
M.6WAWX<_#>Y;,_@KP7#,;F&VNC_S^W,S"YG3_EFVU<*=T::7_!5?_@F+\=_^
M"A_C#X1^+?@_^VY#\)6^$OB&X\06%G=?#"V\3V]]JY6-;6\D@N[J.#?;*LWE
M[XY,-<,PP0*ZC]BO]E7_ (*4_ _XJWWBW]L3_@J[_P +S\,3Z!+:67A'_A16
MC>&?LM\TT#I>_:K&5I'V1QS1^21M;S]Q.46@#S'XF>$/"?@'_@NG^SAX-\">
M%].T71]._9\\;0Z?I6DV4=M;6T8O=,PD<48"HO)X  K[NKQ'Q[^QO_PF_P"W
MW\/?VY/^%C?9?^$#\ ZYX9_X1?\ LC?]N_M&:UE^T?:?.'E>7]FQL\IMV_.Y
M<8/MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cah-20211231_g6.jpg
<TEXT>
begin 644 cah-20211231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?!'Q \+/H/BOPW^T9HOQ#T4ZAXHE-M]I:XEC(BF=9I&2XCBEE9K<1*B@ ,"
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M(^(/QHLK/6;OPOJ@^SZYIDK6A5&="5EA=)"002"'R#S7Z?5_.=^U7J%_J?\
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MA>)J-G-I%W:V46M;8YYC;LIAO-.23STE^[*HWD(BKA5\GO\ _@IW^W?\0_\
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MIVG6.D:?!I.F6J06UK"L-O#&,+&B@!5 ]  !0!-1110 4444 %%%% !1110
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MX2_'W]E_2_\ @HWK.I_"CXN>!=;T#PWX.NO"DC0Z!=Z@8$&K2Q_;1'<7$4$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L+XI:A>Z3\,O$>JZ9=/!<VNA7DMO-&<-&ZPN58'U! -;M<Y\8_^21>
M*O\ L6[[_P!)WH _GJ_X)@?"3_@X5_X*C?LB:K^UM\"?^"P6N:3+I?B:]T:T
M\,^)M7N@UW<6UO!-DRI&Z*K^>JC<I ()/%?>7_!"W_@MK=?'/_@F;XI^/O\
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M0/QKM?A;H\?BWP[\8]2\.Z'KZVH^TV.E-%"YLXW_ (8BR@[?45^U5 !1110
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M=[$I,@AE66".= 2X1T7.X#G\XO '_!J?\0;_ %CPE\'?VI?^"I'COXD?L^>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:^A-+_Y"5O\ ]=T_]"% 'T31110 4444 %%%% !1110 4444 %%%% !1110
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MX8,HSY_VT/A;_P ->6W[&FG6E]>>(WTE[V]O;<1FULB(FF$$A+;O,,85L!2
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MOA_X ?6H-0O;/1X[MKVXNKV:W)B\V:X9"J*241-K<@$_8&E_\A*W_P"NZ?\
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M]74 ?LG\(_\ DE/AC_L7K+_T0E=#7/?"/_DE/AC_ +%ZR_\ 1"5T- !1110
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ML:?N5^^/FKU+Q]_RG0^'/_9MGB'_ -/-A0!4_;"^&'["'[(WC#XE_P#!0?\
M;>TZ7QM%XYT_3_#MAI&L>#O[:&EVUM9SL=.L8DB?R8[@I-/(\A1-^2TBC%=#
M_P $3_#OB7PQ_P $P?A3I_B77+2^,NF7EUI8LM9CU".STZ:_N9K.T^T1LRR&
M"W>*$@$[#&4_@K+^)/\ P59^&G[*G[4?Q"^!7[>=SI_P\\.V=A9:I\+/%<UA
M=RV_BG3WM_\ 3(]Z*ZFZ@N,QF%0&964A3G)C_P"")G@3Q5X3_9+\0^+-5\"7
M_A3P_P"._BSXE\5_#[PGJ5J;>;1_#U[=[[* P_\ +$%0TH3^[*#WH ^Z_@Q_
MR/<'_7"3_P!!KV6O&O@Q_P CW!_UPD_]!KV6@ HHHH *\S_;*_Y-9\=?]B]/
M_(5Z97F?[97_ ":SXZ_[%Z?^0H _)>BBB@ HHHH **** "OTF_X):?\ )K*?
M]C#>?RCK\V:_2;_@EI_R:RG_ &,-Y_*.@#Z.HHHH **** /,/C__ ,A+3O\
MKA)_Z$*\WU/2],UO3I]'UG3H+NTNHFBN;6ZA62.5&&&5E8$,"."#P:](^/\
M_P A+3O^N$G_ *$*\^H **** "BBB@ J?2_^0E;_ /7=/_0A4%3Z7_R$K?\
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MB=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B: /Q]'@W4 ,#5]! '0?\)-8_\
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M5WPS_P"B=Z%_X*(?_B: .%_X;G_9'_Z+UH/_ '^?_P")KAOVE_VMOV:OB#\
M_%G@KPA\:=!N]3U/1I8+*V^U^7YDAZ#<X"CZD@5[G_PJ[X9_]$[T+_P40_\
MQ-'_  J[X9_]$[T+_P %$/\ \30!^/W_  AVH_\ 08T'_P *>Q_^/4?\(=J/
M_08T'_PI['_X]7[ _P#"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__
M !- 'X_?\(=J/_08T'_PI['_ ./4?\(=J/\ T&-!_P#"GL?_ (]7[ _\*N^&
M?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$T ?C]_P (=J/_ $&-!_\
M"GL?_CU'_"':C_T&-!_\*>Q_^/5^P/\ PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9
M_P#1.]"_\%$/_P 30!^/W_"':C_T&-!_\*>Q_P#CU?;G[ _[1GP(^"OP#7P5
M\3?BUH.F:F-9N9S;?V@DW[M]FT[HBR\X/&<U]2_\*N^&?_1.]"_\%$/_ ,31
M_P *N^&?_1.]"_\ !1#_ /$T <+_ ,-S_LC_ /1>M!_[_/\ _$T?\-S_ +(_
M_1>M!_[_ #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
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MXT^)7@NZ\3VOP^\/> [>?7-'L[>Z-M(+ZT-TKQ.&VM\NY0LB$D$XKK_V-_\
M@L7\"?VL_CO+^RMXM^!?Q:^"_P 3FTA]5TGP1\:O!9T6[UJR3/F3V1$LB3A
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MA9K.Z@;YH9XR1E3D$,K*65E8^JT %%%% !1110 4444 %%%% !1110 4444
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M)?"_3O'=OXDU/7?$;PM#;7EW=6JB!(;96>2,+M?><$,&)0 _1"BBB@ HHHH
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MO#F\Z?IBI$(+'2;5G^:2&U@&T,V3EV&6 #'ZMH **** "BBB@ HHHH ****
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M/2:UUGQ1>7*7<]RD4B[=D4L4"Q,5! MHWPK=/.?^"67_ ">O^W'_ -E]L/\
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MCVG[)?AV41!W:1V:2:Z>25V=F9I)&9V9B22:ZSX\_P#!'[]O+QE_P4&\;?\
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M^R-_V[^T9K67[1]I\X>5Y?V;&SRFW;\[EQ@^W4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cah-20211231_g7.jpg
<TEXT>
begin 644 cah-20211231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHW9)WF.GV2O\QW"=A_&0>]\:_LK_ +,W[)W_  >"_LZ^$OV7OAWH/A#2]?\
MACJNLZWX8\,6,=I8V>H-HGB.W+1V\($=OOAMK=BB*H)R^/GR0#]*/B#_ ,%H
M/^"6?PL\/ZGXF\>_MM>"["VT?Q1/X<U!#<RR3QZI!CS[801QM*YCW+O95*IN
M7<1N&;?Q'_X+"_\ !+_X2ZSX0T+X@_MP_#_3[CQYIL&H^%S_ &T)8KJSG.(;
MEY8@R6\3G.V29D4[6Y^4X_'#_@E_^PW^RS^T?X3_ ."E_P 7OCQ\%?#_ (MU
MW0/$/BBR\+7VOZ;'<OH;;=6N&N+0N#]GN#(D)\Y,2+Y*A6 + ^2?#_\ 8;_9
M>/\ P:)^._VR=1^#6@WGQ.D\;6UU9^.+K38Y-3LHT\2V.EBVAN&!DC@-NTN8
ME(1FD+$$X( /Z./VF/VN/V:?V-_A<WQH_:?^-&A>"_#(G2"+5-8N]HN)G!98
MH44%YY"JLP2-6;:K'& 2*'[-?[;W[)?[87PJO/C9^S-\>O#_ (Q\,Z:[IJFI
M:3<DFP=$WLD\3A98&V?-MD525((!!!K\%OVYO'7Q,^,7[6__  38^#'B#]F2
MX^/NC6G[*?AWQ7;?"2ZUZ&P@\3ZK/IMPUQYLURK0G:NG6TKI(K"1(VCP?-Y^
MCO\ @F=^S%^V9\'?^"CW[0?Q\;_@FM<?LW?!7XC?!>\@U'P)9>*],OM-T_7+
M:&!H)(H[,IY6]3=LL8B5$%S(!@$"@#] _%7_  7$_P""2W@OP=X>\?>(_P!N
M[P-#I7BJ>:/0;B.[EF:Y\J4Q22&..-GCB60,AE=5CW*PW?*<>#?\' '_  6G
MN/\ @GA^S3X#O?V6OB+X1N_&7Q1UBT.D:C<$7JVWAV2*2276+55S%.,K"B.Q
M9/WX;:XP*_-G_@F!_P $^OV1OB;_ ,&RG[1G[4/Q)^!OA[7?B!;VOB>ZT3Q?
MJFG)-J&CC3+&&:UCLYF&ZV43"1W$97S/-97W+@#FOV]_A[X'\9_\&VW["WQD
M\4^%K.^\40_$!/#,>NW$>ZX72/.UHFRWG_ED3;PG;T_=KZ4 ?TB_!#XX_"7]
MI+X6:1\;?@5X[L?$WA/7HI)-'UW3'+07:)*\3E"0#Q)&Z].JFOQ(^-M[_P %
M</V\O^"\O[1/[$'[(W_!2SQ)\*=#\ Z/::WIEA-?7!L8H?LNEQM!&D(RA:6\
M+YY'WO6OV[^#/P7^%/[/'PSTKX-? _P%IOA?PKH<3QZ1H.D6XBMK1'D>5PBC
MH"[NQ]V-?S__ !!^#G_!33XV?\'+W[5GAC_@EK^TAX5^&/C6'PQ9SZ_K7BQ<
MPW.E?9=%1X(S]@O")#,T#@A%.$;YQT8 ^G_^".'[;?\ P4C^ ?\ P55^)7_!
M'S_@IC\<+7XEW&A^$3X@\.>,TVR/#LBMK@ 3>5'))#+;7)9EE!:.2#:IVL2?
MO'P;_P %C?\ @F%\0_%O@GP'X&_;0\&ZMK'Q%U-M/\&:?8W,LDFI7(E$.P )
M^[W2GRU,FT.P95)*D#Y;_P""57_!$7X__L<_'KXH?\%"O^"@/[4%I\5OC7XU
M\,7&EC4-,$SVME;,L9DD,L\<;22%;>")%6*-(8HRBA@X"?)W_!J!^P;^S/XA
M_8.\5_\ !0/Q;\$]/\3?%;PE\1M4_P"$&UB^>5GTT6.E6TD$<**X4%IKF<L<
M'=N3NBD 'ZM_M"?\%?O^"9G[*GQ>'P%_:!_;,\&>&O%P9%NM%NKQY7LBX!47
M31(Z6I*D-B9D^5@W0@U\_?\ !Q=_P4[7]B7_ ()IW?B;]G;X_:9HGQ#^)45O
M%\--4TVY2>:]L?M%H;Z\L7 :-MMM<)B4'Y1.KH<@$?$__!O;_P $U?V'/^"B
M/_!,KXQ?M.?MJ>!M)\;_ ! \?^/->@\3>/-?(EO]#*VT,_GV\I.;:827#W+2
M+AG\Q0Q**%KY/A@M_CU_P:4W?Q$^,GA:#5M>^#GQQE\-_##Q!J,1>YTO2;R7
M2[BYB@D/(C>25XR.FV%5& H% 'V9\ ];^.MC^RM^SOX_\*_\'$__  D4GBWX
MTVDGB6^\:ZOJ4;ZB_P!FTTW/A2V?-TUP\<DCY,AB0_:%X7FOHOQ5_P %\_!V
ME_\ !=M/V!M8^,G@_0_A+X=T"YTS5-4,3/<ZGXO:6.!=.DE8'RS%+OC$<8&Y
M]Q9V&T+\K_\ !6/X ?!;]G7X!_\ !-WPK\#?AII/A;3M7^+^A:SJ=GH]L(H[
MG4+B#2#/<N!UD<JNX]\"NM/['G[+WBW_ (.\?$/@CQ-\#?#U[I,WPO'C*33[
MBQ#1-K[&"X;4B/\ GN9F:3?_ 'B30!^WU%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'S1_P %:_\ @G=_P])_8MUG]D#_ (7!_P (+_:^KZ???\)#
M_P (_P#VGY7V6=9MGD?:(-V[;C/F#&<X/2O!/VD_^#?;P)^T?^W-^SI^VKK'
M[0'V"3X$>'_#NF:CX;'@X3+XH_L>Z:YMY&F^UK]EW.V&4QS?* ,G%?HE10!\
M8? 3_@CIX-^%7[8G[3W[3/Q$^*\7C/P_^TWIRZ=KG@.?PR;1-.LS')'-"UT+
MIS<B1)&4D1Q$9KX_L_\ @U0^*#:78_LL:]_P56\=7O[,&F^+O[=M/A$=""7*
M_O6D^SB[%QY:G<[L9%AV[V:00ASNK]CZ* /@;_@J?_P0XT;]NGQ5\,?CS^S+
M^T-J?P.^+/PBLH],\(^,M#LGN%_LM"3':.J312+Y1>0HZOC$TJ.KAP5YS]@G
M_@W_ -3_ &+O^"@=O_P4,\7?MR^(_B;XKO\ P5=:7XT;Q3X=/VK7-4N&!DOQ
M=?:W\B)8TBBCMO*?8D2CS#7Z.44 ?G]^QW_P0(^%/[/G[#OQR_80^-OQGF^(
MOAGXX>+;S6]1O;7PV-(FTII8H!$(@;FY#RPRV\<R2G WJN4(!S\__ G_ (-9
M_B%I'Q(^'>B_M>_\%,_%WQ8^#/PDUE-1\#?"B\T66WME,;AXH9#)>31QQ# 1
MECCRT99%:(&OV!HH _,GX[?\&_?QGUG]O?X@_M@?L=?\%*?%GP5T?XRQ*GQ4
M\.:#X>2XNKL$#SC:733*(&D(9UD,9>!Y9"C,K>6*7P\_X-L;?X9?\$M_C=_P
M2W\.?MFRMX=^*_Q"M/$^B^(KOX?![CP\L%UI\OV:2,7X%Z6CTZ"/S0T&"6?8
M?N5^H=% '#_LR?!K_AG/]FWX>_L]_P#"2?VS_P ()X'TGP[_ &O]C^S_ &[[
M%9Q6WG^5O?RM_E;MF]MN[&YL9/P!_P %'?\ @W<UG]IC]L*Z_;^_89_;>\4?
ML^_%'6;);?Q3>^'H9S#JA6-(O-62VN;>6W=XXXUD7+I*45BJL69OTWHH _/_
M /X),?\ !!KP1_P3K\<^./VA_CI^T%K/QO\ BW\1=-?3?$?C/Q19LJBQE9'G
M@"333R3-*T<?F2RR,66) %0;@WSIXI_X-5OB5;6OB7]FCX+_ /!4KQKX3_9F
M\8>*5UK6O@\- ^TR1XD23[/'<M<A& ,<>)&B_P"6<;2)*T88_L710!^-W_!Q
M!\'?^"9OPR\!_LR?LN?&_P :?$CX,ZGX; L/@K\:_".AQZC9^&8K0V4$L6HL
M;N"X8*/LMQYD9\U6B,@<'>K_ #1_P3M^#GP2?_@Y=^"E[^S!^V9X@_:3E\,?
M"_6=:^,'QBUC4I;YK_59=/U:R!$CO)MACBNM+A51)(JE@N\MD#]\/C_^S3^S
MY^U7X";X7_M)_!CPWXY\/M<+.NE>)M(BNXHYE!"RQB0$QR %@'7# ,1GDU@?
MLP?L*_L=?L66-_8_LI_LV^$/ 8U7;_:EQX>T>.&XO N=BRS8,DBJ22JLQ"DG
M &30!\Y?L4_\$8O^&/? 7[4/@C_AI'_A(O\ AI+6]5U#[5_PA_V3_A'?ML5W
M'LV_;)/M>S[5G.8=WE]%W<<GH7_!!'^Q?^"'>L_\$9O^&K?-_M;4EN_^%D?\
M(+M\K&O0:MM_L_[<=W^I\G/V@?>WXXV']$** /ST_;$_X()Z3^T?^SC^SWX4
M^&?[4>K_  ]^,7[-GA/2]%\#?%[1-&P]REI:6\#>=:K.&57>W610)F,1=QF1
M78-I?\$X_P#@B5K?[(/C?XL?M)_M(_M<ZU\8_C7\7]"?1M<\>:II7V6*RL2B
MJ(HH/.<N?W<&6+J D$<:+&H8O]\T4 ?!W[(O_!$K_AE;_@D9\1?^"5__  TU
M_;W_  G]CK]O_P )W_PAGV7[!_:=LL&[[%]LD\WR\;L>>N_I\O6N)^//_!O+
MIGQG_P"".'PU_P""6#?M136VK_"OQ NM^'?B+'X5\M)[H37[%9+(73,B&*_D
M3Y9R0R(_."A_2>B@#R?]AOX%?&/]FG]E?PG\$OV@/VB]3^+/C#1(;H:W\0=8
MMY(KC57ENYITW+)-*P$4<J0*2YRL*G"YVCQ/]G/_ ().?\* _P""M/QD_P""
MH_\ POW^UO\ A;?A>/1_^$&_X17R/[*V?V=^]^V_:G\_/V#[OD1_ZWK\OS?8
ME% %;6=/_M?1[O2O.\O[5;21>9MSMW*1G'&<9KY7_P""-7_!+W_ATA^R3>?L
MM?\ "\?^%@_:_&5YKW]N_P#",_V3L\^"VB\GR?M-QG;]GSOW\[\;1C)^L:*
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MB&TC*3ZM':(8[83X.)#&A*JQ&0O&<5V5 'R)^WS_ ,$K/^&XOVS?V;OVNO\
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M/+M[822O*^T>K2.[DG)+,2>M=90 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17,>/_B1_P@US
M;6_]C?:OM$;-G[1LVX(']TYZUSW_  T'_P!2C_Y/_P#VN@#TBBO-_P#AH/\
MZE'_ ,G_ /[71_PT'_U*/_D__P#:Z /2**\W_P"&@_\ J4?_ "?_ /M='_#0
M?_4H_P#D_P#_ &N@#TBBO-_^&@_^I1_\G_\ [74EK\?/M-S';_\ ")[?,D"Y
M^WYQDX_YYT >B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YA\?_\
MD):=_P!<)/\ T(5Y]7H/Q_\ ^0EIW_7"3_T(5Y]0 4444 %%%% !4^E_\A*W
M_P"NZ?\ H0J"I]+_ .0E;_\ 7=/_ $(4 ?1-%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH *GTO\ Y"5O_P!=T_\ 0A4%3Z7_ ,A*W_Z[I_Z$* /HFBBB@ HHHH ****
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MH **** "O#/B9_R/>I?]=Q_Z"*]SKPSXF?\ (]ZE_P!=Q_Z"* /#OVQ?VM/
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MM^S-I'Q^^/&A7WAC4=4TQ'B\'7D3"_DORF6LXT8!B0P(WL  I#-MS7"_L?\
M[6?[1'[37[$_B;XXZ1X1T.^\<6VH:C;^'-&AA:*UGDBCC:&)]\RDY9\$^8F?
M45V'[,OB3P-^W+^S]\./VC_BC\.=-N-7M#/=6<,T;/#97\4TEM+-$C$CEH2R
M%MQ3(P<C->6?\$.?^3*)/^QSO_\ T7!0!YOX]_;U_P""MOPM\3^&?!_Q!_9?
M^'>GZCXOU06'AZS"R32WDV5#!5AU-R%7>NYR JY&2*]8_:F_:W_;.TKXW>(/
MA/\ LE_!32;ZS\$>'DU?Q+K?BF"58KL&,2>3;'S(E?"G!P6)8,/EV\P?!@G]
MI+_@J%\0OBIJF9]'^#FDP^&O#<;?=COY]_VF4#IO!6YC)Z[63/05ZM^UKX$\
M0?M._"[6_@1\$/VB;'POXC@=6UM;*99Y_LSQ2K]EG2.19($E8KER#\JMA6Z4
M ;7['W[15I^U7^SQX>^-]OHO]FS:K%+'?6 <LL%Q#*T4@5CU0LA93UVL,\YK
M]<O^"6G_ ":RG_8PWG\HZ_$+_@DK\3M ^(_[&&BZ?H/@FUT'_A%M0N-$O;2R
MD9H9;B/;,\ZER6)D\\.V2?G9L'&*_;W_ ():?\FLI_V,-Y_*.@#Z.HHHH **
M** /,/C_ /\ (2T[_KA)_P"A"O/J]!^/_P#R$M._ZX2?^A"O/J "BBB@ HHH
MH *GTO\ Y"5O_P!=T_\ 0A4%3Z7_ ,A*W_Z[I_Z$* /HFBBB@ HHHH ****
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MH^*&@ZK=6.LO/=1?VI%!LC,3*#F8H#R0, DU\A_\(=J/_08T'_PI['_X]7[
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M?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\
MW^?_ .)KRCQS^T[^SYK'BR^U/3?C!H,D$TNZ-_MRC(P!T.#7TC_PJ[X9_P#1
M.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- 'RS_PT5\"?^BLZ#_X,4_QH_X:
M*^!/_16=!_\ !BG^-?4W_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40
M_P#Q- 'RS_PT5\"?^BLZ#_X,4_QH_P"&BO@3_P!%9T'_ ,&*?XU]3?\ "KOA
MG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q- 'RS_P -%? G_HK.@_\
M@Q3_ !H_X:*^!/\ T5G0?_!BG^-?4W_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_
M -$[T+_P40__ !- 'SS\,OVIOV=?#WBR+4]8^,>@PP+$ZL_VT-@D8'"Y->F?
M\-S_ +(__1>M!_[_ #__ !-=U_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \30!PO\ PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\ /_\
M$UW7_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q- '"_P##<_[(
M_P#T7K0?^_S_ /Q-<-^TO^UM^S5\0?@'XL\%>$/C3H-WJ>IZ-+!96WVOR_,D
M/0;G 4?4D"O<_P#A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: /
MQ^_X0[4?^@QH/_A3V/\ \>H_X0[4?^@QH/\ X4]C_P#'J_8'_A5WPS_Z)WH7
M_@HA_P#B:/\ A5WPS_Z)WH7_ (*(?_B: /Q^_P"$.U'_ *#&@_\ A3V/_P >
MH_X0[4?^@QH/_A3V/_QZOV!_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X
M*(?_ (F@#\?O^$.U'_H,:#_X4]C_ /'J/^$.U'_H,:#_ .%/8_\ QZOV!_X5
M=\,_^B=Z%_X*(?\ XFC_ (5=\,_^B=Z%_P""B'_XF@#\?O\ A#M1_P"@QH/_
M (4]C_\ 'J^W/V!_VC/@1\%?@&O@KXF_%K0=,U,:S<SFV_M!)OW;[-IW1%EY
MP>,YKZE_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V
M1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_ *)WH7_@
MHA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_ .)H_P"&
MY_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@H
MA_\ B: /"?B_^UI^S7XIOK*;0OC1H,ZPQ.LA^V!<$D8^]BN/_P"&BO@3_P!%
M9T'_ ,&*?XU]3?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-
M 'RS_P -%? G_HK.@_\ @Q3_ !H_X:*^!/\ T5G0?_!BG^-?4W_"KOAG_P!$
M[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !- 'RS_ ,-%? G_ **SH/\ X,4_
MQH_X:*^!/_16=!_\&*?XU]3?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\
M%$/_ ,30!\L_\-%? G_HK.@_^#%/\:EL/VC_ (#0WT,TOQ;T$*DJLQ_M!. #
M]:^H?^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_
M *+UH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?
M_B:/^%7?#/\ Z)WH7_@HA_\ B: ,OX9_M!?!?XRWUUIGPO\ B)IVMW%E$);J
M*R<DQH3@,<@<9XKL:S]&\)>%/#DKS^'O#.GV#R+MD>RLHXBX]"5 R*T* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.ZNK6QM
M9+V]N8X888R\TTKA510,EB3P !R2:_/[4?\ @O\ ^%/%=WK'C7]ES_@GK^T!
M\8_A9X<OI[;5OBSX%\)1/IET8&*SR:<DTJ27\<95@SJ%'RG&1AB ?H+17@UM
M_P %+_V,[[]A*;_@I#8?%ZWG^$UOHC:E+KL5LYE7$H@^RF#'F"Z^T$0>21N\
MTA>]>=_LU_\ !8/X<_''X^>'/V<OBK^RE\9_@KX@\>:=<WWPW;XM^$X;"W\3
MQV\?G30P20W$NRY2+,K02;6"XY)(! /KVBBB@ HHHH **** "BBB@ HHKQO]
MN+]NSX!_\$^_@VGQE^/6H:G+'?:I#I/AKPWX=TXWNK>(=3FSY-A8VRD&:=\'
M )50 2S <T >R45\-_"/_@MYX9OOC)X5^#7[8?[$GQC_ &>I?B#J2:?X \1_
M$S0XDTG5KU_]58O<PR,+6[D_AAD')X+ X!]1_;-_X*8_#S]DCXI>'OV>/#7P
M.^(OQ:^)_B;1IM9L/A_\+]#BO+VUTJ*3RGU"[>:6**VMS+F)79LO(-H!Y( /
MI.BO&_V(?VXO@]^WI\)[WXG_  ITOQ#HMUH?B"YT'Q=X/\8Z5]@UGPYJUOM\
MZQO;?<PCE4.C?*S*0XP<Y ]DH **** "BBB@ HHHH ***\/^ 7[>7PN^/7[4
M7Q8_8[A\*>(/#7CKX1W5H=5TSQ'#!&-6TZZ0O;:G8M%*_G6KC )(5D9E5U4D
M"@#W"BOF3XW_ /!4#X?_  K_ &A_&G[,'P^_9_\ B5\4?%GP\^'4/B[Q=8_#
MC18+XV,=Q,(K73]KSH[WTZGSD@53F(%R0 <?/7_$1GI'_"U_^%$?\.B_VQ?^
M$U/A[^WAX3_X5;;?VC_9?G_9_MWV?[;YGD>=^Z\W&W?\N<\4 ?I!17PS\9?^
M"XWAOX.:I\-O!4W_  3P_:2U_P :?$KP7=>)[7X?>'O =O/KFCV=O=&VD%]:
M&Z5XG#;6^7<H61"2"<5U_P"QO_P6+^!/[6?QWE_96\6_ OXM?!?XG-I#ZKI/
M@CXU>"SHMWK5DF?,GLB)9$G" $LN5;"N0K*CE0#ZWHHHH **** "BBB@ HHK
M@OVHOCO!^S!^SUXO_:'O?ASX@\66O@W1)M6O] \*PPR:A<VT(W3&%)I(T=DC
M#R%2X)"$+EB%(!WM%>=_"?\ :J^!WQD_9=T?]L?PGXWMD^'^L>$1XE77+V01
MI:6 @,TK3\D1M$JN)%)RC1N#RIKY9/\ P7"36O@WX%^/'PM_X)??M3>.O#GQ
M"TVYU'0;KP9\.[:_:.SCN7@BFG"7?[GSPGG1*QW-$R/@!A0!]U45\%_L:?\
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M^('BZZU/3M-TO45U:1PVIZ!J%Q<1PR00V-LL*(&66VFF#; 1M'MG_!,OQ/\
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MMS)'$F$C<Y=U'&.I H J_P#!(K]DOQO^SQ^SQ?\ QB_:"FAOOC/\;M;?QO\
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MZBG44 ?BCXH_97_:&\ _M6>(_P#@W1^'4DEC\ _BOXHC^)]CX@M=0\N;P_\
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MMDV/A_P5\6?@3XFU'0_C3I=@7@TZQ$'F30:G#YSNZV4]JOF)(S$$Q2D$J :
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M<[/ \JP137=J;N976^MYC*[ H\1A8,=OEL2 ?H117R=_P48_X*&ZY\!OV>O
M-W^QM::#XW^*/QUU_3=%^!^F7I>73]1:Z"3R:E/Y3JYLH+0M.\BD ;H\E0V1
MQGQ@_:B_X*8?&#]K3Q#^Q/\ L'6WPITR]^$_@W1=0^*WQ*^)NBZC)9WNK:C"
M\MM8:=96LP94:.%I9)'DDV+($^\H,@!]R45\B_L??\%1=!\:_L6^/_VC?VXH
M=!^&>L_!#QMJ_@WXSM97<L^E66K:=)$DDEFY#2RPS+<6S1)AI"TXC&\X+9O_
M  2)_P""F'CO_@I;J/QM\8:_\+KGP?X<\'_$&VTKP+H^KZ=);:H=*DTVWN8K
MB]5V.)9O,\\*H 1)47+[=[ 'V91110 4444 %%%% !17B'_!2C]HWQY^R'^P
M5\6/VG/AA8Z9<^(? _@N\U;1[?6;=Y;62>)<J)4C=&9/4!E/O7RM\.]3_P"#
MG#XE?#_0OB-HWCS]B>&SU_1K74K2&ZT;Q4)8XIXEE57"L0& 8 X)&>YH _1B
MBOD3X5_MR_'#PA_P5+\5?\$\OVL=)\.6MCXF\)0^*_@%XET.QFMQK=I""NIZ
M=<&6617O+=_G&P)N@0R,J[E%9\7_  4=^(7B_P#;A^,GA3P%H^DR? ;]FSP%
M/<_%GQ4--EN-0U'Q.('NCI6GNLJQXMK5-T^4=A*1$0FX-0!]ET5^7>J_\%+_
M /@KA\&OV9_#/_!5/]HGX3_!BV^ .NS:3J6O_#C1AJ7_  E?ASPUJ5Q#%;7Y
MO))/L]S=(MS!)+!Y2#:2!L.XI[7\?OVJ?^"BWQN_;4\:?L:_\$Y=$^&'A^V^
M$_A[2;_XA>/?BWI^H7<-SJ&I1R3V>FV-O9R1DCR(]\L[,VW?M"@@;P#[9HKY
MT_X)D?MG>.OVT_@)KFM_&7X?Z?X7^(WP\^(&K^!/B7HFBW3SZ?#KFFR*LSVD
MC_,UO(DD,J;B2HDVEFV[F^BZ "BBB@ HHHH ***^&/\ @HS^UM_P4:\(_MU?
M"3]B3_@GR_P?M=2\?>"-=U_4M1^+6FZE-;Q#3Y(%V1M82AE)64\%&R1U% 'W
M/17Q/\/=+_X.$]-\/^-K[XR^,/V4KZ[A\#7TG@*U\&:-KY>;Q"C1/:Q70NY8
MT^RNJS1NRN'5I(V&0K [G[+O_!6SX1?%+_@EM=_\%%OC4B>&'\#Z'>Q?%?PZ
M%*3:+K^G_NKS35CD.X2//L$,;'>RW$(/+4 ?7E%?GA_P\&_X*:0_LQ_ +PO+
M\$? $'[1G[3&NW\_A?0]6L[ZWT#P3H,%LU\TVI[96GN+B&S\DM&K1%I9B@4&
M+:_I7[%/[7O[9-G^V=XI_P""=/\ P4%T;P#=^-]/^'L'CSP7XU^&<%U;Z=KF
MAM>_89UGMKIW>WN8;DQJ0&*NL@( QEP#[%HKX&^"O_!:;P]^UE_P5AT7]B_]
MF+1X]8^%MMX,\076L_$B;3Y1;Z[K-C+:(UOIDQ(26"V\XK+* PD>4!<*@>3[
MYH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K\X/\ @OYX4^,OCGXI_L>>$OV>OBO;>!O&M_\ M -%X<\6WFB1ZE%I=Q_9
M-V1,UM+\DP !&UN.:_1^O"?VN_V*?^&JOB_\#/BM_P ++_L'_A2_Q(_X2S[!
M_8WVK^V/]#FMOLV_SH_L_P#KMWF;9/NXV\Y !Q'[$7[-W_!5?X1?%R\\3_MN
M?\%)= ^+WA&709K:S\,:7\)+#0I(+]IH6CNC<6_SLJQI,GEG@^:#U45\D_\
M!:C]B^3Q5_P4/^#5O\,OB=?^#],_:TD_X5C\>[+2H\-KVC:>8M3C=6!'EW+6
M]O-9&7D^3,%^[N#?K'7A'[5?[%'_  TW^T%\!_CM_P +,_L3_A27C:\\0?V5
M_8WVG^VO/L)+3R/-\Y/LVWS-^_;)G&-HSF@#TOQ-XF^#?[+OP3N?$OB?5-(\
M'>!/ OAX-/<3%8++2=.M8@  !PJ)&@55 [  $X%?%7[#^B_%/_@IC^V;I?\
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ML;^VO^%S^/H/$W]G?V1]F_L?R]/M[/[/YGG/]HSY&_?MCQOV[3C) /;J***
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743876170616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,061,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717069576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 45,457<span></span>
</td>
<td class="nump">$ 41,541<span></span>
</td>
<td class="nump">$ 89,425<span></span>
</td>
<td class="nump">$ 80,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">43,841<span></span>
</td>
<td class="nump">39,765<span></span>
</td>
<td class="nump">86,167<span></span>
</td>
<td class="nump">77,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">3,258<span></span>
</td>
<td class="nump">3,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">2,265<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="num">(950)<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="num">(535)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain/(Loss) on sale of equity interest in naviHealth</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(loss) before income taxes</a></td>
<td class="num">(973)<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="num">(604)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 629<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in shares)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income (Loss) from Continuing Operations, Per Diluted Share</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4908<span></span>
</td>
<td class="nump">$ 0.4859<span></span>
</td>
<td class="nump">$ 0.9816<span></span>
</td>
<td class="nump">$ 0.9718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743718185080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717213032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 3,161<span></span>
</td>
<td class="nump">$ 3,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">9,406<span></span>
</td>
<td class="nump">9,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">14,941<span></span>
</td>
<td class="nump">14,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">4,339<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">31,847<span></span>
</td>
<td class="nump">31,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">8,599<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,680<span></span>
</td>
<td class="nump">44,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">24,759<span></span>
</td>
<td class="nump">23,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,669<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,729<span></span>
</td>
<td class="nump">27,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">9,607<span></span>
</td>
<td class="nump">9,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized&#8212;500 thousand shares, Issued&#8212;none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at December&#160;31, 2021 and June 30, 2021</a></td>
<td class="nump">2,721<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common shares in treasury, at cost: 50 million shares and 36 million shares at December&#160;31, 2021 and June 30, 2021, respectively</a></td>
<td class="num">(2,883)<span></span>
</td>
<td class="num">(2,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 43,680<span></span>
</td>
<td class="nump">$ 44,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717219832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743712993704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 2,789<span></span>
</td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Sep. 30, 2020</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">$ 2,760<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2021</a></td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="nump">$ 2,666<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">$ (51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(800)<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2021</a></td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Sep. 30, 2021</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">$ 2,666<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (85)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Dec. 31, 2021</a></td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743712913208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain/(Loss) on sale of equity interest in naviHealth</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="num">(1,842)<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of subsidiaries, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchases of investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets', window );">Proceeds from divestitures and disposal of property and equipment and held for sale assets</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">815<span></span>
</td>
<td class="num">(191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(592)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net proceeds/(tax withholdings) from share-based compensation</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,708)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and equivalents</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CashReclassifiedToAssetHeldForSale', window );">Cash Reclassified from assets held for sale</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="num">(246)<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">2,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 3,161<span></span>
</td>
<td class="nump">$ 3,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedToAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Reclassified to Asset Held for Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedToAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from divestitures and disposal of property and equipment and held for sale assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719355832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the six months ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715634296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold the Cordis business to Hellman &amp; Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No</a><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">te</a><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </a><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719056136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and six months ended December&#160;31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three and six months ended December&#160;31, 2021 also included costs related to the divestiture of the Cordis business. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715633176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,989</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,997</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,656</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2021 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2021 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $2.7&#160;billion and $1.4&#160;billion, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2021, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment and perform interim goodwill impairment testing for the Medical Unit. This quantitative test resulted in a pre-tax $1.3&#160;billion goodwill impairment charge related to the Medical Unit, which is included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings. The goodwill balance of the Medical Unit, after recognizing the impairment, was $2.8&#160;billion at December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our determination of estimated fair value of our reporting units is based on a combination of the income-based approach (using a discount rate of 9 percent and a terminal growth rate of 2 percent percent), and the market-based approach. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,317</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,089</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,228</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">552</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,905</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,974</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,931</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,917</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,974</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,943</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $79 million and $113 million for the three months ended December 31, 2021 and 2020, respectively, and $157 million and $228 million for the six months ended December&#160;31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $157 million, $286 million, $262 million, $237 million, and $210 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719087064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract', window );"><strong>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.6 billion and $6.2 billion at December&#160;31, 2021 and June&#160;30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $24.8 billion and $23.7 billion at December&#160;31, 2021 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2020, we early repurchased a total of $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt during the six months ended December&#160;31, 2020.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2021, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LongTermObligationsandOtherShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715551000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 during the six months ended December 31, 2020 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. As a result, as of December 31, 2021, we had an accrual of $20&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,400 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#8220;Proposed Settlement Agreement&#8221;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement includes a cash component, pursuant to which we would pay up to approximately $6.37&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against us after the Proposed Settlement Agreement becomes effective.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As contemplated under the Proposed Settlement Agreement, in September 2021, the three distributors determined that a sufficient number of states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which was the subdivision sign-on period. The subdivision sign-on period ended January 26, 2022. Each participating state will now make a determination as to whether a sufficient number of its political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. Following that determination by participating states, each of the three distributors will independently determine whether a sufficient number of subdivisions, including both those litigating and those that have not sued, have agreed to participate in the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed to execution. This process is currently contemplated to end in February 2022. The Proposed Settlement Agreement remains subject to contingencies. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the required contingencies are satisfied, the Proposed Settlement Agreement is expected to become effective in April 2022. During the period between the satisfaction of contingencies and the effective date, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Proposed Settlement Agreement in each participating state and dismissing lawsuits of participating states and subdivisions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors have entered into a settlement with each of the states of Florida, New York, Ohio and Rhode Island and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, these states and their participating subdivisions will become a part of it. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national distributors, entered into a term sheet with the Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a bench trial in the case brought by the Washington Attorney General against us and the same two other national distributors began in November 2021 in Washington state court. Trials are inherently unpredictable and it is possible that the outcome of these trials, either individually or in the aggregate, could materially negatively impact our financial results, cash flows or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68&#160;billion accrued at December&#160;31, 2021, of which $480&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the six months ended December 31, 2020, we recorded total pre-tax charges of $1.02&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings.  </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">businesses and individuals alleging personal injury. Private parties had brought approximately 464 lawsuits as of January 25, 2022. Of these, 147 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial in a case involving 21 plaintiffs is scheduled to begin in state court in Georgia in March 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 25, 2022, we are named as a defendant in 443 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,750 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 32 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had a total of $554&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.09&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Action </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related requests and cannot predict the outcome or duration of the investigation.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $13 million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings during the fiscal year ended June&#160;30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div>In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715645672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Goodwill Impairment Charge</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we recognized a $1.3&#160;billion pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $92&#160;million for fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect of the goodwill impairment charge during the three months ended December&#160;31, 2021 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2022. Applying the higher tax rate to the current quarter loss resulted in recognizing an interim tax benefit of approximately $1.0&#160;billion, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months and six months ended December 31, 2021 and prepaid expenses and other assets in the condensed consolidated balance sheets at December 31, 2021. This interim tax benefit will reverse in future quarters of fiscal 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended December&#160;31, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $10&#160;million and $19&#160;million during the three and six months ended December&#160;31, 2021, respectively. The tax effects of these matters during the six months ended December 31, 2021 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $38&#160;million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420&#160;million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a U.S. federal income tax refund of $974&#160;million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have a current asset on our condensed consolidated balance sheets at December&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700&#160;million during the six months ended December&#160;31, 2020 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02&#160;billion pre-tax charges for the opioid litigation recorded during the six months ended December&#160;31, 2020, the net tax benefits were approximately $300 million for the six months ended December&#160;31, 2020 and $228 million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million during the six months ended December&#160;31, 2020, and $219 million for fiscal 2021. We have recognized no tax benefit associated with Opioid accruals made in fiscal 2022. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;105.0 percent and&#160;(47.6) percent, respectively. The effective tax rate for the three months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective tax rate. The estimated annual effective tax rate for the three months ended December 31, 2020 included the benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the treatment of the tax impacts of the opioid litigation accrual recorded in the prior year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was 153.1 percent and 259.7 percent. The effective tax rate for the six months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual effective tax rate. The effective tax rate for the six months ended December&#160;31, 2020 included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss and net tax benefit related to the treatment of the tax impacts of opioid litigation charges.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $937 million and $932 million of unrecognized tax benefits, at December&#160;31, 2021 and June&#160;30, 2021 respectively. The December&#160;31, 2021 and June&#160;30, 2021 balances include $854 million and $849 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and June&#160;30, 2021, we had $45 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $20 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million at both December&#160;31, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures </span></div>and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $3 million at December&#160;31, 2021 and $12&#160;million at June&#160;30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715489336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,077</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,077</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719074024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and six months ended December&#160;31, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended December&#160;31, 2021, we entered into pay-floating interest rate swaps with notional amounts of $100 million and $200 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains recognized in other comprehensive income/(loss) were $1&#160;million and $8&#160;million for the three months ended December&#160;31, 2021 and 2020, respectively, and $3&#160;million and $7&#160;million for the six months ended December&#160;31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $17&#160;million gain and a $27&#160;million loss during the three months ended December&#160;31, 2021 and 2020, respectively, and a $22&#160;million gain and a $52&#160;million loss during the six months ended December&#160;31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during both the three months ended December&#160;31, 2021 and 2020 and $11&#160;million and $10&#160;million during the six months ended December&#160;31, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $2 million gain and a $4 million loss during the three months ended December 31, 2021 and 2020, respectively, and a $4 million gain and $5 million loss during the six months ended December&#160;31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December&#160;31, 2021 and June&#160;30, 2021 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,074</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,643</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719374904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repurchased $800&#160;million of our common shares, in the aggregate, through share repurchase programs during the six months ended December&#160;31, 2021. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8 million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3 million common shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(85)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719074024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">285</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive were 5 million during both the three and six months ended December&#160;31, 2021 and 4 million during both the three months and the six months ended December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719343928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,164</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,040&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,236&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,446</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">639</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,457</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,541&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,956&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,197</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,348&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,013</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,615&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,606&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,382</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,360&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,078</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,457</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,541&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">87,223</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,336&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,615&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,606&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $11 million and $6 million for the three months ended December&#160;31, 2021 and 2020, and $18 million and $11 million for the six months ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a $1.3&#160;billion goodwill impairment charge during the three and six months ended December&#160;31, 2021 which was retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $1.02&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended December&#160;31, 2020 which was retained at Corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">426</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">832</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,427</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1) (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,737</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,516</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,680</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,453&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>(2)Medical reflects a $1.3&#160;billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715543224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $2 million and $3 million for the three months ended December&#160;31, 2021 and 2020, and $6 million and $7 million for the six months ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.47&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45.66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $103 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr></table></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.89&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.36&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52.99</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743876156824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the six months ended December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the six months ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715518824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743800874488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,989</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,997</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,656</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2021 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">At December 31, 2021 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $2.7&#160;billion and $1.4&#160;billion, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,317</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,089</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,228</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">552</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,905</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,974</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,931</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,917</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,974</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,943</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715549592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,077</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,077</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715647352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,074</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,643</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719040824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(85)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715643160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">285</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719093784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,164</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,040&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,375</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,236&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,446</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">639</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,457</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,541&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,778</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,956&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,197</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,348&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,013</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,221</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,234</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,615&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,606&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,382</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,360&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,078</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,460</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,546&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45,457</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,541&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">87,223</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,336&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,431</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,615&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,606&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:50.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">426</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(950)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical (1)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">832</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,005</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating loss</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(535)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,427</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1) (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,737</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate </span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,516</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,680</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,453&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>(2)Medical reflects a $1.3&#160;billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743808350248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AdditionalStockOptionPlanDataTableTextBlock', window );">Schedule of Additional Data Related to Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.47&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45.66</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.89&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.36&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52.99</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AdditionalStockOptionPlanDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A disclosure of additional data related to all stock option activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AdditionalStockOptionPlanDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743714952104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717197864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719167096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719236616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717135528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 6,656<span></span>
</td>
<td class="nump">6,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">2,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743714599848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,905<span></span>
</td>
<td class="nump">4,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,974<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,931<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,317<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,089<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743714592184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization of intangible assets - Year One</a></td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization of intangible assets - Year Two</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization of intangible assets - Year Three</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization of intangible assets - Year Four</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DiscountRateFairValueInput', window );">Discount Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TerminalGrowthRateFairValueInput', window );">Terminal Growth Rate, Fair Value Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DiscountRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DiscountRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TerminalGrowthRateFairValueInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terminal Growth Rate, Fair Value Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TerminalGrowthRateFairValueInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743718376008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member', window );">Floating Rate Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743719543896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term Debt and Lease Obligation, Current</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 5,342<span></span>
</td>
<td class="nump">$ 5,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743708685288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>lawsuit </div>
<div>StateAG </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Jan. 25, 2022 </div>
<div>plaintiff </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>lawsuit</div>
</th>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Estimated Litigation Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NumberofStateAttorneysGeneralfilinglawsuits', window );">Number of State Attorneys General filing lawsuits | StateAG</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | GEORGIA | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateMember', window );">Opioid Lawsuits State [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Alameda County [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Other Jurisdictions [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember', window );">DOJ Investigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NumberofStateAttorneysGeneralfilinglawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of State Attorneys General filing lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NumberofStateAttorneysGeneralfilinglawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_DOJInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743711803000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">$ (1,022)<span></span>
</td>
<td class="num">$ (203)<span></span>
</td>
<td class="num">$ (925)<span></span>
</td>
<td class="num">$ (613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="num">(47.60%)<span></span>
</td>
<td class="nump">153.10%<span></span>
</td>
<td class="nump">259.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 9,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember', window );">Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Medical Unit Goodwill Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember', window );">Net Operating Loss Carryback [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income Taxes Receivable</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember', window );">Patient Recovery Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">$ 6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_GoodwillImpairmentAxis=cah_MedicalUnitGoodwillImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743712957032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 1,077<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=117331979&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743708676392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743716396312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 5,643<span></span>
</td>
<td class="nump">$ 6,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 6,074<span></span>
</td>
<td class="nump">$ 6,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743712849032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis=cah_A500MillionShareRepurchaseProgramMember', window );">$500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis=cah_A300MillionShareRepurchaseProgramMember', window );">$300 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="nump">$ 50.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $500 million share repurchase program [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.53<span></span>
</td>
<td class="nump">$ 51.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $300 million share repurchase program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares | $300 million share repurchase program [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis=cah_A500MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis=cah_A500MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis=cah_A300MillionShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis=cah_A300MillionShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743716842232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,396<span></span>
</td>
<td class="nump">$ 1,425<span></span>
</td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (85)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (85)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743715473400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743716955912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Employee stock options, restricted share units, and performance share units (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743716859992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss Related to Litigation Settlement</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743718395448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 45,457<span></span>
</td>
<td class="nump">$ 41,541<span></span>
</td>
<td class="nump">$ 89,425<span></span>
</td>
<td class="nump">$ 80,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">45,460<span></span>
</td>
<td class="nump">41,546<span></span>
</td>
<td class="nump">89,431<span></span>
</td>
<td class="nump">80,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">41,375<span></span>
</td>
<td class="nump">37,236<span></span>
</td>
<td class="nump">81,197<span></span>
</td>
<td class="nump">72,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,085<span></span>
</td>
<td class="nump">4,310<span></span>
</td>
<td class="nump">8,234<span></span>
</td>
<td class="nump">8,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">41,164<span></span>
</td>
<td class="nump">37,040<span></span>
</td>
<td class="nump">80,778<span></span>
</td>
<td class="nump">71,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
<td class="nump">7,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember', window );">Cardinal Health At Home [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717075880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (950)<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
<td class="num">$ (535)<span></span>
</td>
<td class="num">$ (163)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_JudgmentForLostProfits', window );">Judgment for lost profits</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (1,426)<span></span>
</td>
<td class="num">$ (188)<span></span>
</td>
<td class="num">$ (1,540)<span></span>
</td>
<td class="num">$ (1,444)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_JudgmentForLostProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment for lost profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_JudgmentForLostProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743718193288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 45,457<span></span>
</td>
<td class="nump">$ 41,541<span></span>
</td>
<td class="nump">$ 89,425<span></span>
</td>
<td class="nump">$ 80,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">44,382<span></span>
</td>
<td class="nump">40,360<span></span>
</td>
<td class="nump">87,223<span></span>
</td>
<td class="nump">78,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
<td class="nump">2,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">45,460<span></span>
</td>
<td class="nump">41,546<span></span>
</td>
<td class="nump">89,431<span></span>
</td>
<td class="nump">80,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717153048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 43,680<span></span>
</td>
<td class="nump">$ 43,680<span></span>
</td>
<td class="nump">$ 44,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember', window );">Medical Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,427<span></span>
</td>
<td class="nump">24,427<span></span>
</td>
<td class="nump">23,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,737<span></span>
</td>
<td class="nump">12,737<span></span>
</td>
<td class="nump">15,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 6,516<span></span>
</td>
<td class="nump">$ 6,516<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=cah_MedicalUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=cah_MedicalUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743712759992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ExercisablePeriodOfPlansInYears', window );">Exercisable period of plans (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">103,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ExercisablePeriodOfPlansInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The instrument's contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ExercisablePeriodOfPlansInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717151096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743716957048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 68.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">69.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 69.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743712922056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options at period end</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options at period end</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743714620616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 103,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 49.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">49.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 45.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139743717032872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">52.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">52.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 52.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>cah-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20211231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cah-20211231.xsd" xlink:type="simple"/>
    <context id="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a27e14071854942b0925c5b161e2e00_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="idf89a8993ffb426a9d8312715526954c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A500MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica8231a36d054c5eace0ac4a74d6041c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:ShareRepurchaseProgramAggregatePurchasePrinceAxis">cah:A300MillionShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c1ca3e313f8427ea77ad0ab23207095_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7986a43d300d47c7b6781e8e97cd047e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib4dc68631d57443d8738c75aa59831eb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie7dbe5b201c74f1b89a35df6592c99e4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iada0f823a0f947a3a53d2ee1b5d23237_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9db9ab51c3284580bbffafef36fcd2aa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51ee4fa253c140b78f57a286ba3fd59b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c4a82ec00b448529c5c4233322d86fa_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icead1849b2874394884eddb24215c104_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i126ccb95fe4446f895412bf247fc34d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1422fa549c8c4fd78d87a5e7bddef0cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81e9b369a2e249aa9c82e841d358043c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b36454ae8f34474b633982b25f47ddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76f5c033b2b34568b248de95ea9ae8d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc0f360bdd494ffaacb98ba69e7d9980_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c7f983dad174a65a853a11d93cbf864_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i21dcf5c494534e31b313419407cf51a9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia792665ddedb4fd1be35d86aaee95caa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5840b125eaa8414f900e6f2f22ba8df4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i65d4a4c75a9a47f69d54b19dbcb1e52b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3118c657b147452e88b2cb76079e167a_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib353deb7360145ecb2e83ab126e17961_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00621486915144c58fbb572a1f95a310_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b596c976f3b4341a633bdc33702ce6d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i669eb53209e44369b85bd08b8337e1a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4abc0866cbe848d3893f1f444f75cfc0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28be4398d9154a6ca1b5b457f10d7867_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30ee22a4b8ab44809caa91d6c1c1eeaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12e7de7ce1574c48a5037263df2cd692_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id15c5d3332d947399180c64379abbaad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7eb92e4042fd492b81f82838ab7dfa53_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idb4ca91c9613414a94f9900f8909af66_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8ed791e44eac4a27bd9c7d44a85d03fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifeeec8b34c774e7b9466d999568a65a0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2689810533ba4608b106bf844d197fb4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i247ac8c144e2402e9b7a5cdf73e42b35_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72771dd6f35d4ef389cc86b92183c631_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if521936d67844e53ad65faa8fee63ccc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id81fff506366476385ee6cedef0c063c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i09481b076c1d445abdc3ed3a80f5911a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia20d6610e65a457a868d48435b845bbf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i43dfa1a7cdf74ea793edc03f0339f726_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia1620d434ff84017a4abba4b2b674fee_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i056f47607d66400ab28d51e4b4199aaf_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i006f51b5845242aab04f6d1e5bd5574d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25f992d37c9445a39ce463c943d8a4b4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6898a41bdf2840358d646c0919f44974_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f438da6cbd845748e199c85aa4cdde7_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i689ae4253cf44b73ac84db72214af2a4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic6d5f06ee3664cac9f54724c815b9d73_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4761d672de014c8e9dad6c7102688227_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b760199824642c0a8d322009fa28dcc_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i485b4945d9224029a35f582637d5d038_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54300086ab194a77aea92977e16df53b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1db397a74a1042b9aafec1289ddba925_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i066955108bab4e7e95ad3b02cf4ef347_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifa7745fb78df449faba2302b50698592_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief6dedadffb54d5285c2b49eea80de65_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3492d85ea7b24e60910262ee6d3033ee_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie39aff34d5814c78ac189de6dab4b7ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie965b585dfd74a75884609384471b2b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6990beeb1e8488aa56f362d54b5ae9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf07a0233e7740e1b2eaf72c788bc28f_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">cah:MedicalUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e7b338780e74021a81ef74ef08b7a25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77bebd2a91ae417eb4439959bf9f6d31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i823151805e0f490888d034841f637bc5_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i505ef6105727459882cd4fed2648f6c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a15392899d2482fbb95514624452a8d_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a85889e6ab440f18e191494e3590714_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3aa68d96ad1e4049873af142ed3aef39_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5005f9b9f5c748b6b3dc0a951c8577da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab78dc9db493437ebf096a1f66c9842d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9a260218f5c74e0a818560db3bc26ab5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7828cce062bc44f0951fdcd8139d81b9_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88e4b2aae2ad40a09418ad56348b3b01_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01a126ed6a3341d7babdddc3b8c5a1af_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ab62d58a2744c7d96ab48d178c5edc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id11e26319ddf483d88eafb2ba45b91cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7293644d26734b97832a304248e0d4f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8531707da0e64febbba666aed40d8040_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i285548e776cd4b929eae18d3e9002181_D20140731-20140731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-31</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="i62a27d05945443ad96f59cdcb1edc420_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i66e6258348ea4fc89eb5ef7eb0cb10fe_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1795ede44ce94976805d345dedf32727_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29dc2aedb8bc420db59f14dd8db4e352_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6542622e5ef24933a209e2a96b41e83a_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a5d7197ac224ce9bf2facd8d7e90d5f_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i36ac058f78664b5dbeba5619bf856f61_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c999577462049eda357e2ab78e71683_I20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-25</instant>
        </period>
    </context>
    <context id="i40eadd91b0ae47328a2ae28ff036f822_I20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-25</instant>
        </period>
    </context>
    <context id="id13e0ec03eda43788abcd88f803bccd1_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i1de5fd1605f748fdb2806fef4a6523c5_D20220125-20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="ib222890e5cd8438eae755da882ac9b57_D20220125-20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="i8d18e9c334304d17b47512697546cdfe_D20220125-20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="i5e01245b5cf74dc58ec5bf20e479c9f0_D20220125-20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="ifb2fd3c70f184444bdcf9b9585835c51_D20210731-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i68d6b6246aa54ad59d9d645973f16b87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i726a9874ca6a4682a0a961cf53f77d36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f5f0000b10443bb904f81c8727295ea_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib576ab5afad44195a834e1e7faeb7d53_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i37746254b4ef462ab66acbee39610807_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:GoodwillImpairmentAxis">cah:MedicalUnitGoodwillImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i220be912f8c445d583c34c9d7a197d21_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c6fc69a919e428a9249914f94b4e705_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9770cc98f0834ead8999bddd6f93e81a_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71c85c93cd4f49ccadff2110a5afb040_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i838623ba3e424777903a3d4ab8c49dc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b171a8060ae4f008d8e6a25869806bf_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07d6f83592a1426993ab2a13d023f8f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00fa788fc87340c384b2380104923f42_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia7499fd6ae8f450daef1e62b7f4adf5b_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25f55518522b4794b80ca287b166f5cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i263e5ca49fed4bdbba6851bf32da93f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68578f163e6b4179847e8b41663e8613_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43784f138b914b8391cd15843d15c989_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i488515e2c1534dd59e7585b97320412d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f1090b7d5ea42a8a285ffc9484f2981_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5176a75ae1064d6387d055928f4a88c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec263fc27faf41e9a416ab2454257578_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife056180602548b8811ec73a324b2646_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i490f28555d6e44018c5fb0a7112b17fa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iee2308b88f9c42b991c03554e3e0145e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i97efabb7eafb457086138a0357aee526_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib440b67408ee4c8fb412aeaaf58be6c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f6c7a9a75f64986aefb952c73f437f8_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2aace5f028f4f5594de1fcc97eebe25_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice2850c2b1a44cd8880a41a004525e24_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb4d97276663428da969d731f48e6813_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i357254d5ee414518a4eac711d1ad0070_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i531458b265ea402180368f22e3a18010_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3347233009744e6cb9cc4557b43f558b_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id67592a92eea436081db481ac7010f0d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic72d4b7997b54c948eff89cce7d0a30e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a8c386ef058467d89edcdc41c5d7497_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc1ca71b66fd44c99dc3a2f276433c1d_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48423edd0fde4582afae650327df3fb4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if691da9b0c7f435b9a6464ebf9174366_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i734031661a944622a2d44f3f789e8f7c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i87549c698d84454483818bad997efd4b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i79b64ec0efad4987b3cd7ad0a3914253_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie23cd0947b184af3834849f94339a4a7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0f3694f60c043b6910488f3f4214356_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9442aa8d69b64b3bbce3a40e922f013a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc5e2906bad1404691be6f731cf43612_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02be3554e0b34c02ba6b5f8f3ae72ad0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20447894cbce4626a6e15d3def1fdb5f_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib05957b8776e49b29c6ad2637c8b07dd_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8dc329406284cab850531d536265617_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf577b417acb4a57824e42c61874c5f4_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03a28033a8f04045b695c45def69a4ab_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b2139bac4734db0b0818999413985f5_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7d6f1a08182423896d73aea639446c1_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a826fe2301345b7bcd24179b92b1b2a_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a0384798971475ca8af194b0bac9c64_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6de15b3c68241ae9c0af7734cf7ea0b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc1ac584a6af4ec58101540fb78560fa_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie67c60168405428b9e40371da416b3fc_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i947e256fc55c4846ac6b1768ff3934ad_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3e1e7ccb99f4738bdd4ea38594a9397_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i717134e53834433e8d6ee1a235075718_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica7b6c1cd2234d3a84ff74926dba30cd_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida4501b440f44a0d8c0bc1a50fdbff39_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee36791593e44892a333aec11370f06c_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95c216eac9e0457da077b8544a667522_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b04e2a62607413897d3432b37ed8267_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieec0426076dc43be9eb018d81b355af4_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29e5a616b51d46cd9609f9b8cb936e1b_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad497ebaf0d74ac488be3fdfe5b45c13_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f557d65bffa4e22abc5d6a0ee5bf2c4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7026229bffa24d75a300958db5493173_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d0ef5db6f8c49e99cf83c70272570db_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaabe27c3053040afbee1de4f02ae3a1d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2324d519bd54f24aca9e312c213d51f_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6fcd214eafc844838d0428eba45ceb81_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27b9c7da4d6b4d138668a8f96ece269b_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac8afe0411ae4297994e96fc737d451b_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i105c393d6342437baf627222f66216c9_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c720c252b6845929ee256ffd982829d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib075c6eb340b4000b99c1e4260fff944_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23d97aa974df4ac6bbf2e22959990798_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i41706ccf867d4e078fa68264b8ecf4b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id27ed30ba0c447d8a9e0d8a5e753260e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i644ca4beadff4da38d7416eb70d4e113_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3617e648d299450da968eaf742edafd8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id6a5635665184a6cb80b94e96e68ca69_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic2ae447d46854b319eaccc5ea8e28c28_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia478e26ea8e448b39f3752efae199cfa_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6b6e1f67cfe47c5a29aaad5984e138e_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic237dc8d2be649c6873fe2eb206f1e73_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7abdec1bde440c4b7d2d3fbdb599cd2_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i134b3d6659154128ab88dee849493e4c_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i398269cbf0e54afe862fe609d2944418_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8aa1d951b73947c3936f78f13c7eaa01_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i66dbff1954b94c7c9982013468c26bfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if137af18fd604b45a04f086112f3f149_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i898c45d5227a4196aece99539dfb04a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10f071711d1b4e4ca40dd648ab7f15a4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i91f70075253b4b6f834c3408cbaaac75_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i548763c20950426faab587ffdc5af9cc_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2be505b893554e2596656d949aede2e1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib4c55723711e41b596452e6d75618784_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie37383edad9446b08331ba5cadd97680_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i716d6753e4e540af82ae6e591c9bdeb0_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea669b2da0d447318754dc385014d7b6_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0018e1126c834a38ae1193472508f95b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="stateag">
        <measure>cah:StateAG</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY18yLTEtMS0xLTQ3MjI2_6e2686d5-0025-4999-9c92-86b73d7ce41a">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY18zLTEtMS0xLTQ3MjI2_9f5465a6-42eb-46f5-9693-db055a03af22">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY180LTEtMS0xLTQ3MjI2_763f4353-4a13-48a3-9a29-9d936240d5d0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY181LTEtMS0xLTQ3MjI2_a6b5db89-d2a1-4696-946c-1354df4176d2">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV80L2ZyYWc6ZTQ5YTgwZmVlNzlkNGE5YTkyYjI2MmYwNzkyNTIyYzUvdGFibGU6MzEzZTlkN2IxY2ZmNDViMjhkZWFhMDdkODZmNTU3MGMvdGFibGVyYW5nZTozMTNlOWQ3YjFjZmY0NWIyOGRlYWEwN2Q4NmY1NTcwY182LTEtMS0xLTQ3MjI2_2fa900ee-e13f-4955-b9c7-4e919478cd73">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M184NA_8a6e11b6-f2a0-4001-bb78-f8d26c4215f7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MWM1ZTE4NTA2MDJkNDgyMjhlNjc0YzBhMTkwNjViZTAvdGFibGVyYW5nZToxYzVlMTg1MDYwMmQ0ODIyOGU2NzRjMGExOTA2NWJlMF8wLTAtMS0xLTQ3MjI2_cb7c8025-7411-481b-bd7e-34f925e53d73">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xMjE_16cf2228-4572-4852-9555-ab7e61073c8f">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6YTMwMTk0MTcxZDgxNGNjYWE4NTBlOThlZTZhNzhjOGYvdGFibGVyYW5nZTphMzAxOTQxNzFkODE0Y2NhYTg1MGU5OGVlNmE3OGM4Zl8wLTAtMS0xLTQ3MjI2_5b57d9af-e332-431d-ab82-447caafae442">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTgy_975dc3fc-ca0e-4157-9efe-c109a5b29f52">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTc4_29d21ea7-18b3-46f6-aa3e-aeb2d9fde424">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8wLTAtMS0xLTQ3MjI2_abb5cdd8-4b31-4768-8c1a-b9dd98d58e5c">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8wLTYtMS0xLTQ3MjI2_b97ec9cb-3fa7-4507-959f-ac98c5dff662">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTAtMS0xLTQ3MjI2_bdabed56-31f9-4010-93d0-1bf3dc8bfe11">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTItMS0xLTQ3MjI2_dac0d492-f191-4400-bd1c-7a88dea023c8">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTQtMS0xLTQ3MjI2_c621c84f-ae56-46c9-99ab-eb79af38e920">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV8zLTYtMS0xLTQ3MjI2_4b4b8abc-233f-459c-b3bd-d5ff5e1b332b">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV82LTQtMS0xLTQ3MjI2_bb59ade0-24a7-44e5-8d75-72d502e21464">(614)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZjNmOGVhMmI0MDk2NDJlMzk5MWI5MDJmYWU0YTAwNGEvdGFibGVyYW5nZTpmM2Y4ZWEyYjQwOTY0MmUzOTkxYjkwMmZhZTRhMDA0YV82LTYtMS0xLTQ3MjI2_cd6ab6a4-a58f-4a03-855d-267ab7b96567">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MjliZjZiZjEzNjM1NGM1YmJjZDk0MjVmMTVhYTFjNzgvdGFibGVyYW5nZToyOWJmNmJmMTM2MzU0YzViYmNkOTQyNWYxNWFhMWM3OF8yLTAtMS0xLTQ3MjI2_e46d7109-0bf4-4a58-8548-f5c334881a23">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MjliZjZiZjEzNjM1NGM1YmJjZDk0MjVmMTVhYTFjNzgvdGFibGVyYW5nZToyOWJmNmJmMTM2MzU0YzViYmNkOTQyNWYxNWFhMWM3OF8yLTEtMS0xLTQ3MjI2_b022d027-1567-41c3-ab8b-c7d5c0da325b">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6MjliZjZiZjEzNjM1NGM1YmJjZDk0MjVmMTVhYTFjNzgvdGFibGVyYW5nZToyOWJmNmJmMTM2MzU0YzViYmNkOTQyNWYxNWFhMWM3OF8yLTItMS0xLTQ3MjI2_3bb125a7-499b-4f05-943d-c77d59fb2291">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTc5_843bc66f-ba48-4220-9edf-1ddcc4155f34">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTgw_dbe7aa36-478b-4ab0-8785-60cd90dc2fd7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZDFhZmMyM2VkMWZhNDZkZWJiZjUzYTI5YTg3ODY5YzIvdGFibGVyYW5nZTpkMWFmYzIzZWQxZmE0NmRlYmJmNTNhMjlhODc4NjljMl8wLTAtMS0xLTQ3MjI2_6c8718aa-9daa-4351-a48d-1e82a2fdae67">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZDFhZmMyM2VkMWZhNDZkZWJiZjUzYTI5YTg3ODY5YzIvdGFibGVyYW5nZTpkMWFmYzIzZWQxZmE0NmRlYmJmNTNhMjlhODc4NjljMl8xLTQtMS0xLTQ3MjI2_3584c629-b2a4-428e-ba74-65a009f3f10c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGFibGU6ZDFhZmMyM2VkMWZhNDZkZWJiZjUzYTI5YTg3ODY5YzIvdGFibGVyYW5nZTpkMWFmYzIzZWQxZmE0NmRlYmJmNTNhMjlhODc4NjljMl8yLTQtMS0xLTQ3MjI2_3024d2ec-27a2-4889-ae50-62b0a15a121a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTgx_6723a33b-1e10-43d5-988c-63ec2b731840">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5a27e14071854942b0925c5b161e2e00_I20220131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xL2ZyYWc6MGJlOTAzMTEzNmI5NDZmMGI1N2ZhMGMxYTRjNjkzNjMvdGV4dHJlZ2lvbjowYmU5MDMxMTM2Yjk0NmYwYjU3ZmEwYzFhNGM2OTM2M18xNTc2_1196a648-a52f-45e1-94d9-1073119521bb"
      unitRef="shares">277061392</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="idf89a8993ffb426a9d8312715526954c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ5Nw_d611f62f-7999-4a12-9f47-3151a00cd3ab"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQyOQ_040f0199-7eb1-499a-bbd0-bcd5d23b9ac9"
      unitRef="shares">7800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ0NQ_cc6f49b0-14ee-4fcc-a6f4-3c2e1cccf644"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ2MA_5c155015-2d9d-4e22-8002-ad1ee8a4d6f9"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQ3OA_1b9c0c80-6f76-426f-bf93-4713cdcf934b"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODUyNw_7c05aa20-5dad-46dc-a70d-6cfea97d68b4"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ica8231a36d054c5eace0ac4a74d6041c_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODU0NQ_67f9c0ce-e63e-4559-b6fd-33f5e371e187"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODU1OA_36135926-ccdc-4fde-9dd5-04af2fea3efd"
      unitRef="usdPerShare">50.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODY5Ng_978afb2b-7197-4f61-817d-ad5292e2a005"
      unitRef="usdPerShare">49.39</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODcwMw_cafdcd34-8bea-4d35-9067-b525acdf31af"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV81OC9mcmFnOjMxMjFiMjBjMzUzZTRiZTQ5YWZmMmRhMDRmZTJkNzIwL3RleHRyZWdpb246MzEyMWIyMGMzNTNlNGJlNDlhZmYyZGEwNGZlMmQ3MjBfMTY0OTI2NzQ0ODQwNw_7c05aa20-5dad-46dc-a70d-6cfea97d68b4"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Revenues
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi0xLTEtMS00NzIyNg_0e0ae643-a02f-4865-a238-f27ae35300e0"
      unitRef="usd">45457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi0zLTEtMS00NzIyNg_94cc4876-9965-4162-bf9c-01436770cd1d"
      unitRef="usd">41541000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi01LTEtMS00NzIyNg_f09d20ba-cc5f-4211-b54c-6240846c4312"
      unitRef="usd">89425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMi03LTEtMS00NzIyNg_9697ca9e-7f78-4415-baa0-79d714dd448e"
      unitRef="usd">80606000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy0xLTEtMS00NzIyNg_8bed938a-12e6-430f-b711-52c91d22452a"
      unitRef="usd">43841000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy0zLTEtMS00NzIyNg_845f7bfb-a570-4f2a-84f8-9545f8a5bef9"
      unitRef="usd">39765000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy01LTEtMS00NzIyNg_737d99c4-9caf-4701-bcc7-bc5e53c94976"
      unitRef="usd">86167000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMy03LTEtMS00NzIyNg_e9e3ca14-8c8a-4463-82a5-667a6ebcd2ad"
      unitRef="usd">77115000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC0xLTEtMS00NzIyNg_7dbcb773-4a10-445f-9c77-998b87c7e4e2"
      unitRef="usd">1616000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC0zLTEtMS00NzIyNg_76beb785-3021-4957-8389-ebf19cc54bec"
      unitRef="usd">1776000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC01LTEtMS00NzIyNg_6ca27d13-2b1b-4848-8049-f7aef7cc61f9"
      unitRef="usd">3258000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNC03LTEtMS00NzIyNg_5a8122e1-7618-48ed-8b8b-8f2ef5c45fbe"
      unitRef="usd">3491000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy0xLTEtMS00NzIyNg_949574db-3fa3-4de5-b65e-d929cf635953"
      unitRef="usd">1151000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy0zLTEtMS00NzIyNg_a5e4662c-d8ac-4078-a908-ea1377f95270"
      unitRef="usd">1147000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy01LTEtMS00NzIyNg_c0385ba1-e2bc-462d-bc18-918cbe512bc6"
      unitRef="usd">2265000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfNy03LTEtMS00NzIyNg_d2c5e4e3-d843-493f-84a2-f641eef3c28b"
      unitRef="usd">2284000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC0xLTEtMS00NzIyNg_c8b69298-7d46-4f7a-ad0c-f97d04b2beba"
      unitRef="usd">7000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC0zLTEtMS00NzIyNg_f109ea05-94e4-437e-818d-c150b9e79d86"
      unitRef="usd">20000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC01LTEtMS00NzIyNg_9bb0214a-b7cc-4c62-a606-dddf8be8403b"
      unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOC03LTEtMS00NzIyNg_9126ad52-7e5e-4c84-876d-ccb152275427"
      unitRef="usd">57000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS0xLTEtMS00NzIyNg_72df85c2-491b-4f52-b3e1-d690e2c5a18a"
      unitRef="usd">79000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS0zLTEtMS00NzIyNg_800a6e18-07b3-4ed5-9a5a-93dc586b8878"
      unitRef="usd">116000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS01LTEtMS00NzIyNg_03ab190d-742a-4c16-8296-c770e688ade0"
      unitRef="usd">158000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfOS03LTEtMS00NzIyNg_604d8a28-cf20-4882-b52e-372a8fbc6fa4"
      unitRef="usd">234000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtMS0xLTEtNDcyMjY_7c6abda5-55a3-40c6-96e9-55da0197498b"
      unitRef="usd">-1295000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtMy0xLTEtNDcyMjY_63cca583-80f6-4916-a91c-9aa2a72273cc"
      unitRef="usd">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtNS0xLTEtNDcyMjY_00885525-3792-4c8c-bf61-eadc1ca03b25"
      unitRef="usd">-1293000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTAtNy0xLTEtNDcyMjY_3bc507da-d736-47aa-bc72-8c1272a068c5"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtMS0xLTEtNDcyMjY_9b31f3e3-5d3e-4cb7-a65c-0074bd45bf9b"
      unitRef="usd">-34000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtMy0xLTEtNDcyMjY_6f37f935-48e0-43fe-87c8-b3d44b74f282"
      unitRef="usd">-32000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtNS0xLTEtNDcyMjY_17f31f04-d776-43ff-bc73-b23b6fe7d31b"
      unitRef="usd">-52000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTEtNy0xLTEtNDcyMjY_6f7fe958-6460-4852-a814-976c23e07a71"
      unitRef="usd">-1070000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItMS0xLTEtNDcyMjY_0b4cabe8-14c8-439a-80ac-45e14fa93157"
      unitRef="usd">-950000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItMy0xLTEtNDcyMjY_7fc1cfa6-c4cf-4b28-a143-b827bed4bdbe"
      unitRef="usd">461000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItNS0xLTEtNDcyMjY_13c61c1f-5fc1-44af-8386-768eeb7386c1"
      unitRef="usd">-535000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTItNy0xLTEtNDcyMjY_ea9cc0c8-773b-495a-b3ca-daef8aaeb904"
      unitRef="usd">-163000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtMS0xLTEtNDcyMjY_15f00e32-6569-4dbc-9912-c4bd90510186"
      unitRef="usd">13000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtMy0xLTEtNDcyMjY_6c4ca3f9-9395-4688-a949-eaf0c3908376"
      unitRef="usd">12000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtNS0xLTEtNDcyMjY_5af8f889-f7f5-4ade-9f27-a87f3fa76b8f"
      unitRef="usd">17000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTQtNy0xLTEtNDcyMjY_37853e7c-6b0b-4088-bc7a-5b469bb7f096"
      unitRef="usd">19000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtMS0xLTEtNDcyMjY_f5879ddf-66ff-4607-8c53-ddc96856b96a"
      unitRef="usd">37000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtMy0xLTEtNDcyMjY_93e27324-1a7f-495e-8a9a-5d906c42381c"
      unitRef="usd">46000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtNS0xLTEtNDcyMjY_d45f0275-4d72-44ba-bdd3-2db4369dbe8a"
      unitRef="usd">77000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTUtNy0xLTEtNDcyMjY_3891a1dc-8f78-416e-9ad7-e4f2900cf47c"
      unitRef="usd">91000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtMS0xLTEtNDcyMjY_aa096397-51f9-43b0-a1e8-ff0d93a08fe2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtMy0xLTEtNDcyMjY_2eb1e529-97ab-4ad9-ad25-36c32aca6464"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtMy0xLTEtNDcyMjY_6096310b-eb3a-4239-9d07-2de4dee901a1"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtNS0xLTEtNDcyMjY_dba5ee7e-1bca-4c3d-a3ea-210af48101f6"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTYtNy0xLTEtNDcyMjY_3b88c3e7-e86a-43ca-80f6-9d0457f0a9cf"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMS0xLTEtNzQ2NTQ_e1edd092-ff46-439c-b966-09db976b97dc"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMy0xLTEtODY4OTk_f2f77317-2168-4667-9cf9-7c690ce8a0ee"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNS0xLTEtNzQ2NTE_9b313438-eb71-47ee-91e6-0bd048b58d6e"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNy0xLTEtODY5MDI_3a689123-38cb-48b9-9a82-4828732d31df"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMS0xLTEtNDcyMjY_cecd9aab-43f7-44ed-8818-0f511a47a753"
      unitRef="usd">-973000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctMy0xLTEtNDcyMjY_af9669ce-0e5f-453d-ad7c-674291eae60f"
      unitRef="usd">427000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNS0xLTEtNDcyMjY_4e5149d5-ba71-470c-905e-385f49a5d754"
      unitRef="usd">-604000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTctNy0xLTEtNDcyMjY_e65181ac-974c-4fbc-9b5a-8af1ca312dbb"
      unitRef="usd">-236000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktMS0xLTEtNDcyMjY_6018ce24-2f79-485e-95f8-4a1f50b764f5"
      unitRef="usd">-1022000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktMy0xLTEtNDcyMjY_79f0803a-c422-4f0e-a0b9-685af78e4e60"
      unitRef="usd">-203000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktNS0xLTEtNDcyMjY_37a32831-dbea-45f7-ad57-8ff42d3b94a5"
      unitRef="usd">-925000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMTktNy0xLTEtNDcyMjY_6876234a-675c-4fee-9e28-af9c61250fcd"
      unitRef="usd">-613000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtMS0xLTEtNDcyMjY_10d55440-4d7d-4987-a1cf-bd97074c2308"
      unitRef="usd">49000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtMy0xLTEtNDcyMjY_1819bdf9-619b-4456-9bb2-2060e97e2b20"
      unitRef="usd">630000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtNS0xLTEtNDcyMjY_c698196e-d36f-4095-a09e-9b69a84eb582"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjAtNy0xLTEtNDcyMjY_df13af41-6ddf-48cf-8a99-f4b2a2b970e3"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtMS0xLTEtNDcyMjY_db6b24a9-6324-4078-9845-e3b6cd1d1ff7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtMy0xLTEtNDcyMjY_88ed0536-ff65-4792-a447-1882eba681ae"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtNS0xLTEtNDcyMjY_10780e4d-14f3-4b0f-8aa3-fc54cd7a690e"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjUtNy0xLTEtNDcyMjY_21a02de6-bf83-4500-a624-0e6950295b62"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtMS0xLTEtNDcyMjY_f4d0f4d1-b1be-402e-881b-0ed0ffc7b290"
      unitRef="usd">49000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtMy0xLTEtNDcyMjY_96e1c5f2-6cd4-4c58-985c-5994da8675e2"
      unitRef="usd">629000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtNS0xLTEtNDcyMjY_9d58d5c1-bde8-435a-ba87-05af261304cc"
      unitRef="usd">320000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjYtNy0xLTEtNDcyMjY_a0db859c-6d17-4adf-b050-22b7e06642ca"
      unitRef="usd">376000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktMS0xLTEtNDcyMjY_3428c6d5-a67a-4573-af03-a0b3aa4f5501"
      unitRef="usdPerShare">0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktMy0xLTEtNDcyMjY_cdffa050-ea62-4795-becf-74c2e83a29df"
      unitRef="usdPerShare">2.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktNS0xLTEtNDcyMjY_bf8b3c2f-9af2-44e1-b006-71d6252d0b1b"
      unitRef="usdPerShare">1.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMjktNy0xLTEtNDcyMjY_3b254c30-e985-46a5-b706-5006811c5211"
      unitRef="usdPerShare">1.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtMS0xLTEtNDcyMjY_740d9408-6d27-475a-bb79-8721f273004f"
      unitRef="usdPerShare">0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtMy0xLTEtNDcyMjY_7fd52753-4086-4a83-931d-e2c6844e84dc"
      unitRef="usdPerShare">2.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtNS0xLTEtNDcyMjY_afe2d31c-5c9c-4ea3-99a9-c7731f46fcbe"
      unitRef="usdPerShare">1.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzAtNy0xLTEtNDcyMjY_375c6bcb-d805-4573-bb7e-292372e23892"
      unitRef="usdPerShare">1.27</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtMS0xLTEtNDcyMjY_a10979f4-6999-433c-8cff-383059b72483"
      unitRef="shares">279000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtMy0xLTEtNDcyMjY_181361bd-e496-46a4-b6e3-a068966ce137"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtNS0xLTEtNDcyMjY_381e56df-d239-4bd0-8ff0-7596e1263aaf"
      unitRef="shares">283000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzMtNy0xLTEtNDcyMjY_bec77474-58c0-4c13-905a-ebbf3628f0e3"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtMS0xLTEtNDcyMjY_48eb6580-864f-4e28-acd4-958d55b497eb"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtMy0xLTEtNDcyMjY_3049e1a9-4128-4c2f-ba1a-aceb40071729"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtNS0xLTEtNDcyMjY_1a2e212d-a9ff-40c5-87d9-8d3e3633461d"
      unitRef="shares">285000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzQtNy0xLTEtNDcyMjY_f75a943f-4a13-4d23-aaf4-51df022392b9"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtMS0xLTEtNDcyMjY_3aa6314a-a114-42c7-b5a9-c06e5cdac8cb"
      unitRef="usdPerShare">0.4908</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtMy0xLTEtNDcyMjY_dbae9395-8c14-4b84-9c59-c99d0f4dac5f"
      unitRef="usdPerShare">0.4859</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtNS0xLTEtNDcyMjY_35b6345e-7c75-4a77-9354-e67c912abfc4"
      unitRef="usdPerShare">0.9816</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82NC9mcmFnOmFmYTNhNzVmMjAwYTRmZDg5ZDJmYWJjNGI1OGU4NzljL3RhYmxlOjQ5ZmQ0YzNmZGU3MzQzNDI5ZTk4ZWIyNDNiOTJiMzU4L3RhYmxlcmFuZ2U6NDlmZDRjM2ZkZTczNDM0MjllOThlYjI0M2I5MmIzNThfMzYtNy0xLTEtNDcyMjY_d23eaf03-af4b-4f0a-89c2-4b3703ef0aca"
      unitRef="usdPerShare">0.9718</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi0xLTEtMS00NzIyNg_1e9917e2-0176-44b0-9fe3-ac8aabfd0cb3"
      unitRef="usd">49000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi0zLTEtMS00NzIyNg_9e52f929-00da-4afa-a6bc-ea979a816b69"
      unitRef="usd">630000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi01LTEtMS00NzIyNg_26299ebb-9a05-4cbe-b77e-92b79b5b19e0"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMi03LTEtMS00NzIyNg_6fe7e1ed-42c8-4675-a052-091d7b6e09da"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS0xLTEtMS00NzIyNg_bab49f3d-03b7-4fb8-8e0b-7cb09dcf390c"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS0zLTEtMS00NzIyNg_4a72128d-075d-4cb3-ad84-0f0c7feeca0b"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS01LTEtMS00NzIyNg_48b4c2f9-3f7d-4abd-9b08-8c2649e80355"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNS03LTEtMS00NzIyNg_389e90a4-c7b1-46dd-98c1-b1bbb2901d2b"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy0xLTEtMS00NzIyNg_d46a1ebd-0191-40f0-82ae-5a6e5cd2a8f3"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy0zLTEtMS00NzIyNg_23891904-68cc-4fe9-baf9-06ecc6541a62"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy01LTEtMS00NzIyNg_be7c0b56-a981-4b3a-8c42-c67276931440"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfNy03LTEtMS00NzIyNg_f0eb2b1e-145c-4a7e-b27c-1b1ad3a77ba2"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC0xLTEtMS00NzIyNg_3a5cb8d0-558e-42f5-adaf-18716b4e47a1"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC0zLTEtMS00NzIyNg_6b5ae12a-eedb-4b2f-8627-eda370014dc5"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC01LTEtMS00NzIyNg_b57a1e2a-2b1e-484e-9581-064d9a0ed16a"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfOC03LTEtMS00NzIyNg_2e97a0f1-e027-4b47-8b23-2b82e9962abb"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtMS0xLTEtNDcyMjY_c4b6db70-c94e-48c2-bd38-a4eb6f692538"
      unitRef="usd">25000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtMy0xLTEtNDcyMjY_7c64c126-73d0-4ec5-b7c7-8360656c9f09"
      unitRef="usd">664000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtNS0xLTEtNDcyMjY_a0fd569d-1167-42f0-9c94-e4358c427e56"
      unitRef="usd">270000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTAtNy0xLTEtNDcyMjY_bd382f1f-e2b5-49bf-8e77-97a99147d341"
      unitRef="usd">428000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItMS0xLTEtNDcyMjY_a8df9a13-a742-4cdf-aea2-e82e34151d39"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItMy0xLTEtNDcyMjY_493f0541-7e15-4d49-a7a8-45b0f9d4949a"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItNS0xLTEtNDcyMjY_df29547e-85c6-42ba-8def-8f37d757630d"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTItNy0xLTEtNDcyMjY_7b9f004b-3583-4ca2-aeae-48afd1b13164"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtMS0xLTEtNDcyMjY_d3eac66f-101d-4a06-a33c-1b2001d7a9a1"
      unitRef="usd">25000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtMy0xLTEtNDcyMjY_cba3a038-fa88-4717-9cee-2c8176505660"
      unitRef="usd">663000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtNS0xLTEtNDcyMjY_87692fe4-e3a7-4d4b-a3bf-955b4ae15616"
      unitRef="usd">269000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV82Ny9mcmFnOjlkMTkzNGNjNTA0ZTQ3OGFhZTdmNjJiMmM4ZjdjMDEyL3RhYmxlOmZjN2E4Njg1NTExMzQ2ZWZiZWMzNzAwNDE3OGNiNGFmL3RhYmxlcmFuZ2U6ZmM3YTg2ODU1MTEzNDZlZmJlYzM3MDA0MTc4Y2I0YWZfMTQtNy0xLTEtNDcyMjY_71094e1c-b697-48be-b01a-772afc4d82b3"
      unitRef="usd">427000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNC0xLTEtMS00NzIyNg_c7509dbc-8808-4f41-9116-f102a3872631"
      unitRef="usd">3161000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNC0zLTEtMS00NzIyNg_01dadc52-80cf-4aa9-a458-dd6619935b9e"
      unitRef="usd">3407000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNS0xLTEtMS00NzIyNg_c4f045e6-f739-48f9-bdd4-038a3d6d314c"
      unitRef="usd">9406000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNS0zLTEtMS00NzIyNg_7e795dd4-1f2c-4d65-b0fd-ba5eac7c64f9"
      unitRef="usd">9103000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNi0xLTEtMS00NzIyNg_31f91099-9f30-409e-a94c-1c50d1bc4ac0"
      unitRef="usd">14941000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNi0zLTEtMS00NzIyNg_23e4374f-3e22-403f-b7b6-1d0aca577154"
      unitRef="usd">14594000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNy0xLTEtMS00NzIyNg_cb7d4764-9f5b-4406-881c-64bd2bf4233f"
      unitRef="usd">4339000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfNy0zLTEtMS00NzIyNg_294119bb-9c93-4de5-836c-90f2f151c501"
      unitRef="usd">2843000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOC0xLTEtMS00NzIyNg_af609370-c169-4bcb-bff7-281629f5fd76"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOC0zLTEtMS00NzIyNg_84d6c9bb-0e51-4181-ae20-3e1cca4c5ddb"
      unitRef="usd">1101000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOS0xLTEtMS00NzIyNg_6826a023-debd-4e28-82d3-79694031d570"
      unitRef="usd">31847000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfOS0zLTEtMS00NzIyNg_2a581f4f-7aad-4908-862e-9fe30c877ce9"
      unitRef="usd">31048000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTEtMS0xLTEtNDcyMjY_1e066842-d855-4dca-81ed-daebd144d070"
      unitRef="usd">2321000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTEtMy0xLTEtNDcyMjY_24a24057-ef17-4ec7-9791-dd0bbb93c730"
      unitRef="usd">2360000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTItMS0xLTEtNDcyMjY_58be6934-8de4-4d63-8013-fc76d523f8fa"
      unitRef="usd">8599000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTItMy0xLTEtNDcyMjY_f193a5de-c9da-4518-9c02-4594f33f1b0b"
      unitRef="usd">10094000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTQtMS0xLTEtNDcyMjY_4468b775-fb91-4d9f-8637-0c274c96c08b"
      unitRef="usd">913000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTQtMy0xLTEtNDcyMjY_1c3ad139-321c-4296-b49a-31d6ac20c786"
      unitRef="usd">951000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTUtMS0xLTEtNDcyMjY_896b69d6-32ba-44f6-b4c1-f264135f306f"
      unitRef="usd">43680000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTUtMy0xLTEtNDcyMjY_05e3cdc6-a000-44be-a46e-b2137ba26401"
      unitRef="usd">44453000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTktMS0xLTEtNDcyMjY_0d0e6225-ad41-4363-bd06-b2c4cf943aa5"
      unitRef="usd">24759000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMTktMy0xLTEtNDcyMjY_d5b4ac86-9b04-459c-99b8-24f7f3d82e38"
      unitRef="usd">23700000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjAtMS0xLTEtNDcyMjY_238188f8-5866-4c52-9f7b-7ed76bead861"
      unitRef="usd">301000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjAtMy0xLTEtNDcyMjY_346acd72-183f-4a42-92ce-62fb715e3ec8"
      unitRef="usd">871000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjEtMS0xLTEtNDcyMjY_8ac285c6-7a68-4d03-a31d-c1cf153d4c3f"
      unitRef="usd">2669000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjEtMy0xLTEtNDcyMjY_f25a49a6-09d0-4999-a764-920e26274820"
      unitRef="usd">2957000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjItMS0xLTEtNDcyMjY_9cfd6462-2db1-431d-86b2-e32d1943b404"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjItMy0xLTEtNDcyMjY_33409db7-329f-465a-b9ed-302b510542c3"
      unitRef="usd">96000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjMtMS0xLTEtNDcyMjY_e683e3d2-4652-4ad0-a620-63cdf26a3794"
      unitRef="usd">27729000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjMtMy0xLTEtNDcyMjY_d90941d0-e263-4f04-ba18-88216ff31d7c"
      unitRef="usd">27624000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjUtMS0xLTEtNDcyMjY_7fe6c725-00fa-4877-806a-24ea602604d2"
      unitRef="usd">5342000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjUtMy0xLTEtNDcyMjY_729c1501-7d4a-4f0f-b89a-a607ca742e3f"
      unitRef="usd">5365000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjYtMS0xLTEtNDcyMjY_d9543620-8c38-44e8-8558-3f8b67f68c48"
      unitRef="usd">9607000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMjYtMy0xLTEtNDcyMjY_6a3328b9-6bd5-407f-9bcd-0494a34e8b22"
      unitRef="usd">9670000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8xNQ_11b4cc79-b576-4e1a-9044-81120b4bdfc3"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8xNQ_2a8e9401-7492-4edf-aa88-62e078bcaeb4"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8zMw_2ba74721-572e-4711-b573-8d255ef5edf5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0YzU5YzM5YWFjNzk0MzkwYTc1MWNhMTQzYWI1MWU1OV8zMw_709cea3a-2643-4331-94bc-5506aa868197"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMS0xLTEtNDcyMjY_ff7d329e-0698-4a29-b5ee-d5e4e9765286"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzAtMy0xLTEtNDcyMjY_c04a8417-f473-4c9e-add2-99dabbce4fcc"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18xNg_b1dba955-1fe0-4655-bf91-9aebfc9fe241"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18xNg_ff8a2387-a65d-4d40-80a2-b0fbb32cdfb2"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18zNA_5224094e-e339-477b-b9ed-4d8f0b8c5538"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjoxNzQ1NDRiYTRkNzY0MDNjYjhmNjBiZTljYmUxZTkxN18zNA_703cd52e-7634-42e0-b77f-0d81253bd9ae"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMS0xLTEtNDcyMjY_abfe37cc-3894-4d17-920b-1bba5f63e604"
      unitRef="usd">2721000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzItMy0xLTEtNDcyMjY_de6a1dcb-2212-47c3-8bad-85961971d6b2"
      unitRef="usd">2806000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzMtMS0xLTEtNDcyMjY_ad3b3241-4383-4c90-b521-4fad951559ca"
      unitRef="usd">1245000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzMtMy0xLTEtNDcyMjY_f1ab5242-700b-4165-9b19-f30ed3adeeb6"
      unitRef="usd">1205000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0NTU2YzFhNDZkZTA0ODAzODczMGUwMjQ2MTYzYmRlOV80MQ_b9364d76-541a-4f33-aa56-cc9d331b7dd4"
      unitRef="shares">50000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMC0xLTEtNDcyMjYvdGV4dHJlZ2lvbjo0NTU2YzFhNDZkZTA0ODAzODczMGUwMjQ2MTYzYmRlOV81Ng_1a940049-352a-461c-b92b-758d43fec979"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMS0xLTEtNDcyMjY_024ebd54-8c48-4916-a75b-f16521d260ee"
      unitRef="usd">2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzQtMy0xLTEtNDcyMjY_e6023588-e95c-4950-90f4-8ba13b975c75"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzUtMS0xLTEtNDcyMjY_0da633f4-3feb-4b54-9663-ca181050d839"
      unitRef="usd">-85000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzUtMy0xLTEtNDcyMjY_8b458751-2ecb-4622-bd3e-90f10d2b0e43"
      unitRef="usd">-34000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzYtMS0xLTEtNDcyMjY_65fa8986-9a94-42aa-9932-c3ce9c88d207"
      unitRef="usd">998000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzYtMy0xLTEtNDcyMjY_869a9c4f-b94e-4631-8877-773f9a5e273a"
      unitRef="usd">1791000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzctMS0xLTEtNDcyMjY_afe6f533-271a-4a00-a5e8-71a6b57c4e76"
      unitRef="usd">4000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzctMy0xLTEtNDcyMjY_33b6ea6e-01ae-48e7-9d50-0ac9ba98fc05"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzgtMS0xLTEtNDcyMjY_a78422ab-e979-4802-aff6-d28ee6017152"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzgtMy0xLTEtNDcyMjY_3cc29855-f3e7-4b49-ab5c-64565f400e4f"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzktMS0xLTEtNDcyMjY_d6e91355-02d5-4909-85b9-a0c951abd643"
      unitRef="usd">43680000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83MC9mcmFnOjE1OTkwMzUwY2QyYzRlYTZhZjFjYmI1ZDZhZThmNWVlL3RhYmxlOjJhOWQ5ZDQyNjViODQ2MDM5NGRjMDMzNDVlNTk0OWRlL3RhYmxlcmFuZ2U6MmE5ZDlkNDI2NWI4NDYwMzk0ZGMwMzM0NWU1OTQ5ZGVfMzktMy0xLTEtNDcyMjY_2cd8fcdb-31ee-46d6-b91e-011d7bfb52bd"
      unitRef="usd">44453000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7986a43d300d47c7b6781e8e97cd047e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xLTEtMS00NzIyNg_b5462808-bb11-4c75-af56-a96d8bf2e213"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7986a43d300d47c7b6781e8e97cd047e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0zLTEtMS00NzIyNg_8ea26423-ec54-4a90-9337-d0e10788bb52"
      unitRef="usd">2666000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4dc68631d57443d8738c75aa59831eb_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy01LTEtMS00NzIyNg_be3c188d-a747-4ffb-a056-0685b962506a"
      unitRef="usd">1335000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ie7dbe5b201c74f1b89a35df6592c99e4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy03LTEtMS00NzIyNg_e8d03adf-dbaa-400d-80c7-75b9f81ec604"
      unitRef="shares">-43000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ie7dbe5b201c74f1b89a35df6592c99e4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy05LTEtMS00NzIyNg_6444be0b-f0f7-43ca-8a5a-145381a87a7c"
      unitRef="usd">-2547000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iada0f823a0f947a3a53d2ee1b5d23237_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xMS0xLTEtNDcyMjY_45b6f0e0-e30d-4d43-9b4b-ee1d0b332304"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9db9ab51c3284580bbffafef36fcd2aa_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xMy0xLTEtNDcyMjY_86edecae-8bb5-4972-bff8-40187496f5a9"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51ee4fa253c140b78f57a286ba3fd59b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMy0xNS0xLTEtNDcyMjY_f558c8d7-996e-48f2-9e64-da29dc8fc87e"
      unitRef="usd">1396000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNC01LTEtMS00NzIyNg_f4d0f4d1-b1be-402e-881b-0ed0ffc7b290"
      unitRef="usd">49000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i1c4a82ec00b448529c5c4233322d86fa_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNC0xMy0xLTEtNDcyMjY_2c5192ea-4bde-45e0-98b1-9efa1528ca31"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNC0xNS0xLTEtNDcyMjY_4c440ecb-1937-4cda-8194-f6847551910d"
      unitRef="usd">49000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNS0xMS0xLTEtNDcyMjY_3a5cb8d0-558e-42f5-adaf-18716b4e47a1"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNS0xNS0xLTEtNDcyMjY_43df1be7-888d-4928-82f2-8c4ea935cd58"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy0xLTEtMS00NzIyNg_88fbec25-2ce0-413d-89fd-a36a168eaf30"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy0zLTEtMS00NzIyNg_f72d9406-ee4a-423c-b176-d0da360a8324"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy03LTEtMS00NzIyNg_15a444bf-9e42-4655-9274-8b68b78cb830"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy05LTEtMS00NzIyNg_da1d505e-3ffb-4ac2-8133-8f4bdbdca246"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfNy0xNS0xLTEtNDcyMjY_7e4be696-88f4-4fab-b6f9-8cf6e09587eb"
      unitRef="usd">19000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC0zLTEtMS00NzIyNg_8f30dbc4-3aef-4de1-9439-c88a6bcb7dec"
      unitRef="usd">40000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC03LTEtMS00NzIyNg_6b5d61bf-8436-46c9-98f1-aaf279ca8bdc"
      unitRef="shares">7000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC05LTEtMS00NzIyNg_b4e98091-7ef0-4f32-8f85-d231ab2e9fe6"
      unitRef="usd">340000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOC0xNS0xLTEtNDcyMjY_e1ab3b5f-1929-4b53-8603-a528a3f3dbd8"
      unitRef="usd">300000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="icead1849b2874394884eddb24215c104_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOS01LTEtMS00NzIyNg_fd6d1de3-1bfb-4421-a226-c37c75c1311d"
      unitRef="usd">139000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfOS0xNS0xLTEtNDcyMjY_81318d36-7ab6-45f6-8a1c-727ab839539e"
      unitRef="usd">139000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i897ba5f3ff2d4832b34ee257f7e3b70c_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtMy0xLTEtNDcyMjY_44329c5d-283a-4de0-bb90-1177fa7b0337"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="icead1849b2874394884eddb24215c104_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtNS0xLTEtNDcyMjY_f0c25d36-60ae-4dca-9997-4fd5a2d7b2b1"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i970bb16712714e7eb1be84b8a50b3b81_D20211001-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtNy0xLTEtNDcyMjY_6bdcb543-72b1-4f4d-9cba-d81e3922935d"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i1c4a82ec00b448529c5c4233322d86fa_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtMTMtMS0xLTQ3MjI2_bb653d6b-e929-4697-ae32-fe4d8639a20c"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTAtMTUtMS0xLTQ3MjI2_3c885858-e6a2-4e88-b825-822fbda8b331"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMS0xLTEtNDcyMjY_79d5a720-7642-4798-8954-8fdd2785f429"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMy0xLTEtNDcyMjY_b72aeee3-b366-4704-87f1-b5e9e1eaafdc"
      unitRef="usd">2721000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1422fa549c8c4fd78d87a5e7bddef0cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItNS0xLTEtNDcyMjY_cce56877-c054-449b-aa01-903bb646e214"
      unitRef="usd">1245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItNy0xLTEtNDcyMjY_771aaaa1-1747-4852-a5b5-46f08665da77"
      unitRef="shares">50000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItOS0xLTEtNDcyMjY_bb0ad5b3-6254-416d-bdee-a4058cc7c679"
      unitRef="usd">2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b36454ae8f34474b633982b25f47ddf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMTEtMS0xLTQ3MjI2_9265a0fe-ac6b-41d8-b1f4-a6dabf63b3b4"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76f5c033b2b34568b248de95ea9ae8d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMTMtMS0xLTQ3MjI2_6647d893-435c-4ec8-99f1-98656dcc377d"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjYyNmNmZWIzNDcwZDRjMDNiYjZjNWRhMGYzMGQ2YTFkL3RhYmxlcmFuZ2U6NjI2Y2ZlYjM0NzBkNGMwM2JiNmM1ZGEwZjMwZDZhMWRfMTItMTUtMS0xLTQ3MjI2_f9f3dd51-cf5b-414c-ac76-ae7ee0b94d11"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc0f360bdd494ffaacb98ba69e7d9980_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xLTEtMS00NzIyNg_44dfd6af-6e34-4697-81a1-ad821322cfcb"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc0f360bdd494ffaacb98ba69e7d9980_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0zLTEtMS00NzIyNg_8c83b7fb-86a9-4525-a173-0427fee1659b"
      unitRef="usd">2760000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c7f983dad174a65a853a11d93cbf864_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS01LTEtMS00NzIyNg_828b3aed-e6b7-46dc-a4bd-69b0d0404c99"
      unitRef="usd">771000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i21dcf5c494534e31b313419407cf51a9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS03LTEtMS00NzIyNg_4b411a53-65c6-42c1-937d-48def336b0a5"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i21dcf5c494534e31b313419407cf51a9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS05LTEtMS00NzIyNg_237d0a39-3e6f-464f-b885-72c12eefdee2"
      unitRef="usd">2022000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia792665ddedb4fd1be35d86aaee95caa_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xMS0xLTEtNDcyMjY_493026df-8829-4de5-b48b-54fb99867825"
      unitRef="usd">-87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5840b125eaa8414f900e6f2f22ba8df4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xMy0xLTEtNDcyMjY_a60af51d-9d72-4d1d-8fa9-f00010393545"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65d4a4c75a9a47f69d54b19dbcb1e52b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMS0xNS0xLTEtNDcyMjY_9d1a636d-d5b6-4c7e-bce2-002bac6f9bfd"
      unitRef="usd">1425000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMi01LTEtMS00NzIyNg_4d1a5326-ddae-4485-8783-fbc193eb5c3a"
      unitRef="usd">629000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i3118c657b147452e88b2cb76079e167a_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMi0xMy0xLTEtNDcyMjY_678141ae-a0a1-4076-b6dc-b009d92be3e4"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMi0xNS0xLTEtNDcyMjY_410f8591-f2bb-45fd-943c-b7bf4917ee9f"
      unitRef="usd">630000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib353deb7360145ecb2e83ab126e17961_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMy0xMS0xLTEtNDcyMjY_0f306fc3-1a88-48db-83d2-d19137a57c7d"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMy0xNS0xLTEtNDcyMjY_13c33558-ffce-435a-aaca-2d9b160b7e55"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS0xLTEtMS00NzIyNg_4cd97e58-8047-41bf-bef1-3a81d9a1500a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS0zLTEtMS00NzIyNg_995ff222-4e20-4d94-aa5c-3135865fd01c"
      unitRef="usd">17000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i00621486915144c58fbb572a1f95a310_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS03LTEtMS00NzIyNg_efefa1d4-f61e-47b2-b9c8-f3e0fe1a2bb8"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i00621486915144c58fbb572a1f95a310_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS05LTEtMS00NzIyNg_86ce7e8c-f736-43be-8887-6c51cea6a6ad"
      unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNS0xNS0xLTEtNDcyMjY_73086a45-b5a2-4910-912c-0d5f6e43d9b7"
      unitRef="usd">30000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="i2b596c976f3b4341a633bdc33702ce6d_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNy01LTEtMS00NzIyNg_c73d0ee6-d399-4f53-96b1-7de00f8e28bf"
      unitRef="usd">144000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfNy0xNS0xLTEtNDcyMjY_2f594da4-b97f-41df-9766-1d156df950ac"
      unitRef="usd">144000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i46447d4fea8448c3914f4681a11a3b00_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC0zLTEtMS01OTIzOA_448c3e49-41b7-4c11-a6db-3ba3618cbfb4"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2b596c976f3b4341a633bdc33702ce6d_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC01LTEtMS00NzIyNg_e6b71460-affd-4bd4-a5b4-bbb3f43c7975"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3118c657b147452e88b2cb76079e167a_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC0xMy0xLTEtNDcyMjY_8ca13d44-3932-4897-8d56-e580e927a82d"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfOC0xNS0xLTEtNDcyMjY_2fb07d14-cacf-4a87-a28f-ee8b48e6fefa"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMS0xLTEtNDcyMjY_f1c8699b-84f7-4825-b67e-f516cd9657be"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMy0xLTEtNDcyMjY_3c493cbd-c2ca-4a0a-9cb5-f62591f8ec4e"
      unitRef="usd">2778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4abc0866cbe848d3893f1f444f75cfc0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtNS0xLTEtNDcyMjY_cc12274a-2079-4c48-9ea7-edf11570ae96"
      unitRef="usd">1255000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtNy0xLTEtNDcyMjY_22c0d499-c2c4-4a19-b762-755c56288820"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtOS0xLTEtNDcyMjY_221caf7d-3350-4d9a-87f6-2296a793dd81"
      unitRef="usd">2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30ee22a4b8ab44809caa91d6c1c1eeaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMTEtMS0xLTQ3MjI2_091401b0-25c8-4073-9a13-dfcf1eb9a723"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12e7de7ce1574c48a5037263df2cd692_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMTMtMS0xLTQ3MjI2_3be0f9d2-c2ec-433d-a67f-ebe2534a355d"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id15c5d3332d947399180c64379abbaad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjY5YThhMmMzMjFiNjQ3ZjI5YTQ5MTUzNTdhZmQ1YzJjL3RhYmxlcmFuZ2U6NjlhOGEyYzMyMWI2NDdmMjlhNDkxNTM1N2FmZDVjMmNfMTAtMTUtMS0xLTQ3MjI2_4b746441-d771-4263-8591-cf7e934f192c"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7eb92e4042fd492b81f82838ab7dfa53_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xLTEtMS00NzIyNg_b2361bc1-0e7c-49f7-b8d3-fb7dabd8db8d"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7eb92e4042fd492b81f82838ab7dfa53_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0zLTEtMS00NzIyNg_8e354a2a-b0ea-461b-83f5-c937f2d5b0ce"
      unitRef="usd">2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb4ca91c9613414a94f9900f8909af66_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy01LTEtMS00NzIyNg_5e677403-2700-48b6-bf8d-c6d336090a85"
      unitRef="usd">1205000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i8ed791e44eac4a27bd9c7d44a85d03fb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy03LTEtMS00NzIyNg_c581fcfc-84ba-4e2d-973d-d3021eff7291"
      unitRef="shares">-36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i8ed791e44eac4a27bd9c7d44a85d03fb_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy05LTEtMS00NzIyNg_0e03c227-75d6-4dfa-b67e-aebd50361566"
      unitRef="usd">-2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifeeec8b34c774e7b9466d999568a65a0_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xMS0xLTEtNDcyMjY_1d2ee540-8f98-4043-a77f-bc229c8b2e06"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2689810533ba4608b106bf844d197fb4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xMy0xLTEtNDcyMjY_9ceba5ea-6127-42b9-9a6d-39fc108ad5ec"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMy0xNS0xLTEtNDcyMjY_16e0542e-353a-4dc9-add8-6d48a35f9157"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNC01LTEtMS00NzIyNg_96f44a9b-1e7d-4481-a3ab-61d1eda25139"
      unitRef="usd">320000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i247ac8c144e2402e9b7a5cdf73e42b35_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNC0xMy0xLTEtNDcyMjY_e5aabae2-816f-48cc-9ed7-080dd0b8d2f2"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNC0xNS0xLTEtNDcyMjY_96a93bdc-a3d0-40ad-b648-7c956214d33a"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNS0xMS0xLTEtNDcyMjY_861559ca-e990-4476-8d47-1bcbf840494a"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNS0xNS0xLTEtNDcyMjY_9629d886-2239-44cc-8a64-f4000a8f45fb"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy0xLTEtMS00NzIyNg_bb7eb49d-7374-4ef7-8991-73b9e30e62ed"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy0zLTEtMS00NzIyNg_077785a8-284b-4230-a250-de3b4bdf704b"
      unitRef="usd">-25000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy03LTEtMS00NzIyNg_4775b011-8b56-414e-954b-f6ac9515c59d"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy05LTEtMS00NzIyNg_daba13f8-0d0f-473e-9cb6-64404aabba12"
      unitRef="usd">43000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfNy0xNS0xLTEtNDcyMjY_794d5ea2-79a6-4265-8fbb-1b4d72f11dce"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id80a6d1a4e5e4e43977bfc1e4f976327_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC0zLTEtMS00NzIyNg_7e664dcf-6345-4ef6-97d4-3b6903342926"
      unitRef="usd">-60000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC03LTEtMS00NzIyNg_332f5f78-5b10-4385-8d3f-72a3c48ae212"
      unitRef="shares">15000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC05LTEtMS00NzIyNg_a3574cb4-20a7-4dd4-adac-ebf2d192dfc7"
      unitRef="usd">740000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOC0xNS0xLTEtNDcyMjY_324d05da-c7a2-4a94-8f9e-5d83b50eb36b"
      unitRef="usd">800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i72771dd6f35d4ef389cc86b92183c631_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOS01LTEtMS00NzIyNg_a45db2ea-f640-4c1a-81af-77f452bba7b5"
      unitRef="usd">280000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfOS0xNS0xLTEtNDcyMjY_e93f11af-24b2-46a1-a313-827f7af5fbcc"
      unitRef="usd">280000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i72771dd6f35d4ef389cc86b92183c631_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtNS0xLTEtNDcyMjY_71f74dd9-e1c4-41f9-855b-69f67fa219ff"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ib5d27cafd67e4892b30c701061fd4a72_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtNy0xLTEtNDcyMjY_53fc3d29-7683-4816-b56b-5ebc6e5afc6c"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i247ac8c144e2402e9b7a5cdf73e42b35_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtMTMtMS0xLTQ3MjI2_7a6e2b87-1400-415e-b2ad-af7578307572"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTAtMTUtMS0xLTQ3MjI2_e4bb478f-7485-4a07-9d86-8c43c94dc3b9"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMS0xLTEtNDcyMjY_8f975390-b47c-4b17-9450-fefea6f035ab"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i126ccb95fe4446f895412bf247fc34d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMy0xLTEtNDcyMjY_8e71ac3a-a313-4b2f-aecf-8161f5fae651"
      unitRef="usd">2721000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1422fa549c8c4fd78d87a5e7bddef0cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItNS0xLTEtNDcyMjY_e46015cb-c15d-4815-8396-a2af952a9bd7"
      unitRef="usd">1245000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItNy0xLTEtNDcyMjY_15553481-09a8-4b55-8b62-42a3798531c1"
      unitRef="shares">50000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i81e9b369a2e249aa9c82e841d358043c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItOS0xLTEtNDcyMjY_ffc4570b-61c9-4574-bfbf-e13645b38f04"
      unitRef="usd">2883000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b36454ae8f34474b633982b25f47ddf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMTEtMS0xLTQ3MjI2_422ee3fb-da72-4cb0-bc54-30138ac97125"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76f5c033b2b34568b248de95ea9ae8d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMTMtMS0xLTQ3MjI2_353821fb-8d72-462e-96cf-043f12b71319"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOmYzMTA3NDAwMDk2ZjQ0MWNhNDg5ZGFmODkxOTdjMWY1L3RhYmxlcmFuZ2U6ZjMxMDc0MDAwOTZmNDQxY2E0ODlkYWY4OTE5N2MxZjVfMTItMTUtMS0xLTQ3MjI2_3d53c03d-b01a-4f9e-9211-5f426f7df3a5"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="if521936d67844e53ad65faa8fee63ccc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xLTEtMS00NzIyNg_0484d611-1720-4988-bc20-c75c077a623c"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if521936d67844e53ad65faa8fee63ccc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0zLTEtMS00NzIyNg_6e3e6e50-ceca-4020-993c-889a0ecd7e8e"
      unitRef="usd">2789000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id81fff506366476385ee6cedef0c063c_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS01LTEtMS00NzIyNg_1c8c5a89-71e1-410b-b1de-792d1beaea71"
      unitRef="usd">1170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i09481b076c1d445abdc3ed3a80f5911a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS03LTEtMS00NzIyNg_35357e72-2506-4ed9-b2f7-d621d746005b"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i09481b076c1d445abdc3ed3a80f5911a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS05LTEtMS00NzIyNg_44ab30ae-95c1-4bd5-90aa-b58e7c353b9e"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia20d6610e65a457a868d48435b845bbf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xMS0xLTEtNDcyMjY_aecf53e1-6c71-4d7b-a4c5-bff99093e7d5"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43dfa1a7cdf74ea793edc03f0339f726_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xMy0xLTEtNDcyMjY_e151c20d-5dfa-48fe-8e37-f61c04ffdfae"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1620d434ff84017a4abba4b2b674fee_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMS0xNS0xLTEtNDcyMjY_571f86c4-da32-4826-900e-b367f4647837"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMi01LTEtMS00NzIyNg_f0d0c6b4-2b0e-44db-8ec3-f8a0258fcb88"
      unitRef="usd">376000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i056f47607d66400ab28d51e4b4199aaf_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMi0xMy0xLTEtNDcyMjY_ceb51bcf-4937-4b3c-b7f8-65c2e39f8d37"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMi0xNS0xLTEtNDcyMjY_1edda86e-ff06-455a-82d0-d65ef0da1f84"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i006f51b5845242aab04f6d1e5bd5574d_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMy0xMS0xLTEtNDcyMjY_8939aded-0ef1-4ebe-8ffa-5d74b245ef64"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfMy0xNS0xLTEtNDcyMjY_0ec63712-300b-481b-b27f-20cfd7dd8ec2"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i25f992d37c9445a39ce463c943d8a4b4_D20200701-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS0xLTEtMS00NzIyNg_b9cd2bf8-7b07-43b6-ab26-421a51b96cb5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i25f992d37c9445a39ce463c943d8a4b4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS0zLTEtMS00NzIyNg_0f94909f-058b-40d6-8faf-3630fb88b91c"
      unitRef="usd">-11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6898a41bdf2840358d646c0919f44974_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS03LTEtMS00NzIyNg_fa82e931-5701-4abb-bcf9-76504f108f29"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6898a41bdf2840358d646c0919f44974_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS05LTEtMS00NzIyNg_6fbfab2a-9ae6-492f-8bd4-34a757b79254"
      unitRef="usd">57000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNS0xNS0xLTEtNDcyMjY_ce47f134-61a8-4abf-a959-7cc38b912892"
      unitRef="usd">46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="i2f438da6cbd845748e199c85aa4cdde7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNy01LTEtMS00NzIyNg_2740e362-a444-4b40-9a23-ac6c8654a4ae"
      unitRef="usd">289000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfNy0xNS0xLTEtNDcyMjY_31af18af-601c-4739-948a-14fb9f9033f4"
      unitRef="usd">289000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i2f438da6cbd845748e199c85aa4cdde7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOC01LTEtMS00NzIyNg_d0499e08-fb1f-4ae2-97cf-4b91cf62c2a0"
      unitRef="usd">2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i056f47607d66400ab28d51e4b4199aaf_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOC0xMy0xLTEtNDcyMjY_b2787bae-9314-4901-8c2d-f9d344b4696b"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOC0xNS0xLTEtNDcyMjY_4cf46bd4-f460-45a2-8cdf-00f5f67769dd"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xLTEtMS00NzIyNg_a0833886-c9a2-4456-a6aa-0510c60fcb19"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i669eb53209e44369b85bd08b8337e1a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0zLTEtMS00NzIyNg_68eaceaf-6abb-4307-b473-1166c043cc93"
      unitRef="usd">2778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4abc0866cbe848d3893f1f444f75cfc0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS01LTEtMS00NzIyNg_085639f2-3e3e-48aa-b634-d5c12e4c16be"
      unitRef="usd">1255000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS03LTEtMS00NzIyNg_d6b964e9-56d8-4df8-813d-7308a611b20e"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i28be4398d9154a6ca1b5b457f10d7867_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS05LTEtMS00NzIyNg_d0bc5e9e-d977-49ec-9b37-5a3ab0a048b4"
      unitRef="usd">2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30ee22a4b8ab44809caa91d6c1c1eeaf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xMS0xLTEtNDcyMjY_e8c106ba-9297-4348-8f39-0b0c639b1fbd"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12e7de7ce1574c48a5037263df2cd692_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xMy0xLTEtNDcyMjY_45257e8f-7d66-40dc-b947-e878858afe61"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id15c5d3332d947399180c64379abbaad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83My9mcmFnOjliZjkwZTE5ZjQxYzQ1MmE5MTFlNjQwMjE0N2VjZWQzL3RhYmxlOjU5N2UyMWRiOTNkNzQ2NjZhOWQ1ZDJlYWIyNThiYzY4L3RhYmxlcmFuZ2U6NTk3ZTIxZGI5M2Q3NDY2NmE5ZDVkMmVhYjI1OGJjNjhfOS0xNS0xLTEtNDcyMjY_c4ca6bf3-b104-402d-be77-7dbeb29f12fc"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMy0xLTEtMS00NzIyNg_32c3064d-4743-4b0f-bef6-7da34646b842"
      unitRef="usd">321000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMy0zLTEtMS00NzIyNg_c1b39db7-ac68-4ba7-86e0-83c5d61dba4b"
      unitRef="usd">377000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNi0xLTEtMS00NzIyNg_1d32073b-8069-4adb-8c0a-6af22d986417"
      unitRef="usd">332000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNi0zLTEtMS00NzIyNg_5b66933d-6143-406b-987f-86b190e6ccb1"
      unitRef="usd">404000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0xLTEtMS03NTc5NA_f26f159e-b9f4-4355-8c53-8eb4a94ffe07"
      unitRef="usd">1000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0zLTEtMS03NTc5Nw_45013e52-29f1-4039-9bc9-e2d2a552711d"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0xLTEtMS00NzIyNg_b94145e3-193a-493a-965c-b01910af1de4"
      unitRef="usd">-1293000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOC0zLTEtMS00NzIyNg_c33f3f5b-d36f-49e8-ad21-7bd3ac383b11"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOS0xLTEtMS00NzIyNg_2c0ed403-230d-4907-8147-f624df06d76f"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfOS0zLTEtMS00NzIyNg_a1281eca-c8ba-4326-aae9-1b9cc8c01903"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTAtMS0xLTEtNDcyMjY_646b36ec-38f9-4f4d-bb70-859e99f82b46"
      unitRef="usd">42000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTAtMy0xLTEtNDcyMjY_ec124612-38f0-463b-a51f-3c87f3f70358"
      unitRef="usd">51000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTItMS0xLTEtNDcyMjY_129814f2-137a-40d1-b90e-76b97e307c00"
      unitRef="usd">25000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTItMy0xLTEtNDcyMjY_8785974a-642a-4336-a0d0-1e5bc784b226"
      unitRef="usd">35000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTQtMS0xLTEtNDcyMjY_cc143305-e61d-42c7-8059-de4add81815e"
      unitRef="usd">329000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTQtMy0xLTEtNDcyMjY_e5a03a82-6749-4550-a5dc-33c91c87fd9a"
      unitRef="usd">499000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTUtMS0xLTEtNDcyMjY_03df3f82-ae57-4b8d-bf00-d9f4a467f8e7"
      unitRef="usd">361000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTUtMy0xLTEtNDcyMjY_0c5a4525-a64e-4e45-8476-08fee58ef50f"
      unitRef="usd">1256000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTYtMS0xLTEtNDcyMjY_c1ee48db-0a44-4750-95ff-814a7eeb903d"
      unitRef="usd">1059000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTYtMy0xLTEtNDcyMjY_90b20e78-a637-447b-baa4-e6864a54156c"
      unitRef="usd">1861000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTctMS0xLTEtNDcyMjY_bd45483a-1f7d-4e51-b5a6-1c71c1de9fa4"
      unitRef="usd">1842000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTctMy0xLTEtNDcyMjY_4c7eceee-1be1-4fbd-afc7-e0121f5312bf"
      unitRef="usd">-504000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTgtMS0xLTEtNDcyMjY_7e3b1844-bd43-4260-b692-2009b30919d4"
      unitRef="usd">549000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMTgtMy0xLTEtNDcyMjY_4a9d6d0f-7146-442e-95da-ac163249b024"
      unitRef="usd">1487000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMS0xLTEtNjA3MzE_c3188336-9894-48ee-bf39-89e26776dd66"
      unitRef="usd">938000000</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMy0xLTEtNjA3MzE_eac1ab0b-0e84-4b12-9557-92b741eb7686"
      unitRef="usd">0</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMS0xLTEtNDcyMjY_3d7318a8-387a-4d5b-9a05-8b67167dba01"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjEtMy0xLTEtNDcyMjY_357f9d84-4289-4dac-a715-34f78a7ab096"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjItMS0xLTEtNDcyMjY_598d9d8a-9f08-4fcd-ac09-b8fb21ec7872"
      unitRef="usd">141000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjItMy0xLTEtNDcyMjY_5e6d496a-e08c-4330-a61a-880722dca560"
      unitRef="usd">174000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjMtMS0xLTEtNDcyMjY_9cb0ecf4-92f9-4438-9f78-ce01e3cbd84d"
      unitRef="usd">4000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjMtMy0xLTEtNDcyMjY_60c4b002-4861-43a4-b7dc-e5e8f8620ecb"
      unitRef="usd">18000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjQtMS0xLTEtNDcyMjY_4847b580-99fc-495b-bf2e-e33041804c7d"
      unitRef="usd">22000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjQtMy0xLTEtNDcyMjY_d5ba404c-668e-4369-b6f2-33b73a7c6710"
      unitRef="usd">4000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjctMS0xLTEtNDcyMjY_6bacd0c6-f5b1-4f1e-9401-55ae669c6088"
      unitRef="usd">815000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMjctMy0xLTEtNDcyMjY_27bf3044-e131-4c26-9074-72afca4a135d"
      unitRef="usd">-191000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzItMS0xLTEtNDcyMjY_4074b3a8-5ebc-41cf-b47a-dbe528f0614d"
      unitRef="usd">592000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzItMy0xLTEtNDcyMjY_4c37f356-f937-4eba-ba4c-4c61f2610d81"
      unitRef="usd">49000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzMtMS0xLTEtNDcyMjY_f0d1cd6f-ade2-4ad6-8538-e88c497ad30e"
      unitRef="usd">-27000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzMtMy0xLTEtNDcyMjY_7111e920-3d0b-4e3a-b700-b60cdcb6af73"
      unitRef="usd">-6000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzUtMS0xLTEtNDcyMjY_b758e889-9530-43ba-8c3d-34bb127f5b4c"
      unitRef="usd">289000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzUtMy0xLTEtNDcyMjY_140aad58-1312-4785-9e03-18ed77cad8b7"
      unitRef="usd">289000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzYtMS0xLTEtNDcyMjY_64856848-6e87-45e6-a0c7-779dbd2a2d02"
      unitRef="usd">800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzYtMy0xLTEtNDcyMjY_a92145ed-45c2-4606-a1e4-d597e5790d46"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzctMS0xLTEtNDcyMjY_7072fd6c-4e43-404b-b2fe-fc921b100072"
      unitRef="usd">-1708000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzctMy0xLTEtNDcyMjY_21866da3-1daa-41e5-88c2-5356e87f7c11"
      unitRef="usd">-344000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzktMS0xLTEtNDcyMjY_6a24d0d6-cb4e-4bc2-a41d-8d6ff989e471"
      unitRef="usd">-11000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfMzktMy0xLTEtNDcyMjY_11c3a831-df3e-4471-9774-f3354cf28edb"
      unitRef="usd">14000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDAtMS0xLTEtNDcyMjY_fb74adea-a58d-411b-b1bf-ffbd90aa7047"
      unitRef="usd">109000000</cah:CashReclassifiedToAssetHeldForSale>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDAtMy0xLTEtNDcyMjY_d595a1b0-11e1-43a7-8ac8-bce13c6a5bc4"
      unitRef="usd">0</cah:CashReclassifiedToAssetHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDItMS0xLTEtNDcyMjY_2f8d4677-4917-4ece-923e-05189e4d0447"
      unitRef="usd">-246000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDItMy0xLTEtNDcyMjY_a4d71062-70f6-45ec-a2df-9623e0c008c3"
      unitRef="usd">966000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDMtMS0xLTEtNDcyMjY_01dadc52-80cf-4aa9-a458-dd6619935b9e"
      unitRef="usd">3407000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia1620d434ff84017a4abba4b2b674fee_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDMtMy0xLTEtNDcyMjY_1ca467fc-1f1d-4a40-8e47-693b7ac44240"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDQtMS0xLTEtNDcyMjY_11985bf1-dd4b-4626-9efc-7ddc73fc8478"
      unitRef="usd">3161000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id15c5d3332d947399180c64379abbaad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV83Ni9mcmFnOjdlMDAyNGU3MTQ4NDQ3MTNhNDBkYmZiOGE4ZDE1MzYxL3RhYmxlOjI5ZWJhYTQwN2FmZjRlZjhiYmJhYWQzZjk2ZDFmNWVkL3RhYmxlcmFuZ2U6MjllYmFhNDA3YWZmNGVmOGJiYmFhZDNmOTZkMWY1ZWRfNDQtMy0xLTEtNDcyMjY_7752529a-2d2b-4c16-8743-d7fef0c0bbc0"
      unitRef="usd">3737000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84Mi9mcmFnOjg3NjNmMzhjNjBjMTQxMDhiOGFmODEwODFhOTg3MGQzL3RleHRyZWdpb246ODc2M2YzOGM2MGMxNDEwOGI4YWY4MTA4MWE5ODcwZDNfMzY4Mg_f1fc814d-5077-423f-bbd5-e323658889c0">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the six months ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84Mi9mcmFnOjg3NjNmMzhjNjBjMTQxMDhiOGFmODEwODFhOTg3MGQzL3RleHRyZWdpb246ODc2M2YzOGM2MGMxNDEwOGI4YWY4MTA4MWE5ODcwZDNfMzY4MA_5e538940-9c98-4bd0-a790-ea004ec438a2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended December&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2022 and June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the six months ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84Mi9mcmFnOjg3NjNmMzhjNjBjMTQxMDhiOGFmODEwODFhOTg3MGQzL3RleHRyZWdpb246ODc2M2YzOGM2MGMxNDEwOGI4YWY4MTA4MWE5ODcwZDNfMzY4Ng_1eaf0828-5ef7-4b5f-be59-35652a26b26c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the six months ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84NS9mcmFnOmY3OThiOWQ0NjBmYjQwNjk5MTA5YTU1ZjUxNzIxYjA3L3RleHRyZWdpb246Zjc5OGI5ZDQ2MGZiNDA2OTkxMDlhNTVmNTE3MjFiMDdfMjUwNQ_66f3189c-24df-47c8-a749-b8bc16a7eeb6">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we sold the Cordis business to Hellman &amp;amp; Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;No&lt;/a&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;te&lt;/a&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; &lt;/a&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Cordis business operated within our Medical segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84NS9mcmFnOmY3OThiOWQ0NjBmYjQwNjk5MTA5YTU1ZjUxNzIxYjA3L3RleHRyZWdpb246Zjc5OGI5ZDQ2MGZiNDA2OTkxMDlhNTVmNTE3MjFiMDdfMjE5OTAyMzI1ODE0Mw_1624bf29-0c84-4c51-a82b-88be72345f3b"
      unitRef="usd">927000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RleHRyZWdpb246OGFkMTRiYzlmNTBlNGI2NmI5MmU1ZWRkYTEzN2JkY2RfMTExNQ_a2e8268c-3789-429a-9428-b016b29f641e">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs during both the three and six months ended December&#160;31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three and six months ended December&#160;31, 2021 also included costs related to the divestiture of the Cordis business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RleHRyZWdpb246OGFkMTRiYzlmNTBlNGI2NmI5MmU1ZWRkYTEzN2JkY2RfMTEyMg_6379577c-5ef2-4041-842c-9ccb2b8c198e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMi0xLTEtMS00NzIyNg_32cc95ce-1b9a-4dba-8f5d-1121b29e8a93"
      unitRef="usd">2000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMi0zLTEtMS00NzIyNg_deb46a8c-3db1-4e6e-9e04-b32c100e41b5"
      unitRef="usd">8000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMy0xLTEtMS00NzIyNg_0e1e4fa9-9311-4cd5-bf57-d394b3e9a5cf"
      unitRef="usd">5000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfMy0zLTEtMS00NzIyNg_f752ecde-51c2-4faf-a03e-62bb947fa065"
      unitRef="usd">12000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfNC0xLTEtMS00NzIyNg_0d33bb3e-3f56-4003-bdd6-fd3c62213b94"
      unitRef="usd">7000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjc3OGJkZDk5ODIxNjQ0ODFhNGY2NWM1ZmQzMmE5MzY5L3RhYmxlcmFuZ2U6Nzc4YmRkOTk4MjE2NDQ4MWE0ZjY1YzVmZDMyYTkzNjlfNC0zLTEtMS00NzIyNg_c1fbe86c-6c39-45d9-8d80-1bde2605b146"
      unitRef="usd">20000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMi0xLTEtMS00NzIyNg_8b364fa2-9170-4d8f-b52d-ca5d82c0289f"
      unitRef="usd">10000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMi0zLTEtMS00NzIyNg_c6ee7f6c-0897-484b-935e-cd162d094d5e"
      unitRef="usd">32000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMy0xLTEtMS00NzIyNg_612ef0f3-d23e-4bcf-8ead-f3db230ef9ed"
      unitRef="usd">15000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfMy0zLTEtMS00NzIyNg_342d1e0d-46a6-45d5-8d5e-f60301035e33"
      unitRef="usd">25000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfNC0xLTEtMS00NzIyNg_f02371ea-66aa-4f4d-9d34-c77e442f4d10"
      unitRef="usd">25000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjgyNGRlMzRiMjBiNzRjYmNhMDQ4NGM3ZTJlMDZhZDc1L3RhYmxlcmFuZ2U6ODI0ZGUzNGIyMGI3NGNiY2EwNDg0YzdlMmUwNmFkNzVfNC0zLTEtMS00NzIyNg_f59ad1b9-909f-4e30-94b2-b7b7f9aa16cb"
      unitRef="usd">57000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RleHRyZWdpb246OGFkMTRiYzlmNTBlNGI2NmI5MmU1ZWRkYTEzN2JkY2RfMTExMg_2ee5176b-e56d-40b0-ba1a-e7d3710a408f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i689ae4253cf44b73ac84db72214af2a4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMS0xLTEtMS00NzIyNg_446ee48e-240c-4171-be93-9ff7f561f263"
      unitRef="usd">53000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic6d5f06ee3664cac9f54724c815b9d73_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMS0zLTEtMS00NzIyNg_42b4be39-7ef0-4d48-b17c-f6cf4b88582d"
      unitRef="usd">26000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMS01LTEtMS00NzIyNg_3968e6e1-2216-469f-a656-31919a9c0ca4"
      unitRef="usd">79000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i4761d672de014c8e9dad6c7102688227_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMi0xLTEtMS00NzIyNg_731f4a2a-e315-4a69-aeba-bfaa76b65420"
      unitRef="usd">16000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i6b760199824642c0a8d322009fa28dcc_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMi0zLTEtMS00NzIyNg_9460a4c7-2e83-4da7-b046-2b92e42b277a"
      unitRef="usd">1000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMi01LTEtMS00NzIyNg_1e78fb94-8f1b-455b-a5d3-133f8370b333"
      unitRef="usd">17000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4761d672de014c8e9dad6c7102688227_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMy0xLTEtMS00NzIyNg_597df185-75f0-4033-91f3-e7078134eeea"
      unitRef="usd">25000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6b760199824642c0a8d322009fa28dcc_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMy0zLTEtMS00NzIyNg_1ca3030c-e06e-4b0a-bbbe-4aad749d88e9"
      unitRef="usd">9000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfMy01LTEtMS00NzIyNg_3c3651ab-a785-4d6d-b3ce-c6ecc8d3538e"
      unitRef="usd">34000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i485b4945d9224029a35f582637d5d038_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfNC0xLTEtMS00NzIyNg_8ceeb66a-4064-484a-92fc-e8532a70c3b0"
      unitRef="usd">44000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i54300086ab194a77aea92977e16df53b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfNC0zLTEtMS00NzIyNg_985429a6-883c-4d20-9a31-6e8c3a5ebb6a"
      unitRef="usd">18000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV84OC9mcmFnOjhhZDE0YmM5ZjUwZTRiNjZiOTJlNWVkZGExMzdiZGNkL3RhYmxlOjg3M2E0YWQ3Yzk5MzQ0MzU5NjUzODFlOGZkMWRjM2YzL3RhYmxlcmFuZ2U6ODczYTRhZDdjOTkzNDQzNTk2NTM4MWU4ZmQxZGMzZjNfNC01LTEtMS00NzIyNg_c6d9bea7-066a-40d7-8e17-e27f5e5a64d3"
      unitRef="usd">62000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTExNA_539c1932-52a8-4778-9f29-750856a01ccb">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At December 31, 2021 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At December 31, 2021 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $2.7&#160;billion and $1.4&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2021, the Medical Unit, which is our Medical operating segment excluding our Cardinal Health at-Home Solutions division, continued to experience adverse financial results related to inflationary impacts and global supply chain constraints. Due to the risks and uncertainties related to these impacts, we elected to bypass the qualitative assessment and perform interim goodwill impairment testing for the Medical Unit. This quantitative test resulted in a pre-tax $1.3&#160;billion goodwill impairment charge related to the Medical Unit, which is included in impairments and (gain)/loss on disposal of assets in our condensed consolidated statements of earnings. The goodwill balance of the Medical Unit, after recognizing the impairment, was $2.8&#160;billion at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our determination of estimated fair value of our reporting units is based on a combination of the income-based approach (using a discount rate of 9 percent and a terminal growth rate of 2 percent percent), and the market-based approach. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,905&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,917&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $79 million and $113 million for the three months ended December 31, 2021 and 2020, respectively, and $157 million and $228 million for the six months ended December&#160;31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $157 million, $286 million, $262 million, $237 million, and $210 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTEzMw_d785ab1d-50fb-4004-a3f1-f0c27a5c6bfb">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At December 31, 2021 and June 30, 2021, the Pharmaceutical segment accumulated goodwill impairment loss was $829&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;At December 31, 2021 and June 30, 2021, the Medical segment accumulated goodwill impairment loss was $2.7&#160;billion and $1.4&#160;billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i1db397a74a1042b9aafec1289ddba925_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMS0xLTEtMS00NzIyNg_7234de77-d0e6-44ca-9fd0-6d46cbfb4cb8"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i066955108bab4e7e95ad3b02cf4ef347_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMS0zLTEtMS00NzIyNg_f7e1802d-8fca-4951-b74c-b38691fe6748"
      unitRef="usd">5330000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMS01LTEtMS00NzIyNg_ea9eba39-e667-4939-8338-e943f00e2756"
      unitRef="usd">7989000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ifa7745fb78df449faba2302b50698592_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMi0xLTEtMS00NzIyNg_2ac0b219-09ae-40bd-a003-b521b4f2be73"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ief6dedadffb54d5285c2b49eea80de65_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMi0zLTEtMS00NzIyNg_598b5e3c-d468-4ea5-8c56-796ddcd0917b"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMi01LTEtMS00NzIyNg_36268ce2-9de9-43f3-97c3-31f9d1f67567"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifa7745fb78df449faba2302b50698592_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMy0xLTEtMS00NzIyNg_c95e8192-2b2f-407a-aea7-d91cdd0bb291"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ief6dedadffb54d5285c2b49eea80de65_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMy0zLTEtMS00NzIyNg_63a25188-3add-4766-b571-2270e9ea49b6"
      unitRef="usd">-26000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfMy01LTEtMS00NzIyNg_83d989ee-b0b5-489b-8641-f0405d5bfa19"
      unitRef="usd">-26000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifa7745fb78df449faba2302b50698592_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNC0xLTEtMS00NzIyNg_717dc63b-9e39-4cf2-9a7b-67ee767c95f6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3492d85ea7b24e60910262ee6d3033ee_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNC0zLTEtMS00NzIyNg_70c63a57-a9a5-4c97-a398-54dc8d68b2bf"
      unitRef="usd">1307000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNC01LTEtMS00NzIyNg_31aaa87c-2eb0-40e0-984f-a9e0e431f07f"
      unitRef="usd">1307000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ie39aff34d5814c78ac189de6dab4b7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNS0xLTEtMS00NzIyNg_1604f72a-97f0-4ccb-b445-5dbe8da08a6b"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie965b585dfd74a75884609384471b2b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNS0zLTEtMS00NzIyNg_8a0a803f-d01a-4344-895b-3283b84b7a2b"
      unitRef="usd">3997000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNzgyZTRlM2NlNjQxYzNiM2JhMjcxNTNjNTg3YWUzL3RhYmxlcmFuZ2U6NGI3ODJlNGUzY2U2NDFjM2IzYmEyNzE1M2M1ODdhZTNfNS01LTEtMS00NzIyNg_b387ccc2-4123-4ffa-a6e4-2a0820a24a5b"
      unitRef="usd">6656000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i1db397a74a1042b9aafec1289ddba925_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUzNQ_348f92ed-3a66-401c-9584-33e23d50c1ce"
      unitRef="usd">829000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ie39aff34d5814c78ac189de6dab4b7ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUzNQ_4dc902c6-1583-4b2d-b1be-9465605f1475"
      unitRef="usd">829000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ie965b585dfd74a75884609384471b2b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUyMQ_b7286b45-772d-43e5-b0c8-4f4c43948fed"
      unitRef="usd">2700000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i066955108bab4e7e95ad3b02cf4ef347_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDUwNw_62a53e65-3774-4a7b-819e-5efaf6cc1a16"
      unitRef="usd">1400000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNDM5ODA0NjUyMzQ5Ng_6332aef6-cd71-4abc-8723-b09b71db798c"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ic6990beeb1e8488aa56f362d54b5ae9d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDQ5Mw_1447ebce-081f-4ac9-84bc-29f51966dd05"
      unitRef="usd">2800000000</us-gaap:Goodwill>
    <cah:DiscountRateFairValueInput
      contextRef="iaf07a0233e7740e1b2eaf72c788bc28f_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDU0OQ_9428df11-b575-4022-adae-c116c3f22456"
      unitRef="rate">0.09</cah:DiscountRateFairValueInput>
    <cah:TerminalGrowthRateFairValueInput
      contextRef="iaf07a0233e7740e1b2eaf72c788bc28f_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTA5OTUxMTYzNDU1NQ_fa4be533-c20d-4bab-bbea-f0ec971befba"
      unitRef="rate">0.02</cah:TerminalGrowthRateFairValueInput>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfMTEzNQ_931dcb75-b262-4602-a08b-4746ab16a649">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,905&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,931&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,917&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4e7b338780e74021a81ef74ef08b7a25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMy0xLTEtMS00NzIyNg_8468ae88-5390-4fcf-8c68-e8ea7a117b81"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4e7b338780e74021a81ef74ef08b7a25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMy01LTEtMS00NzIyNg_cfb9eb11-4ffb-45cd-b3ab-d9dd7b8f0863"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNC0xLTEtMS00NzIyNg_1593cd82-ad8a-4094-8152-573fac7ac53f"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNC01LTEtMS00NzIyNg_5e291c48-5f30-4aa0-b7bd-45cb59343a1e"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i77bebd2a91ae417eb4439959bf9f6d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy0xLTEtMS00NzIyNg_fbab86e7-d962-4eae-b276-da1948c36fe7"
      unitRef="usd">3317000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i77bebd2a91ae417eb4439959bf9f6d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy0zLTEtMS00NzIyNg_e4d7e821-5cef-4c98-9323-b0f60d29c73f"
      unitRef="usd">2089000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i77bebd2a91ae417eb4439959bf9f6d31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy01LTEtMS00NzIyNg_e70cf81c-02f5-451e-a234-80dc84176aad"
      unitRef="usd">1228000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i823151805e0f490888d034841f637bc5_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfNy03LTEtMS00NzIyNg_0c2030d2-6aba-4980-aa9e-6d4830dd7001">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i505ef6105727459882cd4fed2648f6c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC0xLTEtMS00NzIyNg_4e6ddca0-98bf-4362-b591-8c5ab916e9d2"
      unitRef="usd">552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i505ef6105727459882cd4fed2648f6c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC0zLTEtMS00NzIyNg_4e46f15a-eab0-4f14-acd1-33a6cd702916"
      unitRef="usd">344000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i505ef6105727459882cd4fed2648f6c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC01LTEtMS00NzIyNg_4077281b-01b3-4c6a-9e64-13964cb90d7c"
      unitRef="usd">208000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i7a15392899d2482fbb95514624452a8d_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOC03LTEtMS00NzIyNg_bd8c10d8-c824-4aef-87d1-41374e571d9f">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4a85889e6ab440f18e191494e3590714_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS0xLTEtMS00NzIyNg_df88c0ad-92d4-4b7e-a930-3c066dd423ac"
      unitRef="usd">1036000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4a85889e6ab440f18e191494e3590714_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS0zLTEtMS00NzIyNg_c97062b6-b787-4a11-80df-e487cf86d936"
      unitRef="usd">541000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4a85889e6ab440f18e191494e3590714_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS01LTEtMS00NzIyNg_a9263eca-922d-4fc0-8c34-860bd8e43fd6"
      unitRef="usd">495000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i3aa68d96ad1e4049873af142ed3aef39_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfOS03LTEtMS00NzIyNg_1101eede-266e-49ec-a2cf-2945966dab23">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtMS0xLTEtNDcyMjY_5e6645a6-e5fd-4738-9681-3616f02c3a39"
      unitRef="usd">4905000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtMy0xLTEtNDcyMjY_537ec560-f840-4206-a0dc-d999164de512"
      unitRef="usd">2974000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtNS0xLTEtNDcyMjY_cb4574cb-7391-49b9-b8c8-7472f41bcd36"
      unitRef="usd">1931000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTAtNy0xLTEtNDcyMjY_2983b0c2-4ca2-4fa5-aec7-efb2f77b7e4c">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTEtMS0xLTEtNDcyMjY_744765a1-0bed-4814-84f5-ae1561923147"
      unitRef="usd">4917000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTEtMy0xLTEtNDcyMjY_6f638467-9521-4b81-9eb3-4e3c1f8f462c"
      unitRef="usd">2974000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOmQ4YTNiYjYwNjUxMTQwOTI5NWI1Y2U1NGI4NjI2MmRlL3RhYmxlcmFuZ2U6ZDhhM2JiNjA2NTExNDA5Mjk1YjVjZTU0Yjg2MjYyZGVfMTEtNS0xLTEtNDcyMjY_2ccf4666-2d64-4fd1-838e-37852badf3da"
      unitRef="usd">1943000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5005f9b9f5c748b6b3dc0a951c8577da_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMy0xLTEtMS00NzIyNg_abd57583-a5ff-4c59-9b14-e35984a219e6"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5005f9b9f5c748b6b3dc0a951c8577da_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMy01LTEtMS00NzIyNg_58ba23e0-e209-47f9-9826-3fcef55ddaf7"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNC0xLTEtMS00NzIyNg_ee05be38-db98-46cd-a492-2f55463823d9"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNC01LTEtMS00NzIyNg_19ac08d0-8bee-4768-a472-4117a32cd404"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iab78dc9db493437ebf096a1f66c9842d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNy0xLTEtMS00NzIyNg_e90ea0d2-0b05-4f15-beec-1ebf11d7b0f4"
      unitRef="usd">3330000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iab78dc9db493437ebf096a1f66c9842d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNy0zLTEtMS00NzIyNg_9ada11b5-5c1c-4bbb-825a-278ee66917f9"
      unitRef="usd">1989000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iab78dc9db493437ebf096a1f66c9842d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfNy01LTEtMS00NzIyNg_32c26ba8-a5f4-4328-afaa-5f8206b61990"
      unitRef="usd">1341000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOC0xLTEtMS00NzIyNg_1520e6ff-9743-4f14-a324-b4b1f6ec577c"
      unitRef="usd">551000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOC0zLTEtMS00NzIyNg_88676d5c-0d1a-482e-bdbf-1367fbff2858"
      unitRef="usd">328000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i98d8196bcf7d42c6a5e8d692d8e2ca5c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOC01LTEtMS00NzIyNg_13ae84d2-c547-4c04-b773-3bdc9e23c358"
      unitRef="usd">223000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9a260218f5c74e0a818560db3bc26ab5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOS0xLTEtMS00NzIyNg_6136b76d-c391-4750-a6a0-83e22ece55b1"
      unitRef="usd">1035000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9a260218f5c74e0a818560db3bc26ab5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOS0zLTEtMS00NzIyNg_fe4fe31a-bfd5-4b1e-83fa-a81cdf98abfb"
      unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9a260218f5c74e0a818560db3bc26ab5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfOS01LTEtMS00NzIyNg_5ddc31db-073e-47db-bea3-b5209a70888c"
      unitRef="usd">529000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTAtMS0xLTEtNDcyMjY_46996364-704f-4fc0-baf9-206213237004"
      unitRef="usd">4916000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTAtMy0xLTEtNDcyMjY_d30cae1b-0e6c-4d55-8464-e362ba49c770"
      unitRef="usd">2823000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTAtNS0xLTEtNDcyMjY_e7f9bb83-7e28-4d4b-aeef-e9c8b7e98bff"
      unitRef="usd">2093000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTEtMS0xLTEtNDcyMjY_b516d8c5-3769-47cd-bfeb-c693aa32a5b6"
      unitRef="usd">4928000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTEtMy0xLTEtNDcyMjY_92ff6174-8c6f-4cea-b78a-edfd4a23886a"
      unitRef="usd">2823000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RhYmxlOjRiNGRlZmIzZTVlMTRjZWFhYzIyZTczNzI3YzFlYmNmL3RhYmxlcmFuZ2U6NGI0ZGVmYjNlNWUxNGNlYWFjMjJlNzM3MjdjMWViY2ZfMTEtNS0xLTEtNDcyMjY_c51096ab-843a-4f80-8dc8-93d3ca3f42f5"
      unitRef="usd">2105000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNjU5_ab106d74-7450-489f-bf24-4cc7741a57e7"
      unitRef="usd">79000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNjY2_4d3af82d-9b2c-43a0-839b-ba2b42dfad4a"
      unitRef="usd">113000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNzI1_a00bd5f6-c368-4371-be48-25d82a69d506"
      unitRef="usd">157000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfNzMy_69f39c53-37e0-40fb-830b-8b76375274e2"
      unitRef="usd">228000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODc5_b405f7d1-2b7a-4c30-87cf-5690df68adc5"
      unitRef="usd">157000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODgz_c83a583e-f945-4872-9b97-26a710862f9f"
      unitRef="usd">286000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODg3_8acd32b8-4209-4671-8438-9780c4ab655a"
      unitRef="usd">262000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODkx_3043f048-c80b-4572-8662-735ac8c6244b"
      unitRef="usd">237000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV85MS9mcmFnOjBkNDlhY2Y0OGQ5ZDQ4OTVhNzUzODdiOTIxMDkyNzg4L3RleHRyZWdpb246MGQ0OWFjZjQ4ZDlkNDg5NWE3NTM4N2I5MjEwOTI3ODhfODk4_420fd482-ba25-4be2-962c-17ea04f302a9"
      unitRef="usd">210000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIzNDg_7ac5fc54-6d80-4b3b-bc69-dcbedc66cf21">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $5.6 billion and $6.2 billion at December&#160;31, 2021 and June&#160;30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $24.8 billion and $23.7 billion at December&#160;31, 2021 and June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2020, we early repurchased a total of $40 million of the Floating Rate Notes due 2022 and $2 million of the 2.616% Notes due 2022. The repurchases were funded with available cash. In connection with the early debt repurchases, we recorded a $1 million loss on early extinguishment of debt during the six months ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;December&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2022. CHF was organized for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of December&#160;31, 2021, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <cah:TotalLongTermandShortTermObligations
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTgwMTI_89df79b8-a148-4d9f-aebd-3ca2dda6dae6"
      unitRef="usd">5600000000</cah:TotalLongTermandShortTermObligations>
    <cah:TotalLongTermandShortTermObligations
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTgwMjA_30198895-1a96-45f6-b642-f3b80535172a"
      unitRef="usd">6200000000</cah:TotalLongTermandShortTermObligations>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzU1Nw_c60717bf-39ee-4f21-ac3d-f69be7cc4dd3"
      unitRef="usd">24800000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzU2NA_bdcda125-44e2-429a-ab60-c2686a314b84"
      unitRef="usd">23700000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i7828cce062bc44f0951fdcd8139d81b9_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTgyMDk_30073f49-2161-4ac1-84ad-61762c988c02"
      unitRef="usd">572000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7828cce062bc44f0951fdcd8139d81b9_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzIxOTkwMjMyNTg0NTY_2e7a4d5d-9542-45bd-ac26-8ac132e370ed"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i88e4b2aae2ad40a09418ad56348b3b01_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzcxNDY4MjU1ODUzMDI_0f566414-52f5-416c-97a5-673c7a89e650"
      unitRef="usd">40000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i01a126ed6a3341d7babdddc3b8c5a1af_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzcxNDY4MjU1ODU2MjQ_329da6ce-89ba-4e06-af22-af9f8f4333a5"
      unitRef="usd">2000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzcxNDY4MjU1ODU2NTk_3b88c3e7-e86a-43ca-80f6-9d0457f0a9cf"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7ab62d58a2744c7d96ab48d178c5edc9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzE0NDA_f0f1e29a-689e-4622-bca2-ebe7ba8d8c9f"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id11e26319ddf483d88eafb2ba45b91cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzE0ODA_2181d63d-aae7-449e-afe6-5dac86d16d87"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7293644d26734b97832a304248e0d4f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzE1MjU_79efa988-b6c3-4bad-81e3-fd8e8c710228"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i8531707da0e64febbba666aed40d8040_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDAvZnJhZzo0NGRiNTBlNGFlYWI0NGEwYjQwODhkMDQ3MjI0OWE2NS90ZXh0cmVnaW9uOjQ0ZGI1MGU0YWVhYjQ0YTBiNDA4OGQwNDcyMjQ5YTY1XzQzOTgwNDY1MTYyNzA_d45b5f2f-6a66-4bd7-aab0-ff301cfd9ed0"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzE3MDU4_fe641388-d2db-4a57-9e1f-61fc2eef79e5">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 during the six months ended December 31, 2020 based on the probable estimated payment amount. In the three months ended December 31, 2021, we paid the State of New York $20&#160;million, our portion of the assessment for calendar year 2017. As a result, as of December 31, 2021, we had an accrual of $20&#160;million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,400 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#x201c;MDL&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#x201c;Proposed Settlement Agreement&#x201d;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement Agreement includes a cash component, pursuant to which we would pay up to approximately $6.37&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against us after the Proposed Settlement Agreement becomes effective.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#x2019; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As contemplated under the Proposed Settlement Agreement, in September 2021, the three distributors determined that a sufficient number of states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which was the subdivision sign-on period. The subdivision sign-on period ended January 26, 2022. Each participating state will now make a determination as to whether a sufficient number of its political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. Following that determination by participating states, each of the three distributors will independently determine whether a sufficient number of subdivisions, including both those litigating and those that have not sued, have agreed to participate in the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed to execution. This process is currently contemplated to end in February 2022. The Proposed Settlement Agreement remains subject to contingencies. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the required contingencies are satisfied, the Proposed Settlement Agreement is expected to become effective in April 2022. During the period between the satisfaction of contingencies and the effective date, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Proposed Settlement Agreement in each participating state and dismissing lawsuits of participating states and subdivisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors have entered into a settlement with each of the states of Florida, New York, Ohio and Rhode Island and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, these states and their participating subdivisions will become a part of it. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. In January 2022, we, along with two other &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;national distributors, entered into a term sheet with the Native American tribes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A bench trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a bench trial in the case brought by the Washington Attorney General against us and the same two other national distributors began in November 2021 in Washington state court. Trials are inherently unpredictable and it is possible that the outcome of these trials, either individually or in the aggregate, could materially negatively impact our financial results, cash flows or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68&#160;billion accrued at December&#160;31, 2021, of which $480&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the six months ended December 31, 2020, we recorded total pre-tax charges of $1.02&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;businesses and individuals alleging personal injury. Private parties had brought approximately 464 lawsuits as of January 25, 2022. Of these, 147 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial in a case involving 21 plaintiffs is scheduled to begin in state court in Georgia in March 2022. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#x201c;National Union&#x201d;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January 25, 2022, we are named as a defendant in 443 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,750 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 32 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, we had a total of $554&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.09&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Action &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related requests and cannot predict the outcome or duration of the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Specialty Solutions DOJ Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the United States Attorney&#x2019;s Office for the District of Massachusetts (the "USAO") commenced an investigation of Cardinal Health regarding possible violations of the U.S. healthcare fraud and abuse laws. The USAO sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. In January 2022, without admitting liability, we settled this matter with the DOJ for approximately $13 million, which was recorded as expense within litigation (recoveries)/charges net in our consolidated statement of earnings during the fiscal year ended June&#160;30, 2021. Additionally, our Specialty Pharmaceutical Distribution business entered into a five-year corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General, under which it agreed to certain remedial measures, including no longer offering term-based up-front discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. &lt;/span&gt;&lt;/div&gt;In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#x201c;Sartan MDL&#x201d;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i285548e776cd4b929eae18d3e9002181_D20140731-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMyNzMyMDA_c0798c92-c7f3-4dc5-9e53-e840ce224e79">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment
      contextRef="i62a27d05945443ad96f59cdcb1edc420_I20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzY5NA_cd93fa11-30c0-4d7a-8fb5-3c55578f6e58"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i66e6258348ea4fc89eb5ef7eb0cb10fe_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIwNDA_6611db5f-c447-4ef9-8a97-400947903dfb"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i1795ede44ce94976805d345dedf32727_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA4MzU_62a10cf3-1046-486b-a209-d3264dea15ae"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i29dc2aedb8bc420db59f14dd8db4e352_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA4MjI_91406b64-1ff7-43f1-b649-53f4fcc0b5f1"
      unitRef="usd">20000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <cah:JudgmentForLostProfits
      contextRef="i6542622e5ef24933a209e2a96b41e83a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTEyNDY_27f44988-c8e4-46fc-80a8-507342d539ad"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i1a5d7197ac224ce9bf2facd8d7e90d5f_I20220131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzU2Nzc_4877fc0a-09a0-48c1-a595-9809ea1c2039"
      unitRef="lawsuit">3400</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i36ac058f78664b5dbeba5619bf856f61_I20220131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzYyNDA_9b19d1ce-d07d-4d3e-9dbc-57f7c4a47fb4"
      unitRef="lawsuit">2900</cah:LossContingencyLawsuitsNumber>
    <cah:NumberofStateAttorneysGeneralfilinglawsuits
      contextRef="i1a5d7197ac224ce9bf2facd8d7e90d5f_I20220131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzY2NDg_90d3a02e-56ed-4508-9c9d-4bd0ebed9224"
      unitRef="stateag">25</cah:NumberofStateAttorneysGeneralfilinglawsuits>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxNDQwNDc2ODEwNDIx_e2626fe7-c130-46aa-b963-d5f57e76b906"
      unitRef="usd">6370000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LitigationReserve
      contextRef="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMDQ3MzY_61ece980-2df9-48e2-9242-8726475bdea6"
      unitRef="usd">6680000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserveCurrent
      contextRef="ie662584fa1ec40a58bcaa56d2e0cc9ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzEzNzQzODk1NDE1NTk0_20e67206-cc01-4761-8d97-755827cec904"
      unitRef="usd">480000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA4OTI_35152ff2-5ba4-498b-8656-e80e9db2b6e0"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i9c999577462049eda357e2ab78e71683_I20220125"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMDk4NTA_36ce283b-c704-433e-b7d0-2604931d4269"
      unitRef="lawsuit">464</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i40eadd91b0ae47328a2ae28ff036f822_I20220125"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMDk4OTc_bfb9294e-e40f-4686-952a-30735093e04e"
      unitRef="lawsuit">147</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id13e0ec03eda43788abcd88f803bccd1_D20220131-20220131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzQzOTgwNDY1OTA5MDA_97588f81-5d8d-47b3-b9f3-e067fd4a53e8"
      unitRef="plaintiff">21</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i1de5fd1605f748fdb2806fef4a6523c5_D20220125-20220125"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTEyODI_220d5d41-2d26-4311-9fb6-1658d2e2a01a"
      unitRef="lawsuit">443</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ib222890e5cd8438eae755da882ac9b57_D20220125-20220125"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE0MDY_f8f3cf92-0aef-4efb-a754-e11d9b737017"
      unitRef="plaintiff">5750</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i8d18e9c334304d17b47512697546cdfe_D20220125-20220125"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE1NTg_b194af45-d9a1-4e80-8ba4-2c546b82da45"
      unitRef="lawsuit">32</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i5e01245b5cf74dc58ec5bf20e479c9f0_D20220125-20220125"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE2MTM_42b6bd3f-c197-41e8-b811-440df12fb4da"
      unitRef="plaintiff">36</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="ifb2fd3c70f184444bdcf9b9585835c51_D20210731-20210731"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTE4MTQ_69c6949a-f2c3-4886-8de5-affbee63f8a9"
      unitRef="lawsuit">1300</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i68d6b6246aa54ad59d9d645973f16b87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTM1OTM_ac77fbfd-bcff-48f8-9782-f7cb60bef68e"
      unitRef="usd">554000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i726a9874ca6a4682a0a961cf53f77d36_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzIxOTkwMjMzMTQwNTA_192156c0-1d26-4159-822d-684a2ae33c90"
      unitRef="usd">1090000000.00</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6f5f0000b10443bb904f81c8727295ea_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDMvZnJhZzpmZDIwNzBmNDgzYjc0OGJiOWY1NzRiYzgzZDlkMWE4Yy90ZXh0cmVnaW9uOmZkMjA3MGY0ODNiNzQ4YmI5ZjU3NGJjODNkOWQxYThjXzE1MDA2_955d1cb5-5f71-4d41-807c-15021dfb05cf"
      unitRef="usd">-13000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzg4NDk_82784c4f-a439-443e-9f24-545d19549cdb">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our benefit from income taxes as a percentage of pretax earnings/(loss) (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Goodwill Impairment Charge&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2021, we recognized a $1.3&#160;billion pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $92&#160;million for fiscal 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effect of the goodwill impairment charge during the three months ended December&#160;31, 2021 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill significantly increased the estimated annual effective tax rate for fiscal 2022. Applying the higher tax rate to the current quarter loss resulted in recognizing an interim tax benefit of approximately $1.0&#160;billion, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months and six months ended December 31, 2021 and prepaid expenses and other assets in the condensed consolidated balance sheets at December 31, 2021. This interim tax benefit will reverse in future quarters of fiscal 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis Divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended December&#160;31, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $10&#160;million and $19&#160;million during the three and six months ended December&#160;31, 2021, respectively. The tax effects of these matters during the six months ended December 31, 2021 were included in our full year effective tax rate forecast. We currently estimate the tax expense associated with this matter for the full fiscal 2022 will be $38&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Self-Insurance Pre-tax Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2020, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, is currently deductible on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net operating loss is being carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, our provision for income taxes during the three months ended December&#160;31, 2020 included a $420&#160;million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have filed for a U.S. federal income tax refund of $974&#160;million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have a current asset on our condensed consolidated balance sheets at December&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700&#160;million during the six months ended December&#160;31, 2020 related to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Opioid Litigation Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the $1.02&#160;billion pre-tax charges for the opioid litigation recorded during the six months ended December&#160;31, 2020, the net tax benefits were approximately $300 million for the six months ended December&#160;31, 2020 and $228 million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million during the six months ended December&#160;31, 2020, and $219 million for fiscal 2021. We have recognized no tax benefit associated with Opioid accruals made in fiscal 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;105.0 percent and&#160;(47.6) percent, respectively. The effective tax rate for the three months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective tax rate. The estimated annual effective tax rate for the three months ended December 31, 2020 included the benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, partially offset by the treatment of the tax impacts of the opioid litigation accrual recorded in the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended&#160;December&#160;31, 2021&#160;and&#160;2020, the effective tax rate was 153.1 percent and 259.7 percent. The effective tax rate for the six months ended December 31, 2021 reflects the impact of the tax effect of the goodwill impairment charge being included in our estimated annual effective tax rate. The effective tax rate for the six months ended December&#160;31, 2020 included the benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss and net tax benefit related to the treatment of the tax impacts of opioid litigation charges.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $937 million and $932 million of unrecognized tax benefits, at December&#160;31, 2021 and June&#160;30, 2021 respectively. The December&#160;31, 2021 and June&#160;30, 2021 balances include $854 million and $849 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and June&#160;30, 2021, we had $45 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $20 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million at both December&#160;31, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures &lt;/span&gt;&lt;/div&gt;and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $3 million at December&#160;31, 2021 and $12&#160;million at June&#160;30, 2021, respectively, and is included in other assets in the condensed consolidated balance sheets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEyODY_6332aef6-cd71-4abc-8723-b09b71db798c"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib576ab5afad44195a834e1e7faeb7d53_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjExODQ_ed4078e0-b277-42d7-9769-59827c7b72b1"
      unitRef="usd">-92000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i37746254b4ef462ab66acbee39610807_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEzMTU_0f407073-5dea-4c8e-a2d2-d06a95679b2b"
      unitRef="usd">-1000000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i220be912f8c445d583c34c9d7a197d21_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjExOTc_a6235101-b6d5-42e8-aac1-5e12e2780335"
      unitRef="usd">10000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjM1MTU_e4a0c750-ee5e-4c10-8e29-43f429c7ac2d"
      unitRef="usd">19000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i0c6fc69a919e428a9249914f94b4e705_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIxOTkwMjMyNjQ4NzI_a34fe44c-3a41-43b4-8b8e-561fd9c327cd"
      unitRef="usd">38000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9770cc98f0834ead8999bddd6f93e81a_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjM0OTg_10716a38-799f-4c56-b448-fcf7bac29639"
      unitRef="usd">-420000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReceivable
      contextRef="i71c85c93cd4f49ccadff2110a5afb040_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjM5OTc_f6c657c3-83e3-4223-8f18-c531bf4dac3b"
      unitRef="usd">974000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i838623ba3e424777903a3d4ab8c49dc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzE2NDkyNjc0NjQwMTg_e7188dd7-de5e-4606-b26d-edebe2ea4e6e"
      unitRef="usd">700000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1Mjc1MDM_56ce0272-e8d0-47b9-adbd-de25ed64c097"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIyNzI_bfdf9f5f-4399-43ff-8b06-206a1fd4c9e0"
      unitRef="usd">-300000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b171a8060ae4f008d8e6a25869806bf_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIyNzk_086583d7-3b8a-492d-8468-04c0d3f70e39"
      unitRef="usd">-228000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i07d6f83592a1426993ab2a13d023f8f3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzI1Njk_91e3f7a3-035e-4a32-bf4a-8679b1603d76"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i00fa788fc87340c384b2380104923f42_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzI1NzY_b5f7b474-3d16-4b24-98b4-dda3dad264d9"
      unitRef="usd">219000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia7499fd6ae8f450daef1e62b7f4adf5b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEzMzM_56e60415-3f70-4419-ae47-79730d147eb7"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzU0MzA_bb49119c-7f58-4b60-a5a9-5942c8ba0c00"
      unitRef="number">1.05</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzU0NDU_3259b70d-d91f-45e3-b0eb-32c687b31ff3"
      unitRef="number">-0.476</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzIxOTkwMjMyNzE1Mzc_93643e5e-7e54-4440-9dc3-b225e308bb36"
      unitRef="number">1.531</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1MzI5MDI_9d8792ec-c826-4ef5-920b-b12561339404"
      unitRef="number">2.597</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYxODI_d5f6a079-723d-4be1-8650-cbc5eb50e308"
      unitRef="usd">937000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYxODk_b1b99f7d-b302-4f4a-8c0d-575040ae3aa6"
      unitRef="usd">932000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYyNjc_6829d7d3-ba37-4830-93fb-8b994f210f28"
      unitRef="usd">854000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzYyNzQ_cce58d64-3f74-4513-8e6a-600114cfa380"
      unitRef="usd">849000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzY0MTE_1852f43c-1a62-4133-a9c5-77f6b58750d7"
      unitRef="usd">45000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzY0MTg_6e30a823-2433-4cc5-a682-ce5bcd16d859"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i25f55518522b4794b80ca287b166f5cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzczMDE_f29cc5fa-4699-4130-a63b-e2cb8cfe234e"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i263e5ca49fed4bdbba6851bf32da93f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzczMzI_9968eb75-1d1b-4b4c-99da-47138687f6e0"
      unitRef="usd">20000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <cah:IndemnificationReceivable
      contextRef="i68578f163e6b4179847e8b41663e8613_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzgwMzk_12af4753-5db8-442d-a00d-470ab752e79a"
      unitRef="usd">72000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i43784f138b914b8391cd15843d15c989_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzgwMzk_5c2e14df-66ee-4c22-a5be-27030b45a6e3"
      unitRef="usd">72000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i488515e2c1534dd59e7585b97320412d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzg1NDk_ca151fc2-820a-45bd-8e34-35229b8c24f2"
      unitRef="usd">3000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i0f1090b7d5ea42a8a285ffc9484f2981_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDYvZnJhZzpjMzdiM2Q5OGY3NjM0NzJmOGE4ODY5NDdmNmMyMDkxMS90ZXh0cmVnaW9uOmMzN2IzZDk4Zjc2MzQ3MmY4YTg4Njk0N2Y2YzIwOTExXzQzOTgwNDY1NjEyMzk_eb3f4e0e-7e47-4cd5-a23c-9fc77774355c"
      unitRef="usd">12000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90ZXh0cmVnaW9uOjdmYzJjMzhlMmYzYzQ1NWRhYWZlMWJlOGI1NGZlZmMxXzE3MTk_b55938ff-c69e-4d7e-aebc-86d9685db75f">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90ZXh0cmVnaW9uOjdmYzJjMzhlMmYzYzQ1NWRhYWZlMWJlOGI1NGZlZmMxXzE3MTY_18fc9bad-bc7a-4c0e-a610-6c5d1609cc00">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5176a75ae1064d6387d055928f4a88c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtMS0xLTEtNDcyMjY_3a96eb36-6b56-43f6-a85f-0c6cc8205aa1"
      unitRef="usd">1077000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtMy0xLTEtNDcyMjY_7f963bc9-38b7-4926-a6f2-ed32acaee7b7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iec263fc27faf41e9a416ab2454257578_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtNS0xLTEtNDcyMjY_8974b65f-924e-4e9d-8267-90ac88d29001"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife056180602548b8811ec73a324b2646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzMtNy0xLTEtNDcyMjY_08396da6-3f3c-462b-9ce6-4b5475698f3e"
      unitRef="usd">1077000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5176a75ae1064d6387d055928f4a88c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtMS0xLTEtNDcyMjY_3ccb7533-7690-4979-ba0e-b54a48b79517"
      unitRef="usd">125000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtMy0xLTEtNDcyMjY_d7afbc57-9895-4812-aa25-8f6dfab699b9"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iec263fc27faf41e9a416ab2454257578_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtNS0xLTEtNDcyMjY_ad7ede8a-f629-4dc0-96ed-21900abb9450"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ife056180602548b8811ec73a324b2646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzUtNy0xLTEtNDcyMjY_623f1979-62b5-41ca-a13b-71941434e13c"
      unitRef="usd">125000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i5176a75ae1064d6387d055928f4a88c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtMS0xLTEtNDcyMjY_f41cdd2b-1df4-4b0f-a80b-ffbb67b71ec1"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i4b44c1fa449a47e3aaa5d0a612586c55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtMy0xLTEtNDcyMjY_590fd848-7a56-4d02-858e-b789000ece1f"
      unitRef="usd">62000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="iec263fc27faf41e9a416ab2454257578_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtNS0xLTEtNDcyMjY_49cc1d4b-b3b1-40c5-9e7c-e04622a67894"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ife056180602548b8811ec73a324b2646_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZToxY2VmMzI3MzEzMTA0N2JjYjNmMWRhNTliZTJkMWExZS90YWJsZXJhbmdlOjFjZWYzMjczMTMxMDQ3YmNiM2YxZGE1OWJlMmQxYTFlXzYtNy0xLTEtNDcyMjY_7a04f7ee-a602-47b0-922b-6f3d0c2181b2"
      unitRef="usd">62000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i490f28555d6e44018c5fb0a7112b17fa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtMS0xLTEtNDcyMjY_57234b8b-4bbc-4e34-837f-b7ae772d6573"
      unitRef="usd">1883000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtMy0xLTEtNDcyMjY_678bc735-6f63-4097-ac2f-35738cd3b7c6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtNS0xLTEtNDcyMjY_809405fa-5e60-4184-a848-a3bbff931433"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iee2308b88f9c42b991c03554e3e0145e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzMtNy0xLTEtNDcyMjY_35cb04af-1dc2-4b6c-bf39-ba1f5a0987bb"
      unitRef="usd">1883000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i490f28555d6e44018c5fb0a7112b17fa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtMS0xLTEtNDcyMjY_96dd243f-f32d-4569-8516-7633fcd663fc"
      unitRef="usd">126000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtMy0xLTEtNDcyMjY_40e0ab3d-bc6c-496b-85f1-5ea459b9f3b8"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtNS0xLTEtNDcyMjY_6d10b030-3fe2-475c-9c2f-46f1f54bd426"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iee2308b88f9c42b991c03554e3e0145e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzUtNy0xLTEtNDcyMjY_4fb6d2bf-a8ea-4994-97ea-7ad12363f2bb"
      unitRef="usd">126000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i490f28555d6e44018c5fb0a7112b17fa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtMS0xLTEtNDcyMjY_63474099-0c31-429e-9eb7-5d38ace896f9"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i5c13f18ce1e2446eb78dcbf5c8b62b5a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtMy0xLTEtNDcyMjY_4ee763a8-3c5a-4b55-b8a1-bce95a17209c"
      unitRef="usd">42000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i6f53e9950fc84bb2bc2e05a39bc3dda7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtNS0xLTEtNDcyMjY_c552fa68-7cd2-4b95-9cca-ca0bd3d9bc4e"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="iee2308b88f9c42b991c03554e3e0145e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMDkvZnJhZzo3ZmMyYzM4ZTJmM2M0NTVkYWFmZTFiZThiNTRmZWZjMS90YWJsZTo2NjMxZThiZGViOGY0NjEzOGFlZWRhNDZjMTRmZWFlNS90YWJsZXJhbmdlOjY2MzFlOGJkZWI4ZjQ2MTM4YWVlZGE0NmMxNGZlYWU1XzYtNy0xLTEtNDcyMjY_ef365bd1-a754-4f28-b985-623ca1d4d082"
      unitRef="usd">42000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzkwODg_e7e4507c-840c-4c67-b627-37d2cc0b03d6">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three and six months ended December&#160;31, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the six months ended December&#160;31, 2021, we entered into pay-floating interest rate swaps with notional amounts of $100 million and $200 million. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains recognized in other comprehensive income/(loss) were $1&#160;million and $8&#160;million for the three months ended December&#160;31, 2021 and 2020, respectively, and $3&#160;million and $7&#160;million for the six months ended December&#160;31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and six months ended December&#160;31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $17&#160;million gain and a $27&#160;million loss during the three months ended December&#160;31, 2021 and 2020, respectively, and a $22&#160;million gain and a $52&#160;million loss during the six months ended December&#160;31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during both the three months ended December&#160;31, 2021 and 2020 and $11&#160;million and $10&#160;million during the six months ended December&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $2 million gain and a $4 million loss during the three months ended December 31, 2021 and 2020, respectively, and a $4 million gain and $5 million loss during the six months ended December&#160;31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, Canadian dollar.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at December&#160;31, 2021 and June&#160;30, 2021 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_19c87aee-222b-4cec-afd2-d8b9d1237225"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_4b30138e-39cb-4c58-95a2-27efd500b454"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_7e7bdfba-a878-48db-a003-4da50f949f99"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzMyODA_9f12a482-9ca1-4441-a5bf-991af521927c"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i97efabb7eafb457086138a0357aee526_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU0OTc1NTgxNTIyNjE_a549df71-daf0-4d7b-9163-27fb1f9d3ccd"
      unitRef="usd">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib440b67408ee4c8fb412aeaaf58be6c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU0OTc1NTgxNTIyNjU_a9efafc3-b451-4351-be3e-7fb992592a28"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7f6c7a9a75f64986aefb952c73f437f8_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU1Mjc_017dfefe-57fd-4f87-a570-b763fa75f9af"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="if2aace5f028f4f5594de1fcc97eebe25_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzIxOTkwMjMyNjc1NDk_c48374d5-dd22-4c23-b926-92e186ee3053"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ice2850c2b1a44cd8880a41a004525e24_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU2MTI_5fbebb2e-de51-4be5-861f-1a9453a1e73a"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="idb4d97276663428da969d731f48e6813_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzU2MjY_e5967267-6589-485b-a402-cb90bb5c926c"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i357254d5ee414518a4eac711d1ad0070_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcwMTY_43de0d3c-3cf3-4b15-b203-0b1ff082d0c2"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i531458b265ea402180368f22e3a18010_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcwMzA_cd84c687-59df-472a-99fa-4cbc9e37d3b2"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3347233009744e6cb9cc4557b43f558b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcwOTk_eedbd01b-846b-4e4f-be79-79e332ab7a70"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id67592a92eea436081db481ac7010f0d_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzcxMTM_74c606e4-41e4-48c4-99f5-ece188c8faed"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i357254d5ee414518a4eac711d1ad0070_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzczNjQ_7cbbb518-e3b5-47c4-b5a4-ab06cc7b24bc"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i531458b265ea402180368f22e3a18010_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzczNjQ_d3db5e29-0c4e-45b3-8e3d-63cc7b6598d4"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3347233009744e6cb9cc4557b43f558b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzc0MTI_38e54d8f-003c-49a4-83d5-ba294f7fc0d0"
      unitRef="usd">11000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="id67592a92eea436081db481ac7010f0d_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzc0MTk_584521b1-174f-44e1-96ba-7c404460486d"
      unitRef="usd">10000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic72d4b7997b54c948eff89cce7d0a30e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzIxOTkwMjMyNjc1NjM_e4481161-d1eb-4885-8406-532f0cebf6dd"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i9a8c386ef058467d89edcdc41c5d7497_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzIxOTkwMjMyNjY5MDQ_b3a0b888-33b7-4453-8a79-560437e7ba59"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ibc1ca71b66fd44c99dc3a2f276433c1d_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzgyNDA_a0fa1a18-7b01-463f-bab2-1ffd6569dd85"
      unitRef="usd">4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i48423edd0fde4582afae650327df3fb4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzgyNTI_c60c6cff-d4aa-40fe-a8cc-b85e48232b10"
      unitRef="usd">-5000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90ZXh0cmVnaW9uOjU1YzRiMjFlM2RlNDRjZDJiYjdhNTE1ZDZlODg5NzliXzkwOTI_5453b4e7-cc11-4cea-89c2-333cbc567433">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if691da9b0c7f435b9a6464ebf9174366_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzEtMS0xLTEtNDcyMjY_661df82b-206a-4259-af64-3ffc1f783f67"
      unitRef="usd">6074000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i734031661a944622a2d44f3f789e8f7c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzEtMy0xLTEtNDcyMjY_27f0b6fd-b414-453e-8580-2a2f568df4a7"
      unitRef="usd">6751000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzItMS0xLTEtNDcyMjY_48ec2530-03b2-43ce-b646-c13cd5ac5613"
      unitRef="usd">5643000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTIvZnJhZzo1NWM0YjIxZTNkZTQ0Y2QyYmI3YTUxNWQ2ZTg4OTc5Yi90YWJsZTpmODljYTAzY2E2ZDg0NGY1YTUzODU0MDlkNzk3NDQ5MC90YWJsZXJhbmdlOmY4OWNhMDNjYTZkODQ0ZjVhNTM4NTQwOWQ3OTc0NDkwXzItMy0xLTEtNDcyMjY_b6a79267-81db-4dc8-af9e-a16edfb50ae8"
      unitRef="usd">6236000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzkyNA_5174001f-cd38-4b34-8273-83d18d17c84b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We repurchased $800&#160;million of our common shares, in the aggregate, through share repurchase programs during the six months ended December&#160;31, 2021. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended December&#160;31, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $300&#160;million. We received an initial delivery of 4.8 million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3 million common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500&#160;million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc4MTI_81f8a17f-03b9-4b25-a08d-b53eaa637e43"
      unitRef="usd">800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1OTk_7c05aa20-5dad-46dc-a70d-6cfea97d68b4"
      unitRef="usd">300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ica8231a36d054c5eace0ac4a74d6041c_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM2MDc_67f9c0ce-e63e-4559-b6fd-33f5e371e187"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i0b3ab008a92748eb820e4b825245f87a_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc1MDM_36135926-ccdc-4fde-9dd5-04af2fea3efd"
      unitRef="usdPerShare">50.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc1MDc_978afb2b-7197-4f61-817d-ad5292e2a005"
      unitRef="usdPerShare">49.39</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2c2a4ce5c8114a61ba44bbd47c9f319f_D20210701-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzE2NDkyNjc0NDc1MTI_cafdcd34-8bea-4d35-9067-b525acdf31af"
      unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="idf89a8993ffb426a9d8312715526954c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzQzOTgwNDY1MTQ3MDE_d611f62f-7999-4a12-9f47-3151a00cd3ab"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1NTU_040f0199-7eb1-499a-bbd0-bcd5d23b9ac9"
      unitRef="shares">7800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ic012c5de266c435f9f0da4c6533b44c3_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1Njg_cc6f49b0-14ee-4fcc-a6f4-3c2e1cccf644"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1Nzc_5c155015-2d9d-4e22-8002-ad1ee8a4d6f9"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iccea55c85f4f4ce1a148c32024f283fb_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzEwOTk1MTE2MzM1OTE_1b9c0c80-6f76-426f-bf93-4713cdcf934b"
      unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90ZXh0cmVnaW9uOjAwNTYxOTc3YWRkYTQwNjhiYjliNWE2ZTljZmRjNDNlXzkzOA_451a5534-f79d-45d3-836b-ad02c12a74d4">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87549c698d84454483818bad997efd4b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzEtMS0xLTEtNDcyMjY_335bb8a2-fedf-4e64-9830-1f69c7396f37"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79b64ec0efad4987b3cd7ad0a3914253_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzEtMy0xLTEtNDcyMjY_b49a05a8-4d5f-4d5c-aecc-80019b5f161c"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie23cd0947b184af3834849f94339a4a7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzEtNS0xLTEtNDcyMjY_78df97fb-79fa-4d9b-9daa-127002377ffc"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzItMS0xLTEtNDcyMjY_92d99113-f047-4bd7-b18f-c193b1630237"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzItMy0xLTEtNDcyMjY_a663d1fe-1da8-4d11-b043-1419be14da12"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzItNS0xLTEtNDcyMjY_46c76763-296f-47f7-939f-c0f7c8d50a92"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzMtMS0xLTEtNDcyMjY_35b4b9ed-50df-42a9-8254-7388052d4025"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzMtMy0xLTEtNDcyMjY_dfbd0bbb-8325-4da0-bfc7-ff9df0153f0f"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2df180df2c9f45bb9d7b559820c75b84_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzMtNS0xLTEtNDcyMjY_50a1b8fe-b4c5-474b-8533-96c2f6369bcc"
      unitRef="usd">3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i37c4517e648b4923b26eb34eedb31cf0_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzQtMS0xLTEtNDcyMjY_3fee1bcd-4f1a-447f-9f8b-3f7de38eaef2"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i17eeb03fb10e48c18eaa664be0597c0b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzQtMy0xLTEtNDcyMjY_94af688e-c3d2-40ae-a74c-572d2f0ed5b8"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie0f3694f60c043b6910488f3f4214356_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzQtNS0xLTEtNDcyMjY_b46fab36-09d2-4fb1-9895-b93f7ccfc0c0"
      unitRef="usd">-51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9442aa8d69b64b3bbce3a40e922f013a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzUtMS0xLTEtNDcyMjY_867617e4-9074-4bff-920f-02f4cf9b626f"
      unitRef="usd">-89000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc5e2906bad1404691be6f731cf43612_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzUtMy0xLTEtNDcyMjY_cbe54bd1-5e8b-4a43-8802-5dab2f3b87a4"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02be3554e0b34c02ba6b5f8f3ae72ad0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTUvZnJhZzowMDU2MTk3N2FkZGE0MDY4YmI5YjVhNmU5Y2ZkYzQzZS90YWJsZTphNzNlZjU5MzA2YTU0N2ZiOGQ1MWQwZjQ1YzE2YTIwNC90YWJsZXJhbmdlOmE3M2VmNTkzMDZhNTQ3ZmI4ZDUxZDBmNDVjMTZhMjA0XzUtNS0xLTEtNDcyMjY_765d7efc-2cfa-49b9-abe3-4e4f835f58d0"
      unitRef="usd">-85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzYxMg_f8645ffc-894c-46fc-94ba-579aa34f8636">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings Per Share Attributable to Cardinal Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units, and performance share units that were antidilutive were 5 million during both the three and six months ended December&#160;31, 2021 and 4 million during both the three months and the six months ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzYxMA_2a949af8-a045-405a-a1df-b51abb18d7b8">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzItMS0xLTEtNDcyMjY_2eef7b7b-2c1e-4ab2-8dc0-779d0004ffea"
      unitRef="shares">279000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzItMy0xLTEtNDcyMjY_8108b7bc-669c-4548-bb95-4d40624cd787"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzQtMS0xLTEtNDcyMjY_2f919906-1acd-4c6e-8741-b32deb7ca3db"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzQtMy0xLTEtNDcyMjY_10420bb8-a4e2-4f09-b9d4-d4f13e2a1a29"
      unitRef="shares">1000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzUtMS0xLTEtNDcyMjY_1d3fc3de-c594-424e-a33c-ffff659378d3"
      unitRef="shares">281000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpiM2MyYjFhMmU4Y2E0NmNjODU0MWQ1YjExOGVjOGQyOC90YWJsZXJhbmdlOmIzYzJiMWEyZThjYTQ2Y2M4NTQxZDViMTE4ZWM4ZDI4XzUtMy0xLTEtNDcyMjY_2a29d4c9-1dee-4342-8896-b18f6ac7a0c0"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzItMS0xLTEtNDcyMjY_cf632032-7a7a-4eea-a9f5-3d03a137c12c"
      unitRef="shares">283000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzItMy0xLTEtNDcyMjY_c99420d8-4df5-428b-bbb3-7524ba5743d7"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzQtMS0xLTEtNDcyMjY_9f8c4c31-6e0e-4939-8089-14ac2e9004c2"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzQtMy0xLTEtNDcyMjY_02947e26-df0d-4d4b-8a03-6b5bda3bf53c"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzUtMS0xLTEtNDcyMjY_d9a9fdb1-acaa-4e15-b710-af36c8db1197"
      unitRef="shares">285000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90YWJsZTpjNTAwODkxYzNlYzI0MjcyODBmNTVkMDZmNjgzZmJlZC90YWJsZXJhbmdlOmM1MDA4OTFjM2VjMjQyNzI4MGY1NWQwNmY2ODNmYmVkXzUtMy0xLTEtNDcyMjY_2e4f4336-29c2-4ab6-a512-8ef675f5207f"
      unitRef="shares">295000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzEwOTk1MTE2MjkzNTE_c6bd8671-d561-425e-a9fa-24ee9afa361b"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMTgvZnJhZzoyNDRlYzkwYjc3OTk0NTM5OGQ4NWY5M2E5ZDljOGIyOS90ZXh0cmVnaW9uOjI0NGVjOTBiNzc5OTQ1Mzk4ZDg1ZjkzYTlkOWM4YjI5XzEwOTk1MTE2MjkyNzU_7aae5cfe-0876-423f-afb4-3485a725357b"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1OTI_aebad472-c194-4565-bc2c-855fc216c042">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;639&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,460&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,078&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,460&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;87,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;surgical gown recall costs/(income);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;(gain)/loss on sale of equity interest in naviHealth; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $11 million and $6 million for the three months ended December&#160;31, 2021 and 2020, and $18 million and $11 million for the six months ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the interim goodwill impairment testing for the Medical Unit as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_91" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized a $1.3&#160;billion goodwill impairment charge during the three and six months ended December&#160;31, 2021 which was retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the opioid litigation as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i6bdf7a21332a418cb7d5503f4cc4365e_103" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized a pre-tax charge of $1.02&#160;billion&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the six months ended December&#160;31, 2020 which was retained at Corporate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;832&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;(2)Medical reflects a $1.3&#160;billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzEwMQ_def2e543-4b34-47a3-9c89-ffe88e24998f"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzEwMQ_e2aa9cfa-b9f2-4c6e-821f-383b0cce4e41"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzE4NDc_def2e543-4b34-47a3-9c89-ffe88e24998f"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzE4NDc_e2aa9cfa-b9f2-4c6e-821f-383b0cce4e41"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1NzQ_5778630e-270b-46ac-b959-a6236ab77e66">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;639&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,460&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i20447894cbce4626a6e15d3def1fdb5f_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzItMS0xLTEtNDcyMjY_873842dd-5310-4ca6-991a-a35ce17bdc5c"
      unitRef="usd">41164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib05957b8776e49b29c6ad2637c8b07dd_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzItMy0xLTEtNDcyMjY_bca1ff3c-8014-4670-b7e2-c113994b4fcd"
      unitRef="usd">37040000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8dc329406284cab850531d536265617_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzMtMS0xLTEtNDcyMjY_a6165a60-9e13-47ac-a529-259324631006"
      unitRef="usd">211000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf577b417acb4a57824e42c61874c5f4_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzMtMy0xLTEtNDcyMjY_1dc7d72e-f1b1-43fd-8ace-f23ea8fccde0"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzQtMS0xLTEtNDcyMjY_d6d3e1de-b089-46e9-93c5-7bececbf2af3"
      unitRef="usd">41375000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03a28033a8f04045b695c45def69a4ab_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzQtMy0xLTEtNDcyMjY_2cd527de-94c3-43f1-b82d-2175fc0663f1"
      unitRef="usd">37236000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b2139bac4734db0b0818999413985f5_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzUtMS0xLTEtNDcyMjY_847f7e99-c681-46e7-9894-387a5a15fd0f"
      unitRef="usd">3446000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7d6f1a08182423896d73aea639446c1_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzUtMy0xLTEtNDcyMjY_e18eb451-1d67-4263-9304-105f3e28d80d"
      unitRef="usd">3729000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a826fe2301345b7bcd24179b92b1b2a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzYtMS0xLTEtNDcyMjY_6b37b6be-e6d7-4234-8c7a-0f4c8d4da105"
      unitRef="usd">639000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a0384798971475ca8af194b0bac9c64_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzYtMy0xLTEtNDcyMjY_91f3b39f-598f-434c-ae08-e7404adade62"
      unitRef="usd">581000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6de15b3c68241ae9c0af7734cf7ea0b_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzctMS0xLTEtNDcyMjY_24f6e199-5d2e-44b6-a468-e72f0dd02853"
      unitRef="usd">4085000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc1ac584a6af4ec58101540fb78560fa_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzctMy0xLTEtNDcyMjY_0563317f-9350-46fe-b764-8c75d382083d"
      unitRef="usd">4310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie67c60168405428b9e40371da416b3fc_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzgtMS0xLTEtNDcyMjY_7a768936-25c7-466b-ba79-c2185426c316"
      unitRef="usd">45460000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzgtMy0xLTEtNDcyMjY_09fe1a4f-ad98-4aac-bfef-297d1d9eed0a"
      unitRef="usd">41546000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzktMS0xLTEtNDcyMjY_c3ff7ee5-4cb9-4d21-92e0-aadb148546c6"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzktMy0xLTEtNDcyMjY_8471bb0c-286e-4692-b294-b2e4c1861e09"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzEwLTEtMS0xLTQ3MjI2_710de791-cf53-44f8-8a6f-3a8d67247cd7"
      unitRef="usd">45457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNzA4YzgxZDE3NjI0OWE1YWVjNDEwNGYxMTlhY2U5ZS90YWJsZXJhbmdlOmQ3MDhjODFkMTc2MjQ5YTVhZWM0MTA0ZjExOWFjZTllXzEwLTMtMS0xLTQ3MjI2_c68b3a5f-f0bd-49d9-822a-94ff60411ce4"
      unitRef="usd">41541000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i947e256fc55c4846ac6b1768ff3934ad_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzItMS0xLTEtNDcyMjY_27738125-73fe-428e-8fbf-c02be4c75f44"
      unitRef="usd">80778000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3e1e7ccb99f4738bdd4ea38594a9397_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzItMy0xLTEtNDcyMjY_4e388b3c-3624-4f99-ba59-4929e3a3b609"
      unitRef="usd">71956000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i717134e53834433e8d6ee1a235075718_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzMtMS0xLTEtNDcyMjY_9273a13e-4b0c-4172-b475-3cd89b20271b"
      unitRef="usd">419000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica7b6c1cd2234d3a84ff74926dba30cd_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzMtMy0xLTEtNDcyMjY_96e456a4-8cd0-402c-9b18-667ef6ca8366"
      unitRef="usd">392000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida4501b440f44a0d8c0bc1a50fdbff39_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzQtMS0xLTEtNDcyMjY_62f33b68-7af3-4e13-b481-f6516e6f02d3"
      unitRef="usd">81197000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee36791593e44892a333aec11370f06c_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzQtMy0xLTEtNDcyMjY_f87b4408-bc17-45ff-ac25-b1b7faed3567"
      unitRef="usd">72348000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95c216eac9e0457da077b8544a667522_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzUtMS0xLTEtNDcyMjY_8f46c77f-0a14-4577-b7c4-f399d05e247e"
      unitRef="usd">7013000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b04e2a62607413897d3432b37ed8267_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzUtMy0xLTEtNDcyMjY_e7bb5788-3434-4dd8-b1d0-fe6e07b812de"
      unitRef="usd">7167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieec0426076dc43be9eb018d81b355af4_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzYtMS0xLTEtNDcyMjY_84ef9821-e53c-4f5d-a6ed-2fc0cc9fbca1"
      unitRef="usd">1221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29e5a616b51d46cd9609f9b8cb936e1b_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzYtMy0xLTEtNDcyMjY_33b8b9e1-3495-4e06-81d7-0e681669c9d6"
      unitRef="usd">1100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad497ebaf0d74ac488be3fdfe5b45c13_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzctMS0xLTEtNDcyMjY_b1f0a309-3e0c-4156-b0ca-5a4184621559"
      unitRef="usd">8234000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f557d65bffa4e22abc5d6a0ee5bf2c4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzctMy0xLTEtNDcyMjY_fbf7f13f-115e-4731-9e31-4cad41abbaeb"
      unitRef="usd">8267000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzgtMS0xLTEtNDcyMjY_2e425339-a2f6-48c5-8d70-5b3857604ec6"
      unitRef="usd">89431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzgtMy0xLTEtNDcyMjY_7bca5db9-8a96-4e29-a3da-f058d9fac01e"
      unitRef="usd">80615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7026229bffa24d75a300958db5493173_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzktMS0xLTEtNDcyMjY_7ad95923-ba21-45de-a2bd-0d14ef263f11"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzktMy0xLTEtNDcyMjY_09330410-6b7b-41dc-9401-44d656a0bee4"
      unitRef="usd">-9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzEwLTEtMS0xLTQ3MjI2_54c70f86-ac0e-4c10-98d5-a4a2ca5aa75d"
      unitRef="usd">89425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpmOTg5ZGQwOWUwMTg0ODZkOTZiODQ0NjJmZDM4NTU2ZC90YWJsZXJhbmdlOmY5ODlkZDA5ZTAxODQ4NmQ5NmI4NDQ2MmZkMzg1NTZkXzEwLTMtMS0xLTQ3MjI2_9697ca9e-7f78-4415-baa0-79d714dd448e"
      unitRef="usd">80606000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1NzU_9604a418-7504-42cb-b211-0a1225cdb251">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,078&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,460&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;87,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i9d0ef5db6f8c49e99cf83c70272570db_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzItMS0xLTEtNDcyMjY_f0040995-6d25-4bc9-84e2-8112fa53abc0"
      unitRef="usd">44382000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaabe27c3053040afbee1de4f02ae3a1d_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzItMy0xLTEtNDcyMjY_342ca1a8-a958-4107-916d-e4b9ca24677b"
      unitRef="usd">40360000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2324d519bd54f24aca9e312c213d51f_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzMtMS0xLTEtNDcyMjY_859b7a56-b696-4723-a5a3-81f6d83b1c9a"
      unitRef="usd">1078000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fcd214eafc844838d0428eba45ceb81_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzMtMy0xLTEtNDcyMjY_492658e1-0ae2-4583-a630-4e8796adb20b"
      unitRef="usd">1186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie67c60168405428b9e40371da416b3fc_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzQtMS0xLTEtNDcyMjY_b376c7f9-fe4c-48de-98c1-1e9ab2ac283a"
      unitRef="usd">45460000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzQtMy0xLTEtNDcyMjY_0f112500-4d86-413a-91cd-7d6ae4191e83"
      unitRef="usd">41546000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzUtMS0xLTEtNDcyMjY_dfcfb0e1-dec7-4b89-a760-8fd288a1005b"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzUtMy0xLTEtNDcyMjY_5b39f1e8-488f-4451-a030-081cd2004831"
      unitRef="usd">-5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzYtMS0xLTEtNDcyMjY_01bb18d1-1c04-4e77-8756-4889b764d681"
      unitRef="usd">45457000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo3Y2YzNzg2NGU5YmY0YTBkOGE4YTVlZjc1OWViMjU4Yy90YWJsZXJhbmdlOjdjZjM3ODY0ZTliZjRhMGQ4YThhNWVmNzU5ZWIyNThjXzYtMy0xLTEtNDcyMjY_8714ba0e-0e20-45c5-8500-8018daddcda8"
      unitRef="usd">41541000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27b9c7da4d6b4d138668a8f96ece269b_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzItMS0xLTEtNDcyMjY_c4e1cbd9-2112-45c1-be9c-2c7a4b007ed3"
      unitRef="usd">87223000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac8afe0411ae4297994e96fc737d451b_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzItMy0xLTEtNDcyMjY_d98f2c35-ccfd-43f7-b6fd-10236ed8d569"
      unitRef="usd">78336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i105c393d6342437baf627222f66216c9_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzMtMS0xLTEtNDcyMjY_f6670c56-76ed-4ba6-b102-6677a8d15e3d"
      unitRef="usd">2208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c720c252b6845929ee256ffd982829d_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzMtMy0xLTEtNDcyMjY_3f6d1a81-5fbe-4966-a3da-66b1c7646b53"
      unitRef="usd">2279000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzQtMS0xLTEtNDcyMjY_c18e4d42-b685-416c-9c3e-d7874f5f7eb9"
      unitRef="usd">89431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzQtMy0xLTEtNDcyMjY_d964c64d-f7d4-4bca-9234-ce955d10e21b"
      unitRef="usd">80615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7026229bffa24d75a300958db5493173_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzUtMS0xLTEtNDcyMjY_390dcb88-ab37-4ca7-9da9-6e2d1e060e18"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzUtMy0xLTEtNDcyMjY_73407b48-622a-4e44-8ebf-8cf877c4c9d5"
      unitRef="usd">-9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzYtMS0xLTEtNDcyMjY_8f1cea6a-4db0-43a9-a5c4-0d46595c7097"
      unitRef="usd">89425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTo1M2I2YjJhYzMyNjg0Yjc1ODc2MmUwNmJlNTg1ZjgxYy90YWJsZXJhbmdlOjUzYjZiMmFjMzI2ODRiNzU4NzYyZTA2YmU1ODVmODFjXzYtMy0xLTEtNDcyMjY_58ca3bd6-c4b6-4455-8b67-ca85d291a6f3"
      unitRef="usd">80606000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzMTg_86d61049-bbc1-4ded-bb8c-3e5ee06c9267"
      unitRef="usd">11000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzMjU_e072bd4d-ab5f-46d4-a400-7b39dd640e9b"
      unitRef="usd">6000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzNzA_d33a06e9-5dda-4586-b0fd-b2d1a1f63c79"
      unitRef="usd">18000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzNzc_7440661e-973e-4552-8da9-9e3769a8f126"
      unitRef="usd">11000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwNTk_6332aef6-cd71-4abc-8723-b09b71db798c"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9d26f1af6b744aa6bb94e8122e1b240a_D20200701-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQ3Mjc_35152ff2-5ba4-498b-8656-e80e9db2b6e0"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzU1ODk_b7944e2c-cff8-438e-85a3-ef4af822eb70">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;832&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16&#160;million judgment for lost profits related to an ordinary course intellectual property rights claim.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzItMS0xLTEtNDcyMjY_636da8a6-e47f-49bc-b062-88d880cdb21c"
      unitRef="usd">426000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03a28033a8f04045b695c45def69a4ab_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzItMy0xLTEtNDcyMjY_5f7c9229-815d-4d93-b7bd-741985bc56de"
      unitRef="usd">413000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id6de15b3c68241ae9c0af7734cf7ea0b_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzMtMS0xLTEtNDcyMjY_296027d9-5a23-44db-9f76-d861437d707c"
      unitRef="usd">50000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idc1ac584a6af4ec58101540fb78560fa_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzMtMy0xLTEtNDcyMjY_a25389b7-b2ca-47ac-861a-774b8129bd2c"
      unitRef="usd">236000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie67c60168405428b9e40371da416b3fc_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzQtMS0xLTEtNDcyMjY_b5baa21e-beda-4fe0-9b94-51d306d40516"
      unitRef="usd">476000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i312d8c2d710c4f9c8c49c49290211e5b_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzQtMy0xLTEtNDcyMjY_9b503814-bc89-4cbe-b810-5230414dad41"
      unitRef="usd">649000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73d5a969bf844179b0a72090d7369f1d_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzUtMS0xLTEtNDcyMjY_f8a771dc-6f7a-4196-9b13-55fc82f49e17"
      unitRef="usd">-1426000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2fdf8eca0e9444418f2f90cb9a2e4039_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzUtMy0xLTEtNDcyMjY_16a739e3-251b-4932-a993-281f0f14b0b5"
      unitRef="usd">-188000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzYtMS0xLTEtNDcyMjY_0e6df7f8-c4f0-4c08-9f92-7a280dab1e4d"
      unitRef="usd">-950000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTpkNTAwMzg3ZmJlYWU0NTM5OGZkNGYyNmEyMWU1NTAxYi90YWJsZXJhbmdlOmQ1MDAzODdmYmVhZTQ1Mzk4ZmQ0ZjI2YTIxZTU1MDFiXzYtMy0xLTEtNDcyMjY_c936338f-8653-4c26-8350-ea079817941c"
      unitRef="usd">461000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ida4501b440f44a0d8c0bc1a50fdbff39_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzItMS0xLTEtNDcyMjY_d1920df8-4d57-4243-876a-11b152a0abe7"
      unitRef="usd">832000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iee36791593e44892a333aec11370f06c_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzItMy0xLTEtNDcyMjY_fefc919b-ec39-4d28-b564-61845b5f86f6"
      unitRef="usd">815000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iad497ebaf0d74ac488be3fdfe5b45c13_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzMtMS0xLTEtNDcyMjY_801e4f86-3ec1-4d79-825d-5ae3179d88f7"
      unitRef="usd">173000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0f557d65bffa4e22abc5d6a0ee5bf2c4_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzMtMy0xLTEtNDcyMjY_90117858-8346-4d22-8b82-b7ea5e9aafa5"
      unitRef="usd">466000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i78d339da50244602a65a9a4cbb0df214_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzQtMS0xLTEtNDcyMjY_d0a38457-86bb-41de-bd86-03df51ec5a6b"
      unitRef="usd">1005000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89869fd1ac7f4cebb70268b088f8e453_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzQtMy0xLTEtNDcyMjY_fab43758-4b8d-4518-8900-a779061b96c5"
      unitRef="usd">1281000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7026229bffa24d75a300958db5493173_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzUtMS0xLTEtNDcyMjY_d3a913c6-aa25-4894-aad4-601cecb6a0f0"
      unitRef="usd">-1540000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4612ee70e5d84494b4a4e3df746c59ea_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzUtMy0xLTEtNDcyMjY_3e9f8fd4-116b-4b6e-81bf-3f889c952ec5"
      unitRef="usd">-1444000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzYtMS0xLTEtNDcyMjY_c2c12d63-2989-4208-bce1-69eb42f8ed7d"
      unitRef="usd">-535000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTplNzM2MDBmMDVmNDU0YzhlOTM1NGYzYzRjZjQyYTk3Zi90YWJsZXJhbmdlOmU3MzYwMGYwNWY0NTRjOGU5MzU0ZjNjNGNmNDJhOTdmXzYtMy0xLTEtNDcyMjY_7297dcbe-0e7d-4bc8-b516-40653a40422c"
      unitRef="usd">-163000000</us-gaap:OperatingIncomeLoss>
    <cah:JudgmentForLostProfits
      contextRef="i6542622e5ef24933a209e2a96b41e83a_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwMzc_27f44988-c8e4-46fc-80a8-507342d539ad"
      unitRef="usd">16000000</cah:JudgmentForLostProfits>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwNDk_5915b352-5f08-4eab-b702-fce8588c148d">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,737&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;(2)Medical reflects a $1.3&#160;billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="ib075c6eb340b4000b99c1e4260fff944_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzEtMS0xLTEtODYxMDg_7fe5da15-8f8d-41f7-814c-9f67f0fb54ed"
      unitRef="usd">24427000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i23d97aa974df4ac6bbf2e22959990798_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzEtMy0xLTEtODYxMDg_104659fa-c901-4ada-9925-48ab2d5ef2e5"
      unitRef="usd">23624000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i41706ccf867d4e078fa68264b8ecf4b3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzItMS0xLTEtODYxMDg_8189d257-10fd-4cd5-9035-0d790ee79acd"
      unitRef="usd">12737000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id27ed30ba0c447d8a9e0d8a5e753260e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzItMy0xLTEtODYxMDg_6090a712-de3f-4cf3-b7f0-831765e7f139"
      unitRef="usd">15408000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i644ca4beadff4da38d7416eb70d4e113_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzMtMS0xLTEtODYxMDg_3195dfb4-ff61-411f-b80b-6da15d5c2991"
      unitRef="usd">6516000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3617e648d299450da968eaf742edafd8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzMtMy0xLTEtODYxMDg_f006e525-7a5e-4209-b238-47d989b6d182"
      unitRef="usd">5421000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzQtMS0xLTEtODYxMDg_5bd4d6c1-0deb-4bab-95f2-d1f5feddf859"
      unitRef="usd">43680000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90YWJsZTphY2MyODc3NjA2ZTE0YThkYWRlMzc3NzFjNDM0MWU1Ny90YWJsZXJhbmdlOmFjYzI4Nzc2MDZlMTRhOGRhZGUzNzc3MWM0MzQxZTU3XzQtMy0xLTEtODYxMDg_75d61afd-c5bf-4b44-a343-5a06a8e98d36"
      unitRef="usd">44453000000</us-gaap:Assets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="id6a5635665184a6cb80b94e96e68ca69_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzEwOTk1MTE2NDUwNDI_86af476a-2658-4b99-b045-48139175fd1a"
      unitRef="usd">1100000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iff789afd0e73479db68d915900ae8e1c_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjEvZnJhZzpiMDMyNGE5M2E0ZmI0MzBmODY3YmQ2NzNkNTkwMzJjOS90ZXh0cmVnaW9uOmIwMzI0YTkzYTRmYjQzMGY4NjdiZDY3M2Q1OTAzMmM5XzQzOTgwNDY1MjkwNTQ_6332aef6-cd71-4abc-8723-b09b71db798c"
      unitRef="usd">1300000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzOTc_3847e718-68e9-494e-b9e5-ccea92b2ab30">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $2 million and $3 million for the three months ended December&#160;31, 2021 and 2020, and $6 million and $7 million for the six months ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $103 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzNzU_2803eebe-e4c9-4176-a561-7af1dffc1c36">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2ae447d46854b319eaccc5ea8e28c28_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzItMS0xLTEtNDcyMjY_40464854-70ca-457a-bc0a-f99ee6a12734"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia478e26ea8e448b39f3752efae199cfa_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzItMy0xLTEtNDcyMjY_f7e3489f-3b87-45e2-ad59-e867f838c0e8"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id6b6e1f67cfe47c5a29aaad5984e138e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzQtMS0xLTEtNDcyMjY_8473e398-67d8-417f-81b0-126f6dabc1a0"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic237dc8d2be649c6873fe2eb206f1e73_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzQtMy0xLTEtNDcyMjY_f29e5104-c136-4d80-9c4d-914b3dd05208"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzUtMS0xLTEtNDcyMjY_182fb7b6-e1ae-44db-80a8-c450ae914353"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo3MTJmMTFlMTExYmY0NTZkOWU4YTMyN2MzZjM1ZTc3MS90YWJsZXJhbmdlOjcxMmYxMWUxMTFiZjQ1NmQ5ZThhMzI3YzNmMzVlNzcxXzUtMy0xLTEtNDcyMjY_da435184-6c22-4501-b5c3-43ce5c510ddb"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzItMS0xLTEtNDcyMjY_4810924c-015e-4c72-a838-6f20849a2b59"
      unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib7abdec1bde440c4b7d2d3fbdb599cd2_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzItMy0xLTEtNDcyMjY_1e617bc6-34b7-4ead-81f8-2cc56c9695a0"
      unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzQtMS0xLTEtNDcyMjY_55d5153a-ed45-478b-9baa-4710da61199a"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i398269cbf0e54afe862fe609d2944418_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzQtMy0xLTEtNDcyMjY_58eeaa41-ff1e-484f-acd3-f269d5e97a2b"
      unitRef="usd">15000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzUtMS0xLTEtNDcyMjY_d4a48946-b3a7-4ab0-877b-aeed78259199"
      unitRef="usd">42000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTowZGI5ZmM2OTc0Njc0ZmNlYWFhNWQ5YmY5OWFhZTlhYy90YWJsZXJhbmdlOjBkYjlmYzY5NzQ2NzRmY2VhYWE1ZDliZjk5YWFlOWFjXzUtMy0xLTEtNDcyMjY_bd8ae8c3-cb5b-4328-a127-534c8158ac24"
      unitRef="usd">51000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzI5Mw_7f17194c-2f6d-4b50-a128-08d8a4c97ea0"
      unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzYwNDczMTM5NTY3Njg_c77c0c30-a13f-414e-b909-76d37125bc44"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzM1Nw_0bcf7086-5979-4f60-a6ca-aa89e2f0e62c"
      unitRef="usd">6000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ifc68b9700023489da77737a2a6a45de7_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIxOTkwMjMyNTgwNTM_dd430fbe-2c88-475c-a67b-94a4d5d418ad"
      unitRef="usd">7000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzUyMA_d5f24758-9c27-4bb2-8fcb-85a0e57161ce">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzOTI_293cbd54-cfd8-467d-ad5d-fc29b124c567">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8aa1d951b73947c3936f78f13c7eaa01_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzEtMS0xLTEtNDcyMjY_2875fd5c-c8d6-4626-987b-5d31de36940d"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8aa1d951b73947c3936f78f13c7eaa01_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzEtMy0xLTEtNDcyMjY_066e4df6-199c-4db4-b25d-5c8309b1dce9"
      unitRef="usdPerShare">49.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzItMS0xLTEtNDcyMjY_fa6fb9fb-7279-49ae-9861-02f6bbd7a8b7"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzItMy0xLTEtNDcyMjY_4621c237-d97e-4222-8843-651b5903efda"
      unitRef="usdPerShare">51.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzMtMS0xLTEtNDcyMjY_5e95fc7b-af12-44ca-8b23-a415b74462b1"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzMtMy0xLTEtNDcyMjY_8fd55a17-1c3d-4f17-b690-a2bfde12d345"
      unitRef="usdPerShare">49.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzQtMS0xLTEtNDcyMjY_2e13e8da-c390-46e7-9c3d-d51e1353c457"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzQtMy0xLTEtNDcyMjY_bf554a3f-b349-445b-85bf-b99324363342"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i66dbff1954b94c7c9982013468c26bfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzUtMS0xLTEtNDcyMjY_fbb7b26d-345c-4ad2-a867-3f8c5faa76bd"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i66dbff1954b94c7c9982013468c26bfd_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo2OGE3ZjA1OGNjOTU0ODU2YWFlOTVjNTg0Zjc2MmZhYi90YWJsZXJhbmdlOjY4YTdmMDU4Y2M5NTQ4NTZhYWU5NWM1ODRmNzYyZmFiXzUtMy0xLTEtNDcyMjY_c7d8868b-804d-4e5c-8328-ac1e2cffacfe"
      unitRef="usdPerShare">45.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i66dbff1954b94c7c9982013468c26bfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzg2Nw_56df157d-ad08-4770-b896-7066a27597af"
      unitRef="usd">103000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzk0MA_c3cf5e7a-4643-4fda-a922-1acbc50403e1">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzEwNTQ_c69d967a-29d5-45a6-8aa5-8391b91e1439">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cah:ExercisablePeriodOfPlansInYears
      contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzEwODE_0c6fcaad-c823-404d-8a4f-4274ad72ca12">P10Y</cah:ExercisablePeriodOfPlansInYears>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzOTM_1c931525-42f3-4461-9098-ddc3724bfbc2">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzEtMS0xLTEtNDcyMjY_ae8587f0-e065-4d1e-9c36-fc235fed08cd"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i971fb9b8eb864c16a90cecd4e38e78f4_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzEtMy0xLTEtNDcyMjY_888fda4e-128f-449b-ba07-3dfc9318116c"
      unitRef="usdPerShare">68.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzItMS0xLTEtNDcyMjY_621e38a9-45fa-4cfd-8e3c-231065c2c8f0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzItMy0xLTEtNDcyMjY_0988a683-1def-4e5d-a088-17f161cda28b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzMtMS0xLTEtNDcyMjY_83077b57-622d-4251-aea3-047b816a0a57"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzMtMy0xLTEtNDcyMjY_5f16eeb0-338e-4fcb-8c8d-d464b565d08f"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzQtMS0xLTEtNDcyMjY_8280368b-1d61-4482-89ea-968708aae4d4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzQtMy0xLTEtNDcyMjY_962e568a-0e4c-46e5-854a-b0bbf4ac2735"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzUtMS0xLTEtNDcyMjY_b1f68564-102c-4ab9-9075-b8147607ebcf"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzUtMy0xLTEtNDcyMjY_fd91c779-87e9-407d-8313-99d023758508"
      unitRef="usdPerShare">69.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzYtMS0xLTEtNDcyMjY_779b977c-4f95-4dbd-ab16-702d335c071c"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9c1ca3e313f8427ea77ad0ab23207095_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo5MjVhNzM0Mjg1ZTA0MzA3YWQ2YTkzOGZhMTg0OGYxOC90YWJsZXJhbmdlOjkyNWE3MzQyODVlMDQzMDdhZDZhOTM4ZmExODQ4ZjE4XzYtMy0xLTEtNDcyMjY_dcbc35f5-b066-4500-93e1-7479bb67f434"
      unitRef="usdPerShare">69.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i898c45d5227a4196aece99539dfb04a9_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE0NTA_a8e90967-c94b-4c6b-aaa1-805f8a94a342"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzU0OTc1NTgxNDI4Mzc_579bdd7e-ae69-4c4a-97e8-21f6a555417c">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:AdditionalStockOptionPlanDataTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzI0MDk_ad612053-b025-4a7e-9c4b-3cf8585ffc3b">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:AdditionalStockOptionPlanDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i898c45d5227a4196aece99539dfb04a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzEtMS0xLTEtNDcyMjY_3ea7bcb9-40d8-4dbf-8c38-c8999a5ded17"
      unitRef="usd">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i10f071711d1b4e4ca40dd648ab7f15a4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzEtMy0xLTEtNDcyMjY_35f1bc0a-9bde-4a47-b042-6bed43ee36f3"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i898c45d5227a4196aece99539dfb04a9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzItMS0xLTEtNDcyMjY_36bdab3b-ffd6-4a60-a2a0-a3644cce663d"
      unitRef="usd">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i10f071711d1b4e4ca40dd648ab7f15a4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpkNzdhNWFlOTA0Y2Q0MzUwYWQ3NDY0Nzk3MWMwZDQ2ZS90YWJsZXJhbmdlOmQ3N2E1YWU5MDRjZDQzNTBhZDc0NjQ3OTcxYzBkNDZlXzItMy0xLTEtNDcyMjY_52476cd1-bfb2-4d00-be6e-f6d6297bdeb3"
      unitRef="usd">11000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzEtMS0xLTEtNDcyMjY_9dee9a87-c70f-4602-9917-b320c1a46083">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i91f70075253b4b6f834c3408cbaaac75_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzEtMy0xLTEtNDcyMjY_2493d6d1-d140-439b-a340-2493eb89f989">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if137af18fd604b45a04f086112f3f149_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzItMS0xLTEtNDcyMjY_1ce8a4a4-5ffc-48d5-b14f-ca43b370042d">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i91f70075253b4b6f834c3408cbaaac75_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTo1Mzk1OTNlMmI0NTc0ZTY3Yjk3ODBmYWZkMjY2YmNlMS90YWJsZXJhbmdlOjUzOTU5M2UyYjQ1NzRlNjdiOTc4MGZhZmQyNjZiY2UxXzItMy0xLTEtNDcyMjY_03720720-7a80-431a-9d97-baf4ab8d12fc">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NjU_920681ee-4f41-4c66-91f1-ffe8d558145e"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i548763c20950426faab587ffdc5af9cc_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MTE_04a5a128-6eb5-4ad0-8f41-d64ca9aadfc3"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2be505b893554e2596656d949aede2e1_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MTE_d1ddeb9d-0a87-4981-ad0b-1daeeb835b04"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib4c55723711e41b596452e6d75618784_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MDE_4617cfbc-5a81-460a-a685-c41d95373e43"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie37383edad9446b08331ba5cadd97680_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE2NDkyNjc0NDQ2MDE_a15bb4ba-e7e3-49bf-9f8f-ec2a24d40542"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i716d6753e4e540af82ae6e591c9bdeb0_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE4Mjg_b411cef9-17ed-4e55-a453-d899004864aa"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iea669b2da0d447318754dc385014d7b6_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzE4MzQ_c8463a0b-682a-4bbb-a4f3-854311629823"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzNjA_c2e528d6-cb88-489e-b816-0d3648f90266">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52.99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzEtMS0xLTEtNDcyMjY_482198d7-1b97-4605-9966-9a30d6085eaf"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzEtMy0xLTEtNDcyMjY_a0c708b4-4920-47ba-83ad-7732a3f901a0"
      unitRef="usdPerShare">54.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzItMS0xLTEtNDcyMjY_aa8808cf-07e4-467b-9671-da7da4df5f10"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzItMy0xLTEtNDcyMjY_e3b1a47d-4c6c-4763-8665-786307b1288e"
      unitRef="usdPerShare">51.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzMtMS0xLTEtNDcyMjY_09f6e05e-d588-4c9a-9ebd-fe7f355e7aa5"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzMtMy0xLTEtNDcyMjY_a4ade0cb-5359-43bd-bed1-bea49783856a"
      unitRef="usdPerShare">52.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzQtMS0xLTEtNDcyMjY_a1b0f8fe-0240-4cd0-84e0-3d0d62e62918"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzQtMy0xLTEtNDcyMjY_30fa2774-89ce-4453-b636-63bbd14bdbc3"
      unitRef="usdPerShare">52.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0018e1126c834a38ae1193472508f95b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzUtMS0xLTEtNDcyMjY_adc8ee87-348b-4c4f-b2d8-f143b33ec27b"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0018e1126c834a38ae1193472508f95b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90YWJsZTpmNGY5YjliMGZmMGU0MWQ0YmMwOGNjZGUzZDQ5ZjJjNC90YWJsZXJhbmdlOmY0ZjliOWIwZmYwZTQxZDRiYzA4Y2NkZTNkNDlmMmM0XzUtMy0xLTEtNDcyMjY_aa673b8f-7e10-4ba7-91d4-f7c7690a9ed6"
      unitRef="usdPerShare">52.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0018e1126c834a38ae1193472508f95b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIyNDM_1ebf0415-5a21-406b-a076-4426aee58a36"
      unitRef="usd">28000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i134b3d6659154128ab88dee849493e4c_D20210701-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZiZGY3YTIxMzMyYTQxOGNiN2Q1NTAzZjRjYzQzNjVlL3NlYzo2YmRmN2EyMTMzMmE0MThjYjdkNTUwM2Y0Y2M0MzY1ZV8xMjQvZnJhZzozNjNmZjg1NzVhZjM0ZmNjODE3ZDExYjFkYWEzNjkwMC90ZXh0cmVnaW9uOjM2M2ZmODU3NWFmMzRmY2M4MTdkMTFiMWRhYTM2OTAwXzIzMTY_ea25ae38-93a3-44b4-a98c-7142131a2617">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+MOO@D/X]C/EA^;T6)*";Z K]R:"UU:W7_[:&R7VS:>ME5!*E,WECJ<9KS4
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M>5>!6YG]P],WKV*"R=O \Y!NFZ_NYE=*59U%*4IK@28F=<;[R6FR/X,>2N0
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M']7G3TF:R@E7G@^$C+6ZXF!:QW6]C@M9XOJ:BS@%FHW<S4;Y8B$G^$3DTV]
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M7TR01;DBQ>;(S>:'>!9D,C5%EFT)*:Y&;JX^V+8@@*,MO(,4/R,W/Y_<N2#
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MM1&@<H"QOMH 5)_J @0 V1Y+*@%"]K#[!XWIF "E>3MK$:5$R!X^?^?!'1-
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MVSF/)0=4 /G]0YZ+UP_5SS5L?F+D\E]02P,$%     @ #H-#5#J"F.7=!@
MM1H  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R566U3VS@0_BN:3#_
M#*EMV7EC@!D(]-J9TF/@>O=9L9585]M*)3G _?I;R8Z=V+* +XE?5M*SJ]U]
M=JV+9RY^R912A5[RK)"7HU2I[;GGR3BE.9&?^986\&;-14X4W(J-)[>"DL0,
MRC,/^_[4RPDK1E<7YMF#N+K@I<I801\$DF6>$_%Z0S/^?#D*1OL'CVR3*OW
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M</Z%8;2]F!=01PZNVX%%0:?M^,4ONSP< 5[.3@"J':#*ND='6>4U!EPMO!O
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M)KP6-$^B90'ZGAOCNP4;Z"?4];]02P,$%     @ #H-#5(B$W-#2!@  TA$
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M:;C+U,:YMRK+[-&5+8H.DES/DDA5YQIV ,Y@+<WGFJN"8&T=A>0C.2"#*HT
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MX*@4+TN<3<FQ -[/+,)N;]C!^K1[^A=02P,$%     @ #H-#5.4LC*M+'P
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M*\EF4A4ANK<$(?*,0]']6@<7(B+%;UWTDED +I-IAE"T)RP>E*TS/!_8\G^
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M\([_/>ZR%/QU0K0>I\ZT]UP^<V53T@ )O]>V<N)<YUUQHW#BA/=]Q(W-3&<
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M.T(L'%_5(4<0IFC;R3NOVPK]D2OTW>21I) /K47&ZC>-25/S]2]Q/@;2-5H
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M!N#YT@"U>$$+M-]@7?X/4$L#!!0    (  Z#0U0U?BV<400  -<*   9
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*U6;6_;-A#^*P<MV&+ D&793IW,
M,> D+=IB18.D73\,^T!+9XDH1:HD%2?[];NC9,=>$P?K]L$VW^ZYY^ZACS=;
M&_O5E8@>[BNEW7E4>E^?#08N*[$2+C8U:MI9&5L)3U-;#%QM4>3!J%*#-$E.
M!I60.IK/PMJUG<],XY74>&W!-54E[,,%*K,^CX;19N%&%J7GA<%\5HL";]%_
MKJ\MS09;E%Q6J)TT&BRNSJ/%\.QBS.?#@=\EKMW.&#B2I3%?>?(N/X\2)H0*
M,\\(@G[N\!*58B"B\:W#C+8NV7!WO$%_$V*G6);"X:517V3NR_-H&D&.*]$H
M?V/6;[&+9\)XF5$N?,.Z/9N2QZQQWE2=,<TKJ=M?<=_E8<=@FCQCD'8&:>#=
M.@HLKX07\YDU:[!\FM!X$$(-UD1.:A;EUEO:E63GY[>EL%@:E:-UO\#K;XWT
M#[.!)V3>'V0=RD6+DCZ#<@(?C/:E@]<ZQWS??D",MK32#:V+]"#@%68QC(9]
M2)-T> !OM US%/!&S^"U@<$?BZ7SEF["GP<PQUO,<< <_\?4'489)C$\A01?
MD"Y]W=BLI$N7P]$T2>@"*,5WV:S -!8R4U4T<VSN^B U^!)!%(7%0GCLT]2:
MIBC;$SMP4%M36%$YR!LK=1'LG+R'JI41648@$;!:HMT*$3.I51,VV>(1T-&U
M]26(.R&56"J$3+@RAD]T:(_D7DC,J425!^)445QC'\ ;6"(TO$\E!PK4:(4B
M%%L;2T$!V=>&/,9P]<B= D5\@7T?UDA['BVR2W(DN"ID5"$8./\^2\?1XO8F
MZFVRQ=QV=O<#8[*,MTD^[.1:9LB2'8T>)8Q;?3.DFI2SH=322PHT1T5+E @R
M&,?3K>3[WAK'D0LNBQ2.SG:]3))XE+2YWQ#/C,Y4PUDAB/="-U1_-WE)07A"
MNC.JJ9!2Q&6,*1$)JLH=;HW[MRTX&I_&HU.BX*@",AV24<!*ZG]$,8Q'3T?Q
MDH*W6/M.PN2 A*31_Z;0Y%\J].K'%!K&D]$!A3YFWG#8XS;J'Q:(_ R3EP5*
MX^0Y@199UE2-"G^/CR23A4M3T>M?\K-\A_";<2[$L3**WO<@9OC_MX^\_(LR
MP>I2GG5!XZY$+842NDV&V/%@@H=LSX-B#\N'L&HT:4]2M!7#>*'.X)B&'7G7
M WJI*3\:/FNJ)XK<YT^$<-%YI[2^;S1N;Q<<P?'XI$<_PY3'HW&OL_B>4I^J
M%%VH<$.4<$ZN9":XSW"$,>K!\80^XVD/%I5IM'<[Y[AX&D!A-:7+P<\_3=-A
M^BNYZX7/)X[K^50([ZU<-FV6">=2V#PH^I8"]F4?WFEZ.C6U<Y1<+^X[.E.F
M-.SMQOY=@>28IZ<<_S@,)[VG7LG!3K-1H2U"2^6(*H79]AW;U6W7MFB;E<?C
M;<OW0=A"4L84KL@TB5]-(K!M&]5.O*E#Z[(TGAJA,"RI\T3+!VA_98S?3-C!
MMI>=_PU02P,$%     @ #H-#5%*MZ!\G P  @0@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&ULO5913]LP$/XKITR:-HDU3=J.PMI*%)C@ 0D--AXF
M'MSDTE@X=F9?*/S[G9TV@+85F+2])/'Y[KOO[GR^3%;&WK@2D>"N4MI-HY*H
MWH]CEY58"=<S-6K>*8RM!/'2+F-76Q1Y,*I4G/;['^-*2!W-)D%V;F<3TY"2
M&L\MN*:JA+V?HS*K:91$&\$7N2S)"^+9I!9+O$#Z6I];7L4=2BXKU$X:#1:+
M:720[,^'7C\H?).X<H^^P4>R,.;&+T[S:=3WA%!A1AY!\.L6#U$I#\0T?JPQ
MH\ZE-WS\O4'_'&+G6!;"X:%15S*G<AJ-(\BQ$(VB+V9U@NMX1AXO,\J%)ZQ:
MW=%N!%GCR%1K8V902=V^Q=TZ#X\,QOT_&*1K@S3P;AT%ED>"Q&QBS0JLUV8T
M_Q%"#=9,3FI?E NRO"O9CF;'PFJIEP[.T<)%*2S" 9&5BX;$0B&0@4-A<ZF%
M@A,4BLH=.-59;Q(3>_<8<;;V-&\]I7_P]!'.C*;2P;'.,7]J'S/KCGJZH3Y/
MMP(>8=:#0;(#:3]-MN -NE0, M[@Y:GX?K!P9/GD7&_!'W;XPX _? 7^)=X1
MS)7);JY_E]'M@$G2@[^M'UR6"(51W)1L#JVRQ<SH3"IT0+RMFVK!J*: S%05
MMY#S^ X:A[D'9FG=$/JND!D(G4,N%0MRP VKFNV#%8B7L-IG6A;QR4D!KC,&
M(K[6[Z3F-E"*.]J]#Y7WCSY<A?;#_(.X1<NWR5/*;]^,TR3YU!)-=_<@W1O"
M<5'PU>##"[3Y<@"'66,E273[<%S5RMPS&>[![ 9,[6\1M\-)XB,A,Q]F&UFC
M);D0/D<;KDF=X9.]%)*7$=SD+QUS6'LCN)!W_S@7XP$[&OS77*2OS<4HY,(?
MV-H0:I)"J?L'HO@J<CM;V5$I"%;HSRO[Z5P$R6B3;,@Y,=PT"T-E:!0*A];C
M.BY8U18,?RU8*)%7&SX#M8;PJE[X+&J_][O[*7XT%BJTRS#\'">[T=1.B$[:
MS=>#=JP\J+?#^4S8I=0.%!9LVN_MCB*P[<!K%V3J,&0X$!Y9X;/D?P2T7H'W
M"\.E6R^\@^ZO8_834$L#!!0    (  Z#0U2UD":NK0L  *LA   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;,5:6W/;-A;^*QAMIFO/T)9(ZN8XR4R2
MWK*S;3-UNWW8V0>(A"0T%,$"H!7WU^]W#GB3+-M)M[O[8)DB@7,_WSD'U(N]
ML1_<5BDO/NZ*TKT<;;VOGH_'+MNJG727IE(EGJR-W4F/KW8S=I55,N=-NV*<
M3";S\4[J<O3J!=][;U^],+4O=*G>6^'JW4[:NS>J,/N7HWC4WOA1;[:>;HQ?
MO:CD1MTH_W/UWN+;N*.2ZYTJG3:EL&K]<O0Z?OYF2NMYP3^TVKO!M2!-5L9\
MH"_O\I>C"0FD"I5YHB#Q[U:]545!A"#&;PW-4<>2-@ZO6^I?L^[0926=>FN*
M7W3NMR]'RY'(U5K6A?_1[+]5C3XSHI>9PO&GV(>UR=5(9+7S9M=LA@0[78;_
M\F-CA\&&Y>2!#4FS(6&Y R.6\DOIY:L7UNR%I=6@1A>L*N^&<+HDI]QXBZ<:
M^_RK&[6!B;UX5P8'PU(OQAZ$Z?$X:XB\"422!XC,Q7>F]%LGOBISE1_N'T.@
M3JJDE>I-\BC!+U5V*=(X$LDDB1^AEW9:IDPO?4++'U5EK-?E1OSS]<IYBYCX
MUR/DIQWY*9.?_F=&?)Q(G%R*$X3$#[45R$'+WYR05HG*ZC+3E2R*.\1"B>3)
M!44X'IB\SCQ6E;EPRM[J3#F*6AUNT>;,[+#?T9:U\'O3$H=17&#O(K'?ZFS+
MR_U6"2=W2D@G#$2Q;$*Y*E2W_+EXOY40-U.UUYDLF-5W*J?K2_$3"*QA:&.=
M@%9(&:\L(ID8$O$3! 74*^H\,(>"I;*XU0@5%&8SJ5M9U-)#1:C %BLSQ4RJ
MVE;&X0%TA)E,%A2TRD$'L@E;PV&%H_O#[;#/"J[)D8A^RQ*4TM>P!)D+WW29
MZUN=U]!S56,W2 1LT5XK=\G^.K)'HY?(-6).KVJ2>&4E)0L+LE'04&>B.M@6
M"5>I3,O"WQT]X4WF5MD+"'21F;J$2<568>DV(Z?1\PS14N]POPL*F) 4^+G4
M'HQO/%F._(/@:"64A3.T 0HJUT>0-\<2P%8U>16&L<&: _8-@<;A#VK1"G;=
MA" 8E756*&G;E;KQE)6Y-@]*0![$E2[8 ]>]_,V.NV',#'7:&E=I#YTIN/>H
M#/1_QX'+J0=K65D=;"=I*CRE:]0X!,N1G3J:D3"T_[1= ID[7%X'!54ELP]@
MXAX(!O>DSUMKA@ALTJ]S[,!?D&R8!<.@?"MMKDML^Y;I=D$:;$(16=M-%X&%
M7!FXS=B[COD0.9PI\I,Q%X%/*7,9B:]J"]='XK73,BC()D-[\$&1)N\ :GFN
M@S-,+RIY_"%9>U'\O<@>ZBJQPTB*K7+#R5VRTRFM+;MGB*5]2M15!=3-MNAW
M>K\SW)JB#A!]& 5RMZJ+8"6RGL+_3)'S\"Q#$6!S=J9L(_Z1V#EE4MX3K'HJ
MHX=Z-[[L]:/D#A'M_@K!*:!/LO!;:^K-EJO L?&EO_@6.\5-9P0"2>K<+E%T
M;U59JU (#,!XS]!/B(\413R2F+991("A)"+H?EEHHU5N-E9M)$G6[B*HALPD
M&56T4R6%#610%0AHGD,8J]1!VR+0=*C="E:GQN,,Y':Z*$B7<VY#Z&-RC.Q?
M=A%)]1<L;CJPZTUQ%I^+L^1</!/3.(KG4URDBV@RG8CO&[BCG>\M=G*OV]BT
M)Y#$L8BOY@^5E=8*H)XN9D0[2><= N3'(G:./TO/11I-IW-\+I*K3W#J/+T2
MLV5\#UTZ":+)<H;/-)Z(GXP_M6(63><3$G4&OIU#Q-GTG.4YFYTW.]L=SWC/
M;!',-YO&XD9__)][;CF)%HLE+A9Q=#6;?ZKGIO&52*^2ISRW1%Q<+<0BB=+I
M\A,]APB*4WS&\\4G>"Z.$A@";":3![VW1-Q,Z1,43WMO>15-TYB,,8]GQ]Z;
MX^_JOO=H3S(+)IQ/YFS3]R?[5+->*PMWKNXXDT\YI$45+C"8WY2E#4 P%.XO
M_K),DLGUD^W& =/+$3OX[; I1L/XD,/:C@_2JH^9JCP#UB<&0P^)Y+][+(_=
M<IK7YR ON:5W4NL2:@P16:YM:%6AT8Z'C@>W--6FBV//]S6IO5,:W[;6P04\
M*31P>_EI: ]/;Y39H,E"UT ^E7\<F0^+%< ",+1,Z&(2I8"<=Z175^/C:()T
M1CXLYY^+5/%_&ZF.-5D"T).4L&<9I4#V0TV2*)DLZ7-Q];E9&W]>UOZ_0JF=
MBH$::^W%+ZH;_#I5AP,<'=+P/-P]Y'W4B1F$8M-B*NFH%^ZIAU5BT#HUXD6B
MH!FOO9L9YTFY#DZHSSU:,T1N-,V8+) $46CMF^99YC0#TQD$'4N)L]'--U_(
M777]>G2.=*]4Z8;"M0^[1]V([ !4ZB+H3*,]G@;[-RN'HTUOXZQS94>01S4B
MEHMU7?*9&3K4P(92N-_2CT/1X.X:CH?YH^9"-WJ&,RQ8G+O8AD&+OI'8UJ#6
MS^7$L#_Z\"K;EJ8PF[LH#!QH^QJJT+30@=] 1(6N#TE%@^ FD,A1(\@*Y#78
M\^U]O7E>?BCX^F!"*Y[SU$6NOE4%A< *_J28:7KS?!C:,O2?[>$#*.R4WYJ<
MU-&J 4CH71=4D7P(%]X"$4I3(K6\-1PX(8\4Y5DH>S!ZWAQ0Z.,POZ3\R,U!
M3K%*/1@#77;<]E.5[0]QN'[.KS&+.'\!NFMM<8$A%Y.L18#^_=W7/XS.R=Y(
M"YYG, 5AH''CLPQ.U=Z=7W=$ND%Q8_;DWXPJ'#MA#-BCL7FPF'2S=3O*DQ$5
MW&ON%#D"(R_YN5^--+9>_RZ[MBA87&:_U:A[=/?"JJ()<T?'"^U.O:NDMOT\
M<+9!M)R/"X/4I5C1KC).LFOI;&BX=1!29^0 2 4OGH\;$T2B5'Z@/4&W,)4V
MNCUF:A"E:*,,M1]676M'1KI#]S!@%A1J[31N0O6(1QL4XO3C5BE0QKRJ/M+,
M#/ML60XHF*O58/61)6 $'HD53(I&JF.%J"CEK0ZMQS6%14N 4X#;'L*1(#FJ
M_D<DV&"(C[H4I2!R/IS(0/R<\;%]R(>TU,J0",2;&Z6+/7*,2.,60>8!VO5Q
MT)+C7'FBLKR[+T4+TL5="[$NI ]G SDJ+&4].X&M^57Q++V5Y&68S;*HEF$2
M'N[U[:9KPCD.M<8X%'C=46Q? MX@=VK"\8ILC$7$&/N=ZMFB:.6*I&+G$O:K
MK&8C#;%Z3]C!\H;M/03Z'AA/&Z6!FAX^]R@GSS"6-OT+V__9O/O:R$AG!DCB
M76B!U/T6B)L>VDN-3P#Y9_'RD.J 2TO6H:_Z9**(W$KQRY_BCH^4 *UE\U*H
M.^/E$-<[P)7)]^ VP J4(<<^:;FWC3KU:516@1NH<HX+I^48A*F^-[#25#16
MS\RFU+]3A8 ^EZE8-0J=8A<@1>0!#7LK\MCRM.+A ([\$YQ-3(_\>]("#5H-
M@.Y1U>8G5$-[?X&<;S5 ;$/92=)I.U#I244F3RORZ(AQ6!5ITGC@1.G//Q2B
M7ADC0#+G02#MXF4V$70P<]BD-_)-%W,QGUX==.?HP*D[CY?+MC\?X(.T] 8%
MU90PF_B=7<TFS'?^)YV0!#66*<U02PP.K1KQ(@63!_3 7#69T6G#,C[493:=
MG+-.T^E];;CN0(59.F-5XCD-6'10<'H,;YC]X11!3*'2ZX )G'N9#P</E)\]
MC/U:YX$AI7Y!C7_@[(:5'/VKX9F<.B*T5"Z@24$OGNMP[@!%448MO2%V(BND
MWIV,WC9XJ3DC X4FY,DST=[.TC\_\NZ!\G^K2R520.*169^)9(I@H\$U2:-Y
M,NU\W1Z Q4FT2!<BQGR+8;-G.(]F,!?NPJH_#65&'(+2<A(&\>DL95*OP\,
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M3)X7X/[*@7WM"3OHO^^=_@M02P,$%     @ #H-#5"]%P3H? P  .P@  !D
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MJ.P!>K^4TNP7-D#]?V'X&U!+ P04    "  .@T-4%1_[09H$   -#   &0
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M^V%.;R-J=X#V,Z7L=N(<M*_M]!=02P,$%     @ #H-#5+>.]BPF!@  *1(
M !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULS5C;;MM&$/V5A6H4$L!8
MO)-R;0.VDS8ID,*(G?8AR,.*'$G;D%QV=VG9?]^9Y<62+"M.T!9]$,7+SO6<
MF5GR="W5%[T",.R^+"I]-EH94Y],ISI;0<GUL:RAPB<+J4IN\%(MI[I6P',K
M5!93WW7C:<E%-3H_M?>NU?FI;$PA*KA63#=ER=7#)11R?3;R1OV-#V*Y,G1C
M>GY:\R7<@/E87RN\F@Y:<E%"I86LF(+%V>C".[E,:+U=\+N M=XX9Q3)7,HO
M=/$N/QNYY! 4D!G2P/'O#JZ@*$@1NO%7IW,TF"3!S?->^\\V=HQESC5<R>(/
MD9O5V2@=L1P6O"G,![E^"UT\$>G+9*'MD:W;M0E:S!IM9-D)XW4IJO:?WW=Y
MV!!(W6<$_$[ MWZWAJR7K[GAYZ=*KIFBU:B-3FRH5AJ=$Q6!<F,4/A4H9\YO
M8(DI-NQ=U0),F1K?\GD!>G(Z-6B!UDVS3MMEJ\U_1EO,WLO*K#1[4^60;\M/
MT;/!/;]W[](_J/ U9,<L\!SFN[YW0%\PA!M8?<%7POT M51&5$OVZ6*NC4)R
M?#Z@/AS4AU9]^)R[0O/E4L&R3:1<H*$[J!I@GVQ.V2W<&W99R.S+YWW9/:S]
M=J4 MC+,,#]0SD'9'(U%A10I"C2M)S9C='#9]8HCM!DT1F2\8.BD46+>M%51
MY>RFADSPPCRP&UG8VYJ-O0D;^Q-VQ$+/\>(03X+$<4.7_=9D!7!E):\52MKZ
M? NH8+6AP/<\YLWB7>.Z T!U>4'M01*1;C] ]D!N5^6[+M9*YDUFT*]@P@(G
M#&,\)OZ,77&5BPI%.@>X>?56EK#A2!S,6)1Z@^XG'CAN&N$Q\%QV*\V^%9$3
MQBZY&J'=*ZF0.]P &X<3Z\\XFG22O<21E8F2-GU1Z+$;<?^?(Y>Z3I*D>))X
MSBR*7XI<Z,U8,/._AER*O)@E+/&=($Q?B!PRR OPZ,7)"Y#S'!\3@69<]UGT
M4N1-2$?4N!^]=.:$@4?)B+UH%[T8?[.GZ)&,'[4IC-W8YO2Z#X2BTJ#N1 8:
M2WP!"N&</S#9J+V Y.*NS3170',,% D8R;AF/_Z0^K[[DQ[$ZNVDU_N,'H\L
MP%>RK)70J O[#"^*YP";-QH;B=;H+=QG4!N&K?ZE9.B=/[;X/3&Y"\M^6U^'
M>L-,.-D J8<DPT7(+,HW,RM@4 @<AD.7%94!]6H7>0I-XFHUW*FD(;=EAKHM
M!*2K$]/'!P9 - R Z&"+[MO]0LF2O;E'KRCL*SO'06FBR2\@EXK7*Y&Q"]Q&
MZ1>.AL-V;S&.A<3(UC33C)W?2![0F_E X\M'X\A&?L*^=Z9\K 2E\,9@)C6U
M.6R@J4\GKA-@LWQ7V=@)($R Y[C8B+"2T_A;>ZSW;_?8W4A2'$5^0%TS=0*<
M2=N1^([OIG1,9M_:;[QOZS?_OR*(AR*(#Y*QWV1AQUP(0[1KMUN6YMW#?10_
MK/4@Q?NHZ\&D>C39/Z14#%G]?NKOM%G""BGHQY:(P= 2(Y?1EF:;))U_81*S
M.)QML0,90.SPTK3G![YYX3.*%AMUA?]Z.BZDUF1O/(M<:S?^A_86;1AI0#6<
M(G'[,+PD0"//Q(%U[48TIW%_M15+%+H3&U,8/HV&8J 0HB"RH7@Q%3B-V/T#
MK#.6-\HBCSPP%CH[$S'VLHT=GL9NHUUCCZVE%O3Z5SPP4=:XVV]'-F='7MQG
MA_W9Y*U!FEGH9&]9(YF*OE@XUIJ=9NH!"[)1&FSA%?2:V;03&P/%2:[H?5"S
MK."B/%15R5!5R4'^7^!4-?KEU718VYYJZHM)8Y@$&&\-4C* 9ZNO5A2.]9,=
MMFV!\6M3 0M<9Q?F(^:'2'YJY'[@Q'XX<*_?RGJ^DP0)\[#?8_-]-!@[$<*'
M=Q'EVTV?L2Y04^JV@RF, JNJRR"VRB/OV&/S#G9$2&NQ$(@O,F4%16YCUKR
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M&]I@0/>5,7XGA ##JBQ^ U!+ P04    "  .@T-4&/D,I^ "  "Y"   &0
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M@;0!YOE*"+U?V 3E/Q6F_P)02P,$%     @ #H-#5)Q?FHFQ!   6A4  !D
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MA\??-"=8)ZXOLM4?&/VB_1\F$(V#A]TD>45JL*(*5N1-Q,=M$KZ\+ F#RMO
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M*S@J9X\A);"?U0+P?<VYVK]H ^65S>0_4$L#!!0    (  Z#0U1777,V6@0
M $82   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+U86V_B.!3^*T=H
M5NI(,TUL(+0516JY['35SB ZL_LPV@>3&+ FB5G;0"OMCQ_;27,A(66W8EX@
M<<[YSM6?+_T=%S_DBE(%3U$8R^O62JGUE>-(?T4C(L_YFL;ZRX*+B"C]*I:.
M7 M* JL4A0YV7<^)"(M;@[X=FXI!GV]4R&(Z%2 W443$\RT-^>ZZA5HO S.V
M7"DSX SZ:[*DCU1]6T^%?G,RE(!%-):,QR#HXKIU@ZXFN&L4K,2?C.YDX1E,
M*'/.?YB7N^"ZY1J/:$A]92"(_MO2(0U#@Z3]^"<%;64VC6+Q^05]8H/7P<R)
MI$,>_L4"M;IN7;0@H NR"=6,[S[1-"#KH,]#:7]AE\JZ+? W4O$H5=8>1"Q.
M_LE3FHB"@L:I5\"I MY7Z!Q0:*<*[6,M=%*%SK$6NJE"]U@%+U7P;.Z39-E,
MCX@B@[[@.Q!&6J.9!ULNJZT3S&+368]*Z*],ZZG!/8^7'[]2$<&7><B6Q)1;
M HD#^*)65,#CB@N5"-QRH<%9O)1P-J**L%"^AX_P[7$$9^_>PSM@,3RP,#0(
M?4=IYXP)QT\=N4T<P0<<:<,#C]5*PC@.:%"C/VK6]QKT'>UWEAG\DIE;W @X
MHOXYM-$'P"Y&-?X,CU=WZ\)YF_7QVZQ/FM7_V,1:W:VS7LIE.^NRML5K'W1G
MKN NEDIL-"LI^'ZO!>!.T4C^W0#?R> [%KYS /XK5R2$O)5-^Q8:M]#9=7V9
M8'L6VQ#Q=M#U7)VT;;%:QPA-JD(>+@B58NMFL74;8_M=KPYP=L^EGFR:B<=/
M2L_ #9,KFTB^ )/;NK 2V&[!F3UWA]V*N_M15S'0GLBX"H+J _:R@+W&@&]\
MGV]B)6%*GLD\I'6Q>16_<.>B4K.CI"9>)0#<[AVJ6B\+HM<8Q)!'$14^TVTY
M)6O-H]\?:#2GHJG;+S+LBU-,ILL,_K+1=8NF^VHH:, 43(C/0J:>/\ #>6+1
MIK .P)"L]5?U7%>BRVKRW4J%7A$J^8_<?$ES&R.8T2T/M];!<@S'5 $55DYT
MBCH@G!O OZ(2J9572O&:5#F&G/A1NS$&2\-@:;@<!J,2DFHTY2I? 5#G),7(
M:1@U\W!Q.Z3*VZ':I+]*OZ-&D;*7.7>B9O+$YQ[R?H//7.GT!AMJ%G!\5-OG
MS(9Z)\ET3F_HXB0KWBC%/;!<E;W)V1 UT^&,KLFSL2R-Z22QAU>F$:I26K>'
M]];,&B%<[R?.20\WDYY9<9A2-( 9]2G;&@<E/!+SF_'?5/"E(%'6$/ OO&V"
MXIPM\4G8$N=LB7\)6Z962AN:*EN^)E6.(6=+W,R6DY 3T^TP(XK^CUF,<[[$
M)^%+G/,E;N;+_S9OQKBZC^SLI],I''/U[FII+R0DV.UB<A;)1K-+CQM[U-\;
MOT570U0S/D)7X^1*(X=/;E@>B%@R?3 .Z4*;<L][VEV17%HD+XJO[2%[SI4^
MLMO'%24!%49 ?U]PG8'TQ1C(KHX&/P%02P,$%     @ #H-#5$V@=81K @
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M,!-6%H0T6OW'KYDCU@3<7H. DPDXFP)-/;B9@+LAX-@- C 3@!L"-FP00)D
MVK4'+Q/P=A7H90*]707ZF4!_5X%!)C#85<"V\IFS=A8I)GL5=*LH24/L'$M\
M>LS9$O"DO=*7_$CC-)57D46C)*6>)%=/J9*3IR,6AE2J')'B"(Q8)&DT4Q?@
MCN)G&E!)B0 X\M6UI#.<9L'[<R(Q#<0'\ [0"-S3(%"WQ7%7*GL2K=U)UO?9
MJF^GH>];''T$KGT$',MQ KP4,95/$DLRO%H$B@:23J<U6D<[:'702FNA)U-?
MH^Y\B[HX*(RTF[5<[*S%AC7BEV;Q<S+11GQY.@?OWWVHT7*UNQ:K6<OU+['E
MYI?8<KO-K4D$6=ML^6S6,ESP7(O=K]7255E5I)93I):3JG4;U-XQ(71*39),
M^G:GVH ;24+QKZ$'M^C!37N IAX>2:!2Q@>2K2>I6@ME0)*\KHNVE5HO59LL
MNB^GKHK*E_50JFGBE)M<5YN@C28WU2:VU;.*1J51PV+4T#CJ\1RKM71"8DDG
M.#"X$14*44L3Y14]>$:3;V-_ELP%4'L@$# AP8*S*95UT+Q<J4+K/O/J/=8K
MNN^9/<:9'T\TU-_ W0ID OP'GN)G07[$B747+Y5X*?77+_KKM^300='#8'OD
MZQ[>CL"?:O<V4K0/!;BD ?'5G3A\)ER-L)G:HT'%UQ"Z]<ZV+;VD6@>ZVS!R
M>VW%MEORKJW193M[^C?S[8HKNWGW/.ND%,JNU9#^MJ:>;<:>,9SO:43#.#1Y
M08/&AFUY6K/'1GMY&@PG$QYO<BW;)*"*/Q': /?UED9E,S7 ;#/!S#['K]M\
MKE%E]]KRN<:3W?]U/N]78]@:6)M.W]*J;*BFG&W&W%],X@ \+"BCI2WXMWN2
M9)_)&X[&E6.UY'%',\NQ]^3)A9!4G8@)8%,P5D_I<T! TJQN$C+MZ^[UW-[F
M)&QK5;9];1MG9F%N:6D&BCRH-;?*/<_K5\S=TJILKJ:C8Z:CV5P%\ICSAFUA
MIKFT'%;--C<J6ZU1ZY@W=;5;5Q4EKPL2"5)WOL@4EE/.:3)$\]@Q\SC91_S#
M^/<\ZYXD66+NBSE=*$S(G5)/4]7QVDH]#53'O/D;SF:<S)),&T:1@AP8"D&$
M:#@:?,ZTE;?L35[5Q'7,Q%T/RGP!2?;"6[Q=.^_]BH'0;K!/@];9;S^9KPA'
M8(S?TNI(;;Y4MX]- >AJ'+OFW>,^BU.FRJLW(#NE&=N4C=0\=\T\SY>D? ^0
M9\5^YPE7,]AM[2R]=IC>X31=6J/RX>VTVSUSJV!T85/JN)J,KIF,6==JF4QK
M8V H)>,1>1/@BD2$JX2>JGR*9KEIZ9EN546KM;**30<UV*BAZ9JA:0B'JXN'
MQZN;X9Z!H0GJMD505Q/4-1.TYK!9S,DX+S F;C=5+<^R3DJ.;^"6J[GJFKEJ
M</R8TY<D7L:8IU7< U-4(]0=M#034+,1[L?&/5-TE*DO[5V\AK,1U#"$!\-0
MG9J5Q</5ZZ/V9@EJD,*V0 HU2&&K(!W!*DAMV&N8I;6JH9FCF[.THNF!_M9D
MA&W5%J%F(#2?S7]VX8+5BJ,S:%JXH,8F_#U51ZAI"-NJ.T*-.?A[*H^PNG=<
M*["7Z]B:C^C0RJ,R9AC@D/A8&1]'ZLEAD8\T%5%;94JD:8;V+5,>L#*/4/4@
MCGJH(?Z1QB#ZB3+E@YPK,V]C3H5/T^7A4/8C34#45CD3K;U*V:^<>>",5&N8
M;L,[$*0QB<R8/'^X!3?1"Q'[E-&0QAUJJW")-.#0#H7+ U[XW:+JH=EN>,^!
M- J1&86CKT_@FN! SDVOR#2\O+;JD)Z&DK>M#AG-_I"$AV <\\D<"P+T%Q#J
ML$\X97[=Z_TM>FT+O!',:U_P=->^SD@^4[K'?$95N@=DJG19'WLJS/GJRY_5
MA62+](.-9Z:.>F'Z<TZP3WC20#V?,B;SB^0;D.+[J]/_ 5!+ P04    "  .
M@T-4NG"R+9 &  #T'@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R]
M65%OXC@0_BL6VI5:J0NQ'0)4;:4M4&Y/V]VJW=X]G.[!) -8F\2<8TI[NA]_
M3D@Q),;07;0O+829L6<\^;[/]L52R._9#$"AYR1.L\O&3*GY>:N5A3-(6-84
M<TCU+Q,A$Z;T5SEM97,)+"J<DKA%/"]H)8RGC:N+XMF=O+H0"Q7S%.XDRA9)
MPN3+-<1B>=G C=<']WPZ4_F#UM7%G$WA =3C_$[J;ZUUE(@GD&9<I$C"Y++Q
M$9^/_';N4%C\P6&9;7Q&>2IC(;[G7SY%EPTOGQ'$$*H\!-/_GJ /<9Q'TO/X
MIPS:6(^9.VY^?HU^4R2ODQFS#/HB_I-':G;9Z#90!!.VB-6]6/X&94+%!$,1
M9\5?M"QMO08*%YD22>FL9Y#P=/6?/9>%V'#0<>P.I'0@50=_AP,M'>BA(_BE
M@W_H".W2H5UU"'8X!*5#<.@(G=*A4RS6JKK%T@R88E<74BR1S*UUM/Q#L;Z%
MMUX1GN:M^*"D_I5K/W7U*0U% N@;>X8,G7QA4K*\-T[1R0 4XW%VBCZ@QX<!
M.GEWBMXAGJ);'L>ZB;*+EM+CYU%:83G6]6HLLF,LBFY%JF89&J811!;_@=L_
MV.=_X_;'Q!&@I0NWKAYYK=XU<48<0-A$%)\AXA%LF5#_<'?/5H^?&WWX<Z/?
MN-U_7Z3:W2O<B<5]=+@[=BP%73<R+>+1 QK9$<Y?A_.+</[><&CXK'$_ W1R
M#2E,N#JU=?XJ6E!$R^'_Z>H#+NKRM-D.%BOBT6VC@<6H1]K;1D.+48!-I*V<
MV^N<V\Z<1T)$2_UVGZ%/R9QQJ1E'H<\BL[WJ@U6H]L8$,/4Z]@D$ZPD$S@D\
MIA)",4WYOQ AI4L_7E7<BC5!;0(]VJF4\@";45"K9(\2>QZ==1Z='\L#J1E3
MFIP7<82XKG&H$$PF4-!Q8:C1%VS)=FJ)=-M^)=D#;$86&[]G3[:[3K;[8\F>
M:;90("%3B*41TB\1BQ77-,/"4"ZL '[=K2V&7^G\P7Z34;>6Y:XD>^LD>\XD
MA^M5V@"&>[U8Z%XGGX8\YBR75F?H#F2HWQM;<NXAL-=N>MY[&XNX'4_\3C/P
MWMM@:;!GR#9M8NN00[<C:?>:G:KC5F&Q9P2(YXPU@ E(J7N'KRJK"BF2=XQ0
M,Y!(5W:LRYMWCE5R>/7W-_"J0'"0U:BTVL*+H./96P=O2"SLS+ O9,0S--#M
MDRFN%A)<A2,F+#D&XV'#H)BZ5X)GNI<53_7+B;[.098M79!@\0(@,4$CO;]!
M)SDMG**)%(G.*YN+C,7YC_80UG6C=0+QJJMFL=GQ(F-#[-C-[+<0\5#/]C'E
M"KU2WB;C_74+R1CDWZZ:&DK%[:,LDJ%([.;(-PJ3 :YSH%8FWJZF-A2'W1RG
M-X(0LLR4"_V'WM;HAF!P]R@U-&".W?#U*QO]IIS+)O30KKWZQ( F<8.FK?K'
M:&QB0(W@8RP*,7!&R#$;^Z8,5]').PIK,)"X,? +J-?E3*>%^$5]O2E^&;/P
M^T$%-#A$_*,4T$ -<<OW-Q:P7X;;*J!/=@ #,0!%W #U<WS>)W6\ZG@58AB2
MNFCO[((T8B"-N"%MZRQ$ZSK@3VP<6_4XJ0OI7J<JR/<8;<_2H"%QZ^U;GO)D
MD;A:Q@ AZ1VC!ZG!)>K&I:'&_43+XDCO9-(IY$@902B!Z6;4:+K8N3%:<C73
M!KI#4 K/"F&"DN*LQE9]6M=I5>G@--E.SD >=>NX6_:\I_+4H!T]BGBC&\<?
M;N#Z196O*S)2*[W39CL]@Y;4K=KN-"#G')9OMYY OJ#K1:9-JF<3V]$-=-*C
MJ#1J0)#N4VD1)"F?:$(N3MS=:$+KF%<]%-IO,K*8X!U\2 TF4C<F:O*#FT5Q
M\7  ^U&#8O0HFHX:**-N3??&BO?J+$.J)=]O,W+;;)\\&A#UW2#Z32@MX[[.
MN> 1^JR9<KI*Z8 %\ V8^4?1;[Y!--^MWPP ;4SY<TGV+]8ST[J""X)N%4Y*
MJ_8NJ^WI&KSTW7CYUGU4&2[8S3E#OPY\'VA5NXQL5H3LV!'X&^?5;H \^IEC
MWZ^?,5._FK)?AZ7JF:,E#MFUC?<-9/MNM;O19 ^@5 SY%N?L=2UM1UI^7>]B
MK\9,K8V[M 3DM+@FS5 H%JE:71^LGZZO8C\6%Y"5Y]?XO(\MSP?X?&A[?H//
M1ZL+6#/LZC[XELDI3S,4PT1/P6MV=")R=<6Z^J+$O+CA&PNE1%)\G &+0.8&
M^O>)$.KU2S[ ^J+[ZG]02P,$%     @ #H-#5)#G>SXO P  )0T  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&ULK5==;YLP%/TK%JNF3EH+AGRU2R*U
MB:IM:K6J5;MG)[E)K!J<VB;I_OUL($ *6)'(2V+C>X[/O;X<F>&.BS>Y!E#H
M(V21'#EKI3;7KBOG:PB)O.0;B/3*DHN0*#T5*U=N!)!% @J9ZWM>SPT)C9SQ
M,'GV*,9#'BM&(W@42,9A2,2_6V!\-W*PLW_P1%=K91ZXX^&&K. 9U,OF4>B9
MF[,L: B1I#Q" I8CYP9?3WS/ )*(5PH[61HCD\J,\S<S^;48.9Y1! SFRE 0
M_;>%"3!FF+2.]XS4R?<TP/)XSWZ7)*^3F1$)$\[^TH5:CYR!@Q:P)#%33WSW
M$[*$NH9OSIE,?M$NB_4<-(^EXF$&U@I"&J7_Y",K1 F .PT /P/XQP*"#! D
MB:;*DK2F1)'Q4/ =$B9:LYE!4IL$K;.AD3G&9R7T*M4X-;XC5*!7PF) #T!D
M+$"?D9+HO+3 E^A&2M!/2;1 ]Y3,**.*@MQ#%L@<"'J">2P$C5;HED@JOZ'S
M*2A"F1Y=E!8OT,OS%)V??4-GB$;H@3*F#U0.7:7S,:K<>:;]-M7N-VB?POP2
M!?@[\CT?U\ G=OCO.-)PKP[NZBKFI?3S4OH)7]# E];HVL(4Y$Q!PM1I8)H0
MN4;P'M,M8>8TZDJ3,O02!O.N;L?8Z_>'[K9<@)J@P2#(@P[$=7)Q':NX/VH-
M0A_<%J0*F]2E%-WRQG[WD[BZF%Z]MFZNK6O5IM_L'1$+-.>1$MHA:K5U*_OV
M_$_2JB$=OUY9+U?6LRJ[ARVPKU]PS_MAZ[5^3M=OV6N#G&G0NM<&U9.J]EI-
M4&.O7>7BKMKWVM41O587T]!KV"NLTVO?;1E'>6OODSAKR*&VDJWC8_O-MW0)
M+LP-MW4W7-@;;N]O&86U;K:00VF%N>$3N!NN6E=%FRWD4%MA;O@$[H:/L+>:
MF"9_PX7!X:,=+K!U26%QN*W'X<+D<'N7PU4'JYRJ+>106F%Q^ 0>AZL&5M%F
M"SF\T!0.YY_ X3*.GD6;-235YI;NL.8#XH&(%8TD8K#4&.^RKQ,3Z9T\G2B^
M2:ZU,Z[T)3D9KO5W# @3H->7G*O]Q-R4\R^C\7]02P,$%     @ #H-#5,KS
MIFHO!   !Q   !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULK5?;;MLX
M$/T50NA# B21*-_2P#:0^+(UD'2#>-,^%'V@Y;%%5"*])'WIHA^_0TF1%5E6
M#"0OB43-A3QG/(?3W4KU2X< ANSB2.B>$QJSNG%='800,WTE5R#PRT*JF!E\
M54M7KQ2P>>(41Z[O>6TW9EPX_6ZR]JCZ7;DV$1?PJ(A>QS%3O^\@DMN>0YV7
MA2>^#(U=</O=%5O"%,SSZE'AFYM'F?,8A.92$ 6+GG-+;\:T8QT2BV\<MKKP
M3.Q19E+^LB^3><_Q[(X@@L#8$ S_;6  460CX3[^S8(Z>4[K6'Q^B3Y.#H^'
MF3$- QE]YW,3]IQKA\QAP=:1>9+;+Y =J&7C!3+2R5^RS6P]AP1K;62<.>,.
M8B[2_VR7 5%PP#C5#G[FX)<=FD<<&IE#X]0,S<RA>6J&5N;0.M6AG3FT$^Q3
ML!*DA\RP?E?)+5'6&J/9AX2NQ!L!YL)6UM0H_,K1S_3'7# 1<!:1B=!&K;%H
MC"9G7YE2S')^3LZ&8!B/]#FY),_3(3G[=$X^$2[( X\B+ [==0UNQ(9S@RSI
M79K4/Y*T01ZD,*$F(S&'>87_L-Z_7>/O(@ Y"OX+"G=^;< A!%>D02^([_FT
M8C^#T]V]JN.\+_OH?=G']>Y36*&[5Y7]%9:-O*(:2;S&T>THODEJA_RXQV]D
M8B#6/VLB-_/(S21R\TCD0<C$$FSI/0OLHA'_#^;D+^R>Y.Q>:BQ0[%1CQA7Y
MQJ(UD"\P7W*Q+!9V5:FF.=M)3MN'-WT$<5,D_TV+X9L6HSJ+5V"T<C!:]6 P
M'9(Q"D-^SA\/$,] U2'=SH.W/YC#3AZY4[OMOTT(B@QDC#H86H'"%!,1R!@R
M$B_(ZY/!19'B"S(#E%,@3Q!$3&N^X %+)4K,R3]L5\5PNJ-6 7M:8OC0XKK$
M\*%%H\3PH46GFN'K'*KK6JA0.5$7!1GM@K3P!]CT%$KQ*4Q_SI-\_F"FJ;>7
M%N^]7'_%N]-$;$ ;^_O\*,*S?;UBO%.BO,+FTB\9#2N,?+_$>U6@EE]-/2W(
M,JW%;B(,*(0E!VRTP\ND!HN9%'BQM/(LE@F"E1#0@UVUR@B\:3*L,*&T?/X*
MFR.]C?K[X_NUQQ^"QM)G!AL\TQ6=G/RIZO1_2 [;$_J2Z9:MZBIY+VGTHS6-
M[D6-UJM:(?8]9S,><?/;DFR+'*]EM[%<BVJ*FX?%Z965Z12C,3U4)^H=XW O
M4+1>H=*??[%:#XHY[V1('9Z8O$E[P?Y=[9'NE9!^M!32O1;2>C$LQ"[>OD]!
M0I>ZY+$VT#E@UB^W@4.3RV:YB@YMFN4V4!&F52HAMS"GQ*"6R42I26 K/+U@
MYJOYU'J;S&JE]3MZ,Z 5ZT-Z,TIGTGWX=$1^8 H1U"2"!:;RKCI8NRJ=.M,7
M(U?)E#23!F>NY#'$21V4-<#O"RG-RXM-D,_^_?\!4$L#!!0    (  Z#0U23
MR_UBI (  *\&   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;,U56T_;
M,!3^*T<1#R !29,V3*BM1-NA,96!*+"':0]N>MI8.'9GG[3P[[&=D!5HJSWN
MI?'E?,??I7&Z:Z6?3(Y(\%P(:7I!3K0\#T.3Y5@P<ZJ6*.W.7.F"D9WJ16B6
M&MG,@PH1QE&4A@7C,NAW_=JM[G=528)+O-5@RJ)@^F6 0JU[02MX6[CCBYS<
M0MCO+MD")T@/RUMM9V'39<8+E(8K"1KGO>"B=3Y,7;TO>.2X-AMC<$JF2CVY
MR=6L%T2.$ K,R'5@]K'"(0KA&ED:?^J>07.D VZ.W[I?>NU6RY09'"KQD\\H
M[P5? ICAG)6"[M3Z&]9Z.JY?IH3QO["N:Z, LM*0*FJP95!P63W9<^W#!J#5
MW@&(:T#\KX"D!B1>:,7,RQHQ8OVN5FO0KMIV<P/OC4=;-5RZ%">D[2ZW..I?
M<LEDQIF *VE(ES8@,C"I,@4UAZ^&N'4+9W#)N(9')DITZV,E%R>$NH";J> +
MYD(QP.0,;BA'#9-<::H*!DI;5EPN#!R.D!@7Y@A.X&$R@L.#(S@ +N&:"^$Z
M=$.RJARW,*L5#"H%\0X%(\Q.(6D=0QS%K2WPX7[X]U):>+0-'EK6C:%Q8VCL
M^R6[#&U<.H8+8Y J4\:<3;G@Q-' -3)3:NNH_1O?859J;;WQ53^4U,W"@!EN
MX-?8'@!7A(7YO8=>TM!+/+WV#GI#IO6+ZWY1J%)2D^2]"\I14!OIW;]/;ULV
MU6FI/\W=&*M^)VTGW7"UF<#GHC1.TJ;HG9!V(Z2]5\@85R@@WF-)I^G4^1\3
M2QMZZ5ZA?U_ N2.Z<D2W)9%^-CDZ:W](8DO16:?U(8EPXSIQ5_DUTPMN7VZ!
M<PN+3L^LG[JZ'JL)J:6_8::*['WEA[G]HJ!V!79_KA2]3=REU7RC^J]02P,$
M%     @ #H-#5",/LNX0!   ZA$  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&ULM5A;;Z,X&/TK%JJTK=0)V(1<JB12<]..-%U5D^WNPV@?'' "*N#4
M-LE4VA^_-CA<4F#3W>0E >-SON-C^W 9'2A[Y3XA OR,PIB/#5^(W8-I<M<G
M$>8=NB.QO+*A+,)"GK*MR7>,8"\%1:&)+*MG1CB(C<DH;7MFDQ%-1!C$Y)D!
MGD019N]3$M+#V(#&L>%[L/6%:C GHQW>DA41+[MG)L_,G,4+(A+S@,: D<W8
M>(0/2^0H0-KCCX <>.D8J*&L*7U5)U^]L6$I120DKE 46/[MR8R$H6*2.MXT
MJ9'75,#R\9%]F0Y>#F:-.9G1\,_ $_[8&!C (QN<A.([/?Q*](!2@2X->?H+
M#KJO90 WX8)&&BP51$&<_>.?VH@20/+4 Y &H%- MP%@:X!];H6N!G3/K>!H
M@'-NA9X&]%+O,[-2I^=8X,F(T0-@JK=D4P?I=*5H:7 0JY6U$DQ>#21.3%8^
M9L2GH4<8_P4LWI) O(/;WS!C6$WY';B=$X&#D-^!+^!E-0>W-W?@!IB *R '
M00Q>XD#P^U+#4Q"&<M7(MIORZ<@44K J:[I:W#03AQK$V>")QL+G8!%[Q*O!
MS]OQO7_#+]OQPQ:\*8W.W49'MZ>HE7!.W ZPX3U %H(U>F;M\!792;C5")__
MO^J+\^%6G9GM\"?,<CAJ\=+.5ZZ=\MD-?+,0<P[H!JP$=5_!CV_R.O@J2,3_
M:F'OYNS=E+W;P/Z<,->7B:4*"!G9/&'O>HG7&9^1]5(R%>;[R<"2'NW+[G[L
M4_2H:'1RC4ZKQAO'LF0FI+LKTR:S?G<4OF-TRW $?LRINL.TF=++"_:N8'D_
M9^]?T/)9_X.=CM5@Z"!7,&@WU#[+T"<2K0EK&_(P+SB\@J'0*L+=NJ"E4\U6
M]M1N\A26[C"P5<3OU<+R84+>91CQ[@'>$R8?7Z2S@2M_"=.FW\J[1L*]HN6N
M5FU6ME]9 1V[02XJY*+SY*YJ?*IR%E$%KY%5L @KV)Y6A6;%?Z^EWX-';76M
M?1FE4[+O2[\:6?.Z/M!I<+B(+=B>6R<.@[_!Q9(,%E$&KY%EL @SV)YF_V%*
M9IIR6)F2SN!T4OH?)P4US$F1?+ ]^JZT26>Z;&63PHYCGXZIMAML&%41KW#X
MV95VJ8A'10@CZPHK#17YBL[,UT]L?DU966G=TDJK2BFR$WTJ.S_MMP2LDC4G
M;PF)!5CLY6^;147^HFOD+RKR%UT\?Y>:LC(%L.GVA8IP16>&ZV4W\E*7+>_0
M[K!C#T_TFJ57T8BP;?K1@ .7)K'(GNWSUOS#Q&/Z.G[2/H4/,UC3/H</B^RS
M0T&??061+QC;(.8@)!M9RNKTI6*6?5C(3@3=I2_":RKD:W5ZZ!,LWWQ5!WE]
M0ZDXGJ@"^>>=R3]02P,$%     @ #H-#5# J'&'O!   F1<  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&ULS5C;;N,V$/T5PEB@"9"-),K7P#'@6]L
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M3\D*/<.HK,%;L+77__^00O\P@+K&*X:!9Y\&'\4*AAG1-V.#Q8B ]A'Q'E*
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MDY+%R>,:HQ!S+:!^7S(FWUZT@_PV?O0/4$L#!!0    (  Z#0U1;["5%?P(
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MIKO"(9\SSU<8Y<(7NL$WB:!H'9EZ +."6NK^+_X,=3@ ,,_+@'0 I,\!TU<
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MW%9?7\<ZE4<"%7)7Y9G84BEK5'A?IR5MLR+]S6I,>11G<K+U<WPMT"U+X5?
M;=L)\4X MVT0I/_-_C!<O_/IYUJ!RK8K<GSU2U,CPH2HWR\Z%39-!:VQM=^3
M E^4&VTY"MDZ$]57?7.UV<R[+K>PE.LW^'*,-=<G^'):;=6U[JN=PWO*%W&6
MHP2>9"CSPI.KD%>;<=6)8*MRMVG.A&!I>;@$&@$O!/+^$V/B]:0(T&R)COX#
M4$L#!!0    (  Z#0U2I:I8:OP,  &H0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;,U86V_;-A3^*X30AP1H(U$WVX%MH+$S+$6#&<FZ/11]H"7:
M)DJ1&DG'+; ?/Y*2)4>FU;3+@U\BD?S.]3O4\<EXQ\57N<%8@6\%97+B;90J
MKWU?9AM<('G%2\STR8J+ BF]%&M?E@*CW H5U ^#(/4+1)@W'=N]A9B.^591
MPO!" +DM"B2^WV#*=Q,/>ON-![+>*+/A3\<E6N-'K#Z5"Z%7?J,E)P5FDG &
M!%Y-O/?P^A:.C(!%_$7P3AZ\ Q/*DO.O9G&73[S >(0ISI11@?3C"<\PI4:3
M]N.?6JG7V#2"A^][[;_9X'4P2R3QC-._2:XV$V_H@1ROT):J![[['=<!)49?
MQJFT?\&NQ@8>R+92\:(6UAX4A%5/]*U.Q(& UN,6"&N!L"L0GQ"(:H'HI1;B
M6B!^J86D%K"A^U7L-G%SI-!T+/@."(/6VLR+S;Z5UODBS!3*HQ+ZE&@Y-7W$
M:TV[ G>L*CI#WL5^<R'XBBBP_ X><,F%0DN*07UX"2[F6"%"Y25X!SX]SL'%
MFTOP!A &[@FE6H\<^TI[:.SX6>W-3>5->,*;"-QSIC82W+(<YP[Y>;]\VB/O
MZ\PTZ0GWZ;D)>Q7.<78%(O@6A$$('?[,7BX>N,+Y?]9O?]GZLV1$3:U$5E_T
M@UJIBH&P]5O]FG&6$8U<@SN%"Z"K"/Q18H',^;Z +CYRJ<MD)7BQ+Q^@.)CI
M&N&4Y$CA''S^J*U9'?)+CZ]QXVML?8U/^/HG5X@"WGB"D6#ZZ:S)2E-J-9D/
MZ]/TW2C1"7LZ)/H8%*?P.6;N4)1$R7/0K0,$TZ@!/8LV::)->J-=;)"^O!G>
M*I(AVI.^M%&8GCW5@\;706_P'[9Y9<<X1+E4H+2^.+FN5"4'V8>I._?#QORP
MUWR;@CI>V1/3J%$Z.OO\PZ#M(<&K7;9:U2$#\2#M7#8'*(U'G=OF ,$@Z%XW
M%RH<0C?G\*!MPI]D'?P+7GP-8=C:"<^_$-H& :/7*X3HN!#"HT)P@&#4+81C
MT# *NW7@ ,'D1!FT70;VMQEG&=SC_$?\MQ]VF)P__VW7@.GK\9\>$7+4=!V8
M,$J[]!^#X"#JTG\,BM,37W[8=A[8WWIF7&A:="[[LM<V$C@\?Z[;#@5'K\?U
MR/&CQW';7;#AL,NW"Y7$09=QI\TX[G#N'\Q.!19K.[1*D/$M4]5/XV:W&8S?
MVW&PLW\#KV?0L3\W@[2=U5KUU11^C\2:, DH7FE3P=5 5Z>H!MMJH7AI)[<E
M5WH.M*\;C'(L#$"?KSA7^X4QT/Q[8?H?4$L#!!0    (  Z#0U3W@8A\@0,
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MVT*&JYS:DS*T7A&:NR<T#]U0(A8<#<D4I@;^H)D?-O!M6::J5NZZ5CVWT>
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MY^U@YR\FWN6Y3;S +AX..E\.G"7<+*@F-X65JE1T<,);5H]?7T),NN'(R\W
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MZH-V?:/XTAP])USI@ZRY7 #-0%0!^OV,<[6YJ09H_^X8_0]02P,$%     @
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M;?T.B-92\30':P]2RK)?_)@'H@) L & <@#:%Q#D@&!?0"\']/8%]'- _P4
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MRJ;+?K&<6+7W/=I&6>KX_#"G'ANUVT#/MTK9\\0%J+KVQ7]02P,$%     @
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M17X6IG /TY%0#*,24G1ZS"#!.C]:MA9.")>PK-5ALS9'/KN#'I.;X0H575S
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M._X*V^O'W2N6C<5ERM8LG353G<_K86 '-FIS@<,A<EU??@3S<9@? 0R+@RG
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MN8*R>WOG9+E_56O_FMFGOP%02P,$%     @ #H-#5!,G[+KO 0  I2(  !H
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:NT[K0!2%X5>)_ !,]BW
M$:&BH46\@!4F%Y'$ECT(>'NB4(1E49P&S:JLL>7MO_IDC7WWE/=MV77'<;OK
MQ]G'87\<E\VVE/Y?2N-JFP_M>-7U^7BZLNZ&0UM.RV&3^G;UVFYRTOE\D8:?
M,YK[NY\S9\^???Z?B=UZO5OEAV[U=LC'\LO@]-X-K^,VY]+,GMMAD\NR21_[
MR^DQG0]R=9K<S!Y?ELWP^")-JAVD$*3U@PR"K'Z00Y#7#PH(BOI!"PA:U ^Z
MAJ#K^D$W$'13/^@6@F[K!\D<99P3)$VP)M!:D&LA\%H0;"$06Y!L(3!;$&TA
M4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%LG+]L$>BOJK01Z*^JM
M!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV2S
MA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]
MG4!O1[V=0&^?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^@=J'<0Z!VH
M=Q#H':AW$.@=J'<0Z!VH=Q#H'9./E01Z!^H=!'H'ZAT$>@?J'7^I]U@^]WF\
M]'RO\?E_274YW9LOCS\OOT^BA(LSS@G^2KG_ E!+ P04    "  .@T-48B/G
M&-@!  !((@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/@S 4!N"_LG!K
M1M>O^1'GC7JK7O@'*IP-,J!-V\WY[RU,331*7&;B>P.!MN<]M,ESQ>7CBZ,P
MV;5-%Q99%:.[8"P4%;4FY-91ET:6UK<FID>_8LX4:[,B)F:S.2ML%ZF+T]C7
MR*XN;VAI-DV<W.[2ZU#;;I%Y:D(VN=Y/[+,6F7&NJ0L3TSC;=N67E.E;0IY6
M#G-"5;MPDB9D[-N$?N3G@+=U]UOROBYI\F!\O#-MFL5V#0OQI:&0CY?XID>[
M7-8%E;;8M&E)'IPG4X:**+9-OB]Z,IX<TP[3_LJ/SA_*C 6FF0_>NI!.S-/A
M<>]'TJ^>NE2(?*S'/_$C,94^^ONH/^V2RE]FI^U]MGX]G$=@P^WX/?Y\QA_U
M#^Q#@/0A0?I0('UHD#[F('V<@O1Q!M+'.4@??(;2"(JH'(54CF(J1T&5HZC*
M45CE**YR%%@YBJP"15:!(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(
M*E%DE2BR2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56A
MR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%DU2BRZO^4]<G:]5__V]#?\];4
MW7L^&WX@N7H%4$L! A0#%     @ #H-#5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  .@T-4:FM&
MH^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  .@T-4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  Z#0U10Q'A+)04  %H5
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  .@T-49SQ9O@$'  "+'0  &               @(%H#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ #H-#5/ZM_GG2
M P  /0T  !@              ("!GQ0  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    (  Z#0U3NRP]-:P8  ,P:   8              "
M@:<8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  .@T-4
MQ13['8$"   J!P  &               @(%('P  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ #H-#5!IT@=X!"@  ;D0  !@
M     ("!_R$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M  Z#0U0Z@ICEW08  +4:   8              " @38L  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    "  .@T-4@.20?XX&  !2$0  &
M            @(%),P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ #H-#5/VVVC!+ P  V 8  !@              ("!#3H  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  Z#0U1*[+WA.@0  *T*
M   9              " @8X]  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ #H-#5(B$W-#2!@  TA$  !D              ("!_T$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  .@T-4=)CT
M&/(%  #Y#@  &0              @($(20  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    (  Z#0U3E+(RK2Q\  &5=   9
M  " @3%/  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M#H-#5%EQC]R&#   (2@  !D              ("!LVX  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    "  .@T-4#'1!X8<$  #!"@  &0
M            @(%P>P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    (  Z#0U3 %3O@:0L  (\E   9              " @2Z   !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ #H-#5#5^+9Q1!
MUPH  !D              ("!SHL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    "  .@T-44JWH'R<#  "!"   &0              @(%6
MD   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  Z#0U2U
MD":NK0L  *LA   9              " @;23  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ #H-#5%)7T>5<!@  1Q0  !D
M     ("!F)\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z#0U1*Y3[[RP(   \&   9              "
M@?ZY  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ #H-#
M5(MT+?'X @  ;08  !D              ("! +T  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    "  .@T-4SPRG-_D"  !Y!P  &0
M        @($OP   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   (  Z#0U2WCO8L)@8  "D2   9              " @5_#  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ #H-#5'@!'G*N!   - \
M !D              ("!O,D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    "  .@T-4:M\;868"   V!0  &0              @(&AS@
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  Z#0U08^0RG
MX (  +D(   9              " @3[1  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ #H-#5*.%@UTY P  @0L  !D
M ("!5=0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  .
M@T-4V0>5QZ4"  "4!P  &0              @('%UP  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  Z#0U07%K/D\ ,  & 0   9
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M970S."YX;6Q02P$"% ,4    "  .@T-4*G>UP]T&  "+)0  &0
M    @(%3[P  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M  Z#0U2Z<+(MD 8  /0>   9              " @6?V  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ #H-#5)#G>SXO P  )0T  !D
M             ("!+OT  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    "  .@T-4RO.F:B\$   '$   &0              @(&4  $ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  Z#0U23R_UBI (
M *\&   9              " @?H$ 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ #H-#5",/LNX0!   ZA$  !D              ("!
MU0<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  .@T-4
M,"H<8>\$  "9%P  &0              @($<# $ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    (  Z#0U1;["5%?P(  *0%   9
M      " @4(1 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ #H-#5$EW/U(W P  I@D  !D              ("!^!,! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  .@T-4K3L;EA8$  #3$
M&0              @(%F%P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    (  Z#0U26)W+"BP0  !X5   9              " @;,; 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ #H-#5*EJEAJ_
M P  :A   !D              ("!=2 ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    "  .@T-4]X&(?($#  #<#0  &0
M@(%K) $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  Z#
M0U0WAFJ!V ,  /H0   9              " @2,H 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ #H-#5,0EI/: !   RA8  !D
M         ("!,BP! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M    "  .@T-4M5WS'P8#  "X"@  &0              @('I, $ >&PO=V]R
M:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  Z#0U1/$-8,0@,  ,$+
M   9              " @28T 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL
M4$L! A0#%     @ #H-#5/<8V0%# P  %@H  !D              ("!GS<!
M 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  .@T-4RU;U
M$10$  #"#P  &0              @($9.P$ >&PO=V]R:W-H965T<R]S:&5E
M=#4W+GAM;%!+ 0(4 Q0    (  Z#0U2$)N&!K@,  '@,   9
M  " @60_ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M#H-#5,T>Z9(= P  $!(   T              ( !24,! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  .@T-4EXJ[',     3 @  "P              @ &1
M1@$ 7W)E;',O+G)E;'-02P$"% ,4    "  .@T-4K7* GJ0$  #J)@  #P
M            @ %Z1P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ #H-#
M5!,G[+KO 0  I2(  !H              ( !2TP! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ #H-#5&(CYQC8 0  2"(  !,
M         ( !<DX! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $( 0@ %
)$@  >U !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>241</ContextCount>
  <ElementCount>342</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails</Role>
      <ShortName>Segment Information Revenue From External Customers By Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cah-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20211231.htm">cah-20211231.htm</File>
    <File>a22q2_10qx123121xex1022.htm</File>
    <File>a22q2_10qx123121xex1032.htm</File>
    <File>a22q2_10qx123121xex1042.htm</File>
    <File>a22q2_10qx123121xexhibit107.htm</File>
    <File>a22q2_10qx123121xexhibit311.htm</File>
    <File>a22q2_10qx123121xexhibit312.htm</File>
    <File>a22q2_10qx123121xexhibit321.htm</File>
    <File>a22q2_10qx123121xexhibit991.htm</File>
    <File>cah-20211231.xsd</File>
    <File>cah-20211231_cal.xml</File>
    <File>cah-20211231_def.xml</File>
    <File>cah-20211231_lab.xml</File>
    <File>cah-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20211231_g1.jpg</File>
    <File>cah-20211231_g2.jpg</File>
    <File>cah-20211231_g3.jpg</File>
    <File>cah-20211231_g4.jpg</File>
    <File>cah-20211231_g5.jpg</File>
    <File>cah-20211231_g6.jpg</File>
    <File>cah-20211231_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="800">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20211231.htm": {
   "axisCustom": 8,
   "axisStandard": 24,
   "contextCount": 241,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 477,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 21,
   "keyStandard": 321,
   "memberCustom": 31,
   "memberStandard": 37,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "ifc68b9700023489da77737a2a6a45de7_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "ifc68b9700023489da77737a2a6a45de7_D20200701-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "icf0e97ab999a4cf9bb41b8f8dd40e422_D20201001-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Restructuring and Employee Severance (Tables)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)",
     "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
     "shortName": "Discontinued Operations and Disposal Groups (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i52fcee9318c84705b5a4c134a0b7ce76_D20210701-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails",
     "shortName": "Restructuring and Employee Severance Narative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i1de5fd1605f748fdb2806fef4a6523c5_D20220125-20220125",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "ife056180602548b8811ec73a324b2646_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "ife056180602548b8811ec73a324b2646_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "idf89a8993ffb426a9d8312715526954c_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i51ee4fa253c140b78f57a286ba3fd59b_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i87549c698d84454483818bad997efd4b_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Segment Information (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "ia61793c90cb848a6aaab2bf31eaebc5c_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "ie67c60168405428b9e40371da416b3fc_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
     "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9d0ef5db6f8c49e99cf83c70272570db_D20211001-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i9c1ca3e313f8427ea77ad0ab23207095_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id6a5635665184a6cb80b94e96e68ca69_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "id1472a4ba7c64614a893ad096781cc1e_D20211001-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i971fb9b8eb864c16a90cecd4e38e78f4_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i898c45d5227a4196aece99539dfb04a9_I20211231",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:AdditionalStockOptionPlanDataTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i898c45d5227a4196aece99539dfb04a9_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i1838109a9f674e1bab45a2a99e3111b7_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i8aa1d951b73947c3936f78f13c7eaa01_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i5d1987e4c66c4c949f14a8e1ffb9ad45_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "if521936d67844e53ad65faa8fee63ccc_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "if521936d67844e53ad65faa8fee63ccc_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Divestitures",
     "role": "http://www.cardinal.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20211231.htm",
      "contextRef": "i0868d409998c4f1caa1cc4eb950e426e_D20210701-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A300MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$300 million share repurchase program",
        "label": "$300 million share repurchase program [Member]",
        "terseLabel": "$300 million share repurchase program [Member]"
       }
      }
     },
     "localname": "A300MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A500MillionShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$500 million share repurchase program [Domain]",
        "label": "$500 million share repurchase program [Member]",
        "terseLabel": "$500 million share repurchase program [Domain]"
       }
      }
     },
     "localname": "A500MillionShareRepurchaseProgramMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AdditionalStockOptionPlanDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A disclosure of additional data related to all stock option activity",
        "label": "Additional Stock Option Plan Data [Table Text Block]",
        "terseLabel": "Schedule of Additional Data Related to Stock Option Activity"
       }
      }
     },
     "localname": "AdditionalStockOptionPlanDataTableTextBlock",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CARESActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act",
        "label": "CARES Act [Domain]",
        "terseLabel": "Net Operating Loss Carryback [Domain]"
       }
      }
     },
     "localname": "CARESActDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home [Member]",
        "label": "Cardinal Health At Home [Member]",
        "terseLabel": "Cardinal Health At Home [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedToAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reclassified to Asset Held for Sale",
        "label": "Cash Reclassified to Asset Held for Sale",
        "terseLabel": "Cash Reclassified from assets held for sale"
       }
      }
     },
     "localname": "CashReclassifiedToAssetHeldForSale",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DOJInvestigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DOJ Investigation",
        "label": "DOJ Investigation [Member]",
        "terseLabel": "DOJ Investigation [Member]"
       }
      }
     },
     "localname": "DOJInvestigationMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DiscountRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount Rate, Fair Value Input",
        "label": "Discount Rate, Fair Value Input",
        "terseLabel": "Discount Rate, Fair Value Input"
       }
      }
     },
     "localname": "DiscountRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ExercisablePeriodOfPlansInYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The instrument's contractual term.",
        "label": "Exercisable period of plans, in years",
        "terseLabel": "Exercisable period of plans (in years)"
       }
      }
     },
     "localname": "ExercisablePeriodOfPlansInYears",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FloatingRateNotesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes due 2022",
        "label": "Floating Rate Notes due 2022 [Member]",
        "terseLabel": "Floating Rate Notes due 2022 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesdue2022Member",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GoodwillImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment",
        "label": "Goodwill Impairment [Axis]",
        "terseLabel": "Goodwill Impairment [Axis]"
       }
      }
     },
     "localname": "GoodwillImpairmentAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GoodwillImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Impairment [Domain]",
        "label": "Goodwill Impairment [Domain]",
        "terseLabel": "Goodwill Impairment [Domain]"
       }
      }
     },
     "localname": "GoodwillImpairmentDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "Trademarks and patents"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification Receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_JudgmentForLostProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment for lost profits",
        "label": "Judgment for lost profits",
        "terseLabel": "Judgment for lost profits"
       }
      }
     },
     "localname": "JudgmentForLostProfits",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LawsuitTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Domain]",
        "terseLabel": "Lawsuit Type [Domain]"
       }
      }
     },
     "localname": "LawsuitTypeDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]"
       }
      }
     },
     "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract",
     "nsuri": "http://www.cardinal.com/20211231",
     "xbrltype": "stringItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "verboseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitGoodwillImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit Goodwill Impairment",
        "label": "Medical Unit Goodwill Impairment [Member]",
        "terseLabel": "Medical Unit Goodwill Impairment [Member]"
       }
      }
     },
     "localname": "MedicalUnitGoodwillImpairmentMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Unit",
        "label": "Medical Unit [Member]",
        "terseLabel": "Medical Unit"
       }
      }
     },
     "localname": "MedicalUnitMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NarativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Narative [Abstract]",
        "label": "Narative [Abstract]",
        "terseLabel": "Narative [Abstract]"
       }
      }
     },
     "localname": "NarativeAbstract",
     "nsuri": "http://www.cardinal.com/20211231",
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Axis]",
        "terseLabel": "Net Operating Loss Carryback [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Member]",
        "terseLabel": "Net Operating Loss Carryback [Member]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net proceeds/(tax withholdings) from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NuclearPrecisionHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Services [Member]",
        "label": "Nuclear Precision Health Services [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthServicesMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NumberofStateAttorneysGeneralfilinglawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of State Attorneys General filing lawsuits",
        "label": "Number of State Attorneys General filing lawsuits",
        "terseLabel": "Number of State Attorneys General filing lawsuits"
       }
      }
     },
     "localname": "NumberofStateAttorneysGeneralfilinglawsuits",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits State and Political Subdivisions [Domain]",
        "label": "Opioid Lawsuits State [Member]",
        "terseLabel": "Opioid Lawsuits State [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsStateMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PatientRecoveryBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Recovery Business [Member]",
        "label": "Patient Recovery Business [Member]",
        "terseLabel": "Patient Recovery Business"
       }
      }
     },
     "localname": "PatientRecoveryBusinessMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "terseLabel": "Proceeds from divestitures and disposal of property and equipment and held for sale assets"
       }
      }
     },
     "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project costs on investment and other spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Line Items]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Table]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePrinceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program aggregate purchase prince",
        "label": "Share repurchase program aggregate purchase prince [Axis]",
        "terseLabel": "Share repurchase program aggregate purchase price [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAggregatePurchasePrinceAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_ShareRepurchaseProgramAggregatePurchasePrinceDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase program aggregate purchase prince [Domain]",
        "label": "Share repurchase program aggregate purchase prince [Domain]",
        "terseLabel": "Share repurchase program aggregate purchase prince [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAggregatePurchasePrinceDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "TaxMattersAgreementAxis",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TerminalGrowthRateFairValueInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminal Growth Rate, Fair Value Input",
        "label": "Terminal Growth Rate, Fair Value Input",
        "terseLabel": "Terminal Growth Rate, Fair Value Input"
       }
      }
     },
     "localname": "TerminalGrowthRateFairValueInput",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cah_TotalLongTermandShortTermObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Long-Term and Short-Term Obligations",
        "label": "Total Long-Term and Short-Term Obligations",
        "terseLabel": "Total Long-Term and Short-Term Obligations"
       }
      }
     },
     "localname": "TotalLongTermandShortTermObligations",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20211231",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r111",
      "r146",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r166",
      "r170",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r111",
      "r146",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r166",
      "r170",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r178",
      "r333",
      "r335",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r308",
      "r346",
      "r349",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r538",
      "r541",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r308",
      "r346",
      "r349",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r538",
      "r541",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r178",
      "r333",
      "r335",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r271",
      "r308",
      "r336",
      "r346",
      "r349",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r538",
      "r541",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r271",
      "r308",
      "r336",
      "r346",
      "r349",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r538",
      "r541",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r121",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r121",
      "r125",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r333",
      "r334",
      "r539",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r333",
      "r334",
      "r539",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r121",
      "r125",
      "r238",
      "r347",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r505",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r61",
      "r66",
      "r73",
      "r74",
      "r75",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r62",
      "r66",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r64",
      "r65",
      "r66",
      "r522",
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r66",
      "r73",
      "r74",
      "r75",
      "r113",
      "r114",
      "r115",
      "r418",
      "r542",
      "r543",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r351",
      "r374",
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r101",
      "r197",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r63",
      "r66",
      "r73",
      "r74",
      "r75",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r108",
      "r154",
      "r161",
      "r168",
      "r181",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r412",
      "r419",
      "r464",
      "r480",
      "r482",
      "r500",
      "r521"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r58",
      "r108",
      "r181",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r412",
      "r419",
      "r464",
      "r480",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r13",
      "r15",
      "r19",
      "r212"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Total assets held for sale",
        "verboseLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r353",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r345",
      "r348",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21",
      "r43",
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r465"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r248",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at December\u00a031, 2021 and June 30, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r84",
      "r512",
      "r533"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r83",
      "r410",
      "r423",
      "r511",
      "r532"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r88",
      "r495"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r285",
      "r292",
      "r293",
      "r295",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r107",
      "r111",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r297",
      "r298",
      "r299",
      "r478",
      "r501",
      "r502",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r283",
      "r296",
      "r297",
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50",
      "r107",
      "r111",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r297",
      "r298",
      "r299",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r107",
      "r111",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r323",
      "r326",
      "r327",
      "r328",
      "r475",
      "r476",
      "r478",
      "r479",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r101",
      "r149"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward contracts"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r59",
      "r434",
      "r436",
      "r440",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r432",
      "r434",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r439",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r426",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r425",
      "r428",
      "r429",
      "r432",
      "r433",
      "r437",
      "r440",
      "r447",
      "r448",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "auth_ref": [
      "r4",
      "r5",
      "r16",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "terseLabel": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r20",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r329",
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r124",
      "r138",
      "r182",
      "r322",
      "r329",
      "r377",
      "r378",
      "r379",
      "r394",
      "r395",
      "r453",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r542",
      "r543",
      "r544",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r283",
      "r296",
      "r297",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r456",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r455",
      "r456",
      "r458",
      "r459",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r283",
      "r337",
      "r338",
      "r343",
      "r344",
      "r456",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r283",
      "r296",
      "r297",
      "r337",
      "r338",
      "r343",
      "r344",
      "r456",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r283",
      "r296",
      "r297",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r456",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r283",
      "r296",
      "r297",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization of intangible assets - Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r198",
      "r200",
      "r203",
      "r207",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r203",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r198",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r203",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r59",
      "r337",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "Gain/(Loss) on sale of equity interest in naviHealth",
        "terseLabel": "Gain/(Loss) on sale of equity interest in naviHealth"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Loss Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r101",
      "r300",
      "r301"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r184",
      "r186",
      "r482",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Transfers"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r187",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r101",
      "r185",
      "r189",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r87",
      "r108",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r181",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r464"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r432",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r498",
      "r507",
      "r515",
      "r535"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r77",
      "r85",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r128",
      "r130",
      "r131",
      "r454",
      "r506",
      "r508",
      "r513",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r77",
      "r85",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r128",
      "r130",
      "r131",
      "r132",
      "r454",
      "r513",
      "r529",
      "r531",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r3",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r14",
      "r17",
      "r18",
      "r19",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r386",
      "r391",
      "r392",
      "r396",
      "r398",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r123",
      "r124",
      "r152",
      "r384",
      "r397",
      "r399",
      "r536"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r42",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Income Taxes Receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r199",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r199",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r196",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r78",
      "r148",
      "r474",
      "r477",
      "r514"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r22",
      "r56",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r40",
      "r108",
      "r181",
      "r464",
      "r482",
      "r504",
      "r525"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r108",
      "r181",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r413",
      "r419",
      "r420",
      "r464",
      "r480",
      "r481",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r13",
      "r15",
      "r19",
      "r212"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r51",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r51",
      "r237",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Estimated Litigation Liability, Current"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion",
        "verboseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "verboseLabel": "Long-term Debt and Lease Obligation, Current"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r241",
      "r245",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r55",
      "r108",
      "r181",
      "r253",
      "r258",
      "r259",
      "r260",
      "r266",
      "r267",
      "r464",
      "r503",
      "r524"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r19",
      "r67",
      "r70",
      "r75",
      "r81",
      "r102",
      "r108",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r123",
      "r124",
      "r129",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r181",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r454",
      "r464",
      "r509",
      "r530"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r70",
      "r75",
      "r123",
      "r124",
      "r415",
      "r422"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r329",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r154",
      "r160",
      "r164",
      "r167",
      "r170"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r48"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r57",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r66",
      "r73",
      "r74",
      "r76",
      "r466",
      "r468",
      "r472"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r435",
      "r438",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r68",
      "r71",
      "r73",
      "r74",
      "r76",
      "r82",
      "r322",
      "r466",
      "r471",
      "r472",
      "r510",
      "r531"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r68",
      "r71",
      "r410",
      "r411",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other Short-term Borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r96",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of subsidiaries, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r33",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r33",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r19",
      "r67",
      "r70",
      "r75",
      "r97",
      "r108",
      "r116",
      "r123",
      "r124",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r181",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r410",
      "r414",
      "r416",
      "r422",
      "r423",
      "r454",
      "r464",
      "r515"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r28",
      "r29",
      "r210",
      "r482",
      "r516",
      "r527"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r86",
      "r183"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r35",
      "r41",
      "r482",
      "r526",
      "r548"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r66",
      "r73",
      "r74",
      "r76",
      "r466",
      "r470",
      "r472"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r161",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r160",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r160",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r159",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r218",
      "r220",
      "r223",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r101",
      "r217",
      "r226",
      "r229"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r220",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r36",
      "r329",
      "r380",
      "r482",
      "r523",
      "r545",
      "r547"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r124",
      "r182",
      "r377",
      "r378",
      "r379",
      "r394",
      "r395",
      "r453",
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r79",
      "r108",
      "r145",
      "r146",
      "r159",
      "r165",
      "r166",
      "r173",
      "r174",
      "r178",
      "r181",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r266",
      "r267",
      "r464",
      "r515"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r66",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r198",
      "r202",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r198",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r192",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r192",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r206",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r229",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r220",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r154",
      "r157",
      "r163",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r353",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r356",
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r52",
      "r105",
      "r139",
      "r140",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r315",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r178",
      "r222",
      "r231",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r143",
      "r144",
      "r154",
      "r158",
      "r164",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options at period end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r358",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Common Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r350",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options at period end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r6",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r178",
      "r192",
      "r213",
      "r222",
      "r231",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r54",
      "r73",
      "r74",
      "r75",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r124",
      "r138",
      "r182",
      "r322",
      "r329",
      "r377",
      "r378",
      "r379",
      "r394",
      "r395",
      "r453",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r542",
      "r543",
      "r544",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r138",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r322",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r34",
      "r322",
      "r329",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r33",
      "r34",
      "r329",
      "r352",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r38",
      "r39",
      "r108",
      "r180",
      "r181",
      "r464",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r74",
      "r108",
      "r113",
      "r114",
      "r115",
      "r117",
      "r122",
      "r181",
      "r182",
      "r329",
      "r377",
      "r378",
      "r379",
      "r394",
      "r395",
      "r408",
      "r409",
      "r421",
      "r453",
      "r464",
      "r466",
      "r467",
      "r472",
      "r543",
      "r544",
      "r568"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Stockholders' Equity, Other Shares"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r473",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r473",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r473",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r53",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r53",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Common shares in treasury"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r34",
      "r322",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Treasury shares acquired (in shares)",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r53",
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common shares in treasury, at cost: 50 million shares and 36 million shares at December\u00a031, 2021 and June 30, 2021, respectively",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r322",
      "r329",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r383",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r132"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r132"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r564": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r565": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r566": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r567": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0000721371-22-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-22-000013-xbrl.zip
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MJ=E,)NA) %.(; ER??3V_%U%[^90^NTQYT_:5M-:#?K5=$M!+C)(\[:N:0Q
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MN3N(1A0--,M6(%4D_,:8T!/"Q=VN^\H14L$PJC:?@F%[_L+J0U!70=[PFJF
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M0ACV@H\&S*;]&HU$RJEP>2MJ7&]W"H\/7,(3I87$^22C5 R.KZ.]B+$( MM
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MKUP/#AX$(==5 5>\B8FM# 6S.^_N7/W+4.CQ_K,UF9+41M*HG@J,]3)4='S
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M2#,RT&?.JQ#\$!O.[)IH=T\[[3TM=%KL(6W7%UX^S-AW0N:HO'B0'[ZT_#
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M3>2![3TM)!O!$(1L2B\;MFT\GR6+%S!,' -/R4J..$(2X%SM&OS2?S'NG<?
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MB6 :#@JCQLUVI_!X[#!4A#1)BDE.Z YVQZ/FA)X+REN$%CXJYJYX'J"#@LQ
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MO[=??/3856<*#DC9'%?W5NDU>QLB"U[['@W@&Y)R826[O(1OZ_G:.6#7>DV
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MY/1S=*^S2!.NSV";.T:X:0A<5(05Q!#![I4EUL+A0G%Y:INBN(B6WRH,)[9
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M]JM8->X<O+@9"M;C49$NX'_3:I;]^O\!4$L#!!0    (  Z#0U29&*GI4RP
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M$$WB+ W1-9QB]WMFGX;0S*NN@9?@A,P0'R*_SH%?DEL:[N&Y^P41(KG[37X
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M!SA"I_NA,X2+Q25\\+J_P!?M3M]O#1MB<.NW.MXU7M7J=0?^7^]@!/RB[=W
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M\C4L(_;^%#G1_AHBG"Y'PV\SK^<X8)XJV3L8&U0B\U=[\9O.4:\9;C)L$_K
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M(F%&_ME<>3T1IV8!7 J^MC)@6U.650?PJWNN!8Q:5Y;2GR9#=CX96 (3M$"
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MR6=/GO6)CG(R*>_G,UMLX)]%NZR>_R]02P,$%     @ #H-#5(O]T\FD70(
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M7!R!FTUN2&^IED8R@Q$C-CE,@\-$:>\MD(HO/B@YM^7^-8!Y#U6U-VRBNK
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M_WLKNP0_SJ''QLO]=#GY4Z[,SWW X2,LTG?*^'B1SOI'(?O/6!"SH5,C"V!
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M[M9>O#O*BY\P^>X1E[&2@O[9OCE],XKD<[4D-!CW/S9['UQE;ZME<-K9%HV
M]1A'8#=P'5O& 8&XCZD6PMH+X/Q4(T\(\4,F;X(FU_>'@#53/ZFU;09&?0%6
M?9D=#\J\\KFK#?LB_F'+9R_RR]JYOK4\--W\6_W]M^73!P^>RS>[>]GH'&U9
MS]Q5<<YVBO7?;N*L>\18_6S(VY+>.F5O^A(O,AO>EZ&J1O]["QW JP7FK@7F
MVW?XR7IC@^>B17'4+88P:FGJ40O;2+U3-@:,UUX C5%V[DQXWS8N3->#OF@8
MZ>ER#>>QI/$E?'Q7[A<G*UMF$EE\<U46O7'(,TU:$6NP91A"+>NQ:TF3\ND9
M1*A3:R\V!Q8(O!*_>^['+;_PU0CX7?F^++X"TEVY&Z8BHA^N1<4)@IUB8( %
M6#.9<+JEM;&M8*4VD:J@"5JY&^;"_N\+X._VY[PW]+6M>/M.WK[F:V"6666L
M:Q%*8XMQ[5J66M_R/$8>L*64V+47C"(L?UTWPXC9TC93KP0UF_?@5>$TN$$_
M_YIVG\!(#M7*F7 Q8R"161+)23P&8N4QF)''8+$ZO?)NW+JF)1-JHPQFM8I-
MLHJ1[Q":M5P;'U"+L.0Q9X&WE)>\)8GGB 2"F6"@E01FO\T-HOWP-/8R,?/;
M @;X_JCH-CGTZ[$9^AHL<UX8*PQK&:X EAE$6XISWR)"&BNM%ES(M1>2RQ8'
M)KD_,B-X.7#&14S8?_]#$2Q_K[)^:(=>XKZL6[/?TPP06WN0QI@9T+$P"3?B
MDGN$MBY *!!99Y0_*$\&7]?T85$I=T08*3K],PEU;R=+OW$CG^N%8O,)=?,>
M&!9EWL]#-8IJ"V7P66]05H,4WM8O,KBCWI/#Y(G]+9DE*:AYP_6?WRWYBV5@
M7,S(/25_/^\/<V\$XXXRUS95U3AOZ'V'7)I:B>V==6S1?G(O>[.1 ]X9A7;6
M) ZG[BBE9,N [4^.<OCE0C::R_7SPF@C%7.&B:TEJ<$8;?NXG7]._3O>2K_C
MG=?;^*#SY_'GS2]H^_BOSO;^7T<'^Z^.=[X=7C\L??;NTY^=G<Z?G12!O?T-
ML-RWO_*#SLZ7=_L?SG8^'9SN?'IUM/UIF[Y[I<Z^VT4-3'B)D6XA&QE@-*X
MHS'5BMQ1RI3"AM#A 0Q@V:K./Y8].<G[1\6@G_5,F7TU[4'X&8/DU^;AD3X<
MJL,5 T_ P%O7K&9$B$=$MC!8$RV&'4V'YVS+2<\=\H82;H&!-_Z]8M&?5+-;
MH\5K>'#E^A9=6MH:OSOW>%Q\;0.=6HL)3VX?K6V+1<1;FE$/7 QLK*,E1&/
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MA@$@[1;U7M:@&OHV8?S#4A,W)' NROI=[;/T\A1F![TYR[KA)#E.R_ UKVJ
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MV\$/"[&&PW37>K8''5Q[6>;#^JP;S@$%Z^&^!S%T>1@2?B]TT[FRK^'R'5M
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MZTT ^R3]W!^48?S32[!^0 '90064K*H?+(8C*DNPH'X?]@-$<ZA^OX:+2N_
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M,U9$!&MO%-ACV_27R71,D%MG<IT\)/4#C0LR8(.J2>2V UM@AE'HP1B3^ 3
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MO\A04&KFVQ2R</3ED[\Q"EKY_O;@^WOO:O^,G*7PK#T1N!ETOX7.J9D9\M_
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M>V6IU8 HW9;1OU&66AV/F1<INLI2*TV4;JMWJTHS*4MM%TMMJ"RU:AGHQ8Y
M"4YQ/0R9;6)O]60SGWP&6.R$N7UI_^UZLG.5K#[,M16)NLY2)-12 G6<;5LB
M81<_F*0'6EX04NH=/KJ:72P&MEU,+;8]U_3E5_DP4\<;X>/18H%Y^3,3QL'L
M_-"'G\(&IE=GM@J;)V":.CXVUH:&-C(#(.3"P[71^@>WV=^5VER^I\7%&](9
MEW.@8Y).G4J4%'FBVAP&YSF6^.&ME1QDM01*K)8%&V;F(\P4'L2DZE2BMJMY
MD:]YP&ZFXV32,8DT/&]\P?R)!]]S+6*X50XJS.^6'_?9Q&'XP#.X]YELVM),
M)_" #&-X>BT1WLU9>1E8\.T1F+H<H/EMANP/S(%'IBWM)^;BSA*%[L9SV\7'
M*)M5N[QX^(ECX2^NM'??%LP-6*"PT'7"0NMHUF;!\OGLUIC-4,!>-5<UU\;-
M50%[%;!7 7L5L%<A"A6BL):\IH"]2@R5&)Z<UQ2P=]T.$DX6C:VZ6%YRX%EA
M1BJ@>_6^JI]=RX#WBQ1=A1FI@.[5>T,E0J5L(84965&\-X9N'*#@X+GJ?84O
M/M<#1]F*Y>_Z+6.@.G/5\J![D:*K;,7R#J>6<=-3(J1LQ1WPQ;K"%U?#%S<.
M7OJ\9E%K/DCMB?F,]Y)9Z^>2 ._BIZD# F\)8;N(WD/8'T$4;9> @80[#)DU
M<X$8TR7^VC>#T(\L@OGA9&>P&N9K7ER -!Z^!8L(0IB Z# S6I;M[-/HIE^E
M=P\?QJ8;UXC2Y.TW>),..P"J$UP8H8T3\]'S@:U3F&%!R53?CE<]78:B-=.R
M_ C6A0U($ 2*U)[3/B\\GW94D-T,8)<"@GIZB$IE@>7;"_[$PO9 ,\P)$<JW
M-9P!5Q%_47L3&#R&A#*$=5)-[?_U_*] > 3?(D[3=( $,#V:H]'1A\0R\,.-
MA)#B,GUF>5,7J+VMG=0#6X0":] A*G;:\#NVK:;Y/JH.YVW[)FS ]V8])J(!
M%2=_O_B+/1B-)T/3T+M=P^SI-]9H..[W.]U)S[)ZW4&?_5?O="]^^-6#G1M\
M_]K\X11UXGE-=<&=%S@7:@-W[\%R7-1<\!,=6<3-/]JNZ6)?.^T!&8YTUP5Q
M/9YCA"5V,HK,XT#YF$\_<B9_"-F3Z8^#F;W0[JQP'2#\_(8MVPN^'V0DU?9&
MM;VI.%O5]F8CP%NUO=E+Y?I;U?9&M;TYYJI5VQO5]J9HBCM:)J>Q0U3;&]7V
M)J5=5-N;&K2]J4>FJ.@QCBV+)_;65N,JX?.P"9_U<$O^QC3V:#H1^N/BK.Y4
MTO>(_,&>FT[Y!N9I:>;<<Z>:%Z)K=\[,(/)9H'QM^_.U&;KPM>G&^3K;LDQ5
MMJ#$H,#I4]"@:5#8H&EPU$91P\)Y#(_;*"I%QC-K':7?[M^7UK2,7357-=?F
MS+7L]5!EF*L,<Y5AKC+,56JK2FT]?6JKRC!78JC$\.1BN&N&>3.._8L?/F5J
M/>Z(]&U6WL!^4WX:DA>0O^B>T<S63K7)-GAF0DZS!&>_"3<-$9S\1??T[GDS
M\ [I,&>1[M)5^K >J31*$2L+IL2B;[J;\'PO3&*5X"@+INRB;_3^>3/P2[5@
ME#ZLB053V74D4)I-<1V)3AV%5MLFN<M9:@-$J]]IB&SE<])!M?'*)W?2QG7G
MB@)?>[=JDV6U/4<4VLMAA5[&^]F99MR<7RY+Z,.FN'F4ICBF4W>@%'DMMJ=
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M^.@Y$78PX1T2><_*N <B]1>,.PIBBT)S#+P=L)6FB?<?__/^[;5^V]:^S.R
M>@_"8"'0-].E<O^=,MO:&NWW0/.X163^:HL[<Y8MQ5T?UMU,B+6ND148FW,!
M=;I[7*6@J;W2!W%?S=^C,?\J5CUWO$!^/L,=0!>/.CWY2^#5"'8%6"%DCL.
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MV;;D1I:&4265XD5?ZCLWIU9EC>HCT6?.NT6=U8VSY=TJ8YQG;W.E!-0!5NH
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M;A#Q'HFR-0V^W-(6)HBUZ< [WF02P.BB/&X(5\I06DZ2I)S(@?R5Z%/C)$V
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MZDVII/.%8W/G /="P@5C$A]/%ERVX.?P<):%NFOL2;7_XKG3ZR_H]\!D:6)
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MD045UD23W/LVT9=@I9%+:-E/H(8M66#F@;GHQ<)RM,D3[T1#J.9%(;Y0>;[
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M78<3]WD+V[/'J3M$)A6(9]FD;)V3&*5$72JYAQ9!4K:;+M69J:,60CUA^;8
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M:\/YH,#Y"IROP/D*G%\_</Y0@?,5.%^!\Q4X7Q5@5#A[A;-7./L]X^R5'^Q
M?K#W*\63L'82.M&+JR>=S!/&;=QBEY3P#W@(&=+X*F0ELX*.G=1/>B5:L]H+
M?*U/7;J9)[K6$M^+[&4DL,N\' +_4JI&5:O *W0$'\VY.9Z;&$[^A1=$P>U-
MPS)\"? B#,WIHL?%XN6!I>8*%QW/S""E06%BC%\2?(2$3^2!\- ?=O\%[K.Q
MJWU<NV,W4<VXCBO+)3;2I8A3IHOI$XMCTEAPS_P&BW;9Q,X$4$U>U@2-#]Y>
MA6!.,88%=65;>R"(D*B6M^+K)7"CB)Q3H!P;LGC8*CBAIY,PAF %:O@J6_G2
M5(47DJKRC!!9@WY,#'ISE!)Y&E-+*!HUX^,>KU+%V-07>^%[.#)6G9-=;%;<
MG:;V2A_(HB-Q:R)RHCO8(8>/$ @$0/QW'%$T6A.-BS'BO<((&.EPD$TBS+GQ
M<0O"I>8C X.&=$Q[SE-O4D5F1)=J<XQ*BS.F3%>0X$FGC$B*$7C;OG-3I$VT
M7'X1%@JC/!MX#EZ.[& F,8%C-CJ)'A78RF!=C=IAT@LQ7"Y0KA #+94@SWD
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MR'%4Y4C-_I]!ZTV.GQK+UXOH'<['5:9SPP_14QYKX)=]?98TH!VY\9-PS52
M?#AR-W]+DQHO_M/.\S>_[?P\L4,S](R?U\;]TLG>5QS_H.[$-;$KL_U925:\
M3!WP51FU)O4Q^#K9P+DCS<PL)),F/<]X@XPB<5/M*A!W1Q2@]&J$I#C=)[M+
MWXNVY]A5G11^J7C@A6C:<37P)5&UV[<YCT:1<@-?5Y')T6"CAYT.>*[ 8<)%
M96B?68Q,<4QX@.3;Y<FJ#=AI,G;"NM;$?:W\1YSK.LS]!#5F6/RXS?)BUT&#
M*4!/)[(HJ::HR2J$.3V+*)ULUO31'$Z<F@'X\UXM"E4'@%SZIG^6J8%I$SA^
MXGR68ZZ>)5UW.+);>U,$ONY<2BYOW=;)QY<ISZ4]J((.$X?X*94'2JUCLI"[
M.+KX^ZCMP'QOJKLX%\BAGW,R6ZO3">58K]G42='X>"=>,442C ]H4L6+BN9I
MC=IYUMJV<I/]=YVJB"2W]FM&]=H,K=C$WK>X)WJGN4!'?^(Z5QT(T\;(<YA#
M3&OW.A.U8]9N,#KY2F(WPJ>Z%V6JTS_2OKD?1+U5HXK--QG-1IS];A:DZ#'8
MM#S9E?N]CC)-N%=WM:F&E/I;#@95%D 5WIY,@VPEYD%,;_?N>,>/]/H5TANO
MEN-K1^9I/9LG%460 X1/6G6]OQF)&943ZN6$@A/?SP 0=W!ZN1IHU6U@W!MG
M"X6IYJ'.ND%_[?7SY%3BD;!K4B1K2B;Z<>H&JTO'Q,&.:BM_Z9*#@1&S?):[
M0>3S@,S(IATP<Y^I:^^.W*STLPJ*3B3%657$IM,.4]IYNO59K4QVYS3)&$G&
MXYZ"F3K[I];/RR>L7;=9'2?L]:9BS]=41",H7]4DO80F*!5N2KQVB=<N\=K-
MB]<F)5Z[Q&N7>.T2KWU%O'8)O2ZAUR7T>FNZ3CR\F[L\&O1O7S<33.Y5E><[
M/B/*?V2O,V7T5C5ZO_BZ,D+T(A//73F#??UM[+;%5[[J=F?$)M2'-7-,9.C$
M[Y[5[F0F;P?)Z:R_6?&#%?LYYJ]R /22KMT#?\58MO"0,46(SD3TC:FP5-X@
ML0OM#JBZHT;GMYW<[M.SSFDZY8E/DN*FX\-_GXH 211-S]6G=X.YM4J,1**3
M1E.XU_JCG]C^[%"WJ[3S3[H^II^BYV88O<QCI!JUJ0I$W6$U+>CTQ:J5FAE+
M.H#K)7>[/B1+ 32CC>&GHS@[YXE33K.03^>JB]=UW^.H_>RY@*\KU]=[8FJW
M^;W6?])I8+<J&5P5%DC!",?CZM;COA<YI'82&I6YB12AW&_['"%U')<LG7%/
MDS+U+E[:C[NNR5LS:*&?EWQ<M+V>DU&#W!0VI"?ASQ,N[R S/).8X?B4J2]M
MKHL\;D8_YI5"NY\J17SKC1YO,/5\U4'H^]GQ=^,<5N5!)L=&EPXF,56#477[
M-.=SH\LG1E54]WCY!SG//A4 'P<37C* <=SB6<:1FAQ:-HR9N9B>_GJ)YX:U
M.SM=.!6*]M7M3D[]L*['<-Z-DFT'DZ;D21S387;[I#T<D6(U'6U\ZZP[)J-U
MSDGHY;/ F<<=4:GUUCGM5\=JKT-UH#[WK'%&.AV?>=9)0&8ZX0TA!7K5W./B
MI(X)VUKXXYO]W)N]CB;HMT;MF6>N,/EB'M?4!7/\1G_<Q_F2+3@)")@_6Q[%
MSWV*U\L%Y+\/T_>&QU'<9Q(NTBE@[LFQA?639O1H':==-6 8!8)'0^5D2E5-
MCC-RWYY9!*LR7*:8^G'X2'63?-S;30<.*>)ZJC_R;O5[%1@RIY53Q8RN[W\Z
M'^ET-P[5J0YWQT=O62-,8_;XZI==LJ)^!Q$$4@V04>VBT;-6/;[/3GR*M9BR
M*-K3CW 69:Q=!VWFJ4JQ'OD0M^I@7C4-R A6]3TZGT0N[U;[?*;_2M5M8,J@
MR.*:3I-S;Y&I'M)3K:5GGR^/6R<+TX]'72W-Z*\QJ3TX;I\.)D*0T;Y_=IJ[
M'M0!R?FL9<*-5[91'&/\> HM;7?';3RFV/ZEJW#I&O>F]-ZRL52WL_7LCE%E
M=*95WW/\A;SUQH=B<7N.7ZS,ABD;95(9?WS?I+&K/9;B^5* 6'6*6VGP?%@_
MG0"7>U=7484Y)")'0M6S'.]3V82#X[,A<+UO"<G2*7G5 69F$JHLF)%Z""U_
MVG8^0WF:G3B]^8])F-6S-W^]?@Y2U;-LI]HZF..\BJ_H]><T]R3$:S ]^JCF
MHNV3++(<Q3&:N6'<WA&OMP_/9D[5W=DXN#\]7@K4'\Z8YE4<?W7R-WLT-@V
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M& ]]JD-?12*\'C6%F@Y8&4S!>T+TB0(=ZX5I,9\HB_CU+SY'P]GTBIU2*>,
MTP0#\6KGH\LEH[!*IQWD#HPY/>W;]/<JVF:52*R1<ED:.OF(@JR?CFV?9.6D
M[?RITS,Y&\"D2*G*[6T/9EB7RT+EY\)&ZS6I]?/<_HU_I 4.46?4E,=D&]0\
MU=K[>O=*>J/)B[/<G$HN[*=>SV44J1BL[!2&Q(7FBA>G.J'*[,:NI3*YK;G
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MN#31&"7W[-IJ&?> )MQ!1BWSVGJH+=4B6C&0(GO=ABGVPX9W2G);N C)@/#
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MK 2&.$J-H %+''$#-^A(J,CO5C$>17XW*;_S3 82(2I^2*,/(E*KS1"2#T*
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M@:+C$$GK,04X")6:PWF@6)" :A08-(+3P')S.%S*739.FAM1FG9=:2X"NY[
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M )#I@#DBD%J;@F2WO7U?@=6FPFJQ&AL1#%Q@]5:P.E_G%SHCF;* .R12"^P
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M>@^(;ER&$=YCZO*WK[KLU>\Q>@>#17N8K0:/=^1-W"_U6 W+>=OKYQXK3R)
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MM!>;LZ.@$%0*J$ @H%!YH!6U %D&'3*6:@MW]A'=5;3019L_2]IFL&B,B5+
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M+6.5<MSB!DXG&XN9C3&\IB)$#WM=.SH/*#BX!@XN]DJFE$LC! -1KZ%H3*D
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M3OU+2@I/(=T;3+H7P+A#P)BCUBVD6E(D0*#1(*,V0D?<GQ@HY;0QUM-@[>6
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M4A7FAJCLLI\:OY\$)-8Q[('@A **H\XV0@0 G428$>.BWM[9)WA9S.0ET/H
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MEK2CAX.^^5ZK&##SE"JD1)"(AV@GQ9DLN" PDT1(F2U%H@OZ%?0KZ'<5_2(
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M\[5AQ@8("$,DB(,#I&.T2 3%'>5)F\JD2,6=2>YR7=:(-L--N<=6 TOM9+L
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M B!+[O[6.M$>E0POEF6IMF/!V!4P]O#Y C4.F!L#6*/H2$2)!U-D5$Y0S2$
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M!VD>_,BJ /%J0#P7U,@%%0IT1#DL-5>,\\@9KA!HI;70-H(D.WN+/=J+E[.
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MNVG/ F+<.4)5%([[Q')T0XRWXF)I&,TIPGJ?PCK'90C'U@:A$6$DF21*"V0
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M$]4=GZ8K9X_HV;,TT3&#WDP=C2Z&>:XS=VMQ]CVH7.3E>W[XU^M]1$PK/3Q
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M!7L,?75+S^%F07N]GL4-@?;F$/P"[?5!^SR_]R0ZT-(CZ9E!7 2#=- 8$1>
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M4.ZXWW^DS[;=I ]C*;2;]'XVZ:*] "IBFJ2)(2[)D94B 6M>:_A)*5MP:04
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MW?O_"Q9D_7:T42P'.!$A\M8E2E"1Y8G5J0;#5>FLO05X=&"T7) U!^5 @]9
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M"@J#OQ^G3%J5&T>$U(IP.#N)\HS!/]*#>96FJ<(<@%OE9$D+00&)^#M#F#'
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M@Y-HSIG2\!RC W7!=8(^^QY&<TWC/=BY0V=]*&Y9WDD\9H_:-7SZ,;GLKV:
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M<J0HF]N(03T%_> \YFG^WGE"?RM/=6SBC\X3]AN>KV%3UY[:R0@$+FR&DE(
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M1C9.#-FPO>GG5.2SL_90@0"=W(ZK8&P?=%&OMF7QLJ-[^^T;Y\[3'&6[6=2
MY#=9.V7V1$>Y2%6, RD/=Q-P3V%A41TRJSE1CMK" #;'],[ 61JD\B_(F@N.
MCHN&T*0]YR((S3SCW@1EB5&!DH6=\1Q='@1,]P=MK#/B%MII/Y40G!WT#[#/
MMRL6Q_TT\[K:A9K+A3KPQU92)@BLDI-!@ L5-;+6$R0BH9$JC1D3 ,SWX?+
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M%'9'^[J;G]5M@BV5I21?VVEVSPN9;[?^CF&SVG;YKP"(Z"IV"K\Z;\C\S7*
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MDRSBWGD3F0K,@1S1Q^2H@*%P=Z:_G'C(@IC&8/B,86P4YU&":^0]%T(YSI(
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MY[* A'6Q5UX;%78HV" Y_QML$<\SYXDF25NB4G9P#$ $%<AB'9 3+%HK&8!
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MYC3.NF&C632R*Q\.N'49._!1-:@2QPJTCG_;5M]F2W#T^"T_Y*K?N6IWX0\
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M;@+XT^:!(X4Q)#$L 0 BN&N<1>VH\,$QJ833*EAUV_?\O*#FYO<DKDV4WFO
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M*"'JO_^A*<6__95_7_Y,?OOG)7ZYV(Y9IP"<)0^>:[XP_-@YZ<)_4@->ZFT
M_P7$['>ZO;(L-K:.FYVS&'NUD?%;;&GX)W\8PTES!'TR[+SK=,> YW6W:]L'
ML<2@UTT H&%!^=4;1Z_2^_TLC]!N]LV?,VIMGW_^2C5F,;J((O> 6D1)!+XQ
M0<HF$E+RQ#.Y/K7AG>^-$"]JPWLE2+D2I/RU)5+$'_GGF 4X^F?',5N)/;7=
M\.O/0&1YRL"K/N)5'_$%'HV7\C95)_&JD_A\GK;J)+ZVG<0_@A,-'#%'6LO]
MM@S07.RP55/Q13S[,ISB/CB1QE,;<\4%EUIPQXB)%D9!1*LCU9[JF8-U0]<@
MALE^P=O!BERB$]W[^0.#$]T.J^_^T0+.WZSOPGM:63QQ_]O.E\\<^/_9-JW#
M_=7)_JYG]4\C)[I'_D>]M?>C_N7SC^PS[!_!\[0^B/W=P\/Z^1;;.]\&O^+O
MYO:Y_S&ISSC'7'*8,J2PMX@+99'SV*)D3(S2$JH8STTK5R2A9E7:.55MQM<=
M41^<%V.Y NR4&4$YUXZ9Q)2@,=E(C/')3@P,5XCZ^(@ZVH]*Q2PVG!!S6@&B
M1HIL$ 9%+5723'L<]41$75)D^PGCO8B P)/$N\'PL=ZY[H(!?\5N>6+9]G$*
MCKX6=<$/IJ=!.AE)DLJGR)47EAIKLUEJ'@G3L:*GRP"FXPU'-5<L,J.15$'G
M<'?*37<P(E0F&:SSQ.;V6:O*3BL9@>7D7IXR%;P.U$7)C9=:L11I=!3+1.*P
M 5_%O9X>+D:Y%S51$,R1)RPW6=<8&<\#,H0[%@(6% /W6J,6ZW/)EYZ:Z5P[
M0;N>4&@6G$YX5[W?;8>"(RF6S[FY3-7&:R&,DG!%+7=6><DEX58;9@,V4FGB
M/:D8Y5)L$>,-68FFR2DG420V(LZ#&_1Y\%Q@&V&C8((!HQQ7G%D12KDL'6ZJ
M7F)+%31XYG#_<(_@/FFZ%=P_/MR/> 3! J 3S9'TE"+ >(*<\ QQYJ/PX"N$
MX+(BZGRCL<M:QE@ENE6);NN<Z/:I\:-*<ZO2W*HTMRK-K4ISJ]+<YA_U(9II
M@HW-K4EX),XZ+BRUQD1&"'%JBM[MS]D-.-U_OR7V6[FDQ>/M(Y\_T]S[\NYP
M^\L' 6Z!V(&?]W>;AWNCPB5'OW_;.VJV]L[WQ/9Y+G/-I3)_'\)WD/W-)K@%
MWP1<IPF?/YJ8YI9GC7*/,,D*?UY19&$JD4P4:VXL=5D[:D(3]Y6,^BQ-5*=*
M<UMW1'UP8,4IZP @"?S!.?;<J4 #2RZ 11H?Z!0]VBM$?0Q$'0FLD"B)<EXB
M!E.6F]H&I$G2B'HOI#?2B)R9P1Y\UEJEN55I;E6:V[3TE.4\!RESQVE.J+9.
MZQ C,!QN6.2^HJ?+ *;C:6Y"!$$$LRB&K)BEM$/&60L_$1QL5I@P]L6KE2W"
MJ-+<EI-[,:.I--XE' 6W*6I)4Y38!&HXYT17W&M)X&*$>PD=H[6<H)0(>+.:
M)V1]8"C!; :1SRFIRYUSJCRW*L_M^20^5'ENBZ"4]]('JO:(1]XCQO/< K=<
M&RZ18U9EL3Z,M%(.V1B#TA0\!)/5\NFJ<LIE2;BH\MR6*FKPS.'^P2Y!\E([
M [L&IKF*-5BE% ,^::7E(D15N01+ O<C+H$+VD;M&?)..,09U2B+-R#!N-=$
M:.NS'*EX</^J98'="7ENHSK:*Z)Z-Q"WZ]L?EX*/UZ3.;]6\.[6]V23TYUVN
M\':H-?DI=K\W?)QLW;OVQ^^#AWK7[;0FVOUJM.MX=+%'43_]JA)1Q'"/:)(!
M<2=PMFF-L 9CY]ZHF(]8QAG<1=Y7J0DZRR*9>Y)SM4@6N4CV3@']S^'>Q/;N
M'ML^.OCJE?+8L[Q.<DME4FH:8X.4#$P1*ISGL N,)SM?KI@+[=E^J1C8&J12
MQANIE(,-XT)#NUQC>3%LS+S:YNY95JMMD:NM3K9/OV+GDX*)0\(H@WB2L-2D
MM\C"?A(IP(>D?E*![;TA:>Y\M%HD"]VW?NSDY@-'];/MW#Q@M_X5]@Z&DXN(
M>IT[J@H/*T8Y9+CE001.M V3CK;&(*G7^#$C('5C[_A";WNDY\H*<,.)*:J]
MXJ!KV_FU,M6[')A2/;PX@/7:M<WF69$[XN3^"?$_)[GQ3;N=_]-H]X!F-DO5
M[:(#U+JX2Q3\7FF.(Z+@$PWKFOCW[V?CTN!9M;G\X^]!+X>_X-8Z@=RP-AA/
M_VLXZ9Z"B]&+[6=G8I_/ZJ^_!I$HV))&QH.3QYVC2"?OD!861Z&()#Z^>#78
MQ<^B[?9&O:-:<<OZLMYW3V+A;>\P=U=JA)B%Y?]STO@.D)873__0]HO\_F-[
M5I8.G1R#E7X?-M_HI')-EOK;O9\U.AJ\.FJ00RM0-#<WZO0:965#Z1.!)5^5
M$?W7S8.:H?WBJX]8!V[G2?_VC]QI^9?U48,G<-V7K^X'(4]4:&5,30MVGSHK
M1FN$B;F7+L%E.9VN=&GFNU6S5$2-K#-1AE)G*>\8]N-X<)G(8UQG075.I04\
MYI8XX8A@@5\_^=2,L\FGK?,=U[MJ-1]]Q-\ C#?:<+%_1=OL'Q9WC/U]N]1,
M-_;_>]=7+W8,/M G>^JG>^AWC>S#9")-BW= O@J"T8>9E_\X%%V$;*=\H+GV
M79Q+4Z%)5.#ZGX?=JT$XB,AUH_V&; +[_=4V3^U9[\7+FU\-WWN=\4Q-5NY)
M39Z"B"A,[T-$**\I>ONO[\L8!*X9;>9?F@V7-=/5BL^<#!5SLTHQ<NIRG0$,
M?C_'U.YAZM>"<&V[TR_;^A3O8'-I^WS93WW;'S2%FKY\]Z<#,3VEFNU2LS:+
MO@>:7+O>F'+"Y'Z</^M-=^.:(];M<DNM,5ON' ]MF.L:)?SJ)'GQG<0FAP^N
M?-9/N<5:[NS8&P0-<IBGT3][]CW"=G:WOE+#O N"(Y^R:*I4(2M0!Y0\-8Y0
M[H54Z](CK'?2@MN%B_0*VVP6_2Y<?Q!![%T_1^U.#G:,!-%^VC#L6O/&VUN(
M78W0HV^T<K !S:RL0FJ4WE?FY/;+$EU3 ]28N[+*= [_3-NW (B;J[+*<J=*
M3:L=LE'$'S["MG@,EC*P'=L";M*?2E5D&24P)E.2:^'0<N\IVP9/PT5FX!JK
M,QI?RK_$@%[#'8$?4]*4]_GHH=@$3"W>V4:W?.UOVSR)Y=HH1^U9B8AL=]HY
M[ TKQO:+/T[:L6!X< AUK^K$N=2^KTCB80DDO9&S7@V,,1A!G&*&YV[R3":E
M$V%>16LQ^;I5$DB9^S+?=<1[[Z.GM_\Y 0ZYU08D."E=D1V@!MW=0]O>.2XI
MQ>6, P%VL;OR![W#K$6Z\QY^?_2:P#T=[>Q^QL V:9EMN/OWT?;N =X_\K3>
MVC_<:XQF+>[QO=W0JF]^YG _8GOW ]_>A?=]^2RVO]3)SB8\P_G>V7[K7>/?
MYV_'DM2I5B(%X9'700)3I1(9K1P2@9$0F33@PTS*5UG2&O)*':-2QWA@.O9?
M<= Q>R[02)\ &2^8PY XE)PA4X;,&$JR< F:N +-Z4!S)-4;2QEY2!+E/F"(
M!\>1H^#>"Z\9!@<_^)@K>TP-/[@ =$G$-U9>R^+](&EG+44KYL'\YBZKMCB@
M*Z>RM]4>I"95#' F,!L79DM6)F>20XKFA%)C(S! 21"F23H7E-5.3<IQKQ0H
M5M#V;^<W#P2 1R0Z-^V_8CMS!X@1M@-.(<GMN% P*B).*45:<X8DD&%A,(LI
M'VT)4I/+!!+K'OKZN^3Z#PESK1BF_;*VA&8PE16AN1=>U<>EO*(1R6>AA40H
MXMQ;I!UER'(BG.( 9XY,(C1CIRDS0L53!JS6V.[7FLO<-/V*R\P=&T:XC$Y!
M"$L4(IX%Q!/\Y*3!R%*70B0T,"[*R V?5W?P*C@S38YSV\=F/L5KAUQHE&*C
MBM6L!;5Y=S&95^SF>MEF:OR( 9W';J=B/3,AV[B *8V$11TL\@SPC,NHD,D8
M%P2!WPCFN5"Y?D-30G];(C^M"N8\:P(T!(@30+DIV,]/L*-B15-BQZAT41*"
M6Y:08]R QR1R&:N#OQK#*&>2,4Z7$3M62M+TL1/(;N1&7>_"-J_\J 6)V:V(
M3N=$9B9E<"D1([@SW"MOC*:8,"ZUIQ(\C$&2P%,2LBI_ZB'0.2[RF9Q3CLJ
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M[Y[VTUTQR1^M!>C.&(M H0ST+I32KMY3JODK.NB*7,T.]LS.ZH$54&VA4WP
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M2XJ^^'>^\EK:!\<G "R([T(#YM:Y/(,J%0[?C<.[ZN$%&=-J[F/.?"(Q7Y8
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M+"/>H EE<HY@=!Z(I@*\HRYEXQM6SUR#<T@.;P4R[*_R0TM]\R"HCA&]]&B
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M7N*7\Y'2*0'$2**&2&02ACBE*&&.TLRXM [X0Z6;KY4X^WE8JMWJ$3\4)G^
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MNMR[!]89Z$(]L5?V]F]/)>X!&\.ZD57 +4]D)PB3D1,IC"(>T!NB0J.N1LZ
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M]))T(YMR%],J .V"JNDYS'9<ISF)Z<_;(XK00^C#J03+(4<3(S$.&)$Y)Q(
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MA3:*L _6.?D0U<2_97/HKQPW8&[[5SZ.IJW[<!?.B5R&>GQM:D)O6;<P#_=
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MJ4;!%O^; 4DE;))4 _$:#-',*:H-=]ZW&91\'-X_@B;5I*QB+Z5'4-_:RC>
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MA( &VK%TGNZZZ??\]W4I%74RX?()B+CL.9#1;;>>Q"1-E-(DL&WR^UW0#>_
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M5+79&;;C.2,MJ"#P%I'&= ;C#Y.??X_+6^'K-=\.&TQ,:I%(YEFA)X5>M9<
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M&Y9:YB@Z9(P8J3S&\BP3[Q0EG@411'1:V<:]R/^88VCZ['2G8?^I7&#N.FE
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M;!ST=DCH/XV:]8-$O3-I?X2<*B?G[]?0IT"C5UH0K7Q1Q0R( =\H7(Q,/O)
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M_F*V#PJF$??$9_]=;O>CEX-GV_/.HPVU5 &4V[('TSI5JS6@E!7DG7/&#<+
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M?6!O0KJU&TPKH@?M"4EZ985%J2B98$-**5MTP69KV!VW3\0 >]-T\':&))/
M% LDI4TK7ZSL=:K,7T2H/I>::I^E=8=K9[A+59YM?X:#\>?4=J*K-<Y8U5P
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M7K0]25!L;(6_I0#_,8'UJ*J(IFBWL#/E>!J.][:-9<)H505D#POEG7.B6A%
M4V"=5*I\.KC$OK*FEBZ-HM.LB@,5RB_:5&; ZL$:CL< ;546]: 35'F4P@IF
M3%8+)OCV)":9X^BCLLZ@EPM;(//6<+P&>]H#9BLNASS1(5CE;&1E>/9>55(0
M#";(/IJ$(AM%:VOD.K*&XV6:TQXP6V,IXCU6#<60@W2@G&]OY"E Q,KJ\<&F
MZJ11=FV]/<?7<+Q,H]H/;.LL#/PP3\=Y+PSSF)U28'R.$)440"+&)*)RSJ_-
MJEY[PW%Q1K2M(!BM!*,5FU#6%I0G$YQUL8@^+[D+$\2*SLK5I)*Z 7%5KOR8
MADWG4+OH(&_U*5IW5R8/WG"8(Q4J6=;FYK\U''<R@06:\RC\KCB[];(@$ODB
M@R7(0;,?5$R$9+6'UL8B4XI.UK5U)[XU'+\*:^Z)Y%5=RV/;-"O%*).N4(W2
M8&K)P#%- D&Z6&E<\75M#8IO#<>OPJ1[(GF-6;YAS9H"BQ9)!)!5%S!!1M9J
M\2 PZJ2JJ(G6-I/]K>%X_<;<#</KS"L..,VTS<QJ 6MC90>E6@@2-0B-KJ@8
MC'=KL^/Y&H[[+?@0WJL8MQL]O&NM!FQ=GN\<692M.CM5TLJV(ZWHQ)PF0[@,
M<'3P0&;>\$0)BQ<4@*\;S]P:/J%R,H!):VVB:AL\UV4*KV=1V"+M8W\8+>FR
MOU^6?<.9/)$.:Y&J@DZ)>7%1,!NM+ZU2U:9M J6%O3H]PL71 ?Y@$/@<SG8Y
MHU:"H4(Y"2!K+1A935M=VVH2$@J#.F*O4L<C'+6R%WP/HO)ECEII@^XCA@K!
M1+Y1*J,+C21 ;YD1E83%\C9J96(D/#MJ98Q&UC*D8@A/;Z-63L>/6AD%ECFF
M5>RBZ;6@."M2J(.'I'-E3\4KP!I;N3F:2LEHZP[TF+L8](X:M;(X\(Y1< ?0
M/NQ5W]Q.62!?(F+-@*)M4W,N0Q(" 7-R%%-2)O3);#Y!T +CG>[:OIA>54]V
M%S\Q$./VK]N7Q&S^Y[_]/U!+ P04    "  .@T-4#L8':E-*  #&6   $P
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M< KVX!1@Q*EJ5D@IARTM-J,.<9-A[[+#S@Q+W7^1?V>/>WR0^V;K<WP<5W"
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M.]+LL?F^V ^9,-NQV>4P2-VN*)5%9>[KD_+/.:MRZ#:=U#, !XMZB/2@\?9
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M9!HZL^-N!%['+V9!B5Y#([ 4R[B';B%$H.Z03ZHU32<&HV*:@DKH=;]_XJ3
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MT$9,0]:H8B5RVXBR&$GJ0!+6Y W#]>D7]6N)Y]+EKHF**VE%S\L';#XH9;M
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MRW0TX'S+6>%DCXD4/W9J?K*-\49S_BCHSA7[61%*%$"<1WU>8@Z MZ_6MPB
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M5H'S""LCWFB,DYC8J\*Q1>U=.MF4;?OX*Y/" ])"OV5Z>/^>T0  0/W1WR5
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M!A1CG%G)P>LP3),JK^I>#3$)L4!5SI=<.)?MX7^GQ_^Z1##,HO+U<_\W O<
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M*'X+@.] H[B2Y9"1VT'W4S6COY<^I\W2%F3UZYDW&M*A*@EM/&[+"GMZR#X
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MK78E/>9<H\:G+6-<?\BFC5"YD/$GL:=P%E23ET$'@</(-A^I;A>)RC,AHN*
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MW+[AN!^#7B_*# 2L/-R6;4_M6N[S]_,O\;#W*:'8"FTH/.23N..%2FQ,X7I
M/:YT$A?25D_I(2<OADGJU4J:G*\AYPRK!"B\O7G-7->JV?*S*(W(5?GQ@NLV
MBD1K-5C;E0I;0&K<G=-.UULYKBSG)*WHGF=4KY]IH::EZ$6[I7M[OBIH_/9>
MJ\$'>'4&9%H>AND1DHFMC.BDWE37R&W'J#3M\H!"'0MD[VCG&U^LA\_\-KCO
MGWAH\?C!\[TS%/L/+4G+42=56PN4P VD-&+;==%3A_#WAGKRHA_[?O\JZWO%
MVWECEW8,1AJ1)Y&BF,_(A':7LCG,D6K4 __G4[BJD;D=5]_NL3SRO,VJ2IR$
ME!): =+I7#+5D%"HH*HU[2:T\H$ZS/PD Y0-W%OP]FWN35.KC=-UYCUB6<HD
MS5WTK;5OD[K/S3H>[%?0[7ES8M6WC"J#0Q"PD6<8RS\A;/*8Q\=OE'2[SCWM
M1KRO4^L'F[^&[D,G8D5@?;#E,H;VE,RTH5*FIR,ZG1P]7E>SRN/0<4UR]<RO
MBO55/[8LG[G(FC#986\UV>"N6)M$8.>>?_EF&J/ 7<=["YZ_@"3:5HC$%N$]
MP- *]DZ5<NSFU!6'L0Q,9EFC3I#Q1 ![Q2@RXD4/^*;B].[YNQ\V9!^T$Q+\
M[,!SCY$7/@8(QFQ#@#@H'>!:GY>30I]0M4@_@#6#HSP/IO_"<@:,8\YP'N8!
M\#7+0$8/JAUDGE^\&1:MO;KGL@DJ>6GLXITGY]LL<,7L6<T;Z&W?%%=W_R%1
MJ)"F$K<(RT8P1=5.^B)/([7I?E&,A.Z_>$P3S.%^- *[+X"BZ&1,C7,G41*G
M:O/[H&,IKMJ[?I 6*:9E1[)X'J&Q2?>C>FO#-O@*AO;J#E>!5X6A?3O/RR;3
MBC$UZY\Q$7_G)H1967]L&Z52Q/V#57J>M$5G6OL%!"=TS),VY1J0KV^]535_
M>A]J:G'\.WN*ET$.<B 9@A<PE*1F@M7KP<%H'C$!?R(HRJKJ/+!D*Y=KJQ6C
M'",^&S04Q+28]N>JYK.(;$?>*X(D/(%A[N,#"'S-/U!)AC^/@K4$C3'EX(.[
M#IC97O/ U'I,MFBQ&FT^-:>W:!UZB?$BTQYCF,=):^LA2<SKJ%O4VHB,XL'R
M<,GJP,+9MUZ/WPR%I\4TY%D$[%>MJY"TJ+)[<*Q74E=#?<46[XHD%)*"<7^1
M*+8BTUYX[VZ$7)BB'>J;/W-]@P)6KD".77M/7G?-'?D!5WF&2@W:F'V:N7/^
M][J9N@7A1#)7?A"6!#EB8(LNJ29$BC!0H#-JBI8/JB,'O6)&Q(>]7S25\7]=
M0GGJ[I>J>VY[V4MOV^TN;)&QB7W6[XJ:)" ,4J^V(%/O:++D.B 3Y]-=,QH=
M7_XD*I%\*S^7,9CP8+%W#6P_'M)V2+HQ]M47T=-VKJ?]S@8]YA6!-#+(/(H>
MMV$_@A(XVMQH*+X<%]5.EK;$K"\G?3DSF["@XU!>]FMS?6W8M16E]?6?!51*
MO+[>?OX)L!XJ(N\%_?N@O5A87(VUTEQ@SIJD=J V0 IXR6=\(&#JA_?>?MFI
MWR?JC<LTQKJ"31@SG[+LFH[YZ"P*RDMLS/V,H>5AF5CG,5%8XC%+TQ7:P[&:
M*]#KQ[L_<WNW[(UFU64J/%Q-*-I;=G?"9%?/IEC'S;KNYP7J+S6? ZQ'BIJV
M(B:_"[8THYG.&&AK7[NC<SRHCK=G.(&=KHJ5DUZ09_/;(Z[U'L&-\3N[KPTZ
M2;F$H(V[OFV4H-<%^^F,@V=1D.[B_*.U)3@(H8BJ&#\4NJG4QS^"[11T>,C0
MJ>[QTS/97S:_B4W9=GBIXMF3*^M'@LMC4.%%9//:$&@O"1;7>X)7&R$83>$&
M._<,X ^&>8*2F=(Z[+J2*R^:[.MO?I+KMM5_ZZYN(IQ]S3W&NI:S$_%2./DL
MEC+(W@.E<(+PNBRC9/"5M7Q@%A;BM.7E9%3^]#BI+_?A6:&[NY:LUK5+Y^_<
MN76Y(5X?$&#KYBD^*!_Q,]Z2&- FW>*@(6NU'O4U6F^8NP*VU*.9[H]0G2#3
M)22=H,XK;=+%]758F_$><T\\=L?O>==8^YN1.-51^T"XD;C;<_=QB^=Q]BKS
M:#-@D2?V6335"Y'K,)GVD!+]I0ZA0_6++8=TXNPR BY +Y[J=])HI8)7;^\7
MVG##U9^9Q,[GY8,!VF^<8\@UZ%CNY9' IGF<34?.C3NQH;?(XU^CGUB>7R%]
M\X?%3B!I<8:7@R3]*\PF<L $EN+9U83Y/$I?2399Z<^,K754]=W9]&98J"F"
M4O8KPG?^SL)$M6J^1=7.!DXTV(()0T'FI;!$/\<<1T0(QP)CTJ?1\05ELBZ;
M8?$QTE0ADW/ PC/-O6!$][AGT/-GN+B_APGN(@Y #&I.)/4O&99 $D/8G9>.
M")!-75]#1</#!6:-<='7(S<SOR>&J6Z.>'FQ1_F$7J+L^\<;C']EV1\4'HZX
M["=Z&XDK?[#E*N8L"=K6^^0EY,P.9EVH+89*[6HX?HOQEG[%6W.>!IL+F>],
MGLG1>R+UH<SW3JJB5TN$G@8:VX_=26@A,D_WC>^")?181@R=%FHLBA&$EN-N
M;\B@=N29IRZ[^)D<'706C#Q[B-/J>'F69Y;CO'@R!V2>=AZW.87,GMF'F*[J
M,['];5*'JKY<Q M>FAVJV,W.0'AEL0+?4O/76;ES\/>'M"&FP'*/PM]I3B#8
MTH=A.A+'XMEQ9%X>]RH#I0R1VO>JT:M9)E-"GWT:J_LK[M%I>8$5FU%;U-5\
M9.^==7DU]\&ZB%G/E3=BGX+B.1LNDIG'J(G8#7R OA7R>X*S=V$I_'KV9&+7
M&</:6\:.H3*Q[+=G-%*&VCEN.UHZ0_>IC]L2 KAV"*RN!&E96)3U!@C+:(5R
MNU2^-NF;&_K3G5!M5YI* X7,49?]WSA<UDP5"M2,COGX;NBR>$;0''@3RSSI
M/"XY39[?B(!A.U@>U[OB!H722:B+'G7DKX$SX9("/H).X4%;&S:<ILN$5N\^
M^_[#IXRR?=9)18TZ;+U_K#<@K+"^;[X>LQ#-E/G3R4RH[5F65?,_HCCJN2!R
MH=UGXE;8=^)%A(W$74=B_ 3HAX7T%EM#9+@7>7FDVO<U:(F?.D=&=%AV]^L,
M-[4*/7RE[BL=MT<^1\N7>!A8W9O*?<]RY:HU(.Z(8I*Z-A+6HS="TRZ#M"'I
MIS!FH%%;^_-0(F5 /[)USBVVKT^M0410__4&YQ\Z<8V!=*-D&#70I &)MN=X
M]"95!#*ILZMU^5>J/:<\#\<R\LR/VSS1%!&ZLE]>H,16_IC OVI@<S#,$]BQ
M(%A< (G_ =X+(Z1Q.V(H_K#,(L65WID4+KU 3;RDE<68ZIP*LZ]OR@@847V:
M&G3[E.S)>Y%EI^HN*ZP^PJ:B_[$F:\Z53Z*O<.6O&T'Z9*[,Q^,.7)_G3Z]!
MQ+;3HR.WO?;CZA@4]R<9S/)WD^_:)9HN&43\S;^OOZ@*6"OP'O.!\VA(C\I5
M*6?5MV!KL&U&E-,?V_D JM&6L2MX:U-FQ-5@W_+[]QRV9I04?W"7>7;3NEOF
MF5Y-U?N,4N)9)*YBP( @8BJ5Z06.,YSLV4$LT<X0,1Q('TDB!8"B-5$..J]9
M<EZ.$5%:YX12?3=?57O[(<Y<6JUB0*R[W"D$:>1(9Y1$_([@HP"TH#O8<MJD
M!@(1_J:2]"CR7<U/TPQM/3:QRIUR:*DG8IN&;4[(9*=XF\"]D&H,K1'#/(2E
MD*>1*>/7,"H1VCIT6H9[!C(*"B[QA"X$O3;L@(E!%GV!7TW;# SZ3:J?=.@+
M&)P(EKXG1D-+X%U9F(58C@,R.Q:Q/Q^8"&5'(6&HC ^!Q(UNXKV>CD&_YC")
ME"S*W(W(IHP]%QX4#19F:!C,O$ET4-V3_%S+X*QK"=R+EK9&P^-D)LZHDP0%
M$J7&H(S1YANFB =-O*Z/7S8\.&*V&IY-^G5>6/5\J,/>N/5:ZYP;=WF/<F2Y
M*H@%4\G!? #2';T)!CE#NMNKHYFB=&)LL(\C'TB"Q5@F.=>]=0/4OGI&O$IE
M?_V@E1V;%Y33DG+=?G1F&D,KQS*=^ !EM0V6^"'*E;>!Q=ZQ/K8H43>F-V[
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MH5W-*\$7"Y)_(WA[BO_?,;.QG]NS!"V<(4$: IIKC^4>"^3Y(_0*3PH[?XB
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ME_]L1/&JF4AP/?^F)M\7M0^>83A5GF(/R@91F6HW:AU251Q<LDX#&GIYU2)
M"L575A*FB8#+&.@ZXM%2[Z+.W6\T^:O0'/EK,) ;=M%$N%P$M!W$"C?%V@XB
MF!G()UW,$42A%Z6*$,\G*91!QK]7!""#V^<L CH]5$MYUL*1Q4[^\X)B3DY+
M%G9;>*8(8*Y^IF%K)0W<77&_0@2TFPJ'<3\]&Y&/)@CZ$;8K%&KD<-L0Y&MB
M8/D&TR#,!KS^O[]X 93 ?(Z)_]O6QMVA)T.OK4Q:4*.>[4.3Y=]%@*:-],J)
M8G=DJ-K/3HFW,HO6U5*9""G%Q8$#(&0@5,P".8?%IJ][)B+B0!1B!2*6^R(
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M%6QZ;CW:\^S#PZ>HJ0:?7[JOAPH,K>M/.*ZYH>74ZA;ZLR06HX]AQ(*/R5?
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M-ABI[33K+%>SU77K'@?C%YF7YX;Z0<C!9!3!#:D*AMPNDQ$*ER!X]DAHP(^
M[T1'4PB[.$-7"*A'-!Q,/1PW&--;D1MN/%68*K4V3N.5F\:RKM3#X9G#SY:C
MZPSX2M^X:_]^%;M5G;@E"%/CD7*/X 3'CZO/US/A^'+\$77^;A95*Z1.33$X
M0T+3.[$CLG?9_2YVK774I6=S8@(Y0=9/7"I12W"#J %'C=^9JK,S?PQ?NC^*
M[V(%1S4^?^#55A?>]YH5H*@8DXU+QXF!C#HRM(]"*^7V-PJ:D:BE"'SZ<E 7
MTFDX'\BSYJMGM]#8;')2F'LM2?Z8667Z8^R#HV+U6UX9Y00M?[9;C8W8#%*J
MS@J8#M6UXS2):I-D6H$&AW@YL!*..LC;_OC2HZ[IY05C$<;^WKJ?M*^,^KHG
MG6Z1WPM$_.%\N!B<SR33ZH12=3R;O\=JI^YH"672_* Q7_  7%7JRO0;)R7.
MALZFF0VP;V(W[7WR;#;GU43]T8+3%X>&<"HBX"1FV$4HD[F4BJ*2A-+Y)3"F
M;9%8_!"3*E2 &UJ$BIK+/8C&@U^#CC<IR.)U+.;":.^_!"U$[^^,3#!#\964
M6IOE.1B^LBQWBMQ1H/+VO&3:>'A6E>U\^MGKZ&&/;N"9I<I"[8VB8"N5U."+
M.CD1@6$ZA(88)U7+(;WL1#?@I9[ %2 ZP"CN?0Z.KRW^B* N2.5[,B;[M';"
MEY2/&0JJ:V+2'%+-/OP<'0DSLMDR@1^-!(/-QCNB53F.2:N*/$?SOO&5JKE1
MV%%)%HXMX!TXAH_L\J"1X[;W:;73 C/XF##]Y,OG8M0#8YC*.:LX4\^R'/(<
M-^JT%)]US[=;JC1-?%)=*Z" X;EAE>LRZ-QLZQ%=H(Z_K](GRXK_JGNB8\%L
M]MO?RASD\K3X;HB:7?X(MFY=NJA"R_O&!%M(R5R/(^3.%^<J4>X-S7!B>4_F
MT=:[TMLGH_-H;98%&XVU;P1K-!:W^DZ(39$AIPA)X9MCFY!NCA-P$<,N'5:X
M=H%N%[B:?^@2;_N$SN9!_8)N>RAA,5U6F^.=>:<PO-"L<;.Y&G[!7]K@D%!*
M#=KTC1L$4W@X@N([HD%HLUGS@)TE#0S!-W0\26[^8+)^8'/IL^>WKF;H#;X8
M/7LA3L)' ^-);,'5YDRY\R((LG;F@CC"^>"EPZMYUZ!7?ECH_72V!-FLZ6EC
MW*!U3 ->?9V]C?IP/G#\[A<G'?VEPKDB('M(\$P$3#4/@Q.VI6\D1_]X(YM0
MC(3\KQ&,WDD<P'!=SIL(U'!HX0M<+9VOR>:HM6-DA1+VC)G+5F32_*B<TBY7
MNV\,\9JABQT_Y)ZEE&3O&_8M#2MQN%2_P^AJZ!0*-H[BWQ?GIB",Z5,.?G\^
MCQW9QJQK+P,#R$D7B^S$!@[^L)$KW)=C6+Q+SWO%;3W+L'JY@LBA[6(<.E]9
M0A8'ZY/YRIA6#.3ANPPSA=@^G,+]:CB:Y](>H3"[V>U:GLF5D^Z2.GORPXH(
MBNLVI,HZA2Q=P"8Q(CHHH[_UCJ/Y*GZL]90R/*8+5Z.6'-YH#=E-QV!-)UN$
M$AEZKJ9XUN9G>5\/FFG(;_&P.["R(>,BHK=B*Q%/TJH)!FTOT#^O(WY!;&B-
MPAEIR0FIY3&I7 OX+0,[$L.534/"(=)"*Y,NQM^0=N3=>$UZ!,^LY/:3FC,4
MH.HPK>+CM0WB<^U+Y30DB3WDQPM\Q;=,W%0BSXY@#?%% 'JZT9\9ILL@I_YL
MDM"*D \IV)PJ'/1I"NK)+]GIYY)2&G!AC^)]5?%>7;8<*)0>YUG;(TIR>&DC
MB?C>4ZC-*6ZN9GS:MF]@LTT4DQ>\F2!;Z.7S:J%7N6[5CR\?G74_[ONB.RQV
M],9F[->E9(90=FEQW/H@W!Z"A@[.P!L-V-41F&Y7XE@,6AIOB@;PJ3/[89^[
MU8]=33M9;VD[PHM^"S=^E_5E1)EM?'(:9#RB0^ZH82KK&U]9\YM0NI07('RW
M@%[9O(Q@55/U3KB)]N.B:F54#$?-_89N??SNN>V3P7ET;*I%JDN2_A'/]6:M
M;M_%YK%\K>Y2*>KO5 TXOU5392P;JNY U@JN@B ]&'X?WTF.+VE"^WD5@GD;
MCK@_SU06 2MCT^.D>6V-6*ZDH ;SNP@8C6=X\@WHCZ.N5IK1Q6"_0PAS!>B>
M8%;TK9>59E=6?E;-'/TTVM*3LIP+_Z?:C_SA]V$.(E/K;[>%V$85!QF/T=7)
M) SC_DVA6C:S!I3FX^1Z8&J;:Z7WI:JOU?(!(\=OWWQA&48V*:.\?P ;<,O>
M_%PJ -T*@@$9%K@!=D1E?ZN)]M:XV4_^N_;4>EE[*>0!'P4)-A&(K#<*&A[:
MK<6'<I%!0F1/KT8S00I'5J@0D8@>/MN<4_ZP+,P_<ZIRS*E$==9?Y5; FM]6
MO<5IP#CN/4$Y]00IGFB.$/0E&X6R"63FM$&F<2U$GAIB512=#83,']4IK:_3
M2[44]CQ-XNB=Z(C0EKJ7$(9[0E-+:-S(C-P(]2=M%UCVDRR'1QQ1N>GC%UJV
MI=\.?#?43M7:_/ STG&ZG>0QVR)74V%?P:;1C>FJZN_"8ELG6Z+0D.Y$D'AY
MCE"JGF=3UTX=J> 2-6][+I6:#:P8O;-OCOFU_+Y^'SE]WJ(:?[>YJ3=1T3'2
MK'-DA9ZW7N[UQ"-SX(AL.UFF<*G>/S^B47"5CRX)&@,@>@O;T!YN%0%23;<O
MT'R'KOY6-D<K=XK-F+[WMO'S=<JK1*ZEW.V72(RX#&P]5(F$2:2DYF6P)).<
MH4J7X[MR"CV?O2V!<\\7'9V0930IBJF-SCLA@6R6]Z/8 DO&7ESSEUZ3G+P/
MR/=N%M+0D,.=J+;'Q%8JM!]'4H(KW"%A<B0+*V]^C^D;@+SDZ6>CX#LQ5.?Y
MX71Q9T?VQ]T-7S\EN>]5Z%H6BZ>WB("14FX6O%3P (9].3ANBZ#0L0-]A2Q/
ME(';Q@\D.U6;/T<GGZJ<GE(=VO]V;<3MO>HW'8)Q*,/Z"VZ=:<3*H0Y0!_QB
MAZ#V-\$U$RT1\",@%Q?^W[Y!^3_M?]J_TR1%(_\+4$L#!!0    (  Z#0U2@
MUAO7NUL  'MN   3    8V%H+3(P,C$Q,C,Q7V<S+FIP9^R\9U@3[[XN/$@'
M,?0J1*6I-$40*1(;("*"E29$1$"DQ(8$"0E%0*F""@)*4)J*$*7%@D2ZB@I(
M#V(**DJ1!"$.9#)YA__:^SW[K+4^['-VN<Z'/5S/$)+),[_^N^^99Q ."YF
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M5:/FP+BI?^I6R8O/-6Z<B@[:$Z;P)X6%F7Z(.&P3N(%_%$FU)OMUB.&O$RZ
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MC+<VZ7/)5^I]<0=]4*@S3=:<^:T%ERK.SS1LRSE=K;]Y2\Z*Q2EYO:2/;!%
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M'?W,J*2_+L/0*\ED(</TRZ]M7Q77'7]=(WZN-^[$6<?+/9*O:9P#C$PRBA1
M&HYA2\ZX<%-:E[H380W\+"]NT)*2?-GBA7'E]MR41U]\FBL>U(E>5.BRRC<O
M7_'H@#JA5&F2ID5BEL/R@BQ:J""8.3%3(B S<2F7*Y+"%MR2L?)!=2]B8@_]
MW)_V8/CXOOA>P]W?[$ZON*&AE^,E'NMS=&&[[K[!JJ;VQS]S_YS])?<-*1RF
MK!Y6O(:R")<&*:0YT08(:&[)^&Q*HW8LJQL@' 9''^'S6-79#SSK2US+WLHU
M8NFRHH"_2_ZZ:)6]Z/5RZ9L,9_XMYW$_LO1_WXJ_XD"C;BB'+$,:;C6$KYX!
M%9OXB-L;$2*V@5,A2#<G_4BFQ*\7G=L]WG"-$[I'0(/\F:11#P=:WXR=\_C+
MR@'NQ0?3NCW?^W#^=7-[/=9T6N0F>>JN/WT65) GCH$_N:16QM.A:2^6$%@)
M27+ENJ\M^'IW]+729#5]WOR:Z ^^NVOTG3;@I6JQ-A[80$_K8&&-X,^,>L)2
M9\<B+(KP+;$314,M\/K^<@Z#MS7?P#+#--9T3M913B]]?SEK!GM9_M%KCJ:Q
M#H4U 2D5\NJXU&94@L[&7OLM.YD4>;Q6*[4J/+!RN+'/LRLJVFZR66ICCFST
MVEU2G\LW;=NX2:1O^2:H4C7!<JAI&V3'M7]D5F^"ZG@R?,;J7IKTQ-7/I3F!
MSZT##0UO%"SMYK5Q)F:LQ[')#7X2@ES(P?_>Y(N/3W(+9J_B?.3*?F:L+/=B
M3=A'<!6K>SQQ>N$="^ L+%U[#SH#>G'[QAEMI-60ETW#+>9=[&&=;7TS,W&Q
M,>YI,RA>G1Y0L7G?#CW4%QE^"B\(%+!H]!1F;AJWN\7&DD>NF"*'\+<7E=5^
MS'K[/'>,&A;DY[W.49J9"BQ6P%*))>15D"CW3\J'T>.Q*>Q;"[2B<0G7W(:T
M9^EWE-(79K$A'IU8CB-N48^A1)NF3)*6UM&;VHM1(Y@KI+E]R\]VGES(@Z_N
M^Q%:!#HMPZI6-,_,B_3C2G7R7Q5&AM-]C3RW?1*[\)GT8]VKCXU;V,%0UN4\
M011Z2:H8E8=AEB)5>K:]FXYC3B2;88)IBB&:46WH9++"1=IJ< -A5_5%_BA?
M86.:3TY^8.;>BEM19FM3Y^PYRPOB _CGP7V^L:1@&GV*%XE+02L\7L"B0XNT
MN!$/>3%WS0Y3==;UFUI>-8X$S,F!MTJ=W>^8^RQ>83Z@(.R">9^$PH2B50A;
M.-0VU'"G[]W& "9:VQ.?C)6\&ULWA57_R956G-A;Y-L,9)]:57Z\&)^WC9F5
MB?'O'ODS3IN9XNJV8!5(IVDC7;!\5A))SA*3.MC2=82[TDKMBT%_HU/EY#$J
MSR?<YZ*\=ZLQQ^+ES<:'-]^QKHO>$=RK^^#!N\-U:J:!&\A9%C]9*1VD^KS6
M&5GF8&&,@E.?G=:J1[_R?%;)N#SX*#=Z2NF;R:,)66Q5Y.(]?@!2%9'T>FJ\
MA&L]QU]/[,A-8-EO J,;2;4=494(6RQ^AJ'G\WTY8M&>;#,&>C'X0RRE?)1P
M$#3CZK+RIA<X+DR50L*:/FC#]N0J]C&NC+3=MH9+W/8*;SW%-T'/%3=.FUK=
M&LFU^QYG'XRD\E/P\+C:ZZSAT':R""T -V+DADO16=<;Z=5DB+^QIREN#!_C
M]N)V4]FYD#);QZ$_<LI4<ZZ%_][55AS!.;[Y)$TNLGND\[4-M;DJ>L%-JILY
MMKEQRX.NNW]4T8%9;Z+>B%EGA9S8L>:K/$J%>^GE\G.=1!#+H70RGJXB\ZV=
MN=X3;59+[>0XV&;*?GMMZL?1O?UZMTIB#TB[T0E3>_+S3NI**MPWV)7 . F_
M10./:8%9(RFO,;6W,I_04_%&+9>\=T\:%Q(']#8]<M[D=RGE['LU0R">CJ!P
M9B>4=?8OJJO)\^92$M%SVYN%P'$](= 3.O*WU3J4+8(:VM=!0B02X_,(IO8H
M_[L+.$A=\_NWZ[G^(ZVWN[*'B$%.XH(P@FI%I!(W+OTM?Y;'O[U <T3%/@^!
M>4:DI5_D)?EBU/W3_][UU!3% 3M9_F67AY^[2@E1G#U;,VP+/<LXC>EO-0+J
MG<?>B@(%B; \&EQO*%!;7D3#VF H!%1VZ"#ZBT<+@9S#+#>^^C)SD<.N\/B1
MU3X[8L:C@+]+Z:=)*O!&4.EH_=-G6^CM@J0HB;<RMPPWO;O"V=NLYX$@L56/
MN R!)$%:",2]J! "^NZ2S44F8  +I84O:25NYHHG=I%8VQU]QE2/WGR0&F+R
ME7K^=2SKVSM(!]R^HSJA"<&U*4?QLW!BDY@0>.U[&!'FP3]Y2Y3]SF@& T9Z
M9 J!'[9,-TA\ +.X,>OOWXBS-[[_[YYR&O7W=>YU7582F5J=5$K_<=FCD[3"
M(30XXKJ/@Q"0:JRJL7!_9'[\1ASP5F^ #.X@,8O)\U@(T?M**1DZ"L24J;!(
MG#@DA7=B?M"6[WA).V/ 1QB6R/*CUJ1>$L<05LPA<8^(_+K%(BLA;*"?-O4,
M"4D'0V@-AN/NMF0&([*U''*#-SZIQXPP>-V#9M_Z%\S2F\1RH@LO9B%"S+Q^
M^[-GKSA@LK,BY')05EA8W5T;6<_]-?M.-B0=C'HS_6O87<)KY'91V>T;;Y'2
MFQPH>$+[0<$OR\(GP[9.T!:SF22$]\:\)H-NGX4 EPX\=?#X3SYP&EY)>O-'
M\J\KE3LI@90[%[%QZ 9*"F7H<"]L@5?4&-B'U+(6Z[/#DHFM>QW"22VBRROE
M$(:+U&TW2!])4_8#T;'U%%G$M)*P#&)AQ '(_/L0[M1^$#$#"E)6@A'N'H_A
MW$1.DEJ,NO@/^6SV3XY[W*T!R0N>$=> WHB;_,S ,:;+JRV'J:?-PFDLS2*,
M^9;^"*>5]L6).] %1SSH),XD11MQ4!1R;ME'I+FCZ+]_ R!X.<16_&,.'/QG
M:=%^\]\YY=]?&O;S^L?I/$HA8T$^+<PLH4E51P8,Y))>%P3=-M4Y%X[H+7C/
M:"1$V);=*KRS:DLJL'0RE4/[AX!%_V.L G_V&;4(@7^(V'_NH3)P>:'C6A/;
MOTCM/9G?DT_9J'@&53(U,#,\:AP7;WCZR.-@6.'A$+# KS;"P!IY/&3V^Z^0
M*0Q_D< 9P/,^$@BMYO P=MZC<5DN0;<0T"[YCQSX<)ZV*.TC!(8N(D9-<O_'
MB'51F^[CGVS=^$&M [5"PG%E!:S +Y(2 @TW1>9?_;LS^*8'F:"!(#[]^V>B
M:J!S8!9KYGPO\V" :EI)?:V#P2^O:X9G.]4I._^;UAK_YPV4B8!*"IF1Y)D*
MLNUUB0-$O;ZF41S33=KO3.]/.*B[P6UU\!OJ&&1_JF/;GTN,H@$.XS4%U'5K
MGZ6/,XLR^$>)GVD<=W+6);)68WCI[NIV3.OL5:73=&R"WO-T5[E,<H#\YD>O
MM0_^4?IN_O3-Q_'Y;D@UAD?B4F>0'!=["K(XNUE-A98\VB-0E1V+=J,>^O3E
ML_<+W[(7(@-?-TGU1P6O>&J__ ]5O#&G;,U 0\/6K-&2MJ9-C?:2 U46K\S:
M+A<EE;@]H"11OLA1I1_JU]C2G<0>]#KK5@^8H-TG]TI>@>0$91AF!4E'")QP
MRR ]G8U'T/H#N)\D::]GV%KETOG(I.K0Q/[<F$M9;5/*[Y]>RRPT_F0<_397
MOOG\Z$83$C,O"Z'M&"IN^1&R=8)Z>W."0Q^\%?_2G4-N,Q,C>' _T\'^<=>M
M/B75/M+)X0;4W&WORS>IY#@<7_]QF@8:SL[$<D)9;DC5#&> QD*@S?<8>XAE
ME@8;K\/;'DS^G,>52\X(4<T3;R_8K(.C_[K=*F][?ER.*I9U>ODA8O@=K4ZM
M@Y:90VI&:![S'GW=3Y+"PEU55UL6IF7@YEL<IZNU%NI0U9-;^O_:^=9PJ-JP
M[;'))C+V0HPBF\@^F\+44T*2H@@Q4D)B0G89,R%[$CV(GJ@HCX3LLWEF[)5-
M))N,W2 4QJR5C%6S9OG&^WW'\3W?]^\]WA_OG_?'_?]>]WVM\SK/^[JN\V4O
M;6K@7B_Z3Z.*:^?1#?__<)?F' 4ZA.O:1E$Q\Q2Z,D!"!-U9&@3<"%%A%2M%
MKS,GS1MWNJ-Y'("M^#N;)PY,<!+EI9!0PUC)QR%B#E%?HS_@"G$-,BEW,!,&
MB) ?RQ3Y@I&N4[]#X8I@S(TU ]4;G>,?E6N&CT1J'QBY)1XIOYA*U\HZ=1_\
M\]9#+D.N)5P=8\T8Q"("7<!=$J1>N*;)<H*]0!6,R'I '3IE5IA\$/KA'F('
MYMR_8<VXHK5B,1"U+_"SUO=[W+I"'^5GL+ZXB3)F\HZA!O$S62%G:Z$A ^9G
MZ;H2M&O'[CPIC$>,Y(R*YK=1HAYG^Z57+LO3-?QVE?RYJBCE86/PCMZZ40EI
MS\*2<32U!*SW-BH= ]C+BU7T@;G=B&@=L!5CIHQ-U"Y2/)3KXEM^H78RP5YU
MS9(9MW2+4'2Z+RW-V9%U%AFB8!"N".4Y&5A<AHE^T./(?G9D-F',:,M#E6QO
M8 >@$^E*#WH7.IT]X_YIZ;Q>?S]NZ8PI/[<IRAA+2Z>($[7VN#'CV)GD_81;
MXV0U/PPWHFLS5\D/GP#MEJEUQ_IDM9XU&1GGFO"M+ W;**IEDZ]E\Z)0F #G
M#*1]M@K?SOB"888,4WP&X[?"FS(R@XR>SV/%5WY$YB<FU44ES(:7NK^WT3$<
M#@X^-RH0MWC"H^W_+6@3^/'@R?E"6(*%"!U4:V>D8L7KV#ZT!KK+K7&LR#(H
M4F,^I2@&OLR7""ENOQ$F/;;UL.')/L_XC; >.50YCNC<-@L$SW8P=D<,(@(3
M(*ZSB9E'<02\OA<H 15%DNG[?GN\%'F.WQ>NV_3P0F=P;QZF0U/D)U<O\M%#
M#N(0FEUQT&>PF?EZA.2+3R8*0W+,$((1I(#N&-P[Y6?_MY5?R%/[+CW)?KQ6
M@SJ3N:&O=]GAQ+WC-P$CSIU?65E A/91WLK YF@F)XCOJR/]=)!WAM3.:D0^
M(2.*^^7"<Y=^6> RO_ZU]F,+OTRT<&7CV'F(5 0_#;\&TC+BME%"!%.^1W.,
M/9!K=X?UY_*>/F&]UA3]NS6*;WH./LY1R;(C9,W^J DF320U(*]2CRLJL\X0
MNQ55P%Q8LH:F!DO$8B;'F5F?S&1>$0?SU\M#*Z&H^<6NBL8W'FXK54E+Y$8!
MA\7VCWV-1=-UY[E1R\7-4#CK. >]I'=JP[&8"4[>J>S*2*5PDX]&K.LD%B@/
M61A A2S\>8"1I',@\V=SGWQUT@?)K%/@!VGNF'=/U]Y?^TGA,)H?5:2V2I;1
MCK74=^KP6RSM;<%1H+!GEMK'_(,=1Y2#8@<O@4W(\%&=3JR8GY.,IA;U=-RS
MKJ"0$//>4M4I:W<'?6CF4OO7%!1;^-_O/A4\S+^A_9$L&^+' CU(]B5L-=Z"
MB9YWW^UO9]Q%E!E5K:8,:R=-[QK1;_U&ZSE4)"7,\[?ZA)/2UL_S_(L<4J<#
M:>&Z[.-)P!F*Q/=ME*SAZ5'LS<KX@D,9<[R(<-A&H)G5@HO;VF^[7DW/0:F1
MJ,");ND3NSY^1%7: ..PF$XGT93]%)&#L#OZ2?(1\VD-V), 8Y7 !\TT=-JX
MD]BJZ\N1[J4E%]ZJ7A?ES'[=F%HMO6>3?SWJAFW8^42AFX7 ';48B_TS$:I\
M(Z_83RK-+MT);\@.*G>YB9D(:_AA];32S"D\N/W!B4-&F;'/QK_;H8AG2&T<
M'G,5*XH,8:JMVBHA]9(N"J1N13<OARH6G$9U=%H.EQ*N-S8"F]^KQ_!OYE/\
M38O"LE139O2_7?_UN&HO+]<@J4V?0LN?4>?$93QQ('^0K@=:(;M)+/>(\,YP
MBCA\J:0M@#;[P%BZ7CIH8F5+U^W7>5O)^+ 7.O)@SUZIGUNPO/DV2OT,Q&&M
M[F9VVZA2H[+SI+:6W_79STEM1CJ;3T,<&VIJZJ%_%I*UM2N6+B\D\_T3GG/#
MBSMFQ9>'@]M<((N9W +R=P_NY)=(4!8. (68=\#TG'RS4/-W*22Q"))C+>O&
MH\C@HHS:QTZ6#V-#JL(-R,OXNK(-!B*X?]Y.F9FYLWN$NHUJP'>D?ME$)R(Z
M8&%\BP*-'CS:X+92.<?6H#,"/8,ZA_(J4#;.AUKW2<3AGOWYGVR5N$W"8&_:
M3]0PG89N$1Q9MO!=(/&>X?0Y@/I]'-$%]Y"?[NF?LWU<%#E]DCSDYKN,RD<Q
M-!>PZ5@ OPR+XQ>6NP;L%^PYX.%=G'%IG!'/2+[U4T?RYMT;A6^F F>7IB:H
M5ZQXTZ[D>(G*>-FNJRR/P#MS##8[7:3P.5"%* *%L"+A ^-U?N7K:HEGARV4
M_+:,Q2UYT68?JWHTO$J%':P[T=D7DFERFY0$K"19#O8'%)^ MK1M5$8M23+"
M__+]ON)5!#-RK;FFY7A__(M\U>NW95UL>&FE"I8H @4-BRXS>1HATWG&1%R7
MASAXK@%([%)4K1U?(TO.0 L7$D\#TS\M@O!K;?Z&CJX=FOW>4:0C+V:>O:Y
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M"$4P'"!W,(JY#-G-98C[;@B$!O![@)OQY8M_Q9_DS=$X*)SHK]'&$[O'%Y)
M=HNQ! D7$BT;(3S+"S8<]P(Q29,=OWF;[--O5<A<&,TQ6302E7R8K&W6Z(77
M"(8RSYE*<FTD/-U&\7$PN>T@C'V%J[Q/W WE6H\M)J@,F5WU!V6<<YV CJX#
M?;Q-US>F/C!M#F1>RH[-"JIKT#AT-R.#!)Q 0ZIH>L#\*CH%6]?3.N VCTT/
M()B6?!LGZXZ;D<HGIU?T7";?B/7INWB<Y'_<9MNLXM\X_3CM$<X)MH9R 0:-
M$5.'39Z5)H040_X=^4>JWHUN3H>??S V_%$KANQR?;]8\/\V3ILGZA,G*57C
M:XPY<Z$>G"+VI@Y7Q#%K\)2&<0(#MIDO<S/9M,Z[U)FSY*P8''#'J^\A#[<U
MWSU3QA<.5M2QI$EM)F;'*B/LF;H0A],)!!;.1WT)W.PC0=9UAZWH!J?2,NM7
M5Y/S=-^<%OW;]*O<UJ&/0&*:F3+(W\Y4- 8XC(\>8CD:X+!L._HS]=MZ %XI
M*#M'X]I!E3],A8MCC\J5S)$XK$RD)6 >)PH9MR%&PYOF;NWAGUPB"L]5M=C<
M&%X_&*.MG!#J<#9PZ,.^&#=^_])OOCQA_Y8B[PJI!LQ0R)CE2I <WT;YX*E"
M'*[Q,,*X2[H47_&-PUEEI O]DKUM+A$F_92S=<'GO4<+](8RW69%B?LA])QQ
M;"@V&2L!>[^*B.J@'GXR[2\W4W,W9ZS^O'J?K5:U:-6S]<Y[FNW8.6 ;!9Q!
M_[;!M'(RCBG59QNE^ S]X@Y+WEV[?8]^MXZVD*^3NF/0L0O'4==_1"BLIF!K
MC-LD6.?0D_L@-43[." +>((89O8@'+.',4G^P"09O.<@1>929 'N"7R,"=<]
M!S86*MOPJ<3]H,Q]L@S!&=A*"L4)X [FIM1.RSLG+$4?F!NIM@R1T_-US[;A
M:E7AMCKSR GZ#"2>@$J+X3UCB)JO48'!>.TOQD_<[BLWJ[2+HOW1OR?F&PXO
MF?G%-;:V]KBB0-QD%"(HP]%0&SO&-Q'-I\!9^A.6!:G=^S44;A>U1VX5$1]P
M.\<R;_ZPI!]0U1R/TP[)X65^U+1E<C1(K"O2B@7L!>OD9[^L,GT^$12BRUJ5
M1D+O-#61*?FB;2V/0J.T/B<U[+JV]W;QZRQ]OJ,9:&1Z&U6%3;4PL6,91EQC
MUD-!?Q/^:"BP5@7<<]/6BD?&K@_FH2?&_EBZN-OV--\F*HM/\R2'[+XE>>M,
M&'VV)[-+2!Q!PQO!;>[AE'&&0^ HG6/4R!;O;H;&C5#]75/&4KS:IX..*V98
M^D38=LU(@%L)6F;^-'N)[]2Q]-?4EQ_SRKX;5TU19XXO:&@Y=)^Q3A/8_^=#
MJY.NAO_*-I$9/=NH26?F<?:?=0K&UO]AI+&-XB)@F\;V9P6H3G9;:-9^+OAA
M\MXY(B=2\IU#KZ!LVX%[A@S*#7SLT5RZ6@DRGDL6G 4E; $"(ET%HIG9[W_4
MYE4X+=GBE6R^&MVPQ.MV7]_;ZJFOV5S)!S3 4FJ(8,W"DP"OC3920V'[85<=
M]'?TZ]5JOUE1PU\)A5Y95A+39QT<%SNK[<1S;ZGKJZME>DS.,42_66@/:1&<
MY]QOCCL,;QXSJ?@Y?;I[SCMV9>84>E]54U9%VIN]NBJB)R2YWA/[MU&<(,1\
MV:#EI')4UT>/G2>1\#:RHK&5U2=*;44@,LA,S0M\Q::/9)UAO2IP_O770AB?
M),KBW#B61L5 ![#)A*M1"P-13)4'C(LCH;)XAL^3>9FD7CNS+%F%-!+5PD-(
M[U@8?7EOC]2F(;:>?ZT(VQY];:&?5%L20YKC!Y#G1Q(:%_C 2\\^:VF_N)UU
MXO"G1[TV4A,72V\E*(6:E,URD?PR)F:9KP!" 9;]Q,(DPK$G7\M8=6;! 2CX
M9Q=\_BQ*54-8:\:-%E?W]O:);H%G>^SOX_@1:9@;PA?#&$B3MD>M?49FJ)PX
M6.SK>C#+;=*U)ZOSD#K/P50#O<6\5'$;U:8S[:-$-?CH$*+DA]E])$/>+VQ&
M=7PMD'''CL^_TZUY-<I1]%V^>O+4=]E\I7X^F?XKF^74_Y1!B>:&%2*B HZO
M+0.#W875QADD_\>UX9#_2S@JLL63K/1)Y.7U6]V/[J"?WE+^L[\Y!6Z6_XY[
M.0K@86GY<Y\W\=0>IL+G4+>]@0%+[*+>OEV=)S[U,,V7=]GS1OMR[0P,#5)]
MD#VLG?%C7ZXY/*26&XN@W6'+H5JWIUZRL '@^6VKWLGS9>UGJQ#M0KXI=JGR
M?ER(5K%G^NC&C>>LLU 9(L #.B[@U@SF*GD]_,G[H$SA CUVNJ%\U(TLTSKZ
MF1^:QPJ%GBF(RZ\^#I36/7VX/\TF\GCE&%VF=68W,#U! 1AQ/YL%J?KI1W(*
M]YV[^/#,XL5]UT7,XPDG.93)O;JFB8,,<4A;UA354EFM>^#:-3//[&U4LLI
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MH&?.HJ(JPI\E,2\#'YC=C7V[&*WCZ'*>VJ<\X=:2>?;PUUY-W?[C?RF\(AL
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M9M1?FI>FJ'!>O+7^>,>O6U+RK(;98/%2:C*9>8<F3@Y9%"/3/;!!A%3,.@%
MH,G"UE!(Y8=S<R\$@'1X?WJA=_U<TO&?0=/*MYQS12Y9'A,JT98<>_/D GXI
M$I%TY6W]1GMJ!FOBJTFO(LGR/\E*GE%R[>I)*<GUSI=FWS3Y:CDK3G]NGW8
MQ+9-],M8B.*F6,>/B6IUH'[2$P#7"P1 :,YOA(-%[H%'Q!<R*?4J"_TJ23]I
M&GV\_9!R.$[6\2F4XT%0\9+VW3QV_?CSPC?C0GJ>P,<S"5]],-(D8W@C](DE
M05H/*T&E+(9JD,KJ5X3J*!^?A".UUPLUKI^],J6:F1D7]89LB@5M*)!>2GL_
MM*61[<$[ *EP"SD]Z1ZLQBL6?DU9/0GPODJ-W3_WG?Z^Z)H\\?D24"!O*SIP
M9%N8F8Q2$VV0!N)'DR+ZQU40:6'>"11.]K5LG]5T. +BDNS+N)NH]T7>;+Q9
MI7>]ON]1W-VSC<^U>^,DA6NJ 6S,E[OIP*;_(NF$KH,K[305RW50 LLE>YD5
M70I1]C</1=RRN3@W<:)]X/5-=OXE3!;9#%=+8=OR0E#%'V#K&#D"(% N!U?[
MMHPCSJ1EUE,:HB*]XEF5);0HNB-AX7O+\PUKZC049P:[F?XYGX^4WD-N;*EN
M+ TJUAO6&R0ZE'E_6QN6Z1Q\.;2F:_URP$EKV X@;Z6 1RB3B]Q1M!V7(H80
MAAO.OXH]U3QEUH&L?O?Y6?RQULLCR?@DQ^EYU[8?LPVU5US%Y#,_4HIM>LOF
M<=!NJLUS< Y6SD$DV:PJZ]GH2E.V^LBEU+S,5]5?7W:>665OW6U%G=HGW%&L
M!3ZX462<M*QAM.OMCD.7"M8^E#E0_.P8(-=;/2".IA9X86Y!CB.'2.F@:=;)
M":2C&L4$<E,R8>S#B2A*>Y/CR7+7YW73-3Z;+:+S?)PO/$V@7RW17>4(YZ(:
MK)OD&+130*?C: _RF4)>6AH)@*2E &88^+9WN=O=)-&''-BSTUN9YS*9)V.<
M^R3YIFT!??OH\AVO-RPY25KJ:+<<*W;WMZ\*:1&V 9@)&X7XNR="N\T#E82@
M4=YVTEL<Z"8';2# &N\LG'BF1%%P)=W2<+[8\%878TV+[$S(ZKFCA<Y#5*.\
M\3R#R]&SP:'KDZ=?W4_]?EPV['K(;01/8M#JJ;"B#R*ER;.(PK<+@!HY>(UQ
M)R+/KR1:5WP%SQU@AB@8A:>%UEA.7/6:.+&M:<D38QA[74^T<6?6?=SOMY6M
M6+J6]%#$9([25S^%(7:].3VCU9[ADJ5_F]RXWO<-5 3 <?Q62W,T6QQ1U,NC
M@4Z$\1RZWWI^ 5&!@V=5YS!C=?;S[];1UD DW].QV(6OH<[7&HM"AJ9F%">E
MT[2O*SK*7ULJ(;S.F:"Z\./(S(>X^KEVXQ0*:$T9R^AAR!$C*^;/SG9'YDUF
MX#76!\1UA%^UC;RH?.]2IY/N-?V\.%&A$U<=?N9]R=/.MI.IW-9K;ZU\BT43
MA<SIKRQ("F#QS?M&KXL#>K\V*+S0(R_N>F&FY:(_$F<R#Z[,$.#J27 1Z=PC
M '[*OYM?D4*9C@>6>9/RI+))'-8T0-G#Z*[\OE+8$&J><8Y1[24^&1^+O3OK
MDF]L_;PK9?C"_!4<#K5<-9RAB<>"/G+0YL.Y8!OL'57T?:5;'KKTY:6\+7%Z
M?;-/Y(>8TS8I^Y[B6O*/B/]H1)/M/+^>?)8V)DVG**,59IR-!0\;*Q&M^-7U
M%.4/8S VF(@1Y99JOBMXM2KXAVE'--=9<ZC/)$?I_)!ARUR?]T\<M(%4+H96
MIQ@/U<":I'BN-Z3%NB2X*7^B[::QXJ1ADWE[\VCCHI$^[A'F('+5HQU1=Y$W
MRUC3T:!S/$K$^&'&?IZM_5[M:QKIO$#EF#BL"8TY=/U/)AM%;;LRVC6]7I_!
MMSP(?P3UV4(\>S+]"19$/\WZ+9Y)#HB-[*'(6.[\EA/&VAS^T(_!.Z@=L:^[
MF+OTZZCN-9O&L$EG,6&QD(ZXXL#E7%P:ILXC'<O\U ]M+(>5Q'L$@#Q)+$JN
MDU%73B<H?2M*&DU8-K(_$(&/W3'QC7G"3KQ0)",2;TK]'1>=5/96Z.6/%Q;"
MB*0>QXQ[%1H7 .(>\P) E8R72\J#='JT],$L[F,R\]=879-I_F_9RJ+8RJ0X
MP@[SM74>'Q[1$\3VGZ_@TB!M8[BRD1=.'EU)0V.M']\JCDC\Z<!\U-XT>#^Z
MOPD?1O=O4%\>:E/VAH0[_;8.,)S!N42%_6XJN48GEX@Y.QP:DS5\[*ZXGUTZ
M\=R__3MY[!$ FZ"(L8_\<58 A"SRUL%8 7"_6.<>NI2F .CMQS8( %ZQO@!X
M5]!+"]M4LBK]OUA:YE!4JU]9H,[<L B++D$&M62?-4 !1"Y.?E&ETWU&3O:#
M]@6.7^];Q:G\;E9";F/P6X,L5-MB9"20JX;^0B9Z\A]5G<F*0.F^S8RO]%N@
M[%R8<L-3=_%'MQZ6B,2LP=W!@DZ+XX^9U/8<:)=P-V+&IT8P%">"&*IU<O)1
M_3/9S:R/V;&GJD+/;.LQW!@1D.>&)X@D1.F$5U_XZP# )T !'!R+T$T3GX1M
M(%..@14G]$JD;AJ^.BK0*QYY>]9^T[=K5J\SCU\Y*L2,E]O0.+\4B$AV\+S)
M=#,L\S8.M.&;<>^@DY@ 2(L9?4&3QD=FK+T_D[5AZN=HT;S/KFIU51'7ZRIN
M3'_,^E>O'@D -1IS 0?I%M(?6AB$Z*=97)SQ@IU+Q\\URD?Y=%QX&[X[]*[7
M::=AH\YSM1)37G=3>[_>WB:>#O"W5N-F&#UR\33 8J=*%LD<QH&-\>'!B^YO
M97W0\F@8#KGW+"#2T]TG9?\.Y:RQ37NT56>!=U@ADCEQ$[_<4A8*FUUYP5"=
MA!+:_0R&%06 [7OV\>N!235[W(5RWR?HZ  O>WM?R-N1?-&D^T+^D8Z3)(^'
M#Y&7WU<>$9^W3ZOZTK9Q\#Q\@-7J-WIDN%[:\_MYXX70M9ZAIW)M=9\VY55G
MWMMVTG%]O.PIV ,:!".9V*24;-)NV OL3S"Q#2_H\.3XM1+*O6_>5GP:W;@Z
MK27IM,H>\\-[/3[UO"!#>XT122S/#-X-.? ,HD9[_ S?&=?A4DA:PQ8.,V^$
M.T[/VP^%#KLT'CA=X+JIR$UC5?7)Y..BCB)7[2X;P^O4*E"=+9!M9/KV98(R
M,H%1;L&'@!0O3G)6Q9=I'<BQH+#0XYI3R 4N5>V.;A9[>N.E#^)8;7&Q.,O7
MG!6V"V\[<0MHG\'9.9/"UF!B92%"9VZ/?@K1F@JU];[M.79@@V*9CXO)XW6L
M,FVZ_9ZCJA??N'#TN=?X=RQE<5]B<%T"(*=-"KP_FO:A/+FJQ6GFL9.:Z5FQ
M;78U_1MNOMS1N>W6\UQLRTX(16=Q>V]X1PV:V<:D;BY.-,+(>XG^A'Y//Y%J
M^F70N'Q8/$7>^]6%BE5I11C#9T>4MI\'#$K0FGX@ #ZR_O!X&E>M60 ,T>2.
MB+,IF;0@VO@2:[335X,I #HQV=.R RT^,\;&"#J'2N,M-]75OXO [K!5(@<V
MY-D5A P9;%AP*S@JKJ,\[O&)"BNK=&#!0VP71#J#9XS'U35VDM,G"-VW3I4*
M@/;Z0=C /W!C0G36N8^3_.>?LNZ?^'!3F;L#ON)(_]Q6BUJ HCW=AWR:C)+3
MA.5^1=)[LOS6TG<10RB/R8'<K)[RSCY^N,7_<L_J3\>R_A+*\]C_:D*U44EH
MN569@X/7!"+2*'**_$ 7*H,FYE@N+[!K\;]5,EEUEY]98&:KMI@;3([)GSU@
M]-K-6692W#!#^T))PU3)DS$^"F?,9SC010",RW'K6OG9Y" RYER;.F?M+98'
M1Q:A1MZ;<TI^$W+FN?!;]ZT_:KI=-SB.%]OO/^(D!?S^D8[R.TG4H[E89A&J
MJ:O<A!X6'443)D8SEHV5&)(TEF9.=Y&,^P7\ ]U@3:,SZ=$7$._:Q!O[7RLQ
MUW2%4\"C-,B8 J^90R0#9O'8)"P&=IC9%];MX2Y-1!3!7;F:[$_W:^?Z\BX5
M!9W*($D>"Q;.39ZL2UZ/.>>A!MIRTR$%WD'HD@#HH@&66X.TM@^'5YT.,7!K
M!;GEFKW>N/U*KT*T;2X=+!W(W[U^VVP1B(4VIL!K4_X&A]7659Y('[+U/1NV
M9LV'/Q^QT)EIW>;U[8C/3A&?I&/1.@5&'S<'?8S-[,6$+D]Q]!>49_HH8^+(
MZE ^FD4GH0>[$$E^B4D_=+C%P/_VAF^(P^3G[=3]1S6.VZA4-*;4Q '8TQ7_
MA;3_?PK<B7J\V<+V41 -M*?(!S<1,S>\AZ-+)G"B%B9.%X;C8EM>^F./&/AP
MXP;/6Z!T3NQ!0]:##:DG^3GA%^Z34^\HOBOXG7? \G.K,+)Z/Y]2CYTP0"0&
M.;<Z$,S3X)_&JX-W36^J/7;B:E'(.P\/?;3Y#?H_A^=[R8'2V%0L> 0'F1+V
M0W@08^M+[BI:7/B-K!ZL*R6+/G_6-OR^KG]3G_F]BWDC=WSS_Y*T&!!OU\*@
M(]]ZTWZ>QAH!X'8YAHM-9#Q)6:A"JY)^-V8TZR.$83V$G1[!^N^(_I=GHI>C
M?%QCCYK?#(PGU"DO*74_[5&,>R'QCFI__J<Z%E8,0Z2$\*A-3\[1P,/2.7$^
MI)T?H*30DR !UO-VG9+G'#/CM8UL;7N)'<R]1[]E$=*]6-!V#8Q<,.4=_8H#
M0SH93TS1"ETTGAF&96G@;\B%%]HY=_2J<XU<O23RYNVG7_!4@L63$AD:9+)R
MM+4-39R-Q+T-S<\"G;#R4+I&@#_%:/7CL(V#7\S,,9VC!?\ ^!Y#-)!@MI#$
MVT_J^-->)9&WC'JS#@9D!_L_P$^\></-X5<%7_[4M6^YIG,ZY%Y-9Z2.<-S'
M3":3<\(,7O>))XF" 7BD'])GI) D2#T,:2S+F&.7TA5K[M6,XD.C83B_P#7X
M=[ZQ\<W+%MMO'[BHR);Q7'PILLI*/(TT0@&=^\=HUFB*G"C+L8:,61FQ3AT,
M89,<M>!IPY0#21&2IF5X0K0I8\+F5^9P\RN-@-3M?4]D2ZT@PNQ<#NPZRX!V
MXED[H$<_?%(&+4WN;.F.OE& ]Z2:NBE^Y-J1C6+7;C/WJ" 2^0EDYMPD8SS,
M'O60:;"E(CB:;BG;VIITA]+I$VO3.QT^.!->8+3W]Z7GQDKN7:Y>.DE3B4(Z
M>5&@QC<"M)D"*]C.OL^!Y0U8C? :%:XVZ,@1 .E$E9D[NWA'A8_7#-LME[.'
M&=/BK<6;WGM__IK>?>*9N^O;H2#ACS1H=Q]R9 U/0@",/671^':GJ%;_6YCW
MN/?GPOK?+A(WKK"#4<1,X5_#!BR.KS QL*[67BBP-*@ ,1L0 *S-0U78VH#&
M 9VZF\3Y6Q6L6^>_N6TW3\C,I)J.D>FQ9.9-3*,XNXI3R+7DX!;Z0"=$,03+
M.GO_HG'.5BQ+;]B05JM0;1+HUO#]\\9;!O@+Y' ,'\=SNBJW'G4/RF]ZWPJ
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MVC^8(G8U6VMSKX>'8,$O'M97BL7,%\S%?]VV6.P?<SFN['(P.2;F\@YR3&2
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M0W/E^V&=I&E&A,+@Y\_MCWW%'PW)+GNMQJC-ZN0AL#R59+I8'/$B&K0NYQ!
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M7\#8D<OHZ_SH]5 T#R,>VG'T>GY#YKZ_FT*$NVU#X9!?!WU#5_FP)&:0*33
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MVZJ2.??X)%6&)'AXTKV_:8OD#U5O8?^!9T/A/:J+)HA?RFF66^R.'+'.X]7
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M1^K6:Q$GD^S.5NV^9Z)FM/=J9]AW4U"GBZ=@Z =7[Q@2I@*;1@GUO(U6OBI
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MVEV7>F-B]]76]$0FUR5>7GP6\TJ9:PS#:\8E$*FJ @2C'J8.&"$B_2D*&,0
M<&7<FCE\M;$<=*0P9+E8SNC8'PQ+AG*1>QYS@0:5VYU\3. @IYY#4E8P8/ZP
M"S<LPN9D@0%#T: /#7@=G7](@.B&:9<-UY=[@N5Q_EHP*P=RIKW[L_YK[JI&
M+#<O%0'J0U*P_XB8 UB>BG ;),O62V=G$9,I<GAAG9]/P73SMIC-'=6]&A^:
M!MYDOM_%+NW:97<T=]TW!F6$>PS);!N!#,[@;)CZG2N@P?Q=7@#;QXDM8M6\
MG=UWUUPJ/9A5*W?)\F]0Y=F+A]QQ,P$[]IIGY9CLSDR<( :'/$4FH>F5<-)Q
MH"02 >_'2$EPN8W9_ P89>;&JY$DP;7#[[CV<EM$"J=Q.:[Y#X(TSU_121VP
ML9&9?.1Y;^,='_V;GR\GB%\13L%2)JLX0VQDUTI*@[DH6FKJY[MOYM<4Q.\:
M1!J-QBCV1FDY][PSV)FI^%[TW[OD5\-'Q69(+!:C!!W1!UIC89)68+ZO=RZ-
M:P=:FFK@/@Q'J*BZVV <U:Y-:?WXV<?C(8\0 TOA;!1,!O5SEP0(KB4T)$"H
M$"^AQ9KK2T#NC.Z?IFF#$5M[0J[HM+B0_.F)S>FV:=%^:14Y.@XJIY:4E^__
M5_W:[7^U_V&+]<P@Z.)&7=A!G$<O?_J?E>NN->>:!PLC_NSR0%RO4682@3J[
M'0)$/\Q)L^X)$&PE8NLW,%GPW]I[]W HO_=??"0YA9S/1A&54#D5FM$!2:7#
M.T),A9Q"A8R,>1QR#D428H12.85!(>,L2LC9Q!Q4*,,S:#R:@_WX?'_[^GV^
MG^\?W\]G7WOO[][7M?]XHLOUK'7?:]WKOE^O9ZW[7HAC@KR3,.%O/RM8>\Y5
M>QTA&DA'<K<BUW9+K",DK3FZ??' RC[@6Q&:8XD(\_@GV_$$/](EDCC'Z!^(
MO6X.R_E>N5FH/J5OD0][7AK-_1/FX'J5N8[@'74*X=Y,7T<<E9T9XEN)D5T.
ME_EW/^S@&/+A)(774,R[MXM_-OM?V(%#P80V*ID3 I6!RK35N)J^&+4]O)[Z
MIA%7T5?XMLWL:4D#OH2'S=_X'_!5P%K28"1=:\>5T^?4$1=YUA6%,.Y +YW<
M2-IVVTKXL[V$63P]PY'U905"?$Q7-@U5F8\M=B8<QPZVU^=%ON@R*G_4%R%G
M[2WS6""6FD_-S7\L8"$X:\TQQ["ZUQ$%<-AYS(*=Z8<5H W^_0;ASU[,6H W
MA9/J*D!#RV+#NE#R@XW>-%U['8:^?57BXIGW]SCI;3OBK!5G!$Z8+[ORL1V
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M!GW^-%5<,[>9QDB[2JSD JY#%O5-I*P46X.>;WHV.DI6[\P"7>09;/8NN*-
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MS<?K!#"HC8)_,8\/^-O!MX9?0%!(&#5#''U#_3K4?'Y^U&A!U&+TU:OHZX"
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M<QD1R6?O_DF1!6FYU'H;CK090S%]O*-E*R2<:>Y$"ZH\L3A?K[(7ZQQ3Z'G
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MS^.O>RD-+.JG2I-@:WRSQ?LM=;<?RV6<"+@_K[OM3>N.!:O/EVL^"(_5_W%
M(;YNM>(<V>OQV%OA*[6X^U3(WG'%Z!8:[82%%1M+C,W?-GCXOF$P/."+9CDX
M(HI6A==5KSB4'R/[W".X%V[R@'WR$,B1JT#$?+"S]@]Z:?K70<%ZQR22-,KC
MRAEE_95*ZC7]8=$[&QP<C^;<M;/Z1DA)7GCUYE69:Y6E!;FT)1P619NS%FS$
M=&%%,J=[,I/_"%5"P^#UD9%<K!QG)^/6R1?0TE#=69=3[:ZGU._I'&!.]WY>
MD_[Y)&86U06"[O 9Y@)C/M%B;229=14NA[IY0,^5\W\2.X*H28ARQIOQKI-0
MM^8-#W-GVP8GZ87#QP0MW(3O7+/$.#MYF;$]D,\X%!J\]]/NFC!R'VDT]73J
M*P<@RE!5W.E7(Q%YBB[2[8,"ONMCI3=&88I7COO</=[%OH!\QJREK+;U/YA.
M7!)F+2>(,<+42IGCF)7 H716NEK)8R^J@\3"MAZ!F];-YQMOFKDV7(P)M53K
M<_X!_I9!VVG5C]6EMS+/VLEM6>P;QYX<J;N+93G $]#'[\8?#H]@%#A"3;M<
M)H-,YQK.F+<$;7_W=(HOKRKHN\._6*&6F /]__Q.'=]".4<./T7IPL=0I9KW
M5A&TT9"?&&+50)[VK/5:U/7)MR4.9PAOW! C24CD 5**7%245H-?7Y:#O_=>
M116H(,H(LYWI:,V<XP']DK@;8&/$W#RM[U-?Q]& _N]YIM.I2ZDJJ>E2U@W7
MFP,VV-F?.O7T]#'IN&R#GJ#39UQCI%Y0Z"A8-SAR%?0YC77SB,T]1$V?O3K9
M61[P-OH(6F975F19SMP*BPW("&9M&7,^)GC^R8.G+4&J00>'3DM[!BS;\?E/
M6*D+K-O/W[>1'J?=1V)]@#U0;(\*9BL'#.>-%*E?U9S'XX,[?8=?)16<$;C>
M,+^C6_ZI7(R&UQ4:_RP%CJ3,H65KC?).O3DS'I#U'6THJ<@H=M&5\GMRD+*B
M1C%O,0?;W+!^V&L8N7IL?!Y1B>F7Y =Q*C#)X?IK?V2]#7JP9^/YB"AGW?OT
MISO6NFA><_I.5> !P9FC*,6<;]4S866.<!SUYA.77I7@I1[D"^>'/FI^[+DY
MQ5AG84["=<_1%X?.BG0!5S/_,<H8B+GZ45*J(N(QAK8N]9$N2HW+7 =4R*)D
MNCV%O&Y6^A>,)-ZW'N)@&69&L3-RA-D;@KX2]V.E]CA_E'AD\=824PNNK??@
M1M!9\56!M2N-+@5&3Y8-9L5;;)+=,@#@7/8%0+[VU'([=D738OTJLK[E 0<T
MPW;]]3X1208^'0-E_!PQU>*H>T6,?AG_QJT-^<7WX^D4N3+"B$Z2Q7Z)_DCY
M^8P'?+ &PD'H [BDC69MM:$$W4.4I9 R#(>$ZLEP)GENM6+L4-E];CY-6:N5
ME$&M,TXLA?-<G[M^J\G^ZAJ@_<&\OY?0RA@V&7M<MK+%__T:F2GJ>?W9<(_U
MX0[;62J%0;=/>D2G1O'WZ)[G<SFYP>"&E< %JV(I%+P2XGC (Y2DH\*1[8GY
M.RO(&R!<)SF1)/UE^ P,3MW5\L"O_1GJ_^?W#_?K$<)'/IX]'A"\Y9-CCH%N
M5F[ZTS>JEX0"1DCK.*+E\.\>>OARZN+W9MM'/QJ5,T@E+\=2*U(/J>TJ",LT
M2_-?.%!6'7-J[2+?+/9_[_9"3S=YK)9UCEOX*^RM_I@P*Q;"QSX8/E65(Y5"
ML T^N^RZ<:>5X2,?@1B/7VEI65F>0^E+&8^\UY8_\+(.#;XH\Q9_4>#:P/$S
M.3YG.M:(;,P0V<4W2Q2'GZ.2@=A<@"9EE=BKF!2R7L*M?0YQ*R,^7D:0-V+S
M#+O:W26C]?XJ7[^!#2Z<@KX,RJP7:45L\<T"=EP'<?#KP;'T'3GQ %&).($3
M:9$D1,$;J*+(#L[A08XF]]%CE/F+3%9'1\LY*#RXO[)9,^OCX4X%Y_5F^6Y/
MK=HP6\$VTQ;3U3M+@!:][]A:Q6[5DR.>D%_*+\)A1'EXG^^,RDN+7TRRZOC\
MLVS7+9<P4>]>[4\S&/F$067/+)FNCVHUVF<>(&;N].140*A-M#PK\XE[MYJ]
M^*L.@5M;U2/'?I5=,MA BXLUQR*B*VB+8C-Q[8[2/<P>5BSS&[D*+K3/<QGD
MF)7-[(Q//)(0-)YI/$MDOGWY*J+0_#0*-3T" "$Y"NIA1'221KU[2 U:<>'C
M#NIT>\X^4[3;"4DNC8SJE]K?=AJS<1/JUG79]DS8UR7DTT=BY@QQQU-N*>C7
M:]:.%2;N<(/%.R=W0L$)%24B&AD><]L'CB=X_CBO<7#CP>Z]'?X"T^9GF_E1
MT(G=^Q-_\3%A%X2?.T/VIXH:]9X/O)(9<W9P^49;3O/]6V\;E8YW&&PXO^_-
M5WZ7^\0!*N1H#=]EX$0)AU&-M)U*,&3BX\(.](=-.!YI,+39?B?EQ,;PM=>#
M)5J-C^Q?9[5B%W,!E>>H)E..C*#;=,RG8ODXH3X/ D8H8@2W,$2/>>S4JS-#
M<?EQ7G8#V?L%ZRY$\0>6 ]-[,&M"S+W1U8?A5H=1QUK8!PL/PXY0$X-!;3TZ
M<>"D@Q=,,^J6LE1R&M^@GR-'R-JDFD/BR'R3Q+ <F3:S"R6$B);43C6SX<T?
M"<%3A1,;/SL\,K#]MOZZUQ7Y?1U[#'9J?M&X"Z_'UBYS9%Y,N;3B5")Q;C5<
M"L$YFCZ_-O#IA,GULP-5P;._2FS->QH_&0D=<)G&JDO=SI8$KI;\(]' %1K]
M(QT)XUL,_YNJ4#OS]UQCQ05UZRGW#B7 4:IM"C=^DW4QU7+X20C6;\*[%2?+
MT:_R-&I^6ZJTI=EAWYO#P8;MO^W<C;L7^2PU.)3'I'_)8W"Y),B-LA9!(5NB
MCI*$4R-*!YAF9K3(1Y)H6\ATG&JD(2)S\;SYSC"!@1[R^/B[]CV)N=^V9N_\
M)I^F=F$'GPLKEEO! \Y1QX41T9ML6RMF(GTDR4(B,M$N8:\ZHR?A%P$K4? U
MMUXK>]?PN)+50]'[;--]7V\<*D[O)[_;S55GE,_E,558S[@W<8A8,'OO.$&C
M?]?=@W2.9H5_Q(>9G7!B5VU G^#+''K&X1]FI0'G#HGDO<LBO.0!6T<' JD0
MVBW'WK*>P3O9APAXN(0>K$,G=U+3+39"+94T4,@K,(MJ7=I#)^O5?:042=RS
MO_!V8YXO7?E5>?8+Q2<C=>#X,B(FSPRB3<<3]Q*[$FD]UUL4" <'F\.G)".<
MF649#_\TE)?K)@SW',D8RD_3VU4XZ6;,2;W6]X:V'@>A#.33-"TQGA!,EQK7
M_J'81,KD.++W$<Q0^5)?G\IZYJG6KL+V;^DYHT)HJ#:SGCXD%Q+E<R.W36RO
M#2+F!YFPAN .YC@K:H1RSE$T\NP,5A FNPV'3X1V1]P>W!4=]Z"^\LZ@1]?F
MSZ?N?#YEH+LQG5E\V3IX:!1L<[!8PW'E%B,*! N(VBXE!@9-?@=5FC7),S>X
M3>*@^I&:CS)!^0MFQ<%9L>-R>2$I3R(?$#\W@ W+L41UPAYN*9JTO<I3W6.X
M^')*/1P/Q1M]"EM@Z*C<SCK;U)A+.+ ]^-R^F8R#T%<KX8="PK,N[./(D!^K
MA)DX*\L.#["0*>PI$+X^U^Q)!Q5@9:620<[^$H<+P5X'8R_[QOI7 >DQ9AX1
M@*"4UO"_E$\M6&XZ<1TRP /D*>=)2F#; 6P@Y;HTQZ2Y!=(KO]:"@?F6'AJ)
MC^]5,VMX^:SI9<'GV\VC54IBI=E.LD&7^+"G _XE;P3^;/EWZ$NI+ J-C/UM
M1]B*$ET)TI]-%9 +(LX/*4Z9>9'G3D %;T:<G@YR^$%ZWWJW4_+4H/*WWZJ?
M6[J&]-Q9&8O8>MS,S=Y[&67X"SQ H[R=Q-KQF@>4*E/$0%HE2H,#@[%V'RV,
M"!N8#J@@CQUO;6S"9C1K7JPP&+<23]S"W>AW/(*OVRZ=UMEL4'N:WX..Y<AY
MTX3RV7J<??#R PZF$<*EF)M$;F8ZQA>]W^W7,JPUN7'[]Z1!I7,R(1%.FU<N
M95N<(HEQ;YD+AD.H%5;0>"=%AH /!ADD)5CX*%,J+61R16GSQZK)92YF(]U-
MW?5H,39RPP7K:'QK'ZQ51&;6MDUBF9ESC<4]9QYS#C,U$RI-$@E['PDJAYV\
MZ*#:5/?0U3#KXA::N(2@QI<;NWD '"8<9Z[.#H[<[PR9Q-3[PCCO4O$)C^.%
MG1>5S@Y-Y?HEKZE-3N$TK(S%1YDOM0I?9%^: 6M[9GT@QQXO,=B#AC/K 54U
MGM<[R$PRHE^DV_WZ;G[,T^#5KQ/'WW\]82FI'G_B:Q*$&;-OQ<F!?G+<+ L1
M]T@O*HZI<'W$Y.0?^:%NO>GA+4V-69NS>@35\]MS7ZGLO\37&QS92"-QY$TQ
MX\Z=F/K<:VS][^Y+]&=%(^W>G6,(:9>[9]*EI^N]/6"6[==PK>::#4)G@T96
M;Z@;9;->P<N0"]UF3AP;%^:)G?+KN'HI^ @HWA&ZKO[Y_DLB\:>.?+<]I#<N
M=&K=@.2;0W)\+]F*A#/,[2_8QSF6L#W;AK . A,1?=<?"LLCDYK0W>K1)S]N
MQ\LIJ>:_<AB>FC^]N*UL+;&*? L\2XW%U)&2P #*>F2,6J\?.VN^M>)G@82I
M0C(]6J?^3EM@I;AYU9M?0H=%TQH8;J_%C..6P@'BZU5J@XJ+3+;B$\KB/I?]
M_UN.FD XC++V^6/H6ICB 5;RO\+_@982M\(_N[  Q9<T'M&Y*NYHI5BI\8X&
M+U-N&<&)D8QL@F\>U+\')[87D.*7[,7%P8:YTY)U>3LMS^)S-[/AE5?LPBG%
MC,7,3_M9*I!^J^.HN,O-SDDMIGQE9BPBV/-HQIZ W[XE:44Q^\V]\[D-#6U5
MGJVC7RT5U2^-O*'4FW#D[M'&.)<&D36K.[J$K:7?1W!K+8PBLWX1C!'EYT6#
MG47K2.U_/BI[SF[5*MCN%;5]4WR.1_)=XG%$A5K=R)&ALL:8V-E!MAG!NQ\;
MK(>C]:411*$1IX$Z+O\)&._#$ T;#][O_*S)N0&Q;!CDQC\))DDGRP>S%(":
MH\)H4VH3;)$I;P43P#JMMGJF->L9HLPMKV>++KUT6#XU8]#S(&"-??X1QS[U
M7Z&_NI_IC]YC$6$V%(&(^] I*L0AK)I-IL6FR!$6<42_?K1NW#GXOC^SY_$G
M#=/+A>*$U_CUNA'8/G4S,^!=*(I( EBT/FQA,T;?W-8JSE%NI2\S(_,,<ZK3
MU+BZF'+MB:[0([*N\O'LH&Y_BTC[#C:INOR7RWQFP4O['NKONU*)6%9PT28>
M,-@;#QSG/FU93VS'U)BD66BN?M<8U51SIC@5ZZF[6$=H+B'K2:09VS_@\O!P
M:/7@D[.'2*\S:/<'7_V6<UC1VYSFLA\UQA&:3R;L_,N]LL[E<-ZINA:#'WEY
M[JXUP]X?U6L''U">%[P?G).NU4T0CTB1X3.3\,'&UB :Z,5.$I6);TCUF$[]
M:[C&N^])T$)'PV4%]_+V/OG>,Q%ZE)2P9=3;PYE7=!XUQ4[MO'U<R,=GTY%+
MWJN?:T3*=GG)<K,Y^QF]+JUYB!S$ S(073BO"Y1JUGKD7AA5!TIY3<S7Q'3P
M %VKHP/7D=GBY6*I)D0"?+4L_!=N8T7V(2O#J.7JGS%+[8Y<H9>Y?]WK^WON
M?L4GBK3ZW9<MM5-DMF(YLB\&J_G]7]Y]MUB(B :@K]>@.#T):O]<\*784FBY
MI-]!J^@O.?T[(\8BXV^[;OSO++ \X)4]2B6J9- FU4QU'ECLQ1\AV0R'?=\^
MM[W4ORHXI,1-/6?]F9R<:Q(BM+@V\J'_XMU#_K?XORAI>_L6TN&/%GO\+Y[R
M.-SO*/MFU.;8_JTK5V)%'E+HJ!XZ!_[1=Y?B(B"RY<5KHC)A=]')(C#QC_J+
M:K^(@1+-Y!G;\=</>$![%>R'HL?\ZC</#V Y#L#J#J.@"DR'0J?Z.N:E_$$Q
M"VU_T\JAC)J%"6ON(SD5]9T&<?DI_*_Y@9LXC%>D6/"^87L5-G5MG\3CDZZ^
M3-4XG4<S(H:G4[@)/"#>$^I#DB=7[_!* N$"+-V%8(CVQH@2D%:*0;;$8#$V
M<>' #J.K GP?P'8'M%9Z'H'TM1_![SN+5^_"6?U'!4L8D8_HP/[1NJ*(B*$K
M@>'_KR8&.$0><-W,B0<4=Z/2-WYO)@]0NX>LF[-!XE#U*<?"<JY03H/_</E,
M^ 15@@=\O_L=!VLG\H#D8JF>>7A_/>:/A#\6=O[$ Y@SV/^(-;_[$G$-F;.5
M)02+#W5[7:9RX^2'BM*#!-_A_/5J#B2?2+#<2(LU$)6OY0&2?6P4V/NO? #G
M4?K -)H _S$C&*BB10E]B]D'"N0DQ0-D+3?H<TRPLZB+UC]1!*#T\8#._O^T
MF49N14ZS[G))1ID*N, K^&Y)H4-;\L+PK*]*Z_E+VLCW_XD@IC9',U9O4W))
MXZA,S2MP]GT(,=)?$^0<V**:QSYH;GU1+Z>K4$%X7C\G=!-_[?60QSHH)B>D
MP+*H'7ZH'6TI8/I55/.(O:"3N+(OQ=&"7(=ZM.M?.0005B,H#VDA*>_1M,?)
MH4H02R]M$4"==/L 0F=)4SCG?R(,&.U C"K6S\'3V\&%89(0<MT@^8RBHA,V
M=^J>Q+3 E8S /LXNEU;2'QU3*43"F1,T@_]'I^_]8U'P3Y,2</4FLS_I\PK6
MCWYBUB^N/^UZUPT94Q%(6ZNXY:4AHD):O9>E= DM+>HT>DI0T[^]7G;CX!!P
M%(.D#J/N@J2_7/@_9YXJ%58>MY+B2T[" APW&EF$$/ A9&FOX\%<<1U\_0KQ
M7&+Q9YKVGVS!:!)GVWP"N'AD49\CM_^OI?>/B>*#N3Q Y/(]%+73A=&7HS'(
M7AO.IK%,KM N#&?K+ @O$5O_-?;\+Q*32842 [&+Z]%DEE?S@*F/8+OJ0Y3%
M>*-ETE[4PP,R76:E_K\T:(@U/2O%/D@0@74@28(\TX0Q'/<@T-OM^9UQT%^#
M^N)JX9'OJ?J[S?V,EO3_"3O;>4!'*/**!RQZU6'8'!ZP:L1G'E"#Y2I6"B,\
M .U'LIXC_ZTST;&*/"#(<93<93+L[(]3WJ4TO/[N.>QY\=A#/9-=%WD U(];
M WY_\AT+[W1DDA]1_FV$R 7_?I7:_/O7UU<2[$^^AET\&8;AK"^'^_\5$/PI
M_+>!>L4/4=:A.7+E[Z)5(;05,=)+G,- RBK???,8D['RFB>]N<5W &+]TC]3
M8_]Y$<^#^EBQL#XS]\_/PS".*7MD^)=NJ<R$];DOMS_<$=K#G\;T3/?[/BD#
ME2=J1G'VTN]:M'WQK-F;<^NBHMKUATKR)?_\I]+RJD-#E>E/\AH;=W9([,PK
M"#BUK?1:=F<1P)_M0 0#L1 .M2^R:MZ529Y%687 $K?88B='%_JZR!IK["*M
M@>VT!K>G29R,VO6EX'@VLOO-4[^C][[N?M6Q3NJ#NTY;)856ABJ4N\NSFBCO
M3^A@+#7S -'*Q8,?RT;.-H1N8S@)CQY>OR X,B82]UH]HF#?,MF,6X!*DJ?@
M6N)N#@&:GOW*=&$=@_L@ETXU\\$J?(M*8Q=%M.,,GA$Y-[7P($%TT[,\GS?6
M^>ZBQD]/7;(%8JY&6\L=Y?N[(3\%-BK.C4)2B.@R%&QAP+GRT6B/=\O0I@&"
M$9VR]D?W\DGFVG)C0J&XBL_&7C,:3>8QH'E[K3__J#8Y 5G]-B7>W/ J\V8[
M18AR'OOIYA1F=DF_4]5V%P\ (C,9OHDR :;U/WG X^KHV^?.!$5H01T;OT"N
M&_AGL UXCEP/?7HVBVG?0:WM26@1)EC#]4QLY]BNL=Y$E.[&_]G@DM?0=/Q8
ME.-#S^:!+OGZYWD[=6I]OJA8FM_@6[R+VEXM-=<%1;,68<=H)I9^)(^AJO!S
M/U/P?1QC7ACNL6,+U=)[W:GXN][1^.?7+ST,P^?D'[H8=^?:[*U_^(@K$FS5
M'W]+C^@ACZ4R>F8CI.+-K>AD58)Z4YUI53YC]^FTP+'P <6&C[/N6W'OZR_&
MV(J]>O=XYOXU2S6Z->$UDX*(74.I.QTW)S7E.!I'7YY%RU6'D9EJH48P3>R:
MW%X-7RQM(YSW?G;;.JA\+JI_\D^XQ27+QZ'KMA\"IJ;)<%+?(=1C,EI2ZHBJ
M(OLL"KF!A+W<9G,M]%\-XVP;MGX?&SO>TL>B&KY:H(1_FPKA 7E[&#'80V@F
MB 9H)BXVFT"AQ^%@VB,*K0A3ETN9<DSV$F]B[B6C;#5R[>354)O:QB;C ?&?
M^\/(L@ECU.U?Q3?+6.VNHK!,T&7?Q1'E/D',WK)U(AMIN"YR++HF"P]==;&%
M;+K)@G<5YMUK#J_<')763=YM*>KSID'^U<GCEXHQ'G__.>(%7+UB3R365VKT
M9Q</J-L[WT%:%UDSTM:D,5:/7*.[GKEY]'G#]9#_IYUS#X>R??O]%)%=8YL0
M4U%(3(6T88:G)(]'4T]%ME,ANYBD&!ESBQ!"2(J'J205FNR3:2;[D!#9QNS2
M1C.9H<;-S-S>V_O/^_NM=1SK6.]_[SJ.]<?UQ_PQQ[4[K^_Y.:_[/*^[+;G.
MN@>,SG[>[JVNFM2C^DCF]4/:+!O+/R4XP#7F-95 HY"&\'4U"3MLN\7VSU?3
MO 2KVA>J.J7!BUOVI)YJ2SMZO.1BS G\#@IHH1Z*EY,H";EL@D1=+'HL'$G!
M; YNV)^9>(75EQ(UPM?_)QHM>^*H^NP"AHC;O]6O\:$_"=$2CYEY2%>29F!9
M-(R!]"7)B?6-K XT6R\C@K_9FG+MCHV=EC@/T5%>0(M=R/K 9(\OM.2?CJ=+
M[NQ3&Y4;?_OF9J*WZ-HR0EX-Q'>(EJ@W,-I \_:5KT@Z8.2186IME^0$BYDT
MO)1Q_8/'>X'WAM(T0<JXL&&CVDU5%00Y;<#WE%B'/ 8?$X  Q(\3^-KBO<3'
M/B[VC&(OKQOH,,^I>=?7UY,*WL_(+3XHWGWXY&?5[FX/C]-+E?_ME$12!BR?
MWX3+B'2Z#M!L  2AM(@&,T'6,BR=BD/]N];=\NG1>L1;^UE-^<.E_5>HT=)<
MS 80Q6+PF@3PCK2Z[I\:<1 L)-3VZ&\W.[E*>==XQP-PQFMV_4Q[ZCZC@G[I
M0_(:(E)4#*IP46,CG*1'N<38#DB/-G#E2E)\]IF720\#;]Z*>MO48.:7?"S6
M?7HV"X:-Q%1(AMQ+1DD3(77R^WRRL="F57JT YD"U.(2,)N"Z@NBFDH]9315
M0PO./\G:A K<;GPJ8+=MR/'W2D=6?:,(<-BQ,A;0CAMW$7&E:?1-X#JF)^AS
MGSS@:9Q>2T#JW7M05__Q.:_RMVG"6I\]CZ(O'H+<HOS//)5-^PY9$9>8D"),
MAFO\P%."$Z(XI2>@L>B$,& D#4(3ET;#Z]+;S /,*[-2*DLWNERD7\[Y]&S:
M[Y1BVWX>E4)7(:'APU)%,EFI]8,&&/)T)7*OP2YLW4(F9/8I!%"U];GR]/MX
M>/Z3YY6&R4._5/[@</;Z)^CI!22I[NX)LVJN7[TGZP+\YP"0 BD:BRV"?!'2
MS%\4<-/?)%/0+Y1XBYC8J2+^"XP]W5B/[NUX&BFKNF-D9%UK)'_SW5O:BL_N
MR_RZ^K]>U=)EI245YF03H+F543,2+[FR^E,0M!I$<K*T0=]AUGDT_^GLIA<Q
M?Q3K'FJ8QIW"[FS^0A=3;\'>I Q?-<+7$*([F,K8<-3H^5E'E"ZDP&3NR7I
MS(R4*^),KE_:FK:,<'IY&W@6>-(IV6W1[]9&_N2733)8%AV[3H(2HB %&>$4
MLT,57E)UK$P?-6C!:3IG\'A5P*NZ.\8;2Q:KMB<\VKA/?T-B(XNP@=S#7,4(
M#+.!%+O$1[O*B('MNI0W_%68343N<5IAK$>%PN7Z=+5+2;V]K=>/Y+[+<=8Z
MS#GI_M68/WT?:+[*"(^A^05RL:,E'.,$#.+'BZ P(8%MA;$3B!K*?2<\?"9>
M?S;0#0U("YMK5XAVUK]SWD+[CAIJI=8K 41!BI9B1_(87@&S36*YDJ,> N@
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MJ@K_)@P0W9(^H)TU2&=GK9N(R3\1QK1^5Q'5'B;K=Z\LK_OAX7WGS_;[9Q4
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M7Y?/1P7/I^1-2POU;!]/,@[D;\!,_@^HL/[_[?_%AEH>^P]02P,$%     @
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M?Z39_Z?8/^LU#L@("V'.$Y8'0(#/*TTW OYG_,_X#PQA!@'9&L%)1SYQ305
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MXPHH)P BS4<5.;D[:5_=F63M!,-#,OM<*:.^>^_KSF?5?4I[PRPT?23T@E(
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MTPQ\\OA(9HLVDNVW.W)GI/W\A'OV_)"";^X7T_U.%E<:?G^2[7+->7Y3"++
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M#X./8YJGQDJ76!X<DOEM:1LY8]R;X;?-U1MOVKD!H9V^\&Q)Y:S&3AX%FQ*
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M^P%FY8NR RY!.[.IZ57X+'^,!N A1AJY)KN1;8-*1G(/0FV*+6L3)IMLI\A
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M>UVTCUHO]A##2DE^ Q29%3+=WR5-65TB[3@T9Z4_&&D5H<*DG3:MCCK3^'M
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MX]V!)]OVO+UD7O1KI N5@4=HD.C*;1^[D+O\&N>1VL8LV\,U"S=!^_&$<>,
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MFP%>J1, ,A'U4UINOST=W+^=L3$H,,^L>M?W5HL7F8\?">V7Z",N82=<>3-
MC]1-AMWQXM]9S.C+_EI#34&5W\=OM+#/]]6.V(COR=]7%*&A9+/?]9/IYJYQ
MPWE.VDTAO1\GY81XOWA!L U/T;R+^L2F$Y<!BA"WW_GVO"^[>K_BE-D118*[
M2^]J%:.0DL>_F3<_W7?P@K&>4>=9DI([!1'G\/@EO#!V ZTHBFR> 8;T;@D<
MBLN*^F!4\-7WJ$*AHJN.]UT=Y^O7'D9?WVW1ZC57@44=@TY ]$$:?1PKT>$Y
M:FBWNG5WNN&[*V7G(U7*$U<7)B5HQ)=L)FNVC^_L6]CV!\?EC)]WC>(WL![B
M*71PI/C4)O$*WG9^!34D$N]=.["A[W5._-W:HLA/F9D M'[J;=DU/>!VF7Y9
MY/Z#U_<#H##$R-LFT[(-J>"Z$ DP^K"\)8/".UP2V]M3]S TCZ&_%!.5V:,[
MYU>X2:LW=V%U! M"'.OPOV1"0>0 5@_8W_FN_!+PN  8,^>X(T[E1&E$&%;M
M>"Y^)3;V>,B)>MVIW<&V-UV#BXDU+K2//7J6VEM;E=]#?Q]A0&)(!V7"F7/X
M30L^U$?[(;MW1_KW_MUU*9_-:U7&='<]Z-"1.[5CC4CZF "X\F7E68:OS:'@
MTK( 0(I^4)E>1$LL5>)O0XQ2/&J0@QRBRV!'E'PE($:I B#MUFK5?Y%.H?]9
M"T6\M(OA[D7[B[HSS.NVVTR+7=17='MNPSV3F2GTAC$R /Y]\CC_BW3M!>&W
MA%70UT=?0623![L,53=A>/"52\0%@)@Q:OW3YN]FO!4 4HU,,E^Q61H#0CG,
M#59"\_T\*Z]6\B^3;3A4Y@!O1;UT!&M;G$)V8#9.A[+.N__+6?_2#\0: 2"K
MC&%L^NN+ N"BD@!0!YFE+2*8 D?>0/ )\C3AP+^8]:_4!SN>!<930PBXA&HS
M#V^D^U;'*MKW?LZ;4?UCIYY9?R/#[S'F"O)5*\51 0!B4_Q&_@$EVP5 1PSZ
M0@ L^M?BN3P!L'+N_ZR53M%KJ:Q(KC5Q!R(^U2^:X#B]]V+\_>_GK)X<\3U/
MZ5W0WR[V1<CYW343[(3_9J#@NN?^+E% YNIWT-=-6-@P/0($0/=#CCBJ'-\!
M_C(\IXI*K?VGD+SL!_>C:1\N8Q7K*H04 3P2AL*VGEC?W(6YX_)VK$)HEZ%R
M+&?THCH.5>* O'/48]!_IS24!O 8-&[)<&XC)$<P*&E4E5HMRP/J?:\^3W!W
M&/ G9L?C=QU);)O>2KG_;\OY7YFG_V<+X201*M>'U$<R;JDNWHF\O?7Z"6UF
M+??8487=]AR3G/_F+#/%HMB)*(EI4(.IR>@$NW*04,H%</%P+)ZG5H&,O*/_
MNZO/_9,@9JKD-W1'*ZK*HMS]]35XE@A#^"?EWO]%_\E0KT"UJFU09L.(3PB6
MJU>+SC:<#I(K^&YBJ-]UB;'IA69(^FP$N!LNO&RWU:2?.2?SC8/39>7./BJ[
M^G1QG<.+2JF_7-7]A\:]'X\K3T8&-C<_RU8[GMDTN(=Y2$FF0!\&-/,B%KA8
MN*=@4A_HC#_7G04%]2.&%)80.X<9DFI>43_48HJHMGO:WX@]=J*FIT)_X$XA
MN^O0Q6V7\<9=N]6222EO_64CL3@PYV?.48\;4QEW-N-5*[\@[M&EF\LW-"K7
MW/!2N&K_\ECW'QM:WNS2=M5H&E!M3J3/CF!S+B(Q[.[I+ZE@B'DZM;JP"TII
MT6%_+HDY#T^VF"%[-:0AQ>YH?(G51E=96N.&_:8OW[C6I4SGN8@(SXS_"\Y)
MT> _I4;U)T.P!_5B&+MP>OCV_5XMSOW5^4R*+!*_U^9YP]6XK34?1[TGC,7"
MZ.+ ]7U"IJTQ#MH]3D0;. >53F06SV7>5$:LN<=1&EE- (3<)^E\=ZU A&F0
MHM66?-<A"H%_*.-]AYZT[S/PRAIQPY16!MZ37P,Q[H(X,# GW5^;?]/.&K:=
M,N^DI*$&;^\.G[3'\\S?3#4UUPV4YK\\OY/UN<"HLO+5LS2_8G.=<:&/R;@[
M7S'!KT)1YA?I#17M2?0T++MBJ7)?&WSP5S?$XE43P*YM7J/6Y-7APUSBC,;$
M^5=ZUQW+B(]>.F9J?L0%_MW--9,.5(CT@2#=LIWTCJ "!CPE&D_A9!-FF%I#
MMX=B^^4[1 (.#SZ^UEQ?<>+M'C3N8>8JE\.[@[P.Z4L!2U(FGSVR5EY"P6$!
M*B4 0B%UTBL\CHJE:!I!B7@$7F"^L]_ CLOIR%*1G@[0HK6;^($1K[.7!N\O
MY(D>^./"&0=Q_':(MON<,\\,0CSQ\%?JA"JJ>( YQV(R0>10/7T<'"-!8^@D
M!ZI?ONE<PJ78:,3SGO4K"?W:X42T9!>BTEE,ZL6BBHYHT14>#?/OU*V\S[('
M]AM)8Y'P"4FM9Q=FBK:7-+^MOT;PT2A/^'/S\'*\T1&Y/,G.N)6O\>"IF#,\
M6"'L#X0QWT[J*M2,J(K\.>[X_;E'BKUU@NG7AG-#>2&O;KY("W1M!]PV''KR
M>&=UV77@UX>_M6(*_UZ+;1MW(ZG?WYQ_>XZDB5SL+&B1?6LP1%G$277(%%WN
MJ]6+[5(J<GD[IH=;NY]Q[=(&[\LZ6BSE+Q!6J\(I%^AKP*!)/*<;)F>Q\IEH
M%5-^ZM"(>:!\>7ER<I^)1X]\[9['^OO/9&E<?%FT'(C5OU/Y/H@-@Y"#EX88
MA?0ZF^RFK6QI]V?O8C4H8D3;>FKH[/2S!-VB4X70LX7VQ+<F6GV*>@PQ):&E
M0\HP838,RR8FO,3JF +%'>%\5)+"]=C!]%CS_<K+[JF]Y?"O"51^9E^-G46_
M]4>;,^L[-:M>9+=N'MXM$JC^I1:';,EI1VT:AH@[X$94THOKE]#?4;2[[OQ=
MCRFR&&]#P[N3!GFOXU,8G:9>E^Q'LIXR,H\EAPHO'DZ?IXSV<OH186X23VP0
M"J6.=71:?/<1Y<V/O]^1%#Z\5!0YJV\Z'+_/ID^&G6=1H7/E\/Z7+[N'0O_=
M7PSS,1HQ=\[A^<&]J,0"UP%YV+IT8,<]/-!WPN#"U=B4']Z5AL><=:X&Y^<.
M5B919V_ W5B3)RH @NBID"2J'C;,>8Y+;5*^Z_W-T^>6Q/'L86M<]WYZ0L-A
M4]<>_>%4EB)LT@K5+K5&JZ&OJ4IF^L4='VS@R<\9#Q^9BF2(TLP4[0(OUCM-
M/O/5M+@X3C4GGL?S-#U@#4X$+ !F\7 ^)[:1#::UX+^?W4BTY9<2Y=G"3K6#
M=9/KWZC=NGATT'I7(L#=ZKGMH7'N]/[L4SX.N%U8S4U$^T!A=#UI@-" GSW$
M%F\]^VNDG27,27]KYU>6D/"^3[:ROC(^*/K^;W([O]7I-:88SM?4Z(FZZ'MA
M#+I[&$O5_2!B@F^GI)!KOOHYMX'5Y(P-35[LI.[ACKA'_FLCC"-/$K='&DWY
M7EZX4_#)RT3]WN&U(T%$/AS!A'C*&4QGGJ(')PO9#OMR0MEI?$I3/-M_^@!R
M86JFTF/O8&RS4UR8YN:*6^&JJO(=^G*C$Z9&%PI\P^[*/I&O30K!.D8:)H(G
M.!:S$Q:?C;^#!?&J?*9'AX8O[2)->TOT>$C'>&=?%2G*VNT/G0O!+4_/:I##
M9&C)3P\= O!E?__R*<856%K'(]B.Z&HM_LTF\>E[*M/.L&HKI)1 ;><T"&^"
M(CT212^^5(('UE'7G[N_? 5GO31)Q$J5Z#9^-C64G$;:C!SGGD([;,X9(2/P
M7G2Y]KPT+>8/JSF5KPUO3;U^;:>5\0]L*[6S:.C53/X2-;<)P&B#*!N)Q]KZ
MJRO?(H3/YJ ;4T D%]$^G^3\'#0M*,K*,!MZ5+7E$[XO[:"R#O/%5YI6OW!"
M!\<?D>7:AE'APQ[C9]UM.^R-WJ'BH9)LX6[UK(\3XWW'W,IKO3-^WQ 5I:F[
MZV9@GLL#&X52ZE8PVDP8E1[BQO1-:X!KT$Z\O)T\+.YWT3$Z Y*\S9Y+K6OV
MX8R__#$YIP,/^IH>B"XP<GON,ENSZ533DZN_YGA*JJTK%B>/FW!>(JYL&R:9
MIY!Q .GE;B5NAX/)CQ$;9E<=VW<7G&F)%"4<WM7X;G;.W_7HV,YVD;J\=0>O
M!T:^*K^>;)^.Q=Y&GBU2\S@45 .CP<R;(HWP^3G66K8.0NEHD:;F! WGWW(,
M4[Y;%'7M5.&!':HENMDW3X2(ZYRG^&MP<;Q$?BUJB\3[OZ.>% "C&JC2AML5
M'SI44N]"[8.#Q /\2FF]-08+IIXJLIFK6,2"R=R!YI=_B]8\%B;#^U#[]?R,
MIA &N/*R0"L=E\&*88RBK4C5K8XS.O9&\"'>C.8U2\T?>>/?7;Y<E4_V^^/+
M,>5?ZP@;L% +@T((F>2Z"IX"=VIIEL6U1VQ1!=R:A+(=#0UO:B&6=))'[<N&
MX8'JY08+9X7C>C&%<9H!]U<EK\?FZE(#J1IH/[ZF4P!TF8]+A4:W6/*BANE=
M D"ESF5Y?NYQ8:SZR1!#%<X^I89=(K=,UOIK-_VD?@K^* !JY*/Y[BHMD_#E
MK.%"YG;SWUHR>F].[$TQSC]EZQ>P;[>S>.YXBW_T6/'T:4S%;Q16MAW&GE7>
MDWJR&%AU9IE$+\N2%3/FJL^37RT(@.G1Q)LAA9^@U7RZ&7"*K"H /IW ^#*!
M<]+>4  ,UI7OPU;Y^(U#4D'2N&K$6)AG@LN(C9[0:"\2NP')T?HJPGMBQ&Z'
M5HX$OMU=G+I3=\T#"-Y'%X+:'.W5H39/TAK2>VI5X2Q^Y46Y/6_L<=]1E>%8
M*O+_M'.M\4S^[W^%Y-0<$EI:.41)^Y:B,EN'KTJEI;Y%#JVHD%@'9:+=22R&
ME0Z2LHKHQ)P5VLPAE5,H&<UL*X6->_%=-]MN_]OOP?_W??C[/?\]^#S9Z[7=
MU^?SNJ[W]7[?^UQOWX6D1%KKF2A@_G#_\7$G@O$JAI%V5+_FD2]0%(CHHYD)
M=F-U,6P&=V!!+RR_LIZH05NH,OQ<B'<7X1*FHM)D*H]G(QQKJB\FK+GZQ0%#
M&^</[39'+W#&KYBOMI\UM?2?MR@][YD76H78)058[JS:^.T/O.'FX>6?]FJ+
MF<G$XT OII98'HQ4X(  2]_G$02BQ=QD:X@5)-8+V-J<53^-0O=&VW2K-NC&
M5Q&=]J7I4:^U65??N&^T%-%?(I8!%>#1,%TJ2Y'CPC[/SK(L\Y<3K1O;EBYR
MKI OV2%V7[1BA?U>;13*X3O7%&X18LIQD&/[56)8,TYS#(IZ K?VYB>P:[:J
MGYS"%_B&G]2[*ZN)M\OF)UC4\"Q2@K3B:MDOGVJ(L)!S#+SW-DB&JZA9TZA]
MX0<S8(/.:=2MR*\ /U#.A5FC(]4SUEHTY!'<H';(EEN/Y;<K4D&2RIJS!AP?
MH?MT<,L*"F'DLW-[J^B_*TH\3$83J:SOYU)[UA_9-(E1+/P"#+SF@B3AE8M<
M*6^ #%DULE+"N2*"?%Y!+O3#2_U8Y794\P9Y^)Q@VZ]#R]/W/B])B5L2E)9,
M?8B><:P*'5( :&"@"*@4\MKG;*GHMV V+)XMWQ+:+3GEW,MY\9BTZM$J;<P/
M:LYMYKZ+"C;7X3L.LJ5(O>4O%"? I@9B&JN\*2DR@"SQ;D);5";!5IZBUA^D
M+E,K0Y\AYY?3J+77>VN=$T_=K]8OFL7\7/9?WBV.10I"*V+F<C>;SST 68!L
MQ1*ZJ$<.O$4G%8C.5T.91V,(#TZQCF8/;% N>F;UH"-H"5%[]/=#=/%/=@I!
M XJ!Y^E@YY?]K<[C6-/>Q_,\*1>J7D#6?\HQPV?>A1]?T&[\M:I!%+%;?[BE
M.F>>QIPEJ11HF;=J/JD16Q95*[QV 5OAR:2K3.7! Z2D<DNT9$_&D<,&&QLV
M#WK.R4??'QTY[O9\,LEZM6;C<LVG<RX37C_FKJ]9_:^@B]8)>TY,HQ2?NVBS
M?GI_P9IS5OM2714DT+.QH/5^QAWO#,^PH&=A^S/-'^_ZWGKVX-J4N3F;,,9)
M9E60I=(?X+D39M.^ FAN$!9:;L"LNT3KDQ#H+P6Q&^2L.C_'+:WAYSU7"2+&
MUO95Q_"/.6+YF=G+/STC'-+/O5FD,;K185Q7">L2D4BH4(YR(]0,ZT8I754V
MT#JD/^I\#3.;PM6WF^;E9:^0N] CGPTF_U();*[H;1"$YZ>;[]Z-0KEDWL9-
M.8(D<5,"[!9K 3*;B)H6W.+84!'#(&J'<HO636GE'?E7]U>S3_?9^#-]44,_
M_RD?V:V)ZA? 0"50]D66*?\]()2Z/X=;IDCQ\#QJ?]>F!(Y=R-30IU6[NPT%
MVKCC#ML&HE.<REU/7T0HBLQT9L F$#A"Y,\6*MCJ%V7 %8(3HXYL['@<8N6J
M5G2</U=:^^NED6?4R8A!;[^1Z)3"VIR&HT>:*'<:+M.N>I'M -XVXL"CJA^U
M%/Y(K0M07)X7+P&2B9;GU2[N$#;O<$8&Z9/O3YM?)_=/[BD\];#,T?5=[JPJ
M_&V#&V]CCZB?<@?RL.;$,)(AC-"5HO.5=0_6_!81XR,#MHHK&]A)5:MR;!^,
M%CRM^]7G$]I]L'3.7R&BT&,WOMT,?&<R9K\&=0F1APPE%H'22.Q"N)%#5.<
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M)H,LJN^/;7 _W*H,[L%_;\KZ%GTC^A4\^G?[TT*):'L<5^03ZPA^J2?)2)5
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M8>;V;6/]W.M/[K=,LAFQK9\\T_CFFVM<K[W&3R:TC"P]\ RNXY9,8 WPYR0
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M^-^=99-?7_$4P__YO\S_6_];_UC3_/\#4$L#!!0    (  Z#0U26)8H(K>
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MV/:V8712[9CKP+%?M!K;W"08KA(2$!IR9O+4!$0<28A-HDHBHX#'F >>[W3
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M[,D-S9>[@P+\L /C3U4UQQH/L ,$&$1 #<D5J!IZN9FC,[]T=O;M<E^EB9?
M!;Q%XQGI+S.+HUK],ZLPZS;B9:;G^;[DA:08D&F>9V++RP\I9>DZ+1\_T&_%
M-BV+7<XY]IDIF@-5(GR(I.20$#_0BZNOL @Q0J%5Z?3^H9:VU6FD!7MQP4Y>
MAZ3K;G#[]SCC038QPY]'JS\)VQ4VAZSUT>";*W_] AC=<MFMD.G*:N]^P'SY
M[5:*/,ETM[MCX&8GN[O+-E_*C/_VR]8\KW$N%)]HG>R@>;]R+K])"[[.3*FY
MXIKI=8!J*S)*?,]3(H#*]TU1'Z0@B\,01MP+D5!,\=AW.7V^1)BET7&M2],M
MZ:KJ(I]M2W!/<_!@5/FSX_[@DGFRM/9G0G]JV[T&OM+C"M2:[/VPQB2GNWX7
MQGJO@U9:&H%?=SJ->$X^!K3C&M27"#2O>3P"=$?&[AC/',:W;Z22>2[%5_I]
M-\B.V%/9C@GS0AZ&+(J@AT,$D0@]4PO:TQ,J/3_@H<#$J0*T[<!+X]&=W""M
M*QR7]+O^2,VGFU6?[OJ@A!NC6L^$'7M.@>_$3+F'5LO<(L.6V-.$\;E"-2KS
M60\^*\NY0O*<T9SO=]]XOU[3HKCF9C_Q;'_CRTBIP+!4'"4041I 1A(?^L2/
MDD3S6&Q?Y^WL*$OCI4I04$MZR=[Q/*S]N^U1P)K:')L<)_OM]2AXS;2S'HB;
MTZ:Z%X^._?3Y>V?;2O>*W]Y%]U\\<Z&?X\(#FKG??K]/\^H)Q;ZEK0H4\R7F
M4&)!(#+%PK$B4A,M05Y$*!>8S=G1V%9PJX]J_E;&'<5ZYFUM;/T"V!F@RYC/
MWTUMG5/5<ZI7HJ7YHGH8NT[3,DKA6$O]^ZARXSH)HQ6P<1YXV&JF]P^O]38B
M+5_3/'_4[&C&_I!NY/M2WA4K'PGLA\)TFPD$1,IC$/LX@$E(. IEHNU]YG(H
MT3W<TDS^IL?25W,"X;9&],!J1_#C@34Q.YOCA%I2T!85_&J$!96T(YZMVL$R
M*AOV##DKE=FI_YR'+.\:>,:9%O=90=<_Y]GVOMB' 9C#U&Q3IINM%$V.A":N
MPQ'K5_F]?*55^VV%>,01PP3&0>A!E"@*&?$(E!$C"GDJB(55LXBQ!%H:$>WT
M ;5"[5"BMD[@H-15R\7A>$QZZ61:'I_..$53'ZM>-#O@5Z,3J)0:D27'PG?<
ML]A+A9KWC'8D"(_.;L=Z[L"F9?O6\%*8%J?-J1J+!0GC*(2!BJ.Z.@P+F82^
M\N, !S+$S*K@8/<P2V/60X54T,CIV';L-)AV''@Y1!,SVS$Z(QY(VJ$P;A>P
MTT/-V^FK4]VC;E[=5[O7=GO3G&:_T[Q"U_\I:?Y._Z1881)AK.(81G[D:Q/,
M1Y!I$H HCC%5 4MPG-C6=SLSQM*^_9V8H)83&$%!):E]H;=S<'83P$@@36W7
MN./C5/6M!X%!E=_./7.VZF\]2K4KP/5=ZNZRK8-;,E4EG5Z7&OJ-?"Q^EAMM
M3:Q5JN^Z63>^D!6F'B=<8.C+@$/$2029BCT8A(((261$[#J..XZ[-!)HQ8L9
MX<%>>M"(#VKYP=HYN-IE-OI]OQ-A/#&'+ 1>>Y?Q1##/Y$0>#VXGO_( T#H\
MS2Y/F\WW/$#%MC=ZR.T#0G;TA:G>,CZ8;%GC-*C[@Z]"&B6))ST8(6Z,N\2'
M1*( LD01$D21\+%5Y<^.,9;&Z[68H"6G8^_X+CS[V7H$E"9FYDD!<@C1N1RH
MN0)T!@#F%IW3#457;,Z9.^>+S.D6_4E<3L^EPPZU6JVMWV6Y3&\VKZL 2/YX
M+?YK6Y3F_=B?M'TRO:^SC:;A/&7;JE;3U\S$3&:;4FMLR/C]1I.4EK YSR%>
MR 7A <1A;(QE'$*2H B&4>!K*SJ,1$Q<#L>F%7=I7-RH"'8Z@J\YW13K)H)C
MK["CCW7B*;<[PEO.1$Z\7+04!4?S>="UY?MHM 5M=4&9@:<*@YW&$YPLSC,Y
MHYY03BSRK">=\\#__,1TIE$'!H]N62'_L=4BO'W0?YAJZHW%Y+/$1Y[$D'N<
M:!,]9)#&BND%1T281I$4H=7Y:^](2UL<#H*"2M*FQ+R3*=H/KQV;CP+:Q$0\
M$"_WN,4^+,:--SP[VKQQ@GU*'\7W]=XPC"@^I&5Z4QE(7V19KJM0P;??30"A
M7"$2*,&9@(F'30W0!$&*35]R'L4Q0F'"?:<L[(ZQED86!U'!0=8KT$CK1A9=
M$-O1Q4C 34P8 S%S)@P+-$:EC*[Q9B4-"\6?TX;-+0,WPG?&I/GOZMD?E39>
M]*N0:K.F[A6PBF1$.%(QC#$5$)$D@,2G"?2],!2^3Z+$K7YP]W!+HX^VM.:0
M/-W+.ZBY1P_6ECO(T1"<>@?X#+R#J$T/D!$W;E:8C+OQZAYRWHV3E?I'&Q^[
MNR[M#?*DZ5#3;>C5HS%\/BK3@^@0""H3' 2*:ZZ1U:%9:(H0:^I!5 9)S*4G
M$Z=^8P-D6!H!M?M$F-S$!U-!Z;.LCU7*K)V*;SZJC*?5;TPQ&?!$Z3ISZ>Y^
MG3U*4VC>M"[6[];0SA_VDVJYD9IVJJ;>8K5FZ2GJC0(FU:S:=ND+C!)-PPXP
M223O!5A.U*7#7HX7ZL?A#-3YSAONCQJXX<LV-U]E?O=&,M/&[36]3TWQ7%-7
M\2-;-\9BL<(L2$B8"$ABI2 *PQC2Q N@B%E(N%0HB9PXU6[8I=&HD1KJ@>Y
M=A#R"JQE48"F\ 6XKX_V'/>$=K.@**41T5\)\J(0(D05U$N=\0Z%/J,^]04*
MW5J>C#\/\_0^.<R$D;Q:E2JAP4'J26; <H,^.JI3[]4O@--]P^Z$SKA[=[NA
MY]W&.\%QM*-WNWM(;"=?2YI_RB5/"_VLOTJZ+F^_Z/4HY7)7&B4F.(J]Q(-8
M),JPDP]II/?X?LAH&(E$QI%5XSW; 9>V,#0R@[W0H)8:[,0>4(C&"OAN/IH"
MSHF9Z,60= G5'!?1V6(T+T;6,3C3'J;.J$R+Q\P8CFFOU-,X3(?[!I[ ;LI4
MI.NMWMW++U*;H]5V_NUWXW*6XIU6PY2"V);-0<U;FF_TUL+45*\J05S?9=M-
MN9*^\$2 .8QPK$U,AGQ(L,!577."@MCGGE-*]"A2+8WN/V6E_EY3NEX_@IUR
M0.Y.10I3[Q-DN[HO^:%O0U7W!VPWIL*6L;'N9:ZR_,Z<H#SY77E+2_!-YJ9T
M[ &^X:6#QGDU+,^5YY[PJ8^?VS-P4 CL- *&($!+)W,XL]/*5/6IBP-=@5JS
M$0^KQP1ZW#/M422;]^A[3#"/3LA'??C,Y>-,^XWR\?W&'$=5T9)5T<^OMW33
ME KZ63^BW-<%^@^9WMQJKKLV)\,WLOKE&UK*?4+IBDCALR1((/>#&"*>1)#$
MGH328Q$.9(!E$CL=SR]%LZ6M4I6$3<6Y;5&M-O7R,5?AN=%?'4LGP%+D7= J
M-D(ANQH=T(*GJ>.LK97-H<Q=C=&AHMT5V.$$&J#J2X"!"APR_1=0^6ZJ^5]&
MA;S1M?M]5-*;:E)'J[@WF8###(5=O^!KKN4JTDH)TZF:40][7%+H^R&%B&()
M:2 (9$E$?"J8%)[5$5_/.$M;1'=B@I:<@_J G\/5;DT; :V)5Y@A0#E3>P\,
MHQ+MN;%FI;T>A9^34-_EPQO5OEMGWY[6&O(\'VM+WH=," 61+P+(."$PB*7^
MA6 QP]*I*=.I499&!U7G32.E?6$B!TCMN.!BH"9F@@$8#>HU>A:#T5N"'H\T
M>^?.L\J>:K!Y_N)A!% 7I*UJ"%26#%V;(\LOMU(:G^.U$!73T'6KC=&K1Z=R
M<]52F/ PQ%QBJ) 70N0% M+$IS"*O)!(Q7S?=\IVG4?LI5'4T[*0X!=]Z2"#
M9:9)M^.\Y4WEQ"0Z8!:=271>4$=EY9E$GY7FYYV.Y^O&S*,/*#*C%[;/DIOV
M*JE*I?B:51'F?Y5KDW#[A:[E*O:Q+Q,OAB$W"TA"$DABE,"8,"XC_40OMJ\W
MTSO<THB_LKO:(M>NJ3K#!-QJP4T;$J"GRS)>VQ+U_AB4<;&<PWQ] F.9U9DF
MX*\[#+^,C:%#X9I1L9RKALVEF+H5M+&&J*NV3?]#YBMS8ZW0DXHW]G<-[3&:
MIP_4>#5;IY>_9.4;6:0W&Y-!<ETTVY#6!3_3=/,A*XI?9+F**,7<,#2.H@"B
M0"208NQ#$7D\X'Z@?^*4%GBQ1$OC](-"3QPO6B5PT$E3_'ZKW;KJ"AC%P ]&
MM3]= :V=:^/22Z?7SK:?==*F-MOGF:\!K5!'PGCD'JF72C5S\]210#SNJCK6
M@R<*#BG..:^J/TQ6DMXC?-)?@MFG[HH_LC QY [U1Q-!Q"2!S),"^@F/$J)8
M0&.G2,(IA%P:W5>27E2)9HJ9'"GL8N+YF9C97:9F_)"%"[";-_I@B*#+"B2X
M &KGF(!+QAI&]7I#H'%*UVD3;-@<SVQN/N692DNSGIB Q"_RII+O:_8ZVQ39
M.A55VU23;;R*$U]Y$E$H0Q5"1#P$B2?TVQ)X$@LL:> YE0R[7*2ET?A3C4Q
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M!&A19#RM%@^C8>4FIG?9MEY=-)D9CYF9+J.[_F[U&E*U!C >8WUMFH/"E(X
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M^Z%P#4A+ZL;B@K2D,P^>.2VI6[WCM*2>ZX?70#--+^CZ$[V7^2Z$.!8!292
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M"!_UQK2D50+P,P_"9VG<YZ9H>+:I)-W2M8D,"U9^@KPP]B(8*9-&F<@0XCC
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M9GZ;/U8%V>O\P14)?!ZKD$$N)(4HB"C$04!ADG#,,:$$)59)+1UC+&VA:+H
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M7FOP=4H-=KC>6F.PZYU^-%+MQ=>5Z!>8"*H03P#3F2V+S&+ ,\Q BG--299
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MT_?2R%-3XU!4>Q1]W'=0Y51TY-5!NZJ:OL;8:PV+<-#Y(Y!IDTX-8>$\9_W
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M BJ40"I-S&-&+\)) BC/4A!CF#(S=AF37D69K[8RM^%[8F1DK>RENG,=4;?
M8S!.(P]G?XB\(X9."()&!-=;FG3&[W3V?$;O?KC?\#]3YOEU_9T5JP4B*=()
MYP#%0@!$H  TC15@2J0ZE[%(A=>2YVHK<QO^YPI2T=\K.SV'_W5$W8;_8)S&
MGLV](?(>_IT0!!W^UUN:=/AW.GL^_+L?'J :_WZ[?5;RUXI6*O'M<FEP_0K>
M@L($)X1G@*1, D0)!CQCF8D-$@DIA8QBK[RJ'C;,C3KJA73EQ%V]KKZ[?OWV
M<(/Q+F+:6-?<L7WVW@'IT7F.^Q_C=LG8NQ]C]T8_*>I^>(;7G?:T8WJ1Z7Y
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M/Y#C_QAXC>G0IZ,&5C,BI[9U9^W$E<5G=/#CU>.G.<5-_ROBI<!QTD#"/=Q
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M_Q4F=Y']#9?/_]_GE8I@7/U-F4SZI&QWJN6+'P%>Z;L\22'+! 0QU#E F''
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MTM\#U@KB;0=87VC&/IR&H1+D_>H2/<KYU3K@9+ZO+G&:KJ_.YR(JG"M5.C7
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M0Q-TL7Q3]-X7S=<I3';Q?%/(YD7T[8<C+Z;E%ZT>EOJC.1RG3CD)!FE34*)
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M_]?E/V0O98DZ C?*@4)1P.EH@%O//!JTP8O_^^,_1)L<]X&!P9A!,9\@R!1
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M1/\X.(6?G4#B+2ZGB_SS/+^BFWC"E2\L,@,9I0!EA:>;5#)(7GKG1 A!JT$
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M'=<.@DV$U0$(=["K>+H>T!C(P3E0JM3+H>8B>IZEULK&T&8TV(GQVW/8:.V
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M0/]][Z&FYCT80QH<A#&2]H,) F?D.]N,7OE@E&M3P?L]RKK)%#E+[OCIPND
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MP(GLG6-92=/&\-R?QG$S,,YL>#827;\1I%^F\S!/CS.2.<&M)49RH>N\-SJ
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M ]35F4#%M$O((+#:2)71.70B6'+)(^.^F&CO3Q+<#U)CJK*!!+9+_$=PKS<
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MZ\"]*!!\[=0E"9F<*?*>0IOA."W5W/OT"?/EC*[X)\[-R\5J?:L&!K/F'ET
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MT%YRN8;'S.)\ NP?G]\V]WNXN'XD4P&EKB\=/DJQ';L3HF" H="F>2++NLW
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M"H]YI]V$_7DEC82YLZ^R#V=[B4P6+SX06^K#\+4.9:&38!:LJTT(WAAB#"_
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M@AU&;X<EZ4U1.*3X^@7IK3_P!T[#Y7*"BQ?3_-N4OI<"W]5Z.<P7G"7EBXU
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MZO530%!66AG \<#)2_&VQGN"*&<A1H'(36L>=- 7<"H4;8^8]Y=&!XF9ZP$
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MKL?>6!^,D[>&0NI$;,A1$QMD+:K/!B$E"G R%W5Q:QLC=!SA79FF?;"T?3M
M>P&>C\$:8!O #A_:R(B=9!/  PA*;>UJTS(B"5\Q5!!S9A!"=)&CU%ZV*:]N
M9<Y65_;+KS_5JH]UBT@N%B6Y_"PD"\J*#(Y9#T68;*.5MJ@V#N(C1'5EAO;!
MP'8S=!SC.T@\W0YQOF9/-:.SZ>IENKZ3!.Y8\9YL=7;DX%%H"M')!$5&41(&
M%1J%&8^2-2Z.!A/^=V[W4)+H %8/SK!^ 7%":J?K@-Q8$Q]!TB&PU$UKV6JI
M$V;9)EF_D9R1832<N&=#\[X# +V?K[)J7U<Z=O/0Q8OU0@2PUC)0]2DM*JO
M*.>2S%B8;V.--A#3PUUVE(AGP_)[U'J?FAQ=>99O\?/5/'T,"_QC/OLP#Y]>
M?/@PQP^D:7_<_OEDFG"E8\4)7XRI-;EDHND7!][R L4X:037/FG_A-M\T!>/
MF\H>^OIJS_N1WTGV.MS-4S\OFA4RVL)1L*E2\1"\JFW^#@5*HUA^*B([\*O'
ML4LG ,&A<#M (B,#[H5F[!^3RTN2V>:3WHQ6DREJ24Q#'XB'*3!PG%36EL2#
MB,7D4G8 V8Y?=R; .D3<L[:\'QM.<K<C1:V9M9@@,E9?)7T %RD^5M$D6R)Z
M*?,N<-KMZ\:Y!$\.IP:\[\ Y?W<5%_BOJQJ\?*%?ZD";E4%/0?/ 0P&1.=;'
M9@=!,068+-ESQ4A-VDQLV4+0N!WAS1(% W"_3Q"MM:WDP()/&62NK;Z>9?"Z
M9 A&>*$%%MFH3V<K22.G"H80^-,@.H#[_<%H;5!-5C)1D J)\_K^[3Q$P1DP
M$R4&8^MHK5- J(=DP4"B?AQ !_"] _"L+/+:/O]^6Y_E4DE$M89L#+&%. %>
MTDF*"4K1A4_<:?/,NY&<<2=#M+K$CN=\!_#Y)FFV<O 6+]*_KB9$R04Z4XKT
M$7BM]%-2U>8]42!$T@1?@N*BS8:]1X@:UPX-(/+'DI9'\']_*/EK*$U7(4-^
M/QBB_@A?KYM(9O.[6.%-^6GVZ1.%$/68%XI,K&3)@V$J4RPBD1B6$EE<68(6
M7I.I;0*LIVD;-[,Y/+X&ED9O%NM&5UY\P7FH$T07RS]J%3%Q^T*J[+5EGBQZ
M(M]2. 5>>0<Z^.RCM\&%-J'<KA2.&]LUMF5#2>9\:IBN9T,N)M/E1]RQMFO(
M:J<COKY17=10#&E30949#RE:!B76!\9<$@2=*/2L-;^,3*%3+5_RAZJ@>C@H
MY\W5<J?2PG6W6TB* AM%CD4N%#XA Y]\)MN?O*XUT*G1NLBCR.[AY?H@'#VT
MF*<37@<7]^/E(B)H;7,R$-'7*?)"T$_,@>%%9^451]LH\=IOG=8)X;%7)=<^
MLNH >)M+33AR42)&$$[4 A.VFD6.8+PTTK@8#6N3HCV[2JZ]Q+U3)=<^O.\
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M,7T( ,8.4P81V6,0.(!_'3P;W:ZT>7FUF$QQL;AY%KO6CX019?"@21/H,*R
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M\O@A^DBF.-2<P)NAE+HW"@T#9WD&X1,Y"X*1]6S39-9+,F6SZ.Y'N"^_?A\
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MWJ"DEN!#W1&;C))"DB1MFVASW&J\GFN+NE2CO8#2@<8<+(=7_[J:++_^-J5
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M@BHJ@HM%0"G9D>^OZ/\Z&P'<AA%G>NF>34*V&2B?=4BZ._LN4N#2Z4 6,%(
MH4PA,V@UA?%"ZE"8-*[1%*<>3O_L\[SMU*=#4[ 7EG^X'/'3[$--T4KM:U$L
MTU60N 8?)(?H0TK!\T*QS)F9@CU9\.RSS,_ 'K1$];-V"KY-&C[-.!.U4=%Q
MX P+J, ">$P<M"O62LQ,X+F9@SU9\.PSW<_ '+1$];,V!_<V(SW--:MR<<0G
M*%J1)17)@G..9,\PH&/)&G&F^?.=SG^F4?X/90B:X?E96X$]HJLZ,#MEZ0&Y
M)9[Q&"$XST"@2TERH8U49V8#!LX4G',6_QE8@$98'O0%H).Y.^0ME=G\4YBN
M2]1[&+RS.TVC3MXYD'5]C-[1&4.,L;8.),)]\1Z<%Q&L%+G8[)TQ;8J3GLOH
M':<P8XH,<#6LBQ=5)^<SR#H&IH+TH=6JO;]'[^R)WW:C=_8!00?>XX.%*"I$
M'UP!I[PC%A+4@N((P6HZ@XA,AS;3MY[EZ)V]H/#X%J0]Y-(!J YGW",C#9)
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M0 -J5I^0^E%4;MVH8(QA13,'$AU)L6 A:V0BA"RQCD3SK-%PH+ZZ8_J[PDZ
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M,C%X97@Q,#(R+FAT;5!+ 0(4 Q0    (  Z#0U3+77L,DC   /9% 0 ;
M          "  6DK  !A,C)Q,E\Q,'%X,3(S,3(Q>&5X,3 S,BYH=&U02P$"
M% ,4    "  .@T-4F1BIZ5,L  #^!P$ &P              @ $T7   83(R
M<3)?,3!Q>#$R,S$R,7AE>#$P-#(N:'1M4$L! A0#%     @ #H-#5%=2&Q'_
M(@  ,:T  !\              ( !P(@  &$R,G$R7S$P<7@Q,C,Q,C%X97AH
M:6)I=#$P-RYH=&U02P$"% ,4    "  .@T-4 P.ZPOT'   ^)P  'P
M        @ '\JP  83(R<3)?,3!Q>#$R,S$R,7AE>&AI8FET,S$Q+FAT;5!+
M 0(4 Q0    (  Z#0U2*OA.1 @@  +4G   ?              "  3:T  !A
M,C)Q,E\Q,'%X,3(S,3(Q>&5X:&EB:70S,3(N:'1M4$L! A0#%     @ #H-#
M5&6_1-CU!   <Q<  !\              ( !=;P  &$R,G$R7S$P<7@Q,C,Q
M,C%X97AH:6)I=#,R,2YH=&U02P$"% ,4    "  .@T-4Y;SC^<X:   *H0
M'P              @ &GP0  83(R<3)?,3!Q>#$R,S$R,7AE>&AI8FET.3DQ
M+FAT;5!+ 0(4 Q0    (  Z#0U2+_=/)I%T" -CP'  0              "
M ;+<  !C86@M,C R,3$R,S$N:'1M4$L! A0#%     @ #H-#5"9,$B_R$0
MAL   !               ( !A#H# &-A:"TR,#(Q,3(S,2YX<V102P$"% ,4
M    "  .@T-4@*5^)G<7  "ZVP  %               @ &D3 , 8V%H+3(P
M,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  .@T-4JKI":M!G  !=K@0 %
M            @ %-9 , 8V%H+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4
M"  .@T-4#L8':E-*  #&6   $P              @ %/S , 8V%H+3(P,C$Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    (  Z#0U3K2R&M\6<  !Q[   3
M      "  =,6! !C86@M,C R,3$R,S%?9S(N:G!G4$L! A0#%     @ #H-#
M5*#6&]>[6P  >VX  !,              ( !]7X$ &-A:"TR,#(Q,3(S,5]G
M,RYJ<&=02P$"% ,4    "  .@T-4TH*CSO].  !*7P  $P
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M              "  <HT!P!C86@M,C R,3$R,S%?<')E+GAM;%!+!08
..%0 5 *<%  !*S <    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
